<SEC-DOCUMENT>0000950170-24-038091.txt : 20240328
<SEC-HEADER>0000950170-24-038091.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240328163053
ACCESSION NUMBER:		0000950170-24-038091
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		24799595

	BUSINESS ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>eldn-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-28T09:32:41.3328+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:eldn="http://www.eledon.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e5f04133-98dc-4ec1-8902-26951bc43866" name="dei:EntityCentralIndexKey" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf">0001404281</ix:nonNumeric><ix:nonNumeric id="F_8a3435ff-6483-41a3-9517-72be74feb111" name="dei:DocumentFiscalPeriodFocus" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf">FY</ix:nonNumeric><ix:nonNumeric id="F_43205817-47d4-4fc9-aeae-d88a8e1b9cf1" name="dei:AmendmentFlag" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf">false</ix:nonNumeric><ix:nonFraction id="F_8862ae79-21b9-4dd3-b094-5f0b37ca3bf5" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_590f46c2-3850-4849-be6f-cc96373a70da" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_00a1069d-cd72-41cb-bc33-200863646b81" name="us-gaap:PreferredStockValue" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_8e1d1e87-5ed8-4476-b947-d11cb0df1b47" name="us-gaap:PreferredStockValue" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_97b04c6c-0e31-4def-bdf9-a4dc995bb41f" name="us-gaap:PreferredStockValue" contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_3ca1e85d-199a-4c47-8f91-7bf01141c98f" name="us-gaap:PreferredStockValue" contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7" unitRef="U_USD" xsi:nil="true"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eldn-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_090932c3-ea52-4d70-b213-7b49b4e7f9bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f06bf133-70a4-416c-a4f6-115eb78648e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c33e93a8-92df-4580-a627-619828841106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eldn:CommonAndPreferredWarrantsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36a0389b-10cb-49c8-b0e4-e5b3b2badc70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52ac3c7f-20e1-4753-802e-f4dad8d28acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1011001-4cbb-4b9f-93e6-39793a44b86c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:WarrantsExchangedForSeriesX1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05c23523-7806-4910-8de2-4ca513419180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fc735f4-0e20-4c55-bc5a-1509ab504714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementThirdClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07827eda-fb88-4fed-aae9-6ed17feba552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_349c064a-f323-4320-a562-2a08dbbdc3ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2aed4a90-b683-4eb4-a34b-231381f0b672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f240e52-3046-4a8c-8a48-212f2e92c63e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementSecondAndThirdClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_606d38b0-f6ba-43cf-b237-35fd69e618d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-21</xbrli:startDate><xbrli:endDate>2021-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_157cedb9-5047-412b-85f9-6fbe8216f23c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31d98449-23a4-498d-bc0e-c00c14f1718b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac320d24-5fbb-42d0-93dd-dad1bc9ba82d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1c703b7-f5c2-420d-baed-484058777e18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">eldn:TimeBasedAndPerformanceBasedVestingRequirementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_497f04cf-da0b-4b5e-b011-34361d789ace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-21</xbrli:startDate><xbrli:endDate>2023-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99647e68-33eb-417c-a4d5-0797361b24f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4d5fab0-b529-4936-88f9-d28a56338778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c94ca06-3730-4b18-9348-e88243d8d2e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f480dcc-a0dc-4708-95ae-152e67a484fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd6fbf82-130d-405c-b4df-97d3c4f5ddb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac3741ad-2290-4551-8fd0-d8b0fd4e7b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdaa1da2-6d2e-4920-84ee-ec3843c595c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eldn:AnelixisTherapeuticsLlcAndOticPharmaLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_539b64d7-b76a-4d73-b8da-2e58862a41c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8711094b-fadc-4a14-9f20-38420f00a8ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95b9fc77-0964-46e8-8014-8c0dbfd4b766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b10db2e1-d9c6-4be4-9ba9-86c0ebed4c56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0af738a-7254-4f32-bf85-c20c9f5d1f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8d96f37-a27b-4675-8ac3-76423e39c728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16a5f966-35bb-40a6-836a-438436efb35a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2338023d-7d9b-4ae4-860d-5a670fc77d43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fd780de-3625-4605-acfa-3c1d91d4974d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdf8105d-12d9-4345-b55c-4de997687b56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4dbd612-6707-4d02-a493-3e3587d5b602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed778020-ad3f-469d-86df-b93a95a7576c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b4e4097-491a-4d6f-afa0-8dd0e72ce61a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80ff1b22-a3d3-4e55-9ed1-30853a838cdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6ce7cd5-abcb-4e3b-a08b-0f8a402a5e5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">eldn:TimeBasedVestingRequirementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4d3a667-0d9f-40ac-bb0e-95f7b4b21745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37373384-6f64-4549-9ed5-b285cc857da3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65b7835c-8f67-4c38-a18d-054d0149baa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d5fba3f-307a-4a36-acdc-6c3371fb0c8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79a2379f-7f54-4178-992c-73f84e1d8b73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c6b3fdb-26ba-4381-9bb7-d9118f53631d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dc70a81-570f-425e-8e77-d3cbed342a71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57551459-8811-4b71-9e9a-189290d077cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6eb2939-62e5-40db-a742-2c39943593d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80152760-f5f1-49d1-818c-7be41d8bad59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_170abf46-8a87-4bdf-bc25-11d52fb87c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37fbd92e-56b2-46ce-8389-9dbd29607f96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac28187a-81e1-43da-a679-686dc898f95a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b395598c-4190-4835-bf33-91c539bcf3da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0abe5b3-eb23-480e-a655-192c844dd5f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f2ef666-c1cc-4c55-a513-878df085d0cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7bc39d7-c639-45d4-a935-4c52633b71fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeriesX1ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-11</xbrli:startDate><xbrli:endDate>2022-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_403020d7-be70-4c12-a4cc-8bc0abf4256e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_200cc8e1-5269-466a-876a-228fe7dd6936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bcb3f59-3ee1-413a-b49d-33149e98e0b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fb153ff-f40b-425f-93b1-c594301d3610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bd49aca-76b8-41b8-851c-421b99dd8a37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed539061-91d5-4d71-9cf6-98e903ea5f7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cff03e8e-4e84-4751-8bed-4bbfff630a65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e474f40b-c32d-4216-952d-084ee8fda28a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ae6940e-5a6a-475f-9b2c-85a5e9f64183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a35f913d-d756-40df-9f78-a4912c356455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_509700d3-0809-447c-94e0-126e7520dc70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd72c38d-208f-4865-8dad-4735385f07ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a8b2ca6-ee48-4d8b-9174-016ccf545018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e831537-98aa-43d1-a911-7e2bb6a241d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eldn:AnelixisTherapeuticsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-14</xbrli:startDate><xbrli:endDate>2020-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb8a89d8-fa9c-4eed-9f5a-4e41b1a1cdb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a6202d9-fada-461a-bd65-85c4b8841070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccdb24f4-ddf1-43b9-891d-1a463b208bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7430787c-94a0-4f8c-8d53-714130bb6ed6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85108846-892e-47c8-9754-3c7dfc301d1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_239720ec-ec16-4abc-a760-ebef1985ac2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaa353e1-e2e4-4e48-84e1-87f26b1fe289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0214fd64-e27d-4163-83ae-6f06bab5710b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0439d622-b345-4d2d-a148-7f5891bdb53e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0adbfddb-526c-4e99-8cac-1ee645fd34e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementSecondClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d67b8fc7-20c1-4f9d-9bf3-e028f161e18b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a9a710c-7ac2-4558-9624-0a06bad3b9b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:FiveHundredMillionAggregateNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f427656a-338e-4bdd-9bad-d6f9b666e78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dec7f080-9ef4-430f-acea-1afbd5a8afda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7801a479-8e65-474f-81b3-70e988f0cb94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeriesX1ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-11</xbrli:startDate><xbrli:endDate>2022-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0208a52-3605-4067-a592-6f1d7092a39c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:OneBillionAggregateNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2215e8a-709f-4e4f-a87d-5319589f877a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df5cb9c5-cc2b-4539-8abf-128c08a87c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3213c02-d3c7-4370-aa17-1e548a1026d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eda5a95-af05-48df-860c-3566c2e5b7b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb8475f5-4660-40c0-8142-92caed57a7c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc7dea4e-952b-4624-b726-7fb18eb4ecb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1b6b20f-2b7f-4988-9b59-14ae1a547e10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f448875a-e2e2-4f12-b2e3-7d76a53fa08d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23d71061-54b9-42a6-9e17-5f08efea1eb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:WarrantsExchangedForSeriesX1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58bb8acc-ddde-40c9-8a7d-dbf46fcb11f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eldn:AnelixisTherapeuticsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1d46794-a5ff-4a00-a67a-113d1f5e5bb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9deefa9-7710-433e-acac-3e9a0bd20f91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7d71759-5259-4d1d-9aa7-792cc31e7654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f418a451-c1a8-49bf-9510-a9346093387d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_514fb2b8-c4b0-4b5c-a2e4-0c1d1d0a3e36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17e67f10-b293-4956-8cef-526a32b65ef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3da60b1-bf6f-43ce-b8eb-e383f1879995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e3151e2-74b6-4f7c-b669-6a6d90422655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eldn:OticPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91677af4-ce57-4e73-97a4-b3d085786c69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:OneBillionAggregateNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a19675bc-9e87-4fa8-a561-20689ac5db3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1db222f1-dbb0-49ac-9c1f-ef8b555d7efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_734d7e73-f1c6-4f08-8277-d9d136b29526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50fac1cc-803f-44be-b716-f8a6c9e0f8d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1772a59-3433-4d38-9a57-13a0ec38ee2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5db2a782-5d40-4e38-afa2-a24096cf9b4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementThirdClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_326577f3-b56f-4806-864f-4daf1c2d3bdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9a7cc9f-d6ce-4f09-85e0-f27ce671852a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5ff90c2-7ab7-4323-9fa7-e9cdeca70a8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b49914b8-f522-4af4-8c0b-fb6529f0205e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_564fb782-4618-449b-be0d-4a8c0d6e8c89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eldn:CommonAndPreferredWarrantsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_148ad8a7-b70c-496a-95b6-25eb9918c6d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cc0ccfc-b7a6-4b18-b60e-c2dd9520c8bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:FiveHundredMillionAggregateNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f447210b-d619-429a-aaa3-21f7e7229a49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:WarrantsExchangedForSeriesX1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdc4a339-8142-476a-b3fb-e83a9b558bde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84888892-87f5-4e23-bd7c-63309c46746a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_085ab3ce-d345-4414-8f9f-ec51eb1a7ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10ef38e2-ed82-4422-8141-1f5959c9d8b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a45cdbc7-e8f2-4e4f-8f6f-ba8e618b1f4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c76111e5-5031-4f89-b4d4-0128b09d2e80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0357e8b8-b1b4-40e1-a1cf-ad729e9511b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_891105d4-f431-4944-af9d-ba738f8db8f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12a2d2e1-2aaf-4445-a36c-14fb7b5c2325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b7b00cf-f725-4f04-abf7-50d2422f6755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89b25922-7cb3-4412-b567-f46abca28cf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94a7e619-bc0a-46f9-82d4-e85969a5f850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5deb814-b818-48f3-be71-4e54d19ae9f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97e359d3-cfa5-442f-9a87-040db5c132e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22837696-6636-4174-85b7-968e5779be90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35052766-c4e5-4be4-af90-aba8bb3300b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7aafb0bd-5f6d-4965-a2d7-c6a51e705c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37fd87ac-684b-41cc-9625-693d26d0ebe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90229839-dc48-46bd-88f4-a22efae9078c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08232590-c5fa-4b08-bc08-e606069533f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f301cf92-7fb0-4ba2-92cb-d9b6ab58209c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-21</xbrli:startDate><xbrli:endDate>2021-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_680c3de3-4af7-4781-b111-7a9f83940645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Reporting_Unit"><xbrli:measure>eldn:Reporting_Unit</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>eldn:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestone"><xbrli:measure>eldn:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:38.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid #000000;margin-right:38.889%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">Form </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf07bad8-684c-4366-801c-bed5331fe371" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:38.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid #000000;margin-right:38.889%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_80cec1e4-5199-4fa9-a0b4-232e0d810e14" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0430965d-dd53-4617-a41f-1bd602873cc0" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d11bf00-bf44-46a7-8c0d-765558bee926" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67e3bc97-f5c9-4edc-b37d-0f65698c7f9d" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_77e5c273-3ada-4b7f-8b0f-7601e301da2c" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                      </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                    </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission file number</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a987da9-ef81-4581-bfed-9f4b13610e80" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-36620</span></ix:nonNumeric></span></p>
  <p style="margin-left:38.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid #000000;margin-right:38.889%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:23pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3eed661c-940b-4f00-83e0-b264c5fc0e7a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:23pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:38.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid #000000;margin-right:38.889%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_23defe9d-9e66-44cf-82a6-833b7cc67434" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a1eb3df0-53fe-4a3b-95b7-3730df60c388" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20-1000967</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_42436286-68e0-477c-8a6e-30e1d6f23780" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">19900 MacArthur Boulevard</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_a4b53e8a-f140-47dd-b20e-f9d9c0207909" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 550</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_96968563-d4ec-4646-9b18-47fc84434fcd" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Irvine</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_45e869ac-9066-418b-9c51-ec5db6534566" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_20dea9de-d652-4c5b-84bc-4a478e88f94c" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92612</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d981c2c-35b3-4934-b45d-e1d88a1bbe8c" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(949) </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_164f850f-1d02-4f21-9b51-9d2e6e0d367f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">238-8090</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33%;"/>
    <td style="width:1%;"/>
    <td style="width:33%;"/>
    <td style="width:1%;"/>
    <td style="width:32%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of Class</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of Exchange on Which Registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_cd46d035-eaa7-4e87-bf8a-0649d3585430" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_a6becb21-c52a-4270-af77-0bf2438dc5c5" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ELDN</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_0d0afc42-974c-4d33-b548-ca9ff502e4ec" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="margin-left:38.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid #000000;margin-right:38.889%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64ce2ad6-2921-457c-a845-f671d9fa204c" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9b6a184-9930-47d2-8913-00ba6657d81a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8698b141-4870-4843-be95-b05a0d7f6b8e" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04479a44-d43a-488b-877c-8ddf54791ef9" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28%;"/>
    <td style="width:2%;"/>
    <td style="width:40%;"/>
    <td style="width:28%;"/>
    <td style="width:2%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_029c62f2-5628-42fb-9d76-d832d429c1cf" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_d53b6406-181f-4231-a152-4e3ef7c51cb5" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_78cc84ae-7bf6-4059-8db7-cbba01132307" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation of the effectiveness of its internal control over financial reporting under Section 404(b) of Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by registered public accounting firm that prepared or issued its audit report </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebc81cfe-ba35-4d19-832f-7e6e64129d6f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant  included in the filing reflect the correction of an error to previously issued financial statements </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5399fac7-3a36-4b91-b547-9904eeffe888" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  &#9744;    No  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_377bf2f9-e5c3-44e7-9a5b-60ae5b673da6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_018dd64b-8c13-4ba1-9e33-14703499d6d3" contextRef="C_37fbd92e-56b2-46ce-8389-9dbd29607f96" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,607,310</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, b</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ased on the last reported sale price of such stock on the Nasdaq Global Market as of such date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of March 25, 2024, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7502d1b6-fea9-4324-b912-3b64e7b0a4cb" contextRef="C_a0abe5b3-eb23-480e-a655-192c844dd5f1" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,813,130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, shar</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">es of Common Stock, $0.001 par value per share, outstanding.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf32b772-91dc-45b9-afd5-7e6ed11b24f1" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:82.46%;"/>
    <td style="width:1%;"/>
    <td style="width:6.54%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 5.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 7A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 9A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 9C.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 12.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 16.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#index_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Index to Financial Statements</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In this Annual Report on Form 10-K, Annual Report, unless the context requires otherwise, &#8220;Eledon&#8221;, the "Company", "we", "our", and "us" means Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) and all wholly owned subsidiaries.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; as defined by the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. Any statements other than statements of historical or current fact in this Annual Report on Form 10-K are forward looking statements. In some instances, you can identify forward-looking statements by the use of words such as &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;targets,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; and similar expressions, although not all forward-looking statements include such identifying words. Forward-looking statements include, but are not limited to statements regarding:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product development plans, expectations for and the timing of commencement, enrollment, completion, data, and release of results of clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our strategies with respect to our preclinical and clinical development programs, including our expectations regarding the production of clinical quantities of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans, strategy and timing to obtain and maintain regulatory approvals of our product candidates; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding competitive conditions for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our review of strategic alternatives and the outcome of such review; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations about our future financial performance or condition.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including the factors listed under &#8220;Risk Factor Summary&#8221; below. These risks and uncertainties, as well as other risks and uncertainties that could cause the Company&#8217;s actual results to differ significantly from the forward-looking statements contained herein, are described in greater detail in Part I, Item 1A. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any forward-looking statements contained in this Annual Report on Form 10-K speak only as of the date hereof and not as of any future date, and the Company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market data and certain other statistical information used in this Annual Report are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on our good faith estimates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in Part I, Item 1A, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors in this Annual Report on Form 10-K</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our short operating history and shifts in our business strategy may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial condition raises substantial doubt as to our ability to continue as a going concern. If we become unable to continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since our inception and expect that we will continue to incur losses over the next several years and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional funding to be able to complete the development of our lead drug candidate. If we are unable to raise such capital, or if we are unable to do so on acceptable terms, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or other convertible securities as well as shares and warrants issued in connection with our recent Private Placement, could result in significant dilution and could cause our stock price to fall.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are in the early stages of clinical development and may not be successfully developed. If we are unable to successfully develop and commercialize these or any other product candidate, or if we experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unfavorable global economic conditions could have a material adverse effect on our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financial performance.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug development involves a lengthy and expensive process with an uncertain outcome, including failure to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration (FDA) or similar regulatory authorities outside the United States. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development, formulation and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of nonclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and there is a risk that additional nonclinical and/or clinical safety studies will be required by the FDA or similar regulatory authorities outside the United States or that subsequent studies will not match results seen in prior studies.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays or difficulties in the enrollment of patients in clinical trials could delay or prevent our receipt of necessary regulatory approvals and increase expenses for the development of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for a narrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may be materially impaired.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our development programs or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our current product candidates, or a future product candidate receives marketing approval and we, or others, later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, the ability to market the product could be compromised.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on third parties for the manufacture of our product candidates for nonclinical and clinical trials, and for eventual commercialization, increases the risk that we will not have sufficient quantities of our product candidates or products at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on contract research organizations (&#8220;CROs&#8221;) and other contracted third parties to perform nonclinical and clinical testing and certain other research and development activities. As a result, the outcomes of the activities performed by these organizations will be, to a certain extent, beyond our control.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain intellectual property protection for our technology and products or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public health crises, including pandemics or epidemics, could adversely affect our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price could be volatile, and the market price of our common stock may drop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpectedly.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our corporate charter and under Delaware law could make an acquisition of the Company more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WEBSITE REFERENCES</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this Annual Report on Form 10-K, we make references to our website at www.eledon.com. References to our website through this Form 10-K are provided for convenience only and the content on our website does not constitute a part of, and shall not be deemed incorporated by reference into, this Annual Report on Form 10-K.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (&#8220;CD40L&#8221; or &#8220;CD154&#8221;) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;). Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tegoprubart is engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as macrophages and dendritic cells, as well as B cells. By blocking CD40L and not the CD40 receptor, tegoprubart inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may play a therapeutic role in autoimmune diseases and in the prevention of allograft rejection after solid organ transplantation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1: Mechanism overview of CD40L inflammatory signaling and tegoprubart site of action</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img116206746_0.jpg" alt="img116206746_0.jpg" style="width:382px;height:298px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interaction of CD40 with CD40L on immune cells mediates activation of the co-stimulatory immune pathway, controlling "cross talk&#8221; between the adaptive and innate immune systems. Blocking CD40L shifts polarization away from pro-inflammatory signaling to T-cell anergy, apoptosis, and polarization to a &#8220;T-reg&#8221; environment. (Source: Adapted from Kant et al., Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022, AJKD.)</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tegoprubart is designed to negate the risk of thrombolytic events seen in the first generation of anti-CD40L antibodies by introducing structural modifications that have been shown in preclinical models to eliminate binding to the Fc&#947; receptors associated with platelet activation without altering the binding of tegoprubart to CD40L. In non-human primate studies, dosing of tegoprubart up to 200 mg/kg per week for 26 weeks, demonstrated no adverse events regarding coagulation, platelet activation or thromboembolism.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategy</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business strategy is to optimize the clinical and commercial value of tegoprubart and become a global biopharmaceutical company with a focused immunology franchise. Our strategy is to develop tegoprubart for the prevention of allograft and xenograft rejection, and for the treatment of autoimmune diseases such as ALS. We selected our indications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on preclinical and clinical data that was generated with either tegoprubart or historical anti-CD40L molecules. In January 2023, we announced our decision to prioritize resources on our kidney transplantation programs, and discontinue the Company funding of the islet cell transplantation program and the IgAN program. We remain committed to further progressing ALS clinical development and are working with key stakeholders on potential next steps to do so. However, as described below, we are unable to continue our clinical development of tegoprubart for people with ALS without additional financing.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following chart summarizes the status of our current clinical development programs. Details for each program are outlined below.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img116206746_1.jpg" alt="img116206746_1.jpg" style="width:672px;height:280px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquisition</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we acquired Anelixis Therapeutics, Inc. (&#8220;Anelixis&#8221;), the company that owned and controlled the intellectual property related to tegoprubart. See Note 8 of the Notes to Financial Statements included in this Annual Report on Form 10-K, for further details of grants and licenses related to this acquisition.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to our acquisition of Anelixis, we focused on developing medicines for patients with disorders of the ear, nose, and throat (&#8220;ENT&#8221;). In June 2020, we announced that our lead program did not achieve statistical significance for the primary efficacy endpoints in the treatment of acute otitis media. As a result of this failure to achieve the primary study endpoint, we suspended the clinical development of our legacy ENT assets while we assessed potential development strategies. Following the June 2020 announcement, we significantly curtailed development expenses as we sought to identify strategic alternatives that would maximize stockholder value. As a result of these activities, we acquired Anelixis and raised additional capital in September 2020, as described above. After acquiring Anelixis, we terminated our ENT activities and returned our product rights to the original license holders in July 2021.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Development of Tegoprubart for the Prevention of Allograft Rejection in Kidney Transplantation</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced plans to prioritize and focus resources on our kidney transplantation programs. We are first focusing on kidney transplantation as this is the most common type of solid organ transplantation in the U.S. with an estimated 255,000 Americans living with a transplanted kidney. In 2022, an estimated 25,000 kidneys were transplanted in the U.S., of which up to 15% were re-transplants in persons that had already received at least one other kidney. Over 90,000 people in the U.S. wait 3-5 years on average for a kidney transplant and about 5,000 people in need of a kidney transplant die each year while waiting for a suitable kidney. There remains a critical shortage of kidneys and other organs available for transplantation.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been little innovation in immunosuppression therapy for organ transplant patients over the past 30 years. The standard of care immunosuppressive drugs used post-transplant have been shown to reduce the risk of organ rejection, but they are also associated with potentially toxic side effects. Organ transplant recipients require immunosuppression on a lifelong basis, and any disruption in the immunosuppression therapy can trigger transplant rejection. Calcineurin inhibitors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(&#8220;CNI&#8221;s) are a critical component of most immunosuppressive regimens to prevent acute and long-term kidney transplant rejection. However, chronic exposure to CNIs (tacrolimus is the drug most commonly used) is associated with nephrotoxicity, hypertension, new onset diabetes due to pancreatic beta cell toxicity, as well as central nervous system (&#8220;CNS&#8221;) side effects, like tremor. Over time, these CNI side effects may significantly damage the transplanted kidneys or result in a requirement for reduced exposures to CNIs which can lead to an increased risk of rejection. Moreover, other side effects, including CNS side effects like tremors, may result in patients decreasing their adherence to their medicines. Today, an implanted kidney is expected to fail within 10-15 years on average using currently available immunosuppression options. The fact that American transplant patients are on average in their 50s means that many of them will ultimately need a second or even third transplant procedure during their lifetime or a return to dialysis.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The central role of CD40L signaling in generating pro-inflammatory responses makes it a highly attractive candidate for therapeutic intervention in the protection of transplanted organs and prevention of transplant rejection. Results from prior studies demonstrate that targeting and blocking CD40L has the potential for better efficacy and improved safety, including reduced risk of lymphopenia, diabetes, hypertension, and other side effects associated with standard-of-care CNIs such as tacrolimus.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tegoprubart seeks to address challenges associated with current immunosuppressive transplantation regimens using CNI-based therapies. The ability to prevent acute and chronic transplant rejection without the need for CNIs has the potential to transform the clinical management of preventing graft rejection by mitigating the adverse events associated with CNIs and improving long-term graft survival, thus potentially decreasing the need for repeat kidney transplants and increasing organ availability for other patients on the wait list. By identifying and advancing novel strategies in immunosuppression including targeting the CD40L pathway, we may be able to help organs remain functional for longer and potentially throughout the natural lifespan of each recipient.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In aggregated data from the published studies referenced in Figure 1 below, non-human primates undergoing allograft renal transplantation receiving anti-CD40L monotherapy (e.g., 5c8, AI794, IDEC-131) had longer average survival than both those receiving anti-CD40 monotherapy (e.g., 4D11, cH5D12, Chi220, ASKP1240), tacrolimus monotherapy or untreated controls (Figure 2).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2: Inhibition of CD40L improved survival vs. CD40 inhibition in non-human primate kidney transplantation monotherapy studies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img116206746_2.jpg" alt="img116206746_2.jpg" style="width:672px;height:326px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kaplan-Meir estimates of the probability of rejection free survival by treatment group from eleven published studies of allograft kidney transplant in non-human primates. Sources: Perrin, 2022; Song, 2014; Song, 2016; Duan, 2017. Note: In aggregated data from published studies, NHPs receiving anti-CD40L (e.g., 5c8, AI794, IDEC-131) immunomodulation monotherapy post kidney transplantation had longer average survival than those receiving anti-CD40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">monotherapy (e.g., 4D11, cH5D12, Chi220, ASKP1240), tacrolimus monotherapy or untreated controls. Tac = tacrolimus. Meta-analysis is not based on head-to-head studies. Differences between any individual programs may vary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received regulatory approvals in Canada, the United Kingdom and Australia, for a Phase 1b clinical trial of tegoprubart in up to 24 subjects, replacing tacrolimus as an immunosuppressive regimen component in patients undergoing de novo kidney transplantation. Each participant will receive rabbit antithymocyte globulin (ATG) induction and a maintenance regimen consisting of tegoprubart, mycophenolate mofetil, and corticosteroids. The primary endpoint of the study is safety. Other endpoints include glomerular filtration rate (eGFR), characterizing the pharmacokinetic profile of tegoprubart, and the incidence of biopsy proven rejection. The first subject in the Phase 1b study was dosed in July 2022.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Better graft function as assessed by eGFR, has been associated with improved long-term patient and graft survival and is an early predictor of future graft failure. Historical studies have reported average eGFRs generally in the low 50 mL/min/1.73m2 range during the first year after kidney transplant using current standard of care immunosuppression. An eGFR of 50 indicates chronic kidney disease.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We reported interim safety and efficacy results from the Phase 1b clinical trial in March 2023, and provided updated data in November 2023. At the time of the November 2023 update, results from 11 participants in the Phase 1b trial demonstrated that tegoprubart was generally safe and well-tolerated in patients undergoing kidney transplantation. There were no cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection commonly seen with tacrolimus. One participant experienced a mild T cell mediated rejection (Banff score 1a) on day 99. This patient was treated for the rejection and remains in the study. There were no cases of graft loss or death. Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2022, we received Investigational New Drug (IND) application clearance from the FDA for our controlled, Phase 2 BESTOW trial of tegoprubart for the prevention of transplant rejection in persons receiving a kidney transplant. The BESTOW study is a multi-center, two-arm, active comparator, head-to-head superiority clinical study, and will enroll 120 participants undergoing kidney transplantation in the U.S. and other countries to evaluate the safety, pharmacokinetics, and efficacy of tegoprubart compared to the calcineurin inhibitor tacrolimus. The study&#8217;s primary objective is to assess graft function as measured by estimated eGFR at 12 months post-transplant in participants treated with tegoprubart compared to tacrolimus. Secondary objectives will include assessment of graft survival, biopsy-proven acute rejection, and the incidence of new onset diabetes mellitus after transplant. The BESTOW study is running in parallel to the ongoing Phase 1b clinical trial of tegoprubart in kidney transplantation. The first subject in the BESTOW study was dosed in August 2023.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Company enrolled the first participant in a Phase 2 open-label extension (OLE) study which is designed to evaluate the long-term safety, pharmacokinetics, and efficacy of tegoprubart in participants who have completed one year of treatment in the ongoing Phase 1b study, or BESTOW study.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Development of tegoprubart for the Prevention of Allograft Rejection in Xenotransplantation</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While inhibition of CD40L has shown it may play an important role in immunosuppression in allograft kidney transplantation, this mechanism of action has also demonstrated that it may be a promising option in xenotransplantation (i.e., transplanting an organ from an animal to a human).</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we entered into a non-exclusive collaborative research agreement with eGenesis, Inc., ("eGenesis"), under which eGenesis gained access to tegoprubart for preclinical and clinical xenotransplantation studies in support of eGenesis&#8217; kidney, heart and islet cell xenotransplantation programs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Development of tegoprubart for the Prevention of Allograft Rejection in Islet cell transplantation ("ICT")</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Type 1 diabetes is a T cell mediated autoimmune disease with progressive loss of insulin producing pancreatic beta cells and affects over one million persons in the U.S. Of these individuals, an estimated 70,000 people have a particularly hard to control type 1 diabetes called Brittle Diabetes (&#8220;BT1D&#8221;) which is in part characterized by large swings in blood glucose levels and impaired awareness of hypoglycemia. Impaired awareness of hypoglycemia for people with type 1 diabetes is associated with severe hypoglycemic events which can lead to significant symptoms and even death. Pancreatic islet cell transplantation is gaining attention as a therapeutic option for type 1 diabetes because it can restore physiological insulin secretion, minimize the risk of hypoglycemic unawareness, and reduce the risk of death due to severe hypoglycemia. The advances made in this field over the past decade have improved patient outcomes, and the procedure has been evolving from an experimental treatment to a clinical treatment option.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A number of issues are believed to continue to hamper the overall success of ICT and to need to be addressed in order for there to be widespread clinical acceptance. These include the acute loss of transplanted islets with current immunosuppressive treatments, particularly those with CNI-based therapies, due to islet cell toxicity and alloreactive immunologic responses to transplanted islets. Over time, the progressive loss of islet cells and decline in islet cell function often leads to the need for multiple donors in order for BTID patients to have optimal response to blood glucose levels and possibly achieve insulin independence. Tegoprubart seeks to address the challenges associated with current ICT immunosuppressive regimens using CNI-based therapies, by replacing the CNIs with tegoprubart. CD40L blockade may abolish many effector mechanisms of inflammation, prevent and intervene in the progression of autoimmunity, and instill transplant tolerance.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historical studies in nonhuman primate models of ICT have demonstrated that treatment with anti-CD40L antibodies induces long term islet cell function and graft survival, even as a monotherapy. Tegoprubart has shown pre-clinical, proof-of-concept efficacy in a non-human primate model of type 1 diabetes, where animals undergoing ICT maintained glucose control and sustained levels of C-peptide with chronic tegoprubart treatment for up to a year. Compared to combination immunosuppressive therapy including CNIs, tegoprubart monotherapy was more effective in preventing long term islet cell rejection, associated with better graft function, and showed an improved safety profile.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we announced that tegoprubart will be utilized in an investigator-initiated trial, at the University of Chicago for pancreatic ICT in patients with type 1 diabetes. This is a pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus and problematic hypoglycemia undergoing islet cell transplantation. The Company is not funding this trial but is supplying tegoprubart.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Development of tegoprubart for ALS</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALS is a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord. In the U.S., the incidence is estimated at approximately 5,000 cases per year with a prevalence of approximately 30,000 cases overall. Despite 3 approved drugs, in most cases, death from respiratory failure occurs between 3 to 5 years from diagnosis, with 50% of patients living at least 3 years from diagnosis and only 20% of patients living at least 5 years from diagnosis.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the exact pathogenic mechanism of ALS is still not fully understood, there is strong evidence indicating that neuroinflammation plays an important role in the disease&#8217;s pathogenesis. Neuroinflammation in ALS is characterized by the infiltration of lymphocytes and macrophages into the central nervous system, and the activation of microglia and reactive astrocytes. Reactive astrocytes and microglia as well as infiltrating lymphocytes, dendritic cells, monocytes, macrophages and immune complexes have been identified in cerebrospinal fluid and neural tissues in both animal models of ALS and at autopsy in ALS patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tegoprubart is designed to block CD40L binding to CD40, thereby potentially inhibiting neuroinflammatory pathways leading to disease progression in ALS. In vitro proof-of-concept studies have shown that tegoprubart binds to CD40L in human cells and blocks CD40L binding on antigen presenting cells and activated T cells. The potential for therapeutic benefit of CD40L blockage in treating ALS has been demonstrated in a SOD1 mouse model of ALS, where a murine anti-CD40L antibody, MR1, prolonged survival and delayed the onset of neurological disease progression. These pathophysiological manifestations are believed to be due to reduced immune cell infiltration of macrophages into skeletal muscle and their destroying denervated nerves. The plasticity of the nervous system to repair itself in the absence of this immune cell attack is believed to result in improved neuromuscular junction occupancy and improved muscle function. Blocking CD40L signaling also prevents pro-inflammatory polarization of lymphocytes, reduced neuroinflammation and improved motor neuron survival in rodent ALS models (Figure 3).</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3: Blocking CD40L Improves Survival and Pathophysiology Associated with ALS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img116206746_3.jpg" alt="img116206746_3.jpg" style="width:657px;height:257px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3: Anti-CD40L (&#8220;MR1&#8221;) treatment decreases CD68+ macrophages, improves neuromuscular junction occupancy and improves motor neuron survival.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (A) Quantification of reduction of CD68+ macrophages by anti-CD40L treatment at day 100. (White bar, control IgG); gray bar (anti-CD40L&#8211;treatment); black bar (untreated age-matched non-transgenic mice) (B) Quantification of neuromuscular occupancy in SOD1 mice prior to overt symptoms (day 70) versus after symptom onset (day 85) treated with an IgG control antibody (vehicle) or anti-CD40L antibody. (C) Quantitative comparison of lumbar spinal cord motor neuron counts per mm2 in IgG vehicle control (White bar) versus anti-CD40L treated mice (grey bar) at day 100 (Lincecum, 2010).</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, the FDA granted orphan drug designation to tegoprubart for ALS. In 2019, we completed a single ascending dose Phase 1 study of tegoprubart in healthy volunteers and people with ALS. In this study, the doses of tegoprubart studied were well tolerated in healthy adult subjects and adults with ALS. Tegoprubart demonstrated low anti-drug antibody responses that were not dose related, linear dose proportionality across the dose ranges, and a half-life of up to 26 days.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, we initiated a Phase 2a, open-label, multi-center study to evaluate the safety and tolerability of multiple doses of tegoprubart in adult subjects with ALS. Fifty-four subjects with ALS were enrolled into the study in the United States and Canada at 13 ALS treatment sites. Ascending doses of tegoprubart were administered as IV infusions to four sequentially enrolling cohorts. The first two cohorts consisted of nine participants, and the last two cohorts of 18 participants each. All enrolled subjects received six infusions of tegoprubart over a 12 week period. Blood samples for target engagement, and exploratory biomarkers for inflammation and neurodegeneration were taken and analyzed. Participant-focused clinical outcomes were also assessed. In May 2022, we completed the Phase 2a study and released positive topline results. Tegoprubart successfully met the primary endpoints of safety and tolerability. Fifty of the fifty-four subjects completed all six study infusions, and adverse events were typical of an ALS patient population. Tegoprubart was well-tolerated, and no drug-related serious adverse events were observed. No new safety signals emerged. Anti-drug antibodies (ADAs) were present in less than 5 percent of samples. All ADAs were of low titer and did not impact tegoprubart drug levels. Tegoprubart target engagement was demonstrated in all dose cohorts with increasing target engagement in a dose-dependent manner, plateauing at the 4 and 8 mg / kg dosing levels using CD40L and CXCL13 biomarkers related to T cell and B cell function, respectively. Tegoprubart exposure decreased inflammatory biomarker levels, in a dose dependent manner, in 20 of 32 pro-inflammatory proteins. Pro-inflammatory biomarkers reduced included biomarkers also associated with IgA nephropathy and kidney transplant rejection, such as IgA, IgE, IgM, C3, CXCL9, and CXCL10.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are seeking to further progress ALS clinical development and plan to work with key stakeholders on potential next steps to do so. However, we will be unable to continue our clinical development of tegoprubart for people with ALS without additional financing specific for our ALS program, and we can provide no assurances that we will be able to obtain financing on acceptable terms or at all.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Development of tegoprubart for IgA Nephropathy</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company announced the deprioritization of its IgAN program and all IgAN clinical development activities were discontinued in 2023. IgAN is the leading cause of chronic glomerulonephritis, a state of inflammation producing damage to the filtering part of the kidney. Disease manifestation and clinical presentation involves renal dysfunction characterized by proteinuria with a slow relentless course. Approximately 30%-40% of persons living with IgAN ultimately reach end stage renal disease (ESRD). The standard of care for ESRD is dialysis or kidney transplant, which represents a significant economic burden as well as a major impact on a patient&#8217;s quality of life. With an estimated prevalence of approximately 150,000 persons in the United States, IgAN is one of the most common autoimmune glomerulonephropathies. In the United States, oral budesonide Tarpeyo was approved for use in IgAN by the FDA in December 2021 and Kinpeygo received conditional approval by the European Medicines Agency (&#8220;EMA&#8221;) in July 2022.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we received IND clearance from the FDA to evaluate tegoprubart for the treatment of IgAN. The Phase 2 global study was a 96-week open-label, dose ranging trial, and included both a high dose and a low dose cohort. The primary endpoint was change in urinary protein:creatinine ratio at week twenty-four. Secondary endpoints included change in estimated Glomerular Filtration Rate (eGFR) at week 96 as well as safety and tolerability. The first subject was dosed in May 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced the deprioritization of our IgAN program to focus resources on our kidney transplantation programs. We reported interim safety data from the Phase 2 high dose cohort in March 2023. All IgAN clinical development activities were discontinued in 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eledon&#8217;s success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, novel discoveries, product technologies and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. We seek to protect our product candidates by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain proprietary protection for our product candidates.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our intellectual property portfolio includes issued patents and patent applications directed toward (i) isolated antibodies and (ii) methods of treatment using the isolated antibodies that block the interaction of CD40L and CD40 to treat CD-40L related diseases or disorders. We have exclusive rights to these patent families, of which two families are directed to tegoprubart and related antibodies. The first family is directed to methods for treating amyotrophic lateral sclerosis with antibodies and includes two issued United States patents and 14 issued foreign patents (Japan, Hong Kong, Belgium, Germany, Denmark, Spain, Finland, France, Great Britain, Ireland, Italy, the Netherlands, Sweden, and Switzerland). The second family is directed to tegoprubart. Tegoprubart is the current clinical candidate, with 13 pending applications, and issued/allowed patents including three issued United States patents, one allowed United States patent application, and 17 issued foreign patents (Australia, Belgium, Switzerland, China, Germany, Denmark, France, Great Britain, Ireland, Israel, Italy, Japan, Mexico, the Netherlands, Russia, Sweden, Singapore). The third family is directed to tegoprubart with 17 pending applications, including one pending United States patent application, and issued patents, including one issued United States patent and one issued Russian patent. In the first family, the patents are set to expire in December 2029, absent any term adjustments or extensions. In the second family, any issued patent would nominally expire in February 2036, absent any term adjustments or extensions. In the third family, any issued patent would nominally expire in May 2038, absent any term adjustments or extensions.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to our acquisition of Anelixis, we undertook a strategic review of the legacy ENT assets. We concluded this review and determined that the best path forward was to terminate license agreements associated with these ENT assets and return the rights to the original license holders, which we did in July 2021. There was no financial impact to returning these assets.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eledon also protects its proprietary information by requiring its employees, consultants, contractors, and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. In addition, Eledon also requires confidentiality or service agreements from third parties that receive confidential information or materials.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 8. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the consolidated financial statements included elsewhere herein under the caption &#8220;Grants and Licenses&#8221; for further information about the Company&#8217;s intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our product candidates, technology, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The competitive conditions faced by the Company are also described in greater detail in Part I, Item 1A. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in this Annual Report on Form 10-K under the caption &#8220;We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities for the production of tegoprubart or any future product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third parties for raw materials and the manufacturing of drug substance and drug product for nonclinical and clinical activities. As of the date of this Annual Report, we have not experienced any difficulty in obtaining raw materials required with respect to the manufacturing of tegoprubart. We believe we have enough drug substance and drug product on hand and manufacturing capacity with our third-party manufacturing providers to meet forecasted clinical trial demand.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on third parties to label, store and distribute drug product for our nonclinical and clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling, and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical and biological products, such as those we are developing. Pricing of such products is also subject to regulation in many countries. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Government Regulation</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations, and biologics under the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;) and its implementing regulations. FDA approval is required before any new unapproved drug or biologic or dosage form, including a new use of a previously approved drug, can be marketed in the U.S. Drugs and biologics are also subject to other federal, state, and local statutes and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulations. If we fail to comply with applicable FDA or other requirements at any time during the product development process, clinical testing, approval process or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the Good Laboratory Practices (&#8220;GLP&#8221;) regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND which must become effective before human clinical trials may begin and must be updated annually;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of manufacturing scale up and stability studies, all performed in accordance with the Good Manufacturing Practices &#8220;GMP&#8221; regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;) or a new drug application, or NDA, after completion of all pivotal clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential review of the product application by an FDA advisory committee, where appropriate and if applicable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA or NDA to file the application for review;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the proposed product is produced to assess compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the clinical trial sites that generated the data in support of the BLA or NDA; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of a BLA or NDA prior to any commercial marketing or sale of the product.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preclinical and clinical testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans in clinical trials. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational new drug. An IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical trials. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence. The FDA may impose a clinical hold at any time during clinical trials and may impose a partial clinical hold that would limit trials, for example, to certain doses or for a certain length of time.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with Good Clinical Practices (&#8220;GCPs&#8221;) which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site&#8217;s IRB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">before the trials may be initiated, and the IRB must monitor the trial until completed. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined.</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1. The drug is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational new drug in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2. The drug is administered to a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse side effects and safety risks, and preliminarily evaluate efficacy.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3. The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites to generate enough data to evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational new drug product, and to provide an adequate basis for physician labeling.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, the FDA may condition approval of a BLA or NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after approval. In other cases, a sponsor may voluntarily conduct additional clinical trials after approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical trials.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sponsors must also report to the FDA, within certain timeframes, serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure, or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climate.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical trial process can take three to ten years or more to complete, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Results from one trial are not necessarily predictive of results from later trials.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A drug being studied in clinical trials may be made available to individual patients in certain circumstances. Pursuant to the 21st Century Cures Act (&#8220;Cures Act&#8221;) which was signed into law in December 2016, the manufacturer of an investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational drug (compassionate use). This requirement applies on the later of 60 calendar days after the date of enactment of the Cures Act or the first initiation of a Phase 2 or Phase 3 trial of the investigational drug. At this time, Eledon does not have a program for the compassionate use of an investigational product outside of a clinical trial as it is not applicable to our investigational products.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Submission of a BLA or NDA to the FDA</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assuming successful completion of all required testing (e.g., completion of pivotal clinical trials) in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted to the FDA in the form of a BLA or NDA requesting approval to market the product for one or more indications. Under federal law, the submission of most BLAs and NDAs is subject to an application user fee and these fees are typically increased on an annual basis. Applications for orphan drug products are exempted from the BLA and NDA user fees and may be exempted from product and establishment user fees, unless the application includes an indication for other than a rare disease or condition. No application user fees were paid for tegoprubart in calendar 2023.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A BLA or NDA for a new molecular entity must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from several alternative sources, including investigator-initiated trials that are not sponsored by Eledon. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational new drug product to the satisfaction of the FDA.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once a BLA or NDA for a new molecular entity has been submitted, the FDA&#8217;s goal is to review the application within ten months after it accepts the application for filing, or, if the application relates to an unmet medical need in a serious or life-threatening indication, six months after the FDA accepts the application for filing. The review process is often significantly extended by the FDA&#8217;s requests for additional information or clarification.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving a BLA or NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA or NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA&#8217;s Decision on a BLA or NDA</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA evaluates a BLA to determine whether the data demonstrate that the biologic is safe, pure, and potent, or effective, and an NDA to determine whether the drug is safe and effective. After the FDA evaluates the BLA or NDA and conducts inspections of manufacturing facilities where the product will be produced, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application is not ready for approval. A Complete Response Letter may require additional clinical data or an additional pivotal Phase 3 clinical trial(s), or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the BLA or NDA does not satisfy the criteria for approval and issue a denial. The FDA could also approve the BLA or NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Trials and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;) as amended, BLAs and NDAs must contain data to assess the safety and effectiveness of an investigational new drug product for the claimed indications in all relevant pediatric populations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. A sponsor who is planning to submit a marketing application for a drug product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within sixty days of an end-of-phase 2 meeting or as may be agreed between the sponsor and the FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers if certain criteria are met. The FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considered based on data collected from preclinical studies, early phase clinical trials, and/or other clinical development programs. The requirements for pediatric data do not apply to any drug for an indication for which orphan designation has been granted. In the future we may seek pediatric approval for tegoprubart applications in connection with renal and islet cell transplantations, which may require the submission of a PSP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of non-patent exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the five-year and three-year non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA or NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of FDA-requested pediatric trials are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection covering the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application relying on the BLA or NDA sponsor&#8217;s data.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties for the production of clinical quantities of our product candidates and expect to rely in the future on third parties for the production of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production, distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA or NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, untitled or warning letters or holds on post-approval clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending BLAs or NDAs or supplements to approved BLAs or NDAs, or suspension or revocation of licenses or withdrawal of approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Designation and Exclusivity</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product is the first to receive FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. The Company received orphan drug designations for tegoprubart for the treatment of ALS and prevention of allograft rejection in pancreatic islet cell transplantation.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration, and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA or NDA, plus the time between the submission date and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent and within 60 days of the product&#8217;s approval. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of the patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA or NDA.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Abbreviated New Drug Applications for Generic Drugs</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 1984, with passage of the Hatch-Waxman Amendments, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;).</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &#8220;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider an &#8220;AB&#8221; therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of an &#8220;AB&#8221; rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hatch-Waxman Patent Certification and the 30-Month Stay</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, the applicant must certify with respect to each patent that:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the required patent information has not been filed;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent has expired;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union/Rest of World Government Regulation</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. The cost of establishing a regulatory compliance system for numerous varying jurisdictions can be very significant. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union (&#8220;EU&#8221;) and in other jurisdictions, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial authorization application (&#8220;CTA&#8221;) must be submitted for each clinical protocol to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance with a country&#8217;s requirements, the clinical trial may proceed.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements and process governing the conduct of clinical trials vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP the applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain regulatory approval of an investigational medicinal product under EU regulatory systems, we must submit a marketing authorization application. The content of the BLA or NDA filed in the United States is like that required in the EU, except, among other things, country-specific document requirements.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement vary from country to country.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Countries that are part of the EU, as well as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval of pharmaceutical and biologic products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Authorization Procedures in the EU</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicines can be authorized in the EU by using either the centralized authorization procedure or national authorization procedures.</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Centralized procedure. The EMA implemented the centralized procedure for the approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area (&#8220;EEA&#8221;). This procedure results in a single marketing authorization issued by the EMA that is valid across the EEA. The centralized procedure is compulsory for human medicines that are: derived from biotechnology processes, such as genetic engineering, contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions, and officially designated orphan medicines.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the European Commission following a favorable opinion by the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">National authorization procedures. There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, a Pediatric Investigation Plan (&#8220;PIP&#8221;) or a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application. A PIP describes, among other things, proposed pediatric trials and their timing relative to clinical trials in adults. A PIP will be submitted to EMA and other EU countries, as required. The PIP will need to be submitted early during product development before marketing authorization applications are submitted. The timing of PIP submission cannot be after initiation of pivotal trials or confirmatory (phase 3) trials. In the future we may seek pediatric approval for tegoprubart applications in connection with renal and islet cell transplantations, which may require the submission of a PIP.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity of New Chemical Entities and New Fixed Dose Combinations</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, new chemical entities, sometimes referred to as new active substances as well as new fixed dose combinations, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to assess a generic (abbreviated) application for eight years, after which a generic application can be submitted, and the innovator&#8217;s data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exceptional Circumstances/Conditional Approval</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drugs or drugs with unmet medical needs may be eligible for EU approval under exceptional circumstances or with conditional approval. Approval under exceptional circumstances may be applicable to orphan products and is used when an applicant is unable to provide comprehensive data on the efficacy and safety under normal conditions of use because the indication for which the product is intended is encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive information to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization may be applicable to orphan medicinal products, medicinal products for seriously debilitating or life-threatening diseases, or medicinal products to be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted on the basis of less complete data than is normally required in order to meet unmet medical needs and in the interest of public health, provided the risk-benefit balance is positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and unmet medical needs will be fulfilled. Conditional marketing authorization is subject to certain specific obligations to be reviewed annually.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accelerated Review</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, EMA ensures that the opinion of the CHMP is given within 150 days, excluding clock stops.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical Coverage, Pricing and Reimbursement</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we obtain regulatory approval. In the United States and in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third- party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Some of the provisions of the Affordable Care Act have yet to be fully implemented, while certain provisions have been subject to judicial and congressional challenges. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, that while not a law, is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the Affordable Care Act. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of the Affordable Care Act that are repealed. Thus, the full impact of the Affordable Care Act, any law replacing elements of it, or the political uncertainty surrounding its repeal or replacement on our business remains unclear. Adoption of government controls, measures and tightening of restrictive policies in jurisdictions with existing controls and measures could limit payments for pharmaceuticals.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In European countries, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, the emphasis on cost containment measures in the United States and other countries has increased, and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we obtain regulatory approval for any of our product candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal transparency laws, including the provision of the Affordable Care Act referred to as the federal Physician Payment Sunshine Act, that requires drug and biologics manufacturers to disclose payments and other transfers of value provided to physicians and teaching hospitals and ownership interests of physicians and their immediate family members;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Affordable Care Act broadened the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. &#167; 1320a-7b. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial condition and result of operations.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 25, 2024, Eledon had twenty employees, all of whom are full time. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Otic Pharma, Ltd. (&#8220;Otic&#8221;) was founded in the State of Israel in 2008. In 2015, Otic established U.S. operations and moved its corporate headquarters to Irvine, California. In 2017, Otic consummated a reverse merger with Tokai Pharmaceuticals, Inc. (&#8220;Tokai&#8221;), a Delaware corporation that was incorporated on March 26, 2004, pursuant to which, among other things, Tokai purchased from Otic and its stockholders all of the common and preferred shares of Otic in exchange for the issuance of a certain number of shares of common stock of Tokai (the &#8220;Reverse Merger&#8221;). Following the Reverse Merger, Tokai changed its name to Novus Therapeutics, Inc. On September 14, 2020, the Company acquired Anelixis Therapeutics, Inc. (&#8220;Anelixis&#8221;), a Delaware Corporation, after which Anelixis became a wholly owned subsidiary of the Company. On January 4, 2021, the Company changed its name from Novus Therapeutics, Inc. to Eledon Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive offices are located at 19900 MacArthur Boulevard, Suite 550, Irvine, California 92612. The Company also has a research and development office in Burlington, Massachusetts. Our telephone number is (949) 238-8090 and our website is www.eledon.com.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You are advised to read this Annual Report on Form 10-K in conjunction with other reports and documents that we file from time to time with the Securities and Exchange Commission (&#8220;SEC&#8221;). In particular, please read our definitive proxy statement, which will be filed with the SEC in connection with our 2023 annual meeting of stockholders, our quarterly reports on Form 10-Q and any current reports on Form 8-K that we may file from time to time. You may obtain copies of these reports after the date of this annual report directly from us or from the SEC at its website at www.sec.gov. We make our periodic and current reports available on our internet website, free of charge, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this Annual Report on Form 10-K and in our other public filings. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Operations</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our short operating history and shifts in our business strategy may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biopharmaceutical company. Our ongoing operations to date have been limited to organizing and staffing the Company, business planning, raising capital, acquiring and developing technology, identifying potential product candidates and pursuing nonclinical and clinical trials. We have not yet demonstrated our ability to successfully manufacture drug product in large enough quantities and with stability to support additional clinical trials, execute pivotal clinical trials, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. It can take many years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions made about our future success or viability based on our short operating history to date may not be as accurate as they could be if we had a longer operating history. In addition, as a result of the acquisition of Anelixis and our decision to discontinue our Company funding of the islet cell transplantation program and the IgAN program, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or previously projected by our management.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as an early-stage business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. To successfully market any of our current or future product candidates, we will need to transition from a company with a clinical development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our financial condition raises substantial doubt as to our ability to continue as a going concern.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As a result of the Private Placement described in Part I, Item 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may receive up to an additional $105.0 million in tranche financing in a second and a third closing of the Private Placement, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $45.5 million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement. Due to the contingent nature of the Common Warrants and the second and third closings of the Private Placement, the Company has excluded them from its going concern analysis. Accordingly, based on recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. Additionally, our independent registered public accounting firm has included in its audit opinion for the year ended December 31, 2023, an explanatory paragraph that there is substantial doubt as to our ability to continue as a going concern. There is no assurance that the milestones required to complete the second and third closings of the Private Placement will be satisfied, that the Common Warrants will be exercised or that other funding will be available to us, will be obtained on terms favorable to us or will provide us with sufficient funds to meet our objectives. The reaction of investors to the inclusion of a going concern statement by our auditors and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital or enter into partnerships. If we become unable to continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant operating losses since our inception and expect that we will continue to incur losses over the next several years and may never achieve or maintain profitability.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant annual net operating losses in every year since our inception. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other general and administrative expenses related to our ongoing operations. If tegoprubart or any future product candidates we develop are not successfully developed and approved, we may never generate any revenue from sales of products. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. The Company&#8217;s net loss for the year ended December 31, 2023 is $40.3 million. As of December 31, 2023, the Company had cash and cash equivalents and short-term investments of $51.1 million, working capital of $52.2 million and an accumulated deficit of $243.2 million. We have not generated any revenues from product sales, have not completed the development of any product candidate and may never have a product candidate approved for commercialization. We expect it will be several years, if ever, before we have a product candidate ready for commercialization. We have financed our operations to date primarily through the sale of preferred and common stock, and the sale of warrants and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials. Our net losses may fluctuate significantly from quarter to quarter and year to year and will depend, in part, on the rate at which we incur expenses and our ability to generate revenue. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will continue to incur significant expenses as we:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct nonclinical and clinical development of our product candidates or any future product candidate;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek to identify and acquire additional product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or in-license other products and technologies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enter into collaboration arrangements with regards to product discovery or development;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop manufacturing processes;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek marketing approvals for any of our product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional personnel;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operate as a public company.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates and manufacturing, marketing and selling those products for which we obtain marketing approval. We may never succeed in these activities, including if we do not have available financial resources to allow us to pursue clinical trials and other clinical development activities, and, even if we are successful, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the Company, could impair our ability to raise capital, maintain our nonclinical and clinical development efforts, and expand our business or continue our operations and may require us to raise additional capital that may dilute the ownership interest of common stockholders. A decline in the value of the Company could also cause stockholders to lose all or part of their investment.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require additional funding to be able to complete the development of our lead drug candidate. If we are unable to raise capital, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. As a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result of the Private Placement described in Part I, Item 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we may also receive up to an additional $105.0 million in tranche financing in a second and a third closing of the Private Placement, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $45.5 million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement. There is no assurance that the milestones required to complete the second and third closings of the Private Placement will be satisfied or that the Common Warrants will be exercised. We can also provide no assurance that other funding will be available to us, will be obtained on terms favorable to us or will provide us with sufficient funds to meet our objectives. If we are unable to raise such capital, or if we are unable to do so on acceptable terms, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. For example, we are currently unable to continue our clinical development of tegoprubart for people with ALS without additional financing, and we can provide no assurances that we will be able to obtain financing on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our funding needs may fluctuate significantly based on a number of factors, such as:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of formulation development and manufacture of drug product to support nonclinical and clinical development of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we enter into additional collaboration arrangements regarding product discovery or development, or acquire or in-license products or technologies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish additional collaborations with favorable terms, if at all;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting formulation development, nonclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Even if we generate positive clinical data or are able to successfully commercialize one or more of our product candidates, additional financing may not be available to us on acceptable terms, or at all.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In addition to the dilution of our current stockholders&#8217; ownership as a result of the Private Placement, we currently have a significant number of securities outstanding that are exercisable for our common stock, which could result in significant additional dilution and downward pressure on our stock price. Future issuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or other convertible securities, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were 24,213,130 shares of our common stock outstanding. As a result of the first closing of the of Private Placement on May 5, 2023, we issued 8,730,168 shares of our common stock, Pre-Funded Warrants to purchase 6,421,350 shares of common stock and Common Warrants to purchase 15,151,518 shares of our common stock to the Purchasers therein. Additionally, up to 20,202,024 and 25,252,530 shares of common stock or Pre-Funded Warrants may be issued in a second and third closing of the Private Placement, respectively, subject to our achievement of certain milestones and conditions (which may be waived). The issuance of the common stock in the first closing of the Private Placement diluted the ownership interests of our existing stockholders, and the issuance of shares of common stock upon exercise of the Pre-Funded Warrants or the Common Warrants issued in the initial closing of the Private Placement or any additional shares of common stock that may be issued, including pursuant to the exercise of additional Pre-Funded Warrants, in the second or third closings of the Private Placement, would result in significant additional dilution to our current stockholders, which could adversely affect the price of our common stock and the terms on which we could raise additional capital. If we sell additional shares of common stock, convertible securities or other equity securities, investors may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are in the early stages of clinical development and may not be successfully developed. If we are unable to successfully develop and commercialize these or any other product candidate, or if we experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not have any products that have gained regulatory approval. We have invested substantially all of our efforts and financial resources in the development of our lead drug candidate tegoprubart, including funding nonclinical studies, clinical trials, drug formulation and the manufacturing of clinical trial materials. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of one or more drug candidates. As a result, our business is substantially depending on our ability to successfully complete the development of and obtain approval for one of our potential future additional product candidates.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical area. For example, to execute our business plan, we will need to successfully:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain additional financing in order to advance our drug product through clinical development, and to manufacture, obtain regulatory approval for and commercialize our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">execute formulation, manufacturing, clinical, and nonclinical development activities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacture drug product at commercial scale;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish and confirm commercially acceptable stability (shelf-life) of our drug products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in-license or acquire other product candidates and advance them through clinical development;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain required regulatory approvals for the development and commercialization of tegoprubart or other product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, leverage, and expand our intellectual property portfolio;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">build and maintain robust sales, distribution and marketing capabilities, either on our own or in collaboration with strategic partners;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gain market acceptance for any approved and marketed drug products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain and maintain adequate product pricing and reimbursement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop and maintain any strategic relationships we elect to enter; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manage our spending as costs and expenses increase due to product manufacturing, nonclinical development, clinical trials, regulatory approvals, post-marketing commitments, and commercialization.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unsuccessful in accomplishing these objectives, we may not be able to successfully develop and commercialize our or other product candidates, and our business will suffer.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public health crises, including pandemics or epidemics could adversely affect our business.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business and operations, including but not limited to ongoing or planned research and development activities may be impacted by public health crises. For example, our business was adversely affected by the COVID-19 pandemic, which also caused significant disruption in the operations of third parties upon whom we rely. Other future public health crises, including any future pandemics or epidemics could have a similar impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have experienced, and may in the future experience disruptions as a result of the COVID-19 pandemic or from another public health crisis, including any future pandemic or epidemic, that could severely impact our operations and development activities, including, but not limited to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in manufacturing of our drug candidates due to increased competition for manufacturing capacity as a result of the pandemic;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations in employee resources that would otherwise be focused on the conduct of our development activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to accept data from clinical trials in affected geographies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in procuring drug substance and/or in manufacturing drug product due to limitations in employee resources or forced furloughs at our contract manufacturing organizations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in initiation of future clinical trials, including delays in receiving authorization from local regulatory authorities to initiate such clinical trials; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or disturbances in enrollment and trial execution, for example, because clinical trial sites may be unable to operate normally, or patients may elect to forego visits to medical facilities or undertake voluntary medical procedures.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing factors, or other effects of any public health crisis, including any future pandemic or epidemic, could materially affect our business, possibly to a significant degree. The severity and duration of any such impacts cannot be predicted.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition and results of operations</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global economy, including the financial and credit markets, continues to experience extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, rising interest rates and uncertainty about economic stability. Likewise, the current conflicts in Ukraine and the Middle East have created extreme volatility in the global capital markets and global economic consequences, including disruptions of the global supply chain and energy markets. A severe or prolonged economic downturn or continued volatility in the financial and credit markets could negatively impact our ability to obtain necessary debt or equity financing in a timely manner or on favorable terms, if at all. The severity and duration of any such impacts cannot be predicted. Any such failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies or cause us to delay our clinical development plans, research and development programs or commercialization efforts, out-license intellectual property rights to our product candidates or sell unsecured assets, or a combination of the above. Any of these actions could materially harm our business. For example, we do not currently have sufficient liquidity to fund the continued clinical development of tegoprubart for people with ALS without additional financing, notwithstanding the positive topline results of our Phase 2a study of tegoprubart for adult subjects with ALS. In addition, if we are unable to raise capital, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, inflation has recently increased throughout the U.S. economy. As a result of inflation, we have experienced and may continue to experience cost increases, including costs of clinical trials and research and development of our product candidates, production costs, the price of labor, administration and other costs of doing business. Although we may continue to take measures to mitigate the impact of this inflation, if these measures are not effective, our business, financial condition, results of operations and liquidity could be materially adversely affected. Further, in an inflationary environment, cost increases may outpace our expectations, causing us to use our cash and other liquid assets faster than forecasted. If this happens, we may need to raise more capital to fund our operations than expected, and such capital may not be available in sufficient amounts or on reasonable terms, if at all.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financial performance.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently maintain domestic cash deposits, for short term operating requirements, in Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured banks, which exceed the FDIC insurance limits. Our additional cash and cash equivalents are held in accounts managed by third&#8209;party financial institutions and consist of primarily of cash invested in money market funds and government bonds. Bank failures, events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, or concerns or rumors about such events, may lead to widespread demands for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customer withdrawals and liquidity constraints that may result in market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank failed and was taken into receivership by the FDIC. At that time, we maintained deposits amounting to approximately 78% of our total cash at Silicon Valley Bank. On March 26, 2023, the assets, deposits and loans of Silicon Valley Bank were acquired by First-Citizens Bank &amp; Trust Company. In response to the failure of Silicon Valley Bank, we diversified our cash deposits into money market funds, U.S. treasuries and U.S. government agency securities and, as of the date of this report, our total cash maintained in FDIC insured banking accounts is less than 3% of our total cash and cash equivalents and short-term investments. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S. or any applicable foreign government in the future or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a future failure or liquidity crisis. Additionally, our cash investments outside of FDIC insured bank accounts are subject to general credit, liquidity, market, and interest rate risks. If the carrying value of an investment exceeds the fair value, and the decline in fair value is deemed to be other-than-temporary, we are required to write down the value of the investment, which could materially harm our results of operations and financial condition and could limit our access to liquidity.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug development involves a lengthy and expensive process with an uncertain outcome, including failure to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the formulation and commercialization of our product candidates.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the early stage of development for our product candidates, the risk of failure is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct nonclinical trials, and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Formulation and device development, nonclinical and clinical testing are all expensive activities, difficult to design and implement, and can take years to complete. Failure can occur at any time during the development program, including during the clinical trial process. Further, the results of nonclinical studies and early clinical trials of our product candidates, as well as earlier generation formulations may not be predictive of the results of later-stage clinical trials. Interim results of a clinical trial do not necessarily predict final results. Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in nonclinical and clinical trials have nonetheless failed to obtain marketing approval of their products. There is a risk that additional nonclinical and/or clinical safety studies will be required by the FDA or similar regulatory authorities outside the United States and/or that subsequent studies will not match results seen in prior studies. It is impossible to predict when or if any of our product candidates will prove effective, safe and well-tolerated in humans or will receive regulatory approval.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in our clinical trials, and we do not know whether planned clinical trials will begin or enroll subjects on time, need to be redesigned or be completed on schedule, if at all. There can be no assurance that the FDA or equivalent foreign regulatory bodies will approve investigational new drug applications and allow us to start clinical trials for any of our product candidates in the future, including for islet cell transplant. Once a clinical trial has commenced, there is also no assurance that the FDA or equivalent foreign regulatory body will not put any of our product candidates on clinical hold. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates. Clinical trials may be delayed, suspended or prematurely terminated for a variety of reasons, such as:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we want to execute;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in completing formulation development and manufacturing as a prerequisite to commencing clinical work;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability, delay, or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in other clinical programs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or failure in having subjects complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials and increased expenses associated with the services of our contract research organizations (&#8220;CROs&#8221;) and other third parties;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays or difficulties in the enrollment of patients that our product candidates are designed to target;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may have difficulty partnering with experienced CROs and study sites that can identify patients that our product candidates are designed to target and run our clinical trials effectively;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be changes in governmental regulations or administrative actions. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA. For example, a prolonged shutdown may significantly delay the FDA's ability to timely review and process any submissions we may file or cause other regulatory delays, which could materially and adversely affect our business.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, or if there are safety concerns, we may:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not obtain marketing approval at all;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings that would reduce the potential market for our products or inhibit our ability to successfully commercialize our products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to additional post-marketing restrictions and/or testing requirements; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have the product removed from the market after obtaining marketing approval.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our nonclinical studies or clinical trials will need to be restructured or will be completed on schedule, or at all. Significant nonclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or may allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented and expenses for the development of our product candidates could increase.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to demonstrate safety and efficacy. We do not know whether the ongoing or planned clinical trials will enroll subjects in a timely fashion, require redesign of essential trial elements or be completed on its projected schedule. In addition, competitors may have ongoing clinical trials for product candidates that treat related or the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment is affected by other factors including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for the study in question;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same disease indication;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ambiguous or negative interim results of our clinical trials, or results that are inconsistent with earlier results;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">feedback from regulatory authorities, IRBs, ethics committees (&#8220;ECs&#8221;), or data safety monitoring boards, or results from earlier stage or concurrent nonclinical and clinical trials, that might require modifications to the protocol;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decisions by regulatory authorities, IRBs, ECs, or the Company, or recommendations by data safety monitoring boards, to suspend or terminate clinical trials at any time for safety issues or for any other reason; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unacceptable risk-benefit profile or unforeseen safety issues or adverse effects.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to conduct clinical trials in some jurisdictions outside of the United States may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have clinical trial sites in regions outside the United States, including Asia, the European Union and the United Kingdom, and we will continue to conduct future clinical trials in these markets. Our ability to conduct clinical trials at sites located outside the United States is subject to numerous risks unique to conducting business in jurisdictions outside the United States, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in establishing or managing relationships with qualified CROs, physicians and clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different local standards for the conduct of clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in complying with various and complex import laws and regulations when shipping drugs to certain countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential burden of complying with a variety of laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of consistency in standard of care from country to country;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished protection of intellectual property in some countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign exchange fluctuations;</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural differences in medical practice and clinical research; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in country or regional regulatory requirements.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ongoing conflict in Ukraine and the resulting imposition of economic and other sanctions by the United States, European Union and many other nations on Russia, individuals in Russia, Russian businesses and the Russian central bank, or any escalation of tensions in the region, could have a broader impact that expands into other countries. The ongoing conflict in the Middle East could have similar impacts. Although the length and impact of any military action and expansion of the conflict into other countries are highly unpredictable, if either conflict spreads or has effects on additional countries, we may experience disruptions or delays in our plans to conduct clinical trial activities in affected regions outside the United States.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are associated with undesirable effects in nonclinical or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Any occurrences of clinically significant adverse events with our product candidates may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tegoprubart is an early&#8209;product candidate, and the side effect profile in humans has not been fully established. Currently unknown, drug-related side effects may be identified through ongoing and future clinical trials and, as such, these possible drug-related side effects could affect patient recruitment, the ability of enrolled subjects to complete the trial, or result in potential product liability claims.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the product development, clinical and business development expertise of the principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executives and key employees, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Our recent decision to discontinue the islet cell transplantation program and IgAN program and uncertainties regarding our financial condition may increase the likelihood that employees depart in the foreseeable future.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recruiting and retaining qualified scientific, clinical, manufacturing, sales and marketing personnel is critical to our success. Due to the small size of the Company and the limited number of employees, each of our executives and key employees serves in a critical role. The loss of the services of our executive officers or other key employees could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of, and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating drug product, nonclinical development, clinical development, regulatory strategy, and commercial strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to provide services to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for a narrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may be materially impaired.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates must be approved by the FDA pursuant to a new drug application in the United States and by other regulatory authorities outside the United States prior to commercialization in the respective regions. The process of obtaining marketing approvals, both in the United States and outside the United States, is expensive and takes several years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any country. We have no experience in filing and supporting the applications necessary to gain marketing approvals for our products and may engage third-party consultants to assist in this process. Securing marketing approval requires the submission of extensive nonclinical and clinical data, and other supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product formulation and manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other data. In addition, varying interpretations of the data obtained from nonclinical and clinical trials could delay, limit or prevent marketing approval of a product candidate. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an application.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any marketing approval we ultimately obtain may be for fewer or more limited indications than requested or subject to restrictions or post-approval commitments that render the approved product not commercially viable or its market potential significantly impaired. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market and sell our products in the EU and other international jurisdictions outside of the United States, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may require additional nonclinical, clinical or health outcome data. In addition, the time required to obtain approval may differ substantially amongst international jurisdictions. The regulatory approval process outside the United States generally includes all the risks associated with obtaining FDA approval. In addition to regulatory approval, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation that are specific to those defined by regulatory authorities in the countries where the product is approved. In the United States and other countries that follow the International Conference on Harmonization, these requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities, requirements regarding the distribution of samples to physicians and recordkeeping.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA, or other regulatory authorities, may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products and if we promote our products beyond their approved indications, we may be subject to enforcement action for off-label promotion. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on such products, manufacturers, or manufacturing processes;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning or untitled letters;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of the products from the market;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes intended to contain healthcare costs and modify the regulation of drug and biologic products. These and other regulatory changes could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, on August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022, which, among other things, includes policies that are designed to have a direct impact on drug prices and reduce drug spending by the federal government, which shall take effect in 2023. The Inflation Reduction Act requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for certain drugs used by Medicare beneficiaries. The mechanics of the rebate calculation would mimic those of the Medicaid rebate, but the expansion of inflation-based rebates may further complicate pricing strategies. The Inflation Reduction Act of 2022 or other similar legislation could have the effect of reducing the prices we can charge and reimbursement we receive for our products, thereby reducing our profitability.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that additional state and federal healthcare reform measures and regulations will be adopted in the future. Any of these measures and regulations could limit the amounts that federal and state governments will pay for healthcare products and services, result in reduced demand for our product candidates or additional pricing pressures and affect our product development, testing, marketing approvals and post-market activities.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laws, restrictions, and other regulatory measures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for us to obtain marketing approval and commercialization of our product candidates and which may affect the prices we may obtain.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations and relationships with healthcare providers, physicians, third-party payers, and customers will be subject to applicable anti-kickback, fraud and abuse and other broadly applicable healthcare laws, which could expose us to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians and third-party payers will play a primary role in the recommendation and prescription of any product candidates for which we receive marketing approval. Our current and future arrangements may expose us to broadly applicable fraud and abuse and other healthcare laws that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute the products for which we receive marketing approval. Even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payers, federal and state healthcare laws are and will be applicable to our business. Such laws include, but are not limited to federal false claims, false statements and civil monetary penalties laws, including the federal civil False Claims Act (&#8220;FCA&#8221;), the federal Anti-Kickback Statute, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), patient data privacy and security regulation, including, in the United States, HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 (&#8220;HITECH&#8221;), the federal transparency requirements under the Physician Payments Sunshine Act, and analogous state, local or foreign law.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laws, restrictions, and other regulatory measures are also imposed by anti-kickback, fraud and abuse, and other healthcare laws and regulations in international jurisdictions, and in those jurisdictions we face the same issues as in the United State regarding exposure to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm, and diminished profits and future earnings.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on our information systems and those of our third-party collaborators, service providers, contractors or consultants. Our information systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our development programs or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and have a material adverse effect on our reputation, business, financial condition or results of operations.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. Our information systems and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infrastructure, and those of our current or future third-party collaborators, service providers, contractors and consultants are vulnerable to damage from cybersecurity incidents, including computer viruses, denial-of-service attacks, hacking, phishing and other social engineering attacks, unauthorized access or use resulting from malware, as well as disruptions due to natural disasters, terrorism, war and telecommunication and electrical failures. We may also experience cybersecurity incidents stemming from persons inside our organizations (including employees or contractors), or other persons with access to information systems inside our organization. Attacks on information systems are increasing in their frequency, levels of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized foreign governments, groups and individuals with a wide range of motives and expertise. In addition to extracting or accessing sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the security, confidentiality, integrity and availability of information. The prevalent use of mobile devices that access sensitive information also increases the risk of data security incidents which could lead to the loss of confidential information or other intellectual property. While to our knowledge we have not experienced any material information system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or the operations of third-party collaborators, service providers, contractors and consultants, it could result in a material disruption of our development programs and significant reputational, financial, legal, regulatory, business or operational harm. The costs to us to mitigate, investigate and respond to potential security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the loss of clinical trial data from completed, ongoing or planned clinical trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any real or perceived security breach affects our information systems (or those of our third-party collaborators, service providers, contractors or consultants), or results in the loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could be found to have violated applicable U.S. and international privacy, data protection and other laws, which could subject us to litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the U.S. and by international regulatory entities, resulting in exposure to material civil and/or criminal liability. and the further development of our product candidates could be delayed. Such a breach may require notification to governmental agencies, the media or individuals pursuant to various foreign, domestic (federal and state) privacy and security laws, if applicable, including HIPAA, as amended by HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to cybersecurity incidents.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure or perceived failure by us or any third-party collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations, or any data security incidents or other security breaches that result in the accidental, unlawful or unauthorized access to, use of, release of, processing of, or transfer of sensitive information, including personally identifiable information, may result in negative publicity, harm to our reputation, governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us, could cause third parties to lose trust in us or could result in claims by third parties, including those that assert that we have breached our privacy, confidentiality, data security or similar obligations, any of which could have a material adverse effect on our reputation, business, financial condition or results of operations. To the extent we maintain individually identifiable health information, we could be subject to fines and penalties (including civil and criminal) under HIPAA for any failure by us or our business associates to comply with HIPAA&#8217;s requirements. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to increased harm. While we have implemented data security measures intended to protect our information, data, information systems, applications and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or cybersecurity incidents.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may collect, process, use or transfer personal information from individuals located in the European Economic Area in connection with our business, including in connection with conducting clinical trials in the EEA. Additionally, if any of our product candidates are approved, we may seek to commercialize those products in the European Economic Area. The collection and use of personal health data in the European Economic Area is governed by the provisions of the General Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Protection Regulation ((EU) 2016/679) (the &#8220;GDPR&#8221;), along with other European Union and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data protection laws and regulations. These legislative acts (together with regulations and guidelines) impose requirements relating to having legal bases for processing personal data relating to identifiable individuals and transferring such data outside of the European Economic Area, including to the United States, providing details to those individuals regarding the processing of their personal data, keeping personal data secure, having data processing agreements with third parties who process personal data, responding to individuals&#8217; requests to exercise their rights in respect of their personal data, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers or corporate representatives, conducting data protection impact assessments and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the European Economic Area and other states in the European Economic Area may result in substantial fines, other administrative penalties and civil claims being brought against us, which could have a material adverse effect on our business, financial condition and results of operations. European data protection authorities may interpret the GDPR and national laws differently and may impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our nonclinical or clinical development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Commercialization of Our Product Candidates</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payers and others in the medical community. In addition, physicians, patients and third-party payers may prefer other novel products to ours. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety and potential advantages and disadvantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to offer our products for sale at competitive prices;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of our marketing and distribution support;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement, including patient cost-sharing programs such as copays and deductibles;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to develop or partner with third-party collaborators to develop companion diagnostics;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of our products together with other medications.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our current product candidates, or a future product candidate receives marketing approval and we, or others, later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, the ability to market the product could be compromised.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent beneficial effect of a product candidate that is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater than the actual positive effect in a broader patient population or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following events could occur:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or seize the product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product may be required to be recalled or changes may be required to the way the product is administered;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the creation of a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional restrictions may be imposed on the distribution or use of the product via a Risk Evaluation and Mitigation Strategy;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product may become less competitive; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could have a material and adverse effect on our operations and business. The commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no marketing and sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming, will require significant attention of our executive officers to manage and may nonetheless fail to effectively market and sell our product candidates. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our products that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, there are a number of companies developing competing anti-CD40 and anti-CD40L therapeutics in clinical trials for transplant, autoimmune or central nervous system indications, including: Novartis, Sanofi, UCB, Amgen (post-acquisition of Horizon Therapeutics), Bristol Myers Squibb, and Kiniksa. All of these companies are larger than Eledon and have significantly greater resources to develop their drug candidates.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved, we expect that tegoprubart will face competition from numerous FDA-approved therapeutics for the prevention of transplant rejection, including PROGRAF</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, ASTAGRAF XL</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, ENVARSUS XR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, NULOJIX</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, CELLCEPT</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, MYFORTIC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and numerous other branded and generic immunosuppressive agents. Multiple companies are working on islet cell and kidney transplant solutions that may ultimately potentially negate the need for immunosuppressive agents in these indications altogether.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that tegoprubart will face competition from FDA-approved therapeutics for the treatment of ALS including RADICAVA&#174;, RELYVRIO&#153;, RILUZOLE, and numerous other branded and generic immunosuppressive agents. Multiple pharmaceutical and biotechnology companies, including but not limited to Biogen, Ionis Pharmaceuticals, Alexion Pharmaceuticals, Orion Pharma, Orphazyme, AZTherapies, Voyager Therapeutics, Apic Bio, Brainstorm Cell Therapeutics, and Cytokinetics, are also working on competing ALS pharmaceutical, gene therapy and cell therapy approaches.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generic products are currently available, with additional generic products expected to become available over the coming years, potentially creating pricing pressure. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, conducting nonclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payers, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Increased expense is incurred to cover costs of health outcome focused research used to generate data necessary to justify the value of our products in order to secure reimbursement. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many private payers contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our products.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates or products that we may develop; injury to our reputation and significant negative media attention; withdrawal of clinical trial participants; significant costs to defend the related litigation; substantial monetary awards to trial participants or patients; loss of revenue; reduced resources of our management to pursue our business strategy; and the inability to commercialize any products that we may develop.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of our product candidates for nonclinical and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have utilized, and intend to continue utilizing, third parties to formulate, manufacture, package, and distribute clinical supplies of our drug candidates. We have no experience in manufacturing and do not have any manufacturing facilities. Currently, we rely on third parties for the manufacturing of drug substance and drug product for nonclinical and clinical activities. Our manufacturing vendors utilize proprietary cell culture media, cell lines, buffers, manufacturing equipment, manufacturing supplies, and storage buffers for the manufacturing of tegoprubart and other product candidates. These materials are custom-made and available from only a limited number of sources. Although we believe that our third-party suppliers maintain a significant supply of these materials and equipment on hand, any sustained disruption in this supply, could adversely affect our operations. We do not have any long-term agreements in place with our current suppliers. If we are required to change manufacturers, we may experience delays associated with finding an alternate manufacturer that is properly qualified to produce supplies of our products and product candidates in accordance with regulatory requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and our specifications. Any delays or difficulties in obtaining or in manufacturing, packaging or distributing approved product candidates could negatively impact our clinical trials.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to rely on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of any other product candidates for which our collaborators or we obtain marketing approval. Despite drug substance and product risk management, this reliance on third parties presents a risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. For example, these third parties experienced disruptions in their operations in conjunction with the COVID-19 pandemic. Any delay or performance failure on the part of our existing or future manufacturers of drug substance or drug products could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply. If suppliers cannot supply us with our requirements, we may be required to identify alternative manufacturers, which would lead us to incur added costs and delays in identifying and qualifying any such replacement.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Formulations and devices used in early studies are not final formulations and devices for commercialization. Additional changes may be required by the FDA or other regulatory authorities on specifications and storage conditions. These may require additional studies and may result in a delay in our clinical trials and commercialization activities.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also expect to rely on other third parties to label, store, and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The third parties we rely on for manufacturing and packaging are also subject to regulatory review, and any regulatory compliance problems with these third parties could significantly delay or disrupt our clinical or commercialization activities. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Additionally, macro-economic conditions may adversely affect these third parties, causing them to suffer liquidity or operational problems. If a key third-party vendor becomes insolvent or is forced to lay off workers assisting with our projects, our results and development timing could suffer.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on CROs and other contracted third parties to perform nonclinical and clinical testing and certain other research and development activities. As a result, the outcomes of the activities performed by these organizations will be, to a certain extent, beyond our control.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The nature of outsourcing a substantial portion of our business will require that we rely on CROs and other contractors to assist us with research and development, clinical testing activities, patient enrollment, data collection, and regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submissions to the FDA or other regulatory bodies. As a result, our success will depend partially on the success of these third parties in performing their responsibilities. Although we intend to pre-qualify our CROs and other contractors and we believe that the contractors selected will be fully capable of performing their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to these activities. Additionally, macro-economic conditions may affect our development partners and vendors, which could adversely affect their ability to timely perform their tasks. If our contractors do not perform their obligations in an adequate and timely manner, the pace of clinical development, regulatory approval and commercialization of our drug candidates could be significantly delayed, and our prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain intellectual property protection for our technology and products or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in relevant countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and internationally that are related to our novel technologies and product candidates. This patent portfolio includes issued patents and pending patent applications covering pharmaceutical compositions and methods of use.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, India and China do not allow patents for methods of treating the human body. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the EU, the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risks described pertaining to our patents and other intellectual property rights also apply to the intellectual property rights that we license, and any failure to obtain, maintain and enforce these rights could have a material adverse effect on our business. In some cases, we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain and enforce the licensed patents. Any inability on our part to protect adequately our intellectual property may have a material adverse effect on our business, operating results and financial position.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The USPTO and various non-U.S. governmental patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In certain situations, non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Institute, and may in the future enter into other license agreements with third parties for other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property rights or assets. These license agreements may impose various diligence, milestone payment, royalty, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our drug candidates than if we had developed the licensed technology internally.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, patent prosecution of our licensed technology may be controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we may control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly, or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. If we were not able to obtain a license or are not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly materially.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Any NDAs or similar agreements entered into by the Company may not be with all relevant parties, or adequately protect the confidentiality of our trade secrets. Moreover, to the extent we enter into such agreements, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate them, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims of misappropriation of trade secrets from former employers of Company personnel.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees and certain of our directors were previously employed at or affiliated with research foundations or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees and directors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees or directors have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s or director&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect our stock price to be volatile, and the market price of our common stock may drop unexpectedly.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biopharmaceutical, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertainties regarding our financial condition and our ability to raise sufficient capital to fund our ongoing operations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain regulatory approvals for our product candidates or other product candidates, and delays or failures to obtain such approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of any of our product candidates, if approved, to achieve commercial success;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issues in manufacturing our approved products, if any, or product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our current and any future clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the entry into, or termination of, key agreements, including key commercial partner agreements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation of, material developments in, or conclusion of litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by commercial partners or competitors of new commercial products, clinical progress, or the lack thereof, significant contracts, commercial relationships, or capital commitments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the introduction of technological innovations or new therapies that compete with our potential products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the loss of key employees;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, who cover our common stock;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general and industry-specific economic conditions that may affect our research and development expenditures;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period-to-period fluctuations in our financial results; and</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future issuances of shares of common stock.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that we will have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully maintain internal controls over financial reporting, the accuracy and timing of our financial reporting, and our stock price, may be adversely affected and we may be unable to maintain compliance with the applicable stock exchange listing requirements. Additionally, as we become a larger company, we will become subject to Section 404(b) of the Sarbanes-Oxley Act, which requires our independent auditors to document and test our internal controls. These additional requirements are costly, and our auditors may identify control deficiencies.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Implementing any appropriate changes to our internal controls may distract the officers and employees of the Company, entail substantial costs to modify its existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of the internal controls of the Company, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase operating costs and harm the business. In addition, investors&#8217; perceptions that the internal controls of the Company are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm the stock price of the Company.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of the Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our corporate charter and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the Company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by stockholders to replace or remove the current management by making it more difficult for stockholders to replace members of our Board. Among other things, these provisions:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified Board such that not all members of the Board are elected at one time;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our Board;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from our Board;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit who may call stockholder meetings;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our Board to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board; and</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of the Company&#8217;s charter or bylaws.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not expect to pay any cash dividends in the foreseeable future.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain, if any, for any stockholders for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d Staff Comments.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategy and Oversight</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical studies and employees, or our information systems and the data contained therein.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We retain a Chief Information Consultant to collaborate with the company, including the Chief Financial Officer, and Executive Leadership Team, to help identify, assess and manage the company&#8217;s cybersecurity threats and risks. This group identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example, automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and actors, and evaluating threats reported to us. We also use a third-party security management vendor to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our information systems, including, for example, incident detection and response policy, route risk assessments, data encryption, network security controls, data segregation, access controls, physical security, asset management, tracking and disposal, systems monitoring, penetration testing, and cybersecurity insurance. As part of our information security program, we provide mandatory periodic training for all employees on how to identify potential cybersecurity risks and protect our resources and information. This training is supplemented by firmwide testing initiatives, including periodic phishing tests.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. For example, the Chief Information Consultant works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. In addition, our Chief Financial Officer evaluates material risks from cybersecurity threats and, as appropriate, reports to the Audit Committee of the Board of Directors, which evaluates our overall enterprise risk.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we do not believe that known risks from cybersecurity threats, including as a result of any previous cybersecurity incidents that we are aware of, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. However, we can give no assurance that we have detected or protected against all such cybersecurity incidents or threats. For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including the risk factor titled &#8220;We depend on our information systems and those of our third-party collaborators, service providers, contractors or consultants. Our information systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our development programs or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and have a material adverse effect on our reputation, business, financial condition or results of operations.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board addresses our cybersecurity risk management as part of its general oversight function. The Audit Committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats. Our cybersecurity risk assessment and management processes are implemented and maintained by our Chief Financial Officer who oversees the work performed by our Chief Information Consultant.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Chief Financial Officer is responsible for hiring appropriate consultants, helping to integrate cybersecurity risk considerations into our overall risk management strategy and communicating key priorities to relevant personnel. Our Chief Financial Officer, with support from our Chief Information Consultant, is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Audit Committee receives periodic reports from our Chief Financial Officer concerning our significant cybersecurity threats and risks and the processes we have implemented to address them. The Audit Committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation. The Chief Financial Officer also promptly informs and updates the Board about any information security incidents that may pose significant risk to our Company.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Chief Financial Officer has over 20 years of operations and leadership experience, including experience in information technology strategy and execution. The Chief Information Consultant has over 20 years of experience managing and securing technology infrastructure.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive offices are located in Irvine, California. We lease approximately 5,197 square feet of office space under an operating lease that expires on December 31, 2024. Additionally, we have an operating lease for approximately 6,138 square feet of office space in Burlington, Massachusetts, that expires on November 20, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Proceedings.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Neither we nor any of our subsidiaries is a party to, and none of their respective property is the subject of, any material legal proceeding, although we are from time-to-time party to legal proceedings that arise in the ordinary course of our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;ELDN&#8221;.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 25, 2024, there were approximately 44 stockholders of record of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our common stock. Future determination as to the declaration and payment of dividends, if any, will be at the discretion of our Board and will depend on then existing conditions, including our operating results, financial condition, contractual restrictions, capital requirements, business prospects and other factors that our Board may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eserved]</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is intended to help the reader understand the results of operations and financial condition of the Company. The Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2023. In addition to historical information, this Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this report. Our actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under the Part I, Item 1A. Risk Factors section and elsewhere in this report, as well as, in other reports and documents we file with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RECENT DEVELOPMENTS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strategic Updates</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we announced our decision to prioritize resources on our kidney transplantation programs, discontinue the Company funded islet cell transplantation program and the IgAN program. We also remain committed to further progressing ALS clinical development and are working with key stakeholders on potential next steps to do so. However, we are unable to continue our clinical development of tegoprubart for people with ALS without additional financing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Equity Distribution Agreement</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 31, 2021, we filed a registration statement on Form S-3 containing a prospectus and prospectus supplement under which we may offer and sell up to $75.0 million in shares of our common stock, from time to time, pursuant to an open market sale agreement with Jefferies LLC and by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the &#8220;ATM Program&#8221;). Pursuant to the &#8220;baby shelf rules&#8221; promulgated by the SEC, if our public float is less than $75.0 million as of specified measurement periods, the number of shares of common stock that may be offered and sold by us under a Form S-3 registration statement, including pursuant to the ATM Program, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the Company&#8217;s public float.  As of December 31, 2023, due to the SEC&#8217;s &#8220;baby shelf rules,&#8221; we were permitted to sell up to $12.3 million of shares of common stock pursuant to the ATM Program. We will remain subject to the &#8220;baby shelf rules&#8221; under the Form S-3 registration statement until such time as our public float exceeds $75.0 million. During the years ended December 31, 2023 and 2022, no shares were sold under the Prospectus. This Form S-3 registration statement pursuant to which the ATM Program is registered will expire in May 2024, and no shares of common stock may be sold under the ATM Program after that date.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">September 2021 Exchange Agreement</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 21, 2021, we issued warrants exercisable for 298,692 shares of common stock in exchange for warrants exercisable for 5,376.456 shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock previously issued as part of the Anelixis merger. We replaced these Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock warrants for the outstanding warrants issued by Anelixis that were not settled upon completion of the merger. For information regarding the terms of our Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock, see Note 10 of the Notes to Financial Statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Exchange Agreement</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 11, 2022, we entered into an exchange agreement (the &#8220;Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange Agreement&#8221;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, L.L.C. (collectively, the &#8220;BVF Exchanging Stockholders&#8221;), pursuant to which the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchanging Stockholders exchanged (the &#8220;Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange&#8221;) 550,000 shares of our common stock for 9,899.99 shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Convertible Preferred Stock. For information regarding the terms of our Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-Voting Convertible Preferred Stock, see Note 10 of the Notes to Financial Statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Securities Purchase Agreement</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, we entered into an agreement (the :Securities Purchase Agreement") with certain institutional and accredited investors (the "Purchasers"), pursuant to which we agreed to issue and sell to the Purchasers in a Private Placement (i) in an initial closing, (a) an aggregate of 15,151,518 shares (the &#8220;Shares&#8221;) of our common stock, $0.001 par value per share, or pre-funded warrants in lieu thereof (the &#8220;Pre-Funded Warrants&#8221;), and (b) common stock warrants exercisable into an aggregate of 15,151,518 shares of common stock (or Pre-Funded Warrants in lieu thereof) (the &#8220;Common Warrants&#8221; and, together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;); (ii) in a second closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of 20,202,024 shares of common stock (or Pre-Funded Warrants); and (iii) in a third closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of 25,252,530 shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the Securities Purchase Agreement, Pre-Funded Warrant agreement or Common Warrant agreement, as applicable. Each Common Warrant has an exercise price of $3.00 per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of $0.001 per share. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 5, 2023, the initial closing occurred and we received $35.0 million, or net proceeds of approximately $33.0 million after deducting offering costs, in exchange for 8,730,168 shares of common stock and Pre-Funded Warrants to purchase 6,421,350 shares of common stock. We may receive an additional $105.0 million upon sale of the shares to be issued in the second and third closings, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $45.5 million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Private Placement, we filed on May 18, 2023, a registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The Registration Statement became effective on June 2, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Conversion Agreement of Non-Voting Convertible Preferred Stock</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 16, 2023, Cormorant Global Healthcare Master Fund LP provided us notice of its intention to convert (i) 1,782 shares of Series X Non-Voting Convertible Preferred Stock for 99,000 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting Convertible Preferred Stock, and (ii) 7,883.586 shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock for 437,977 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023. For information regarding the terms of our Series X and Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock, see Note 10 of the Notes to Financial Statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Exercise of Pre-Funded Warrants</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 10, 2023, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase 501,197 shares of common stock at an exercise price of $0.001 per share, which were issued in conjunction with the Securities Purchase Agreement. On July 14, 2023, we issued 501,197 shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 2, 2023, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase 653,000 shares of common stock at an exercise price of $0.001 per share, which were issued in conjunction with the Securities Purchase Agreement. On November 6, 2023,we issued 653,000 shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, 21,564,302 warrants were exercisable into common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers). The shares of common stock underlying the registered direct and private placement warrants are registered for offer and sale under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to our effective registration statements on Forms S-1.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series X</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Preferred Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, 50,207.419 warrants were exercisable into Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock which are convertible into 2,789,301 shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers). For information regarding the terms of our Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock, see Note 10 of the Notes to Financial Statements included in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities as of the date of the financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company&#8217;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions that are subjective and require significant judgment and estimation by management. The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. The expected dividend assumption was based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units (&#8220;RSU&#8221;) are measured and recognized based on the quoted market price of our common stock on the date of grant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RESULTS OF OPERATIONS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides comparative results of operations for the years ended December 31, 2023 and 2022 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.081%;"/>
    <td style="width:1.681%;"/>
    <td style="width:1%;"/>
    <td style="width:12.549%;"/>
    <td style="width:1%;"/>
    <td style="width:1.681%;"/>
    <td style="width:1%;"/>
    <td style="width:12.549%;"/>
    <td style="width:1%;"/>
    <td style="width:1.681%;"/>
    <td style="width:1%;"/>
    <td style="width:12.549%;"/>
    <td style="width:1%;"/>
    <td style="width:1.221%;"/>
    <td style="width:1%;"/>
    <td style="width:13.009%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$ Variance</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">% Variance</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,312</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,080</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,688</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,700</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(48,648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(45,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-51</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(43,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(88,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,674</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,212</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">479</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(40,326</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(87,966</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,640</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased $3.2 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. The increase was primarily due to higher clinical development expenses, primarily with external CROs of $5.0 million, and an increase in personnel related costs of $1.2 million, due to increased headcount. The increase was partially offset by a decrease in stock-based compensation of $1.7 million, lower manufacturing costs of $1.0 million, related to the production of clinical trial materials, and a decrease in consulting expenses of $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were consistent for the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill Impairment</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized $48.6 million of goodwill impairment for the year ended December 31, 2022. No impairment was recorded for the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $2.2 million increase in other income, net was primarily due to an increase in interest income associated with higher interest rates on our cash and cash equivalents and short-term investments for the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LIQUIDITY AND CAPITAL RESOURCES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any approved products for commercial sale and have never generated revenue from product sales and have incurred significant net losses since our inception and expect to continue to incur net operating losses for the foreseeable future. We do not expect to receive any revenue from any product candidates that we develop unless and until we obtain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory approval and commercialize our product candidates or enter into collaborative arrangements with third parties. We currently have no credit facility or committed sources of capital.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents and short-term investments of approximately $51.1 million. To date, our operations have been financed primarily by net proceeds from the sale of preferred and common stock,  and the sale of warrants. Additionally, in view of our expectation to incur significant losses for the foreseeable future we will be required to raise additional capital resources in order to fund our operations, although the availability of, and the Company&#8217;s access to, such resources is not assured. Accordingly, management believes that there is substantial doubt regarding our ability to continue operating as a going concern. We have based this estimate on assumptions that may prove to be incorrect, and we could utilize our available resources sooner than we currently expect. In addition, we may receive up to an additional $105.0 million in tranche financing in a second and a third closing of the Private Placement, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $45.5 million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement. There is no assurance that the milestones required for the second and third closings will be satisfied or that the Common Warrants will be exercised. If these events do not occur or we are unable to secure additional capital or to do so on acceptable terms, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. Further, from time to time, our operating plans may change, and we may need additional funds to meet operational needs for clinical studies sooner than planned or to fund additional clinical studies. For example, we do not currently have sufficient liquidity to fund the continued clinical development of tegoprubart for people with ALS without additional financing, notwithstanding the positive topline results of our Phase 2a study of tegoprubart for adult subjects with ALS. We will continue to monitor our liquidity position in light of various financing alternatives and may pursue additional financing or other alternatives to allow us to continue our product development. However, there can be no assurance such financing or other alternatives will be available to us on acceptable terms, or at all.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our primary use of cash is to fund operating expenses, which consist of clinical research and development expenses, manufacturing expenses, legal and compliance expenses, compensation and related expenses, and general overhead costs. Cash used to fund operating expenses is impacted by the timing of when we pay or prepay these expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase in connection with our ongoing activities, particularly as we expand our clinical program with tegoprubart, continue the research and development of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will continue to require additional financing in order to advance our drug product through clinical development, to manufacture, obtain regulatory approval for and to commercialize our product candidates, to develop, acquire or in-license other potential product candidates, and to fund operations for the foreseeable future. Therefore, we will seek to raise additional capital through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. The ability to raise substantial additional capital will depend on many factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, progress, timing, costs and results of our ongoing and future clinical trials of tegoprubart, including as such activities may be adversely impacted by global events or macroeconomic conditions; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of global macroeconomic trends and uncertainties, which continue to experience volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, rising interest rates and uncertainty about economic stability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of indications we decide to pursue for tegoprubart development; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost, timing and outcome of regulatory review of any biologics license application, or BLA, we may submit for tegoprubart;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of manufacturing for tegoprubart, if approved;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of tegoprubart;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with being a public company; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost associated with commercializing tegoprubart, if approved for commercial sale.</span></div></div>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conditions in the financial and credit markets may also limit the availability of funding or increase the cost of funding. As a result of any of the foregoing factors, adequate additional funding may not be available to us on acceptable terms on a timely basis, or at all. The severity and duration of any such impacts cannot be predicted. Any such failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies or cause us to delay our clinical development plans, research and development programs or commercialization efforts, out-license intellectual property rights to our product candidates or sell unsecured assets, or a combination of the above. Any of these actions could materially harm our business. As a result of the shares of our common stock issued in the initial closing or that may be issuable in the second or third closings of the Private Placement or upon the exercise of the Pre-Funded Warrants or the Common Warrants, our stockholders&#8217; ownership interests will be diluted. To the extent that we raise additional capital through the sale of additional equity or convertible debt securities in the future, our stockholders&#8217; ownership interests may be further diluted, and the terms of these securities may also include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Debt financing, if available, would result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Please see the section of this Annual Report titled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements and the challenges we may face in raising capital.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 31, 2021,we filed a registration statement on Form S-3 containing a prospectus and prospectus supplement under which the Company may offer and sell up to $75.0 million in shares of its common stock, from time to time, pursuant to an open market sale agreement with Jefferies LLC and by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the &#8220;ATM Program&#8221;). Pursuant to the &#8220;baby shelf rules&#8221; promulgated by the SEC, if the Company&#8217;s public float is less than $75.0 million as of specified measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement, including pursuant to the ATM Program, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the Company&#8217;s public float. As of  December 31, 2023, the Company was permitted to sell up to $12.3 million of shares of common stock pursuant to the ATM Program under the SEC's &#8220;baby shelf" rules. The Company will remain subject to the &#8220;baby shelf &#8221; rules under the Form S-3 registration statement until such time as its public float exceeds $75.0 million. Through December 31, 2023, no shares of common stock have been sold under the ATM Program. This Form S-3 registration statement pursuant to which the ATM Program is registered will expire in May 2024, and no shares of common stock may be sold under the ATM Program after that date.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease our office facilities in Irvine, California and Burlington, Massachusetts under non-cancelable operating leases that expire in December 2024 and November 2024, respectively. As of December 31, 2023, we expect to make total lease payments of $0.4 million through December 2024.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the normal course of business with third-party contract organizations for preclinical and clinical studies, manufacture and supply of our preclinical and clinical materials and providing other services and products for operating purposes. Contracts for preclinical and clinical studies and other services generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. We do not have any long-term manufacturing and supply agreements with our third-party contract manufacturers but enter into specific contracts on an as needed basis for individual batch production runs.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary of our net cash flow activity for the years ended December 31, 2023 and 2022 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.72%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(39,527</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28,424</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(45,287</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,017</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(51,797</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28,424</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, operating activities used $39.5 million of cash, which primarily consisted of our net loss of $40.3 million. Operating activities include adjustments for certain non-cash charges including $6.5 million of stock-based compensation, $0.4 million of operating lease amortization, partially offset by accretion of investment discounts of $1.2 million. Net operating assets and liabilities changed by $4.9 million, primarily driven by a decrease in accounts payable and accrued expenses of $2.6 million, a decrease in operating lease liability of $0.4 million and an increase in prepaid expenses and other assets of $2.0 million.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, operating activities used $28.4 million of cash, which primarily consisted of our net loss of $88.0 million. Operating activities include adjustments for certain non-cash charges including $48.6 million of goodwill impairment, $8.1 million of stock-based compensation, $0.4 million of operating lease amortization. Net operating assets and liabilities changed $2.4 million, primarily driven by an increase in accounts payable and accrued expenses of $2.1 million and a decrease in prepaid expenses and other assets of $0.7 million and a decrease in operating lease liability of $0.4 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2023 was $45.3 million. We purchased $78.3 million of short-term investments, which was partially offset by the maturing of $33.0 million of our short-term investments during the year. There was no cash provided by or used in the investing activities for the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2023 consisted of the Private Placement, totaling $33.0 million in net proceeds from the sale of 8.7 million shares of common stock and 6.4 million pre-funded warrants to purchase common stock. There was no cash provided by or used in financing activities for the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per &#167;229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in &#167;229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s and Supplementary Data.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report of Independent Registered Public Accounting Firm, our consolidated financial statements and accompanying notes listed under Part IV, Item 15. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exhibits, Financial Statement Schedules </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of this Annual Report on Form 10-K are set forth beginning on page F-1 immediately following the signature page hereof and incorporated by reference herein.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tants on Accounting and Financial Disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the end of the period covered by this Annual Report on Form 10-K, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, management concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control system is designed to provide reasonable assurance to our management and Board regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO Framework&#8221;) in its 2013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Internal Control&#8212;Integrated Framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Management believes that the COSO Framework is a suitable framework for its evaluation of financial reporting because it is free from bias, permits reasonably consistent qualitative and quantitative measurements of our internal control over financial reporting, is sufficiently complete so that those relevant factors that would alter a conclusion about the effectiveness of our internal control over financial reporting are not omitted and is relevant to an evaluation of internal control over financial reporting.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on this assessment, our management has concluded that as of  December 31, 2023, our internal control over financial reporting is effective.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a non-accelerated filer, we are not required to provide an attestation report on our internal control over financial reporting issued by the Company&#8217;s independent registered public accounting firm.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act) during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Insider Trading Arrangements</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign J</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">urisdictions that Prevent Inspection.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> III</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 10 is incorporated herein by reference to information in our proxy statement for our 2024 Annual Meeting of Stockholders (the &#8220;2024 Proxy Statement&#8221;), which we expect to be filed with the SEC within 120 days of the end of our fiscal year ended December 31, 2023, including under headings &#8220;Board of Directors and Corporate Governance&#8212;Election of Directors,&#8221; &#8220;Executive Officers and Executive Compensation&#8212;Executive Officers,&#8221; &#8220;Board of Directors and Corporate Governance&#8212;Director Nomination Process&#8221; and &#8220;Board of Directors and Corporate Governance&#8212;Committees of the Board of Directors&#8221;.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is available on the Corporate Governance section of our website, which is located at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">http://ir.eledon.com/corporate-governance/governance-overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We intend to disclose on our website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days following the date of the amendment or waiver.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 11 is incorporated herein by reference to information in our 2024 Proxy Statement, including under headings &#8220;Executive Compensation,&#8221; &#8220;Director Compensation,&#8221; and &#8220;Board of Directors and Corporate Governance&#8212;Compensation Committee Interlocks and Insider Participation&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 12 is incorporated herein by reference to information in our 2024 Proxy Statement, including under headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Transactions, and Director Independence.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 13 is incorporated herein by reference to information in our 2024 Proxy Statement, including under headings &#8220;Board of Directors and Corporate Governance&#8212;Related Person Transactions,&#8221; &#8220;Board of Directors and Corporate Governance,&#8221; and &#8220;Board of Directors and Corporate Governance&#8212;Committees of the Board of Directors&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accountant Fees and Services.</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_acct_fees_svcs"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e information required by this Item 14 is incorporated herein by reference to information in our 2024 Proxy Statement, including under headings &#8220;Matters to be Voted&#8212;on Proposal No. 2&#8212;Ratification of the Appointment of Independent Registered Public Accounting Firm&#8221;.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Financi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">al Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following documents are filed as part of this Annual Report on Form 10-K:</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements:</span></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report of Independent Registered Public Accounting Firm, our consolidated financial statements and accompanying notes are set forth beginning on page F-1 immediately following the signature page of this Annual Report on Form 10-K.</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules:</span></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statement schedules are omitted as they are either not applicable or the information required is presented in the financial statements and notes thereto under Part II, Item 8. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Statements and Supplementary Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.462%;"/>
    <td style="width:0.982%;"/>
    <td style="width:35.794%;"/>
    <td style="width:0.992%;"/>
    <td style="width:5.873%;"/>
    <td style="width:0.992%;"/>
    <td style="width:12.837%;"/>
    <td style="width:0.992%;"/>
    <td style="width:0.992%;"/>
    <td style="width:1.012%;"/>
    <td style="width:0.992%;"/>
    <td style="width:0.992%;"/>
    <td style="width:4.851%;"/>
    <td style="width:0.992%;"/>
    <td style="width:1.012%;"/>
    <td style="width:0.992%;"/>
    <td style="width:1.012%;"/>
    <td style="width:10.714%;"/>
    <td style="width:1.012%;"/>
    <td style="width:0.992%;"/>
    <td style="width:1.012%;"/>
    <td style="width:6.498%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="9" style="background-color:#ffffff;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td colspan="5" style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;2.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312520246314/d26397dex21.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Agreement and Plan of Merger, dated September 14, 2020, by and among Novus Therapeutics, Inc., Nautilus Merger Sub 1, Inc., Nautilus Merger Sub 2, LLC and Anelixis Therapeutics, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 15, 2020</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001404281/000119312514354857/d793658dex31.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restated Certificate of Incorporation of Novus Therapeutics, Inc., a Delaware corporation, dated September 22, 2014</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 26, 2014</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001404281/000119312517170677/d393884dex31.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a reverse stock-split), filed with the Secretary of the State of Delaware on May 9, 2017</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 15, 2017</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001404281/000119312517170677/d393884dex32.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a change in the corporation&#8217;s name to &#8220;Novus Therapeutics, Inc.&#8221;), filed with the Secretary of the State of Delaware on May 9, 2017</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 15, 2017</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312520264806/d18987dex31.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc., (effecting, among other things a reverse stock-split) effective as of October 5, 2020</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 6, 2020</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.5</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000110465921000921/tm211620d1_ex3-1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc., (effecting, among other things a change in the corporation&#8217;s name to &#8220;Eledon Pharmaceuticals, Inc.&#8221;) effective as of January 5, 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 5, 2021</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.6</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001404281/000119312517211880/d406180dex34.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated Bylaws of Eledon Pharmaceuticals, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 5, 2021</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.499%;"/>
    <td style="width:1.007%;"/>
    <td style="width:35.851%;"/>
    <td style="width:1.007%;"/>
    <td style="width:5.881%;"/>
    <td style="width:1.007%;"/>
    <td style="width:12.89%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:4.814%;"/>
    <td style="width:1.007%;"/>
    <td style="width:2.034%;"/>
    <td style="width:12.769%;"/>
    <td style="width:2.034%;"/>
    <td style="width:6.163%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.7</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312520041903/d888744dex31.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Designations of Series X Convertible Preferred Stock</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 19, 2020</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.8</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312520246314/d26397dex31.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of Designations of Series X</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> Convertible Preferred Stock</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 15, 2020</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001404281/000119312517211880/d406180dex41.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-A/A</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 23, 2017</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312519135059/d740901dex41.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Warrant</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2, 2019</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312519135059/d740901dex42.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Placement Agent Warrant</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2, 2019</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000119312520008426/d873828dex41.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Common Stock Purchase Warrant</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 16, 2020</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.5</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459021016828/nvus-ex45_320.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2021</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.6</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023016017/eldn-ex4_1.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.7</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023016017/eldn-ex4_2.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Tranche A Warrant to Purchase Common Stock or Pre-Funded Warrants</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459021016828/nvus-ex11_777.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Open Market Sales Agreement by and between the Registrant and Jefferies, LLC dated March 30, 2021</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2021</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023016017/eldn-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Securities Purchase Agreement, dated April 28, 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023016017/eldn-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Registration Rights Agreement, dated April 28, 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.4</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023049046/eldn-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Indemnification Agreement to be entered into with each of the directors and officers of Eledon</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 21, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.5</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001404281/000119312517252847/d406704dex102.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease Agreement, dated as of September 2, 2015, by and between The Irvine Company LLC and Otic Pharma, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 9, 2017</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.6</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459018019519/nvus-ex101_165.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">First Amendment to Lease Agreement, dated April 19, 2018, by and between The Irvine Company LLC and Novus Therapeutics, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 7, 2018</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.7</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459022011698/eldn-ex1013_1071.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Second Amendment to Lease Agreement, dated May 3, 2021, by and between Newport Gateway Office LLC and Eledon Pharmaceuticals, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 24, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.8</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459022011698/eldn-ex1014_1072.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease Agreement, dated as of November 4, 2021, by and between Corporate Technologies, Inc. and Eledon Pharmaceuticals, Inc.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 24, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459018007314/nvus-ex1011_429.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tokai Pharmaceuticals, Inc. 2007 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 2, 2018</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.10</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459018019519/nvus-ex102_213.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tokai Pharmaceuticals, Inc. 2014 Stock Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 7, 2018</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.499%;"/>
    <td style="width:1.007%;"/>
    <td style="width:35.851%;"/>
    <td style="width:1.007%;"/>
    <td style="width:5.881%;"/>
    <td style="width:1.007%;"/>
    <td style="width:12.89%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:1.007%;"/>
    <td style="width:4.814%;"/>
    <td style="width:1.007%;"/>
    <td style="width:2.034%;"/>
    <td style="width:12.769%;"/>
    <td style="width:2.034%;"/>
    <td style="width:6.163%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.11</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459018019519/nvus-ex103_212.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Novus Therapeutics, Inc., 2014 Employee Stock Purchase Plan</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 7, 2018</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.12</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459021016828/nvus-ex108_318.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Employment Agreement, dated September 9, 2020, between Novus Therapeutics, Inc. and David-Alexandre C. Gros, M.D.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2021</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.13</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023016017/eldn-ex10_3.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David-Alexandre Gros, M.D. Letter Agreement, dated April 27, 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.14</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459021016828/nvus-ex1010_316.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Employment Agreement, dated March 15, 2021, between Eledon Pharmaceuticals, Inc. and Paul Little</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2021</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.15</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023016017/eldn-ex10_4.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steve Perrin, Ph.D. Letter Agreement, dated April 27, 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 1, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.16</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459021016828/nvus-ex1011_319.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Novus Therapeutics, Inc., 2020 Long Term Incentive Plan</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 31, 2021</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.17</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/eldn-ex10_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan, as amended</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 22, 2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.18*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459022011698/eldn-ex1012_1073.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Performance Stock Option Agreement, dated February 1, 2022, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D.</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 24, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.19</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017022016935/eldn-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amended and Restated License Agreement by and between ALS Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc, dated February 18, 2020</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 11, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.20</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017022016935/eldn-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">First Amendment to Restated License Agreement between ALS Therapy Development Foundation, Inc. and Anelixis Therapeutics, Inc. dated September 5, 2020</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 11, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.21</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000095017022016935/eldn-ex10_3.htm" style="-sec-extract:exhibit"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License Agreement between Lonza Sales AG and Anelixis Therapeutics, LLC, dated September 11, 2018</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 11, 2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.22*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex10_22.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Stock Option Agreement, dated May 1, 2023, between Eledon Pharmaceuticals, Inc. and each of David-Alexandre C. Gros, M.D., Steve Perrin, Ph D. and Paul Little</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;10.23*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex10_23.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Form of Amendment to Stock Option Agreement, dated December 30, 2023, between Eledon Pharmaceuticals, Inc. and David-Alexandre C. Gros, M.D., Steve Perrin, Ph D. and Paul Little</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;21.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1404281/000156459020011260/nvus-ex211_11.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-36620</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 17, 2020</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;23.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex23_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consent of KMJ Corbin &amp; Company LLP, independent registered public accounting firm</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.462%;"/>
    <td style="width:0.982%;"/>
    <td style="width:35.794%;"/>
    <td style="width:0.992%;"/>
    <td style="width:5.873%;"/>
    <td style="width:0.992%;"/>
    <td style="width:4.851%;"/>
    <td style="width:7.986%;"/>
    <td style="width:0.992%;"/>
    <td style="width:0.992%;"/>
    <td style="width:1.012%;"/>
    <td style="width:0.992%;"/>
    <td style="width:0.992%;"/>
    <td style="width:4.851%;"/>
    <td style="width:0.992%;"/>
    <td style="width:2.004%;"/>
    <td style="width:11.726%;"/>
    <td style="width:1.012%;"/>
    <td style="width:0.992%;"/>
    <td style="width:1.012%;"/>
    <td style="width:6.498%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;31.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex31_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;31.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex31_2.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;32.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex32_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;32.2</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex32_2.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;97.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex97_1.htm"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incentive Compensation Recoupment Policy</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INLINE XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INLINE XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover page formatted as INLINE XBRL and contained in Exhibit 101</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indicates a management contract or compensatory plan</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">#</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">These certifications are not deemed filed by the SEC and are not to be incorporated by reference in any filing we make under the Securities Act of 1933 or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K Summary.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">URES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"/>
    <td style="width:4%;"/>
    <td style="width:47%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">David-Alexandre C. Gros, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">and Director (Principal</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Executive Officer)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Little</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paul Little</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.2%;"/>
    <td style="width:1.92%;"/>
    <td style="width:40%;"/>
    <td style="width:1.92%;"/>
    <td style="width:27.96%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">David-Alexandre C. Gros, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal Executive Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Little</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paul Little</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Keith A. Katkin</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Keith A. Katkin</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jan Hillson, M.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jan Hillson, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James Robinson</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James Robinson</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Allan Kirk, M.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Allan Kirk, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ John S. McBride</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">John S. McBride</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Walter Ogier</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Walter Ogier</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ June Lee, M.D.</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June Lee, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Steven Perrin</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Steven Perrin</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="index_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.5%;"/>
    <td style="width:1%;"/>
    <td style="width:7.5%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_pub_acctg_firm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (KMJ Corbin &amp; Company LLP PCAOB ID#: </span><span><ix:nonNumeric id="F_2d94ec1a-495d-4257-a4e5-35daf8992ffd" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">170</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="text-indent:18pt;vertical-align:top;text-align:center;"><p style="margin-left:5.75pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="text-indent:18pt;vertical-align:top;text-align:center;"><p style="margin-left:5.75pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="text-indent:18pt;vertical-align:top;text-align:center;"><p style="margin-left:5.75pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:18pt;vertical-align:top;text-align:center;"><p style="margin-left:5.75pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="text-indent:18pt;vertical-align:top;text-align:center;"><p style="margin-left:5.75pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="text-indent:18pt;vertical-align:top;text-align:center;"><p style="margin-left:5.75pt;text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_pub_acctg_firm"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Board of Directors and Stockholders of<br/>Eledon Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Eledon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Going Concern</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred recurring operating losses and expects to continue to incur net losses into the foreseeable future. In addition, the Company has an accumulated deficit of $243.2 million as of December 31, 2023 and is dependent on its ability to raise capital. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-Process Research and Development Intangible Asset Impairment Assessment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Note 3 to the consolidated financial statements, the in-process research and development (&#8220;IPR&amp;D&#8221;) intangible asset is tested for impairment at least annually and more frequently when indicators of impairment exist. Management considers various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Certain indicators of impairment could relate to adverse clinical trials, a decrease in the projected market size, changes in anticipated pricing of the product once approved or increases in cost factors, among others. Management performed a qualitative assessment as of December 31, 2023, in which it assessed significant factors, including those mentioned above, to determine whether it is more likely than not that the IPR&amp;D intangible asset was impaired. Based on the qualitative assessment, management determined that it was not more likely than not the IPR&amp;D intangible asset was impaired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auditing management&#8217;s impairment test for the IPR&amp;D intangible asset was complex and required a high degree of auditor judgment when performing procedures due to the significant assumptions used in determining if it was more likely than not that the IPR&amp;D intangible asset was impaired. Significant judgments made by management were related to: (i) cost factors such as increases in materials, labor and other costs; (ii) regulatory factors affecting the Company&#8217;s product development; (iii) industry and market considerations; and (iii) macroeconomic conditions, including the Company&#8217;s ability to access capital to continue product development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit procedures to evaluate the significant judgments made by management described above included, among others, comparing to observable industry data and external market data, evaluating the most relevant drivers of fair value used to record the IPR&amp;D intangible asset when initially acquired and the impact of those drivers since the IPR&amp;D asset was acquired through December 31, 2023, and determining if the available information corroborated or contradicted management&#8217;s conclusions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cb071c9-72f7-472b-ad68-d7cb15346d92" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KMJ Corbin &amp; Company LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company's auditor since 2019.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d92aa12d-1297-4a3b-8b90-35f74dbf1d9d" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Irvine, California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>March 28, 2024</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.28%;"/>
    <td style="width:1.7%;"/>
    <td style="width:1%;"/>
    <td style="width:12.66%;"/>
    <td style="width:1%;"/>
    <td style="width:1.7%;"/>
    <td style="width:1%;"/>
    <td style="width:12.66%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aa17541-c16d-4d61-96e5-33b17ed80913" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,612</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f97033f9-2e49-4a58-9032-d49608e2cc61" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,409</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_670f7c38-9113-4826-9a51-0813371b5c8b" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c555b69f-1713-4026-8896-25d5f2127bf0" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,027</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0956aab9-0040-495a-954a-97f50362f898" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,109</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d14259b-96e8-4827-bf2c-06a57b216c61" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf0c4b5-8e3f-4ac0-9526-11b9457d9388" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33c05a30-b15b-475a-ab36-336e72d4427f" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fe61d3e-d3be-4349-8206-7a48e3e8b467" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_150a0183-2fa5-4ae6-b825-ba679c641fc6" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:InProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce26d43f-63c2-4856-8e75-0e02f9bfcd4d" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:InProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bede115-874b-428d-afd1-a8720001ad3c" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_107e5072-0bea-4eda-8cff-702217d52414" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6bbe112-8097-42ba-bea0-67cd5302a1a7" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,066</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62c98e1d-ab58-4c5d-adf7-0a9ae6eeea02" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41d116d4-4575-4c05-88cb-b6fedfb90e05" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">967</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd3fe0be-e41a-4ac5-9920-6e872ec99c46" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76b0168e-7b12-4712-bfe2-cdac537940cb" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c9222ec-6506-49ab-9a3e-108cadbbf3be" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70b8c345-e8b2-4e0f-af1f-f380a6e39f38" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_524221d4-0004-4ca4-abf0-60ca81d7f0e6" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,912</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c096abf-3504-4073-b470-1f433691b27e" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f91e4a5-2ae3-4a7b-966f-a74e662c0f7c" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3617bae0-c316-4877-9c06-1f1b51ef2b65" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e9205fd-60e1-4917-bbd8-212da13d9997" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46e9cd31-c897-46a4-9fae-c0d43f2d4912" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_252f4feb-88af-452b-88b5-464456165f8d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_836e9c71-7555-4e3d-9b65-dd5274eace9e" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,610</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8862ae79-21b9-4dd3-b094-5f0b37ca3bf5;"><span style="-sec-ix-hidden:F_590f46c2-3850-4849-be6f-cc96373a70da;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 8)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_634cf72b-f91d-4977-bc49-4feb4cee8dba" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ecfbb060-3072-4fd4-8a1d-5bc12516fb7d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e2bff72-7390-497d-a23f-ff0d8bcc5799" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a53b2929-6211-47a9-aff5-d757e2b3202b" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31, <br/>&#160;&#160;&#160;2023 and 2022:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series X</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;non-voting convertible preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d388986f-e0dc-4aad-8b66-b2251ca97968" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f2a90ec3-56cc-4649-b897-685511ed052e" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e89025b-0a72-4c4a-a929-96fb82b26edc" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dcdcd3b0-e03b-4e96-acc2-e649881fd482" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">515,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;<br/>&#160;&#160;&#160;shares designated; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0321c789-a8b0-4200-b4c9-e4d1e344db68" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ae30179a-b559-46be-a62c-90d9ea9daa81" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">110,086</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c132b11f-f994-44fd-ba79-212f5b646e2b" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6de91791-6a96-4b56-b7b0-75945a2de28e" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">117,970</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at <br/>&#160;&#160;&#160;December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_00a1069d-cd72-41cb-bc33-200863646b81;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_8e1d1e87-5ed8-4476-b947-d11cb0df1b47;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Series X non-voting convertible preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba6ba3f7-ab34-4280-b431-22b378d7b55c" contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b3df92b1-98a6-4862-bbdd-0c81a3aef3e1" contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63e8795f-0701-4b18-8441-f2f975dab1ad" contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_453b78b1-b28d-432b-ab87-926abcc9db50" contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;<br/>&#160;&#160;&#160;shares designated; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db5acc85-7bfe-4799-938f-60ff456d19a1" contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e05e3b11-dd8f-4e4a-8b82-4145468f5696" contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,422</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeb95553-5d24-4315-9497-ba0c952b47a2" contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b5b9f84e-a2e7-4859-805a-d196e2293300" contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,204</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at<br/>&#160;&#160;&#160;December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_97b04c6c-0e31-4def-bdf9-a4dc995bb41f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_3ca1e85d-199a-4c47-8f91-7bf01141c98f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac471336-f8ec-459a-be1e-440c406575ee" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bd16b8e4-d796-4a70-bc05-5d34a9d6eae8" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca6a4b6f-5c73-4a3d-b10f-df1353218a08" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3d16ea70-f7e0-4df3-92b9-3fbcd9192829" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at <br/>&#160;&#160;&#160;&#160;December 31, 2023 and 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a71c806d-ba06-47b6-b0f1-0e7931a1ab5b" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_df82aaab-9f4e-4ad8-b944-09dfcc737414" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,213,130</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee391e3-9bbd-4658-9233-28dd932671fb" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2e5e0272-d4ee-4a1a-9aa2-c56d13b741d1" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,776,788</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued<br/>&#160;&#160;&#160;&#160;and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c7665c1-c3b1-4275-a2d2-48d12d74626f" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">24</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a024f9b7-1407-4932-a108-b93996338440" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96401be9-a88e-4864-b6d7-f73fa67cd55a" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,586</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dff3189-3222-461b-8a0a-11e0e9706fa1" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,034</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6389da56-e80b-4374-8ff3-9c391e50741a" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">243,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83c2bea9-e8cd-4641-b4eb-976dcf6b7697" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">202,865</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_817c936d-7509-45d9-894a-2a8abdb35854" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1da74889-913a-4d42-89b8-0b6f63e515f5" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fc14c5e-d3df-4d45-b033-c791e086be2c" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,066</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1c574a2-196a-49b7-a7c3-4cbcb1512da3" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OPERATIONS AND COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.72%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21b761ed-7df7-4b29-b470-a2b997dd168f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7b30a0f-abb6-42d1-9a09-d604dd3538ad" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58a02c00-1a0f-44ff-a141-bae80cb8cba0" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,688</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_611edccb-d134-4e36-a260-e1dbcefccb9a" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,700</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d79ffe4f-529b-4110-a568-b846985f1ed5" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84047d93-23fa-4ea5-ae41-74376ad1c9ab" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82635281-a890-4eee-af54-66f3e37fa2fe" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3cffaed-e726-4e05-8b87-0642e3939d03" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">43,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97504281-6be3-4194-a2cc-37ccc7adac93" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47f428ab-c8c1-40f0-ba28-5c6a15c8ded4" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,674</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e9f61e2-ec0f-4f9f-b1fb-73a559548b67" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b7fb375-8480-4bdb-ac85-0012147ea852" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ac1584d-1044-44f5-9e2a-a50a5297530c" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf0dfbc2-c96f-4367-8717-cfd9b488cb19" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a406f864-4aab-4379-b77f-6cbe2faf1217" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed3774a0-804e-4aad-ab11-7af2aa64734c" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fca1f300-6c1b-4009-bbb5-5a7f35448b46" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d645900-05ef-48be-9425-4159060c285a" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fafc21f7-23f3-450f-a67c-27baea893bf7" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">6.16</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98380704-9ab6-4240-935a-6cc3548a9494" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_45dd1926-1456-4b89-9efa-f0bfd2d5d084" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">24,619,197</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6fff231-29b7-4e19-be96-8fd8c280be73" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7e3a8f8a-1396-4f88-9859-29f081867822" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,285,254</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF ST</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.126%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.561%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.260999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.561%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.260999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.561%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.760999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.0809999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.021000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.04%;"/>
    <td style="width:1%;"/>
    <td style="width:4.760999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Non-Voting Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series X Non-Voting Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional <br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1f82e0b-15e0-4ad0-b03a-bd850fbc7604" contextRef="C_52ac3c7f-20e1-4753-802e-f4dad8d28acc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">108,070</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3aa1e827-1d10-4566-b1ef-de5b479af532" contextRef="C_bd72c38d-208f-4865-8dad-4735385f07ae" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,204</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b6ea693-a898-423e-8807-0b07f6201269" contextRef="C_37373384-6f64-4549-9ed5-b285cc857da3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,306,788</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c38eac8-f35b-42c7-9b8d-22f677efef67" contextRef="C_37373384-6f64-4549-9ed5-b285cc857da3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68b0d414-5714-4a0f-bccb-610d31d7003f" contextRef="C_99647e68-33eb-417c-a4d5-0797361b24f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,880</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_370d204f-b4d0-4aa7-903d-e53543699274" contextRef="C_8711094b-fadc-4a14-9f20-38420f00a8ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114,899</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9485249a-75a9-43e6-96a2-6269ff0aa26b" contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,995</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancellation of common stock in connection with exchange for X</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;non-voting convertible preferred stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c000b5fd-32b5-48e3-a31d-5c81e9f928a1" contextRef="C_b395598c-4190-4835-bf33-91c539bcf3da" name="eldn:CancellationOfCommonStockInExchangeForPreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c8ae642-c0c9-4bf9-aaa6-a80057ad94ed" contextRef="C_80ff1b22-a3d3-4e55-9ed1-30853a838cdc" name="eldn:CancellationOfCommonStockInExchangeForPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">550,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_576c3bf5-4be9-4939-9d9b-26d5e084b5ee" contextRef="C_7aafb0bd-5f6d-4965-a2d7-c6a51e705c60" name="eldn:CancellationOfCommonStockInExchangeForPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b83be05d-cab6-4c5a-b4b7-78e0eca4df6a" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:CancellationOfCommonStockInExchangeForPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79c20bf1-4e6b-4c2e-8fc9-00a19ff93928" contextRef="C_80ff1b22-a3d3-4e55-9ed1-30853a838cdc" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45d940eb-125e-4d65-915a-b58d77f785ce" contextRef="C_7aafb0bd-5f6d-4965-a2d7-c6a51e705c60" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_506bd908-e556-4607-8488-20ac44ce2e5a" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fd503c1-8c66-485d-92df-6a4a23762ba6" contextRef="C_bb8a89d8-fa9c-4eed-9f5a-4e41b1a1cdb0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0023fb30-0d1c-458a-9af8-5a645060c6cd" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ecb72bf-d70a-46d6-bec8-2ad510dc30c1" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">117,970</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26c0a405-a99b-4310-9415-bc0ab660ccaf" contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,204</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67e45b30-f1cf-42a4-b74d-b38f46637379" contextRef="C_36a0389b-10cb-49c8-b0e4-e5b3b2badc70" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,776,788</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67106241-aa76-48c2-a29b-58eebb644349" contextRef="C_36a0389b-10cb-49c8-b0e4-e5b3b2badc70" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c5206d8-0f21-4dc2-bc23-91ae1940e147" contextRef="C_ac3741ad-2290-4551-8fd0-d8b0fd4e7b4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,034</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_909f73b8-fdba-41a4-b683-4b4a0967bca8" contextRef="C_50fac1cc-803f-44be-b716-f8a6c9e0f8d2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">202,865</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8ebb939-d08c-4709-8c03-bb013adea62d" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_861df009-ad43-4717-8c12-179e90c25925" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,730,168</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8471e29d-b4ae-46fa-8140-56f21e7c613c" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b60da300-7a9b-4ccb-aaa4-df712bbe2846" contextRef="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d" name="eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,008</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d087058f-6a35-4ca1-8c13-8306541fe9f0" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,017</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with conversion of X non-voting convertible preferred stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e24b7f4-4c59-42b7-a189-ba0d33631d95" contextRef="C_a45cdbc7-e8f2-4e4f-8f6f-ba8e618b1f4d" name="eldn:IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11263c83-aff0-4f41-9373-2ca306a5564a" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="eldn:IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with conversion of X</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;non-voting convertible preferred stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2524424-b1db-492d-a824-073ed6aa3d35" contextRef="C_0357e8b8-b1b4-40e1-a1cf-ad729e9511b7" name="eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">7,884</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8a3aa48-dc26-41c7-bc11-28fb5e32c0f6" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">437,977</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8fd24d7-cc93-4bd4-8491-f8f06865ee77" contextRef="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d" name="eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4042218d-d192-4ccf-ba3c-fc3f349943f9" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with exercise of pre-funded warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9e63bb2-753a-478e-b52b-ab4d02e05dc4" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,154,197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c00df0d-e293-4510-be21-e51c0688d162" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4f4d0ae-fbf7-40e9-b748-ac08908a6a63" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in connection with vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_828d6705-bbef-4ef7-9b65-82735dd97aaa" contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_694900d2-1da6-4c83-bf85-30f7b59d237f" contextRef="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af940dec-c753-4589-9156-6bd784f84d8f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss and other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_767f066e-7d1a-4441-9a9e-586d4ba30a8e" contextRef="C_a19675bc-9e87-4fa8-a561-20689ac5db3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57ff46b9-82c2-4ec1-b3be-0c5b5f5f7642" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9f70a2b-f37a-458d-9902-e9ccc07115f6" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">110,086</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_396364ec-6547-4fbb-ae3c-cc11297cfe61" contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37c880da-4f99-4e02-a415-ba55c5e5da44" contextRef="C_b7d71759-5259-4d1d-9aa7-792cc31e7654" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,213,130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ede8ce0d-443b-495d-8b3f-dd2289256a28" contextRef="C_b7d71759-5259-4d1d-9aa7-792cc31e7654" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a336fa04-f2dc-4b4a-8f49-100cfac2e507" contextRef="C_c76111e5-5031-4f89-b4d4-0128b09d2e80" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,586</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22090f12-3f44-4ea8-8f63-2e9ce6cf25d5" contextRef="C_37fd87ac-684b-41cc-9625-693d26d0ebe0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">243,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_261fcf62-50eb-4514-b132-bec9536cdae3" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TATEMENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.32%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.860000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.860000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a28aafc3-838a-4854-a16f-c4ccbfe9e9bd" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd3525c8-ffad-406e-9682-c8eda9373f5e" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of operating lease asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70a5cc06-2422-44f5-a89e-5242b9363234" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:AmortizationOfOperatingLeaseAsset" unitRef="U_USD" scale="3" decimals="-3">374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abaecdfe-148f-4ab3-9241-2cd51790afda" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:AmortizationOfOperatingLeaseAsset" unitRef="U_USD" scale="3" decimals="-3">373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion on investment discounts</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6ee1d80-d9dd-4de0-812e-a0f191528a32" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:AccretionOnInvestmentDiscounts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_757b9b1e-fbd1-4cfa-9061-b7d9eb85f36c" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e96d558-b4b4-454f-a10c-3a66b4a740d3" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44ff5088-24d7-4f08-bc84-54e9dc28d0d7" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d6a3047-9c64-4ecf-915d-d5ed3150a0a6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,954</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8962cad-16f3-4e11-b1e9-57c51bc2b1ad" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">654</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable, accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86507b05-b40c-493b-9621-9226665e3680" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:AccountsPayableAccruedExpensesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63a7373e-234f-46ab-bc78-9092e2f52c71" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:AccountsPayableAccruedExpensesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,081</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edbcd797-24fc-48c0-830e-db8ad54d0004" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-">363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_801273e7-2b3d-43ac-92c0-aedf52cf4c29" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-">367</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d225fe-d881-4913-88ea-27c09db199cf" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74fb3f9f-a308-4a59-a03f-b9200f8977e7" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of available-for-sale short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_060a62c1-8589-4ada-991f-08b20211e974" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,287</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of available-for-sale short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca6beb4e-0fe7-4ee3-962a-1f817e48f9a5" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b0f3bb1-dc9d-47a8-9fcd-694011fd3f90" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,287</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuances of common stock and pre-funded warrants, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13b162d9-8252-42eb-b4e9-edde9d97adf8" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,017</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab25d478-85c0-4745-8ef5-1030700839eb" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,017</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84245ce5-b171-48c8-a85b-104abe90ca62" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">51,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0eb12cd-6735-4344-9de5-a6a84d692d06" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f794ebf8-94de-4f4c-b74d-65729eab248d" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,409</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f0494cd-642c-4e0d-9edb-311e740b728c" contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55d0a8b8-ed44-4c38-a273-13d1ddfccd77" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,612</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_366ae1e1-143d-4735-bccf-717df9b1d9fb" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,409</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of non-cash investing and financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock exchanged for X and X</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;non-voting convertible preferred stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_488a361b-f83c-4bb9-bb1d-578341f63ef8" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dad2c8a-1e7e-4c49-b3db-11e9bb45c7ab" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase in operating lease asset and liability due to lease modification</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_313ec41d-0b76-4b11-a8a7-a470275ac2ee" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" unitRef="U_USD" scale="3" decimals="-3">344</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLID</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bada55aa-71b6-4fc3-9ff5-b6eb97ce101a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (&#8220;CD40L&#8221; or &#8220;CD154&#8221;) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;). The Company&#8217;s lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. Unless otherwise indicated, references to the terms &#8220;Eledon,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;we,&#8221; or the &#8220;Company&#8221; refer to Eledon Pharmaceuticals, Inc. and its wholly owned subsidiaries, on a consolidated basis.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98295a7f-84a9-4140-8888-6ddf9a64f911" contextRef="C_9e831537-98aa-43d1-a911-7e2bb6a241d8" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 14, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Eledon acquired Anelixis Therapeutics, Inc. (&#8220;Anelixis&#8221;), a privately held clinical stage biotechnology company developing a next generation anti-CD40L antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. The Company maintains its corporate headquarters in Irvine, California and has research and development facilities in Burlington, Massachusetts.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd63ef57-382a-4b04-9654-829f3d94a560" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Going Concern and Management&#8217;s Plans</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company had a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5be0fb9a-afe0-4460-ae02-ed8b5d2aadfc" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">40.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5758a43-8464-48a3-b19b-4b8585d160a0" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">243.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, as a result of incurring losses since our inception. Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. The Company expects to continue to incur net losses into the foreseeable future in connection with its ongoing activities, particularly as the Company expands its clinical program with tegoprubart, continues the research and development of, and seeks marketing approval for, its product candidates. In addition, if the Company obtains marketing approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company has financed operations primarily by net proceeds from the sale of preferred and common stock and warrants.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain institutional and accredited investors (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the &#8220;Private Placement&#8221;) shares of common stock and warrants in a series of three potential closings. On May 5, 2023, the initial closing occurred and the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_200a299a-34cf-4119-aa14-780c2e09a9c4" contextRef="C_90229839-dc48-46bd-88f4-a22efae9078c" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6627d82-cda8-4d52-9f06-a6f950de84f5" contextRef="C_2f480dcc-a0dc-4708-95ae-152e67a484fe" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,730,168</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2176b9b-10ad-414e-b683-44635d4aef36" contextRef="C_9a6202d9-fada-461a-bd65-85c4b8841070" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,421,350</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and additional common stock warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c0a319-4084-4560-82b1-9a8eb07d339b" contextRef="C_2f480dcc-a0dc-4708-95ae-152e67a484fe" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,151,518</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or pre-funded warrants in lieu thereof). The Company may receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2051c421-5a94-4af6-ab59-5c3b5d9e2a62" contextRef="C_2f240e52-3046-4a8c-8a48-212f2e92c63e" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in tranche financing in a second and a third closing, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05dae30e-7e1f-4eb4-b457-1986a7b13653" contextRef="C_8b7b00cf-f725-4f04-abf7-50d2422f6755" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million assuming the exercise of all common stock warrants issued in the initial closing of the Private Placement. See Note 10. &#8220;Stockholders&#8217; Equity&#8221; for further information regarding the Private Placement. Due to the contingent nature of the exercise of the common stock warrants and the second and third closings of the Private Placement, accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires the Company to exclude them from its going concern analysis. If these events do not occur or the Company is unable to secure additional capital or is unable to do so on acceptable terms, it will be forced to significantly alter its business strategy, substantially curtail its current operations, or liquidate and cease operations altogether.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023, the Company had cash and cash equivalents and short-term investments of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31082f2e-ad00-4d9f-8d04-f1cfa889540a" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">51.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Additionally, in view of the Company&#8217;s expectation to incur significant losses for the foreseeable future, the Company will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company&#8217;s access to, such resources is not assured. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, management believes that there is substantial doubt regarding the Company&#8217;s ability to continue operating as a going concern through at least the next twelve months from the date of this filing.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_ef8378f1-1722-4882-918b-47b3317bd43f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c03c2b0b-3b08-45bd-9862-11761ccedbd8" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are prepared in accordance with GAAP. Eledon, a Delaware corporation, owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e889aa5c-8ce3-47da-9199-6a42da266161" contextRef="C_cdaa1da2-6d2e-4920-84ee-ec3843c595c9" name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (&#8220;Otic&#8221;). Otic owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbcd0aa5-aa96-4d3a-a505-3a47d2a29e9f" contextRef="C_2e3151e2-74b6-4f7c-b669-6a6d90422655" name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company&#8217;s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company&#8217;s foreign subsidiary are not significant to the consolidated financial statements.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant intercompany accounts and transactions among the entities have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_897e61eb-f84a-472b-80a6-7c1b830423a8" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8d7cced-9b5d-4e4e-b781-8b2ab281b3c4" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c989a7ba-063e-494a-bf8f-b9323f73f979" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2433ff0c-4ff8-486b-8306-1ec1c902a84a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:CashCashEquivalentsAndRestrictedCashMaturityPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months or less</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fb390c2-3120-4ab9-83e2-19cb4ffa12ff" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all of the Company&#8217;s long-lived assets were located in the United States.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products will require approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company&#8217;s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f1a490b-2ef7-41d0-8b71-c8b06cf09e4c" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reportable Segments</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments under GAAP are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer and the Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dac78ce2-edb2-49aa-90e7-d6303aa5dcbe" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business segment, which is the development of products for therapeutic medicines selectively targeting critical pathways associated with the underlying molecular pathogenesis for patients with severe inflammation and autoimmune diseases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2305c6f-fec9-493d-b7ba-974d3a4a4ea2" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired under the acquisition method of accounting. Goodwill is not amortized but is evaluated for impairment as of December 31 of each year or if indicators of impairment exist that would, more likely than not, reduce the fair value from its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company performs its goodwill impairment analysis at the reporting unit level, which aligns with the Company&#8217;s reporting structure and availability of discrete financial information. The Company performs its annual impairment analysis by either comparing the reporting unit&#8217;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#8217;s fair value from the last quantitative assessment to determine if there is potential impairment. The Company may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#8217;s estimated fair value was significantly in excess of the carrying value of its net assets and it does not believe there have been significant changes in the reporting unit&#8217;s operations that would significantly decrease its estimated fair value or significantly increase its net assets. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies. Key assumptions for these projections include revenue growth, future gross and operating margin growth, and its weighted cost of capital and terminal growth rates. The revenue and margin growth is based on increased sales of new products as the Company maintains investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including timing and probability of regulatory approvals for Company products to be commercialized. The Company&#8217;s market capitalization is also considered as a part of its analysis.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s annual evaluation for impairment of goodwill consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35b62d03-a36f-461f-9f34-f4b348746d59" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NumberOfReportingUnits" unitRef="U_Reporting_Unit" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reporting unit. In accordance with the Company&#8217;s policy, the Company completed its annual evaluation for impairment using the quantitative assessment, utilizing the market approach and due to declining market conditions, determined that the fair value of the reporting unit was below its carrying value. As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f284be6-d3d6-4da9-b85e-946e916063e4" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of goodwill impairment, reducing the goodwill balance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f036fbc-a19a-4544-a4fe-5f0f423312e9" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2817d80d-a95b-4dbe-90dd-54aae9711b5f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill impairment was recorded for the year ended December 31, 2023.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_566298c3-6d57-45cd-8d9c-c9f7e7fd2359" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which the carrying amount of an asset exceeds its fair value. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17a5e5f9-c4d0-4a92-8cad-cc24d7417e69" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_512a67d5-4132-4940-afd1-48817cb66f3a" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments of long-lived assets have been identified during the years presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0c30d25-bdba-4761-b39d-0b80fe3aaa46" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-Process Research and Development</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of in-process research and development (&#8220;IPR&amp;D&#8221;) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (&#8220;R&amp;D&#8221;) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d362df2-03e2-4282-b7bb-d63d40556ad5" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company&#8217;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_0dd6b39f-c81d-4296-b960-d3c3ca10eb85" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, incentive stock options, restricted stock units and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company&#8217;s net loss position. Basic weighted average shares outstanding for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> include </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe994004-078e-491e-b316-24c0019fb672" contextRef="C_403020d7-be70-4c12-a4cc-8bc0abf4256e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,776,270</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4187fa1-9213-4986-80b2-5244ec8fcd96" contextRef="C_3c6b3fdb-26ba-4381-9bb7-d9118f53631d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">509,117</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, shares underlying pre-funded warrants to purchase common shares. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_606c1d61-6f56-4761-81f1-5c5555b8b2d1" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_606c1d61-6f56-4761-81f1-5c5555b8b2d1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the shares underlying these pre-funded warrants can be issued for little </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_606c1d61-6f56-4761-81f1-5c5555b8b2d1_1" continuedAt="F_606c1d61-6f56-4761-81f1-5c5555b8b2d1_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(an exercise price per share equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ddc6b20-996f-4d32-9560-7ff598e19eac" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share), these shares are deemed to be issued for purposes of basic earnings per share.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_606c1d61-6f56-4761-81f1-5c5555b8b2d1_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.3%;"/>
          <td style="width:1.66%;"/>
          <td style="width:1%;"/>
          <td style="width:14.34%;"/>
          <td style="width:1%;"/>
          <td style="width:1.66%;"/>
          <td style="width:1%;"/>
          <td style="width:14.040000000000001%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4b78f38-1bae-446c-8e84-591f0a9b64ed" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11330913-fe7f-42a0-8b98-9b4b5810078e" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e762d62-8e4e-4858-9881-09053b734307" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_709c177a-ab08-4716-9116-420e4eaeaa45" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.64</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bef169c-1335-4b61-a68d-2de5d327595f" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6ac4cc73-a230-4f01-ab33-2721ed76cc95" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">6.16</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a8ef3e9-e048-4a9e-87b6-d89b1aae6c82" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_44b98e6e-195f-4a00-9379-02ed4818c302" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">24,619,197</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be8c09a1-ed57-4ff6-96b4-e46db9f8b57b" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d2f98377-b2a6-4b5c-8e34-e87f58476269" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,285,254</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of diluted earnings per share excludes incentive stock options, restricted stock units, and warrants that are anti-dilutive. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25fb9f17-6e02-4565-89be-bf36e0fa6a49" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_25fb9f17-6e02-4565-89be-bf36e0fa6a49_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary as of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_25fb9f17-6e02-4565-89be-bf36e0fa6a49_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.247%;"/>
          <td style="width:1.44%;"/>
          <td style="width:1%;"/>
          <td style="width:14.937%;"/>
          <td style="width:1%;"/>
          <td style="width:1.44%;"/>
          <td style="width:1%;"/>
          <td style="width:14.937%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding and other equity awards</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7065d340-5893-45fe-a932-5ceab07a0407" contextRef="C_6ae6940e-5a6a-475f-9b2c-85a5e9f64183" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,909,155</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f286c04e-efdd-4538-b4da-cea51ec8e9cc" contextRef="C_b1d46794-a5ff-4a00-a67a-113d1f5e5bb3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,012,035</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common and preferred warrants outstanding</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81dc0f26-20c8-4031-8fd6-b4a819e08f52" contextRef="C_c33e93a8-92df-4580-a627-619828841106" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,577,332</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e315ac22-2ffd-4a2c-95c6-992acc05594c" contextRef="C_564fb782-4618-449b-be0d-4a8c0d6e8c89" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,127,121</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8620a78-e11d-4abe-9095-e6499568bfe3" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,486,487</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4a129ab-18ef-482a-8c7b-f33a8414be28" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,139,156</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9204a36a-e421-49fd-8dff-1998c07c0302" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. The expected dividend assumption was based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units (&#8220;RSUs&#8221;) are measured and recognized based on the quoted market price of our common stock on the date of grant.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11831e7c-c631-4339-81af-4b21cafc0b8a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. We assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. We have provided a valuation allowance on our deferred tax assets as of December 31, 2023 and 2022 because we believe it is more likely than not that a majority of our deferred tax assets will not be realized as of this date.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company evaluates the accounting for uncertainty in income tax recognized in its consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positions </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">where it is &#8220;not more likely than not&#8221; that a tax benefit will be sustained, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb14b65a-b590-4d81-acda-3caa2b968ef3" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued any liabilities for any such uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or processes, if any. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65c33f2a-dcfa-44a3-9f24-2015679a10a7" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59c85fea-8a5d-4673-950f-1a589ebacddf" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:IncomeTaxExaminationLikelihoodOfFavorableSettlement" unitRef="U_pure" scale="-2" decimals="INF">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likely of being realized upon settlement.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. For additional information, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 9. Income Taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_591efb97-35e3-4b47-8870-6af069f55cca" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements Issued But Not Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bab7abfd-04f1-4d2c-8070-95ce67c139ab" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4. Short-Term Investments</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The objectives of the Company&#8217;s investment policy are to preserve principal, meet the Company's liquidity requirements and safeguard invested funds. Short-term investments consist of U.S. government securities and U.S. government agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. Investments are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ff15270-e69c-4df2-b4ad-fa234cae7e4a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of short-term investments, which were classified as available-for-sale securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.98%;"/>
        <td style="width:2.38%;"/>
        <td style="width:1%;"/>
        <td style="width:18.56%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:18.56%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75929201-9f66-4fae-88db-120d48a7a831" contextRef="C_89b25922-7cb3-4412-b567-f46abca28cf8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d16f9cd-0364-4d7f-afdd-0078b61f25da" contextRef="C_89b25922-7cb3-4412-b567-f46abca28cf8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fb580dc-3cab-4415-a2f9-c812aec2f9c3" contextRef="C_05c23523-7806-4910-8de2-4ca513419180" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,277</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4c27227-d126-48a7-841b-34198baf9039" contextRef="C_05c23523-7806-4910-8de2-4ca513419180" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,277</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dababdc-1c4f-4920-b6fa-88846c0bfd5c" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55eb48f3-2bbf-46f4-8860-3e3d374712f8" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company's available-for-sale securities have a stated maturity of less than one year. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77a69893-ae01-49f6-8cf0-13038109d744" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:ShortTermInvestments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t hold any short-term investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78966eb7-c714-4395-8023-1347a051a46e" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial assets and liabilities are recorded at fair value.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies fair value measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted market prices (unadjusted) in active markets for identical assets and liabilities.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. These fair values are obtained from independent pricing services which utilize Level 1 and Level 2 inputs.</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_789ff192-05bb-48ce-9a85-9fa12d90bcc0" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. Included within cash and cash equivalents on the consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.095%;"/>
        <td style="width:1.641%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e00306ab-f6f0-480f-8596-8cf585e8d26b" contextRef="C_f06bf133-70a4-416c-a4f6-115eb78648e6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c839a69-49e0-4966-ab5e-fe2360d07120" contextRef="C_08232590-c5fa-4b08-bc08-e606069533f3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa3df16a-9f16-477e-936a-b7092ca759da" contextRef="C_f427656a-338e-4bdd-9bad-d6f9b666e78f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,246</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea77c7f2-e0e6-458a-a37e-ce5df3ed2468" contextRef="C_85108846-892e-47c8-9754-3c7dfc301d1c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,246</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48aaa204-e5d0-4439-a4ed-fcd4118ca665" contextRef="C_ac320d24-5fbb-42d0-93dd-dad1bc9ba82d" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115df286-815f-4bcd-9aed-1af2e85c2fdd" contextRef="C_200cc8e1-5269-466a-876a-228fe7dd6936" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7fd06e3-7ef3-4e25-b85b-b5ef4d122750" contextRef="C_514fb2b8-c4b0-4b5c-a2e4-0c1d1d0a3e36" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,277</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_648790a9-5218-4305-ac74-aac65d4c0a52" contextRef="C_680c3de3-4af7-4781-b111-7a9f83940645" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,277</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2526ba2c-07ee-43ce-8e0d-07a8bc0ca45f" contextRef="C_97e359d3-cfa5-442f-9a87-040db5c132e8" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_706610a5-ecd0-41e1-90e1-338b224832fd" contextRef="C_85108846-892e-47c8-9754-3c7dfc301d1c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb408008-c5aa-437c-a1bd-b39e0c3744ef" contextRef="C_f427656a-338e-4bdd-9bad-d6f9b666e78f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,246</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3695d138-f5c4-4cea-9e31-75b0f04e6f59" contextRef="C_97e359d3-cfa5-442f-9a87-040db5c132e8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66c67ed9-1888-42cf-945a-c6f3c74019c0" contextRef="C_85108846-892e-47c8-9754-3c7dfc301d1c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,736</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.095%;"/>
        <td style="width:1.641%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.04%;"/>
        <td style="width:1%;"/>
        <td style="width:12.245000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b175895c-d228-4403-976f-9517d748507b" contextRef="C_f9a7cc9f-d6ce-4f09-85e0-f27ce671852a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_452a5a97-867f-48fb-9ebf-1b2871d3a542" contextRef="C_df5cb9c5-cc2b-4539-8abf-128c08a87c60" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae467995-0719-4024-86e1-802de458426b" contextRef="C_65b7835c-8f67-4c38-a18d-054d0149baa8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3620ac9b-f0ec-4e1c-ac65-c0b4676c4115" contextRef="C_10ef38e2-ed82-4422-8141-1f5959c9d8b4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef30c832-e417-4f71-8c6f-99b172808de0" contextRef="C_65b7835c-8f67-4c38-a18d-054d0149baa8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23d7cf72-6659-4281-8b15-e20348146d2a" contextRef="C_10ef38e2-ed82-4422-8141-1f5959c9d8b4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75a4433a-af5f-4383-ac99-1441b220a8b6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6. Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_839d1be0-c968-45f2-b87c-4bbd409b05fa" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.36%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.1%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:13.06%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbaaa5da-f7fc-4ff5-9db7-ea480d92af40" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">624</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2da882f2-3280-4496-bc0a-9f5a0f716c8f" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">823</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3514016c-eeb1-437f-9316-067bdf96cbfe" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:PrepaidClinicalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,128</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2f07417-0c9f-48cc-aad3-b6aa928d2b8c" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:PrepaidClinicalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d5ad3c5-1cdc-4489-949c-be40ebe9e499" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74ac05b-b738-415c-bf17-046f6d982f9a" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92bad184-ab76-46da-9b79-b3101487921a" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db532db4-d3e5-433d-903b-2976761f111b" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_724b09aa-07c3-42e5-985a-1a69f47f6a87" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,027</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af87ae35-1b11-415f-afc1-a47fec0890f0" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,109</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0919702e-fa0f-4884-b4ac-8528be7192fa" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other liabilities consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9731d953-d4bc-4740-af3c-cbf5751088f9" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,003</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b27ed9-2c7f-468a-91f4-50d674c8b5a3" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db714a31-6dee-45b1-a877-4f96fdfebdb6" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:AccruedClinicalCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">451</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e5edd08-41e7-4970-abb8-39481799258d" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:AccruedClinicalCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,826</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc10d3a8-a505-44c0-8fb4-42c0b1d2b5cc" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64eae932-bd2d-49bf-bfc9-25dd14bc8c34" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef5f6edb-8d0d-472b-b338-38243623275d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54237953-60fd-4f9d-bb8f-f1bdac2a3338" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8838856a-25fb-43ad-b00e-e42a24e1fb3f" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,545</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_083513fa-4a2f-4096-b525-d1efb8d30efd" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,912</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c226b90-918e-4330-b1b8-fff74050b118" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:GoodwillDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7. Goodwill</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company determined that the sustained decrease in our market capitalization constituted an indicator of impairment and as a result, a quantitative goodwill impairment test, utilizing the market approach, determined that the fair value of the reporting unit was below its carrying value and the goodwill was fully impaired.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded an impairment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_533cdab8-ccd3-42cc-874a-703fb6753111" contextRef="C_58bb8acc-ddde-40c9-8a7d-dbf46fcb11f2" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">48.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022 for the full write-down of the goodwill recorded as part of the acquisition of Anelixis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_783f52b2-6f1c-480f-93ff-06d7283b31b6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment was recorded for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04e71cfd-2689-4f1b-a9f8-4fa301fc0daa" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfGoodwillTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6a6e49e-a344-4e5a-80eb-1833cea91892" contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,648</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8379acf1-9294-49e7-8e3c-15489eb9e001" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a96f80d-7f84-42e0-be35-74bdbf453e45" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c326e10-f54b-405c-ad7e-4c0dc40983f0" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7e30182-560a-4215-96f5-a3c8913f7ad5" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52a9b461-0751-4913-b7b7-88a4b7c20af3" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space under various operating leases. Total rent expense for all operating leases in the consolidated statements of operations and comprehensive loss was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13cb91ca-cc63-4a46-8e07-c3992d4112f6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_e0fe06e5-3dbc-458b-8b56-c657d3cb0ae8" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d51b4cd-143d-49ae-8541-be8cc6f0b48c" contextRef="C_fdf8105d-12d9-4345-b55c-4de997687b56" name="eldn:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">5,197</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Irvine, California, that expires on  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2fd5b06-23e2-4579-b707-540f59e4cb29" contextRef="C_b10db2e1-d9c6-4be4-9ba9-86c0ebed4c56" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as amended.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 4, 2021, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a2b5e5e-8787-40a6-a64a-cfc752c0f321" contextRef="C_ed539061-91d5-4d71-9cf6-98e903ea5f7b" name="eldn:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">6,138</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Burlington, Massachusetts, that expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64d3e78c-0b1e-47cc-9fb5-d864b0ae8d61" contextRef="C_ed539061-91d5-4d71-9cf6-98e903ea5f7b" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 20, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if a contract contains a lease at inception. Our office leases have remaining terms of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d93d923-9af3-4fa0-84b6-c579f3faeb65" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:LesseeOperatingLeaseRemainingTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and do not include options to extend the leases for additional periods.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities as adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental secured borrowing rates corresponding to the maturities of the leases. As we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f603cdc7-5d3b-4ad6-ae61-988f5044d235" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding debt nor committed credit facilities, secured or otherwise, we estimate this rate based on prevailing financial market conditions, comparable company and credit analysis, and management&#8217;s judgment.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our leases contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce our right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we do not currently have any lease agreement with lease and non-lease components, we elected to account for lease and non-lease components as separate components.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected the short-term lease recognition exemption for all applicable classes of underlying assets. Short-term disclosures include only those leases with a term greater than one month and 12 months or less, and expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less, that do not include an option to purchase the underlying asset that we are reasonably certain to exercise, are not recorded on the consolidated balance sheet.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1685f13d-1f54-40e0-94c1-e431ffb3e23f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.68%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd4a6b21-984b-45c2-befb-90363abb4caf" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3">400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebe75a57-d481-4a29-8b5b-999f85a42745" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3">403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Includes variable operating lease expenses, which are immaterial.</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afde88f3-d68d-43dc-b567-2b366d0f73f6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:OtherInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information related to leases was as follows (in thousands, except lease term and discount rate):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.367%;"/>
        <td style="width:1.341%;"/>
        <td style="width:1%;"/>
        <td style="width:13.466000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.341%;"/>
        <td style="width:1%;"/>
        <td style="width:13.486%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Cash Flows Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows from operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15a4389f-9f44-4969-837a-aae9da62fa08" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3">378</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5634d83-a18b-4e13-9412-5d74430dfd04" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3">387</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset obtained in exchange for lease liability:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78363493-fa7a-4511-9f40-937cc58f2b80" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining lease term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_044bad78-bc74-421d-b9af-019b383efcb0" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.95</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_50bb3ca8-1ed3-4d77-b0ab-94da1c6f4a42" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.95</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8d250f7-2604-4e0d-a59b-38d349b39043" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4">2.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_045f0e55-3dad-4b95-9e68-f86c1e55aec3" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4">2.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77190969-39c8-42b0-907b-d3a0c2ae0feb" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.64%;"/>
        <td style="width:2.84%;"/>
        <td style="width:1%;"/>
        <td style="width:23.52%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7dc6ca5-c7fa-47e8-bdf6-1c3808f6d67a" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3">388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a44b4d0-95e5-4df8-b6f3-32fd92a8c3a0" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3">388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8968d6ba-88f5-421d-89d9-0091a0a84368" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c71e3195-a273-4291-9884-b45580c59929" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3">383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a00fa622-366b-42a4-9402-60270aeec8e7" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1285f0c5-22bb-47ea-888b-a9d8b5de2446" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grants and Licenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ALS Therapy Development Foundation, Inc. License Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2015, Anelixis executed a License Agreement (the &#8220;Agreement&#8221;), which is an exclusive patent rights agreement with ALS Therapy Development Foundation, Inc. (&#8220;ALS TDI&#8221;) for certain patents and &#8220;know-how&#8221; of ALS TDI. This agreement continues until the licensee terminates the agreement with ninety days written notice. The Agreement requires license fees payable to ALS TDI, subject to the achievement of certain milestones and other conditions.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first and second milestones of the Agreement are the dosing of the first subjects in a first toxicity study in non-human primates and the dosing of the first patient in a Phase I Clinical Trial, respectively. Both of these milestones were achieved as of December 31, 2018 and 2017. The fee due for the achievement of these milestones was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eec89bbc-0eef-4eb4-98f5-8d404851d000" contextRef="C_80152760-f5f1-49d1-818c-7be41d8bad59" name="eldn:FeeDueForMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_c0bcaa92-bfc3-4ada-a40a-b287965f4471" contextRef="C_bd6fbf82-130d-405c-b4df-97d3c4f5ddb1" name="eldn:FeeDueForMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5">1.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each. During 2018 and 2017, Anelixis issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61472b9b-c013-42bf-8c8c-eca0a426f094" contextRef="C_b1b6b20f-2b7f-4988-9b59-14ae1a547e10" name="us-gaap:StockIssued1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_75faa493-4f58-413e-b437-14a39c4c9a00" contextRef="C_e3da60b1-bf6f-43ce-b8eb-e383f1879995" name="us-gaap:StockIssued1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million worth of its common stock in lieu of making a cash payment. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c667c10b-1d64-4b36-9b0b-9a2fe0ea435a" contextRef="C_17e67f10-b293-4956-8cef-526a32b65ef4" name="eldn:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e645bd29-28c5-49ae-8032-52496c8c69f9" contextRef="C_1c94ca06-3730-4b18-9348-e88243d8d2e7" name="eldn:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milestones achieved during 2023 or 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Agreement was amended and restated in February 2020, and a first amendment to the restated license agreement was executed in September 2020. As amended in September 2020, the remaining milestone payments for a first licensed product total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b345447-e609-4dfb-b40a-8758e6ff0f02" contextRef="C_0214fd64-e27d-4163-83ae-6f06bab5710b" name="eldn:RemainingMilestonePaymentsForFirstLicensedProduct" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In the event that the Company develops a second licensed product, the Company is obligated to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d01c33e-1160-4927-97ab-1f43dc745481" contextRef="C_e474f40b-c32d-4216-952d-084ee8fda28a" name="eldn:RegulatoryMilestonePaymentsObligation" unitRef="U_USD" scale="6" decimals="INF">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in additional milestone payments.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the milestone payments, the Company is required to pay ALS TDI an amended annual license maintenance fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a017330-15a4-497b-b8a5-0e318100f8aa" contextRef="C_c4d5fab0-b529-4936-88f9-d28a56338778" name="eldn:AnnualLicenseMaintenanceFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million beginning on the earlier of January 1, 2022, the Company&#8217;s first sublicense, or change in control, as defined in the Agreement. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41f351f9-561e-4990-af95-41abd367d8ac" contextRef="C_17e67f10-b293-4956-8cef-526a32b65ef4" name="eldn:AnnualLicenseMaintenanceFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_51024e76-31a8-4e49-88e4-04bd7dd84a04" contextRef="C_1c94ca06-3730-4b18-9348-e88243d8d2e7" name="eldn:AnnualLicenseMaintenanceFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annual license maintenance fee in each of 2023 and 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the Company shall pay ALS TDI fees based on reaching certain levels of annual net sales of any product produced with the patent rights. A royalty in the low single digits will be due on aggregate net sales. Upon the first calendar year of reaching $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b97e784f-07db-48e5-a5d7-8aac2ae028cd" contextRef="C_9cc0ccfc-b7a6-4b18-b60e-c2dd9520c8bb" name="eldn:AggregateNetSalesAchievement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate net sales, the Company shall pay ALS TDI a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f574257a-4681-4a3a-83e6-4c2a7d176c49" contextRef="C_8a9a710c-7ac2-4558-9624-0a06bad3b9b1" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the first calendar year of reaching $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b42cc8ae-20c7-435e-9387-810ca0d1a336" contextRef="C_e0208a52-3605-4067-a592-6f1d7092a39c" name="eldn:AggregateNetSalesAchievement" unitRef="U_USD" scale="9" decimals="-8">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion in aggregate net sales, the Company is obligated to pay ALS TDI a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_525cfd44-a0a1-48b0-9bf6-9ec0ec667715" contextRef="C_91677af4-ce57-4e73-97a4-b3d085786c69" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lonza Sales AG Inc. License Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2018, Anelixis executed a License Agreement (the &#8220;Lonza Agreement&#8221;), which is a manufacturing know-how rights agreement with Lonza Sales AG Inc. (&#8220;Lonza&#8221;) for the use of certain processes and know-how related to the manufacture of tegoprubart. The Lonza Agreement continues until the later of the last Valid Claim (as defined therein) or ten years from the First Commercial Sale of tegoprubart, as defined and subject to the conditions therein. A royalty in the low single digits will be due on aggregate net sales of tegoprubart that is manufactured by Lonza or any other third-party or licensee.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">eGenesis, Inc. Collaboration Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, and subsequently amended in January 2023, Eledon executed a non-exclusive collaborative research agreement with eGenesis, Inc. (the &#8220;eGenesis Agreement&#8221;), under which eGenesis will gain access to tegoprubart for eGenesis&#8217; ongoing preclinical research and development xenotransplant studies of human-compatible organs and cells for the treatment of organ failure. eGenesis will pay Eledon for supplies of tegoprubart based on the number of study days per animal needed for the eGenesis preclinical xenotransplant studies. The eGenesis agreement continues until September 2025, unless terminated earlier by either party.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Matters</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company&#8217;s results of operations, financial condition or cash flows.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8979e013-8d3d-4a88-878c-5c970de9a39f" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts associated with such indemnifications have been recorded to date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69dd6d2a-45e5-42c8-ab6f-ec28d7b59e4d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:ContingentLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a435c4d0-4457-4f17-851a-c2f1a7c4d64c" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:ContingentLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contingent liabilities requiring accrual at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc0346d0-cb67-4718-9e28-23d04fc49a70" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9. Income Taxes</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ec88bdd-bfad-4ec7-931f-abbdd4206c06" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss before income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses before income taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fff2b6b2-7b51-4ff0-b84b-bd54b5d15874" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,525</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29c1ac32-1a79-4d81-a4a5-967d483d12b4" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,159</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa95a023-0e93-45fd-aa23-5983e65c422d" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3">199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8941f030-46cc-4004-b3bb-a4810490eeee" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3">193</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9637abab-4235-43e9-bb01-10304d68af9b" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,326</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b6933dc-8f81-498c-b625-198b2501a047" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,966</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_369cb136-87c8-4a24-a429-d40c13105bdc" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision (benefit) for income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.88%;"/>
        <td style="width:3.4%;"/>
        <td style="width:1%;"/>
        <td style="width:12.64%;"/>
        <td style="width:1%;"/>
        <td style="width:3.4%;"/>
        <td style="width:1%;"/>
        <td style="width:12.68%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
       <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to income taxes under U.S. tax laws. The Company is</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to an Israeli corporate tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96a825f1-f3b9-4c00-b44a-e7617d9b315f" contextRef="C_148ad8a7-b70c-496a-95b6-25eb9918c6d2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2">23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in 2020 and thereafter. The Company was subject to a blended U.S. tax rate (federal as well as state corporate tax) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87b9ee6f-702a-4627-994a-082cb5a2b48a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:EffectiveFederalAndStateIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2"><ix:nonFraction id="F_24f9e00e-8e00-481e-bf2b-550eac9b839b" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:EffectiveFederalAndStateIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2">21</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its review, the Company concluded that it was more likely than not that they would not realize the benefit of a portion of its deferred tax assets in the future. This conclusion was based on historical and projected operating performance, as well as the Company&#8217;s expectation that its operations will not generate sufficient taxable income in future periods to realize the tax benefits associated with the deferred tax assets within the statutory carryover periods. Therefore, the Company has a valuation allowance on its deferred tax assets as of December 31, 2023.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will continue to assess the need for a valuation allowance on its deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab9ffac1-22ab-42df-95d9-b5cf7713b50f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.913%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:14.783000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:11.422%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5345da40-968f-424e-819e-f6bcfd23f5eb" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4812d1f-1756-483f-a226-182e58f0fc9f" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,473</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal tax benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9fd51e8-66b9-4027-b65a-a9b9d8cb5e86" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:StateIncomeTaxesNetOfFederalTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,097</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73cc4ee7-2f9b-4bad-a622-4a4ff6bf4696" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:StateIncomeTaxesNetOfFederalTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,678</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_beac2f22-0d3d-4923-aebc-5863ae4543c4" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f86536-f4c5-479f-bd97-9f7fdc2143b4" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d0a97b4-e245-494f-8588-1262fdd40a18" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">728</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5803f6e-be3f-4a4f-924d-c599cf946d0e" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15c21510-9095-48aa-87fb-8b28828b6945" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c28f528-b0b6-4c94-afb0-c45765d4efaa" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:IncomeTaxReconciliationPermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01f11a74-f722-4035-ab26-21847da961b6" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:IncomeTaxReconciliationStateTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1226041f-d2dc-42da-8ff3-6b80f7970ff6" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:IncomeTaxReconciliationStateTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NOL true-up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63e2bdb7-52bf-4358-8877-b936e89a54ae" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:NOLTrueUp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f20f06fd-aba3-4aa0-bbc4-aa841a9a38dd" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="eldn:NOLTrueUp" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">337</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f668584-44d0-4544-b667-e7a1f635202b" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">566</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21e45250-644a-4b84-88e9-f05d24f8dc1c" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9917f6e6-300c-4940-9a20-d9de8cd45ac5" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f93a4481-e347-442e-87ac-cdb26aaf5504" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,697</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73865efe-e9d4-437e-99e6-0f05081ec762" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7abe1af1-d28f-427d-9f00-a320e387ea94" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efb166c4-bfb4-48eb-9ca5-2c00efc89fc7" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa4f0508-51f3-4e4f-8bdf-cbb4e98a8ece" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f884e9a2-c917-4242-9543-026cf13a39ef" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7b9a729-8397-4891-af25-f0a0e76f7fe1" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,089</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e288e59-e37d-4136-a30d-7e7934fb237f" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,230</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1b8b0da-24f2-4fcf-ba05-3f9aa092e925" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,202</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51a29037-05be-4ec1-ba2a-81ef8009f883" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6c821c8-dbd8-4d44-8f80-288b065d2000" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c602c27-1a1a-4469-8a56-c44be6f32382" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">452</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec130425-36e4-40d6-bbbc-6bbf24551aa0" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e94e731f-4298-4c4e-8c39-122d7d7fa263" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_448d7e7a-6ac6-4404-9a11-d11cc6571daa" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,085</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87ef1e0c-e3c7-42e1-b918-adb2d676a5d3" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,874</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c43ca884-da06-49d4-9b79-48b1b7bcb36d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:DeferredTaxAssetsDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6b1b705-f7ad-4147-a66b-5d6bcb80846c" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:DeferredTaxAssetsDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3313328d-2009-456f-80e5-492386f91ee4" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42427eb8-b130-4fb9-b0a8-944db630b351" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2532339-9b00-4be2-9d8c-4ff96f1d17d7" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,828</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d9c0d2d-1f22-4f6b-bd78-3f307a586049" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e2dab18-f656-4472-bca1-25031b589468" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:DeferredTaxAssetsRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2a2c575-1361-4677-95ad-b1fb29bfc0d6" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:DeferredTaxAssetsRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b23b97a9-efec-4b8e-b570-4ec76f0cf674" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="eldn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afa85a54-684e-47f3-9a80-510cb00a3a46" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="eldn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,787</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e2114b0-2438-4aab-ba64-8c6ad2953c54" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,769</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90c31700-14ea-4fbb-ba5b-d21216e69feb" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,965</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_439484a7-c763-447c-8698-76842dd1276e" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1eb76a-c160-4da2-89a6-37a642624e9f" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bcdb487-3cb3-4156-9af2-e380507b4f08" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_febf2f4f-39f3-413f-9c36-c5a2234df58d" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3688dd32-3d1f-426e-bdda-7939ed632350" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the years presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross unrecognized tax benefits at the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e8fb02e-a7c8-49dd-bdba-c8efbab81fc2" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9d8b728-b14f-48ae-8d40-37eadf2b3a2b" contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions from tax positions taken in the current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3db5e83-85bc-4462-8545-1f9282603b91" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbdbbdab-1792-4030-8cdc-bdfaf9d988aa" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">914</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions from tax positions taken in prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56d6da77-5323-42de-be1c-0ae40e73e17f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1574c4-e098-4b01-9a6b-bdf31cac1d7d" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross unrecognized tax benefits at the end of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecc2558c-4921-40bf-9d19-435b8d38dba2" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,636</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_033e008f-ea24-4db6-b183-ab03aac36808" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,664</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred income tax assets have been offset by a valuation allowance, as realization is dependent on future earnings, if any, the timing and amount of which are uncertain. The net valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c090cf5d-bcd6-438f-96e4-b8e37a141bc2" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_18aceca3-bd25-44f5-966c-7b24d1a4defd" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from December 31, 2022 to December 31, 2023. The net valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72e17236-98df-4cf6-bbb1-6e318ad5f457" contextRef="C_a2215e8a-709f-4e4f-a87d-5319589f877a" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from December 31, 2021 to December 31, 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#8217;s deferred tax assets, and the timing, likelihood, and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a valuation allowance has been established.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7055052f-6d77-4e78-9ac0-123a1ad88c11" contextRef="C_8dc70a81-570f-425e-8e77-d3cbed342a71" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdda703f-6739-42b1-9611-8bbf05831602" contextRef="C_ed778020-ad3f-469d-86df-b93a95a7576c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">56.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, available to reduce future taxable income. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also has state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a6081bc-dde0-422c-926f-41c9b8c0f721" contextRef="C_f0af738a-7254-4f32-bf85-c20c9f5d1f80" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa686741-7246-43b5-b2e8-139c6ed16ccc" contextRef="C_ac28187a-81e1-43da-a679-686dc898f95a" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Both the federal and state net operating loss carryforwards incurred before 2018 begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_358d834c-f3d0-4c4d-8924-c0008ce53cb6" contextRef="C_9bd49aca-76b8-41b8-851c-421b99dd8a37" name="eldn:NetOperatingLossCarryforwardsExpirationPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if not utilized. The federal net operating losses incurred since 2018 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_601da595-43d4-438d-9837-866b0b20c6d1" contextRef="C_8dc70a81-570f-425e-8e77-d3cbed342a71" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million do not expire. The state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17e30db9-fc78-4f07-a1ba-fc3913346707" contextRef="C_84888892-87f5-4e23-bd7c-63309c46746a" name="eldn:NetOperatingLossCarryforwardsExpirationPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had Israeli net operating losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cd43ac9-0ead-4fd5-8eee-88ff78606704" contextRef="C_f418a451-c1a8-49bf-9510-a9346093387d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_d88fcc7f-d2ad-40dc-a851-9f7aa936b395" contextRef="C_5fd780de-3625-4605-acfa-3c1d91d4974d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="U_USD" scale="6" decimals="-5">7.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which carryforward indefinitely.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa3fd50-7cd8-4f08-8fef-0b2d20d99380" contextRef="C_8dc70a81-570f-425e-8e77-d3cbed342a71" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5209db54-afb4-4116-a639-40d308b8754f" contextRef="C_ed778020-ad3f-469d-86df-b93a95a7576c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. If not utilized, the carryforwards will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04cc231b-d79f-4fe4-9d71-6815be157637" contextRef="C_9bd49aca-76b8-41b8-851c-421b99dd8a37" name="eldn:TaxCreditCarryforwardExpirationPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_767ec8d8-d85c-48b8-ad80-bae2f970ba02" contextRef="C_1d5fba3f-307a-4a36-acdc-6c3371fb0c8a" name="eldn:TaxCreditCarryforwardExpirationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has state research and development credit carryforwards or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f85b072-4e75-4d9f-9891-074c41b343ed" contextRef="C_f0af738a-7254-4f32-bf85-c20c9f5d1f80" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb25e494-52c3-4244-a1f3-3d74022dcc04" contextRef="C_ac28187a-81e1-43da-a679-686dc898f95a" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, which will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86d38534-250e-4b53-9d7c-6eb185f32ca9" contextRef="C_1d5fba3f-307a-4a36-acdc-6c3371fb0c8a" name="eldn:TaxCreditCarryforwardExpirationPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> if not utilized</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Internal Revenue Code (&#8220;IRC) Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_649ff934-ef04-4faa-ac98-f05990f6e193" contextRef="C_fc7dea4e-952b-4624-b726-7fb18eb4ecb2" name="eldn:PercentageOfCumulativeChangeInOwnership" unitRef="U_pure" scale="-2" decimals="INF">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% occurs within a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df75a998-0ebb-4ba6-8519-5538d1900d35" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s ability to use its remaining net operating loss and tax credit carryforwards may be further limited if the Company experiences a Section 382 ownership change in connection with future changes in our stock ownership.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the Company files income tax returns in the U.S. Federal jurisdiction, California and Massachusetts. The Company&#8217;s tax years for 2018 and forward are subject to examination by the Federal and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88b22af4-ae6f-42f5-8c53-a8b6f2d3a923" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_20e2cdfb-77cb-452f-aecc-c82137bd4e3f" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest and penalties associated with uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e7c81bb-457f-47bc-bdf0-bbcbc60074fa" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a176d74a-ce97-47f7-845d-3ce07332ca49" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded any interest or penalties in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4079bba3-c595-4671-bc45-6892350b3f24" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10. Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc7f483e-fe04-430b-a954-520a086c808f" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> authorized shares of preferred stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb6c09cd-929b-46d3-a623-1805e1c44264" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share:</span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> non-voting convertible preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37d79de2-91fa-459a-8599-fb1ff6ed25df" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fb576c27-7c36-4671-9741-86c2c1f0b8a1" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">515,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares designated; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51b642aa-3930-46a2-86aa-1a543bb67ba6" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cbd042f4-f654-4c2d-b567-2c927384d8e0" contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">110,086</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd85bc06-6cfe-4d7e-a715-06c0db747e72" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1111e993-df92-406f-970f-8ee57d611ad7" contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">117,970</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued and outstand</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ing at December 31, 2023 and 2022, respectively; and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series X non-voting convertible preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d340f872-bdcc-4a02-9e80-01353d3705a1" contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_aba4f1e2-2ff3-4811-8e2a-d0b37924b17f" contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares designated; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ae30458-5fb6-4380-8743-2dfeec898650" contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_54c5f5d3-dad8-4709-b21f-528dbe59336d" contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,422</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccd4c4f9-3729-4d1d-a58c-0d95bd2c5c29" contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_be8df7e1-689f-40ce-b997-ac475b0e4650" contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,204</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued and outstanding at December 31, 2023 and 2022, respectively.</span></div></div><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or X non-voting convertible preferred stock (the &#8220;Preferred Stock&#8221;) is convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7cda5d-2bab-43fb-ab2c-82ac6a81ffc5" contextRef="C_b4d3a667-0d9f-40ac-bb0e-95f7b4b21745" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_929efce6-4c7d-49b3-86b0-bb83616e6a85" contextRef="C_9eda5a95-af05-48df-860c-3566c2e5b7b4" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">55.5556</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, at the option of the holder at any time, subject to certain limitations, including, that the holder will be prohibited from converting the Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d560fef-7109-47a7-b71f-a81d9d88361e" contextRef="C_539b64d7-b76a-4d73-b8da-2e58862a41c3" name="eldn:ConversionOfPreferredStockConversionBlockerPercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9e9b97da-10b1-4ac9-840b-854fe3f5a68f" contextRef="C_dec7f080-9ef4-430f-acea-1afbd5a8afda" name="eldn:ConversionOfPreferredStockConversionBlockerPercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1dd96f0-8295-468f-b7ac-ef13d33806ee" contextRef="C_3f2ef666-c1cc-4c55-a513-878df085d0cc" name="eldn:ConversionOfPreferredStockConversionBlockerPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_62640bcf-e864-45ed-b726-25b85f078908" contextRef="C_e5deb814-b818-48f3-be71-4e54d19ae9f1" name="eldn:ConversionOfPreferredStockConversionBlockerPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total common stock then issued and outstanding immediately following the conversion of such shares of Series X Preferred Stock or Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock, respectively. The holder of the Preferred Stock is entitled to receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to-common-stock basis and without regard to any beneficial ownership limitations) to and in the same form as dividends actually paid on shares of the common stock. No other dividends will be paid on shares of the Preferred Stock. In the event of any liquidation, dissolution or winding up, the holder of the Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Preferred Stock were fully converted to common stock, which amounts shall be paid pari passu with all holders of common stock. Shares of the Preferred Stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of either series of outstanding Preferred Stock will be required to amend the terms of the such series.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Equity Distribution Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 31, 2021, the Company filed a registration statement on Form S-3 containing a prospectus and prospectus supplement (the "Prospectus") under which the Company may offer and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38dc2eee-6133-4b2a-8252-a4e6b3451911" contextRef="C_5bcb3f59-3ee1-413a-b49d-33149e98e0b2" name="eldn:EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of its common stock, from time to time, pursuant to an open market sale agreement with Jefferies LLC and by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the &#8220;ATM Program&#8221;). Pursuant to the &#8220;baby shelf rules&#8221; promulgated by the SEC, if the Company&#8217;s public float is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76119121-601e-44a5-a233-7bca97678eff" contextRef="C_12a2d2e1-2aaf-4445-a36c-14fb7b5c2325" name="eldn:PublicFloatMinimumBalanceToBeMaintained" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of specified measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement, including pursuant to the ATM Program, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the Company&#8217;s public float.  As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, due to the SEC&#8217;s &#8220;baby shelf rules,&#8221; the Company was permitted to sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f1d3e1c-44ee-4e35-9666-7354eac0dbf5" contextRef="C_1db222f1-dbb0-49ac-9c1f-ef8b555d7efb" name="eldn:EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock pursuant to the ATM Program. The Company will remain subject to the &#8220;baby shelf rules&#8221; under the Form S-3 registration statement until such time as its public float exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27015a6f-156f-4317-a138-91bd38914af1" contextRef="C_12a2d2e1-2aaf-4445-a36c-14fb7b5c2325" name="eldn:PublicFloatMinimumBalanceToBeMaintained" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f0c4922-8f18-4544-a923-d3763298b004" contextRef="C_ccdb24f4-ddf1-43b9-891d-1a463b208bfb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a4e707ab-9c4a-45d7-a846-f6263d5001e8" contextRef="C_23d71061-54b9-42a6-9e17-5f08efea1eb0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were sold</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Prospectus. This Form S-3 registration statement pursuant to which the ATM Program is registered will expire in May 2024, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4398531c-f290-415d-9eab-8a2edf0e5b6e" contextRef="C_c5ff90c2-7ab7-4323-9fa7-e9cdeca70a8f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock may be sold under the ATM Program after that date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Warrant Exchange Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 21, 2021, the Company issued warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70b99c42-d489-4512-9805-25072589f507" contextRef="C_606d38b0-f6ba-43cf-b237-35fd69e618d0" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">298,692</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in exchange for warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a077176-86ce-441b-8198-7633dc5e8eca" contextRef="C_f301cf92-7fb0-4ba2-92cb-d9b6ab58209c" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,376.456</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock previously issued as part of the Anelixis merger. These Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock warrants were replaced by Eledon for the outstanding warrants issued by Anelixis that were not settled upon completion of the merger.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Exchange Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 11, 2022, the Company entered into an exchange agreement (the &#8220;Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange Agreement&#8221;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, L.L.C. (collectively, the &#8220;BVF Exchanging Stockholders&#8221;), pursuant to which the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchanging Stockholders exchanged (the &#8220;Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange&#8221;) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28fff4f1-8b9d-408e-a95c-ea943128978b" contextRef="C_7801a479-8e65-474f-81b3-70e988f0cb94" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">550,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d377f00-d8d3-485e-a484-9505cf4ca2a7" contextRef="C_d7bc39d7-c639-45d4-a935-4c52633b71fd" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,899.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Securities Purchase Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, the Company entered into the Securities Purchase Agreement with Purchasers, pursuant to which the Company agreed to issue and sell to the Purchasers in the Private Placement (i) in an initial closing, (a) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_244a6946-0c07-410d-8150-de89a46384b4" contextRef="C_cff03e8e-4e84-4751-8bed-4bbfff630a65" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,151,518</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fcd5cfa-fdeb-49ad-bbd0-bc5b03497294" contextRef="C_cff03e8e-4e84-4751-8bed-4bbfff630a65" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share, or pre-funded warrants in lieu thereof (the &#8220;Pre-Funded Warrants&#8221;), and (b) common stock warrants exercisable into an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93f4da79-3dfe-4f2f-92d7-39ea8f687c7e" contextRef="C_cff03e8e-4e84-4751-8bed-4bbfff630a65" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,151,518</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants in lieu thereof) (the &#8220;Common Warrants&#8221; and, together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;); (ii) in a second closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f7c6e3d-3de3-44c4-b417-dde220a36d7a" contextRef="C_0adbfddb-526c-4e99-8cac-1ee645fd34e6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,202,024</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants); and (iii) in a third closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb7e118f-7795-48bf-b453-def14091ae33" contextRef="C_5db2a782-5d40-4e38-afa2-a24096cf9b4c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,252,530</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_492d115b-6321-47f6-8931-7f08a3a01b84" contextRef="C_3a8b2ca6-ee48-4d8b-9174-016ccf545018" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_059f57e4-f9e1-46b8-8f56-b6448c39b666" contextRef="C_31d98449-23a4-498d-bc0e-c00c14f1718b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 5, 2023, the initial closing occurred and the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca20fbc3-6272-4020-a86a-4d8c663fa33b" contextRef="C_90229839-dc48-46bd-88f4-a22efae9078c" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19d861d8-5595-4296-9f35-9bfb99af9838" contextRef="C_90229839-dc48-46bd-88f4-a22efae9078c" name="eldn:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting offering costs, in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7448835-396f-486b-9850-e3b50e5dd841" contextRef="C_b9deefa9-7710-433e-acac-3e9a0bd20f91" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,730,168</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70817560-1b5b-4b47-b75f-e50c7708a38d" contextRef="C_9a6202d9-fada-461a-bd65-85c4b8841070" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,421,350</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The Company may receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5da965b-f4a8-46b6-91b0-997fc7c604d0" contextRef="C_4fc735f4-0e20-4c55-bc5a-1509ab504714" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon sale of the shares to be issued in the second and third closings, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40c612be-185a-4f0e-9486-3662564aa7ea" contextRef="C_8b7b00cf-f725-4f04-abf7-50d2422f6755" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (&#8220;Registration Statement&#8221;) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The Registration Statement became effective on June 2, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Conversion Agreement of Non-Voting Convertible Preferred Stock</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 16, 2023, Cormorant Global Healthcare Master Fund LP provided notice to convert (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feae639d-325a-4b3a-a775-2250abd7dcc4" contextRef="C_d67b8fc7-20c1-4f9d-9bf3-e028f161e18b" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,782</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X Non-Voting Convertible Preferred Stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edb6d53f-6bd2-4cda-9214-539baed8e866" contextRef="C_f1772a59-3433-4d38-9a57-13a0ec38ee2b" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting Convertible Preferred Stock, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_216ef66b-74e7-49e4-bab3-075625500014" contextRef="C_22837696-6636-4174-85b7-968e5779be90" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,883.586</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f903687-f676-408d-a73e-5f29efb6efec" contextRef="C_891105d4-f431-4944-af9d-ba738f8db8f6" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">437,977</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Exercise of Pre-Funded Warrants</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 10, 2023, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae26f71e-1d67-45f7-b0fd-da91fb97bd80" contextRef="C_2338023d-7d9b-4ae4-860d-5a670fc77d43" name="eldn:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">501,197</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1babefd-0104-46d9-b68c-0f8f8665cc21" contextRef="C_2338023d-7d9b-4ae4-860d-5a670fc77d43" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which were issued in conjunction with the Securities Purchase Agreement. On July 14, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17f303ab-560a-4536-bb01-a3ec86f20b38" contextRef="C_16a5f966-35bb-40a6-836a-438436efb35a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">501,197</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 2, 2023, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc28621a-1925-41c6-a843-cc6911946677" contextRef="C_5b4e4097-491a-4d6f-afa0-8dd0e72ce61a" name="eldn:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">653,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c82fb231-7fef-4f1e-bc87-1e8ed7fe4f20" contextRef="C_5b4e4097-491a-4d6f-afa0-8dd0e72ce61a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which were issued in conjunction with the Securities Purchase Agreement. On November 6, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b910540e-3cb7-4acc-bc5a-0cbeba1d7f6d" contextRef="C_085ab3ce-d345-4414-8f9f-ec51eb1a7ed0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">653,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_831f9d78-880b-48c7-a3c9-0d27da770451" contextRef="C_b7d71759-5259-4d1d-9aa7-792cc31e7654" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,564,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants were exercisable into common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_384bfbd9-6532-4395-94c0-7d4ef3f3678a" contextRef="C_f448875a-e2e2-4f12-b2e3-7d76a53fa08d" name="eldn:ScheduleOfWarrantActivityTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the warrants to purchase common stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.074%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.757%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.757%;"/>
        <td style="width:1%;"/>
        <td style="width:1.42%;"/>
        <td style="width:1%;"/>
        <td style="width:13.757%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.757%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Roll Forward of Warrant Activity</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Private placement warrants</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pre-funded warrants</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrants exchanged for  Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">preferred stock</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13b7ddf5-0ea8-42b2-91f4-a6e22e222c29" contextRef="C_95b9fc77-0964-46e8-8014-8c0dbfd4b766" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">337,822</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01bebc93-c226-4096-883d-2fe2f3b83e07" contextRef="C_f3213c02-d3c7-4370-aa17-1e548a1026d5" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">509,117</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79a2be02-bfb9-416d-9568-011846b30e45" contextRef="C_f447210b-d619-429a-aaa3-21f7e7229a49" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">298,692</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5756f4ef-a424-4e34-abb0-8f25541c6864" contextRef="C_2aed4a90-b683-4eb4-a34b-231381f0b672" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,145,631</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87bc9940-0cf6-4746-b45c-37d80053fc1c" contextRef="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,151,518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff6585bc-6829-493d-ac04-7fc47014f623" contextRef="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,421,350</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b764d00-8d61-434c-903e-550e02279769" contextRef="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_705a82fe-40ed-4959-9a2b-bca1c160f052" contextRef="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,572,868</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82ab8e0b-ec31-42d0-85ca-0b0fced8f17e" contextRef="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fbc8b93-fcfb-436a-81f2-6618d4a49f89" contextRef="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,154,197</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8361d72-2788-42f5-8a72-7df7d2170619" contextRef="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13562481-befc-423d-aa91-fdec7a2f3c12" contextRef="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,154,197</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93cb3bc4-37bc-48b0-bace-e97a1f5d1835" contextRef="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf81be00-9bee-4f81-a0a9-79c06034290d" contextRef="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0be75af6-98d2-45b1-bce5-55e2271c2c26" contextRef="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9daf19fa-f4b1-4cbd-9651-c0ff8d7f804f" contextRef="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82a80836-21c2-4f77-ac09-4375a2621ab7" contextRef="C_94a7e619-bc0a-46f9-82d4-e85969a5f850" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,489,340</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2b42be9-780f-49c5-8d8f-8755931a20a6" contextRef="C_157cedb9-5047-412b-85f9-6fbe8216f23c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,776,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77d4119f-3552-484f-b3f7-04a3eb59f2c6" contextRef="C_c1011001-4cbb-4b9f-93e6-39793a44b86c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">298,692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c188ace-59ca-445c-b04e-c29d392b31a2" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,564,302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_785ad75f-7734-4074-ae5d-40ddbb6adb68" contextRef="C_326577f3-b56f-4806-864f-4daf1c2d3bdf" name="eldn:ScheduleOfWarrantActivityTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4abee987-7f01-4724-b072-27631695de96" contextRef="C_170abf46-8a87-4bdf-bc25-11d52fb87c8e" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,207.419</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants exercisable into Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock which are convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc6c4f29-fcee-4d7b-8fe7-ec043742e5fb" contextRef="C_170abf46-8a87-4bdf-bc25-11d52fb87c8e" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,789,301</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.52%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:41.04%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Roll Forward of Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Convertible Preferred Warrant Activity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b00c2814-1c2e-40c9-ab96-c8d48ea2faca" contextRef="C_b49914b8-f522-4af4-8c0b-fb6529f0205e" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,207.419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed and replaced</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bf0b5a0-2637-44aa-a738-db6b505c8d0a" contextRef="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29e3e0b1-b04c-41a4-b6c5-820345d3723a" contextRef="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3df8f589-0288-443a-bdb3-84e69c840400" contextRef="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de" name="eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c29d86c-994b-40f7-b46f-94aac5c11ca8" contextRef="C_07827eda-fb88-4fed-aae9-6ed17feba552" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,207.419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c726a467-c9b9-4454-9f8f-f15888d74636" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11. Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Plans</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 21, 2023, the Company held its Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s 2020 Long Term Incentive Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company&#8217;s common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5566e52-a84b-47e4-940e-8eee1c0affb9" contextRef="C_497f04cf-da0b-4b5e-b011-34361d789ace" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares so that the new aggregate share limit under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_933a0956-c673-42e2-99cd-ad69d29d096c" contextRef="C_497f04cf-da0b-4b5e-b011-34361d789ace" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,460,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 26, 2033.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_608056c4-8324-4c03-b229-8fa7701f7c21" contextRef="C_d1c703b7-f5c2-420d-baed-484058777e18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,381,857</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e68bab5-e128-4ff7-a62a-9e03753c984c" contextRef="C_f6ce7cd5-abcb-4e3b-a08b-0f8a402a5e5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,476,372</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the granted stock options subject to the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customary </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">time-based vesting schedule. The remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70738a62-669b-41b1-9b38-1bf079bb882e" contextRef="C_d1c703b7-f5c2-420d-baed-484058777e18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,905,485</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options granted are subje</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ct to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the second and third closings of the Private Placement as specified in the Securities Purchase Agreement. Further, for the performance-based stock options granted to senior management, upon such second and third closing, a full or prorated amount of each closing shall vest based on the percentage of funding received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative to the total funding opportunity represented by the purchasers' second and third closing subscription amounts. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee2de176-1ae6-4b88-896b-3e2a535bbc51" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="eldn:NumberOfSpecificClinicalDevelopmentMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> specified clinical development milestones were achieved during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2014 Plan was closed to new grants following the approval of the 2020 Plan, and therefore, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cbe153d-0490-4074-8d6d-0ab524b3b7aa" contextRef="C_79a2379f-7f54-4178-992c-73f84e1d8b73" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares reserved for issuance under the 2014 Plan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The number of shares reserved for issuance under the 2020 Plan and ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71837b2e-6dd4-44bf-938c-90c4a8a242d5" contextRef="C_7fb153ff-f40b-425f-93b1-c594301d3610" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,093,742</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b23fcfc3-09cd-41b1-94a7-f014507eba1a" contextRef="C_734d7e73-f1c6-4f08-8277-d9d136b29526" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,077</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b1c8438-f22a-4971-a87d-58c2f14711f4" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes all option activity under the 2007 Plan, 2014 Plan, 2020 Plan and inducement grants:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.88%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.020000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.66%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares<br/>Issuable<br/>Under Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05e55ce5-fc8d-4e28-97c3-3f844ca59b55" contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,213,977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0832b427-9df5-4021-83f0-bcfcdf85e246" contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a7427691-2236-47ea-91dc-00b8022e2b72" contextRef="C_a2215e8a-709f-4e4f-a87d-5319589f877a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_388c5546-7518-466b-9ef7-0eb46bf07cfc" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,267,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f26cfd10-5146-43cb-a736-9036f76cb95f" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f218a3bc-b213-45f8-bbd9-78999b27f386" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">263,644</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3009fe31-42f3-493a-8737-790c5c32b9f6" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c4f1f82-6da3-431c-a338-d55b2fc6a7bf" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,218,033</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07d911e4-4d5a-490b-97e3-e5f37d3d78e6" contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.69</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e6171437-1fd1-4bd1-877c-1b24ebfef367" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd6c72a9-e3f8-4354-a7f2-98d035e90363" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,026,451</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c39436a4-7648-4904-ad51-58b6c8e2aae3" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9ef32e7-2935-4d6a-a070-dcd611ada7cf" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">862,631</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f65159eb-d8a3-4a0b-8eea-90084dea179b" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f64912e-99dc-44f2-90be-5e70c77f52de" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,381,853</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d93901c-f411-4404-a541-cb918dd82afd" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c8035666-9db4-47fd-b055-fc4be88f93c5" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74f32cd0-c384-400a-bdfb-9cacadd48524" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest as of<br/>&#160;&#160;&#160;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db0a5360-41f9-4637-bb99-65cb6bb67896" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,476,369</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10ba948f-df44-49ad-ab57-9337fe1c3cb9" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cf9c3141-f56c-414c-a79d-ddbe0734b18b" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c2ccaa-66f0-464c-ace5-5f3de664db7d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8d5bd97-a3ee-482d-9b39-268f42dd7d0c" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,065,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8078a832-54ac-4877-b947-4bc819ace5fc" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.54</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_da5ef851-2f60-491a-95bc-1358688946c2" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4990b182-71e9-4719-9a80-b0d1a3acccc8" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that had exercise prices that were lower than the fair value per share of the common stock on the date of exercise. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f73d105c-30c8-46bb-9a8d-0f850190cf19" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> aggregate intrinsic value of options exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8412f3c5-748c-423d-b692-1c3a493b3bd4" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.471%;"/>
        <td style="width:1.88%;"/>
        <td style="width:19.384%;"/>
        <td style="width:1.88%;"/>
        <td style="width:19.384%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e364dda2-bda3-4870-9fc6-3363e42d0c4a" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">90.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90c0ae82-8d42-43ee-b65d-e3aaa487bced" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">83.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_818f8766-8820-4dc1-9ad2-b4ff7cbf47dc" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1016b991-ada0-4d6b-8eab-5112e67d06fa" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life of options</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_40020ef9-2a4d-415b-96f8-b1d909ef1046" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d1606ee9-874b-4955-b0b2-9c409e256ecb" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Estimated dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fe9c1cb-ff7d-4cc1-a603-ca546ea2c5d1" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f8176aa-e350-4d63-a010-eefb7d45d7ef" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The per share weighted average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a0e32bb-a279-484d-84bb-f34ab854c646" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_968b3530-a956-41e1-944c-14b90294c2a9" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">espectively.</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.75in;"><h5 style="text-align:left;"><a href="#toc_page"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;display:inline-block;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></h5><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e1f8df9-6559-41c6-abff-8edb3a307453" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the RSU activity, as follows:</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.38%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares<br/>Issuable<br/>Under RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d91a984-54e2-43a7-9e05-383475d89faf" contextRef="C_cb8475f5-4660-40c0-8142-92caed57a7c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e966eee-d2a0-4750-a00b-e231321eb4d9" contextRef="C_cb8475f5-4660-40c0-8142-92caed57a7c8" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7fce9a9-f58a-40c4-984d-238180ed4829" contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1de3ec52-ee39-42ef-9cf0-5de279b2220a" contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8523fd58-0310-4632-8ace-f59aa55de761" contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_612e7ab9-77fd-48b3-847c-0d30e00e0cbd" contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88841667-0f2e-4184-b5a3-6b88e5d01614" contextRef="C_aaa353e1-e2e4-4e48-84e1-87f26b1fe289" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_238175c3-bb44-4f3d-bd2a-8f3e00347eee" contextRef="C_aaa353e1-e2e4-4e48-84e1-87f26b1fe289" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8da6af3-70ac-4195-834d-184f4a6b39b3" contextRef="C_0439d622-b345-4d2d-a148-7f5891bdb53e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a33e8a9a-b65d-47ea-a870-4b0a4d775a9e" contextRef="C_0439d622-b345-4d2d-a148-7f5891bdb53e" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b89a75cd-8416-4bda-9cc7-718c977c4a7c" contextRef="C_7430787c-94a0-4f8c-8d53-714130bb6ed6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a53580c-3780-4471-9c5c-a02dff03b9bf" contextRef="C_7430787c-94a0-4f8c-8d53-714130bb6ed6" name="eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32237441-1438-4be3-8cf4-35463439776f" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total compensation expense related to all of the Company&#8217;s stock-based awards for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 was comprised of the following (in thousands):</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.68%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1735025-2b7a-4e9b-8d28-0f68db83d518" contextRef="C_a4dbd612-6707-4d02-a493-3e3587d5b602" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,491</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4113d219-cf31-4ba2-8d4e-d0ac5200d450" contextRef="C_509700d3-0809-447c-94e0-126e7520dc70" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,230</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3c23089-7229-48d9-8354-5672be717dc2" contextRef="C_349c064a-f323-4320-a562-2a08dbbdc3ba" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,054</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44cc118e-fd5f-49c1-a722-93cc54c44710" contextRef="C_090932c3-ea52-4d70-b213-7b49b4e7f9bc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7573098-940d-467c-9caa-caa790322325" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,545</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_534b6bfb-51e9-4f25-9927-caedf0a8ef98" contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,153</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation expense related to non-vested equity awards was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97687e25-db8d-421b-a456-8cabe3c2e94d" contextRef="C_a35f913d-d756-40df-9f78-a4912c356455" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fd1d77b-88e6-4aad-b7c8-d5816e36b241" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b943fa0-81cf-4226-a9e1-9639f8036433" contextRef="C_57551459-8811-4b71-9e9a-189290d077cf" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 12. Subsequent Events</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 30, 2024, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29316969-4acf-46a1-b597-a5d8dbe7842e" contextRef="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1" name="eldn:NumberOfPreFundedWarrantsExercisedForCommonStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56cf46f0-6cd3-4e37-8570-d5618af76e03" contextRef="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which were issued in conjunction with the Securities Purchase Agreement. On January 30, 2024, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4774a77a-7af4-4c3a-9d92-ae72f1c01554" contextRef="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;min-height:0.75in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>2
<FILENAME>eldn-ex10_22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<html>
 <head>
  <title>EX-10.22</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.22</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Granted Under 2020 Long Term Incentive Plan</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GRANT OF OPTION.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This agreement evidences the grant by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), on May 1, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to [  ], an Employee or other eligible service provider of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of an option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to purchase, in whole or in part, on the terms provided herein and in the Company&#x2019;s 2020 Long Term Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), a total of [   ] (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of common stock, $0.001 par value per share, of the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), at an exercise price of $2.30 USD per Share.  Unless earlier terminated, this Option shall expire at 5:00 p.m., Pacific Time, on May 1, 2033 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Final Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  This Option is subject in all respects to the terms and conditions of the Plan, a copy of which has been made available to the Participant prior to the date hereof.  Capitalized terms not otherwise defined herein, shall have the meanings ascribed to them in the Plan.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">B)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between the Participant and the Company as may be in effect (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Service Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Service Agreement shall control, and this Agreement shall be deemed to be modified accordingly as long as the terms of the Service Agreement are consistent with the Plan.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">C)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Option is a non-qualified option under Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">thereunder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Except as otherwise indicated by the context, the term &#x201c;Participant&#x201d;, as used in this Option, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VESTING SCHEDULE.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Subject to early termination and adjustment as provided in this Agreement and the Plan, the Option shall become vested and exercisable subject to satisfaction of the time-based and performance-based vesting requirements set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Twenty percent (20%) of the total number of Shares subject to the Option shall vest solely based on the time-based vesting schedule set forth below.  The remaining eighty percent (80%) of the total number of Shares subject to the Option shall vest subject to the achievement of both the time-based and performance-based vesting requirements set for the below.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Time-Based Vesting Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to Participant&#x2019;s Continuous Service through each applicable vesting date, the Participant will satisfy the time-based vesting requirements as to twenty-five percent (25%) of the total number of Shares subject to the Option on the first anniversary of the Grant Date and, as to the remaining seventy-five percent (75%) of the total number of Shares subject to the Option, in twelve (12) substantially equal quarterly installments on each of the quarterly anniversaries of the Grant Date thereafter (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Time-Based Vesting Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">B)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-Based Vesting Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to satisfying the Time-Based Vesting Requirements, the Option shall vest and become exercisable if the Company also </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.22</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">achieves the performance-based vesting requirements set forth below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-Based Vesting Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Twenty-seven percent (27%) of the Shares subject to the Option will satisfy the Performance-Based Vesting Requirements upon achievement of both of the following clinical milestones:</font></div></div>
  <div style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the tenth (10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) test subject is dosed in the Company&#x2019;s Phase 1b kidney transplantation trial; and </font></div></div>
  <div style="margin-left:20%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.3337499999999998%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the twelfth (12</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) test subject is dosed in the Company&#x2019;s planned BESTOW Phase 2 kidney transplantation trial (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fifty-three percent (53%) of the Shares subject to the Option will satisfy the Performance-Based Vesting Requirements and vest and become exercisable subject to the seventy-eighth (78</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) test subject being dosed in the Phase 2 Trial. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">C)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent any Time-Based Vesting Requirements or Performance-Based Vesting Requirements are not satisfied, such unvested Shares subject to the Option shall automatically be forfeited for no consideration. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">D)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition to any accelerated vesting provided for in Participant&#x2019;s Service Agreement, if the Participant&#x2019;s employment with the Company is terminated by the Company without &#x201c;Cause&#x201d; or by the Participant for &#x201c;Good Reason&#x201d; (in each case as defined below) prior to the Committee&#x2019;s determination of the level of achievement of the Performance-Based Vesting Requirements, (A) 100% of the Shares subject to the Option (and for these purposes ignoring the level of achievement of the Performance-Based Vesting Requirements) that would have vested based on achievement of the Time-Based Vesting Requirements had the Participant remained in Continuous Service for 12 months following the termination shall accelerate and become vested on the date that the Participant&#x2019;s executed release of claims in favor of the Company (in a form provided by the Company) becomes effective and irrevocable, and (B) in lieu of the accelerated vesting provided in clause (A) above, if the Participant&#x2019;s termination without Cause or for Good Reason occurs either within 90 days before the consummation of a Change in Control or within 12 months after the consummation of a Change in Control, 100% of the Shares subject to the Option (and for these purposes ignoring the level of achievement of the Performance-Based Vesting Requirements) shall accelerate and become vested on the date that the Participant&#x2019;s executed release of claims in favor of the Company (in a form provided by the Company) becomes effective and irrevocable.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXERCISE OF OPTION.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each election to exercise this Option shall be done electronically through the Company&#x2019;s equity plan administrator&#x2019;s website or in writing, in the form of the Stock Option Exercise Notice attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annex A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, signed by the Participant, and received by the Company at its principal office, together with payment in full in the manner provided in the Plan.  In the event the Company does not have sufficient shares available under the Plan to accommodate the Option exercise, the Company may settle the Option upon exercise by making a cash payment equal to the &#x201c;spread&#x201d; value of the Option on the date of exercise (i.e., the excess of the Fair Market Value of the underlying Stock above the Option exercise price).</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.22</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">B)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Continuous Relationship with the Company Required</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise provided in this Section 3, this Option may not be exercised unless the Participant, at the time he or she exercises this Option, is, and has been at all times since the Grant Date, an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Eligible Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">C)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination of Relationship with the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (D) and (E) below, the right to exercise this Option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that this Option shall be exercisable only to the extent that the Participant was entitled to exercise this Option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this Option shall terminate immediately upon such violation.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">D)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Period Upon Death or Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#x201c;Cause&#x201d; as specified in paragraph (E) below, this Option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided that this Option shall be exercisable only to the extent that this Option was exercisable by the Participant on the date of his or her death or disability, and further provided that this Option shall not be exercisable after the Final Exercise Date.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">E)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If, prior to the Final Exercise Date, the Participant&#x2019;s employment is terminated by the Company for Cause, the right to exercise this Option shall terminate immediately upon the effective date of such termination of employment.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4)</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  No Shares will be issued pursuant to the exercise of this Option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this Option, including pursuant to any permissible method set forth in the Plan.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">A)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the purposes of this Option:</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in any employment or other agreement between the Participant and the Company or, in the absence of such an agreement, shall mean that, in the good faith determination of the Company, the Participant has: (a) committed gross negligence or willful malfeasance in the performance of the Participant&#x2019;s work or duties; (b) committed a breach of fiduciary duty or a breach of any non-competition, non-solicitation or confidentiality obligations to the Company; (c) failed to follow the proper directions of the Participant&#x2019;s direct or indirect supervisor after written notice of such failure; (d) been convicted of, or pleaded &#x201c;guilty&#x201d; or &#x201c;no contest&#x201d; to, any misdemeanor relating to the affairs of the Company or any felony; (e) </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.22</font></p></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">disregarded the material rules or material policies of the Company which has not been cured within 15 days after notice thereof from the Company; or (f) engaged in intentional acts that have generated material adverse publicity toward or about the Company.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in any employment or other agreement between the Participant and the Company or, in the absence of such an agreement, shall mean any action on the part of the Company or a successor in interest not consented to by the Participant in writing having the following effect or effects: (a) a material diminution in the Participant&#x2019;s duties, authority or responsibilities from and after a Change in Control; (b) a material reduction in the Participant&#x2019;s base salary from and after the Change in Control, other than a reduction comparable to reductions generally applicable to similarly situated persons; or (c) the Company&#x2019;s requiring the Participant&#x2019;s ongoing and regular services to be performed at a location more than fifty (50) miles from the geographic location at which the Participant was providing services before such requirement.  Notwithstanding the occurrence of any such event or circumstance, such occurrence shall not be deemed to constitute Good Reason unless (1) the Participant gives the Company&#x2019;s Chief Executive Officer (or the Chief Executive Officer of the Company&#x2019;s successor in interest, if applicable) written notice specifying that such event or circumstance will give rise to a right of termination no more than thirty (30) days after the initial existence of such event or circumstance, (2) such event or circumstance shall not have been cured within thirty (30) days following such written notice from the Participant and (3) the Participant terminates the Participant&#x2019;s employment within forty-five (45) days after the end of the 30-day cure period and prior to such event or circumstance having been cured.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise indicated by the context, the term &#x201c;Participant&#x201d;, as used in this Option, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms.</font></div></div>
  <p style="font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Signatures page follow.]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:396pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.22</font></p></div>
  <p style="text-indent:7.092%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:6%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Option to be executed under by its duly authorized officer.</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	Paul Little</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	Chief Financial Officer</font></p>
  <p style="text-indent:7.092%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:6%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof.  The undersigned hereby acknowledges receipt of a copy of the Plan.</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT:</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature of Participant</font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Grant Acceptance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:50%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Print Name of Participant</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>eldn-ex10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html>
 <head>
  <title>EX-10.23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.23</font></p></div>
  <p style="margin-left:28.32%;font-size:10pt;margin-top:2.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:69.111%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">December 30, 2023</font></p>
  <p style="font-size:10pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:60%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[   ]</font></p>
  <p style="font-size:10pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:60%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Re:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendment to Stock Option Agreement</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dear [   ],</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.73%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You and Eledon Pharmaceuticals, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; or the &#x201c;Company&#x201d;) have mutually agreed to enter into this letter agreement (the &#x201c;Agreement&#x201d;) in order to document an amendment to your outstanding stock option agreement, effective as of the date hereof (the &#x201c;Effective Date&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.73%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You were granted an option to purchase [   ] shares of the common stock of the Company under the Company&#x2019;s 2020 Long Term Incentive Plan (the &#x201c;Plan&#x201d;) on May 1, 2023 (the &#x201c;Award&#x201d;) pursuant to a Stock Option Agreement (the &#x201c;Award Agreement&#x201d;). Capitalized terms used and not otherwise defined in this Agreement will have the meanings set forth for such terms in the Award Agreement. The Compensation Committee of the Board of Directors of the Company (the &#x201c;Compensation Committee&#x201d;) has approved an amendment to the Award Agreement, and you hereby agree, to amend the Award Agreement as of the Effective Date as set forth below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.973%;text-indent:6.796%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1. 	Section 2(B) is hereby replaced in its entirety with the following:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.215%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-Based Vesting Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to satisfying the Time-Based Vesting Requirements, the Option shall vest and become exercisable if the Company also</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">achieves certain funding levels related to that certain Securities Purchase Agreement, dated as of April 28, 2023, by and between the Company and the purchasers identified on the signature pages thereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Purchase Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-Based Vesting Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) set forth below. With respect to this Section 2(B) only, capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Securities Purchase Agreement.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.215%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">i) 	The Performance-Based Vesting Requirements applicable to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">twenty-seven percent (27%)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of the Shares subject to the Option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Second Closing Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) relate to the funding terms governing the Second Closing set forth in Section 2.1(b) of the Securities Purchase Agreement, and will be satisfied as set forth below.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-8.432%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a)	Upon the Second Closing, a full or prorated amount of the Second Closing Shares shall vest based on the percentage of funding achieved relative to the total funding opportunity represented by the purchasers&#x2019; Second Closing Subscription Amounts, rounded up to the nearest decile if achieved funding exceeds any prior decile achieved (e.g. if the Second Closing is 71% funded, 80% of the Second Closing Shares will vest); and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-7.215%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-8.432%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">b)	Upon the Second Closing Date, the Performance-Based Vesting Requirements applicable to the Second Closing Shares shall vest in full.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.215%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ii) 	The Performance-Based Vesting Requirements applicable to</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> fifty-three percent (53%)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> of the Shares subject to the Option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Third Closing Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) relate to the funding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.23</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">terms governing the Third Closing set forth in Section 2.1(c) of the Securities Purchase Agreement, and will be satisfied as set forth below.</font></p>
  <p style="margin-left:13.333%;text-indent:-8.432%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-8.432%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a)	Upon the Third Closing, a full or prorated amount of the Third Closing Shares shall vest based on the percentage of funding achieved relative to the total funding opportunity represented by the purchasers&#x2019; Third Closing Subscription Amounts, rounded up to the nearest decile if achieved funding exceeds any prior decile achieved (e.g. if the Third Closing is 71% funded, 80% of the Third Closing Shares will vest); and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-7.215%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-8.432%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">b)	Upon the Third Closing Date, the Performance-Based Vesting Requirements applicable to the Third Closing Shares shall vest in full.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2. 	Section 2(D) is hereby replaced in its entirety with the following:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">D)	In addition to any accelerated vesting provided for in Participant&#x2019;s Service Agreement:</font></p>
  <p style="margin-left:0.973%;text-indent:6.796%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.64%;text-indent:-6.641%;padding-left:5.693%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">i) 	If the Participant&#x2019;s employment with the Company is terminated by the Company without &#x201c;Cause&#x201d; or by the Participant for &#x201c;Good Reason&#x201d; (in each case as defined below), 100% of the Shares subject to the Option (and for these purposes ignoring the level of achievement of the Performance-Based Vesting Requirements) shall accelerate and become vested on the date that the Participant&#x2019;s executed release of claims in favor of the Company (in a form provided by the Company) becomes effective and irrevocable; and</font></p>
  <p style="margin-left:7.64%;text-indent:-6.641%;padding-left:5.693%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.64%;text-indent:-6.641%;padding-left:5.693%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ii)	Upon the consummation of a Change in Control, 100% of the Shares subject to the Option (and for these purposes ignoring the level of achievement of the Performance-Based Vesting Requirements) shall accelerate and become vested.</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Except as modified above, the provisions of the Award Agreement remain in full force and effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.73%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We appreciate your service to the Company. Please sign where indicated below to confirm your agreement to the terms of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.973%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ELEDON PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:40.973%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">____________________________________________</font></p>
  <p style="margin-left:40.973%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By: Paul Little</font></p>
  <p style="margin-left:39.627%;text-indent:2.231%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:  Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accepted and Agreed:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	_____________________________					</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	[   ]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>eldn-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We hereby consent to the incorporation by reference in Registration Statement Nos. 333-200413, 333-203032, 333-210058, 333-216432, 333-232428, 333-237380, 333-255173 and 333-273900 on Form S-8 and Registration Statement Nos. 333-254890 and 333-272052 on Form S-3 of our report dated March 28, 2024 (which includes an explanatory paragraph regarding Eledon Pharmaceuticals, Inc.&#x2019;s ability to continue as a going concern), relating to the consolidated financial statements of Eledon Pharmaceuticals, Inc., appearing in this Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc. for the year ended December 31, 2023.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">                                                                                    </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ KMJ Corbin &amp; Company LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Irvine, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">March 28, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;">
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;"></td>
     <td style="width:33.333%;"></td>
     <td style="width:33.333%;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>eldn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, David-Alexandre C. Gros, M.D., certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc.; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3.74%;"></td>
    <td style="width:1%;"></td>
    <td style="width:47.26%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David-Alexandre C. Gros, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>eldn-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Paul Little, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc.; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:5%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.508421052631579%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.065%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.251%;"></td>
    <td style="width:1%;"></td>
    <td style="width:3.499%;"></td>
    <td style="width:1%;"></td>
    <td style="width:47.251%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Little</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Paul Little</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>eldn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="exhibit_321"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned, David-Alexandre C. Gros, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(1).</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of <br>1934; and </font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(2).</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:5%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David-Alexandre C. Gros, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>eldn-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="exhibit_322"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 32.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Eledon Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned, Paul Little, Chief Financial and Accounting Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(1).</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of <br>1934; and </font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(2).</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:5%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 28, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Little</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Paul Little</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>eldn-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Incentive Compensation Recoupment Policy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective as of December 1, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">In the event Eledon Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;) is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company shall recover reasonably promptly the amount of any erroneously awarded Incentive-Based Compensation from each Covered Individual unless an exception (set forth below) applies.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Incentive-Based Compensation shall be considered &#x201c;erroneously awarded&#x201d; under this policy to the extent such Incentive-Based Compensation (1) is received by the Covered Individual on or after the effective date of Rule 5608 of The Nasdaq Stock Market LLC (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;) Rules and while the Company has a class of securities listed on a national securities exchange or a national securities association, (2) is received by the Covered Individual during the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement (and any transition period applicable to a change in the Company&#x2019;s fiscal year as required by Nasdaq listing rules), and (3) the amount of such received Incentive-Based Compensation exceeds the amount of the Incentive-Based Compensation that would have been received by the Covered Individual had it been determined based on the restated financial results (with such Incentive-Based Compensation computed in each case without regard to any taxes paid).  For purposes of this policy, the date that the Company is required to prepare the accounting restatement is the earlier to occur of (A) the date the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;), or a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such accounting restatement, or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare such accounting restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">For purposes of this policy, Incentive-Based Compensation is considered &#x201c;received&#x201d; by a Covered Individual in the Company&#x2019;s fiscal period during which the Financial Reporting Measure applicable to the Incentive-Based Compensation is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that fiscal period.  For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the amount of erroneously awarded compensation will be determined by the Compensation Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;) based on a reasonable estimate of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received.  The Company must maintain documentation of the determination of that reasonable estimate and provide</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">such documentation to Nasdaq as required by Nasdaq listing rules.  If the erroneously awarded Incentive-Based Compensation consists of shares (including share-denominated equity awards) or options that are still held by the Covered Individual at the time of recovery, the recoverable amount is the number of shares or options received in excess of the number of shares or options that would have been received based on the accounting restatement (or the value of that excess number).  If the options have been exercised but the underlying shares have not been sold, the recoverable amount is the number of shares underlying the excess options based on the restatement (or the value thereof).  If the shares have been sold, the recoverable amount is the proceeds that were received in connection with the sale of the excess number of shares.  Amounts credited under plans (other than tax-qualified plans for which the exception set forth below applies) based on erroneously awarded Incentive-Based Compensation and any accrued earnings thereon are also recoverable under this policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">The Company shall not be required under this policy to recover erroneously awarded Incentive-Based Compensation if the Committee has made a determination that recovery would be impracticable and either of the following conditions are met: (1) after making a reasonable attempt to recover such erroneously awarded Incentive-Based Compensation, the Committee determines that the direct expense paid to a third party to assist in enforcing this policy would exceed the amount to be recovered (documentation evidencing the reasonable attempt to recover the erroneously awarded Incentive-Based Compensation must be maintained and provided to Nasdaq as required by Nasdaq listing rules), or (2) the recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Internal Revenue Code Section 401(a)(13) or Internal Revenue Code Section 411(a) and the regulations thereunder</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">For purposes of this policy, the following definitions will apply:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Covered Individual</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d; means any current or former officer of the Company who is or was subject to Section 16 of the Securities Exchange Act of 1934, as amended, at any time during the applicable performance period for the relevant Incentive-Based Compensation, regardless of whether such individual continues to hold such position or continues to be employed by the Company or any of its subsidiaries.</font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures that are derived wholly or in part from such measures (including, for purposes of this policy, stock price and total shareholder return).  A Financial Reporting Measure need not be </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">presented within the Company&#x2019;s financial statements or included in a filing with the Securities and Exchange Commission.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This policy is intended to comply with the requirements of Rule 10D-1 promulgated by the Securities and Exchange Commission and the related listing rules of Nasdaq, and the terms hereof shall be construed consistent with that intent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This policy does not limit any other remedies the Company may have available to it in the circumstances, which may include, without limitation, dismissing an employee or initiating other disciplinary procedures.  The provisions of this policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 (applicable to the Chief Executive Officer and Chief Financial Officer only) and other applicable laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">The Company shall not indemnify any Covered Individual against the loss of erroneously-awarded Incentive-Based Compensation that is recovered by the Company pursuant to this policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">	The Committee shall have the sole authority to construe and interpret this policy and to make all determinations required to be made pursuant to this policy.  Any such construction, interpretation or determination by the Committee shall be final and binding.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">The Committee may revise this policy from time to time.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> -</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img116206746_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img116206746_0.jpg
M_]C_X14Z17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    -    L8=I  0    !    P    .P /0D    G$  ]"0
M "<0061O8F4@4&AO=&]S:&]P(#(T+C4@*%=I;F1O=W,I #(P,C0Z,#(Z,C<@
M,#DZ-34Z-30 =VEN9&]W<R!U<V5R      .@ 0 #     ?__  "@ @ $
M 0  !C>@ P $     0  !-@         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M34ZPB8X'B3PLNRRRUVZP[C^ _JM3>*O%=P7X,K/JWT/+P6T9'3ZJVV!KK65
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M?Z;=T220 !W),!5OVA7I)8)\7D>>OL4KK]75N8"WCGYH'KX^K?;_ "F^H?\
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M_>/WE NQ*+K!<0:L@?1R:CLM'_7 /TK?^"O;;3_P:7!'Q'_._P"]1QRZT?\
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M;F1O=W,@=7-E<AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VXX0DE-!"4
M     ! 0!"7_&+6X&:N/1:5&SS?#.$))300Z      %#    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    P $@ 4  @ $, ;P!L &\ <@ @ $P 80!S &4 <@!*
M &4 =  @ $, 4  T #  ,@ U "\ -  U #( -0 @ %  0P!, #8 ( !# &P
M80!S ', ( !$ '( :0!V &4 <@      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!Y            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 9     !
M  $!D     $  3A"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))301$       0
M     @   D    )      #A"24T$'@      !      X0DE-!!H      U$
M   &              38   &-P    X 1 !$ $0 ( !0 &D 8P!T '4 <@!E
M ', +0 Q     0                         !              8W   $
MV                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
MV     !29VAT;&]N9P  !C<    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !-@     4F=H=&QO;F<
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M# P,# P,# P,# P,# P,_\  $0@ ?0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M94#40Z&^I7ZE);9M]OI6-W_S?Z-7.I,?9B665B;Z/UBG_C*OTK6_]=A]#_\
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M;?0?_A5DT7XG5F9#>O48YZKB5%[:R(#:VAKW,R=UK,9_I6?I+:K,CV4Y'O\
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M5[-SK@UKGW^E6UNW^I6E=]6^GE_ON>QCFO#FDM#B7EGN;86[O;M]]G\_D?\
M:BZRO]&I.Z'TPV>H+W- =N8UKJP&>YUVVK]'NK_2/^DUWJ?X/U/33APC42_!
M!XB"#'3^\Z=3:*6MK;L87DD-8 T.=])[FM_Z2H=6M=?:SIK"6L>WU<QS2015
M.QE+7#Z+LNP.9_Q%61_(38/1.FXMM=E+S9;4XO:YQ8YT%ME99+6#;7^G>_V?
MGJHU]EF3D6M)8[(R;&;MNX!F.WT&;OW?>RY__7$R==#:"30!%7_T6T   UH#
M6M #6@0 !]%K0/S6H-MS8>&V>F:G!MC]I=!(W;-OYWM^F[\Q,RQUVYM-[0\
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MIN9B4Y3!M%K XM/+2?I5N_E,=[%3GNI]&,4Y-0^C5E7M;\'/-W_HU"7R^13
MU+S'Y/\ _]3U5))))36NQK'O+F/VS!D:'0;=O#O9_P!_0_L61&E[@3R=T_\
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M9HT&)<[W?O[$%6&QAM L=K^;&I\U$=5=@9>4YF'DY@ML8PG'9O#=E>,QP?\
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M+Y:)$A6JX ) )@=R>P\5/H<NP!D$1]KLLR!_5M>ZRG_P$UJG>TYEIZ943NL
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M(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
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MT  ' !H !0 I #5A8W-P05!03     !!1$)%                     0
M]M8  0    #3+4%$0D4
M                      ID97-C    _    '1C<')T   !<    "MW='!T
M   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "CN   H@9"
M,D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT  ?OW
MD)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                     '1E>'0     0V]P>7)I9VAT
M(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:  "\9P
MDC!M9G0R      0#"0   0                    $
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MU.OE[/7N!.\2\"#Q+/(X\T/T3O59]F/W:OAN^6_Z;/MD_%;]1/XO_Q?__P
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M@H.;:*KD@9F)?J;:@.!V^Z,3@&-CJ)^;@"9/4YQ_@",Y=)H%@$P?H9F6@1<
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MKP.7HJ=]JKB%PJ-RIL-S0)^LHT-@*9PVH$],09D<GCLV]I: G7T=\Y7(E$
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MB=6-FK/>B$E\SZ\:ANYK5:JCA>U9'J9ZA31%X:+&A,PP^I_LA,07@: <A@0
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MM(R+(K#4K]MZ5ZP#JZMHZ:=YJ#%6WZ-+I;!#_)^5I)XOG)R&H#$7%9P7CYL
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MD&N Z+TCCE]PZ;>\C)5@:[*&BR9/.JVRBB4] *EJB9,H]J9(B>,/VJ<$B0(
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MN<E_KKHMM)MO[;2;L"U?AZ]1K/I.>ZIPJUP\@*8@I_4HW*+(FZ 0L**XBT@
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MEH5U6,9XE =F'<!PD?!6:KJ7D$E&(;45CR0TQ+!5CM\A6JT@CWL)S*Q"AJ
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M>(,@@*;>A(%*C:O)3H#AB]ZS48"'BB^<9X!1B,.$U( RAXQLAH NAH%3#(!
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MF8J==IF3EP2+<I;BE*=XLY1EDG-E,9(;D()0MI SCNXZRHZGC=PA%XYMCB\
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M=#F3GZ;L=+R"L:-\=4]Q!:!%=?Q><YU*=L5*O)JH=Z(U5YB^>&L;0)EK>.P
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MG]Z/[:*)G/-^_)\6FC5M5IO:E[9:^)C:E89'H)8YD^4RNY0[DXD9A)16D.H
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M? &&'Z_%>[1V-*N>>Y!ECJ>R>Y93^Z01>\A!.*#I?!HLCY[)?&D25*"=?*\
M (C$@ "4U;,9A"R%C*[#@S1UL*J3@F5D_*:I@=A3;Z,'@7] O9_@@5LL+YVT
M@6<2/Y\_@@D  (@A@ "43K(?C%.$[*W/BL)T^ZFDB6!D6:6QB#]2UJ(8AVA
M/9[RAM@KTIRZAL$2*YX&ALH  (>3@ "3N[%3E)*$5*T$DG!T6:C<D(ACLJ3I
MCM]22J% C80_R)X?C*$K@9O;C*@2&YSNBN(  (<9@ "3*K"WG/F#RZQFFDMS
MU*@XE]5C+Z1!E:U1SJ"4D^4_9IU9DL,K0)L+DQ,2$)ORC#8  (:S@ "2OK E
MI86#8*O5HDMS:*>EGTIBQJ.MG*=1;J !FHX_&YR_F7HK$)I&F)02"9L,C#(
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M@NEY8KC]@?1J7K0F@2Y:EJ^/@+5)]JM,@'0X&J>L@&PD$Z6!@)0*WZ:#@28
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MJI5WU;5:IQYHQK!KH_99#ZNSH65(FJ=>G^4W%*.FGPHCJJ#\F!T+P*"TA_(
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MB11M?<)SAYY?%[T1AF=0);?4A85 7K,!A0(O2J\"A-\;K:T=A80%$JJ;@VX
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MKSYM/K[AJY-?";DXJ%M0*K/,IC- A:[7I,XON:JPH$4<LZ@QDV<&R*5&A)8
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MHGT5@R9."WUV@I@RDWWM@B4-3'[2@8/1;GJ&DAB]97J\D!FHH7KWCC"3#7M
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MDH9R<MJ,&X71<^YVMX5'=0M@7(3<=C5(M(2>=U4MQ83T>%((W(9/>6#%1H:
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MBD"5PI3JB1^$QI+'B UR]I#-AP]@&X\3AD%,.8V6A94VP(Q^A1L<_(S=A68
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MN9J22)'@M5N!(X^NL/-O.(VAK+]<JHO8J5))-XI@IT@T4HDPHM<;-XD8DF<
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MD-V(0YU\CT)X1YJAC;UG=)?WC%A5T96!BQI"_)-[BC4N;)(,B=$4RI,;B4
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M;@!^5ZM[;Q=O7:@#<"]?>:3 <4M.C*&[<F@\09\W<W<GS9WW="0-+Z"X<\4
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MEL1[KJ:6E,ULF*,%DNQ<NI^AD3E,"9R%C]$Z,IG=CO0F6Y@_CUL-0IDGB/<
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M=5!QQ[3)=8QCD;">=>E4BJRI=F)$=JD)=O RZZ8F=W4>Q*4P=Y(&(*4A>,4
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MF^9P"[ 2F;9AQJO)EYE2OJ>OE<1"XJ/VE((QTJ#>E'H>?I\NDJ<'3IUXA/$
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M>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR>S@5;JW>>P0 HZ?3?2X
M (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ9J^M@)8IG*R*@) 5KZPP
M@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%A[9)=;*HAMHZ4:YSAE$I
MGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE2KL?C\M7LK9.CE1)9[&H
MC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (  @ !R,+]0F--E/[IBEN!7
MKK5_E0I)8[#/DXTZ/ZR0DL(IMJDXDP<68*@MCR$"1Z&T@8H  (  @ !R$[[3
MH&!E/;G,GAI7L;35F^Y)9+ 6FCHZ.JO2F;8IMZA]F'D6A:=-CSH"C:"S@;H
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M<V6<!XCX=%6*[H@,=3)XN8<_=@AE<8:-=N)1!X8&=[P[$87 >'@@]H9J>,<
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MHS*6R(-%H(B%K8)VG:QSF8'"FLI@Q($WF"9- (#-E?(WQX!VE+H>48!LDE<
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M>TZ.$)!B>WU^(8[&>Z=M (U8>]A:X(P-?!A'CHL!?%\R?HIC?)$8?HM\?&P
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MJ,R)]8O8I>EYW(I$HLUHW(C)G[=7$H>(G0]$0(:+FTDOYH6]FBD6OH7ACV$
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M@CV DIAN@=MQA)8M@7EAD)03@290>Y(W@.H^*I"S@,(IWH_B@*D/TI&2@*H
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MK<1]PY3TJMQND9*:IZA>@I!6I)%-M(Y;HE$[SXS&H/4H'XNOFR$/'(OYBC<
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MB$=S\*$DAWAEM9X\AJU6GYMYA?%&EICZA5PU&Y</A0(A6I9"A10(O)7?@]$
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M9W]I]; X:0A<@*SE:HQ.&*F\; (^AZ;B;5PM/:3K;FL8N:67;FP!B:*J< (
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MC8IH**IUC'):KZ;CBUA,7Z-YBE@]'J!HB9HL7YX8B6@8TIVVB8,#(YBV@A\
M (  @ !TE*UEE3UGYJG!D\I:;J8CDD-,&**MD-X\U)^:C^XL,)T[D <8VIR5
MCED#5I=J@D(  (  @ !T7:S7G0)GL:DMFSM:,J6&F59+V*(&EZ,\E)[LEK4K
MZYR3EG88NYO&D+D#B993@F0  (  @ !T+JQ^I1=GM*B^HQE:+J3\H-!+N*%=
MGLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (  @ !J,K\#9K1=SKM : Y0
MX[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,  )\$<[   (  @ !I[;X]
M;C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8  )W >"D
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MD?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8RCD40(J99BND  )C?@
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M9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+\8/R;JPV@80@<$@<985A<.8
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MDNZ.)'UED95^"GTZD ]L\GT9CG=:]7T.C/A'UWT9B[$S''TDBMT9QWS[BF8
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M;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3<S\MWXA]=!X38HI]<ZP
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MF+6!FH5XEQ=RA82)E3EB9X.IDT91;8+RD8H_58)ED$(K;X'[D!T1Y8(>C!D
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M<]MX[I.(=*5JTI'9=61;>Y!1=AY+#([U=M0Y+HWZ=W0E#HW4=[L+'([(=WT
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MG<YU=HY"G 5G.HR7F>]8!(KVE\Q'ZHF3EAHVCXB,E6LC-(?IE!4*MH<0ASX
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M>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\>T\;]Y1G>S$$=)' ?$P
M (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U :)0T@/@O9)+O@-P;M9+U
M@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<PB'5/.I4)AZT_XI,BAP<O
M&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J@)B>D,1=%998CX9.NI0K
MCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (  @ !VLYI%F>MJ2Y@&F(-<
MW96NELM.<Y-AE0P_'I%ED]8N8X_[D](;,(^,D3T$U8P<@T4  (  @ !V:YG6
MHBMJ I>-H'M<BY4GGEQ.')+,G$0^TI#$FQDN)X]+F? ;!X[-DD8$V(M2@T8
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M?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP?O(2DIR&?N,  )+H@
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M8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$9[@(7*ZD9VL  )-8<M@
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M@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00@J *)Z/,@CD  (WC@
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M>_>2C7$7?$^"6'(??(QQ&7,>?+E>N'0E?.E+/'4>?1@V-775?38<\W5W?0,
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MK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*G0,S5F__FW@:Q&Y'DAD
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M@PZ%KG=_@O-VA'?J@K!F37A2@E)5'WC'@?M"EGE(@;0N5WF2@784Z7E-@5,
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M7?!^$8>M8,=OTX<=8VI@1X:X9=M/=(9Q:"<]*X9F:CLHO(;M:[D.!HC^:T<
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MB4]Y-G[8B--K GZ;B"-;PGY>AU9+C7XWAI<Y_7XLA@DF47XDA=D-#7YZA*,
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M9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M];D4?CHPG;N &:HOV;O
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MCHQM.H<:C<Y?XX8GC,I1=X4PBZ="&81IBK(Q8(/>BC(>*8.CBHD&BX+SA&P
M (  @ !Y!(<JEMULN894E;%?7859E"=0]815DGQ!FH.#D3$PU(+XD,@=N(*;
MC]8&B8'EA&L  (  @ !XHH:2GTUL4H6^G<M>ZH2XF\90@H.EF:)!-H+"F"4P
MAH(FE[8=@8&OD_,&?8$4A&,  (  @ !QKYO87+)E\9GW7T)9.YA@8;1+3I;\
M8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (  ?TIP]YH.9(QE9YA'9F]8
MM):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0 +Y"^;K8  (  @ !P3Y@3
M;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"<<H6%9+<<84 <XYP=#,
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MDPIAL9 7DC55$HYYD0%':8S3C[$XO(MTCM,H<(J>CP05&8K'C* !&H;1@+X
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M<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>=,,,CIH9=%4  (D4>^4
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MELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);D>\,OY'LB)\  (2<@
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M=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)==RD$PI\&>.$  (0^@
M (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\FDJ!T?3,6&Z"7?18$_YSO
M?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U@\<T0:$"@VPF=)\T@T<6
M'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,$Z4RBOU JJ*#BF<T,I_^
MB<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (  @ !68J<TDGY,#*1ZDB)
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ME720,ER\D\R &E\^D?MO!F&;D"1=$6/BCF]*$V7<C/,UOV;EB^$=CV4SBXP
MS'ZH@(J>G5B[GV&/<UN(G/=_65X-FEMN2F!LE[]<6F*XE6%):&2YDVDU-V6R
MDC<=.F0$D#8 P7ZZ@(*>'5?8J3:.ZEJEI@Q^PUTCHJ=MLE][GTY;T&'$G%A(
M]6/"F@<TPV2BF.4<RV,-DW@ N'[)@'R;-G"R6/>,U7',7&!]9W+Q7Y!LO'0;
M8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (  <AV9X6V'8HV+HV[N90]\
M,7!!9VEKHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8TG3);]P  (  =LB8A6JA
M;""*/VQ ;<=[$6V];U5JA6\F<,98[G"#<BA&&'')<W0QF7*E='P88W(F=),
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MFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2D;(NDVHND2465FH5C>4
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M<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/=_LICG6]>&D0 W;L=_
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MH+-Y3VI_GK1K"FN>G%%;T&RAF=Y+IVV=E](Z16Y?EJXG%6X)E64.IW"1B>@
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M>DMP^7@+>MQCC'AY>TE5+'C:>YE%M'D_>^$TBWFI?!LA&7G ?" (JGNA?)8
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M5]II@(G[6O!<LHE\7=Y.I(DG8)L_-(C^8QLM\XE*92D9?XKY9?,!]8H49Q@
M (  ?%]T6(@;7^=HLX>98E-;Z(<N9)Y-^(;99L4^J8:K:+DMCH;B:DL93X@P
M:KL"+(=L:_H  (  ?X-S:H619^=GK(4^:;-;"X3I:V9-(X2A;/D]^(1X;F0M
M!X2A;WT9 (69;Z "3H43<38  (  @ !R<(,_;]]FH8,(<1E9]H+'<CA,2H*,
M<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (  @ !Q?8%"=^!EN8$=>)%9
M#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,";H%$>\   (  @ !PIG^0
M?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I?^48,W[S?^@"C7^]?_@
M (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[<GV;A@LK*7U]A=07]WTJ
MAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T CF=)JGRUC3PZ]7Q\C& J
MI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC:GQ@ET)6TWPLE;]).WO6
ME"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (  @ !I Y1_5PI=T)-(6?=1
MKI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<  (@):9H  (  ?M1H'9(C
M7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<:%L/:9%M9_H  (8B;F0
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MA(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @
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M9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0
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MB&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @
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M:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\
M (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98
M=0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.
MV)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/?; LMYHW
M?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#2IQSA'$X
M@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (  @ !,\9TI
MBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8  (  @
M (  @ "ISEKJ4ZF9K5W'5WR(\V"&6S5W4&,L7LQDJ&6Z8D-0X6@5994[PFG=
M:*,C)6EP:ND#YWEG;,NGPE:C7B"8%%G@8/Z'AUSN8\9V#5_89GAC@&*?:1!/
MUF4B:XTZTV;G;= B9678;VP#R'F<<6>EW%+,:(V61U95:G.%^UFG;$QTE5S&
M;AQB,E^[;]].MF)><9 YY608<Q4AL6*Q=!D#K7G*=F*C^4]3<MV4>E,@<]J$
M/%:A=-1S'UGQ=<A@X5T4=KM-F5_0=Z@Y 6%\>'@A"F $>/D#E7GR>O6B,DQ
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M4X".I&1E5UA^]F:56P9N.FBW7HA<86K%8>9)46RI91<TLVX&9^T;UVV":9L
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MA+6'/%4!A&1X*U@Q@_IH%5LE@X)7#%WC@Q)$U6 D@KDQ&F#T@H$92&&E@J$
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M7+Z"4V? 7[=SMFFA8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(
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MBT][YUI]BIYMQ5T8B;Q>EE]_B,A.9&&NA^T\^F-+AT(IZ6,GAO\1LV>PAD,
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M9-UUTFP!9Q=H6&V#:3)9C6[N:RE)F'! ;/\X(W%>;IXD@G&\;[(+976";XH
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MD.5PLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*BZ4B+F78B^D*LVWJASP
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M:]]I<W$Z;7U<NG)/;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@
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ME8UEA&@:E(Y8]VEPDR)+96J#D9X\O6M8D( LBFN%D%\9T&JTCH@$;'B'@OT
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M<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(
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M49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D
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M=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @
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M5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@
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M>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @
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M6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D
M (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>
M;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(
M=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^
M<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP
M@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!
M?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @
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MS7SU@3B3@UJ^3>Z%0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA
M9+$6JFEU9E0  (  ;=*1>5695YF#U5B[6OYU+5NV7DIE?UZ-8794HV$Q9'A"
M@&-J9THNN61=:;<63F9@:MH  (  <K"/FE#D84F" E1M8]=SF5>Y9E!D EK/
M:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (  =V*-RDR3:NN 1U!S;*=Q
M]50!;E9BM%=2;_)2*5I9<7A :ERO<N<M$UT*=!@5.&&X=',  (  >W:,'$BN
M=(9^Q4S;=7MPDE"M=F-A8%0L=SQ1-%=<> T_E%F[>-0L<5FZ>7L4U5_G>:P
M (  ?O.*L45(?AM]A$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5;
M?PD4AUYD?U@  (  @ ")B$);AYY\?D<&APUNETM$AFU?GD\>A<U/E%)^A4,^
M6%34A-\KFU1,A,0455VBA/H  (  @ "(H3_PD/][LD3*CZUMXDDPCDI? 4TF
MC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L  (  @ "'_SX1FAY['$,,F!9M
M5D>*E?5>ADN2D_).H$\*DD4]@E%%D1TJX5"MD1,3WUYIC4   (  @ "('6'L
M3@QZPV0'4AULL68F5A==FV@Y6>Q-5FHN79$[I&O:8.\G\FR88ZD.DW#K9&@
M (  <;2&)USY5QMY2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB'
M:)0.0VX1:/\  (  =FB$;EAB8$9WM%M;8M]J+5X<96-;7&"C9\5+:6+H:@,Z
M"V2A; TFN622;9D.$VN';<4  (  >HN"NU0P:6EV%U=Y:T)HE5IT;0M:%%TP
M;KI*/U^@<$HY%&%5<;0E^6#(<KT-N&EX<L\  (  ?B.!,E!K<HATJE/T<ZIG
M05<I=+E8U%H/=;))7%R?=ITX3%Y+=W$E9UV#> D-?FDQ>#H  (  @ !_ZTTA
M>Z=S@%#A?!=F-E1'?&]7WU=6?+5(>UGV?/DWLEN0?4,D]EK,?8D-4FE\?@D
M (  @ !^X4I-A+1RCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1
M@T0-/&FA@Q,  (  @ !^$T?UC:5QTDP*C,-DJD^VB[)6=U+XBIQ')U6JB;@V
MA%<*B2LD-U;"B6(-)6G(AS8  (  @ !]@D8@EF=Q2$I3E/)D'TX1DS95\U%;
MD7I&NE0+D!<V,55/CU$CWU50CV0,X6H\B+4  (  @ !\E6ES3A-P!FL-4?QB
MNFRW5=)486Y868-$QF_=7/LSCW$K8!,?U'&L8CD',W>V8Q   (  =89ZLV2R
M5I%NG&:W6=QA@VBI70M36&I]8!5#XFPA8NHRTFUE96@?1&U/9PH''W3J9[\
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M@;EH8%7/@<9;X5BQ@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D
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M7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H
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MAL!=1%N[AH]1>5X+AA=$H%_CA8DVB6$(A2DFM&!AA284!F54A40!,'W^@,X
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M9#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$
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MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @
M (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?5
M6Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6
M\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?
M8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U
M5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y
M:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(
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M2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T
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M;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @
M (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (
M>T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*
M;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y
M@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4M
MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\
M3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$
M (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (
M:2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"
MJHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB
M9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$H
MD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I
M<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @
M (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (
M@    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"
MB8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF=#(
M! ,)   !                     0                    $   $   (
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M>9P4?Z-^98-,?\9^A6J%?_Y^P%&_@&-_/3D @1* #_S%?GR+-.2U?F.);,Q
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MWWRR@Q>=RFBD@G.8H%39@=V3/4%7@7*-?BZ @1:')\J@AL>\#[><A8JV :0
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M.X7J<W6K?G!@=0JCIUL3=KV;=T7W>)R2QC%1>J^)8=<@?Q5R&L.:?QES.:^
M?RAT3IK)?T!U:(6J?V1VEW!B?Y9WY5LS?]AY3D8>@#YZ]3%^@-Y\_=6C?69\
MF<)R?8M\FJYH?;-\HYFX?>)\P82>?AY\^V]I?FU]3UI1?M%]LD5F?UU^-S$
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MC/Y[2TB4BL)\+#A(B(1]0BD'AC5^F:G#ET.!+)I_E-B OHJRDH* 7GHZD$^
M&FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^ )ZC5EBN)M)F D\6(AXFE
MD7J'97E;CTB&3VBGC3:%65?WBRJ$:T>>B1:#?3>_AP."CBD)A-^!DZ?VE2N2
M2YB;DM"078B]D(^.<7ATCF:,A&?OC$^*IE=@BEF(U4<UB%B&\C>(AEV$^2D*
MA%6"W*<JE'*:WY?EDAJ8,8@+C]>5<'>WC;"2J6<\BZ./Y%;0B:V-'4;/A[R*
M03=1A=2'."D*@^"#_J9_D^&C4Y<VD8^?XX=:CTF<27<.C2"8G6:GBQF4[E98
MB2F1,49^AS6-4C<HA5Z)/BD+@W^$]Z7WDW2KI9:JD26G;(;'CMNB\G9]C*N>
M5&8@BJ:9LE7EB,&4_$8OAM*0(#<%A/V+""D+@R^%RJ65DR.SWI8\D->NUH9)
MCH>I:G7\C$ZCRF6OBD2>)U6-B&*8<T7KAH&2F3;;A+F,BRD+@N^&=YW-HPMO
M6X^EG[5PHX#YG(MQ[G'"F7-S2F(TEE-TQU*1DR-V<$-*C]AX/C1HC'%Z7R:B
MB.%\Y)TVH?1WHX\GGJIX#H!PFWUXC7$\F&!Y)V&SE4)YYE(?DAQZRT+OCMU[
MS#1!BX9]!B;+B A^@)R9H,E_Q(YJG8Y_:7_'FF!_(G".ETQ_ &$9E#I^_U&B
MD21_&D*5C?9_1C0=BK)_DB;PATA_^YOBG[*'QHV=G'Z&MW[JF5N%N&_5EDF$
MU&!SDTB$#E$@D$.#6$(^C2:"I#/[B?6!^R</AJ&!5)LBGL^/M(SAFYZ-^7XL
MF(",2&\4E7.*HU_?DFN)!%"KCWB'>$'TC&F%WC/@B4R$.2<JAA&"B9J%G@B7
ML8Q"FN*51'V-E\:2SFY^E+>05%]7D;*-W5!(CKB+:$&UB[J(YS/)B+6&2"=
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MZ['T9&"T4I\99I^N5XO8:.BH+7B1:VNB!V5M;BF;T%*G<1657$ _=$".C"[
M=["'6L""=/]F-*^/=?YHIIWE=O]J]8MX> %M,'B*>0YO<V5K>BYQT%)\>VET
M4#_$?-9W%"W3?I!Z2[\G<LAP>ZZ!<_]QU)SC=2-S'HJ$=D9T9W>C=W1UO62=
M>+YW*E'/>B5XKC]%>\1Z8BV.?:]\6+VO<-%ZGZSJ<B=Z\IMS<VI[0(DH=*][
MF79X=@5\ V.C=WE\?U$'>0I]!#ZZ>M-]G"U2?.1^2+PH;Q>$F:M9<(*#_IGI
M<=V#7H?;<SV"P750=+J".V*P=E.!O%!0> N!/#Y!>?N MBT=?#" &+J[;9^.
M>ZGX;QN-!)B-<(N+>H:-<@")Z'0_<Y.(7F',=5&&XD^F=RN%5#W4>3Z#J"SO
M>Y.!PKF2;'684ZC4;?R6 )=O;W63AH5[</J0^7-'<J".;&$!='&+W4\0=FN)
M/SUT>)V&:BS)>PV#0+BF:XBB"Z?H;1:>W):";I*;;(26<!^7W7)X<=B436!7
M<[R0KTZ3=<B,[STF>!6(\2RI>IV$C[?W:M>KF*<T;&>GB)7!;>&C'(/4;VV>
M@G&_<3"9Y5^Y<RJ5.4X@=4F07SSB=Z6+-BR/>D"%K[>&:F&TZ*:S:^VO[94I
M;5RJ?(,R;N"DSW$I<*6?(%\\<JJ98$VV=-J3;#R5=TJ-*2QZ>?6&GK+5?2%E
MI*-U?41H+),Y?8%JB8(<?=!LSW!P?BYO'UZ2?IUQCDSP?R%T(CN-?\]W 2L(
M@+IZ5;'$>PQO2Z)J>VEPSY(;>\=R/H$3?#)SIV^$?*UU'5W*?4!VK$Q/?>IX
M5#LB?L)Z+2KF?]5\3+"<>2AXX:$J>:MY<I$->B1Y^8 ">JMZ?FZ5>T1[%%T%
M>_I[O$NZ?,M\<CK#?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!
M46V%>@.! EPG>MV O$L5>]* =SI>?/B ,"JN?E1_VZX$=A6+H9Z/=KJ*CHYF
M=V")7'VD>!*(%VR5>.2&U5M>>>&%G$J#>O6$5CH'?#R"]BJ7?;>!:ZSZ=/B4
M\)V(=:B3#HUF=E:0^'RP=Q:.QFNX=_B,CEJP>06*4DH$>C>(!SF\>YN%C"J$
M?3&"T*PF=!2>'YRQ=,R;:XR/=7V8;'OA=D2516K^=S>2%EH:>%6.V$F=>92+
M?#F >Q.'YRIU?,&$!ZN'<VBG))P)="2CF8O==-.?JWLR=9F;A6I9=I:75EF+
M=\F3%4DW>1F.KCE+>J2* 2IH?&6%$*L?<O*O\9N.<ZZKB8M-=%2FHGJ<=1&A
M=6G2=@^</ED>=TN6]DC;>*V1@CD+>DR+S"I>?!R%[*6+A7QE.Y=_A,AGR(B-
MA$1J+'BV@]YL>VA1@X-NV%>]@S-Q5T=R@O!S_C=R@LQV]"AJ@M1Z7*2O@XAN
M4Y:5@Q)O[X>,@J]Q='?&@EQR]F=^@AATB%<-@>5V-$;J@<%W_#<C@<!Y^2AK
M@>A\/J.P@<!W195H@7!X"89_@2-XNW; @.EY;V:?@+]Z+U9:@*U[ T9H@*I[
MYC;;@,U\Y"AK@19^ :*;@!B (Y1(?]^ ((53?ZZ  W7<?X=_XF7:?WI_RU7'
M?X9_OD8%?Z9_M3:F?_%_K"AK@%Y_H*%_?L*([Y-+?I:(+X19?G.'273,?EV&
M2F3Z?F2%354)?I*$6$5]?L^#639??S6"1RAK?[^!&*"6?;*1LY)<?9&0,8-Q
M?76.=G/T?6J,EV0Y?7Z*L51V?;>(QT46?@^&T38H?I.$L2AK?SB"99_9?-F:
M4I&>?,*8#(*U?*>5=G,^?*"2L6.5?,*/X%/U?0J- 43%?6N*"S7^?@F&XBAK
M?L>#AI]*?#2BR)$&?"2?NX(4? :<0W*B>_R8C&,#?"24R%-S?("0\D1J?/&-
M #78?9B(U"AK?FN$>Y[H>\"K#)"1>[.G-(&.>XVBT7(:>WF>'F*->Z&97U,7
M? 24CD0>?(>/GC6G?4**>2AK?B&%19B=CC%DZ8NIC*YG;'W=BVAIT&\ZBD%L
M*& =B1QND5#>A_EQ($'ZAM=SV3-RA<EVYB7_A-5Z89?HC&IM>8KPBR%O&GT0
MB?)PKFY_B--R15]ZA[QS[U!9AJ]UN4&8A:AWH3-&A+AYQ28A@^!\,)<7BK1U
MWXGUB9)VN7PQB'1WBFVFAVMX7U[#AFMY1D_+A7IZ1$$VA)%[53,=@\%\AR8^
M@P=]W98BB2-^&HCYB!!^1WLFAPQ^7VS9AA!^<5X2A2Y^CT]*A%M^N$#F@Y%^
MZC+]@N-_)298@DE_9I4UA\N&5X@0ALB%TGI'A=*%*VP"A.6$;EU\A R#L4[;
M@U:# T">@JN"4#+@@A^!DR9N@:: R)1KALF.CX=CA=&-6GF@A-Z+[&M)@_:*
M5ES/@RF(O$Y:@GR'*4!'@>J%CC*Y@7F#U": @1R" )/'A?N6GX:WA0V4MGCU
MA!F2>FJF@S.0"EPW@G&-DTWC@="+&$ (@4.(D#*@@.R%W2:/@*F##)-'A5^>
M@88RA'F;XGAH@X&8TVH?@I.5?ENY@=22(4UN@4:.O#^X@,:+2C**@'B'J2:<
M@$N#[Y+LA.^F.H7)A ZBY7?O@PV>]VFE@A.:KUM3@4^69$TC@,>2%#^#@%F-
MM3)M@!Z)+2:F@ "$J8PHEP-DK8 >E-!G('-9DM1I@V7?D.AKXU@$CNMN5TH9
MC.%P]CR@BLUSP"^<B+QVWR/,AK=Z8XN.E7ALPG^1DVYN8'+!D7=O_659CX=Q
MIE>2C8]S9TG"BY=U3#QGB9AW4R^5AZ%YF20.A;5\(8KFD]ITI'[$D?!UB7(0
MD 9V;V2LCB5W85<%C$!X:TE:BF%YD#PIB'UZS2^-AJ-\,B1(A--]NXH>DE=\
M77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^ A<)^I21Y
MA Y_,8E5D1:$ GTICT>#I7!KC7N#,6,WB[6"L57GB?*",TB%B$F!QSNMAIN!
M6"]WA/J ["2D@V6 ?HBMD ^+JGR"CDZ*J6_(C(F)?6*DBL.(,E5FB0F&Y$@[
MAV.%GSN!A<Z$6B]MA$V# R3(@M:!HH@ECT>3+7P,C9*1C&]4B\>/GF(GB?N-
M@53KB$J+8D?:AK2)13M5A2.'(R]D@[J$Y"3E@F""G8>YCK.:?GN>C0&8.&[A
MBS&5A6&ZB5Z2D52%AZ^/FD=\AB>,H3L9A**)I2]=@T*&B23]@@"#;X=HCD:A
MGGM&C)6>LFY_BKR;,F%9B-^7750TARR3AT="A:F/L3KQA#.+V"]-@N>'ZB40
M@;.$&X!"H QD6W3VG3AFOVDDFH)I(5S+E\)KC5 ME-UN%4.4D=MPRS> CK]S
MJRP#BY5VWB'8B&YZ9'^ZGKIK_720F_1MF6B]F3)O05QVEF1P_T_KDW]RW$-J
MD(ITXC=SC8!W"BPDBFUY<R(XAU]\$G\VG3)S8W/QFH-T4V@ZE\=U3EOXE0)V
M84^)DBQWD4,KCTUXXS=;C%MZ3BP^B6-[Y2*,AG)]G'Z>F[5ZFW-)F1-Z\V>'
MEFA[3%MPD[![M4\7D/)\-$+@CBM\R3<[BU-];RQ/B'A^,"+5A:1^_WX$FG:!
MP7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J D#<:BFF :BQ<AZF 4",2
MA/6 .WU]F7Z(W7(TEO&($F9XE$^'(EIHD:"&'TY-CO"%'D)EC$"$*#<'B9>#
M."QIAO6"02-&A&&!3GT2F*Z/SG''EBJ.;&8+DXF,S5H D-N+#$WUCC*)2$(M
MBXR'AC<"B-^%QRQYAEF#_2-P@^>".7R]F!V6E7&7E9Z4J&7;DN^23EG&D"J/
MM4VZC7V-(D'NBNV*F#;8B%6(%2R A=N%@2.2@X2"_7Q\E[2=*'%7E2R:IF65
MDG.7C%E_CZ:4(4V!C/:0OD''BFJ-93;#A^**%RR!A7V&PR.N@S6#G73KJ5!C
MZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C CDAVV2 B
MB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET;C+=D4]V
MO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TATF"-VK3U?
ME"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQYN5-6FJ)Z
M3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C H)=_9UWP
MG19_3U+MF7)_.D?NE;9_03T4D>]_7C+LC@Y_A2F6BB1_OB&UAE5__W+AHON&
M'FANGZ"%A5VCG!V$SU*CF'F$#D>OE,*#6CSXD/^"N#+LC3."("FTB6B!CB'W
MA;R!!'*2HC>,CV@OGMN+=5UJFU**'%)HEZJ(ID=VD_J'.CS9D$&%V3+TC':$
M@RG2B,:#*B(MA3V!X7)9H9F2Q6?[GCR1(ETRFJ^/)%(QEP*,]D=$DU2*SSRI
MCZN(KS+EB^2&H2GPB#^$D")9A->"F7(KH3"8U6?]G<B6O5TOFB:4!%(<EF"0
M_$<[DJ:.##RTCP.+-#+VBUZ(=2H$A]J%N2)\A(6#+VH)LM=C:E_\KNAEJ57A
MJKEH#4NPIB1JFT& H2MM6#>)F^AP32X]EG1S:R6]D-EVTQZ@BUQZ8&F8L?)J
M0%_7K=)KRU76J6EMB4NZI+%O>$&<GZYQFS>YFG1S\RZ%E0__XO_B24-#7U!2
M3T9)3$4  @EV<"8HCXUY*!\VBC![]6E;L(1PPE^3K&!QNU6LI_)RVTN9HS5T
M-T&2GCQUP3?+F15W>BZXD\=Y42:"CF-[5A^WB2M]9&DDKOEW"%]/JMMW@U5?
MIG9X&DMKH<AXWT%VG.%YT#?-E])ZXR[=DI]\#B;,C5Q]6R GB$M^JFCJK:)]
M.5\<J8M]054MI2E]5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%
MAXU_RFBWK)F#8U\ J'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!
M$R=!B[" YB#3ANZ PFB.J\J)6U[QIYZ(?E4.HS"':DL2GHN&14%#F<2%,3?7
ME.*$,2\WC^F#1"=RBPF"8B$4AFN!DVANJR^/&U[OIO"-R54/HG6,&TL-G<J*
M14$XF0B(@3?-E#F&T"]!CT^%-R>8BG^#JR%(A@&"06A:JKZ4H5[VIF*2V547
MH=B0B$L/G2>-_4$\F&>+@S?;DZ.))"],CLV&WR>JBA2$MB%RA:V"S<+/: Y@
MX+%*:DYCOY]1;'EFC(S";IEI37G#<,-L$V:6<PAN\%.?=7)Q\D#H>"!U/"\(
M>RQY L#N945K?Z_39\AM19X&:BIO!XN?;(!PS'B\;N-RFF6N<61T?U+8= IV
M?$!5=O5XL2[!>CU[.;\I8MAV!*XB989VMYR5:!AW;(I%:IMX-G>/;3!Y$&2Q
M;^9Y_%(1<L1Z]S_,=>=\$2Z!>65]4[UI8+" 6:QJ8X. #IKJ9C9_S(C=:.-_
MEG92:ZE_>6.N;I!_9U%.<:%_63]+=/A_4RY*>*5_3+O/7MF*C*KF8<F)69EQ
M9)N()8=V9V:&]'4O:D^%SF*\;6:$NU";<*6#G3[9="B";RX:=_Z!'+J!75Z4
MJZFI8&.2EYA#8TB0;(969BN..W0I:3",#V'H;&2)YT_^;\R'M3YT<W>%6RWR
M=VZ"O[EW7"V>IJBN7T&;KI=-8C"8B85K92.54W-3:$&2(6$W:Y&.YT]\;Q2+
MDCXC<N&("RW0=O:$,+BQ6T2H;J?P7F&DC):+85.@:(2J9$R<)7*;9WN7YV"8
M:N63GT\';H*/+3W<<F:*=BVU=I*%;;@S6J2QZJ=P7<*M"Y7[8*ZGW(028Z2B
MC7(-9MB=0V @:E*7ZTZ?;@*28CV1<?Z,CBV?=D*&=[5^;ZY@7J6C<29C8Y46
M<IUF0H/'=!AI"W'U=:-KVE_T=TENQ4XQ>1%QV#RX>Q9U."PM?7!Y%[08;1-J
M>:24;LYL<)09<'1N4H+><AAP+W$?<\]R%5\[=:AT%$V>=Z=V,CQ4>>EXB2P$
M?'Y[-K*9:K]T;J+\;*9U9I*M;G1V5(&)<$5W1F_\<BMX1EY*=#AY6DSB=FMZ
M?SO;>.![Q2O@>Z9]-K$,:*]^-*%L:K9^1I$H;*9^3(!&;IE^46[?<+!^95UE
M<NI^ADPZ=4U^K3MS=_1^WRO >N9_%*^;9NJ'X: -:0R'&H_2:QF&/'[_;2J%
M4FW>;U^$;ER/<<>#F$N@=%6"NCL7=R:!SRNE>D" R:YO97Z1?Y[J9[*/X(Z\
M:=&.&'WX:_F,.FSP;DB*6UO5<,J(?DL9<X"&F3K&=G>$CRN.>;*"4:V!9%B:
M^9X!9IJ8?XW7:,*5QWT?:OF2\&PL;6&0%ELW;_Z--$JL<LJ*.CJ&=>.'$RM[
M>3N#J*S08WBD0)U/9<"@YXT=9^R=.7QH:BB98&N ;*"5A5JA;UB1GTI"<CV-
MF#I.=6F)5"MK>-F$SJQ?8MZM/YS092:H_HR-9TJD4GO2:8.?<FKX; *:DUHT
M;L>5ITGC<<*0E#H*=0>+02M?>(J%PZB'=XA@!IHN>#!C&XKX>.]F WKB><)H
MT6H_>J9KIUEM>Z-NGDCE?+UQP#BP?@UU-2E]?Z1Y*:=J=1%IA)D?=?YKGHG<
M=NAMGGGA=]]OE&E>>.QQE5BS>A9SLDA6>V!U[3A:?.1X92ER?JU[,:8X<M-R
M[9?;<_%T'(C4=0)U.WC;=AUV4VA_=TYW>5@!>*5XM4?8>A]Z!3@2>]=[>"EH
M?=)]&:3:<--\*I9]<A%\B(=F<T-\SG>M='Y]"F=T==]]45<K=V-]I$<]>0I^
M 3>[>NY^:BE@?1!^W:.2;R.%3I4]<'B$XH8Q<<6$4W:)<QN#KF:4=):#"U9R
M=D6"<D:[>!2!UC=T>B&!,"E9?&F >**%;<>.9Y0W;RV-+X4V<(F+PW6=<?6*
M-F7 <XB(I572=4V'$T9+=T"%?#<W>7*#Q2E3>]J!YJ&O;*V76Y-A;B"5581E
M;X63!737</Z0C&4.<JB."U5%=(6+@47P=HR(Y#<(>-Z&'BE.>V.#):$/:]2@
M'9*[;4^=1(.X;K>:"W0P<#26G&1Q<>V3)52\<^2/HT62=@*,!C;=>&2(-2E*
M>P&$-J"E:SRHG))";+FD[8,M;AN@PW.C;Y6<5V/U<5.7YE1;<U>3:$4^=8J.
MRS:C> 2)_"E'>K.%%YOH?YU?T8[#?WIBXX"^?X-ES'':?ZEHGV)M?]YK?E+6
M@"1N@4.7@']QL32Y@09U-R;X@<1Y-YKZ?4=HOXW3?6MJZ7^_?9]L^G#S?>)O
M!6&F?CAQ'E(W?J5S5$,C?RIUJS2 ?]YX02<,@,9[*IGP>R9QAXRD>WMRX'Z\
M>\YT)F_Z?#)U9V#9?*MVM%&8?4%X%D*X??%YCS1.?M)[+B<=?^5\^YC/>39Z
M/XMW>:UZTWV,>B%[3&\8>I][P6 4>S]\.5$%>_Q\P$):?-5]4C0E?>-]]2<L
M?Q]^II>O=YB"W8I\>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6
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M@5!YV&9J@0AZ>5B8@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%"
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MC=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU DK*
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M36-9A^)]KUEHANE][T\MA>%^'D3LA.%^53KF@_%^HC%<@Q]^_"B7@FY_6B%
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MCG5[N$@%C'=\*S[BBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,&
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M83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]>
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M>F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6
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M^3$D@0]_,"M4@,I_?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P
M;69T,0     #!"$   $                    !
M 0    $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F)R@I
M*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%56
M5UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#
MA(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^P
ML;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:V]S=
MWM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_P ! 0(" P,$! 4&
M!@<'" @)"0H+"PP,#0T.#P\0$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @
M(2(B(R0D)28F)R@I*2HK+"TM+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)
M2DQ-3U!24U576%I<7F!B9&9H:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6G
MJ*JLK:^PLK.UMK>YNKN\O;_ P<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8
MV=G:V]O<W=W>W]_@X>'BX^/DY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T
M]/7V]O?W^/CY^?K[^_S\_?W^_O\  0$" @,#! 0%!@8'!P@("0D*"PL,# T-
M#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@("$B(B,D)"4F)B<H*2DJ
M*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(24I,34]04E-55UA:7%Y@
M8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.EIZBJK*VOL+*SM;:WN;J[
MO+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7V-G9VMO;W-W=WM_?X.'A
MXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S]/3U]O;W]_CX^?GZ^_O\
M_/W]_O[__Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=X
MN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG
M@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
M_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"Z
MI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y
M,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&
MMJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B
M1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'
MR[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]
MH$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@
MA]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@
M\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"O
MG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,
M<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6
MJYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G
M3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+
MW:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:
MJ%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6
MSZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99
MIL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E
M9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$
MIV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^V
MP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=X
MN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG
M@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
M_Z8Y,O^B14K]H4Q@\J5+<>:I2H/:JDV5SZE6I<BH8;#%JFNUPJQUNKZK?;^Z
MJH/%MJB'RK*FA]"KHH?6I)Z)W)J:C^&:FH_AFIJ/X9J:C^&:FH_AFIJ/X9J:
MC^&:FH_AFIJ/X9J:C^&:FH_AFIJ/X9J:C^&:FH_AFIJ/X9J:C^&:FH_A_Z8X
M,O^C14K]HDM@\J9)<>:J2(+;K4J3T*Q2H\FL7:_&KV>SP[%QN+^S>;VXKX'$
MLJJ'RZRFAM"EHX;5G9^&VI.=B]Z3G8O>DYV+WI.=B]Z3G8O>DYV+WI.=B]Z3
MG8O>DYV+WI.=B]Z3G8O>DYV+WI.=B]Z3G8O>DYV+WI.=B]Z3G8O>_Z<X,O^C
M14K]HDI?\J=(<.>L1H'<KT>2TK!.H<JQ5ZW(MF*PQ;ILM;JS>+ZRKH'%K:J'
MRZ>GA<^@I(33F*&%UX^?B-J/GXC:CY^(VH^?B-J/GXC:CY^(VH^?B-J/GXC:
MCY^(VH^?B-J/GXC:CY^(VH^?B-J/GXC:CY^(VH^?B-J/GXC:_Z<X,O^C1$O^
MHTE?\ZE&;^BN1(#=LT.0T[9(G\RW4:K*P%RLO;ALM[.R>,"MKH'&J:J&RJ*H
MA,Z;I831E*.$U(RAA]>,H8?7C*&'UXRAA]>,H8?7C*&'UXRAA]>,H8?7C*&'
MUXRAA]>,H8?7C*&'UXRAA]>,H8?7C*&'UXRAA]>,H8?7_Z<W,O^C1$O^I4=>
M\ZI$;NFQ07_?N#Z.UKU"F\_#2J3"OEROMK=LN:ZQ>,&IKH'&I:N%R9ZIA,R8
MIX//D:6$THJCAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JC
MAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JCAM2*HX;4_Z@W,O^D1$O^ID9>]*U"
M;>JT/GWAO3N+VL8\ELK&2*2YO%RRK[9MNZFQ><&EKH+%H:R$R)NJ@\N5J8/-
MCZ>$SXFFAM&)IH;1B::&T8FFAM&)IH;1B::&T8FFAM&)IH;1B::&T8FFAM&)
MIH;1B::&T8FFAM&)IH;1B::&T8FFAM&)IH;1_Z@W,O^D0TO_J$-=]:\_;.RX
M.GKDPS>'W=,UD,'$2:>QNEZUJ;5NO*2Q>L"BKX+$G:V$QYBLA,F2JH3+C:F%
MS8BHALZ(J(;.B*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.
MB*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;._ZDV,O^E0DO_JD%<]K([:NZ]-G?H
MRS. T-(SD[C#2ZBJN6"VI+5PO*&R>\">L(/#FJZ$Q96MA,>0K(3)BZN%RH>J
MALR'JH;,AZJ&S(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&
MS(>JALR'JH;,AZJ&S(>JALR'JH;,_ZDU,O^E0DO_K#U:^+<W9_'$,7'?URQ[
MQ= UE;#"3JFDN&.WG[5RO)VS?+^;L8/!EZ^$PY*NA,6.K87&BJR&R(>LA\F'
MK(?)AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>L
MA\F'K(?)AZR'R8>LA\F'K(?)_ZHT,O^F0$O_L#E8^;TQ8N?.+6G0X"1_N<\W
MEZ?"4JF>NF:UFK5SNYBS?;Z7LH/ E+&%P9"PA<.-KX7$B:Z&Q8:NA\:&KH?&
MAJZ'QH:NA\:&KH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&
MKH?&AJZ'QH:NA\:&KH?&_ZLS,O^J.TG_MC)3\,<J6MC>(6;"WR2"K<X\F)_#
M5J>9O&BREK=UN)2T?;V3LX.^D;*%OXZRAL"+L8;!B+"'PH:PB,.&L(C#AK"(
MPX:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#
MAK"(PX:PB,.&L(C#_ZTQ,O^P,T7XP"E,W]8C3<?H(&JSWB:$H<]!EI?&6:23
MP&JLD+QULH^Y?;:/MX.XC+:$NHJUA;R(M(:]AK.'OH2SB+^$LXB_A+.(OX2S
MB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(
MOX2SB+^$LXB__Z\O,O^Y*3_HSAX_S.8;4K?N(6VEWBR#E])%DI#+6YV,Q6NE
MB\)UJHJ_?*V'OG^PA+R L8.\@K*!NX.S?[J$M'ZZAK5^NH:U?KJ&M7ZZAK5^
MNH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZ
MAK5^NH:U_[(J,O'&'#/1XA0ZO/,;5JCN)FV8X35_CMA*C(C0796&S&N;A,ET
MH(''>*-^Q7NE?,1]IGO$?J=YPX"H>,*"J7?"@ZIWPH.J=\*#JG?"@ZIWPH.J
M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIW
MPH.J^KX<*-;=#B/ \!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/
M=)=USG>8<\UYFG+->YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N
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M@*:<T("CI<^ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#_YXW&O^;1"[_FTQ
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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M#O^4/1[_G4 I_Z0^,O^K/SO_L4)"^+A'2>V^3D_EQE=3VL9>7\N^9'&^MFJ
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M=LR:FG?-F9EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8_WXB!O^
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MD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[*>C8#!GHR R9Z+@,J=BH#+FXJ
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M6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E8QK@$ +;$! "JTP4
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M?<ICX'[#9.!_O6;?@+=GWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TK@[&=*W^QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG_YP- -NQ!@#*O0<
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ML4<CRZM2,L&E6D"XGV),L)EI5ZB4<&"ACW=GFXM^;I:(AG.1A8YXC(*6?(B
MGX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^ ?N!_@'[@
M?X!^X'^ ?N!__VP@ _]\' /_C24&_YHN"?^C,POTJC0-Z;$Y#]^W/Q+2M$8B
MQZY0,;VH63^SHF!+JYUG5J.8;E^<E'5GEI!\;9"-@W.+BHMXAHB4?(&&G8!^
MA*B">X2U@WF$Q81XA=V#>83>@7J#WX!Z@N!_>H+@?WJ"X']Z@N!_>H+@?WJ"
MX']Z@N!__VT? _]^&P/_CR0%_YTL!_ZF, GPKC$+Y;8U"]N\.1'.MT4@P[)/
M,+BL5SZOIU]*IJ%E59Z=;%Z7F7-FD)5Z;(J2@7*%D(EW@(V1?'N+FW]WBJ6"
M=(FR@W*)PH-RBMJ#<XG>@72'WX!UAN!_=8;@?W6&X']UAN!_=8;@?W6&X']U
MAN!__V\> _^ &P/_DB,$_Z K!OJI+ ?MLBP'XKPQ!]7 -A#)NT,?OK9-+K2P
M5CRJJUU)H:9D5)FB:EV1GG%EBIMX:X28?W%_EH9V>9./>G61F'YQD*.!;I"O
M@FR0OX-KD=6";8_>@6^-WX!PB^!_<(O@?W"+X']PB^!_<(O@?W"+X']PB^!_
M_W$< _^#&0+_E2$#_Z,I!?:M)P7HMR8$WL,J ]##-0[$OT$=N;I,+:ZU5#NE
ML%M'FZQB4I.H:5N+I6]CA:)V:GZ??&]XG(1T<YJ,>6^9EGQKEZ%_:)>M@&:7
MO(%EF-& 9I;??VB3X'YJD>%^:I'A?FJ1X7YJD>%^:I'A?FJ1X7YJD>%^_W4:
M O^'& +_F" #_Z8E _*R( /DOAX"U\DB LK',PV^PT <L[]**ZFZ4SF?MEI%
MEK)A4(VO9UF%K&U@?JET9WBF>FURI()R;:**=FBAE'EDH)]\89^K?E^@NGY?
MH,Y^7Y_A?6*;X7UCF.)\8YCB?&.8XGQCF.)\8YCB?&.8XGQCF.)\_W@8 O^+
M%P'_G1T"_:L> NRX%P'>R!$ S\T? L3,, NXR#X9K<5(**/!43:8O5A"C[E?
M38:V959_LVM=>+%R9'*O>6ELK8!N9ZR)<F*JDG5?J9UX7*FJ>EJIN7I9JLQZ
M6*GD>ENDY'I=H>1Y7:'D>5VAY'E=H>1Y7:'D>5VAY'E=H>1Y_WT5 O^0% '_
MH1@!]K$4 -G!"P#2SPL R-(< ;S1+@FQSCL7ILM&)9S(3S.1Q%8_B,%=28"_
M8U)XO&I9<;IP7VNY=V1FMW]I8;:';5VUD7!9M9QR5K2I=%2TN'13M<MT4[7D
M=%2PYW56K.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U_X,2 ?^6$0#_J!$
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M<F62ZG%GC^IP9X[J<&>.ZG!GCNIP9X[J<&>.ZG!GCNIP_W,5 O^%$P'_E!0
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M3$;:[4Q$V/E/0]C[3T/8^T]#V/M/0]C[3T/8^T]#V/M/VYH  ,JI @"[LP(
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M)0/_920$_VXJ!O]V- O_>CT1_WI&&/]X3R#[=%@H]F]A+_%K;#;M9W8\Z6.
M0.9@BD7D79)(X5N:2M]9HDW=6*I/VE>R4-A6O%'55<A2TE7;4\Y6ZU/+5O95
MQE;]5K]8_5:Z6?U7MEK]5[9:_5>V6OU7MEK]5[9:_5>V6OU7_U,F _]?(@/_
M:2$#_W,H!?][,@K_?SL0_X!$%OM^3![T>U0E[G9=+>EQ:#3D;7([X&E\0=QE
MA4;88HY*U%^63=%=G5#.7*52S%JM5,E9ME;'6<)7QEG05\)9YEB_6?-9NUK[
M6;5;^UJP7?M:K5W[6:U=^UFM7?M9K5W[6:U=^UFM7?M9_U8D _]B( /_;2 #
M_W<F!/]_, C_A#D-_89!%/6%21ON@E$BYWU:*N%X9#+<<VXZU&YW0=!J@$?,
M9HE,R&214,5BF%/#8*!5P%ZH6+Y=L5F[7;Q;N5S)7+=<X%RT7>]<L%[Y7:M?
M^5VH8/E<I6'Y7*5A^5RE8?E<I6'Y7*5A^5RE8?E<_U@B _]E'@/_<1\#_WLD
M _^$+@?_B38+^(L^$>^+1A?HB$X>X817)ME^83'1>&HZRW-S0L9O?$C";(1-
MOFF,4;MFDU6X9)M8M6.C6K-AK%RP8+=>KF#$7ZQ@V%^I8>M?IV'W7Z)C]U^?
M9/=?G63X7IUD^%Z=9/A>G63X7IUD^%Z=9/A>_UL@ O]H' +_=!T"_WXC _^(
M*P7]C30)\Y [#NJ00Q3BCTH:VHI4)="#73#)?F<ZPWAO0KYT>$BY<8!.M6Z(
M4K)KCU:O:9=:K&>?7*EEJ%^F9+)AI&2_8J)DT&*@9.=BGF7U8IIF]6&89_9@
MEFCV8)9H]F"6:/9@EFCV8)9H]F"6:/9@_UT? O]J&@+_=QP"_X(A O^+*03Y
MD3$'[Y4X"^:6/Q#=E$<7THY1),J(6R_"@V0YO'YL0;=Y=$BR=7Q.KG*$4ZIO
MBU>F;9-;HVN;7J!JI&"=:*YCFVBZ9)EHRV67:.-DE6GS9)-J]&.1:_5BD&OU
M89!K]6&0:_5AD&OU89!K]6&0:_5A_U\= O]M& +_>AL"_X4? O^.)P/UE2X%
MZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW> 4Z-TB%B?
M<9!;FV^87YANH6*5;:MDDFRW9I!LQF:/;-]FCFWQ98QN\V2+;O1CBF[T8HIN
M]&**;O1BBF[T8HIN]&**;O1B_V$< O]O%@+_?!H!_X@> ?^1) +RF2L$YYXQ
M!=V@-@G1G$$5QY=-(;^15BVWC%\WL8=G0*N";DBE?G9.H'M]4YQXA5B8=HU<
ME'257Y%RGF*.<:AEBW"T9XEPPVB'<-MGAG'N9H9R\F6%<O-DA'+T8X1R]&.$
M<O1CA'+T8X1R]&.$<O1C_V,: O]Q%0'_?Q@!_XH< ?R4(0+NG"<"XZ(L ]BD
M,@C,GT 4PYI+(+J552RSD%TWK(ME/Z6';$>@@W--FX![4Y9]@E>2>HI<CGB2
M8(IVFV.'=:5FA'2Q9X)TP&B =-5H@'7L9W]V\F9_=?-E?W7S9']U\V1_=?-D
M?W7S9']U\V1_=?-D_V49 O]T% '_@1<!_XT: ?F7'@'KH",!WZ8F M*G, ?(
MHSX3OYY)'[:94RNNE%LVIX]C/Z"+:D:;AW%-E81X4I"!?U>,?X=<B'V08(1[
MF6. >J-F?GFO:'MYO6EZ>=%I>7KJ:'IZ\F9Z>?)E>GGS9'IY\V1Z>?-D>GGS
M9'IY\V1Z>?-D_V<7 O]V% '_A!8!_Y 7 ?6;&@'GI!T!VZL? <ZJ+P;$ICT2
MNJ%('K*=42JJF%DTHI1A/IR0:$66C&],D(EV4HN&?5>&A(5;@H*-7WZ EV-Z
M?Z%F=WZL:'5]NVES?LYI<W[H:'1^\69T??)E=7SS9'5\\V1U?/-D=7SS9'5\
M\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0; J3L1MJ5&
M':VA4"FEG%@SGIA?/)>49D20D6U+BXYT48:,>U:!B8-;?(>+7WB&E&)TA)]E
M<8.J9V^#N&EM@\MI;8/F:&Z#\F9O@O)E<('S9'"!\V1P@?-D<('S9'"!\V1P
M@?-D_VL4 ?][$@'_BA( _Y82 .VB$ #>K0X T+$9 ,6P*P6[K3D/LJE$&ZFE
M3B>@H58RF9U>.Y*:9$.+EVM*AI1R4("2>55[CX!:=XV)7G*,DF%NBIQD:XFH
M9VF)MFAGB<AH9XGC9VB)\F9IA_-E:H;S9&J&\V1JAO-D:H;S9&J&\V1JAO-D
M_VX2 ?]^$ #_C1  ]YH. -NG"@#3L L RK06 ,"T*02VL3<.K:Y#&J2J3"6;
MIE4PDZ-<.8R@8T&&G6E(@)IP3GN8=U-VEGY8<92&7&R2D&!HD9IC99"F96.0
MM&9AD,9F89#A9F&0\F5CCO-D9(ST8V2,]&-DC/1C9(ST8V2,]&-DC/1C_W$0
M ?^"#P#_D0T WI\) -.J"0#,LPD Q+@3 +JX)@.QMC4,I[-!&)ZO2B.6K%,N
MCJE:-X>F83^ I&=&>J%N3'6?=5%PG7Q5:YR$6F::CEUCF9A@7YBD8EV8LF1;
MF,-D6YC>8UN8\&-<E?5B7I/U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B_W4. /^&
M#0#KE@@ U:,' ,RM" #%M@< O;P1 +2](P*KNS(*H;D_%9BV2""0LU$KB+!8
M-("N7SQZJV9#=*EL2&^H<TYJIGI29:6"5F&CC%I=HI9<6J*B7U>AL&!6H<%@
M5:+<8%6A[V!6G_=?5YSW7U><]U]7G/=?5YSW7U><]U]7G/=?_WH, /V+"0#:
MFP0 SJ<& ,2P!@"\N00 M<$. *S"( &DP3 (FK\\$Y&]1AV)ND\G@;A6,'JV
M73ASM&0_;K)J1&BQ<4EDL'E-7ZZ!45NMBE18K9575*RA65*LKUM0K,!;4*S:
M6D^K[EM/JOI;4:;Z6U&F^EM1IOI;4:;Z6U&F^EM1IOI;_X ) .&2 0#1H 0
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M.#WB^S@]XOLX/>+[.#WB^S@]XOLXQJ$  +>K  "JM   GKX  )/) @"(U 8
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M2(@L_T:2+O]%FS#_1*(R_T.I,_]"L#3_0K<U_T&_-O]!R3;_0-<W_T#E-_U
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M65^,[EE?C/M888K]5V&)_5=AB?U788G]5V&)_5=AB?U7_V\, /]_"0#?C0,
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M2DBP_TI(L/]*2+#_2DBP_TI(L/]*XH8  ,Z4  #"H0  MJD  *NQ  "AN@$
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M4&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO=_],_V0- /]R"@#P?@8
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M2EB._TE8CO])6([_25B._TE8CO])_W$! ."   #/C   Q)8" +N> @"RI
MJ:H% **L%0";K"8"E*LT!XRJ/P^%J$@7?J90'GBD6"5SHEXK;J%E,&J?;#1E
MGG,Y89U[/%Z;A$!:FHY#5YF:1529IT=2F;9(49G*2%&8YDA1E_5(49?_1U&6
M_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0  OYL! +2B  "KJ   H;
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M-T"W_S= M_\WSHL  +^8  "RH0  IZD  )RP  "1N   AL " 'O(!P!TRQ(
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MCPXK]9T/*O:K$"GVO! H]LX1)_?F$2?U\1$G]?$1)_7Q$2?U\1$G]?$1HZ@
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M1'QG[T-\9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\:/\__UL, /]G"0#W<0<
MWGH% -2 !P#.A0D QX<1 +Z((@&VAS$$KX0^"ZB!21.B?5(:G'I:()=W82:3
M=6@KCW-O+XMQ=S.(;WXVA6Z&.H)MCSU_:YD_?&NC0GEJL$-X:K]$=FK4179K
M[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/] _UT* /]I!P#L= , VGP$
M -"#!@#)B < PXH/ +J+( &RBB\$JX@\"J2%1Q*=@5 9F'Y8'Y-\7R6.>68J
MBG=M+H9U=#*"='PV?W*$.7QQC3UY<)9 =F^A0G1NKD1R;KU%<&[117!OZT1P
M;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@  U'\# ,N&
M!0#%BP8 OHT- +6/'@"NCBT#IHPZ"9^)11&9ADX8DX-6'HZ 722)?F0IA7QK
M+8%Z<C)]>'DU>G>".7=VBSQS=94_<72?0FYSK$1L<[M%:W/.16MSZ41K<_A#
M:W/_0FQS_T%L<_] ;'/_0&QS_T!L<_] _V$% /IN 0#=>0  T((" ,>)! #
MC@0 N9$, +&2&P"IDBL#HI X")N-0P^4BDP7CHA4'8F%6R.$@V(H@(%I+7Q_
M<#%X?G<U=7Q_.'%[B#QN>I(_:WF=06AXJD-F>+A$97C,165XYT1E>/=#9GC_
M0F9X_T%F>/] 9GC_0&9X_T!F>/] _V0# .YQ  #8?   RX4" ,., P"[D0,
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M/$^1_SQ/D?\\Y'0  ,^!  #"C   N)8  *V<  "CH0  F*@  )"J#0"+JQL
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MG!\\PZL@.\.\(3K#U2$[PNXA.<#Y(CB__R0XO_\D.+__)#B__R0XO_\DO9$
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M""3QN @C\<P((O+E""+P\P@B[_4((N_U""+O]0@B[_4(GJ8  )&O  "$N
M=\$  &K)  !=T   4=<  $;=   _Z@4 //8. #GV%P V]R  ,_<H #'X,  N
M^38!*_D] 2GZ1 $G^DH")?M2 B/[6@(@_&,#'OQN QS]>P,;_HD$&?Z8!!C_
MJ 07_[<$%O_(!!;_X 06_^0$%O_D!!;_Y 06_^0$DZX  (6W  !XP   :LD
M %W2  !0V0  1-\  #KD   U]P, ,O\, "[_$@ K_QH */\A ";_)P C_RT
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M-(Y7\#2-5_TSC%C_,XQ8_S*,6/\QC%C_,8Q8_S&,6/\Q_U$, /];"0#_8P@
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M-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=;@  SW8! ,=[ P# ?P0
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M-5YX_S5>>/\U]60  -QP  #*>@  P(,  +:)  "NC0  I(\  )V1$ "7DB
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MFRQ(FJDM1YFZ+4::T"U&F.LM1I?Y+D:6_RY&EO\N1I;_+D:6_RY&EO\NT7<
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M&#:]RA@WO.<7-;OV&36Z_QHTN?\;-+G_&S2Y_QLTN?\;N(\  *J8  "?GP
MDZ8  (>L  ![LP  ;[D  &.^  !8Q 0 4,@, $W(%P!,R24 2LHQ $?*.P%%
MRD0"0\I, T'*5 0^REP&/,ID!SK+;@DXRW@*-LN%##3+D@TRRZ(.,<NR#S#,
MQP\PR^4.+\GU#R[(_1$NQ_\2+L?_$B['_Q(NQ_\2KI<  *&>  "5I0  B:T
M 'RT  !PNP  9,$  %G&  !.RP, 1= ( #[5#@ ]U1H /-8F #O7,0 YV#L
M.-E% 3;930$UV58",]I> C':: ,PVW,$+MM_!2S;C04JW)T&*=RM!BC=P08H
MW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0  ?K0  '&\
M  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ NYC, +>8\
M "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWKL@,<[,<#
M'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT  &7%  !9
MRP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL (O0R "'T
M.0 ?]4$ '?5) !OV40 9]UH!%_=E 17X<@$4^8$!$_F2 1+ZH@(1^K,"$/O&
M A#[W0(0^^D"$/OI A#[Z0(0^^D"CZL  (&T  !SO0  9L8  %G-  !+TP
M0-D  #7>   LXP  )O$  "3^"@ A_Q  '_\6 !S_'  9_R( %_\H !7_+@ 3
M_S4 $O\\ !#_0P ._TP #?]6  O_8@ )_V\ "/]_ 0?_D $%_Z !!/^N 03_
MO $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@  6L\  $O5   _W   ,^$
M "GE   A[   'OT  !K_!0 7_PP %?\0 !+_%  0_QD #O\>  W_(P +_R@
M"/\N  ;_-0 #_ST  /]&  #_40  _UT  /]K  #_>P  _XL  /^9  #_I0
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M(*=&\R&E1O\AHT;_(J)&_R&B1O\AHD;_(:)&_R&B1O\A_T4. /]+"@#_4PP
M_U<- /E:$ #K6Q0 WUH< -1:*P#,6CL"QEA(!<%64PF\5%P-N5)E$;50;12S
M3W47L$Y\&:Y-A!JL3(L<JDN2'JA*FA^F2J,AI$FL(J-)N".A2<8DGTK>))U*
M\"2;2OTEF4O_))E+_R282_\DF$O_))A+_R282_\D_T@, /]/" #_5@@ ]5L)
M .E>"@#D7@T U5\5 ,M@)P#$7S8"OEY#!;A;3@FT65@.L%=A$JQ5:16J5' 8
MIU-X&J52?QRB488>H%".()Y/EB*<3I\CFDZH)9A.LR:73L(GE4[6)Y-.[">1
M3_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0 XE\# -IB
M!@#48PD S6,2 ,1E(P"\93("MF- !;%A2PFL7E0.J%Q=$J5;91:A66P8GUAS
M&YQ6>AZ:58(@F%2*(I54DB234YLFD5*E)X]2L"F-4KXJC%+0*HI3Z2J)4_DI
MB%3_*8=4_RB'5/\HAU3_*(=4_RB'5/\H_TP% /]6 0#I70  W&," -%G!0#,
M: < QF@0 +UJ( "V:2\!L&@\!*IE1PFE8U$-H6%:$IU?81::7FD9EUQP')5;
M=QZ26GXAD%F&(XU8CB6+5Y<GB5>A*896K2N%5KHL@U;,+()7YBR!5_<K@%C_
M*H!8_RJ 6/\I@%C_*8!8_RF 6/\I_T\" /U9  #B8   U6<  ,QJ P#&; 4
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M*VIG_RMJ9_\K_E@  .%C  #/;   Q',  +MX  "S>@  JWH$ *1[$@">?"(
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MG"M6>ZDL5'NY+5-[SBU4>NHM5'KY+%1Y_RM5>?\J57G_*E5Y_RI5>?\JX64
M ,QQ  "_>@  M((  *N'  "AB@  E8L  (V-"0"'CA8 @H\D 7V/,0)XCCL%
M<XU$"6^,3 UKBE019XE:%62(81AAAV@;7H9P'EN%>"%8A((D582-)E*#FBE0
M@J<J3X*W*TZ"S"M.@N@K3H'X*D^ _RI/@/\I3X#_*4^ _RE/@/\IVVH  ,=U
M  "Z?P  L(<  *:,  "<CP  CY$  (:3!0" E!( >Y4A '>5+0%RE3@$;91"
M!VF32@MEDE$.8I%8$EZ07Q5;CV886(YM&U6.=AY2C8 A3XR+(TV+F"5+BZ4G
M28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\  ,%[  "U
MA   JXP  *"0  "5E   B9<  'Z:  !WFPX <YP< &^=*0%KG#4"9IP_!6*;
M1PA?FD\+7)I6#UB97!)5F&,54YAK%U"7<QI-EGT=2I6)'T>5E2%%E:0C1)2S
M(T.4R"-#E.4C0Y+U)$.1_R1#D/\D0Y#_)$.0_R1#D/\DRG4  +N!  "PBP
MI)$  )J5  "/F0  @YT  '2B  !NHPL :J07 &:E)0!CI3$!7Z0[ UND1 58
MI$L(5:-3"U*C6@U/HF$03:)H$TJA<15'H'L81*"&&D*?DQQ GZ(=/I^R'CV?
MQAX]G^,=/9WT'CV<_Q\\F_\?/)O_(#R;_R \F_\@PGP  +6(  "ID   GI8
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M""G"^PDHP?\**,'_"RC!_PLHP?\+J)4  )V;  "1H@  A*D  'BO  !KM0
M7[L  %2_  !)PP  /\@$ #;-"0 SSA$ ,L\< #'/)P PT#$ +] Z "[10P M
MT4P *])5 "K27P$HTVD!)]-V 273A (DU)0"(M2F B'5N0(AU=("(-/K B#2
M]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0  >;$  &VX  !@O@  5,,
M $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  BWR4 (> N "#@-P ?X4
M'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;FK $5YL !%.?= 1/E[P$3
MX_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@  2,H  #W/
M   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4[S4 $_ ]
M !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GVV0 (]>T
M"/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](  #'8   G
MW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D "OXP  C_
M.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP  _\X  /_/
M  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A   <Y0
M%.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C  #_*@
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M"L8Q]PS#,?\.P3'_#\ Q_P^_,?\/OS'_$+\Q_Q"_,?\0_S83 /\Y#P#_/A
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M&Y1&_QN31O\;DT?_&Y-'_QN31_\;_T(% /]* 0#R4   X50! -E6!0#350D
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M(758_R%U6/\A_TT  .57  #37P  R&0  +]G  "W:   L6<' *EH% "C:20
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MG"-B9JDE8&:Y)E]FS29?9N@F8&;Y)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@
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M(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T_R%1=/\AV&,  ,5M  "X=@
MKGT  *6"  ":@P  C8,  (2$ P!]A1  >88> '6'*P%QAS8";88_!&F%1P=E
MA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]
MQ")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T>P  JH(
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M%CF7_!8XEO\7.)7_%SB5_Q<XE?\7NWH  *^%  "DC   F)$  (V5  "!F@
M=9T  &B@  !;I   5J4, %.F%P!1IR, 3Z<O $RG. %*IT$!2*=) D:G4 1#
MIU@%0:=?!C^F: @]IG(*.J9]"SBFB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B
M^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@  DI<  (:<  !YH0  ;:4
M &&I  !5K   2Z\% $>P$ !%L!P 1+$G $*Q,@!!LCL /[)# 3VR2P$[LE,"
M.;); S>R9 0ULFX%,[)Y!C&RAP<OL98(+K*F""VRN DLLM (++#L"2NO^0HK
MKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ   9*T  %FQ
M  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  QODP +[Y5
M 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,CO\L#([[H R.\]P0BN_\%
M(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K  !GL   6[4  $^Y  !$
MO   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP "3*.0 CRD( (LM+ "'+
M50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4 &,WD !C,] $8ROP!&,K_
M AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<N0  4+T  $3!   YQ
M,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H] !+;2  1
MW%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO< #-W[  S=
M^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   NS0  )=$
M ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4
M!>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO  #L[P
M[.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@  &]L  !/?
M   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@  ]3<  /9"
M  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #XT   ^-
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M ?\.BP'_#I(!_PZ8 ?\.G0'_#J,!_@ZH ?P.K@'[#K4 ^@Z^ /@.R0#U#ML
M\@[J .X.]0#L#O\!ZP__ >H/_P'J$/\!Z1#_ >D0_P'I$/\!_R(? /\B' #_
M(1P _Q\@ /\?*0#_'#0 _QI  /\73 '_%5@!_Q1C ?\3;@'_$W<!_A.  ?P3
MB 'Z$HX!^1*5 ?@2F@'V$J !]1*F ?02K 'S$K,!\1*\ ? 2QP'M$M@!Z1/H
M >83]0'D%/\!XA3_ N$5_P+A%?\"X!7_ N 5_P+@%?\"_R4; /\F%P#_)!8
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M"ZXP_PNN,/\+K3#_"ZTP_PNM,/\+_S,, /\V!@#_/ D _SX, /T]$ #O/!4
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M%85'_Q6%1_\5_S\  .Q(  #=3P  SU,  ,95  # 4P, NU$, +-2&0"M4RD
MJ%,V :-20@*?44L$G%!4!IE/7 B63F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)
M2I 4ATF:%85)I1>#2;$8@DG &(%*UAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+
M_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $ M%8) *Q7%@"F6"4 H5@R
M 9U7/@*85D@$E551!I)46 B/4E\*C%)F#(I1;0Z(4'00A4][$H-/A!.!3HT5
M?TZ7%WU.H1A[3:X9>DZ]&GA.T1IW3NL:=T_Z&79/_QEV3_\8=D__%W9/_Q=V
M3_\7^$8  .)0  #05P  Q%P  +M>  "T70  KEH& *9;$P"@7"( FUPO )=;
M.P*26D4#CUE-!HM850B(5UP*AE9C#(-5:@Z!5'$0?E1X$GQ3@!1Z4HD6>%*4
M&'92GQET4JL:<E*Z&W%2S1QP4N@;<%/Y&G!3_QIP4_\9<%/_&'!3_QAP4_\8
M[TD  -U3  #+6@  P%\  +=B  "O80  J%X" *%?$ ";8!X EF L )%@. &-
M7D(#B5U+!85<4@>"6UD*@%I@#'U99PY[6&X0>%AU$G97?11T5X<6<E:1&&]6
MG!IN5JD;;%:X'&M6RQUJ5N8<:E?W&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP
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M85ZT'6!>QQU@7N,=8%[U'&!>_QM@7O\:85[_&F%>_QIA7O\:Y%(  ,]<  #
M9   MFD  *QL  "C;   F6D  ))J"P",:A8 AVLD ()K, %^:CH">FE#!'9H
M2P9S9U((<&=9"FUF8 UK968/:&1N$69D=A1D8X 68F.+&&!BEQI>8J0<7&*R
M'5MBQ1U;8N$=6V+T'%MB_QM<8O\:7&+_&EQB_QI<8O\:X%4  ,M?  "]9P
MLFP  *EP  "?;P  E&P  (QM" "&;A, @F\A 'UO+0%Y;S@"=6Y! W)M205N
M;% ':VM7"FEK7@QF:F4.9&EL$6%I=!-?:'X676>)&%MGE1I99J(;5V:P'%9F
MPQU69M\=5F;S'%=F_QM79O\:5V;_&E=F_QI79O\:VUD  ,=B  "Z:@  KW
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M&$=V_!A'=O\81W7_%T=U_Q='=?\7R64  +IO  "N=P  I'T  )A_  "+?P
M?G\  '.!  !L@PD :(03 &6%( !BABP 7X8V 5R&/P)9A48#5X5.!52%50=2
MA%P)3X-C"TV#:PU+@G0/2()_$4:!C!-$@9H50H"I%D& NA9 @-(607_M%D%^
M^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0  GX(  )*#  "%A   >84
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M"BV;_PHMF_\*KX   *.)  "7C@  C9,  '^5  !RF   9IP  %N@  !/I
M1:<  #ZI#  \JA0 .JH? #FJ*0 XJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $O
MK&8"+:QQ BNL?P,JK(X#**R>!">LL 0FK,4$)JOD R6I]00EJ/\%):?_!26G
M_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@  7Z8  %.J  !(K0  /;
M #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ HMT, )[=, ":X50 DN%\
M([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;
MM/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@  -;D  "R\
M   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A
M !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\
MEY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$  "/%   ;
MR0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD "=-5  G3
M8@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !U?8 CIT
M ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.   2T@
M#=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'  #B5
MXV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN< @Z0  '6L
M  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +W0  !>$
M  #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O10  \%,
M /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT  &JU  !<
MO0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@   .H   #N
M    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0  _4,  /Y2
M  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5(0#_$2$
M_PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"# /\ B@#_
M )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$ \@#D /$
M\0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_%1T _Q ?
M /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#AP#_ XT
M_0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C .H![P#H
M OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3
M)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0
M /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*\ #?"_L
MW@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_
M&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8 ZA", .D0
MD@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P VA#A -41\ #2$OL SQ+_
M <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_(0\ _R(4 /\B' #_("<
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M")PQ_PB<,?\(_S   /\U  #O.   XCH  -LY! #6-0D SC03 ,8V(@"_.#$
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MGP]^1*L0?$6Y$7M%RQ%Z1>81>4;W$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\
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M%&91PQ5E4MX595+R%&52_Q-E4O\295+_$F52_Q)E4O\2Y$H  ,]3  # 6@
MM5X  *Q@  "B7@  FED  )):"P"-6Q8 B%PC (1<+P" 6SH!?5M# GE:2P-V
M65($=%A8!G%87P=O5V8);5=M"VM6=0UI5GX/9U:)$655E1)C5:$48E6O%6%5
MP19@5=L68%;Q%6!6_A1@5O\385;_$F%6_Q)A5O\2X$T  ,M6  "]70  LF$
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M%5)A^Q128?\34V'_$E-A_Q)38?\2T58  ,!?  "S9@  J6L  )QK  "0:@
MA6<  'UI  !W:@T <VL7 &]K) !L;"\ :6PX 69K00)C:TD#86M0!%YJ5P9<
M:ET'6FEE"5AI;0M5:'8-4VB!#U%GC1%/9YH23F>I%$UGN11,9\\43&;K%$UF
M^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@  I6\  )AN  ",;0  @&P
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M#CUW_PX]=_\.O&@  *]R  "D>0  EGH  (AZ  !\>@  <'P  &-_  !<@@
M5X0+ %.%% !1AB  3X8J $Z'- !,ASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1
MAFP&/H5V!SN%@P@YA9$*.(2@"S:$L0LVA,8+-H/D"S:"]@LV@?\,-H#_##:
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M=@$CI84!(J66 2"FJ $?I;L!'J77 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8
M )>,  "+CP  ?9$  &^4  !CF   5YT  $VA  !#I0  .*@  #"K   HK@<
M)*\0 ".O%P AKR$ (+ I !^P,0 >L#H ';%" !RQ3  ;L58 &K%A !FR;P 8
MLGX %K*0 !6RH@ 4LK8 $[+. !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2
M  "$EP  =9H  &B?  !;HP  4*@  $6L   [L   ,;(  ">U   @N   &+H'
M !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .ODP #KY7  V^90 ,OW0
M"[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0  (>9  !Z
MGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0  $<0!  S(
M"  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60  RV@  ,MY
M  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA  !OIP
M8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX   32 @
MTPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H  -UJ  #=
M?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !DL   5K<
M $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>    WP,
M . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:  #M;
M[H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0  2\   #W%
M   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H    Z0   .H
M  #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\6P  _6T
M /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@ /\ * #_
M #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2 /D
MEP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M /< [ #_
M .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#)0#_ #$
M_P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/ /( E #Q
M )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4 XP#^ .(
M_P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y
M /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H )8
MYP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#] -4"_P#4
M O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*
M00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?!I( W0:8
M -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\
MQPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M
M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-
MG #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_
M ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X&AL [A8F .84,P#@$S\
MVA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85A #$%8H PQ61 ,$6F #
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MI 26+Z\$E2^]!),OSP21,.@%CS#X!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT
M .HU  #<.@  SCT  ,8\  # -P( NS,- +,T&0"N-B< J3<T *4W0 "B-TH
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M"G5 PPMT0-T+<T'Q"W)!_PIR0?\*<D'_"7)!_PER0?\)Z3P  -5%  #%2P
MNDX  +!.  "G2P  HD8  )M&#@"61QH D4@G (Y(,P"*2#T AT=& 81'3@&"
M1E4"@$9< WY%8@1\16D$>D5P!7A$> 9V1($(=$2+"7)$E@IP1*(+;T2O#&Y$
MP QM1=D-;$7O#&M%_0MK1O\+:T;_"FM&_PIK1O\*Y4   ,])  #!3P  M5(
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M#EM1^@U;4?\,6U'_#%M1_PM;4?\+UDH  ,-3  "V60  JUP  )Y:  "360
MBU0  (16 P!^5A  >E<: '97)@!S6#$ <%<Z &U70@%J5TD":%90 F965P-D
M5EX$8E5E!6!5;0=>578(756!"EM5C0M95)H-6%2G#E95N ]65<P/5E7I#E95
M^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7   IUX  )I=  "/7   AE@
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M"TE@_PM)8/\+Q%@  +5@  "J9@  FV8  (UF  ""90  =F0  &YE  !H9@4
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M? 0T?XH$,G^:!3%^J@8P?KT&,'[:!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P
M *1U  "4=0  AG4  'EV  !N=P  8WD  %=]  !/@0  1X0  $*&#  _AQ,
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M !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&  ""A@
M=(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+ !JI$0 8
MJ1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0 #JN&  ZK
MF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !ZC0  ;)$
M &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U"@ -MA
M#+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[  "WC@
MMZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP  99P  %BA
M  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #P0T  ,$1
M  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%@0  Q94
M ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D  %"N  !$
MLP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <  ,P-  #-
M$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P  UH<  -:;
M  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X   XO
M*[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%  #;"P
MW X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<  .F,  #J
MGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    LQ   (,@
M !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G 0  Z0<
M .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ  #ZC@
M^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #( _P _ /\
M2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V )@ ]0"=
M /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@ _P#H /\
MZ #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_
M %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0 [ ": .L
MGP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#= /\ W0#_
M -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z $X
M] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6 .$ G #?
M *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\ S0#_ ,T
M_P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O $D Z@!3
M .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -( F #0 )X
MS@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_ , "_P#
M O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T( WP-. -L$
M5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C
M , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,_P"T#/\
M_Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,40#)
M#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.
MJ0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH
M /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\%%0
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M HTIQ@*+*=\"B2KR H<J_P*&*O\"ABK_ H8J_P*&*O\"]"@  .,Q  #1-@
MQ3@  +PV  "V,   LBL) *LL% "F+2( HBXO )XN.@";+D0 F"]- )8O50"4
M+EP DBYB ) N:0&/+F\!C2YV 8PN?@&*+H8"B"Z/ H<NF@*%+Z4#@R^R X(O
MP@.!,-H#?S#O WTQ_@-],?\#?#'_ WPQ_P-\,?\#[2\  -LW  #)/0  OCX
M +,\  "L.   IS,$ *(R$0"=-!T F34J )4U-0"2-4  CS5) (TU4 "+-5<
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M!V9 ^09E0/\&94#_!F5 _P5E0/\%W#X  ,=&  "Y2P  K$P  *!*  "71P
MD4,  (M#" "&0Q( @D0> 'Y$*0![130 >44] '9%10!T1$P!<D13 7!$60%N
M1& ";$-G FM#;P-I0W<$9T.!!69#C09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%
M^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@  IT\  )M-  "22P  C$<
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M!U%/_P913_\&R4L  +E3  "K5P  G%8  (]5  "%5   ?%   '51  !P4@D
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M?01 8HL%/V*:!CYBJ@8]8KP'/&+6!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D
M *MA  ":80  BV$  ']A  !T80  :6$  %]B  !99   5&8) %%G$0!.9QH
M3&@D $MI+0!):38 2&D^ $9J10!%:DP 0VI4 4)J7 % :64"/FEO CQI>P,[
M:8D$.6F8!3AHJ 4W:+H%-VG3!3=H[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E
M  "590  AF0  'IE  !O90  9&8  %EH  !2:@  36P$ $EN#@!';A8 16\@
M $1P*0!"<#( 07 Z $!Q0@ _<4D /7%1 #QQ60$Z<6(!.'%L C9P> (U<(8#
M,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L_P0Q;/\$KV0  *%I  "/
M:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,  $)U"P _=A( /7<< #QW
M)0 Z>"T .7@U #AY/0 W>44 -GE- #5Y50 S>5X ,7EH 3!Y= $N>8,"+7F2
M BMXHP(J>+4"*GC, BIWZ@(J=OD#*G7_ RIT_P,J=/\#JFH  )IM  ");
M?&T  '!M  !F;@  6W$  %!U  !(>   07L  #I^!0 V?PX -( 6 #.!(  R
M@2@ ,($P "^".  N@D  +8)( "R"4  K@EH *H)D "B"<  F@G\!)8*/ 22"
MH $C@K(!(H+) 2*!YP$B?_<!(G[_ B)]_P(B??\"I7$  )-Q  "#<0  =G$
M &QR  !@=0  5G@  $Q\  !#@   .X,  #.&   MB0H *HH1 "F+&0 GBR(
M)HLJ "6,,0 DC#D (XQ" "*-2@ AC50 ((U> !^-:P =C7D '(V* !N-G  9
MC:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@  <G<  &5Y
M  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <EAH &Y<B
M !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8E@ 0F*D
M#IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX  %^!  !4
MA@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ( $*,9  ^C
M(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $HZ$  J.T
M  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,  !-D0
M0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2  *O&0 !
MKR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<  *^J  "O
MOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%G0  .Z(
M #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z$P  NQD
M +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?  "]LP
MOL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP  ,J\  "BT
M   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@  QQ(  ,@8
M  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/I@  S[@
M ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H  !V]   3
MP   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P  -80  #9
M%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF   Y:D  .6V
M  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(   ,RP
M \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(  #H#0
MZ1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD  /BE  #X
ML   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!>
M /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$ G@#P *0
M[@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D
M /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!: /<
M8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E *  Y "G
M .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@ _P#8 /\
M_PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5 .T 7@#J
M &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P U0"C -,
MJP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#( /\ _PP,
M /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$ 60#> &$
MVP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@ ,4 J ##
M +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\ _PX% /\)
M  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#. %L RP!C
M ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D I "W *X
MM0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q   /\.  #_
M#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8 O@5= +P%
M9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW
M *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L$P
MXA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7 + .7P"N
M#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D GQ"U )T1
MQ0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@'P  TA\
M ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *0660"B%F
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M 7<K^0%V*_\!=BO_ 74K_P%U*O\!Y2P  - T  #!.   LS@  *@U  "B,0
MG2T  )DJ#@"4*Q@ D"PD (TM, "*+3H ARU# (4M2@"#+5$ @2Y8 ( N7@!^
M+F0 ?2YK 'LN<P%Y+GL!>"Z% 78NCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ
M]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@  K#T  *$Z  ":-P  E3,
M ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![,TT >3-4 '<S6@!V,V$
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M UD__P-9/_\#S#\  +Q&  "K2   G$<  )%&  "(1   @D   'P_  !W0 P
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M?0))3HL#2$Z9!$=/J 1&3[H$1D_1!$9/[01&3OP$1D[_ T=._P-'3O\#O4P
M *Y2  "<40  C5$  (%1  !W4   ;DP  &=.  !B3P  75 - %I0% !741X
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M CA=HP,W7;4#-EW+ S9<Z ,W7/D#-UO_ SA;_P,X6O\#LE<  *!:  "/60
M@5D  '59  !K60  8%H  %9;  !170  3%X" $A@#0!%8!0 1&$> $)B)@!
M8BX /V(V #YC/@ ]8T4 /&-- #MC50 Y8UX .&-H 39C= $U8X$!,V.1 C)C
MH0(Q8[,",6/( C%BYP(Q8?@",6'_ C)@_P(R8/\"KEP  )M=  "*70  ?%T
M '!=  !F70  7%X  %)@  !,8@  164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L
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M !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J  !9;
M3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B !R%*@ ;
MA3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%
MU@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3<P  27<
M $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0(@ 1D"H
M$)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 '
MC^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0  0X$  #F&
M   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ 'G"( !IPJ
M  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";OP  FML
M )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P  #*1   I
ME0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P  *@C  "H
M*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0  J,L  *?D
M  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>   AH@
M&:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;  "U(@
MMBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X  +?2  "W
MY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9KP  $;,
M  NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##&0  Q"
M ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!  #)T0
MR=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O   "K\   '!
M    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$   TQ8  -8>
M  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@O@  X,,
M9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H   #-
MT0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X  .<3  #J
M'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@  ]+( _P 3
M /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X 8P#[ &L
M^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F .H K@#H
M +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\ _P 0 /\
M#@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M
M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X J@#; +0
MV0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P - /\ "0#_
M  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &( X@!I .
M;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+ *\ R0"Z
M ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\  0#_  8
M_P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C ,\ :@#-
M '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L NP"V +D
MQ "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_    _P &
M .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$ 9 "_ &H
MO0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R *P OP"J
M -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P  Z    .$
M!P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R &4 L !J
M *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *  NP"> <T
MG0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\  ,X+  #(
M PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\ I0=E *,'
M:P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3"\P D@SE
M ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5  "Y$
MMPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@ )@09@"7
M$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL AA/F (44
M]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K&@  J10&
M *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P780"+%V<
MB1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y
M'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P  G1\  )H:
M#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I
M 'T@< !\('@ >B"! 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D\P!O)/\
M;R3_ &XD_P!N)/\ W2D  ,@P  "W,@  J#   )XN  "7*@  DR<  ) C"@",
M(Q, B"0? (0E*@"")30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX =29E '0G
M; !R)W0 <2=] &\HB !N*)0 ;"BA &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_
M 68J_P%F*O\!U"\  ,(V  "O-@  H34  )8T  "0,   BBT  (<J!@"#*1
M?RH: 'PK)0!Y*R\ =RPX '4L0 !S+$< <2Q- ' L5 !N+%H ;2QA &LM: !J
M+7  :"UZ &<NA0!E+I$!9"Z> 6(OK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P
M_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0  @S(  '\P 0![+PX =S 6
M '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G,E< 93)= &0R90!B,FT
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M? %2/8D!43V7 4\]I@)./K<"3C[- DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\
M *Y#  "<0P  CD,  ()"  !Z0   <ST  &T\  !H/04 9#T. &$^%P!>/B$
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M 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P) 2/\!MDD  *)*  "12@
M@TH  '=*  !N20  944  %Y'  !92   54D( %%*$ !/2A@ 3$HA $I+*0!)
M2S$ 1TLX $9,/P!%3$8 1$Q. $--5@!"35\ 04UH $!-= $^38$!/4V0 3Q-
MH $[3K$".D[& CI.Y ([3?8".TW_ 3M,_P$\3/\!LTT  )Y,  "-3   ?TP
M '1,  !J3   8$H  %E+  !43   4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X
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M 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6  !>5@
M5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K "]C,@ N
M8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D (V2] ")D
MV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:6@  4%P
M $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J+@ F:S4
M)6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;
M:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@  3&$  $-D
M   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  ==#  ''0X
M !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%TSP 2<^P
M$G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<  #YK   W
M;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^
M.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST
M  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES   Q=P
M*GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK  F),P (
MB3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H  (;L  "&
M]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J@0  (X4
M !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5+   E34
M )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F  "2\@
MDO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0  &Y$  !24
M   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0  HBT  *(W
M  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "AZP  H/(
M<W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X   ZA   )
MI    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0  + M  "Q
M.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX   L>D ;'X
M %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N    L@
M +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C  #!+0
MPCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H 98D  %B.
M  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\    OP   ,,
M  #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2(0  U2T
M -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8  %&<  !$
MHP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0   -    #2
M    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@  Z"   .PM
M  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\ #@#_  X
M_P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M /0 = #R
M 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +, XP#  .$
MT@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_  D _P /
M /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D ;P#G '4
MY0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z -  R@#.
M ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4 _P , /P
M% #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8 '  U0!U
M -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$ PP"_ -H
MO@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 ' /$ $ #J
M !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H Q0!P ,,
M=0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q ,\ KP#H
M *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! ., # #: !0
MT0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J +0 ;P"S
M '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@ H@#B *$
M\P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)  \ P@ 8
M +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *< :@"F &\
MI !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#< )0 [P"3
M /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H M@ 1 +$
M' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ": &H F !P
M )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&[0"(!_H
MAPC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8- *<#%0"B
M!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4 C0IK (L*
M<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\#_T >P__
M 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-#P"8#AD
ME XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_
M$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT <1;_ '$6
M_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-%!0 B14?
M (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88:0!T&'$
M<QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_ &<>_P!G
M'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=
M) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K(&T :2!V
M &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?)/\
MRBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5 ',C( !Q
M)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD 829R %\G
M?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$
M *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI&P!I*24
M9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO %@M>@!7
M+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\ P38  *HV
M  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J
M %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0
M3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5
M.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX 6C,F %@S
M+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+-X( 2C>0
M $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\  "1/
M@SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0
M-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X  13N. $0\
MG@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-/@  ?SX
M '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\
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M #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&  !A10
M640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN #E*-@ X
M2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-
MU0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=2   54@
M $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/,P R4#H
M,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I
M4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3   44P  $A-
M  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L5C< *U8^
M "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7SP B5^P
M(U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35   $52   _
M4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#, )%TZ "-=
M0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;7>D &USY
M !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7   [60
M-5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :
M94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.< $V/W !1B
M_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V7P  ,&(
M "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M.0 2;D(
M$6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -
M:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L
M   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='
M  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P
M>UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7
M>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""
M3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(
M &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P
M#88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1
MCE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G
M  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(
M  "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@
M )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1
M<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
M    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-
M  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@
M/X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P
ML    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]
M4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(
M "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP
M ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110
MTE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H
M   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\
M  #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H
M .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_
M "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P
M?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W
M -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$
M^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#=
M '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,<
M_P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G
M .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H
MR0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V
M /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4
M+0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z
M +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\
MIP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_
M #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D
M>@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_
M )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L
MK0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0":
M 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P
M_P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N
M )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8
MBP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_
M /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )(
M,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z
M 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\
MW14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%
M"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-
M@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T
M +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T
M>1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H
M$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C
M  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P
M &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4
M71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9
M*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=
M,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0
M %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+
MABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<
M(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $TH
MG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3
M '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#(
M4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&
M+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S
M  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV
M $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@
M0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F
M-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q
M.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y
M #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P
M738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _
M-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4Z
MSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D
M %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL
M.3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q
M/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ
M  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]
M #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND
M+$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$
M/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%
M10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X
M "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1
M.T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G
M2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*
M_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD
M #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@
M(%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <
M3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0
M   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=.
M !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\
MA$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D
M60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?
M50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT
M &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P
M&6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )
M9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2
M  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH
M  ]M!@ +< P "'#_XO_B24-#7U!23T9)3$4 ! D1  =P%@ %<!T !' D  -P
M+  "<#4  ' _  !P2@  <%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE
M  !M\@  ;?D <%8  &-6  !95@  45<  $=8   ^6P  -E\  "YB   F9@
M'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?  !Z)@
M>B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(  'C?  !X
M[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @<   &70
M !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&(   AB@
M (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73  "$Z@
MA/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P  $H    V#
M   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0  DR   )0I
M  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3X@  D^X
M864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T   :1
ME    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@  *,@  "E
M*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0  I.0 6VP
M $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@    HP
M *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7  "U(
MMBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]  5'8  $A\
M   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N    L@   +8
M  "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&%@  R2
M ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,  $&*   U
MD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@   ,8   #(
M    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@  W14  .$A
M  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\ !0#_  8
M_P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C .X :0#L
M &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H V@"V -<
MQ@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_  $ _P ,
M /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\ 9 #= &H
MVP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P ,8 O@#$
M -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_    ^@ ' /$
M#P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J
M ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8 MP"T ,H
ML@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ " .$ # #7
M !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\ MP!D +4
M:0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D ,$ HP#<
M *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L " ## !
MO0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!> *8 8P"E
M &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H E #/ ),
MZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S  P K0 2
M *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )< 70"6 &,
ME0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#' (4 Y "$
M /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  < H  . )T
M%@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ") %T B !C
M (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D W0!X /$
M=P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 * )$ $0".
M !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@ ? !> 'L
M9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M NT ; /Z
M &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%# "$ 1,
M@0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059 ' &7P!N
M!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ &(,
M_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\"@X > H6
M '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E#6,
M8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61'] %D1_P!9
M$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0
M&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H
M %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1%_\
MLB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4. &,6%0!A
M%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P 4AED %$9
M;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*'?\ K"0
M )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;$@!9'!H
M5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(
M('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I
M  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2(18 4"$>
M $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D:0!")74
M0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK  !_
M+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1, 2B8: $@F
M(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \*G( .RJ!
M #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN  ![+P
M;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!
M*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G  -B]_ #4O
MCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W,@  :S(
M &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN'  [+B(
M.2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-] # SC0 O
M-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-   :#4  %XU
M  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V,R  -#,F
M #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LWBP J.)P
M*3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<  %LW  !4
M-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T +S@D "XX
M*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E/)L )#RM
M ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z  !1.0
M2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA "D]*  H
M/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D 'T&K !Y!
MP  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-/   1SP
M $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#)0 B0RP
M(40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I !A&O@ 7
M1=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P  1#\  #U
M   V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <22D &THP
M !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+O  12]D
M$DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(  #I#   R
M10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4 %% L !-1
M-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L
M  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(   O2@
M*4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H  U8,  -
M6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H !5?F  57
M\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K4   )5(
M "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@*P $8#0
M V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B  !>\
M7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@  (%D  !I<
M   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@  :2X  &DX
M  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F[@  9O<
M9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(  !1E   0
M:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@  ',Q  !S
M/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP  </0 85,
M %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O   +<@
M!G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J  " -0
M@$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$ 7%@  %18
M  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #?P   ((
M  "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/+   CS@
M (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T  $Y?  !#
M8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0   )    "2
M    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P  H"X  * \
M  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H   \;0
M,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\   "A
MH@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,  +(Q  "R
M0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U>@  *H$
M !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q    L0
M +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F  #%-P
MQDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0  (I   !>8
M   /GP  !Z4   "J    KP   +,   "W    O    +\   #!    P@   ,0
M  #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=*@  WCP
M -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P , /\ $P#_
M !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D YP!O .4
M= #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/ -H S@#Q
M ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L $ #V !D
M\@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/
M '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T O #J +L
M_ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D !0 WP ?
M -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\ :0"] &X
MNP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A *L ]@"J
M /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$ QP 9 ,0
M(P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L &@ JP!M
M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L [@": /\
MF@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4 +$ '@"N
M "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &( FP!G )H
M;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+ /D B@#_
M (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *  & "= "$
MFP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A (L 9P"*
M &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /( ?0#_ 'T
M_P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0 !P C0 D
M (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X 8@!] &@
M>P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[ '  _P!P
M /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8 @0 > '\
M)P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q &, ;P!K
M &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4 _P!E /\
MP P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S
M "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\ 90!G &,
M< !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;!O\ M1
M *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$&P!I!2,
M9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC %H);0!8
M"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\ K14  )D7
M  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A#!T 7PPE
M %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.:P!0#W8
M3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D  )(<  "#
M'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41
M)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(%', 1A2
M $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@  !](0
M<2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8< $X6(P!,
M%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7  /QI] #X;
MC0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X)   ;"4
M &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;( !%&R8
M1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W
M(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P  :"@  %\H
M  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _(", /B I
M #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H
M,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H  %PJ  !5
M*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\ -R0F #8D
M+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L*9@ *RJJ
M "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM  !1+0
M3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C # H*0 O
M*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9< )BZH "4N
MO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.+P  2"X
M $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM)P J+BT
M*BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G "$RNP @
M,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0  13$  $ P
M   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E,RL )3,R
M "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;-M(
M'#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,  #TS   W
M,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX
M-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL
M !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV   T-@
M+C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^-  7
M/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X $3_K !(_
M^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q.@  *SP
M "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$,0 21#H
M$45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E  U$]@ -
M1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@  *$   "-"
M   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -2S8 #$M
M  M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*\  &2?H
M;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4  !]'   :
M20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43( !%([  -2
M1@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@  4/< :$
M %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-   64
M$5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV  !900
M64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8 8T0  %9%
M  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   16   #5H
M  E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B.P  8D<
M &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@  %))  !*
M2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8   "&,   -F
M 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-   ;4   &U.
M  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-  !(3
M/DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X   !P
M<@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD  'I'  !Z
M5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"4@  .%4
M "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\    ?@
M '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^  ")30
MB5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@  ,E\  "AD
M   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*    C    (T
M  "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";1   FE8
M )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH  "%Q   7
M=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP   )T   "?
M    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0  K4L  *U?
M  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_   0A@
M"8T   "3    F    )T   "A    I0   *@   "K    JP   *X   "O
ML0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD   ,)4  #!
M:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *EP   )T
M  "C    J    *T   "R    M@   +D   "[    O    +X   #     P@
M ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)  #:7@
MVW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D _@ D /P
M+P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#> ', W !Y
M -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8 _P#% /\
MQ0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ? .L *@#I
M #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T QP!S ,4
M>0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T /\ M #_
M +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -( ) #/ "X
MRP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M +, <P"Q
M 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\ HP#_ *,
M_P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q
M +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$ ; "@ ',
MG@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_ ), _P"3
M /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "( HP K *(
M,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0 &T CP!T
M (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0 _P"$ /\
MY0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E )$ +0"0
M #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &< @ !N 'X
M=P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U /\ T
M +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ (( )P"! "\
M?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I '$ <0!P
M 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\ P    *P
M  "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T "D <P P
M '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4 ; !D '8
M8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <  * )  "0
M"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ", :  J &<
M,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !: '( 6 !^
M %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.  "'$
M>A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E %T *P!<
M #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$
MB@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^%   <Q0
M &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4')P!3!RT
M4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$
M#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&   ;!D  &,9
M  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN
M $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@
M.Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT  %X=  !8
M'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20 1!$J $(1
M, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V%98 -!:G
M #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@  !3(
M3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G #L5+0 Z
M%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0 +ANE "T;
MN  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/(@  2B$
M $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:*0 T&C
M,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G
M(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0  1R0  $(C
M   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S
M "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(DM0 B),P
M(B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<  #\F   [
M)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH )R,Q "8D
M.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH
M !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH   W)P
M-"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @
M*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D &"SG !DK
M]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T*@  ,"H
M "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM,P ;+CP
M&BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E !0P]@ 5
M+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0  +"T  "<O
M   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6,SD %3-#
M !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T]0 0-/\
M<BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$  "0R   A
M,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y
M2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,./P ;B\
M %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V   =.
M&3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\  L_1P *
M/U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O< :3,  %LT
M  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :/   %C\
M !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%0@ "14X
M $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8  %<W  !,
M.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@  $D0   Y'
M!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@  3$D  $Q7
M  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([  !(.P
M0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL   M. P '
M4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4  %-2  !3
M80  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%/@  /CX
M #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95 @  5P<
M %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-  !<6P
M7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@  /$(  #1#
M   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>    8 0  &$(
M  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G50  9V8
M &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<  "]*   F
M30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@   &L$  !L
M"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@  <U\  '1R
M  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2   @5@
M&%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<   !Y @
M>@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8  (-J  "#
M@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   98@  $F<
M  QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(    B0
M (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@  "5=@
ME)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P  #'4   1[
M    @    (4   ")    C0   )$   "3    E    )8   "8    F@   )P
M  ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H;0  IH<
M *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4   "+
MD0   )8   ";    GP   *(   "D    I0   *<   "I    JP   *T   "P
M    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80  O'H  +N4
M  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<    H@
M *<   "L    L    +,   "V    MP   +D   "[    O0   +\   #"
MQ0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX  -2&  #4
MFP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V #0 \0 ]
M .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -, >0#0 (
MS@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_ +< _P"R
M /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X WP X -@
M0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"] 'H NP"!
M +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D _P"F /\
M_P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R ,  .@"\
M $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ', J0![ *<
MA "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9 /\ _
M .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T - "I #P
MI@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T )4 ?0"3
M (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\ [0   -@
M  #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7 #4 E0 \
M ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4 =@"$ (
M@@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0   ,$   "Q
M    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\ A0 V (,
M/ "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U 'H <P"&
M '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\   "@
ME    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P '4 -@!T
M #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0 9@"  &4
MC@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1    A@
M 'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D , !H #8
M9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z %D B !8
M )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P  >@<  '(&
M  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!= #  6P V
M %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\ A !. ),
M30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T  &@-  !B
M#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$
M-@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !% )  1 "A
M $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1  !:$
M5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D",@!(
M C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX / >? #L'
ML0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4%   4!,
M $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)+@! "3,
M/PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V? #,-L0 R
M#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&   2A8  $<5
M  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y#3  . XW
M #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K$<@
M*Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH  $(8   _
M%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T ,A$S # 1
M.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E%<8 )17D
M "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<   Z&@
M.!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P "H5-P I
M%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0 'QGB " 9
M]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W'0  -!P
M #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:-0 C&CT
M(AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;
M'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(   ,!\  "T=
M   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >'SH '1]#
M !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6(?X
M<R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(  "DA   F
M(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D
M2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2)?T <"(
M &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D   B)0
M'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1
M*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF
M  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >*0  &RH
M !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN1@ -+E(
M#2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<  %HI  !.
M*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0  &"X  !4O
M!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ ),TX "#-;
M  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L  !++0
M0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(  !(T P /
M-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H  #E7   Y
M90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(+P  /S
M #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y P ,.P@
M"#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3   _80
M/W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@  /#(  #4R
M   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (00@ !$,,
M  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&70  1FX
M $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34  #,T   N
M-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8  $D*  !*
M#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6   36D  $U]
M  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W   J.0
M)#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(  !2"P
M4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,  %9W  !6
MC@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F/P  'T(
M !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;"   7 P
M %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P  !@B
M8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@  &DH  !-.
M   .40  "E4   18    6P   %X   !A    8P   &0!  !E!   9P@  &@+
M  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M?P  ;9@
M &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0   Y8   (
M7    F    !D    9P   &L   !M    ;P   '    !R    = (  '4&  !W
M"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P  ?)   'NH
M  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E    :@
M &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4   "' P
MB@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8  (Z?  "-
MM0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T    >0   'X
M  ""    A@   (D   ",    C@   )    "2    E    )8   "8    FP
M )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4  "AJP
MH;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@   (\   "4
M    F    )L   ">    GP   *(   "D    I@   *@   "K    K0   +
M  "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "WH0  M[,
M,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$   "F
MJ@   *X   "P    L0   +0   "V    N    +L   "]    P    ,,   #'
M    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@  S*D _P
M /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D 0 #F $@
MX@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R "" ,8 C ##
M )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\ _P   /\
M  #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#, $( R !(
M ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +( A0"P )
MK@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0   /8   #K
M    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P LP!# +
M2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0"> (@ G "5
M )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8   #1
MP@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \ )T 0@";
M $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($ B@"- (@
MFP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z    K
M *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L / ") $$
MB !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"& '@ E !W
M *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F    F@   )(
M  "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z #L > !
M '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D C0!H )T
M9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@   ($   !\
M    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4 :@ Z &D
M/P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H
M %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',   !N
M:@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U %T .@!<
M #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X
MM0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B 0  7P
M %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %( - !1 #D
M4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"= $4 L !$
M ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0  50<  %0$
M  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !( #4 1P Z
M $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P JP \ ,$
M.P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P  $L+  !*
M" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$ /@ V #T
M/  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S +P ,P#8
M #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.  !"#0
M00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R #8$.0 U
M!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H *P?2 "L'
MZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \$   .@X!
M #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*-@ N"CT
M+0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2 ",-ZP C
M#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P  -1$  #,0
M P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H#CL )PY$
M "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D
M<Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4  "X3   M
M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D (1%" " 2
M2P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8
M & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6   H% $
M)A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9
M%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H ;!D  %T;
M  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D&   (A<$
M " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:1P 4&U(
M$QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L  %H=  !.
M'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P  '1L! !L;
M!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0'U  #R!=
M  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,(0
M0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2   !8@!  4
M( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T "R19  HD
M9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)(P  0",
M #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D P 1)0@
M#R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5  4I9  $
M*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0  /24  #4E
M   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /*0@ #"P,
M  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N8   +G$
M "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<  #,G   M
M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@< "3 ,  8Q
M#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70  ,VT  #.!
M   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J   K*0
M)R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+  (V#@
M-Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D  #E]   X
MDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J*P  )2L
M " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \#0  /0\
M #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X   _CP
M/J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@  (B\  !TP
M   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P  1 T  $80
M  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'B@  1J(
M $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0  !DV   3
M.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L  $X.  !/
M$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A   3YT  $ZU
M  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^   000
M#$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+  !9#@
M6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<  %FO  !8
MRP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +2@  !4X
M  !1    5    %<   !:    7    %T   !?    8 0  &('  !D"P  9@X
M &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H  !EP@
M9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50   %H   !=
M    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@  = H  '8.
M  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !UMP  =-(
M/$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<   !K
M;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,  (<)  "*
M#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0  A\4 -D<
M "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![    ?P
M (,   "&    B    (H   "-    CP   )$   "4    EP   )H!  "=!P
MH0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;< ,%   "55
M   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-    D0   )4
M  "8    F@   )P   "?    H0   *,   "F    J0   *P   "P    M <
M +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L  !YB   4
M:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I    *@   "K
M    K    *\   "R    M    +8   "Y    O    ,    #$    R    ,T'
M  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\   #[
M^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!) -H 3P#6
M %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )( NP"> +D
MK@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R    \
M .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\ 20"\ $X
MN@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7 *4 I@"C
M +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C    TP   ,@
M  #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H $@ I@!-
M *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ), G@"1 +
MD #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N    *X   "H
M  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $( D@!' )
M2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_ *< ?0"\
M 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D   "3
MCP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !  '\ 10!^
M $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\ ;@"R &T
MSP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "     ?  $
M 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X /P!M $0
M; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J %X P@!>
M .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q    ;0   &H
M" !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@ #X 7P!#
M %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %( N !1 -P
M40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8    %X !0!<
M  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@ 4P ] %(
M0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!' ,P 1@#P
M $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,  0!2  @
M4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X $< /@!&
M $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,, /0#F #T
M^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)  0 1P *
M $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X .@ ] $
M.P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #= #0 ]0 U
M /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$ /P$' #X
M"P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T #P ,P!#
M #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P [@ L /P
M=PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D# #<%"  V
M @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@ + !  "L
M20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E /< <@T
M &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +!0 P" H
M+P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04] "0%1@ C
M!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?, ;0X  %X1
M  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J#0< *0L+
M "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+1  ="T\
M' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1   %H2  !.
M%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0 (PX( ",-
M#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7#E  %@]<
M !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4  !+%@
M0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$& !T0"0 <
M$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX $1): ! 2
M:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)&   /QD
M #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2!@ 7$@L
M%1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97  T690 ,
M%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@  /1H  #4;
M   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3%@D $18-
M ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:80 '&W$
M!AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP  #,<   L
M'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P< #AL,  T<
M$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "'VX  1^
M   ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >   J'@
M)1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+  H@#@ (
M(!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL  "-^   C
MDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H(   (Q\
M " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E#0 $)1
M B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[   GD
M)Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0  (B$  !X@
M   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0  *P\  "P2
M   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   LC0  +*0
M "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(  !TB   9
M(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X  #(0   S
M%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@  ,J$  #&X
M   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE   6)@
M$B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.   Z$@
M.A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X  #BV   W
MU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3*P  $"X
M  TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!$   0Q0
M $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R   ^SP
M/N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@  #34   @X
M   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@  3!$  $T6
M  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(R@  1^P
M.S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T   )
M0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X  %@2  !9
M&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@  4N8 .#,
M #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*    30
M %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.  !F$P
M9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP -3<  # U
M   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6    60   %P
M  !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T#P  =Q4
M '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H  "L[   B
M/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :    &L   !N
M    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@  B@\  (P7
M  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$   <20
M$TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T   "
M@P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D  *(0  "B
M&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   55   #EL
M  5B    :0   '    !W    ?0   ((   "&    BP   (\   "3    E0
M )<   ":    G0   *    "C    I@   *H   "N    L@   +<*  "[$0
MNA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@  !VH   !S
M    >P   ((   ")    D    )4   ":    GP   *,   "F    J    *L
M  "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3"P  U!4
M -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0   /, !0#T
M  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\ S@!4 ,L
M60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q ,  KP#F
M *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\   #9  D
MT@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!. +, 4P"Q
M %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8 FP#4 )D
M^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X  0 M0 -
M +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X 3 "< %$
MFP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#% (@ [@"&
M /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?    G  ) )D
M#P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0
M (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\
M<@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # ""
M !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ',
M3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_
M &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X
M;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B
M $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8
M_P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P /
M %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D
M4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!*
M /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %(
M$ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !*
M $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\
MA0   '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!&
M !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P
M3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?
M &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X
M/  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R
M %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%
M  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  /
M #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\
M*0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2
M"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P
M$  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7
M "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0
M0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D
M 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!
M80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!
M #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X
M'@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4
M!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41
M   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0
M !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X
M#@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L
M$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,
M$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_
M  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%
M)10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .
M#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42
MD  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4
M !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$
M"A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@
M%:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6
M   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83
M  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(
M !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8
M%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;
M%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV
M   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&
M%!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%
M(1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?
MT0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD!
M !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@
M "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0
M(^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=
M   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<
M   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\
M0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *
M)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U
M(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",
M #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P
M 2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'
M/B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G
M   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4
M   X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$
M $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G
M*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G
M  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P
M'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,
M3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B
M+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,
M !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P
M %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0
M<C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!
M   '1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T
M  !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L
M (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.
M5    %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
M    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S
M  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P
M &H   !Q    =@   'L   "     A@   (H   ".    D0   ),   "6
MF0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W
M/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P
M  "#    B0   (\   "4    F@   )\   "B    I    *<   "J    K@
M +$   "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0
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M__________________________________________\
M     0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V
M-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO
M<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>H
MJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#B
MX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O______________________________
M________________________  $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:
M&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'
M2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T
M=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"A
MHJ.DI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.
MS]#1TM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[
M_/W^_VUF=#$      P0A   !                     0
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MQ\S-"0S+TPHMQ]0*6;+8"X">S2N:F,%0JY:X9[>5M76\E+1^OI2SA;^0LH7
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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M@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
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ME*^$PY"OA<2-KH7%BJZ&QHBMAL:'K8?&A:V(QX.MB<>!K8O'@*R+QX"LB\>
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M'DZ-^B];AO(_9X#K3G%[Y5MY=N!E@''=;(1NVG*(:]EWBVG7>HUGUGZ.9M6
MCV74@I!DU(218].&D6+3B9)ATHN38=*,DV'2C)-ATHR38=*,DV'2C)-ATHR3
M8=*,DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,D_^Q& G_L2,>_ZXQ.O^I/EGM
MHDMYV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#
MEL:Y@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NI
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMY
MV9I<E\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y
M@9G'N(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<
ME\B5<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'
MN(";R+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5
M<K#%E7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";
MR+A^GLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%
ME7VUPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^
MGLFW?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NI
MRK1[J<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VU
MPY>%N,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW
M?:+*MWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%
MN,&7B[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*
MMWRGRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRO^Q& G_L2,>_ZXQ.O^I/EGMHDMYV9I<E\B5<K#%E7VUPY>%N,&7
MB[N_DXR]OH^.P+R,C\*[B9+$NH:4Q;F#EL:Y@9G'N(";R+A^GLFW?:+*MWRG
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRO^Q%PG_LB(>_ZXP.O^I/5GLHTIYV)M;F,>5<K'%EWNUPYB#N,&9BKN_
ME8N^O9&,P;N.CL.ZBI#%N8>2Q[B$E<FW@IC*MH";R[9^GLRU?:/,LWRGS:]\
MJ,NO?*C+KWRHRZ]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRH
MR_^R%PG_LB$>_Z\O.O^J/%GLI$EZV)M:F<:6<;+$F'BUPIF!N<";B+R^EXJ_
MO)2+PKJ0C<6YC(['MXB1R;:%E,NU@Y?-M(&:SK1_G\^S?J3/KGVFSJM]J,RK
M?:C,JWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS/^R
M%@G_LR$>_[ N.O^K.UGLI$AZUYQ9FL:7;[+$F7:VPIM_N<"<A[V]FHG NY:*
MP[F2B\:WCHW)MHJ/S+2'DLZSA);0LH&:T;* G]*N?Z/2JG^ESZ9_I\VF?Z?-
MIG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS?^S%@G_
MLR >_[ M.O^K.EGLI4=ZUIQ9FL:8;;+$FG2VPIQ]N;^=A;V]G(C!NYB)Q;B4
MBLBVD(O+M(R.SK.(D=&QA973L(.:U+""H-6J@:+3IH&ET*.!I\VC@:?-HX&G
MS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS?^S%0C_M" >
M_[$M.O^L.5GKI49[UIQ8F\:9:[+$G'*VPIU[N;^?@[Z\GHC"NIJ(QK>6B<JU
MDHK-LXZ,T+&*C].OAY36KH6:V*N#G]>F@Z+4HH.DT)^#ILV?@Z;-GX.FS9^#
MILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS?^T%0C_M!\>_[$L
M.O^L.5GKID5[U9U8F\>::;+$G7"VPI]YNK^@@KZ\GXC"N9R(Q[:8B,NTE(G/
ML9"+TZ^,CM:MB9/9K(>;VZ:&GMFBA:'5GH6DT9R%ILZ<A:;.G(6FSIR%ILZ<
MA:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSO^T% C_M!\=_[$L.O^M
M.%GKID5[U9U7G,>;9[+$GFZVPJ!WNK^A@+Z[H8C#N)Z'R+6:A\VREXC1L).*
MU:V/C=FKC)/=J(J;WJ*(GMF>B*'5FX>DT9F'ILZ9AZ;.F8>FSIF'ILZ9AZ;.
MF8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSO^T% C_M1X=_[(K.O^M.%KK
MID1[U9U7G,><9;+$GVRUPJ%UNKZB?K^[HX?$N*"'R;2=A\ZQF8C3KI:)V*N3
MC-RHD)+AHXZ:WYZ,GMJ:BZ'5EXJDT9:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFF
MSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSO^T% C_M1X=_[(J.O^M-UKKIT-\
MU9Y5G<>=8[+$H&JUPJ-SNKZD?+^[I(7$MZ*'RK.?A]"PG8?5K)J)VZF8C."E
MEY/FGI2:WYF1G=J6CZ#6E(VCTI.,I<^3C*7/DXRESY.,I<^3C*7/DXRESY.,
MI<^3C*7/DXRESY.,I<^3C*7/DXRES_^U$PC_M1X=_[,J.O^N-EKKIT-\U9]3
MG<>>8++%HFBUPJ5PNKZF>K^[IH/%MZ6'R[.BA]&OH(?7JIZ)W*2;B^"=F8[C
MFIN9X)66G-N3DZ#7D9&CTY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<^0
MCZ7/D(^ESY"/I<^0CZ7/D(^ES_^U$PC_MAT=_[,I.O^N-EKKJ$)\U:!1G<>?
M7K'%I&2UPJ=MN;ZI=[^[J8'$MJB(R[&EA]&KHH?7I9^(VYZ=B-V7FXO@DIN3
MWY*<G-R/F)_7CI6BTXV3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-"-DZ30
MC9.DT(V3I-"-DZ30C9.DT/^U$PC_MAT=_[0I.O^O-5KJJ$%\U:).G,>A6K'%
MIF"TPJIIN;^M<[Z[KGW$M*J'RZVEAM&GHH;5H*"&V)F?AMN2G8G=C9V.W8R>
MF-N,GI_8BYJBU(J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT8J7I-&*EZ31BI>D
MT8J7I-&*EZ31BI>DT?^V$@C_MQP=_[0H.?^P-%KJJ4!]U:1)G,BD5;#&JENS
MPZ]CM\"S;+VVKGS%L*F'S*FFAM"CI(74G**$UI6AA=B/GX?:BI^+VX>?DMJ(
MH9S7B)^AU(><I-&'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRDT8><
MI-&'G*31AYRDT?^V$@C_MQL=_[4G.?^P,UKJJCY]UJA$F\FH3Z_'L%.RQ;A9
MM;FS;;^QK7W&K*J&RZ6GA<^?IH31F*2$TY*CA-6,HH;7B*&*UX6ACM>#HI;6
MA*2?U(2BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$
MHJ/1A**CT?^W$0?_N!H<_[8E.?^Q,5KJJSQ^UZP[F<JM1*W)N46NO;A9N+*R
M;\"LKG[&J*N%RJ&IA,V;IX//E::#T(^EA-**I(;3AJ.(U(.CC-2!HY'4@*29
MTX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1
M@*:AT?^X$ ?_N1D<_[<D.?^S+UKIK3E^V;0OELRX,JG"O4"PL[9=NJRQ<<&G
MKG[%I*R%R)VK@\J7J8/,DJB$SHVGA,^)IX;0A::(T(*FB]& IH[1?J:4T'VG
MFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:
MS_^Y#P?_NA<<_[DB.?^U+5KLLS!ZW< ?D,G#(:BUNDBTJ[5BO*:R<\"CKW[#
MH*Z$QIFL@\B4JX3)CZJ$RHNJA<N(J8;,A:F(S8*HBLV J(W.?JB1S7RIELU\
MJ9;-?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S?R[
M#@?\O!4;_KL?./^W*5KPO21TW],.AKG!*JJJN4^VI+5EO*"R=+^>L7_"FZ^$
MPY:NA,61K83&C:V%QXJLALB'K(?)A:N(R8*KBLJ JXS*?JN/RGRKDLI\JY+*
M?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RO&]# ;Y
MOA(:^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:XG;5HNYNS=;Z9LG_ F+&$P9.P
MA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!K8O&?ZV.QWVMD,=]K9#'?:V0
MQWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0Q]_ " 7UP@\9
M]L(6-N[(%5#-W QFM=H/B*+)-J":OE:PE[=JN96U=KR4M'Z^E+.$OY"RA<"-
ML8;!BK&&P8BQA\*&L(C"A+")PH.PBL.!L(O#@*^-PWZOC\-^KX_#?J^/PWZO
MC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/P]G"!P7DQPL8[\@0
M--':"T6ZZ0YHIMX8@IC1-Y61R%.AC\)EJ8Z^<JZ-O'NRC+J!M8FX@K>'N(2X
MA;>%N8.VAKJ"MH>Z@;6(NX"UB;M^M8J\?;2,O'RTC;U\M(V]?+2-O7RTC;U\
MM(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O=3$!P36RPD5T]0+)[WB
M#$FI]!1EF>8E>([<.8:(U$^0AL]@EX3,;9R#R76@?\=XHGW&>Z1ZQ7VF><2
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MJK!YPZ>MA,>?JH3+F*B#S9"GA-")I8;2A*2*TX"DD--_I9?2?Z:@T'^EILZ
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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ME)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'#
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M)"J4_S YBO\Z18'_1D]Z_5%8<OA87FOU7F-E\F5H8.]L:UWM<FY:ZWEP5^J
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MKRD1^KLI$^S(+!/>V#<0T^%!'LG?23"\VE%$K]-85J'-7V:4R&5TB,1L@'S
M=(IQO7^3:;N,F6*YG)U>NK&>7;C)GF*NR)]FILB?::')GFN=RIUNFLN;;IG+
MFVZ9RYMNF<N;;IG+FVZ9RYMNF<N;;IG+F_^(#P'_B1D#_YHC!_^H)PK_M2(,
M\<0@#.#5) G1X3 4Q^8])+WC1C2RX$Y$IMQ64IG776&,TF-O@,]K>G3,<X1K
MRGZ+8LB,D5S(G)59R+&65\C.EEN[S9A>LLR98:O,F62FS9EGHLV89Z#-EV>@
MS9=GH,V79Z#-EV>@S9=GH,V79Z#-E_^*#@'_BQ@#_Y\A!?^N( ;XO1@&X]$3
M!-#A'@G%ZBX9NNDZ*;#G0SFDY$I(F.)05HS@5V* W5]L=MMH=6S:<GUCV'Z#
M7-B,B%?8G8M4U["-5-C-C%7+TX]7P-*16KC1DURRT9-?K-&38*K1DV"JT9-@
MJM&38*K1DV"JT9-@JM&38*K1D_^,#@'_CQ8"_Z4> _^U%0/:R@L"T.$. L3K
M'@VX[RP=K>XW+J+L0#V7ZTA*C.E/5H'H5F!VYUYI;.=E<&3F<'=>XWQ\6>")
M@%;>EX-3W::$4=RXA5'=U(13T-J'5,;8B5:_UXI8N-:+6;;6BUFVUHM9MM:+
M6;;6BUFVUHM9MM:+6;;6B_^.#0#_EQ(!_ZT5 =F_"0#,S@D P^L.!+;U'A&K
M]2PAH?0W,);S0#Z+\TA*@?-05'?S5UUM\UUD9?!F:E_M<&Y:ZGIR5N>%=E/E
MD7E1Y)Y[3^.L?$WCO7Q-X]E\4-C@?%'.X']2QMZ!4\3>@5/$WH%3Q-Z!4\3>
M@5/$WH%3Q-Z!4\3>@?^2# #_H T V[<& ,K#!P# T@D M?00!JG['Q2?_"PC
ME/PW,8K\03V!_4E'>/U14&[]5U=E^EY<8/9F85OT;V56\7AH4^^":U#NC&U.
M[)=O3.NC<4KJL'))ZL%R2.K8<DOCY').V.9S3M7G=$[5YW1.U>=T3M7G=$[5
MYW1.U>=T3M7G=/^6"@#>K ( R[H% +W'!@"RV @!I_\2")S_(1:2_RXCB?\Y
M+X#_0CEW_TI";?]0267_5DY?_UY36OYE5E7\;5I2^G5<3_A^7TSWAV%*]9%B
M2/2<9$;SIF5%\K-F1/+!9T/RU&=%[N=G1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&
MZ^AG1NOH9^ZB  #-M ( O+X$ *_-! "DW@<!FO\5"9#_)!6'_S @?O\[*G3_
M0C)K_T@Y8_]./UW_54-8_UU'4_]D2E#_:TU-_W)/2O]Y44?_@E-%_XM40_Z4
M5D']GE= _:A8/_RS63[\OUH^^]%:/?O;6CW[VUH]^]M:/?O;6CW[VUH]^]M:
M/?O;6M*M  "]N ( KL4" *'5 @"6]PL"C?\8"(3_)A%\_S$:<?\X(FC_/BE@
M_T4O6O],,U3_4S=0_UHZ3/]@/$G_9CY&_VU 1/]T0D'_>T,__X-%/?^,1CO_
ME4<Z_YY).?^G2CC_L4HW_[Y+-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"
M2[^S  "NO@  H,T  )+>  ")_PT!@?\:!7?_(PQM_RH39/\Q&5S_.!Y5_T B
M4/]()DS_3RE(_U4K1/];+4+_82\__V<Q/?]M,CO_<S,Y_WHU-_^"-C7_BS<S
M_Y0X,O^<.3'_I#HP_Z\[,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.["X
M  "@QP  D=@  (3O  !\_PT!;_\1 V;_&09>_R$*5O\I#U#_,A-+_SH61O]!
M&4+_2!L__TX=//]3'CG_62 W_UXA-?]D(C/_:2,Q_W D+_]W)2W_?B8L_X<G
M*O^/*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1
MT0  @N$  'C_  !L_P@!8/\- E?_$0-/_Q@%2/\@!D/_*0@__S$*._\X##C_
M/@XU_T0/,O])$##_3A$N_U,2+/]8$RK_710I_V,5)_]I%B7_;Q<D_W<7(O]^
M&"'_A1D?_X\:'_^1&A__D1H?_Y$:'_^1&A__D1H?_Y$:'_^1&O]H&0+_9",$
M_U\O!O]>0!#_8TL:_V=4)?]H72__9F<Y_V1R0?]B?4C_8(=._UV04O];F%;_
M6IY9_UBD6_]7JEW^5K!?_56U8/Q4O&'\5,1B^U/-8_E2W&/V4N9C\5/J8^Q4
M[6/F5N]BX%?P8^!7\&/@5_!CX%?P8^!7\&/@5_!CX%?P8_]I& +_92,$_V N
M!O]?0!#_9DD:_VI3)?]K7##_:64Z_V=P0O]D>TG_8H5/_U^.5/]=EEC_6YU;
M_UJC7?U8J5_\5Z]A^U:U8OI5O&3Z5<1E^53.9?=3W6;S4^9F[E7J9N=6[67A
M6.YEVUGO9MM9[V;;6>]FVUGO9MM9[V;;6>]FVUGO9O]J& +_9B($_V$N!_]@
M/Q#_:4@;_VU1)O]N6S#_;&0Z_VEN0_]G>4O_9(-1_V&,5O]?E5K_79Q=_5NB
M8/M:J6+Z6:]D^5BU9?E7O&?X5L5H]U7/:/54X&GP5>9IZ5?J:.)9[&C;6NUI
MTUON:=-;[FG36^YITUON:=-;[FG36^YITUON:?]J& +_9R($_V(N!_]C/A#_
M;$8;_W%0)O]R63'_<&([_VQK1/]I=DS_9X%2_V2+6/]ADUS]7YM@^UVA8OI;
MJ&7Y6JYG^%FU:/=8O&GV5\9J]5;1:_)5X6SL5^=LY%GI:]Q;ZVO47.QLS5WM
M;,U=[6S-7>ULS5WM;,U=[6S-7>ULS5WM;/]K%P+_:"$#_V,M!_]G/!#_<$4;
M_W1.)O]V5S'_=& [_W!I1?]M<TW_:GY4_V:(6OYCD5[[89EB^5^@9?A=IVCV
M7*UJ]5JT;/19O6WT6,=N\E?4;^Y7XF_F6>9OW5SI;M-=ZF_-7NMPQU_K<,=?
MZW#'7^MPQU_K<,=?ZW#'7^MPQU_K</]L%P+_:2$#_V4M!_]K.A#_=$,;_WE,
M)O]Z53'_>5T\_W5F1?]P<$[_;7M6_VJ%7/QFCV'Z9)=E]V&?:/9?IFOT7:UM
M\URT;_):O7'Q6<ER[UC:<^A:XW/>7>9RTU[H<\M?Z'3&8.ATP6'H=,%AZ'3!
M8>ATP6'H=,%AZ'3!8>ATP6'H=/]M%@+_:B #_V8M!_]O.!#_>$$:_WU*)?]_
M4C'_?EL\_WMC1O]V;$__<7=7_FV"7OMJC&/X9I5H]62=;/-AI&_R7ZQQ\%VT
M<^]<OW7N6\MVZEO==^!=XW;38.5WRF'E>,1BY7B^8^5XNF3E>+IDY7BZ9.5X
MNF3E>+IDY7BZ9.5XNF3E>/]N%@+_:R #_V@L!_]S-A#_?3\:_X)')?^$4##_
MA%@[_X%@1?]\:4__=G)7_G%]7_EMB&7V:I)J\V:;;_%CHW+O8:MU[5^U>.Q=
MP7GL7-!ZXUW?>]1AXGO*8N)\PF3A?;QEX7VW9N)\LV?B?+-GXGRS9^)\LV?B
M?+-GXGRS9^)\LV?B?/]P%0'_;!\#_VDL!_]W- __@3P9_X=%)/^*32__B54Z
M_X==1?^"94__?&Y8_79X8/ARA&?U;8YM\6F8<N]FH7;L8ZMYZV"V?.E>Q'[G
M7MA_V&'??LICWX#!9=Z!N6?>@;1HWH&P:=^ K&G??ZQIWW^L:=]_K&G??ZQI
MWW^L:=]_K&G??_]Q%0'_;1\#_VLK!_][,@__ACH8_XQ#(O^/2RW_CU,X_XU:
M0_^)8DW_@VE7_7QR8/AV?V?T<8IN\&R5=.UHGWGJ9*I]Z&&W@.9?R(+=8=N#
MS&3<A,!FW(6X:-N%L6K;A:UKW(2I;-V#IFS=@J9LW8*F;-V"IFS=@J9LW8*F
M;-V"IFS=@O]R% '_;QX#_V\I!_]_, [_BC@7_Y%!(?^42BS_E5$V_Y-80?^0
M8$O[BV=5]81O7_!]>F?K=X5OYW*0=N-MFWS>:*:!VF6SA-5CQ(;/9-J'P6?9
MB+=IV(FO:]B)JFW9B*9NVH>C;MJ&H&_;A:!OVX6@;]N%H&_;A:!OVX6@;]N%
MH&_;A?]R% '_<!X#_W(H!_^"+@W_CC86_Y5 '_^92"G_F4\T_YA5/OJ67$GT
MDF13[8QK7>>%=F;A?X%OVWB,=]-REG[-;:&$R6JMB<5HNXO!:-",MFO5C:YM
MU8VG;]:,HW#6BY]QV(J=<=F)FW+:AYMRVH>;<MJ'FW+:AYMRVH>;<MJ'FW+:
MA_]S% '_<!T#_W4F!O^&+ W_D385_YE '?^<1B?_G4PQ_)U2._2<647MF6!/
MYI1H6=^.<V/5AGUNS7^'>,9XD8# <YN'NV^GC+9MM(^S;,B1K&[2D:5PTY"@
M<M2/G'/5C9ETUHR7=-B*EG79B99UV8F6==F)EG79B99UV8F6==F)EG79B?]T
M$P'_<1T#_W@D!O^)*PS_E343_YP^&_^@0R3_HDDN]Z-0-^^B5D'GH5U*WYUG
M5-25;V++C7ANPX6">;M_C(*U>9:)KW6ACJIRKY*F<<&4H7/0E)QTT9*8=M*1
MEG?3CY1WU8V2=]:,D7C8BI%XV(J1>-B*D7C8BI%XV(J1>-B*D7C8BO]U$P'_
M<AP#_WLC!O^,*0O_F#02_Y\\&?^C02+[ID8J\JA-,^JI5#SBJ5M$UZ-C4\R:
M;&+"DW5NNHM^>;*%AX.J?Y&*I'N<D)YXJI2:=KN6EW?/EI1YT)21>M&2CWK3
MD(YZU(^->M6-C'K7BXQZUXN,>M>+C'K7BXQZUXN,>M>+C'K7B_]U$P'_<QP#
M_WTA!?^.*0K_FS00_Z(Y%_^F/A_WJD0F[JY*+N6Q4C7<KUE!SZAA4L6@:6&[
MF')NL9%Z>:F+@X.AA8V+FH&8D91^I9:0?+:8C7W-EXQ^SY6*?M"3BG[2D8E^
MTX^)?=6-B'W6BXA]UHN(?=:+B'W6BXA]UHN(?=:+B'W6B_]V$@'_=!P#_X @
M!?^1* G_GC,/_Z0W%?ZJ.QOSKT$BZK1(*.*Y4"[4M%9 R:U?4;ZE9V"TGF]M
MJI=W>*&1@(*9C(J+D8>5D8N$HI:&@[*9@X3+F(2#SI:$@]"4A(+2DH2!TY"$
M@=2.A(#6C(2 UHR$@-:,A(#6C(2 UHR$@-:,A(#6C/]W$@'_=!L#_X(>!/^4
M)PC_H#(-_Z<T$_JN.!COM3T<YKQ&(=R_3"S.N50_P[%=4+>J95^MI&QLHYUT
M=YF8?(&1DX:*B8^2D8*,GY9]BJ^8>HO'F'R)SI9]B-"4?H;2DG^%TY!_A-2.
M@(/6C("#UHR @]:,@(/6C("#UHR @]:,@(/6C/]X$@'_=1L#_X4<!/^7)@?_
MHR\+_ZLP$/6S-!3KNSH7XL1$&-7$2"O(O5,]O+9;3K&P8UVFJFIJG*1Q=I*?
M>H")FH.)@9:.D'F3G)5TDJR7<9+#F'.1SY9VCM"4>(O2D7F*TY!ZB-6.>X?6
MC'N'UHQ[A]:,>X?6C'N'UHQ[A]:,>X?6C/]X$@'_=AL#_X@; _^:)0;_IBL)
M_J\L#/&Y+P[FPS8/W<T\%L[(1RG"PE$[MKQ93*JV85N?L&AHE:MO=(NF=WZ!
MHH"&>9^+C7&<F9)LFZF5:9N_EFN9T)1NE-&2<9'2D7./U(]UC=6-=HO6BW:+
MUHMVB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E
M".O * CAS3 'U-(W%,C-12>[R$\YK\)72J.]7UB8N&9EC;-M<8.O=7MZJWZ#
M<:B)BFJFEH]EI:>28J:]DF.CTI%GG=.0:IC4CVV5U8UNDM:,<)#8BG"0V(IP
MD-B*<)#8BG"0V(IPD-B*<)#8BO][$0'_?!<"_Y 7 O^B(0/_KB $\KL=!.7*
M'@/:VR0#S-DU$L#30R2TSDTVJ,E51YS$7561P&1BAKQK;7NX<W9RM7Q^:K.'
MA6.QE8I>L*6,6[&\C5NOU8U?I]6-8Z'6C&:<UXMHF=B*:I;9B&J6V8AJEMF(
M:I;9B&J6V8AJEMF(:I;9B/]\$ '_@10"_Y45 ?^G'0+\M18"Z\80 =K;#P#-
MX"4$P]\V#[C;02&LU4LSH-%30Y3-6E&)R6)=?L9I9W3#<7!KP7MX9+^&?EV^
ME()8O:6%5KZ[AE6]VX98L]J'7*O:AU^FVH=AH=N&8YW;A6.=VX5CG=N%8YW;
MA6.=VX5CG=N%8YW;A?]^$ '_AQ$!_YH1 /^M% #:O@H T<T* ,OD$ '!Y"4'
MM^,U$ZWA0"&CWDDOE]M2/HO764N U&!7=M%H86W/<&EES7IP7LR&=5C,E7E4
MS*9[4<V\?%#,XGQ3P>!_5;??@%BQWH%:J]Z!7*;?@5RFWX%<IM^!7*;?@5RF
MWX%<IM^!7*;?@?^ #P'_C@X!_Z(- -NU" #.P0@ QM ) +[I$@*TZ24*JN@S
M%Z#F/B66Y4<RB^-./X#A54EVX%U3;=YF6V7=;V%>W7IG6-R&:U/<E6]0W:9Q
M3=Z[<DW?X7%.T>=T4,;F=U*^Y'A3N.1Y5;+C>E6RXWI5LN-Z5;+C>E6RXWI5
MLN-Z5;+C>O^##@'_E@L W:L$ ,VX!@#"Q 8 NM0) +'O% .G[B4-GNXS&I3M
M/2>*[$8S@.M./G;K54=LZEM.9.IC55WJ;5I8ZG=>4^J#8D[JD65*ZZ%G1^RS
M:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/P.IP3\#J<$_ ZG!/P.IP
M3\#J</^)"P#IH $ T+$$ ,&\!0"WR08 KMH) *3U%P6;]2<0DO4T'(CV/B=_
M]D<R=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'W
MOE] ]]]@0^[L8$?C\5](V_%A2=+R8TG2\F-)TO)C2=+R8TG2\F-)TO)C2=+R
M8_Z5  #4J0  PK4# +7! P"JSP4 H.<+ 9C]&@:/_BD0AO\U&W[_0"5T_T8M
M:_],-6/_4CI<_UD_5O]@0U#_:$=,_W%*1_][3$/_ATY _Y10/O^A4CW_L%0[
M_\-5._[A53SY\%5 \/150^?W5$/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5-NA
M  #%L   M;H" *C' @"=U@0 D_P. 8O_'0:#_RL/>O\U%W'_/!]H_T(F8/])
M+%G_3S%3_U8U3O]=.$G_93M%_VT]0?]V/S[_@$$[_XM#.?^813C_I$8V_[)'
M-?_$2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "V
MM   J,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_
M2R5+_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R
M.B[_P#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO
MFLD  (S9  "!]0, >?\0 6[_%@-E_Q\&7O\G"U?_, ]1_S<32_\^%T;_11E!
M_TP;/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^ )BO_C"@I_Y<I*/^B*B?_
MK2LF_[DL)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+:JW  ":Q0  B],
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M3D+F^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@
MN[   *Z[ 0"BR ( F-4% )#X#P&)^" $@O@N"WGY-Q-P^3\;:/E&(F#Z32A:
M^E0M5/I<,4_[935+^VTX1_QW.T/\@ST__9 _//V?03K^KT,X_\9$-__J13;\
M_44[\O]$/NK_1#[F_T8^YO]&/N;_1C[F_T8^YO]&/N;_1M"?  "]K   KK4
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M'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5P@  AL\  '?>  !K]
M8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_- 8R_SH'+O] ""O_1@@H
M_TP))?]2"2+_60H@_V(+'?]K#!K_=@T7_X0.%?^2#Q3_H! 3_ZT1$_^Z$1/_
MPQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S   =]L  &GG  !<_0  5/\
M $O_!0!#_PP!/?\1 C?_%P(R_QX#+O\D RK_*@0E_R\$(O\U!1__.@4=_S\%
M&O]%!AC_2P86_U(&%/]:!Q+_8@<0_VP'#_]W" W_A @,_Y (#/^<" S_H@@,
M_Z((#/^B" S_H@@,_Z((#/^B"/]0( +_2RH#_T0V!?]'.@;_2C\(_TY)#_]/
M5!?_3V >_TUL)/]*>2K_2(4N_T:0,O]$FC3_0Z(W_T*J./]!L3K_0+D[_T#!
M//\_RSW_/MP^_S[H/O\]\S[_/?L__S[_/O] _S[Z0_\]]$3_/NY&_S_N1O\_
M[D;_/^Y&_S_N1O\_[D;_/_]0( +_2RH#_T4U!?]*. ;_33T(_U%(#_]24A?_
M45X>_T]J)?]-=RO_2H,O_TB.,_]&F#;_1*$X_T.I.O]"L#S_0K@]_T'!/O]
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M7TZQ]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC
MTYL  ,:H @"[L0( LKL" *K'!@"BTPH G=8: 976+ :,U#H1@])&'7K03R=R
MSE@Q:LU@.&3+:#]>RG)%6,I\253)B$U/R9513,FE4TK)N51)RMQ31\CW54C
M_%A*N/M93++[6DZM^EI.K?I:3JWZ6DZM^EI.K?I:3JWZ6O]_  #<DP  RJ(
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M-CGE_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R
M@]0  'GH!P!S_!(!:_T= F3])P1>_C$(6/X[#5/_0Q%-_TL52?]3&$7_6AI!
M_V,=/O]L'SO_=B$W_X(C-/^0)3+_GR<P_[ H+O_(*2W_ZBHL__\J+/__*B_Y
M_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@  G+D  ([%  "!T0  ==X
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M"0W_TPD-_],)#?_3"9&\  "!R0  <M<  &3D  !4ZP  2_\  $3_   ]_P0
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M\E24//!2G3_N4:9![%"O0^I/ND3H3L=$YD_=1>%/[D7=3OM(U$__2<A1_TK
M4_]*NE3_2K95_TJT5O]*M%;_2K16_TJT5O]*M%;_2O]-'P+_4"$"_UH> O]B
M'@+_:24#_VTM!?]Q.0O_<402_V].&OMK6"+U9F,I\6-O,.U@>C;I7(4[YEJ/
M/^18F$+A5J)$WU6K1MQ3MDC:4L-*UE+82M%3[$O,4_I-Q53_3KQ6_T^U5_]/
ML%C_3JQ9_TVJ6O]-JEK_3:I:_TVJ6O]-JEK_3?].'@+_4QX"_UX; O]G&P+_
M;B(#_W,J!/]W-0G_>$ 0^7=*&/)S5"#L;UXHYVMJ,.)G=3;>8X \V5^*0=1=
MDT;16YU)SEFF3,M8L$[(5[Q0QE;-4<-7YE&^5_=2N%C_4[!:_U.K7/]2IUW_
M4J-=_U&B7?]0HEW_4*)=_U"B7?]0HEW_4/]/'@+_5QL"_V(7 ?]L&0+_=" "
M_WDG _]^,@?Y@#P-\7]&%>I[4!WD=ULFW7-F+M5M<#?0:7H^RV6$1,=BCDG$
M8)=-P%Z@4+U=JE.[6[95N%O%5K5;WU:R7/-7K%W]5Z9>_5:A8/Y5GF#_5)QA
M_U.:8?]3FF'_4YIA_U.:8?]3FF'_4_]0'0+_6AD!_V45 ?]P%P'_>!T!_W\D
M OV$+@7SAC@*ZH9"$>.$2QG;?U<CT7EB+\MT;#C%;W9 P&Q_1KQHB$NX9I%0
MM6.;4[%AI5:N8+!9JU^_6JE?U%NF8.];HF'Z6IUC^UF99/Q8EF3]5Y5E_E64
M9?Y5E&7^591E_E649?Y5E&7^5?]0'0+_71<!_VD2 ?]T%0'_?1H!_X0A ?>)
M*@/MC30'Y(T]#=R+2!;1A50CR7]>+L)Z:#B\=7% MW%Z1[)NA$VN:XU2JFB6
M5J=FH%FC9:M<H&2Y7IYDS5Z;9.I>F&;X791G^5R2:/M:D&C\68YH_5>.:/U6
MCFC]5HYH_5:.:/U6CFC]5O]2' '_7Q0!_VP1 ?]X$P'_@1<!_X@= ?*/)0+G
MDR\$WI4X"=.0117*BU$BPH5;+KN 93BT>VY!KW=W2*IT?TZE<(A3H6Z25YUK
MG%N9:J=>EFFU8)1HR&&2:>9@CVKW7XUK^%V+:_E<B6S[6HAL_%B(:_Q8B&O\
M6(AK_%B(:_Q8B&O\6/]4&@'_8A,!_V\0 ?][$@#_A10 ^HT9 .V3'P'BF2@"
MV)DS",R50A3$D$XAO(M9+;2%8C>N@6M J'QS2*)Y?$Z==H54F7..6)5QF%R1
M;Z1@C6ZQ8HMMPV.);N)BAV_V889O]U^%;_E=A&_Z6X-O^UF#;_Q8@V_\6(-O
M_%B#;_Q8@V_\6/]6& '_9!$!_W(. /]^$ #_B!$ ]9$4 .B8&0#=GB !T9XQ
M!\>:0!.^E4P@MI!6+*Z+8#>GAFA H8)P2)Q^>4Z6>X)4DGB+68UVE5V)=*!A
MA7.N8X)ROV2 <]YD@'3U8G]T]F!_<_A>?G/Y7'YR^EI^<OM9?G+[67YR^UE^
M<OM9?G+[6?]8%P'_9Q !_W4. /^!#@#_C X \940 ..=$0#6HQL RZ$O!L*>
M/A*YF4H>L)14*ZF073:BBV8_FX=N1Y6$=DZ0@']4BWZ(689[DEV!>9YA?7BK
M9'IXO&5Y>-EE>'GT8GEX]F!Y=_A>>7;Y7'EU^EIY=?M:>77[6GEU^UIY=?M:
M>77[6O]:%0'_:0X _W@, /^$# #OD L W9H* -FB"P#0IA@ QJ4L!;VB/!"T
MGD@=JYE2*:.56S2<D6,^E8UK1H^)<TV)AGQ3A(2%6'^!D%UZ?YMA=GZH9'-]
MN65Q?M-E<7[R8W)]]F!S>_=>='KY7'1Y^EMU>?M:=7G[6G5Y^UIU>?M:=7G[
M6O]=$P'_; T _WL+ /:("0#<DP8 U9T) -&E"@#*JA4 P:DJ!+>F.@^NHD8;
MIIY0*)Z:63.6EF$\CY-I1(F/<4R#C7E2?8J#5WB(C5QSAIE@;X2F8VR$MV1J
MA,]D:H3P8FR"]F!M@/=>;W_Y7&]]^EMP?/M:<'S[6G!\^UIP?/M:<'S[6O]?
M$0'_;PH _WX( .., P#6EP4 SZ ' ,JH" #$KA, NZTG [*K-PVIIT09H*1.
M)IB@5S&1G%\ZBIEG0X.6;TI]DW=0=Y& 5G*/BEIMC99>:(NC866+M&-CB\QC
M8XON866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_
M<@< ^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F
M52Z*HUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M
M7UZ0^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P,
MXX<  -.3 0#*G@0 PJ<$ +NO! "UM@T KK<A J6V,@F=LS\5E+!*((RM4RN$
MJELT?:AC/':E:D-PHW)*:J%[3V6@AE1@GI%86YV?6UB=L%U6G<==5IWK7%>:
M^EM:E?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?C?Q77XW\5_]J"@#_?   W(P
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M2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP
MH+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9(5K18B=5
MT&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_] 0,/_0D&]
M_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@M   E;X
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M'2KW_QTJ]_\=*O?_';.C  "DJP  E[8  (G!  ![RP  ;]8  &/?  !;]08
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M56YZ_%-O>?]1<'?_3W%V_TUQ=?],<77_3'%U_TQQ=?],<77_3/];#@#_:00
M]G<  -V"  #0BP, R9,% ,29!@"^GA  MI\D JZ=- BFFD$3GY9,'9B352>1
MD%XOBXUE-X6*;3V B'5#>X5^2':#B$QR@I-0;H"@4VM_KE5H?\)69W_C56B
M^E-I?O]1:GS_3VM[_TUL>?],;'G_3&QY_TQL>?],;'G_3/]># #_; $ YGH
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M3%F-_TM;BO]*6XK_2EN*_TI;BO]*6XK_2O]H  #E>0  T8<  ,62  "[G
ML:(  *FI  "AL0( F[,5 )6S* *.LC8)AK!"$G^N3!MXK%0C<JI<*FRH9#%G
MIVPV8J5U.UVD?T!9HXI#5:*71U&AITE/H;I*3J+924Z@]4E.G_])4)G_25*6
M_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P  RHT  +Z8  "SH   JJ<
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M-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":KP  CK<  (._  !XQP,
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M":*G  "3L0  A;L  ';&  !IT   6]H  $[@  !#Y0  /OL! #K_#  V_Q,
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M1W]G^$5^:/]#?FC_07UG_S]\9_\^?&?_/7QG_SU\9_\]?&?_/?]2#@#_70,
M_6D  .%R  #6>@( SG\% ,J#" #%AA( O(<F ;6&-@:N@T,/IX!.&*%\6"";
M>6 GEG=I+9)T<#..<GDWBG"!/(9NBS^#;95#?VRA17QKKD=Z:[](>&O=2'AL
M]D9X;/]$=VS_0G=K_T!W:O\_=VK_/G=J_SYW:O\^=VK_/O]4# #_7P  \FP
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M0V=X_T%H=O\_:';_/VAV_S]H=O\_:';_/_];! #W:0  W78  ,V   ##B
MNXX  +23 0"MEPD IY@: *"8+ .9ECH*DI1%$HR23QJ&CU<B@(U?*'N+9RYV
MB6\S<H=W.&V%@3QIA(M 9H*70V*!I49@@;9'7H'-1UZ![T9?@?]$8'__0F%]
M_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0  UGD  ,B$  "^C   MI,
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M.U"/_SM0C_\[4(__.^MM  #3?   PXD  +>3  "LF@  HI\  )FE  ".JP
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M(;Z/  "OF@  HJ$  ):I  "*L   ?;@  '&_  !FQ@  6\P" %#2!P!'V@P
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M Q7_LP04_],$%/[T!!/\_P,3^O\#$_G_ Q/Y_P,3^?\#$_G_ YVE  "/K@
M@+@  '+"  !DRP  5M,  $G:   ^WP  -.0  "[T   K_PH */\0 "7_%P B
M_Q\ '_\F !S_+0 9_S0 %_\\ !3_1 $2_TX!$/]9 0[_9P$,_W<!"_^* @K_
MGP()_[4""/_5 @?_] ('__\"!___ @?__P('__\"!___ I&M  ""N   <\(
M &3,  !6U0  2-T  #OB   PYP  )^X  "/_   @_P0 '/\, !G_$0 6_Q8
M$_\; !'_(0 ._R< #?\N  K_-@ '_SX !/](  #_5   _V(! /]S 0#_AP$
M_YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0  9<P  %;8
M  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P  $?\$  __"P -_PX "?\1
M  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00  _TT  /]<  #_;0  _X(
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MX#O"%M\[TA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ_Q_$._\?P#S_'L \_Q[
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M-)-5]C.25?\RD5;_,8]6_S"-5O\NC%?_+8Q7_RV,5_\MC%?_+?])#@#_404
M_UH! .YB  #?9P, V&H& -5K"@#-;14 Q6XI ;YM.02W:T<+L6A2$:QF7!BH
M9&4=I&)M(J%@=2:>7GXIFUV&+9A<CR^56IDRDUFD-)!9L#:.6< VC%G;-XI9
M\S:)6O\TB%O_,X=;_S&&6_\PA5O_+X5;_R^%6_\OA5O_+_]+# #_5   ^UX
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M-G-H_S5S9_\S<V;_,G-F_S)S9O\R<V;_,O]1! #_7   XF<  -)P  #'=@
MP'H  +I] @"T?PP K8$= *>!+@*@?SP(FGU'#Y5Z41:0>%H<BW9B(8=T:2:#
M<G$K?W%Z+WQO@S)X;HTU=6V8.')LI3MP:[0\;FO)/&UKZ3MM;/XY;6S_-VYL
M_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P  WFH  ,US  ##>@  NWX
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MC ( G(X4 )>/)@&1CC0%BXQ "X6*2A& B%,8>X9;'7:%8R)R@VHG;H)R*VJ
M>R]G?X8S8WZ1-F!]GCE=?*XZ6WS!.UM\XSI;?/HX7'O_-UU[_S5>>?\T7W?_
M,U]W_S-?=_\S7W?_,_Y<  #A:@  S74  ,!^  "VA@  KHL  *6.  ";D0
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M*]=R  ##@   MHP  *J4  "?F0  E)X  (FC  !^J   <*X  &JP#@!HL1T
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M#S#(TP\PQO00+L3_$RW"_Q4LP?\6*\#_%RO _Q<KP/\7*\#_%[B-  "JEP
MGIX  )&E  "$K   >+(  &NY  !@OP  5,,  $K( @! S0< .M(. #G2&P X
MTR@ -],U #;40  TU4L!,]55 3'68 (OUFP#+==Z!"O8BP4JV)T%*-FQ!B?:
MS08GU^\&)M3_"272_PLDT?\,(]#_#2/0_PTCT/\-(]#_#:Z6  "@G0  E*0
M (:L  !YM   ;+L  &#"  !4Q@  2,L  #[0   UU00 +=T* "SA$P KXA\
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M  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(  !2T
M0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1  G_%@ &
M_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4  /^L  #_
MQP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP  8<D  %+3  !#VP  ->$
M "GF   >Z@  %>X  !#X   ._P  "_\   C_   $_P8  /\*  #_#@  _Q$
M /\5  #_&P  _R,  /\K  #_-@  _T,  /]3  #_90  _WH  /^1  #_I@
M_[@  /_/  #_SP  _\\  /_/ /\<+P'_("P!_R$L ?\>+@'_&C,!_Q0\ ?\/
M1@'_#50"_PMA O\);P+_"7L"_PF& O\)D +_"9D"_PF@ O\)IP+_":T"_PFT
M O\)O '_"<4!_PG1 O\)XP+_">\"_PGY ?\*_P'_"O\!_PK_ O\*_P+_"O\"
M_PO_ _\+_P/_"_\#_PO_ _\?+0'_(RD!_R0I ?\B*P'_'C !_Q@X ?\40P'_
M$5 "_Q!> O\.:P+_#G<"_PZ# O\.C0+_#I4"_PZ= O\.I +_#JH"_PZQ O\.
MN0+_#L$"_P[- O\.WP+_#NP"_P[X O\._P+_#O\"_P__ _\/_P/_#_\$_Q#_
M!/\0_P3_$/\$_Q#_!/\C*@'_)B8!_R@E ?\G)P'_(RL!_QXS ?\;0 '_&4T"
M_Q9: O\49P+_$W,"_Q-^ O\3B0/_$Y$#_Q.9 _\3H +_$Z<#_Q.N _\3M0/_
M$[X#_Q/) _\3V@/_%.D#_A3V _L4_P/Y%?\#^17_!/@5_P7X%?\&^!7_!O@5
M_P;X%?\&^!7_!O\F)@'_*B(!_RP@ /\K(@'_*"8!_R<P ?\D/ '_(DD"_Q]5
M O\=8@+_&VX#_QMZ _\:A /_&HT#_QJ5 _\:G 3_&J,$_QNJ!/\;L@3_&[H$
M_QO%!/P;TP3Y&^<$]1ST!/(<_P7Q'/\&\!S_!^\=_PCO'?\)[QS_">X<_PGN
M'/\)[AS_"?\J(@'_+AT _S ; /\P' #_,"( _S L ?\N-P'_*T0"_RA1 O\F
M70/_)&D#_R-U!/\C?P3^(X@$_2.1!?LCF 7Z(Z %^".G!O<CK@;U([<&]"/!
M!O(DSP;N).0&ZB7R!N@E_@CF)/\*Y"7_"^,E_PSC)/\,XB3_#.$D_PWA)/\-
MX23_#?\N'@#_,Q@ _S46 /\U%0#_.!T _S@G ?\W,P'_-#\!_S)+ O\O6 /[
M+F0$^"UO!/4L>@7S+(,&\2R,!N\LE ?M+)P(["RC".HLJPCI++,(YRR^">8L
MS GB+>((WBWQ"MLL_@S6+?\.U"S_#](L_Q#1+/\0SRS_$,XM_Q#.+?\0SBW_
M$/\R&0#_-Q0 _SH1 /\\$@#_/QD _T B /\^+0'_/#D!^CI% O0X4@/P-UX$
M[#9J!>DU= ;F-7X(Y#2'".(TD G@-)@*WC2?"MPSIPO:,[ ,V#.[#-4SR0W2
M--\-SC3P#\HT_1+'-/\3Q33_%,,T_Q7#,_\5P#3_%;\T_Q2_-/\4OS3_%/\V
M%0#_.Q  _SX- /]##P#_1A0 _T8< /]&)@#V1#(![T(_ >E 3 /D/UD$WSYD
M!ML];PC8/'D*U#R"#-$[BPW/.Y,/S3J:$,LZHA').JL2R#JU$\8ZPA/$.M44
MP#OK%;PZ^Q>Y.O\8MSK_&;8Z_QFU.O\8LCO_&+$[_QBQ._\8L3O_&/\Y$@#_
M/PT _T,) /](# #_2Q  _TP5 /5,'P#K2BH Y$DW =U)1@+51U,$T$9?",Q%
M:0O)1',-QD-\$,-"A!+!0HP3OT&5%;U!G1:[0*87ND"P&+A O!FV0,P:LT'F
M&J]!]QRM0?\=JT'_':E!_QRI0?\<ID'_&Z5!_QNE0?\;I4'_&_\]$ #_0@D
M_T@% /]-" #_4 L ^5$/ .M0%0#A3R  V% Q ,]000+)3TX%Q$Y:"<!,9 V]
M2VT0NDIV$[=)?A6U2(<7LT>/&;%'EQNO1J <K4:J'JM%MA^I1<8?IT;@(*1&
M]""A1O\AGT?_()Y'_R">1_\?FT?_'II'_QZ:1_\>FD?_'O] #0#_1@0 _TP
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M*(-6_R>"5O\E@5;_)(%6_R2!5O\D@5;_)/]' P#_3P  YU@  -E@  #-9
MQF8! ,%F! "[9@X M&D@ *YI,0*H:#\%HV9*"I]E5 ^:8UT4EV%E&)-@;1R0
M7G4?CEU](HM<AB6(6Y HA5J:*H-9IBR 6;0M?UG'+GU9YBU\6OHL>UK_*GM;
M_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@  XUP  -)C  #':   P&L
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M*&IF_R=J9O\G:F;_)_]0  #G6P  TV8  ,5N  "[<P  LW<  *MY  "D> ,
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M(#^:R" _F>L?/YC_(#Z6_R$^E?\A/Y3_(3^4_R$_E/\A/Y3_(<UP  "\?0
ML(@  *2/  "9E   CI@  (.=  !WH   ::0  &"G" !=J!0 6ZDD %FI,0%6
MJ3P"4ZE%!%"H3@9-J%<)2JA?#$>G: Y$IW,10:9_%#ZFC18\IIT7.J:O&#FF
MQQ@YI>H8.*/_&C>A_QLWH/\<-Y__'#>?_QPWG_\<-Y__',1X  "UA0  J8\
M )V5  "2F@  AI\  'JC  !NJ   8JP  %6P  !0L@X 3K(; $VS* !+LS4
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M Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4  "<F@  D*$  (*H  !TKP
M9[8  %N\  !.P   0\,  #G'   OS   )] $ !_6"@ ;VA  &]L: !K;)@ :
MW#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4 %.&: !/BL0 2X\\ $N#T !+>
M_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !HN   6[\
M $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K'0 0ZR8
M#NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D  +Q_0 "
M[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@  3<@  $#,
M   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '^QP !/PD
M  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\ZP  _/\
M /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$  #+7   G
MW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(  /\7  #_
M'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@  _^<  /_\
M  #__P  __\  /__ 'RS  !LO   7<8  $[/   _U@  ,=T  "7B   :Y@
M$>H   SN   %\@   /\   #_    _P   /\   #_!0  _PH  /\.  #_$@
M_Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,  #_I   _[D  /_4  #_
MW@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#  _PLX ?\#1 '_ %$!_P!>
M ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_ *@ _P"O /\ M@#_ +X
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M ](D^07/)?\&S27_!\LE_PC*)?\(RB3_",HD_PC*)/\(RB3_"/\N% #_,1
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M-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_#_\U#@#_. < _SP" /]
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M%YA!_Q>80?\6ET'_%9=!_Q670?\5ET'_%?\[!@#_/P  ^48  .5+  #<3@
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M''96_QMV5O\;=E;_&_]%  #L3@  VE@  ,E>  "_8@  MV0  +%C  "K80@
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M(DYYPR)->.4B37?[(4YW_Q].=O\>3W7_'4]U_QU/=?\=3W7_'=]<  #(:
MN7(  *YZ  "E@   FH(  (Z"  " @P  >84" '2&$0!QB"  ;H@N 6J(.0)G
MAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748* &DZ!C1Q+@9L>28&L'TB
MP2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<27S_'-9A  #";@  M'@
M *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!HCQH 9H\I &*0-0%?CS\#
M7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*BAA%BID:0XJJ&T**OQM!
MBN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=   KWX  *6&
M  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0 7)<C %J8+P!7F#H!5)A$
M U*73 5/EU0'3)=<"4F690Q'EF\.1)5Z$4&5B!,_E)<5/92H%CN4O18[E-\6
M.I+X%SJ0_Q<ZC_\7.H[_%SJ._Q<ZCO\7.H[_%\5N  "V>P  JH4  )Z+  "4
MCP  B)(  'N4  !NEP  8IL  %>>  !2H X 4: ; $^A* !-H30 2Z$^ 4FA
M1P)'H5 #1*%8!4*A80<_H&L)/:!W"SJ@A0TXH)0.-J"F#S6@NQ TH-T/-)WW
M$#.<_Q(SFO\2,YG_$S.9_Q,SF?\3,YG_$[UW  "O@P  HXL  )B1  "-E0
M@9D  '.<  !GGP  6Z(  $^F  !'J0@ 1*H2 $.J'P!!JRL 0*LW #^L00 ]
MK$H!.ZQ3 CFL7 ,WK&<$-:QS!3*L@08PK)$'+JRC""VLN DLK-D(+*KU"BNH
M_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP  G)$  )&6  "%G   >*
M &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 SMB$ ,K8L #&W-P PMT$
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M  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_   ]P@
M,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D  +A+@ !
MXCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\  .C_  #H
M_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   PRP  )<\
M !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K(0  [2L
M .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_  #W_P
M]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@  &=P  !'@
M   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%   ^!T  /HG
M  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_^0  __D
M /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8   CJ
M[0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q   /\8  #_
M(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0  _]4  /_5
M /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\ :0#_ '0
M_P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#  /\ S #_
M -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6
M)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z
M /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X R #] -D
M^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_
M&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\
M?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U -( \P#F
M /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>'0#_'AD
M_QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q /\&>@#_
M!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X ZP7D .D&
M\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_(1, _R 1
M /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.=0#T#GX
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M!;8E_P6U)?\&M27_!K4E_P6U)?\%M27_!?\L#0#_+04 _RX! /\Q!0#_,0L
M_2\0 /$K& #G*24 WR@S -@H0@#1*D\ S2M: ,DK90''*VX!Q"QV L(L?@+
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MD3S_#9$\_PV1//\-D3S_#?\U  #_.0  ZD$  -U&  #01P  R48  ,9!!0#
M0!$ N4(A +-$,@"O14 !JT5+ J=%50.D1%X%H41F!Y]#;@B=0W8*FT)^"YE"
MA@V708\.E4&9#Y-!I!&10; 2D$' $HY!V1*+0?$2B4+_$HA"_Q&(0O\0AT+_
M$(="_P^'0O\/AT+_#_\X  #S/0  XT<  -),  #(3@  P$T  +M* @"V1PX
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M%/)#  #?3P  RU@  +U=  "S80  JV(  *)@  ";7   E5X0 )!@'P",82X
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M'%IBOQQ98M\<66+W&EIB_QE:8?\76V'_%EMA_Q5;8?\56V'_%>=-  #/60
MOV(  +-H  "I;0  GFT  )-K  "):0  @VL) ']M%0!\;B4 >&XR 75N/0)Q
M;D8$;FU/!VML5@EH;%X,96ME#V-J;1%@:78476F!%EMHC1A89YL:5F>J&U5G
MO1Q49]P<5&?V&E1F_QA59O\7567_%E9E_Q569?\55F7_%>)1  #*70  NV8
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M%D-Y_Q5#>/\41'?_%$1V_Q-$=O\31';_$\U?  "[:P  KG0  *1\  "7?@
MBGT  ']^  !R?P  9H,  &&$" !>AA, 7(<A %J'+@!8AS@!58=" E.'2@-0
MAU(%3H9:!TN&8@E)A6P+1H5W#4.$@P]!A)(1/X2B$CV$M1,\A,\3/(+P$CR!
M_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0  JGL  )^"  "2@@  A8(
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M!B2>_P<DGO\'))[_!Z]^  "CB   EXX  (V3  !^E0  <)@  &.;  !7GP
M3*(  $*F   XJ0  +ZP# "JN#@ IKA@ **\C ">O+0 FL#< );!! "2P2P C
ML58 (K%C "&Q<0 ?L8( 'K*4 1RRJ0$;LL$!&['G 1NO_@(:K?\"&JS_ QJK
M_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP  :*(  %NE  !/J0  1*T
M #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6O"H %;TU !2]0  3ODL
M$KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]^P /O/\ $+K_ 1"Z_P$0
MNO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M   .K8  "^Y
M   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &RSX !<M+
M  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*_P !RO\
M <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\  "/#   ;
MQ@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$  -L^  #<
M2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P  W_\  -__
M (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-   0T0
M"]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO  #K/
M[4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\  /#_ (&E
M  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   'W@   .(
M  #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X*P  ^SD
M /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U '2N  !E
MMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0   .P   #P
M    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P  _R@  /\W
M  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/) #_#B(
M_PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ A #_
M (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -, _P#G /\
M] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_$!X _PT=
M /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (<
M_P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B /@ \ #W
M /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+
M&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^ (, _ "*
M /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X [ #M /H
MZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_
M"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X \@"% /$
MC #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A /< WP#_
M -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2#@#_$A4
M_P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*  .8#AP#D
M XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@ S@K_ ,P+
M_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_&!$ _Q89
M /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-@P#6#8H
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M Z$F_P.A)O\#H2;_ _\I  #_*   ]BT  .<P  #?+P  V2L$ -8B"@#.(Q8
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M"O8V  #F0   T4@  ,--  "Y3@  L4T  *E)  "D108 GT83 )I((P"623(
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M$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE3_\,94__#.Q!  #43
MPU0  +99  "L7   H%H  )=7  "15   BU4, (97&0"#6"< @%DT 'U9/P%Z
M64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!#V95C1%D5)H28E2I$V!4
MNA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-7U/_#>=$  #/4   OU@
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M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/  ##6@  M&,  *EI  ";:
MCV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH &=L- !D;#T!8FQ& E]K3@1=
M:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(03&>A$DMGLA))9\D226?K$DEF
M_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@  L6<  *9M  "7;   BFL
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M"CAX_PHX>/\*.'C_"KYD  "P;P  I7@  )9Y  "'>0  >WD  '!Z  !D?
M6(   %"#  !+A0H 2(84 $>'( !%B"L 1(@U $.(/@!!B4<!0(E/ 3Z(6 (\
MB&$#.HAL!#>(> 4UB(<&,XB8!S*'J@<PB, ',(?D!S"%^P@P@_\(,(+_"#"!
M_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@  =G\  &J   !>@P  4X<
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M :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G   JJP
M(:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.  JV7  )
MMFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-
M  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   AM0  &+@
M !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##4   Q%\
M ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_ ).4  "'
MF@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P   $,,   K&
M   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P  U%(  -1C
M  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;  ![H@
M;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX   #2
MUP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(  .A4  #H
M9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !NJP  7[(
M %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A    Y
M .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!  #Z50
M^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0  4KT  $3$
M   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L    [P   /$
M  #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_00  _U8
M /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P = /\ ( #_
M "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (< _P". /\
ME #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^ /T _0#_
M /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\ &@#_ !\
M_P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P") /\ D #_
M )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D \P#_ /(
M_P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_ !D _P E
M /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /< BP#V )$
M] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F
M /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4 _P @ /\
M+ #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J (P Z "3
M .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4 _P#4 /\
MTP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,: /\ )@#]
M #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (< V@". -@
ME0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_
M ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P''P#Q RL
MYP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2) ,@%D #&
M!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\ M W_ +0-
M_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C"2( V@DP
M -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/C0"Z$)4
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M O\F  #R*0  XS$  -(T  #(-   P#   +LI @"X(PX L28< *PH*P"H*C@
MI"M$ *$L3@"?+5< G2U? )LM9P&9+6X!F"YU 98N?0*4+H8"DRZ0 I$NF@./
M+J8#C2ZS XPNQ0.*+^$$AR_V!(4O_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI
M  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L IR\7 *(Q)@">,S0 FC1
M )@U2@"5-5, DS5; 9$U8@&/-6D"C35Q HPU>0.*-8(#B#6+!(8UE@2$-:(%
M@C6O!8$UP 9_-MP&?3;T!GLV_P5[-O\%>C;_!'HV_P1Z-?\$>C7_!/4M  #D
M-P  T#\  ,)#  "W1   K4   *<Z  "C-@8 G3<3 )DY(@"5.B\ DCP[ (\\
M1@",/$\!BCQ7 8@\7@*&/&4"A#QM X(\=02 /'T$?SR'!7T\D@9[.YX'>3NL
M!W<[O AV/-4(=#SQ"',\_P=R//\&<CS_!7(\_P5R._\%<CO_!?$R  #>/0
MR40  +Q(  "P20  ID8  )]!  ";/0$ E3T0 )$_'0"-02L BD(X (=#0@"$
M0TL!@D-3 8!#6P)^0F(#?$)I!'I"<05X0GH&=D&$!W1!CPAR09L(<$&I"6]!
MN0IM0= *;$'N"6M"_PAJ0O\':D'_!FI!_P9J0?\%:D'_!>TW  #60@  Q$D
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M#%A/_0M83_\)64__"%E._P=93O\'64[_!]]#  #'30  N%0  *Q9  "=5P
MD54  (A4  "!4   >U($ '=3$0!T5!X <54K &]6-@!L5D !:E9( 6A64 )F
M5E<#9%9>!&)59@5@56\'755X"%M4A I95)$+5U2@#%53L U44\4-4U/F#%-3
M_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4   M5@  *A;  "96@  C5@
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M"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",8P  @&,  '9C  !J8@
M8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J10%0:DP!3FI4 DQJ7 -*
M:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>"3YG]PD^9O\(/V7_!S]E
M_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P  >V<  '%G  !E:   7&H
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M [%J  "E=   E78  (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0
M-8@) #*)$0 QB1L ,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P F
MBWH!)(N+ 2.+G@$BB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR
M  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$
M ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0
M&9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9
M@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V>
M 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]
M  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0
M@X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /
MJP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "N
MAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y
M &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP
M ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P
MO)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?
M  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"
M  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,
M ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,
ML@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T    -$   #2
M 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+
M  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O
M,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .    #B
MY    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #X
MDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD
M !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O    \0
M /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P
M_YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\
M. #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P";
M /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\
M^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_
M $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H
MG0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_
M .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P
M_P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M
M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$
M_P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!#
M /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H
MW0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#,
M /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D
M2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"=
M ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\
MO #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3
M $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H
MH0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_
M /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4
MP -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K
M":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7
M  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y)
M +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8
MGA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T
M'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *49
M30"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO
M ) >OP"/']@ C"#Q 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@
MVBT  ,HP  "^+@  M2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7
M)%$ E219 ),E8 "2)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80G
MNP&#*-$!@"CN 7XI_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4
M ,$X  "T-@  JS$  *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P
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M!60\^@1D//\#8SO_ V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10
ME4,  (Y   ")/   A#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P
M05D!;D%@ FQ!9P)J07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!
M^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P  N4H  *E+  ";20  D$<
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M!$U-_P1.3/\#3DS_ \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30
M;$\  &A0"P!E414 8U(A &%3+ !?4S8 750_ %M41P!:5$X!6%16 59470)4
M5&8#4E-O U!3>P1.4X@%3%.7!DM3IP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1
M_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50  ?U0  '93  !L40  9U,
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M [Q5  "M7P  G&   (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H
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M 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@
MBFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G
M@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$
ME0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(
M '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X
M&HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /
MCZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W
M  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.
M  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL
M )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=
M@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E
M$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H
M  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C
M29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#
MLA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "U
MM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\
M #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^!@  OPP
M , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0
MQ\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS
M   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,    S0,  ,X)
M  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4
M -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4
MP@  #,8   /)    S    -    #5    V0   -H   #<    W@   .    #B
M!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_
M  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@
M -(   #7    W    .    #E    YP   .D   #K    [0   .\   #Q
M\P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_
MO@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/
M /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *,
M_P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I
M /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\
M5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F
M /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\
MW@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[
M %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8
MJ0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_
M /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0
MZ@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/
M *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*
M!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7
M -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@
MO0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_
M!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,,
M60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O
M *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P
M] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R
M %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!
MN0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0
M -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4
MI E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2
M#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA
M  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7
M )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD
MA!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S
M)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<
M60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D
M '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@
MH"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_
M)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI
M]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(
M )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@
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M  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]
M &1 2 !B0$\ 84!7 %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#
M4D#/ U% [P-00/\"4#__ E __P)1/O\!43[_ <\[  "]10  JD<  )E&  "+
M10  @40  'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4 7T0^ %Y$
M10!=14T 6T54 %E%7 %8160!5D5M 51%> )2184"4423 T]$HP--1;0#3$7,
M TM%[0-+1/\"2T3_ DM#_P),0O\"3$+_ LH_  "Y2   IDH  )5)  "'2
M?4<  '5%  !N0@  :4,  &5$"0!B11, 7T8> %U'* !<2#( 6D@[ %E)0P!7
M24H 5DE2 %1)60%326$!44EK 4])=@)-28("2TF1 TI)H0-(2;,#1TG* T9)
M[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3   HDP  )%,  "$2P  >4H
M '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!63"\ 54TX %--0 !234@
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M C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X5   ;50  &14  !85
M4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<-@!!7#X /UQ& #Y=3P ]
M75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W" C%<Y0(Q6_P",5K_ C%9
M_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P  :5<  &!8  !460  3EL
M $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y8CH .&-" #=C2P V8U0
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M :9F  "190  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O   P<P
M*78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5
M?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK
M  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I>P  (G\
M !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'4P +AV$
M"H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_ )5Q  "#
M;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0  &XD  !2,
M   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P  DUD  )-I
M  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW  !]=0
M<'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0   Z7   )
MFP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%   *!?  "@
M<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X?   :7P
M %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D    IP
M *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4  "O9@
MKWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA   88<  %.+
M  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R    M@   +<
M  "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  # 6@  P6X
M ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690  $N:   ]
MH   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q    ,4   #&
M    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53   UF   -AW
M  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J   UL
M*+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,   #6
MV    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$  .YG  #O
M@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   JO@  ',(
M !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F    Z
M .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5  #_;@
M_XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D _P E /\
M,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_ (L _P"1
M /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8 _P#V /\
M[P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @ /\ +0#_
M #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8 ]@", /4
MD@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G /\ Y0#_
M -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\ * #_ #4
M_P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"& .8 C0#D
M ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\ T@#_ ,X
M_P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S "X [P Z
M .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$ AP#/ (X
MS0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_ +X _P"]
M /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "< W0 S -D
M/@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "] (@ NP"0
M +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X _P"N /\
MK@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L ,0 . #!
M $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M (( K "* *H
MDP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P"> /\ G@#_
M /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0 ,0"Q #L
MK@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"% )P C@":
M )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\ CP#_ /T*
M  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E #0 H@ ^
M )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $B@".!)4
MC 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F
M%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X E@HX )0+
M00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"##I, @0^?
M ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0
MQB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R (D3/ "'
M$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08
MJ@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0*0  O"L
M *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<-P!\'4
M>AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I
M(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P  M#$  *,P
M  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S)3P <25#
M ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(II !@*;4
M7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34  )TT  "0
M,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M
M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0 7"^2 %HOH0%9+[(!6##(
M 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "].@  J#D  )<X  "*-P
M@#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q*P!D,C0 8S(] &$S1 !@
M,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360 50UGP%2-; !437& 5 U
MYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0  HSP  )(\  "%.P  >SH
M '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>-S$ 73@Z %LX00!:.4@
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M 3]!_P% 0?\!0$#_ ;]!  "J10  ED4  (9%  !Y1   ;T0  &="  !@/P
M6T$  %="  !40PT 4405 $]%'P!.12@ 3$8Q $M&.0!*1T$ 24=( $A'4 !&
M1U@ 14=A $-(; !"2'@!0$B' 3Y(EP$\2*D!.TB^ 3I(WP$Z1_@!.D;_ 3I%
M_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P  :T<  &-&  !;0P  5D4
M %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%2SX 0TM& $),30!!3%8
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M :]1  "840  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5   [6
M.%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I
M76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\ )%C_ *A5
M  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V70  ,& %
M "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D7  A9&D
M'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__ *%9  ",
M6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P  *F8  "1I
M"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT
M !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=  "%70
M=5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T  !YP 0 7
M<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU
M@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_80  <&$
M &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y   1? 0
M#7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G  !_>0
M?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P  :V8  &%F
M  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,A@( !HD*
M  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+<0  BX8
M (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P  %IM  !.
M;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@   )0&  "5
M#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:   F7T  )F4
M  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V  !&>@
M.W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$   "B!@
MH@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(  *B)  "H
MH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^AP  ,HT
M ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P    L00
M +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]  "ZEP
MNK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP  *IT  !^B
M   5IP  #:P   6P    M    +<   "[    O@   +\   #     P0   ,,!
M  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1B   T*0
M -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T  !:S   .
MN   !KP   #     PP   ,8   #+    S0   ,X   #0    T0   -0   #6
M    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>   ZY0  .NO
M  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["   $Q0
M ,H   #-    T0   -@   #;    WP   .    #B    Y    .8   #I
MZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(  /^=  #_
MM0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_ #L _P!'
M /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X DP#] )D
M^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_ .  _P#8
M /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8 _P!! /\
M3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O )0 [0";
M .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$ _P#, /\
MR #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [ /< 1@#S
M %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X W "5 -H
MG@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_
M /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .< 0 #B $H
MW0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/ ,0 F #"
M *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\ L #_ /\
M  #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+ $, QP!,
M ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +( D@"P )L
MKP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_ /\   #_
M    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T M0!& +(
M30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@ )8 GP"A
M )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\   #U
MYP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _ *, 1P"A
M $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$ D "< (X
MJ0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I#   U X
M ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8 00"4 $D
MD@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8 (( I0"
M +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0  Q14  +04
M  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(!$, A@5+
M (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*HP!U"K,
M<PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T  *D<  "=
M&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX ? Y& 'L.
M30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K$K( :1+'
M &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C  "4(0
MBQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9! '$62 !O
M%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;
MY !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",*   @R4
M 'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>1 !F'TL
M91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5
M(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0  ?"L  '8H
M  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?)D@ 729/
M %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\IW@!.*?<
M32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C   ' M  !K
M*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M
M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(+_8 1R__
M $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR  !F+P
M8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43)) % R4 !.
M,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S
M_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A,P  73(
M %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW3@!).%8
M1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_ #TW_P ]
M-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P  6#8  %0W
M  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ<
M $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[_P X._\
M.#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH  $\[  !,
M/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$ /4%: #Q!
M9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S/_\ -#[_
M +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I   !&004
M1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98 #9&8@ U
M1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#
M  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!1@$ /D<,
M #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+7P O2VL
M+4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_ *=&  "1
M1@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P  -TP) #5-
M$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H4&@ )U!W
M "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)  ",20
M>DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($ "U3#0 L
M5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4 'U9T !Y6
MA0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&30  =4T
M &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:"0 C6Q
M(EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP !5=@0 4
M794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40  <%$  &11
M  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :8PP &&01
M !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE?0 -99$
M#&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4  %]5  !6
M50  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4 $&T-  YN
M$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ ";HH  &V?
M  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9  !360
M2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*  5W$  !
M=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0  'B9  !W
ML   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-7P  0F(
M #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!#0  @1$
M ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23  "#J@
M@L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P  /&L  #%O
M   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0  C0X  (X1
M  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1H@  D;P
M )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8  "I[   @
M@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@  )P-  ">
M$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@  H;,  *#8
M  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*   7CP
M$)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&  "M"P
MKQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@  +3&  "S
M[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0GP  ":0
M  "I    K0   +    "T    MP   +@   "Y    NP   +P   "^ @  P @
M ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX  #*W0
MRO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L    +4   "Y
M    O0   ,$   #&    R    ,D   #+    S    ,X   #0    T@   -0%
M  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #EQ0  Y><
M .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4   #)
MS0   -(   #6    V@   -L   #>    X    .(   #D    YP   .D   #M
M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP  _<<  /WD
M /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\ 30#_ %<
M_P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"< /< I0#U
M *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\ R@#_ /\
M"@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9
M /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@ GP#F *D
MXP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_ /\  P#_
M    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L [ !4 .@
M6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/ *( S0"N
M ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\   #_
M_P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!- -$ 50#.
M %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P N0"G +<
MM0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_    _@
M /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P 3@"Z %4
MMP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@ *4 K0"C
M +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\    [@   .
M  #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H $\ I0!5
M *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4 IP"3 +<
MD0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP   ,D   "]
M    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D E@!/ )0
M50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"% +$ @P#$
M ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'  "L P
MI@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!) (< 4 "&
M %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P =@"^ '4
MW0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">#@  EPL
M ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P 2P!Z %$
M>0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H
M!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0  BQ(  (80
M  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P"DP ;PI3
M &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -V !>#O,
M70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H  'L7  !X
M$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D 9A%/ &01
M5@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_
M %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>  !O&P
M;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+ %P94@!:
M&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<
M_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H(0  9AX
M &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@3P!3(%<
M42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&
M(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@  7R0  %TB
M! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,)E0 2R=<
M $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H_P! )_\
M0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@  %<G  !4
M)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$ 12Q: $0L
M9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_
M +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L  !/+0D
M3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ]
M,FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS
M  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !),08 1S(/
M $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV7P W-FL
M-C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2
M-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@, 03<- #\X
M%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV
M "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X  "..0
M?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+ #H\$0 X
M/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E
MA  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*/   >#T
M &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!#P R0A8
M,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q "-%@@ B
M194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P  =$   &=
M  !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K2!( *D@:
M "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*?P ;2I(
M&DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,  &-#  !8
M0P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A  (DX6 "%/
M'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  44(\ $U"D
M !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'  !51P
M34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81 !E6&  7
M5B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP #5>@  M7
MM@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !12@  2DH
M $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>$P 07AH
M#EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;  )>L0 "
M7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@  1TX  #Y/
M   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &9Q4 !6<<
M  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !FK   9<<
M &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,  #E5   P
M6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(  &\8  !P
M'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP  ;\$  &_G
M  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=   J80
M(F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3  ![&0
M?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H  'OB  !Z
M^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C:P  &F\
M !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "($P  B1D
M (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8  "(]P
MB/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>   $WT   V!
M   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@  F!(  )H8
M  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":\   F?\
M )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P   21
ME0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P  *H1  "M
M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@  K/P  *S_
M %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B    I@
M *H   "N    L    +$   "S    M    +8   "X    N@0  +P*  "^$
MP1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\
M  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R    MP   +L
M  "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2"   U0X
M -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T $Z+  !
MD@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R    ,X   #1
M    U    -4   #8    V@   -T   #?    X@   .0   #G    ZP4  .\.
M  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\ "P#_  @
M_P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_
M &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H \@"W .\
MR0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_    _P
M /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /< 7 #T &,
M\@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P -T P #:
M -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_    _P   /\
M  #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A %P W@!C
M -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0 MP#! ,P
MP #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P   /H   #R
M  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8 Q !< ,(
M80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N ,$ K0#@
M *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@   #<
MT  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5 *X 6P"L
M &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@ F@#0 )D
M[P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%    NP %
M +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P 50": %H
MF !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#% (@ Y@"'
M /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S    J@   *,
M"@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"* %0 B0!:
M (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H VP!X /4
M> #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP   )8 !0"1
M  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\ ? !5 'H
M6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L .X :P#_
M &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"  "%  D
M@0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0 &X 5@!M
M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D 8 #\ &
M_P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y"0$ > ,+
M '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$4@!C!5D
M8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5
M"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$   ;0T% &T)
M#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;#58 60U>
M %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0_P!-$/\
M31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0  &00" !B
M#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U, 41-; % 3
M90!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%%?\ 117_
M +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7 @!:%0T
M5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8 $@:8@!'
M&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C
M  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3' L 41P2
M $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@7P! (6H
M/R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_ *HF  "4
M)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@< 2B(0 $@B
M%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z)F< .29U
M #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I  "/*@
M?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<- $(H% !!
M*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K
M@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "++0  >2X
M &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL$0 [+1D
M.BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P "PP@  J
M,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',   =C$  &@R
M  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V,A8 -3(>
M #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U?@ E-9
M(S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0  &4T  !:
M-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q, +S<; "XW
M(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB
M !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W  !7-P
M3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8 "@]'P F
M/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP &#^@ !8_
MM0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3.@  2SH
M $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"&P @0R,
M'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2> !%$LP 0
M1-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0  2#T  $(]
M   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 821X %TDF
M !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*L  *2LH
M"TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14   #]    Y
M00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D $% A  ]0
M*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "4,4  T_H
M  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$   U10
M+D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<  =8)  &
M6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\   %;E  !6
M^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P2@  *4T
M ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@'P  8"<
M & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B  !>^0
M7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40  (U0  !Q7
M   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0  :B$  &HI
M  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H]P  9_\
M &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T  !9@   0
M9   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L  '8C  !W
M+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0  <_\  '+_
M &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L   *<
M!',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;  "%)
MAB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\  (#_ %];
M  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !?@   ($
M  "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5&P  ER8
M )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_ %UA  !/
M80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@   )(   "6
M    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P  J1P  *HH
M  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H  !(;
M.G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,   "G
MJ@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(  , <  #
M+0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  ! >0  ,G\
M "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y    O
M +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42  #6(0
MUS0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0  *Y   !V8
M   2H   "J<   "N    M    +D   "^    P@   ,@   #+    S@   ,\
M  #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O$P  \"4
M /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P % /\ "P#_
M !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0 _P!J /\
M< #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I .0 YP#Y
M .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\  @#_  L
M_P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C .P :0#J
M &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0 SP#R ,T
M_P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_  8 ^0 /
M /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0 8P#1 &@
MSP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H +@ _0"W
M /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $ Y  , -X
M$P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G
M +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *, ]0"C /\
MH@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP ' ,$ #P"\
M !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H HP!@ *$
M9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1 /\ D #_
M )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L # "G !(
MI  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !: (\ 7P"-
M &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D ?P#_ '\
M_P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5  X D@ 5
M )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\ 60!^ &
M? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_ '  _P!P
M /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L @P 1 ($
M& !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P %H ;P!B
M &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &, _P!C /\
M9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P . '4 $P!R
M !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8 8P!= &(
M90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_
M ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L $ !I !8
M9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7
M &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0
M  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A!!$ 7@,9
M %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )7P!."6D
M30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9
M%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T 5PP4 %4,
M' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U
M $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9  "2&P
M@1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0 $X1& !,
M$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4 /A5R #P5
M@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-'@  >R
M &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7%0!%%QP
M1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO #4;?@ S
M&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@  =R,  &DD
M  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _'1D /ATA
M #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@?  M(8X
M+"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8  &4G  !;
M)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8 ."(> #8C
M)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H)8P )B6?
M "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J  !7*@
M3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P
M*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH (2J= !\J
ML@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4+   3"P
M $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL'P J+28
M*2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^; !HOL  8
M+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P  22\  $,O
M   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E,B, )#(J
M ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0SK@ 3,\@
M$S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(  $ Q   [
M,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R  'C<G !TX
M+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK
M ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT   X-
M,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC !8]*P 5
M/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$ "CWD  L]
M^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U-P  ,#<
M "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$)P /1"\
M#D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@  -#]@ $
M0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@  +3L  "<]
M   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (2BL !THT
M  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)]0  2/\
M $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4   "-"   =
M10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428  %$O  !1
M.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0  3_\  $__
M &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(   72P
M$DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI  !:,P
M6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\  %?_ &5%
M  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   24P  #E8
M  I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D+0  9#@
M &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_ %]*  !3
M2@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70  "&    )C
M    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@  <3$  ' ^
M  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/  !03@
M2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L   !O
M<@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@  ( U  "
M10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.4P  0E0
M #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]    @
M (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L  "2.P
MDDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@  .UT  "]A
M   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".    D0   ),
M  "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F,0  ID,
M *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD  "=N   ;
M=0  $7P   N#    B0   (X   "3    F    )T   "A    I    *4   "G
M    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0  O#<  +M,
M  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_   3A@
M"XX   &5    FP   *$   "F    JP   +    "S    MP   +<   "Z
MO    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L  -1   #3
M6   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -F0   Z
M  "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-    SP
M -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS  #N2P
M[V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X _P 5 /\
M'@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W
M /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .( _P#; /\
MRP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0 /\ &0#_
M ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H Y !P .(
M=@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#% /\ NP#_
M +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X
M[  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$
M '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4
M_P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B
M ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X
MJ@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3
M /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !, L0 < *\
M)0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N
M )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\
M@@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8
M "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G ((
M;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_
M .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$
MA  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q
M ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(
M  "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V !P =  C
M ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T
M8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J
M 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8
M)0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S
M %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0
MC0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!;
M "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P
M?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q
M '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ",
M40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!"
M XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4
M  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E
M $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H
M. R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>
M&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.
M* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"<
M "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'
M41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z
M$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5
MK@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\
M $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@
M,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A
M&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A
M   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL
M "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\,
M&Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \
M(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C
M,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E
M !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@
M-28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @
M*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H
M^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@
M "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3,
M&"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .
M+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK
M   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y
M !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\
M"S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C
M,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX
M/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_
M ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P
M&S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %
M/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR
M  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H
M !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$
M $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8
M-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"
M   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)
M  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P
M23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (
M3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !4
M4@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\
M #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92    5
M %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3
M7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!
M   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;    7@   &
M  !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8
M &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L
M2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@   &P   !N
M    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB
M  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P
M'%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P   !]
M?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+
M;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4
M  UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".    D0
M ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90
MH($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[
M    @0   (<   "-    D@   )8   ":    G0   )\   "A    I    *8
M  "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78
M +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".
ME    )H   "@    I0   *H   "N    L0   +(   "U    MP   +H   "\
M    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*
M  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A    IP
M *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X   #2
MU0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #K
MF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O
M /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (
M\0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P
M /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L
M,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"
M -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\
MH0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C .4 +0#>
M #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D
M@0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_
M /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\
MNP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"?
M (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<
M  #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P
M )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L
MB0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7
M    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L
M,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_
M '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_
MK    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W
M #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8
MA@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP
M (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P
M9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7
M )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\
M  !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L
M %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H
M2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J
M"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %
M+0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8
M $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0
M6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!&
M "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@
MIP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q
M $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL
M/00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O
M!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3
M  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN
M #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L
M)0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _
M%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /
M,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@
M !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0
M.!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H
M$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5
M^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L
M #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0
M(AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4
M&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=
M   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ
M !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\
M$1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G
M(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C
M00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_
M '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P
M(",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0
M*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B
M  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<
M !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48
M"BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=
M)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L
M   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).
M  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@
M3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0
M,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X
M6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\
M #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$
M"CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5
M/F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR
M   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %
M  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\
M $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R
M-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(
M!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM
M  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P
M*3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\   !1!
M4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8
M?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X
M !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;    70(
M %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P
M9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*
M   03@  "E(   -6    6@   %T   !@    8P   &4   !G    :0   &L!
M  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL
M '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )
M6@   5\   !C    :    &L   !O    <@   '4   !W    >0   'L   !]
M    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@
M  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED    :0
M &\   !T    >    'P   "!    A    (<   "(    BP   (X   "0
MDP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9
MM0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T    >P   ($
M  "&    BP   )    "4    EP   )D   "<    GP   *$   "D    IP
M *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@
MKL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@   )4   ":
M    GP   *0   "H    K    *T   "P    LP   +4   "X    NP   +\
M  ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X
M ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@   "N
MM    +@   "]    P    ,(   #%    R    ,L   #.    T0   -8   #;
M    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4
M /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X
M_P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J
M )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\
M  #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !
M .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$
MQP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z
M    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L
M0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5
M *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O
MYP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N
M $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0
MFP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0
M +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D
MDP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^
M *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<
M  "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X
M 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H
M:@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")
M    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P
M-P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E
M %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y
M<0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!<
M #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X
MM !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K    9
M &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$
M3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !"
M ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!
M  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R
M $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\
M. #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)
M!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L
M-  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#>
M "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#
M/PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S
M #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "<
M\@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X
M #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0
M*P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?
M!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0
M   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ
M "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P
M& S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K
M$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X0
M0@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_
M '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0
M)A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7
M%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5
M  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<
M " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@
M$1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>
M&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:
M   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1
M  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0
M31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5
M'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B
M6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$
M $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A   2(P(
M$"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@
M)V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD
M   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'
M  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,
M "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R
M)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O
M"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R
M   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0
M*2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0
M-0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   X
MA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H
M "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH
M #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @
M/YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M
M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!   0P<  $4+
M  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<
M $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6
M-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0  $X'  !/
M"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N
M  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0
M#$$   =$    2    $H   !-    4    %,   !5    5P   %@"  !;!@
M70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<
MS   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL
M  !/    4P   %8   !9    7    %\   !A    8P   &4   !G 0  :@4
M &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0
M:?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=
M    80   &4   !H    :P   &X   !Q    <P   '4   !X    >P   'X#
M  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<
M 'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@   !M
M<0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@   )(   "5
M 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z
M #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "     A
M (H   ".    D@   )4   "7    F@   )T   "@    HP   *<   "K
MKP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5
M   D6P  &&$   YI   %<0   'D   "!    B    (\   "4    F@   )\
M  "D    J    *D   "L    KP   +,   "U    N0   +T   #!    Q@
M ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <
M:0  $7$   =[    A    (T   "5    G0   *,   "I    KP   +0   "Y
M    O    +X   #"    Q0   ,@   #,    T    -0   #:    WP   .0
M  #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_
M_P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^
M %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .
MM0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@
M /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D
MX@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[
M ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<
M  #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!(
M +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4
MH #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&
M    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$
M1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$
M (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8   "I
MH0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"(
M $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ',
MWP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3    B@
M (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X
M<@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A
M /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^    >    ',
M  !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \
M &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D
M4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P   &,   !@
M    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %(
M/ !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\
M $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8   !3
M40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!%
M #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L
M_P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)    1P
M $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@
M.@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R
M /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P
M P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [
M #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\
M*@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T
M @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D
M/P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_
M 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0,
M+08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B
M 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,
M  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP%
M "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0
M&@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?
M$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-
M!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/
M !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0
M3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <
M#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X0
M70 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4
M $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8
M%A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )
M%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8
M   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8(
M !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,
M AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R
M&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;
M"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR
M   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0
M*1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )
M'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   A
MA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX
M "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT
M B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P
M)9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?
M   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.
M   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH
M "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <
M(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q
M#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S
M   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P
M%"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*   Y#0
M.A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   W
MVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H
M  XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!"@  0PX
M $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@
M/_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT
M   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P  3 L  $X.
M  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@
M $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H   (]
M0    $0   !'    20   $P   !/    40   %,   !5 0  6 8  %H+  !=
M#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_
M #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)    3
M %    !3    5@   %D   !;    70   &    !B    90   &@%  !K"P
M;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y
M   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6    6@   %X
M  !B    90   &@   !K    ;0   '    !S    =@   'D   !]!   @0L
M (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L
M/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P   &\   !T
M    >    'L   !^    @    (,   "&    B@   (T   "1    E@,  )L,
M  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$   E2
M&DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0   ")
MC0   )$   "3    E@   )D   "=    H    *0   "H    K    +(#  "W
M#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL
M  IB    :@   ',   ![    @@   (D   ".    E    )H   "?    I
M *8   "I    K0   +    "S    MP   +L   #     Q0   ,L   #1!
MU0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T
M    ?0   (<   "0    EP   )X   "D    JP   +$   "V    N@   +P
M  #     Q    ,@   #+    SP   -0   #:    X    .8   #K    \08
M / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T
M  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /<
M6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V
M ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D   #I
M[  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3
M %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X
M_P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;    W
M -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\
ML@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ",
M /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\    M@   +
M 0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!-
M )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\
M<P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F    )0   "1
M  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X
M2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_
M &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P   !Z  $
M>  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H
M $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0
M_P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F    90 $
M &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $,
M5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!'
M /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7    50 ! %0
M!P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$
M $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\
M/@#_ )0   !_    ;P   &,   !9    40   $T   !*    2    $< ! !'
M  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P
M1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_
M (@   !T    90   %@   !/    2    $,    _    /0   #P  @ \  <
M.P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P
M $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\
M  !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R  4 ,@ )
M #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8
M)P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E
M!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D
M"P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !.
M !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"
M40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B
M 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@
M5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P
M $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L
M' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2
M V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/
M   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD,
M !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$
M#0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R
M$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,
M#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ
M  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@
M*!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .
M#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0
MA   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0
M "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T
M"Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@
M$IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5
M   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/
M  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6@   %ID
M !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9
M%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:
M$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS
M   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P
M%18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$
M(!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >
MVP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<"
M !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$
M "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@
M(OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;
M   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3
M   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L
M "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +
M(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T  #81   V
M%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__
M #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE   &*
M BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .  !!$@
M01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH
M   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M    ,    #,
M   V    .    #L    ^    0    $(   !% @  1P8  $H*  !-#@  314
M $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M
M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@   #T   !
M    0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9
M  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P   L+@
M)RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D   !,
M3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP  &P2  !K
M'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(
M !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;    7P
M &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-  ""%@
M@"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)
M   +10   DL   !1    5@   %L   !@    90   &D   !N    <@   '8
M  !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<#@  FQH
M )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "
M5    %L   !A    :    &X   !S    >0   'X   "#    B    (P   "/
M    D@   )4   "9    G0   *$   "E    J@   +    "W!P  N!$  +4A
M  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<    9
M &T   !U    ?    (,   ")    CP   )4   ";    H    *,   "F
MJ0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H  -86  #2
M*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N    =P   '\
M  "(    D    )@   "?    I0   *T   "S    N    +H   "^    P@
M ,8   #*    S@   -,   #:    X    .<   #M    \P   /0.  #R'@
M[S8  .Q1  #H;@  Y)   -^Q                       ! P0%!@@)"@L-
M#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&
M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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M________________________________________________
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M^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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MQVZLG\=NK)_';JR?QVZLG\?_GAX$_YTI"?^I,@[_MCH4^L)#'_#.2B[GW4]
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M;+2RO6RTLKW_FAL#_YDF"/^G+0K_M38/^<$_%^[.1B/DW$PRW>=/2<_H5E[
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M5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU39N@4
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
M&?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW
M[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?3
M8-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY &?^3
M22+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN
M>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?38-J'
MTV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY &?^322+_
ME54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NIL
MLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@VH?38-J'TV#:
MA]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_]],@S_B#<1_Y _&/^522+_EU0M
M_Y9?.?^3:T7_CG=1_XB"6_J$C&3U?Y1K\7J;<NYVHG?K<J=[Z6^M?^=LLH+E
M:KB$Y&F_A^)HQXG@9L^*UF/6C,]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8BL]B
MV(K/8MB*SV+8BL]BV(K_A!L#_X$G!_^ ,0S_BS81_Y,^&/^91R+_G%(M_YI=
M.O^8:4?_DW13_HY^7_>(B6GQ@I%R[7V8>>EXGW_E=*2$XW"JB.!ML(S>:[>/
MW6J_D=MIR)/59L^5RV31D\9EU([&9=2.QF74CL9EU([&9=2.QF74CL9EU([&
M9=2.QF74CL9EU([_A1L#_X(F!_^", S_CC40_Y8]&/^<1B'_H% M_Y];._^<
M9DC_F'%6^Y-\8O2-AFWNAXYWZ("5@.1ZG(?@=:*,W7*HD=IOKY78;;>9U6O
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M8E#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF+_HPL UK@& ,;$!P"[U D
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M?53#X7U4P^%]5,/A?53#X7U4P^%]5,/A?53#X7W_AQ,!_YP2 ?^N$0#:P@H
MT-(* ,?H& &\["P*LNL\%ZCJ0R6=Z$@SDN900(CD64M^XF!4=N%H7&_@;V)H
MWW=H8]Y_;%[>B'!:WI%S5]Z;=53>IW=2W[1X4-_$>$_@WGA/UN5U3]/G=$_3
MYW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW3_CP\!_Z0. -NX" #-Q0D Q=4*
M +KQ&@.P\BT,IO$[&)OP0221[T<OA^Y..G[N6$-W[6%*<.UI4&KL<55E['E9
M8>R!7%WLBE]:[)-A5^V=8U7MIV52[;-F4>[ 9T_OU&A.Z^9H3>CH:$WHZ&A-
MZ.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&C_F0L W:X$ ,R\!@#!R0< N-L* *WX
M' 2D^"\-F?@Y%X_X/R&%^$8J?/A-,G7W5SEN]V _:?=I0V3X<4=A^'E*7?B!
M3%KXB4]8^))15OF;4E/YI511^J]54/J[5D[ZRE=-^^-73/OI5TS[Z5=,^^E7
M3/OI5TS[Z5=,^^E73/OI5TS[Z5?EI0  SK0$ +^_!0"TS@8 JNL- :#_'P:7
M_R\-C/\V%8+_/1UX_T0D</],*FK_5"]E_UXS8?]G-UW_;SE:_W8\6/]^/E;_
MAC]3_XY!4?^70E#_H$-._ZE%3?^S14O_OD9*_]!'2?_<1TG_W$=)_]Q'2?_<
M1TG_W$=)_]Q'2?_<1TG_W$?1K@  O[D# ++% P"GU04 G/T/ I3_(@:)_RL,
M?O\R$G7_.AAL_T(=9?])(E__425:_UHH5_]C*U3_:RU2_W(O4/]Y,$__@#%-
M_X@R2_^0-$K_F#5(_Z$U1_^J-D;_LS=$_[\X1/_%.$3_Q3A$_\4X1/_%.$3_
MQ3A$_\4X1/_%.$3_Q3C!LP  LKX" *7, 0"9W0, D/\2 H;_'P5[_R<*<?\N
M#FC_-A-A_SX76O]&&E7_31U1_U4?3O]=($O_9"))_VLC1_]Q)$;_>"5$_W\F
M0_^&)T'_CBA _Y8H/_^>*3W_IRD\_[ J//^T*CS_M"H\_[0J//^T*CS_M"H\
M_[0J//^T*CS_M"JSN $ I<8  )?5  "+[P0!A/\3 G?_&@1M_R('9/\J"US_
M,@Y5_SD14/]!$TO_2!5(_T\71?]6&$+_7!E _V$:/O]G&CS_;1L[_W,<.?]Y
M'#C_@!TV_X@=-?^/'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?
M,O^D'S+_I!^FP   E\X  (G>  !__P<!=/\0 FG_%0-?_QP%5_\D"%#_+ I*
M_S,,1?\[#D'_00\]_T<0.O]-$3C_4A$V_U<2-/]<$S+_81,Q_V84+_]K%"[_
M<14M_W<5+/]]%2K_@Q8I_XL6*?^.%BG_CA8I_XX6*?^.%BG_CA8I_XX6*?^.
M%BG_CA;_9B #_V$J!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P;2G_;GPP
M_VN)-?]IECG_9Z$]_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US42O];WDO[
M6>1,]UCJ3/17[TWP5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3>Q5
M^$W_9B #_V$J!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P;2G_;GPP_VN)
M-?]IECG_9Z$]_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US42O];WDO[6>1,
M]UCJ3/17[TWP5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3>Q5^$W_
M9B #_V(J!?]C,0C_:S4+_W \#_]S117_=4\<_W9=(_]S;"K_<'HQ_VV'-O]K
ME#O_:9\__VBH0O]FL$7_9+A'_V/ 2?]AQTK_7\Q,_UW33?Q<WD[Y6N1/]5GJ
M4/%8[U'M5_11Z5?Y4.E7^5#I5_E0Z5?Y4.E7^5#I5_E0Z5?Y4.E7^5#_9Q\#
M_V,J!?]E, C_;C,+_W0Z#_]W0Q7_>4X<_WI:)/]W:"O_='8S_W&$.?]ND#__
M;)M#_VJE1_]HK4K_9[9,_V6^3O]CQ5#_8<M2_5_25/E=W57T6^16\%KJ5^M8
M\%CG6/57XUGZ5.-9^E3C6?I4XUGZ5.-9^E3C6?I4XUGZ5.-9^E3_:!\#_V,I
M!?]H+@?_<3(*_W<X#_][0A7_?4P<_WY8)/][9BW_=W,U_W2 //]QC$+_;Y='
M_VRA2_]JJD__:+)2_V>[5/]EQ%;^8LI8^6#16O5>W%SP7.1=ZEKK7N99\5_B
M6O5;W%OY5]Q;^5?<6_E7W%OY5]Q;^5?<6_E7W%OY5]Q;^5?_:1X#_V0I!?]K
M+0?_=# *_WLW#O]_017_@4H<_X)5)?]_8R[_>W V_WA\/O]UB47_<91+_V^>
M4/]LIE3_:JY8_6BW6_QFP%WZ9,E@]6'08O!>W&/J7.5EY5OL9MY:\&/86_1@
MT5WX6]%=^%O17?A;T5WX6]%=^%O17?A;T5WX6]%=^%O_:1X#_V4H!?]N*P?_
M>"X*_W\V#O^#/Q3_A4@<_X=3)?^$8"__@&PX_WQY0?]XA4G^=)!0^W&95OEN
MHEKX:ZI?]FBR8O1FNV7S9,5H\&+0:^I?W6WC7>=NVUOJ;=-<[VC-7O-DR%_W
M7\A?]U_(7_=?R%_W7\A?]U_(7_=?R%_W7\A?]U__:AX#_V8H!?]Q*0?_>RP)
M_X,U#?^'/A3_BD<;_XQ0)?^)72__A6DZ_8%U1/I\@$WW>(M5]'.57/%OG6+O
M;*5G[6FM:^MFMF_H8\!RYF',=>-@WW?67.1XSE[I<LE?[6W$8/!HOV+T8[]B
M]&._8O1COV+T8[]B]&._8O1COV+T8[]B]&/_:QT#_V<G!?]T)P;_?RL(_X<S
M#?^,/!/_CT4;_Y%.)?^/6C#\BV8[^(9Q1O.!?%'O?(=:[':08NAQF&GE;*!P
MX6BH==YDL'K;8KI^V&''?]1AVG_+7^%^Q&'E=[]BZ7*[8^UMMF3Q9[9D\6>V
M9/%GMF3Q9[9D\6>V9/%GMF3Q9[9D\6?_;!T#_VHF!?]W)@;_@BH(_XHR#/^0
M.Q+_DT,:_Y9,)/V55S#WD6(\\HQM2>R&>%3G?X%?XGB*:=QRDG+6;9IXTFJB
M?,YGJW_+9K2!R66_@\=DSH3!8]V#NF3B?+9FYG:R9^IQKFCO:JYH[VJN:.]J
MKFCO:JYH[VJN:.]JKFCO:JYH[VK_;1P#_VPD!?]Z) 7_A2D'_XXQ"_^4.1'_
MF$(9_YM*)/B;5##REU\]ZY)J2^6*<UC>@GQDU7R%;L]VC77*<I5ZQFZ=?L-L
MI8*_:J^$O6FYAKIHQX>W:-J'L6C>@:UIXWJI:^ATIFOL;:9L[6VF;.UMIFSM
M;:9L[6VF;.UMIFSM;:9L[6W_;1P#_VXC!/]](@7_B"@'_Y$P"O^8.!#_G$ 8
M^Y])(_2A4B_MG5P]Y99F3-V.;UK3AWAES(&!;L9[B7;!=Y%[O'.9@+APH82U
M;JJ'LFVTB:]LP8JM;-**J&S<A:5MX7ZB;N5WGV_K<)]OZW"?;^MPGV_K<)]O
MZW"?;^MPGV_K<)]OZW#_;AP#_W$B!/]_(07_BR<&_Y0O"?^;-P__H#\7^*1'
M(?"G3R[HHEH]WYMC3=24;%K+C'5EQ(9];[Z A7:X?(U\LWB5@:]UG86K<J6)
MJ'&OBZ5PNXRC<,N-H''9B)UQWX&;<N1ZF7/I<IESZ7*9<^ERF7/I<IESZ7*9
M<^ERF7/I<IESZ7+_;QL#_W,@!/^"( 3_CB8&_Y<N"/^?-@[]I#X5]*A&(.RL
M32WCIU@\V:!A3,V8:EG%D7)EO8MZ;K:%@G:P@(E]JWV1@J=YF8:C=Z**GW6K
MC9QTMXZ:=,:/F'76BY9VW8.4=N)\DW;G=))VZ'22=NATDG;H=))VZ'22=NAT
MDG;H=))VZ'3_;QL"_W4?!/^$'P3_D"4%_YHM"/^B-0SZJ#T4\:Q%'NBP3"O?
MJU<[TJ1?2\B<:%F_E6]DMX]W;K"*?W:JA89]I(&.@I]^EH>;>YZ+EWFHCI1X
MLX^2>,*0D7K5C8]ZVX6.>N%^C7KF=HUZYG:->N9VC7KF=HUZYG:->N9VC7KF
M=HUZYG;_<!L"_W8> _^&'@3_DR4%_YTL!_^E- OWJSP2[K%#'.6T2RG:KU4Z
MS:A>2L*@9EBYFFUDL9-U;JJ.?':CBH-]GH:+@IF"DX>4@)N+D'ZECHU]L)"*
M?;Z1BG_3CXE^VH>(?M]_AW[E=X=^Y7>'?N5WAW[E=X=^Y7>'?N5WAW[E=X=^
MY7?_<!L"_W@= _^('@/_E20$_Z K!O^H,@KTKSH1Z[5"&N&X2B?4LU,YR*M<
M2;ZD9%>TGFMCK)AR;:23>76>CH%\F(N(@I*'D(>-A9F+B8.BCH:"KI&#@KR1
M@H/.D8.#V8B"@M^!@H+D>8*"Y'B"@N1X@H+D>(*"Y'B"@N1X@H+D>(*"Y'C_
M<1H"_WH< _^*'0/_ER,$_Z(I!?RL,0GQLSD/Z+I %]V\2"7/ME(XPZ];2+FH
M8E:OHFIBIYQP;)^7=W68DWY\DI"&@HR-CH>'BI>+@XB@CG^'JY%\A[F1>X?+
MD7R(V(E]A]Z"?8;D>GV&Y'E]AN1Y?8;D>7V&Y'E]AN1Y?8;D>7V&Y'G_<1H"
M_WP: _^-' /_FB(#_Z4H!/FO+P?NN#<,Y+\_%-C 1B3*NE WO[-91[2L856J
MIFAAH:%N:YF<=722F'Q[C)6#@8:2BX:!D)2+?(Z>CGB-J9!VC+:1=(W(D7:.
MV(IWC-V"=XKC>G>*XWIWBN-Z=XKC>G>*XWIWBN-Z=XKC>G>*XWK_<AH"_W\9
M O^/&P+_G2 #_ZDF _:S+07JO34)X,8\$-+$1"/%O4\UNK=81J^Q7U2EJV9@
MG*9M:I2B<W.,GGIZAIN!@("8B85ZEI*)=92;C7*3IH]OD[20;93%D'"5V(IP
MDMV#<9#C>W&0XWMQD.-[<9#C>W&0XWMQD.-[<9#C>W&0XWO_<QD"_X(7 O^2
M&@+_H!\"_ZTD O*X*@3FPS$&V\PU#\S(0B' PDTTM+Q61*FV7E*?L61>EJQK
M:(ZI<7&&I7AX?Z)_?GF@AX-TG8^(;YR9BVN;I(UHF[*.9YO"CFF=V(IJF=V"
M:Y;C>VN6XWMKEN-[:Y;C>VN6XWMKEN-[:Y;C>VN6XWO_=!D"_X45 O^6& '_
MI!P!^[(@ >V_)0+AS"H#U-$R#<?,01^ZQTPQKL%40J.\7%"9MV)<D+-I9H>P
M;VZ K79U>:I]>W.HA(!MIHV%:*67B&6DHXIBI+"+8*3!BV*FV8ACHMZ!99[C
M>F6>XWIEGN-Z99[C>F6>XWIEGN-Z99[C>F6>XWK_=A@"_XD3 ?^:%@'_J1@!
M]K@; >?'&@';V1P!S=8P"\#2/QVTS4HOJ,A2/YW#6DV2OV%8B;MG8H"X;6MY
MMG1Q<K-[=VRQ@WQGL(R 8J^6@UZNH89<KJ^'6J^_AUNPVH1=K.!_7J?E>%ZG
MY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7C_>A4"_XX2 ?^?$P#_L!, [\ 0
M -G4# #.WQP!Q-TO";G9/1JMTT@LH<]0.Y7+6$F+QU]4@L1E7GG";&9RP')L
M:[YZ<F:]@G9ANXMZ7+N5?5FZH7]7NJ^ 5;N_@%6\V7]6N.-Z6++G=5BRYW18
MLN=T6++G=%BRYW18LN=T6++G=%BRYW3_@!(!_Y00 /^F#P#CN L TL8* ,S7
M"P##XQX"N>(Q"J_@/1BDW48GF=E.-XW45D2#T5U/>L]D6'+-:E]KRW)E9<IY
M:F#)@F];R8MR5\B6=53(HG=2R*]X4<G >%#*VW=1QNAS4L#K;U*_[&]2O^QO
M4K_L;U*_[&]2O^QO4K_L;U*_[&__APX!_YL- -^N!P#0O @ Q\D( ,';"P"W
MZ" #K><Q#:3F/1F9Y$0FCN),,X3@5#Y[WEQ'<]UC3VO<:E9EVG)<8-IZ8%O9
M@V17V8QG4]F7:E#9HVQ.V;%M3=K";4S;W&Q-V.QJ3L_P9T[/\&=.S_!G3L_P
M9T[/\&=.S_!G3L_P9T[/\&?_CPL Z:0$ -&T!@#%OP8 O,T( +3I#@&J[B(%
MHNXS#I?M.QF-[$(D@^M)+GOJ4S9SZ5P^;.ED1&?I;$EBZ'1-7NA\45KHA516
MZ(Y64^F865'IHUI.Z;!<3>J^7$SKTEU+ZNE=2N/S7$KC\UQ*X_-<2N/S7$KC
M\UQ*X_-<2N/S7$KC\USYF0, U*P" ,6W! "YPP4 L-(( *?V$0&>]20&E?4R
M#HKU.A>!]4$@>/5()W#U4"YJ]%HT9?1C.&#T:SQ=]70_6?5\0E?UA$14]8U&
M4?:72$_VH4I-]JQ+2_>Y3$KWR$U)^.!-2/?S34CW]$U(]_1-2/?T34CW]$U(
M]_1-2/?T34CW]$W:HP  Q[$" +B[ P"MR00 H]D' )K]% *2_2<'A_XO#7W^
M-Q1T_S\;;/]'(&;_3B5@_U<I7/]@+5G_:3!6_W$R4_]X-%'_@#9/_XDW3?^2
M.4O_G#I)_Z8[2/^Q/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^
M1/_G/D3_YS[+K   N;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H
M_SP58?]$&5O_2QU6_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_
ME"Q"_YXM0?^G+D#_L2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-
M,#[_S3"[L0  K+P  )_)  "3V0  B?P+ 8#_%P)V_R %;/\H"63_, U=_S@0
M5_] $U'_1Q9-_TX82O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^ 'SO_B" Z
M_Y$A./^;(C?_I"(V_ZTC-?^X(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_
MN2.MM@  G\0  )+2  "$X0  ??\- 7+_$P)H_QL$7_\C!EC_*PE1_S,+3/\Z
M#4?_00]#_T@10/].$CW_5!,[_UH4.?]?%#?_914U_VL6,_]R%C'_>A<O_X(7
M+O^+&"S_DQ@K_YP9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQFA
MOP  DLP  (3<  !X]P  ;O\* 6/_$ ):_Q4#4O\=!$O_) 9&_RP(0?\S"3S_
M.@HY_T +-?]%##+_2@TP_U -+O]4#BS_60XJ_UX/*/]D#R;_:@\E_W$0(_]X
M$"+_@!$@_X@1'_^1$1__D1$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1'_7"(#
M_U<M!?]8,P?_7S8)_V,]#?]E1A+_9E 7_V5>'/]D;B+_87PG_U^**_]>EB[_
M7*$Q_UNJ,_]:LC7_6;HV_UC#-_]8S3G_5]@Y_U;@.O]5YCO_5.P\_U/Q//Q2
M]3WX4OD]]5']/?-1_SWS4?\]\U'_/?-1_SWS4?\]\U'_/?-1_SW_7"(#_U<L
M!?]:,@?_834)_V4\#?]G11+_:$\7_VA<'?]F;2+_8WLH_V&(+/]?E"__7I\R
M_UVI-?];L3?_6KDX_UK!.O]9RSO_6-4\_U??/?]6YC[_5>L^_53P/_E3]3_V
M4OE \U+]0/!2_S[P4O\^\%+_/O!2_S[P4O\^\%+_/O!2_S[_72$#_U@L!?]<
M, ?_9#,)_V@Z#?]K0Q+_;$X7_VQ:'?]J:B3_9W@I_V2%+O]BD3+_89PV_U^F
M./]>KCK_7;8\_UR^/O];R#__6M)!_UG=0O]7Y4/]5NI$^57P1/54]47Q5/I%
M[E3^1.Q4_T+L5/]"[%3_0NQ4_T+L5/]"[%3_0NQ4_T+_7B$#_UDL!?]?+@;_
M9C()_VPX#/]O01'_;TP7_W%7'O]N9R7_:W4K_VB",/]ECC7_9)DY_V*C//]@
MJS[_7[-!_UZ[0O]=Q$3_7,Y&_UK<1_Y9Y$CZ5^I)]5;P2O!5]DKM5?I*Z5;^
M1^=6_T7G5O]%YU;_1>=6_T7G5O]%YU;_1>=6_T7_7B$#_UDK!?]B+0;_:C (
M_V\V#/]R0!'_=$H8_W55'O]R9";_;W(M_VQ_,_]IBSC_9I8\_V6@0/]CJ$/_
M8;!&_V"X2/]>P4K_7<M+_US:3?I:XT[U6>I/\%?Q4.M6]E'G5_M.Y%C_2^%9
M_TGA6?])X5G_2>%9_TGA6?])X5G_2>%9_TG_7R #_UHK!?]E*P;_;2X(_W,U
M#/]W/A'_>$@7_WE2'_]W8"?_=&XN_W![-?]MASO_:I)!_V>;1?]EI$G^8ZQ,
M_6&T3OM@O%'Z7L93^5W45?5;XU;O6NI8Z5CR6>59]U;@6OM3VUO_3]=;_TW7
M6_]-UUO_3==;_TW76_]-UUO_3==;_TW_8" #_UTI!?]H*0;_<2L'_W@S"_]\
M/!#_?487_WY0'_]]72C_>6HP_W5V./]Q@C_\;8U%^FJ72_AGGT_V9:=3]&*O
M5O-@N%GQ7\%<\%W-7NU<X&#H6NQAX5KR8-I;]EO37/I7SUW]4\Q>_U',7O]1
MS%[_4<Q>_U',7O]1S%[_4<Q>_U'_81\#_V G!/]K)@7_=2D'_WPQ"O^!.A#_
M@T07_X1-'_^#62C_?V8R_'IR._AU?D/U<8A+\FV24>]IFE;M9J);ZF.J7^A@
MLF/F7KQFY%S(:>%;VFO=6NIKTUSP9LU>]6'(7_E<Q&#\6,%A_E7!8?Y5P6'^
M5<%A_E7!8?Y5P6'^5<%A_E7_8A\#_V,E!/]O) 7_>2@&_X$P"O^%.0__B$(6
M_XE+'O^)5BCZA6(S]8!N/?!Z>4?L=8-0Z7",6.5KE5[A9IUDWF.D:=M@K6W7
M7[=OU%[#<-%>TG'-7>=QQU_N:\)A\F:^8O9ANF/Y7+=C_%BW8_Q8MV/\6+=C
M_%BW8_Q8MV/\6+=C_%C_8Q\#_V8C!/]R(@3_?2<&_X4N"?^*-P[_C4 5_X])
M'OJ/4RCTC%\T[H9J/^E_=$OC>'Y5WG*&7MAMCV73:IAJSV>@;<QEJ'#)8[%S
MQF*\=,1AR77!8>!VO&/J<;=D[VJT9?-EL&;V8*YG^5RN9_E<KF?Y7*YG^5RN
M9_E<KF?Y7*YG^5S_8QX#_V@A!/]U( 3_@24%_XDM"/^/-0S_DCX4_)1''?66
M3RCND5LTYXMF0>"$;T[9?7E8T7>"8,QSBF?';Y-LQ&R;<,!IHW.]9ZQVNF:V
M>+AEPGFV9=5YLF;F=JYH[&^J:?!IJ&GT8Z9J]U^F:O=?IFKW7Z9J]U^F:O=?
MIFKW7Z9J]U__9!X#_VL@ _]X'@3_A"0%_XTL!_^3- O_ESP2^)E%&_";32?H
MEUDTX9!B0M>);$[.@W58R'U^8<-XAFB^=(YMN7"6<K9NGG6R;*=XKVJQ>ZUI
MO7RJ:<U]J&KC>J5LZ7*B;.ULH&WR9IYN]6*>;O5BGF[U8IYN]6*>;O5BGF[U
M8IYN]6+_91T"_VT> _]['0/_AR,$_Y J!O^7,@K]G#L0])]#&>RA2R7CG%8S
MVI9@0<^.:4['B')8P()Z8;I]@FBU>8INL762<ZQRFG>I<*-ZIFZL?:-MN'ZA
M;<=_GV[@?IQPYW6:<.MOF7'P:)=Q\V27<?-DEW'S9)=Q\V27<?-DEW'S9)=Q
M\V3_91T"_V\= _]^' /_BB($_Y,I!?^;,0GYH#D/\*-!&.>F22/>H50QTII>
M0,B39TW C&]8N8=W8;."?VBN?8=NJ7J.<Z1WEGB@=)][G7.H?IIQM("8<<*!
MEG+8@95TY7B3=.IQDG7O:Y%U\F:1=?)FD77R9I%U\F:1=?)FD77R9I%U\F;_
M9AT"_W$; _^ &P/_C"$#_Y8H!?^>+PCVI#<-[*@_%>.K2"#8IE(PS)Y<0,.7
M94V[D6U7LXMT8:V&?&BG@H-NHGZ+=)U[DWB9>9Q\E7>E?Y)VL(&0=;Z"CG;1
M@HYXXWJ->.ASC'CM;(MX\6B+>/%HBWCQ:(MX\6B+>/%HBWCQ:(MX\6C_9QP"
M_W,: O^"&@+_CR #_YDF!/ZB+@;SJ#4+Z:T]$]^O1A[2J5$OQZ):/[Z;8TRU
ME6I7KH]R8*>+>6BAAX%NG(.(=)> D'B2?9E\CGRB@(MZK8*(>KN#AWK-@X=\
MXGR'?.=UAGSL;H9\\&F&?/!IAGSP:89\\&F&?/!IAGSP:89\\&G_9QP"_W49
M O^%&0+_DA\"_YPE _NE+ 7PK#0)YK([$-NS1!W-K4\NPZ99/KF?84NPF6A6
MJ)1P7Z&/=V>;BWYNEHB&<Y"%CGB,@I9\B("@@(1_JX*!?[B#?W_*A(&!X7V!
M@>9V@8#K;X" [VJ @.]J@(#O:H" [VJ @.]J@(#O:H" [VK_:!P"_W@7 O^'
M& +_E!T"_Y\C _BI*@3LL3$'XK<Y#=6W0AS)L$XMOJI7/;2C7TJKGF=5HYAN
M7YR4=6:6D'QMD(V#<XN*BWB&B)1\@8:>@'V$J()[A+6$>83'A'J&X'][A>9W
M>X7K<'N$[FM[A.YK>X3N:WN$[FM[A.YK>X3N:WN$[FO_:1L"_WH6 O^*%P+_
MEQP"_Z,A O2M)P/HM2X%WKTU"M"Z0!O$M$PLNJY6.Z^H7DFFHF54GIUL79>9
M<V:0E7ELBI*!<H60B7=_C9)\>XN;?W>*IH)TB;.#<HK$@W2,X']TB^5X=8GJ
M<7:([6QVB.UL=HCM;':([6QVB.UL=HCM;':([6S_:QH"_WT4 O^-%@'_FAH!
M_Z8> ?"Q(P+DNRD#V<(P"<N]/QG N$HJM;)4.JJL7$>AIV-2F:-J7)&?<62*
MFW=KA)A_<7Z6AG9YDX][=)*9?G"0I(%MD+&":Y#!@FV2W7]ND>5X;X_J<7".
M[6QPCNUL<([M;'".[6QPCNUL<([M;'".[6S_;A@"_X 2 ?^0%0'_GA<!^ZL:
M >RW'@'@PR$!TL8M",;!/1BZO$DHK[=2.*6R6D6<K6%1DZEH6HNE;V*$HG5I
M?I]\;WB=A'1SFXUY;IF6?&J8HG]GEZZ 99B_@669V']HF.5X:9;J<6J4[6QJ
ME.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0 ]; 4 .:^
M% #9S!4 S,HK!\#&.Q:UP4<FJKQ1-I^X6$.6LV!.C;!F6(6L;6!^JG-G=Z=Z
M;'*E@G)LHXMV:**4>62AH'Q@H*U]7Z&]?EZBU'UAH>9V8IWK<&.;[FQCF^YL
M8YON;&.;[FQCF^YL8YON;&.;[FS_=!,!_X<0 ?^8$ #^IQ  Y[<- -;%"P#0
MT!$ Q<\H!;G+.12NQT4CH\-/,YF_5T"/NUY+AKAD5'ZU:UQWLG%C<;!X:6NN
M@&UFK8ER8:N3=5VKGGA;JJQY6:N\>5BLTGE:J^AS7*?L;EVD[VI=I.]J7:3O
M:EVD[VI=I.]J7:3O:EVD[VK_>1$!_XP. /^>#0#<K@@ TKL) ,S("0#'U@X
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M)CK_KR8Y_[HG./_*)SC_W"@X_]PH./_<*#C_W"@X_]PH./_<*#C_W"BUKP
MI[H  )K&  "-U   @>8! 'K_$ %P_Q@"9_\A!5__*0=8_S$*4O\Y#4W_00])
M_T@11?]/$T+_511 _UP5/?]B%CO_:1<Y_W 8-_]Y&37_@ADS_XP:,O^7&S#_
MH1LO_ZH<+_^U'"[_OQPN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQRIM0  FL(
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M7VZ,]U]NC/=?;HSW7VZ,]U__;!,!_WT/ ?^-$ #_FQ  ]*@/ .6U#0#5OQ
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M1T7AS$=%X.A'1=_V1D7>_T1%WO]$1=[_1$7>_T1%WO]$1=[_1$7>_T39EP
MQZ8  +BP  "LN0$ HL4" )C1!@"/ZPT B>X? H#N*P9X[30,<.T]$VCM1AEB
M[4X>7>U7(UGM8"=5[6@J4NUQ+4_M>2],[8,R2NZ--$?NF#5%[J4W0^^S.$+P
MQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA [/\X0.S_.$#L_SC+H   NJL
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M%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,  !ZV@
M;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O] "#/_10@P
M_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^ #1[_C X=_Y<.'/^A#AO_
MK \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !KXP  7_8
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M O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X:3C.<W-
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M47Y]_U%^??]1?GW_47Y]_U'_8Q0!_W(/ ?^!$ #_C1$ _)@2 .RA$P#?JA8
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M64^NQEE/KN184:[V5%.N_U!4K/]-5*S_352L_TU4K/]-5*S_352L_TW_?0
MWX\  ,Z=  ##J ( N; " +"Z @"HQ 4 H<P/ )O,(P*2RC,*B<@_%8'&21]Y
MQ%(H<L):,&O!83=FOV@\8;YP05R]>$58O(%)5+R+3%&[ED].NZ-13+NS4DJ[
MQE)*N^113+OV3DVZ_TM.N?])3KG_24ZY_TE.N?])3KG_24ZY_TGOA0  U)4
M ,>C  "ZK $ L+0  *>_ P">R08 E=0+ )#5'0&)U"X&@-(\$'C01AEQST\A
M:LY8*63-7R]?S&<T6LMN.5;*=SU2RH! 3\F+0TS)ET5)R:1'1\FS2$;*R$A&
MRN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0  RYP  +VG
M  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-HW4T:8MQ5
M(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<R#Q"V^4[
M0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,  +*L  "G
MM0  G,   )'* P"'U@< @.D1 'GI( )RZ2P%:^DV"F3I/P]>Z4@46>E1&57H
M6AQ1Z6(@3NEK(TOI="5(Z7TG1NF(*D/IDRM!ZJ M0.JO+C[KP"X][-LN/>KO
M+CWH_"X]Y_\M/>?_+3WG_RT]Y_\M/>?_+3WG_RW%GP  M:D  *BQ  "<O
MD,<  (32 0!ZWP8 =/03 &WT( )F]"H$7_0T"%KU/0M4]44/3_5,$DSU511)
M]ET71O9E&$3V;AI!]G<</_>!'3WWC1\[]YD@.?BF(3CXM2(W^<@B-OGC(C;X
M\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@  J:X  )RY  "0Q   @\\
M '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*_T *1O](#$/_3PY _U8/
M/?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__J1<N_[<8+?_(&"S_X1@L
M_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S   ==D  &GD
M  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V_TX),_]4
M"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_P1 A_] 0
M(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(  %OQ  !4
M_P8 3O\. $C_% %"_QP"/?\D CG_*P,U_S($,?\X!"[_/@4K_T,%*/])!B7_
M3P8C_U8'(?]=!Q[_90@<_V\(&?]Z"1?_APD6_Y0)%?^?"A3_J@H4_[,*%/^S
M"A3_LPH4_[,*%/^S"A3_LPJ3NP  A,<  '73  !GX0  6.@  $[[  !(_P
M0?\* #O_$ $V_Q4!,?\< 2W_(@(I_R@")?\M B+_,@,?_S@#'/\] QK_0@,7
M_T@$%?].!!/_5001_UT%#_]G!0W_<@4,_WT%"O^)!@K_DP8)_YP&"?^<!@G_
MG 8)_YP&"?^<!@G_G ;_/RH"_S\P _]$, /_2#,$_TDY!O](0@C_1DT+_T5;
M#O]#:1'_07<3_T"%%?\_D1;_/IL8_SZD&/\]JQG_/;,:_SVZ&O\]PQK_/,P;
M_SS;&_\\YQO_// ;_SSX&_\]_QO_/?\;_SW_&_\]_QK_/?\9_SW_&?\]_QG_
M/?\9_SW_&?\]_QG_0"H"_T$N _]'+@/_2C$$_TPW!O]+0 C_2DL+_TA9#_]&
M9Q'_1'44_T."%O]"CQC_09D9_T&B&O] J1O_0+$;_S^X'/\_P!S_/\D=_S_6
M'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y _QO^0/\;
M_D#_&_Y _QO_0"H"_T,L _])+ /_32\$_T\U!O]0/@C_3DD,_TQ6#_]*9!+_
M2'(5_T=_&/]&BQG_198;_T2?'/]$IQW_0ZX>_T.U'_]"O1__0L8@_T+1(/]"
MXB'_0NTA_T+U(?]"_2']0O\A^T/_(/I#_Q_Y0_\>^4/_'OE#_Q[Y0_\>^4/_
M'OE#_Q[_02D"_T8J _],*0/_42P$_U,R!O]4/ C_5$<,_U%2#_]/8!/_36\7
M_TQ\&?]*B!S_29(>_TB;'_]'HR'_1ZLB_T:R(_]&NB/_1L,D_T7-)?]%WB7_
M1>HF_$7T)OE%_";V1?\F]4;_)/1&_R/S1_\A\T?_(?-'_R'S1_\A\T?_(?-'
M_R'_0B@"_TDG O]0)@/_52@$_U@O!?]:.0C_6D0,_U=/$/]57!3_4VH8_U%W
M&_]/@Q__3HXA_TV7(_],GR7_2Z<F_TJN)_]*MBG^2;XJ_4G)*OI(V2OW2.<L
M]$CR+/%(^RSO2?\J[4K_*.Q*_R?K2_\EZTS_)>M,_R7K3/\EZTS_)>M,_R7_
M0R@"_TTD O]4(P/_6B4#_UXL!?]@-@?_8$$+_UY,$/];5Q7_6689_U=R'O]5
M?B+^4XDE_%&3*/I0FRKY3Z,L]TZJ+O9-LB_T3+HP\TS$,O)+T3/N2^0TZDKP
M-.=+^C/E3?\PY$[_+>)/_ROA4/\IX5#_*>%0_RGA4/\IX5#_*>%0_RG_1B4"
M_U A O]8( +_7R$#_V0J!/]F,P?_9CT+_V5($/]B4Q7_8&$;_%UM(/A:>27U
M6(0I\U:-+?!4EC#N4IXS[5&E->M0K3?I3K4YYTZ_.^9-S#SC3. ]WTWN/-Q/
M^3G94?\UUE+_,M13_S#35/\MTU7_+=-5_RW35?\MTU7_+=-5_RW_2B,"_U0>
M O]<' +_9!\"_VDG!/]L, ;_;3H*_VQ$#_UJ3Q7X9UP<\V-H(N]@="CK77XN
MZ%J(,^57D3?C59DZX%.@/MY2J$#<4;%!V5"[0M90R$/34-Q$SU#L0\Q2^#_+
M5?\[R5?_-\A8_S3'6?\RQEG_,<99_S'&6?\QQEG_,<99_S'_32 "_U<; O]@
M&0+_:1T"_V\E _]R+07_=#<(_7-!#O9Q2Q3P;E@<ZFID).5E;BO@87DSW%Z"
M.-A<BSS36I0_T%B<0LY7HT3+5:Q&R56U1\=4P$G%5-!)PE/F2<!6]46^6?]
MO5O_/+Q<_SF[7?\UNEW_-;I=_S6Z7?\UNEW_-;I=_S7_4!X"_UL9 ?]D%@'_
M;1L"_W0B O]X*@3_>C,']GH]#.]X1Q/G=50;X7!?)=IK:BW39W0TSF1].LIA
MAC_'7XY"Q%V61<%;GDB_6J9*O%FO3+I8NDVX6,A.MEC?3K19\$NS7/U%LE__
M0+)@_SRP8?\YL&'_.+!A_SBP8?\XL&'_.+!A_SC_4AL!_UX6 ?]H% '_<AD!
M_WD? O]^)P/Y@# %\($Y"N> 0Q'@?% :UG=;),]R9B[);6\UQ&IX.\!G@4"\
M9(E$N6*12+9@F4JS7Z%-L5VJ3ZY<M%&L7,%2JES44JA=ZU"H8/I)J&/_1*AD
M_T"F9?\\IF7_.Z9E_SNF9?\[IF7_.Z9E_SO_51D!_V$4 ?]L$@'_=A<!_WT<
M ?^#(P+TABP$ZH@U!^&'0 [6@DP9S7U8),9W8BW <VLUNV]T/+=L?$&S:81&
MKV>,2:QEE$RI8YQ/IF*E4:1AKU.B8+Q5H&#-59Y@YE2>9/=-GV?_1Y]I_T.>
M:?\_G6G_/9UI_SV=:?\]G6G_/9UI_SW_5Q<!_V,2 ?]O$0'_>10!_X$9 ?N'
M( 'OC"<"Y(XP!=J-/0S/ATH8QX)5([]]7RVY>&@ULW1P/*]Q>$*K;H!&IVR(
M2J1ID$Z@:)A1G6:A4YMEJU689+A7EF3(6)1DX5B5:/10EFO_2I=L_T66;?]!
MEFW_0)9M_T"6;?] EFW_0)9M_T#_614!_V80 ?]R$ #_?1( _X46 /:,&P'J
MD2(!WY0K ].1.@O)C$<7P(=3(KF"7"RR?64UK7EM/*AU=4*C<WU'H'"$2YQN
MC$Z9;)52E6N>5))IJ%>0:;19CFC#68QHW%J-;/)3CV[_3)!P_T>/<?]#CW'_
M08]Q_T&/<?]!CW'_08]Q_T'_6Q0!_V@/ /]U#P#_@!$ _XD3 /*0%P#EEAP
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M65^-PUI>C>!88H_U4F20_TUFD/](9H__1V:/_T=FC_]'9H__1V:/_T?_; @
M_GP  -Z*  #0E@( R)\$ ,"G! "YK@, LK(4 *JQ* .AKS<,F:Q#%Y&H32&)
MI54J@J-<,GR@8SEWGFH^<IQQ1&V:>4AHF8%,9)>+4&"6E5-=EJ)56I6P5UF5
MP5=8E=Y66Y;S4%V7_TQ?E_]'8);_1F"6_T9@EO]&8);_1F"6_T;_< , ZX$
M -:/  #*F@$ P:,# +FJ @"QL@$ JK<1 *.W) *;M30*D[) %(JO2AZ#K5,G
M?*M:+G:H835PIV@[:Z5O0&>C=T1BHG](7J&)3%J@E$]7GZ!15)^N4U.?P%-2
MG]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0  X(8  ,^3
M  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\M5 B=;-8
M*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJP$U-JMQ-
M3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP  ,B9  "]
MHP  LJL  *FR  "@NP( E\0) )+%&P"+Q"P$@\(Z#'O!1!5TOTX=;KU6)&B\
M72ICNV0P7[IL-%JY=#E6N'P\4[>'/T^WDD),MI]$2K:M1DBVP$9(M]U%2;;R
M0TJU_T%+M?\^2[3_/4NT_SU+M/\]2[3_/4NT_SWB@P  S9(  ,&?  "TIP
MJJ\  *"X  "6P , C,H' (;-% "!S28">LPU"'/+00]LRDH79LE3'6'(6R-<
MQV(H6,9J+%3&<C!0Q7PS3<6&-DK$DCE'Q)\[1<2N/$3%P3Q#Q=\\1,3S.T3#
M_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "KK   H+0
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M&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5  !EW@
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M_Q#_-BT"_SLL O] + /_0R\#_T,U!/]"/@;_0$H(_SY7"_\\90W_.G,/_SB
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M4&YWQ%!M=^!/<'GU2')[_T-T?/\^=7W_.W5]_SMU??\[=7W_.W5]_SO_80H
M_V\" .A\  #9A@$ SXX$ ,B5!@##F@8 NYP6 +.<*@.JF3D+HI5%%)N13AV4
MCE<FCHM?+8F(9C.$AFTX@(1T/7N">T%W@(1%='^-2'!]ETMM?*-.:GRP3VA\
MP5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO@?\\;X'_/&^!_SS_9 @ _W(
M .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@)P*EG38)G9I#$Y:731R/DU4D
MB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+1VJ#E4IG@J%-9(*N3V*"OT]A
M@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0 ]G8  -R"
M  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*F5,BA)=;
M*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)O4Y<B=9-
M7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH  -6&  #)
MD0  P)D! +B? 0"PI0  J*D. **I(0&:J#$&DZ4^#XNC2!B$H%$@?IY9)WB<
M8"USFF<R;YAN-VJ6=3QFE7T_8I2'0U^2D49;DIU)69&K2E>1NTM6D=-+5Y+O
M1UJ2_4)<D_\^79/_.UV3_SM=D_\[79/_.UV3_SO_;@  X'X  ,Z+  #$E0
MNIT  +&C  "IJ0  H:X+ )NO'0&4KBX$C*P[#(6J1A5^J$X<>*96(W*D72IM
MHF0O::%K-&2?<SA@GGL\7)V%/UF<CT)5FYQ%4YNJ1U&;ND=0F]%'49ON1%.;
M_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=   V8,  ,B0  "^F@  LZ$
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M+4&\_RU!O/\M0;S_+4&\_RW.B@  OY@  +&@  "FJ   F[   )"X  "%OP
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M"B#\_ JBIP  E;$  (>[  !YQ@  ;,\  %_9  !2WP  2.@  $/_"  __Q
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M$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:298PYCV25/(QCGSZ)8JI
MAV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I_RV':?\MAVG_+8=I_RW_
M5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4: +Z$+0.V@3P)KWU($JAY
M4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZB&B2/(5GG#^"9J=!@&:T
M0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!;/\O@6S_+X%L_R__60L
M_V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'*P*QA3H(JH%&$:-^4!B=
M>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR//7]KF4!\:J5">6JQ1'=J
MPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_6P@ _V8
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M0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_80  ZF\  -EZ  #,A
MPXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"02!2*CE$;A(M9(7^)8"=[
MAV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI0V!^N41??L]$8'_L0&*
M_#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9   Y7(  --^  #'AP  OH\
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M,%*6_S!2EO\P4I;_,%*6_S#F<@  T(   ,*,  "XE@  K9P  *.A  "9I@
MCJT  (BN$0"#KB(!?:TQ!'>L/0IRJD<0;*E/%F>H5QMCIUX?7Z9E)%ND;2=8
MI'4K5*-_+E&BB3%.H98T2Z&D-DFAM#9(H<@W2*#G-4F@^3)*G_\P2Y__+DN?
M_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@  IJ   )RF  "1K   AK(
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M'#;$_QR^D0  L)L  *2C  "8J@  C+(  ("Y  !TP   :,<  %W-!0!3TPH
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M!![YF@4<^:L%&_K !1KZW@4:^?(%&O?]!1GV_P49]O\%&?;_!1GV_P6>I@
MD:\  (.Y  !UP@  9\L  %K3  !-V@  0M\  #CE   U^P< ,?\/ "[_%@ K
M_Q\ *?\F "7_+0 C_S0 (/\[ 1[_0P$;_TL!&?]3 1;_70(4_VH"$O]X A'_
MB (0_YH"$/^K P[_O@,._]4##O_M P[_\ ,.__ ##O_P P[_\ .3K@  A+@
M ';"  !GS   6M4  $S<   _X0  ->8  "WT   J_P( )O\+ "/_$0 @_Q<
M'?\= !G_(P 6_RD %/\O !+_-0 0_ST #O]% 0S_3@$*_U@!!_]E 07_= $#
M_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP  =\$  &C,
M  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P  &_\% !?_#  4_Q  $?\4
M  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0  _T<  /]2  #_7@  _VT
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M,Y-5RC.15>4SD5?W+9%9_RF16O\ED5O_(Y%;_R&16_\AD5O_(9%;_R'_3PL
M_U<" /]A @#J: $ WFT$ -AP" #5< L RW(; ,)Q+@*Z;ST&M&Q)#:YI5!.I
M9UT9I&1E':%B;2&=870EFE]\*)A>@RN578LMDEN4,)!;GC*-6J@TBUFU-8I9
MQC:(6>$VB%ST,(A=_RN)7O\HB5__)8E?_R.)7_\CB5__(XE?_R/_40D _UH
M /5D  #@;   UW$# -!T!@#-=0D Q'87 +QV*@&T=#H%KG%&#*=N41*B:UH8
MGFEB'9IG:2&697$EDV1X*)!B@"N-88@NBV"1,8A?FC.&7J4U@UZR-X)>PC>
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M-G1I_3!U:O\L=FO_*7=K_R=W:_\G=VO_)W=K_R?_5P  ]F,  -]M  #1=0
MR'L  ,%_ @"[@ , M($0 *R"(P&E@3($GGX_"9A[2A"2>5,6C79;&XET8B"%
M<FDD@7%P)WYO=RM[;G\N>&V(,75LDC1S:YXW<&JJ.6YJN3IM:LXZ;6OK-V]M
M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60  ZV4  -MP  #->   Q'X
M +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.?5$5B7M9&H1Y8!^ =V<C
M?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AOMSIG;\LZ9W#I-VEQ^C)K
M<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P  P((  +B&
M  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[?&4B>'ML
M)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V^3)E=O\N
M9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4  +2*  "L
MC   HXX* )V.&@"7CBL"D(PX!HJ*0PR$ATP2?X55&'J$7!UV@F,A<X!J)6]_
M<2EL?GDL:'V"+V5\C#)B>Y@U7WJD-UUZLSA<>L<Y7'KE-UY[^#)?>_\N8'S_
M*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  # @P  MXD  *^.  "FD0
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M)$>:_R34=P  PH0  +:/  "KE@  H9P  ):@  "+I0  ?ZH  '2N!0!OKQ0
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M$C7#JQ,SP\ 3,\/@$S/!]1,RP/\4,K__%#&^_Q0QOO\4,;[_%#&^_Q2XD
MJYD  )^@  "3IP  AZX  'NT  !NNP  8\   %C% 0!-R@4 1,\, $/0%P!"
MT"4 0- R #_1/0$]T4<!.]%0 CG260,VTF,$--)N!3+2>@<PTH@(+M*8"2W3
MJ0DLT[X*+-/?"2O1\PHJS_X+*<[_#"G-_PTIS?\-*<W_#2G-_PVNF   HI\
M ):F  ")K@  ?+8  &^]  !CPP  5\@  $S-  !"T@, .=D) #7?$  TWQL
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M 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_  !CR0
M5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3 !'_&0 /
M_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT  /^0  #_
MHP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0  <[\  &3)  !6TP  1]L
M #K@   NY0  (^D  !KM   5_0  $O\  !#_ @ ._PD "_\-  C_$  $_Q,
M ?\8  #_'@  _R0  /\K  #_,P  _ST  /])  #_5@  _V8  /]X  #_B@
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M';!#V1ZM0^T=JT7\&JE%_QBH1O\6J$;_%:='_Q.G1_\3IT?_$Z='_Q/_1 X
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M*8-8_B2#6?\@A%K_'H1:_QR$6O\<A%K_'(1:_QS_3@$ _U<  .5?  #89@
MSFH  ,=L P##:P4 O&P2 +1M)0"M;#4#IVI"!Z%G30R<9581F&->%91B91B1
M8&P;CE]T'HQ>>R&)78,DAER,)H1;E2B!6J J?UJL+'U:NRU\6L\N>UOL*WQ<
M_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4   ]5D  .%C  #2:@  R6X
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M(FQJ_R!L:O\@;&K_(&QJ_R#_5P  Y&(  -)L  #&<P  O7@  +5[  "M?
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M(%=\_R#E9   SW   ,%Z  "V@P  K8D  *.,  "9C@  C8\  (:0#@"!D1T
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M($.7J"%"E[HB09?3(D&6[R!"E?X>0I7_'4.4_QQ#E/\<0Y3_'$.4_QS,=0
MO($  +&,  "FD@  FY<  )&;  "%GP  >:,  &JG  !EIPX 8Z@< &"H*P%=
MJ#8"6:= !%:G2093IE$)4*99#$VE8 Y*I6D11Z1R%$2D?19"HXD8/Z.7&CVC
MIQL\H[D<.Z/2&SNB[QL[H/X:.Y__&3R?_Q@\G_\8/)__&#R?_QC$?   MHD
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M!"7+[@0DR?P&(\C_!R/'_P<CQ_\'(\?_!R/'_P>IE@  GIT  )*C  "%JP
M>+(  &NX  !?O@  4L(  $?&   ]R@  -,\$ "O4"0 FV0\ )=D9 "7:)0 D
MVC  (]L[ "/;10 BW%  (=U; "#=:  >WG8 '=Z' 1S?F0$:WZP!&=_$ 1C>
MYP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G   E*,  (>K  !YLP  ;+H
M %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >Z X '>@5 !OI'@ 9Z2<
M&.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#NB@ .[YX #O"S  WPS0 ,
M[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO   7\0  %+*
M  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0^!X #ODE
M  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\M0  _-$
M /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT  $32   W
MV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0 !/\:  '_
M(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP  _[,  /_'
M  #_Y0  _^4  /_E  #_Y0!_M   <+T  &''  !3T   0]8  #;=   JX@
M'^8  !;J   0[0  #/H   G_   &_P   O\$  #_"0  _PT  /\0  #_%
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M!M4KYP;0*_4'S2S_!\LL_P?)+/\'R"S_!\<L_P;'+/\&QRS_!L<L_P;_-1(
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M%YE%_Q681O\3F$;_$9A&_Q"71O\0ET;_$)=&_Q#_0@4 _T<  /=/  #E4P
MW54! -=5!@#54@L RU,9 ,-4*P"\5#L!ME)(!+%14@>M4%P*J4YD#:9-; ^D
M3'01H4M[$Y]*@A6=2HH7FTF3&)E)G!J72*8;E4BR')1(P1V22-@=D$GO&X]*
M_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10  _TL  .E3  #>6   TUL
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M&7=9_Q=W6?\6=UG_%G=9_Q;_3   Z58  -E?  #+90  P6@  +II  "T:
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M&6)H_QGL5P  V6(  ,=K  "\<@  LW<  *IY  "A>0  EW<! )!X$0"+>"$
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M(5%WIB)0=[<C3W?.(T]W["%0=_T>47?_&U)W_QE2=_\94G?_&5)W_QG>8@
MR&X  +MW  "P?P  IX0  )V'  "2AP  A(<  'V'"0!XB!8 =(@F '"(,@)L
MAST$:(9&!F6%3@EAA54,7H1<#UN#8Q)9@FL55H%T%U. ?AI0@(D<3G^6'DQ_
MI2!*?[8A27_,(4E^ZQ]*?OP<2W[_&DM^_QE,?O\83'[_&$Q^_QC59P  PW,
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M$S>=Z!(VF_H2-IK_$C:9_Q$WF?\1-YG_$3>9_Q&^>P  L8<  *6/  ";E
MD)@  (2<  !WH   :Z0  %^G  !2J@  3:L. $NK&@!*JR< 2*LS $:K/0%$
MJT8!0JM. D"K5@,^JU\%.ZMH!CFJ<P@WJH )-*J/"S*JGPPQJK ,,*K'##"I
MYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA   JHX  )Z4  "4F0  AYX
M 'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]MAX .[8I #JW-  YMSX
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M !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]  !.P0
M0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,
MY3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y  #G
M_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!R@  -<X
M "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R(@  \BH
M /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E  #T]@
M]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP  *-@  ![=
M   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@  _!X  /PF
M  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_V   _^0
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M ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /T
M_P#_'R, _Q\A /\>(0#_&2, _Q,I /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S
M ?\#?0'_ X<!_P./ /\"E@#_ IP _P*B /\"J #_ J\ _P&V /\!O@#_ <D
M_P'; /\ Z@#\ /8 ^ #_ /<"_P#W _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_
M(A\ _R(< /\A' #_'A\ _Q@D /\5+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+
M>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4
M /<*YP#S"O0 \ K_ .\+_P#N#/\ [0S_ >T,_P'M#/\![0S_ >T,_P'_)1L
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M!K@L_P:V+/\%M2S_!;0L_P6T+/\%M"S_!;0L_P7_- P _S8% /\Y P#_/ @
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M#HA&_PV(1O\-B$;_#8A&_PW_0   \D<  .-/  #44P  RU4  ,14  # 4 0
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M$6Q8_Q'Q2P  WU8  ,Q>  # 9   MV<  *YH  "G9@  GV(& )AC% "29"0
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M&EUBIAQ;8K8=6F+,'5IBZAQ;8_P87&/_%EQC_Q1=8_\376/_$UUC_Q/F50
MSU\  ,%H  "V;@  K'(  *1T  ":<P  CF\  (=O#0"";QL ?7 I 'EO-0%U
M;C\#<FU(!6YL4 =K;%<*:6M>#&9J90YD:6P186EU$U]H?Q9<:(H86F>6&EAG
MI!Q69[0=56?*'55GZ!M69_L85V?_%E=H_Q189_\36&?_$UAG_Q/A6   RV,
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M&$1ZY!A%>?@61GG_%$9X_Q)'>/\11WC_$4=X_Q'-90  O7   +%Y  "G@
MG(0  )*&  "&A@  =X8  &N&  !FAPT 8X<9 &"()P!>B#,!6X@\ EB'10-6
MATT$4X94!E"&6PA.A6,*2X1L#$F$=@]&@X$11(./$T*#G11 @JX5/X/"%3Z"
MXA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P  MW8  *Q_  "BA0  EXD
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M!RF@_P@IG_\(*9__""F?_PBQ@@  I8L  )J1  "0E@  @YH  ':?  !JH@
M7J8  %*I  !&JP  /*T  #6O#  SL!4 ,K A #&P*P OL#4 +K$^ "VQ2  L
ML5$ *[%; "FQ9P$GL70!)K&# 22QE (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M
M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G   >J(  &VG  !@JP  5:\
M $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  AO2H (+TS !^^/0 >OD<
M';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4
MNO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M   2K<  #ZZ
M   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .S3H #LU&
M  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+_P )R_\
M"<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L   #+#   H
MQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX  =LY  #<
M10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@  W_\  -__
M  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,   =T
M%-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K  #I-@
MZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8  /#V  #P
M]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2W   #.
M  7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T)P  ]S,
M /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?  #_WP!W
ML   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@   .D   #L
M    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0  _R,  /\O
M  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_N@#_%B,
M_Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_
M (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,< _P#6 /\
MYP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_&B  _QD>
M /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (,
M_P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W
M /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P _QP9 /\9
M&0#_%!L _P[_XO_B24-#7U!23T9)3$4 " DA /\,+ #_"3D _P5& /\"4P#_
M %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4
MM0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_
M .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H
M_PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#J
M!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\ W S_ -P,
M_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\$%4 ^ ]@
M /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.KP#@#K@
MW@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_ <H2_P'_
M)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\ ZA=: .86
M90#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP TA>C - 7JP#.&+4 S!C!
M ,L8T@#'&N@!PQOX < ;_P&^'/\!O1S_ KP<_P*\&_\"O!O_ KP;_P+_*PP
M_RL% /\K P#_+0D _RP. /\I%0#W)B  [B,M .<A.@#A'T@ VQ]4 -4@7P#1
M(&@ SB!Q ,PA>0#*(8$!R"&( <8ACP'$(98!PR&> <$BI@&_(J\!O2*[ KPC
MR@*Y(^,"M23T K,D_P.Q)/\#KR3_ Z\D_P.N)/\#KB3_ ZXD_P/_+P8 _R\
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M"X\Z]PJ-.O\)C#O_"(P[_P>,._\'C#O_!XP[_P?_.   \3X  .-%  #420
MRTH  ,5'  #!000 NC\1 +-!(0"M0C$ J$,^ *1#20&@0E,"G4%; YM!8@28
M0&H%ED!Q!I0_> >2/W\(D#^("H\^D0N-/IL,BSZF#8D^LPV(/L0.AC_@#H0_
M] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/   ZT,  -Q*  #,3P  PU
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M#FQ/_PQL3_\+;$__"VQ/_PON10  W%   ,E7  "]7   M%X  *Q>  "D6P
MG%8$ )56$@"05R$ BU@O (=7.P&#5D0"?U9- WQ55 5Z5%L&=U1B"'53: ES
M4W +<5)X#6]2@@]M48T1:U&9$FE1IA1G4;859E'+%652Z11E4OL19E/_#V93
M_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P  L&(  *AB  "?7P  EEH
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M#5=>_PW>4P  R%T  +MD  "P:@  IFT  )UN  "3;0  A6<  'YG"0!X9Q4
M=&<C '%H+P!N9SD!:V=" FAF2@-E9E(%8V58!F!E7PA>9&<*7&1O#%IC>0Y8
M8X0056*1$E-BGQ-28JX546+"%5!BX1518O8246+_$%)B_PY28O\-4F+_#5)B
M_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0  ?VL  'AK!0!R:Q( ;FP?
M &ML+ !H;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9:64)5VEM"U5I=PU3:((/
M4&B/$4YGG1--9ZP42VC %$MHWA1+9_423&?_#TQG_PY-9_\-36?_#4UG_PW2
M6@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\ :'$< &9R
M* !C<C0 8'(] 5YR10);<4T#67%4!5=P6P94<&,(4F]K"E!O= Q-;H .2VZ-
M$$ENFQ%';:L21FZ^$T5NW!)&;?011FW_#T=M_PY';/\-1VS_#4=L_PW,7P
MO&D  +!Q  "E=P  G'L  )%\  "&>P  =7@  &MW  !E=PP 87@7 %]X) !=
M>3  6GDZ 5AY0@)6>$H"4WA1!%%W6 5/=V '3'9H"$IV<@I(=7T,176*#D-U
MF0]"=:D00'6\$$!UV1! =/,/0'3_#D%S_PU!<_\,07/_#$%S_PS&9   MVX
M *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %> ( !5@"L
M4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ("SU]EPP\
M?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0  LG0  *=\
M  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-B28 2XDP
M $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'E0DUAZ8*
M-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H  **"  "7
MAP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\ 09,J $"3
M-  _DST /9-% #N330$ZDU8!.)-? C:3:0,TDW4#,I*#!#"2DP4NDJ0&+9*W
M!BR2T08LD>\&*X__!BN._P8KC?\'*XW_!RN-_P>S>   IX(  )R(  "1C
MAY   'J3  !ME0  89<  %69  !)FP  /YP! #F=#@ WG1< -IXB #2>+  S
MGC4 ,IX^ #&>1P PGU  +I]: "V?9 $KGW$!*9Y_ B>>D (FGJ$"))ZU B.>
MS@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0  H(@  )6.  "+D@  ?Y8
M '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 IJ0\ **D8 ">J(@ FJBP
M):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VKBP ;JYT &JNQ !FKR@ 9
MJNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0  =9X  &BB
M  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7MR$ %K<J
M !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VYQ  -N.<
M#K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8  %ZK  !2
MKP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14 "<4>  C%
M*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@  QM(  ,7O
M  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T  !&N
M.KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6  #1'@
MTB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\  -;@  #6
M\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   YP0  +<0
M "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?%   X1P
M .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%  #IX@
MZ?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@  (,X  !;2
M   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0  [1$  .\8
M  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #ZP@  ^MH
M /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H   W?   %
MXP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D  /H.  #]
M$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP  _[D  /^\
M  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P /\ N #_
M ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\ ^@#_ /H
M_P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L M #Y +T
M^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_ /  _P#_
M%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P +@ [@##
M .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4 _P#_&A,
M_Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B /H ; #U
M '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0 X@"_ .
MS0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_'A  _QP-
M /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$9@#J!&\
MY@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[ - &R0#.
M!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P _R & /\<
M P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=#6D V0UQ
M -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00R #"$-\
MOA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,  /\C  #_
M) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6, R!9K ,46
M<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D MQFT +4:P@"T&M8 L!OM
M :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_*   _R<  /XJ  #O*@
MYR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@4P"\(5T N2%E +<B;0"U
M(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O :<CO &F),X!HR3H J E
M^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+   _RT  .TR  #B-   VC,
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M!GP[_P5\._\%?#O_!7P[_P7T-P  Y4   -)'  #%2@  O$L  +5)  "O0P
MJ3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M 60*)0& #AT!G X4_;02#
M/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-"G4_Z@IT0/P(=$#_!W1
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M"&!._PCC1P  S5   +Y7  "S6P  JET  *%=  "86@  C5,  (92# " 4Q@
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M"U19F@U26:H.45F\#E!9V Y06?(-45G_"U%9_PI16?\)45G_"%%9_PC440
MPEH  +1A  "J9@  H&@  )=I  ",9P  ?6   '5? P!O7Q  :U\< &A@* !F
M8#, 8V \ 6%@1 %?7TP"7%]3 UM?6@197V$%5UYI!E5><PA37GX)45V*"T]=
MF0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)3%W_"$Q=_PC/5   OEX
M +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I9 X 9609 &)D)0!@93
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M"CMPS0HZ;^P).V[^"#MN_P@[;?\'.VW_!SMM_P>_8@  L6L  *9S  "=>0
MDGL  (=\  ![?   ;7H  &!X  !6=P$ 4'<. $YX& !,>"0 2WDN $EY-P!(
M>4  1GE( 41Y3P%">5<"07E@ C]X:0,\>'0$.GB"!3AXD08W>*$'-7BS!S1X
MRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:   K7$  *)Y  "8?@  C8
M (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#@1X 0H(I $&",@! @CL
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M 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5  !AF
M59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M !ND-@ :
MI#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.( $:+X !&A
M_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8H0  3*0
M $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ*P -L34
M#;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O  6O_@ &
MKO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP  0:T  #6O
M   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@  OBL  +XV
M  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]]@  O?\
M +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8  "JX   @
MNP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(  ,LK  #-
M-0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP  SO@  ,[^
M  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["   5Q@
M#LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?  #>*
MX#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H  .7S  #E
M\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,T0  !-4
M  #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M&@  [R0
M /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??  #WWP!P
MK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP   .(   #E
M    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$   _!8  /\A
M  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_OP#_#1P
M_PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M /\ =P#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T _P#) /X
MW0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_$!D _PT7
M /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\ <@#_ 'L
M_P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@## /0 T@#S
M .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0 _P\2 /\+
M$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[ '8 ^0!]
M /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@ RP#G .$
MY0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$. /\-#0#_
M!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '  [0!X .L
M?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6 -D U #L
M -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/!0#_#@L
M_PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R -X >0#;
M (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -  Q0#H ,,
M]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_$P4 _Q$-
M /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%<P#*!7H
MR 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE +4+]P"S
M#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@  ]18% /81
M#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]#G0 NP][
M +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4]P"E%?\
MHQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$  -P9!0#;
M$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X K!EU *L9
M? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4 GAS? )H=\P&8'O\!EQ[_
M 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:+P  SRT  ,HG  #''P@
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M VTZ_P/J.0  U4(  ,1(  "Y2P  KTL  *=)  "?1   F#X! )$\$ ",/1T
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M!EY'F@=<1ZD(6TB["%I(U A:2/$'6DG_!EI)_P5:2/\%6DC_!%I(_P3;1
MQDT  +A3  "M5P  HUD  )I8  "15   ADX  'U+" !W2Q( <TP? '!,*P!M
M3#4 :TP^ &A,1@!F3$T!9$Q3 6),6@)A3&("7TQJ UY,<P1<2WX%6DN*!EA+
MF =73*<(5DRY"55,T0E43.\(5$W_!E5,_P953/\%54S_!55,_P752   PE$
M +57  "J6P  H%P  )=<  "-60  @5,  '=/! !Q3Q  ;E < &I0* !H4#(
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M"$99R@A%6>H(1EG]!D98_P9&6/\%1UC_!4=8_P7'4@  N%L  *MA  "A9@
MF&@  (YI  "#9P  <F   &A>  !A70D 7%T3 %I='@!772D 5EXS %1>.P!2
M7D, 45Y* 4]>4@%.7ED"3%YA DI>:@-(7G4$1EZ"!41=D 9#7J '05ZQ!T!>
MR = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@  M%\  *AF  ">:@  E6T
M (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!28R4 4&,O $YD. !-9$
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M RYP_P,N;_\#+F__ RYO_P.S9@  IV\  )UV  "3>@  B'P  'Y]  !R?0
M9'P  %=[  !,>@  0GD# #QY#@ Z>A< .7HA #AZ*@ W>S, -GL[ #1[1  S
M>TP ,GM5 #![7P O>VH!+7MW 2M[AP$J>Y@"*'NJ B=[OP(F>^$")GKW B9X
M_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P  A((  'B#  !LA   7X0
M %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  LA2T *X4U "J%/@ IA4<
M*(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&O $>AMX 'H3U 1Z"_P$>
M@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP  6(P  $R-
M  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >D4  '9%)
M !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2._P 4C?\
M%(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4  $67   Y
MF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC< $9Y! !">
M3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +FO\ "YG_
M  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@   PH0
M)J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX  *J1  !
MJE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\  *?_  "G
M_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   FJP  ':T
M !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X.0  N$8
M +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_  "V_P"/
MD@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@  $[@   V[
M   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@  R#H  ,E'
M  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(_0"%F0
M=Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,   /'
MR@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT  -TY  #>
M20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !YH0  :Z@
M %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3    V0
M -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK  #P.@
M\4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@  7K$  %"Y
M  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B    Y@   .D
M  #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_*0  _SH
M /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7 /\ %P#_
M !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L _P"# /\
MB@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\ .H ^P#X
M /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\ $P#_ !0
M_P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^ /\ A0#^
M (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q ., [P#S .X
M_P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_ !  _P 6
M /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0 ?P#S (8
M\0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M -\ ^P#>
M /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P _P 2 /\
M'0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E (  XP"&
M .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P ]@#* /\
MR@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P . /\ %@#W
M "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H T "  ,X
MAP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[ /X N0#_
M +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!$ #H !H
MXP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z +\ @0"]
M (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L JP7_ *H&
M_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #= Q( U ,@
M ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(>P"O"((
MK@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_ )P/_P";
M#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L QPL6 , -
M)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B$7T H1&%
M )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7_P".%_\
MCA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0 +(5'@"M
M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W< E!M_ )(<
MB "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H A"#_ 8,@_P&#(/\!@B#_
M 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P)0  K!T, *8>& "A("8
MG"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD:P"))'( B"1Z (8D@P"$
M)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_ 7@H_P%X*/\!>"C_ 7@H
M_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P  H2@' )LG$P"6*"  D2DM
M (XJ. "+*T( B"M* (8K4@"$*U@ @BQ? ( L9@!_+&T ?2QU 'LL?@%Z+(@!
M>"R4 78MH %U+:X"="W  G(NW0)Q+O0"<"__ F\O_P)O+_\!;B__ 6XO_P'H
M,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP B# H (0Q
M,P"!,CT ?S)& 'TR30![,E0 >3); '<R80!U,FD!=#)P 7(R>0%P,X0!;S.0
M FTSG0)L,ZL":C2\ FDTU0-H-?$"9S7_ F<U_P)F-?\"9C7_ F8T_P+B-@
MS#\  +U$  "R1P  J$<  *!$  "8/P  D#D  (@T#0"#-1< ?S8D 'PW+P!Y
M-SD =SA" '0X20!R.%  <3A7 &\X7@!M.&4!;#AM 6HX=0%H.( "9SB, F4X
MF0-D.:@#8CFY V$ZT -@.NX#8#K_ U\Z_P)?.O\"7SK_ E\Z_P+=.P  QT,
M +E)  "N2P  I$P  )M*  "210  B3\  ($Z"0![.A0 =SL@ '0\*P!R/#4
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M!$]'QP1.1^<$3D?[!$Y'_P-.1_\#3T?_ T]'_P/,1@  NTX  *]4  "D5P
MFE@  )%7  "&5   >TX  '!*  !I2 T 94@6 &))(0!?22L 74DT %M)/ !9
M24, 5TE* %9)4@!52ED!5$IA 5)*:@%12G4"3TJ! TY*CP-,2Y\$2TNP!$I+
MQ01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20  N%$  *Q7  "A6P  F%P
M (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:32@ 6$TQ %9-.@!434$
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M SI8_P,[5_\#.U?_ SM7_P.\5   KEP  *-C  "99P  D&D  (5I  !Y9P
M:V(  &!@  !570  3EL, $M;% !)7!\ 1UPH $9=,0!%73D 0UU! $)=2 !!
M7E  0%Y8 #Y>80$\7FP!.UYX CE>AP(W7I<"-EZI S5>O0,T7]T#-%[U S5=
M_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;   C&X  (%N  !V;   9VD
M %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^8S4 /60] #QD10 [9$T
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M 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^  !#?@
M.'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W]( !Y_4@ =
M?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\ %GO_ !=[
M_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \B   ,H@
M "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*3  2BU@
M$8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_  Z&_P"?
M>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@  *I(  "&3
M   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (EU  !I=>
M  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2_P"8@@
MCH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT  !F>   2
MH   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@  *16  "D
M90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1B@  B8X
M 'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J   ,K
M!:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),  "R6P
MLFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D   ?Y4  '&:
M  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "N    +L
M  "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##3P  PV
M ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT  &6C  !7
MJ   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0   ,<   #(
M    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800  V%,  -EF
M  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL  !+L@
M/+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4   #6
MV0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,  .Y6  #O
M:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^O   +\
M "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F    Z
M .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&  #_6@
M_W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !< _P = /\
M* #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_ (L _P"1
M /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@ _P#W /\
M]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7 /\ ) #_
M #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8 ^@", /D
MD@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J /\ Z0#_
M .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\ 'P#_ "P
M_P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"' .P C0#J
M ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\ UP#_ -4
M_P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[ "8 ]P T
M /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P AP#: (T
MU@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_ ,, _P##
M /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\ Z@ M .8
M.@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#& (< Q ".
M ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +( _P"R /\
ML0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E -, ,@#.
M #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($ M "( +(
MD "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B /\ H@#_
M *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0 *@"_ #<
MNP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"# *0 BP"B
M )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\ E G_ )0)
M_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R!BX K@@Z
M *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,A@"6#)
ME R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_ (<1_P#V
M&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R< H1 S )T1
M/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")%(L AQ26
M (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O(0
MW2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM )$:. ".
M&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88 ?!Z1 'H>
MG@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H*   TC
M ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B,@"#(SP
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M 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2.   P$   +-%  "H2
MGD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT)0!I-2\ 9S4W &4V/P!C
M-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>" 5@XCP%6.)X!53BO E0Y
MPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/   O$0  *])  "D3   FDP
M )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C.BL 8#HT %XZ/ !=.D,
M6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\C0%0/9P!3SVL DX^P0)-
M/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4   EU$  (Y/
M  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7/D  53]&
M %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"O@)(0MX"
M2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50  (M3  "
M4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT 3T)# $]#
M2P!.0U( 341: $M$8P!*1&X!245Z 4=%B %&19@"14:I D1&O0)#1MP"0T;U
M D-&_P)#1O\!0T7_ 4-%_P'!1P  LD\  *94  "<5P  DE@  (A8  !^50
M<4\  &9*  !<1@4 5T8/ %1&& !11B( 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!%26P 1$EX 4))A@%!298!0$JG C]*NP(^2]@"/DKS CY*
M_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P  D%T  (9<  ![60  ;5,
M &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'2S@ 1DP_ $5,1@!$3$X
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M 2Y6_P&R5P  I5\  )ME  "1:0  AVH  'QJ  !Q:   8V4  %AB  !-7P
M0UT" #Q;#0 Z7!0 .%P= #=<)@ U72X -%TV #-=/@ R748 ,5Y. #!>5P O
M7F( +5YN "Q??0 J7XX *5^@ "A?LP$G7\P )U_M 2=>_P$G7?\!*%W_ 2A<
M_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)9P  /V4
M #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE5  G95\
M)F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_ 2%C_P&I
M8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P  .FX  #!M
M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >;EL '6YG
M !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK_P"D:0
MFG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@  "MW   B
M=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8 $WAC !)X
M<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?<0  E7@
M (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"   <@@
M%(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=  F#;  (
M@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0  D'X  (:#
M  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5C@  #X\#
M  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/90  CW8
M (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4  (*)  !T
MC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@  "IL   *<
M"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7   G6X  )R!
M  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0  !JE
M7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@   "I!
MJ0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,  *QW  "K
MC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?G   4:
M $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U    M0,
M +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK  "]@0
MO9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0  1JH  #BM
M   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"    PP   ,0
M  #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2<P  THL
M -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,  "JV   =
MN0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@   -0   #6
M    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9   ZGP  .N5
M  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W    1Q
M"<@   #,    SP   -,   #9    W0   .    #A    XP   .4   #G
MZ@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH  /^#  #_
MFP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_ #0 _P!!
M /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\ DP#_ )D
M_P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I
M /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X _P \ /\
M2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V )0 ] ";
M /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@ /\
MV0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V /\ 0@#[
M $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X Y0"5 .,
MG #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_
M ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /  / #M $<
MZ0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/ ,T E@#+
M )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\ O #_ +P
M_P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#; $$ U@!+
M -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P D "Z )@
MN "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_ *L _P#_
M!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H PP!$ ,
M30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I )( IP"<
M *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L _P#_!P
M]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ] +  1@"M
M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T F0"7 )<
MH@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(
M -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *( /P"@ $@
MG0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62 (H&G@"(
M!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@
M  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3#$$ D Q)
M (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@
M>Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J  "X
M*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL A!-# ((4
M2P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT
M &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P,P
MIS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U
M'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z  92"P &0A
MQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J.0  H3@
M )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@
M:2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M %LHP0!;
M*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P  G#\  ),\
M  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C*4, 82I*
M & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3+MP
M4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0  (]!  "%
M/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O
M30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I< 3C*H $TSNP!---@ 3#3S
M $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">20  E4D  (M'  "!0@
M=ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1
M-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X
M_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30  DDT  (A+  !^1P  <T(
M &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/.#D 33A  $PX1P!+.$X
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M 3A#_P"W20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,  !32
M2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/ #I'6  Y
M1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(
M_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !03@  1DH%
M $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,5@ S3&
M,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P
M4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50  0U$! #M/
M#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M4ET +%)I
M "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1_P"L50
MH%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@  #56"  Q
M51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H )5AG "18
M=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H6@  G6(
M )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%> P J70T
M*%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;
M8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8   F6@  )!N
M  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C9@@ 'V8/
M !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H;@ 2:'\
M$6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\  (QS  ""
M=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0  %G * !-P
M$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-
M  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y  !^?
M='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$  Q\#  *
M?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0  'R'  ![
MG   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y@P  ;(0
M %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)"@ !B0\
M (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!  "'E0
MAZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0  8XL  %:-
M  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@  E@P  )40
M  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5C@  E:0
M )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690  $R7   _
MF0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<  *,,  "C
M$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA   I9L  *2S
M  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@   SH@
M)J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %  "Q"P
ML@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY   +:I  "V
MP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   FJP  &JT
M !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #  @  P0@
M ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<  #+M0
MS,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0  $+@   >[
M    O@   ,$   #$    R    ,L   #+    S0   ,X   #0    T@   -4#
M  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #FI0  YKP
M .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0   #'
MRP   ,\   #4    V    -P   #=    WP   .$   #C    Y0   .@   #J
M    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0  _*H  /R[
M  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\ 20#_ %0
M_P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@"; /T HP#[
M *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\ W #_ -8
M_P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_ $\ _P!9
M /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M *4
M[ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_
M  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D \P!3 /
M7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#< )\ V0"I
M -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X _P#_
M_P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!- .  5@#<
M %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D Q "C ,$
MK0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_    _P
M /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H 3P#' %<
MQ !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"< *\ IP"M
M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_    _    /$
M  #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U %  LP!7
M +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\ H0"= *T
MF@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5
M!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H HP!1 *$
M5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP". *< C "V
M (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2  #%$0
MO0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!* ), 40"1
M %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *, ?@"Q 'T
MQ ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z'   L1D
M *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&2P"$!E$
M@@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO '$+P0!P
M#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@  J"0  * >
M  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X#DL =PY1
M '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82P !E$M\
M9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T  )@H  "0
M(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48 ;!5, &H6
M4P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS
M %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q  ")*P
M@24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?
M'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=( 4B+Q %(C
M_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#,@  >BT
M '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$
M52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+
M*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0  =3,  &PM
M  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5
M $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N_P!$+O\
M12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D  &<T  !>
M+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N
M6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_
M #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y  !:-
M4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 !
M,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV
M_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6.0  334)
M $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [.&
M.CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T
M0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P  2#H& $0Y
M#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V/%T -3UI
M #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P
MI$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 # #\^#0 \
M/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L ,$%G "Y"
M=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N2@  H5$
M )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#"@ V0Q$
M-$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D "E'<@ H
M1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P  GU4  )1:
M  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P20X +DD5
M "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,<  A3(
M($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(
M8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P )T\2 "90
M&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :4WT &5.0
M !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E  "%:
M>VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<. !Y7%  =
M5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH $EJ- !%:
MH0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  "";0  >&X
M &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@$  48!<
M$V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)  IAG0 )
M8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P  =74  &IT
M  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -:A( #&H9
M  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !JF   :JT
M &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L  &-[  !6
M>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\  '85  !V
M'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP  =*@  '/
M  !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"  !.@@
M08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1  ""%P
M@AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(  '^Z  !_
MW0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%BP  .8P
M "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/$@  D!@
M ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS  "-T
MC/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0  +I8  "*6
M   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0  GA$  )X7
M  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=Q@  G>D
M )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\  !>@   .
MH@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P  *T0  "N
M%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@  K]T  *_R
M  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK   %K@
M +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)  "^#@
MP!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@  ,7E  #%
M\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W    N@   +T
M  #     Q    ,8   #&    R    ,D   #+    S    ,X   #0!@  TPT
M -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/  #AY@!@
MH0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP   ,H   #/
M    TP   -8   #7    V@   -P   #?    X0   .,   #F    Z0$  .P+
M  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #XR0#_  T
M_P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9 /\ 8@#_
M &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *< ]P"Q /8
MO@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_  < _P $
M /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L 70#Y &0
M]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K .8 M@#D
M ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_    _P   /\
M  #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I %X Y@!E
M .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\ KP#- +X
MRP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P   /\   #^
M    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@ T !? ,X
M90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y +8 MP#(
M +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H   #Q
MZ  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X
M &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X I0"^ *(
MV "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A    U@
M ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D 6 "G %X
MI@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V )( R@"0
M .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0  Q    +T
M @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8 %@ E@!=
M )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (, P0"! .
M@ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L  *\#  "I
M  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$ B !7 (8
M70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T -0 <@#P
M '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0  "="@
MEP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1 'D 5P!X
M %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L &8(
M_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2%   C X!
M (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*4@!L"E@
M:@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;
M$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P  @A@  'L1
M!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A$%, 7Q%:
M %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5_P!2%O\
M4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$  '(:  !K
M$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6 %47
M7@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_
M $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC  !D' <
M7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+
M'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B
M_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>) ( 5R -
M %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C5P!$(V
M0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X
M-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@  424+ $TE
M$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^*%T /2EI
M #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U.@
MIT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L' $<I#P!%
M*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N
M<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0
M )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N#0 _+A,
M/2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D #$R<0 P
M,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00  HD@  )=,
M  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y,Q$ -S,8
M #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW;P K-W\
M*CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL  )1/  "+
M4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \ ,C@5 #$X
M'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/
M ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3  ")5@
M?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3 "L]&@ J
M/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H 'D&- !U"
MH  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&6P  ?5P
M ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#%@ D0QX
M(T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>* !='G@ 6
M1[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8   >F$  '!@
M  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =2AH '$HA
M !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-G  03;$
M#D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8  &UF  !C
M9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8 %%(= !-2
M)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )5*T "%3%
M  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML  !?:@
M4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8  U;(  ,
M6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@  %O   !:
MX@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9<   3&X
M $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D&P "9",
M &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[  !BW0
M8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@  1G4  #ET
M   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P  ;Q\  &\F
M  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !LU@  :_(
M &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX  #)^   F
M?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D  'PA  !\
M*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@  =^\  ';^
M  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'   =AP
M%(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:  "*(@
MBBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H  (7[  "$
M_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4D@  #9,
M  24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9&@  F2(
M )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W  "5_P"
MB0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@   Y\   "A
M    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0  J1D  *LC
M  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I^P!UCP
M9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L   "N
ML0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ   +T8  "_
M)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!JEP  6YP
M $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\    OP
M ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/  #5&
MV"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP  3Z4  $"J
M   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+    S@   -$
M  #1    U    -8   #9    VP   -X   #@    Y    .<&  #K#@  [QD
M / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P & /\ !P#_
M  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L /\
M<@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q ,L \ #H
M .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\   #_  0
M_P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F /  ; #O
M '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$ W0#= -L
M] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_    _P +
M /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X 9@#< &P
MV@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#- ,, ZP#
M /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y    \@ & .L
M#P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K
M ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X X "L /<
MJP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0   -8 # #/
M !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\ L !E *X
M:@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@": .X F0#_
M )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0 !@"]  \
MMP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!> )T 9 ";
M &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") ., B #Y (8
M_P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N  L J  2
M *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T 70"+ &,
MB@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R '@ _P!W
M /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4 FP . )8
M%0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!] %T >P!C
M 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H _ !J /\
M:@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  ) (H $ "%
M !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %< ;@!> &T
M90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_
M %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$"P!Y !(
M=0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19 &$$8 !?
M!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+
M_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N"0T :0@4
M &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5#60
M5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_
M)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0< 7PX0 %P/
M%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K
M $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P
MJS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1
M%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT 0QAG $$8
M= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U,   J#8
M )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9$ !*&A<
M2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y
M'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-   I#H  )D^
M  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#'Q0 01\;
M #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C;@ S)'X
M,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX  )9"  ",
M0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$ .R08 #DD
M'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L +"F-
M "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&  "*1P
M@$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5 #,H'  R
M*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D )RV+ "8N
MG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(2P  ?DP
M '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM&0 M+2
M*RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?
M,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P  ?%   '-/
M  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H,AX )C(D
M "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LWFP :-Z\
M&3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0  '%3  !F
M4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L (3@B " X
M*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4/*T $SW&
M !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8  !D5@
M6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX> !H^)0 9
M/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P #D+$  Y"
MYP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B6P  5E<
M $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%(@ 212D
M$44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^  A'X  )
M1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80  4UX  $=:
M   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -324 #$TN
M  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-VP !3?(
M 4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0  $)A   W
M7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(  U4J  )5
M-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U   5/$  %/]
M  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH   R9@
M)V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F  !?+P
M7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\  %O]  !;
M_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K;P  (&X
M !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I*@  :30
M &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\  !D_P"+
M<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0  &7@  !%W
M   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P  =BX  '4Z
M  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P_P"&>0
M?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,   J#   "
M@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8  (0R  "$
M/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""@   >H0
M &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/    D0
M )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H  "4-@
ME$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP  <(H  &&-
M  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<    G@   *
M  "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F*@  ICH
M *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$  %:5  !'
MF0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K    *X   "N
M    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@  N2X  +I
M  "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>   [H@
M+*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P   "\
MO@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2   -$R  #2
M1@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   OK   'Z\
M !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,    S@
M -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD  #M.
M[DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D _P / /\
M& #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y
M /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H ^ #I /\
MYP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P , /\ % #_
M "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T Z !S .<
M>0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0 /\ S@#_
M ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /< $ #S !H
M[P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L ,\ <@#-
M '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L N #_ +<
M_P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#? !4 V@ @
M -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H ; "X '(
MM@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_ *, _P"A
M /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$ P@ : +X
M) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E &L I !Q
M *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$ _P"0 /\
MC0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5 *P '@"H
M "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J )
M<0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_ /\ ?P#_
M 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P & "8 "(
ME0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D ($ :P!_
M ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\ < #_ '
M_P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"* !L AP D
M (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '( 9 !P &T
M;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0
M#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4 >@ > '8
M)0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q
M &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&%@
MMAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H
M "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L %4
M=P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_'0  L"(
M *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"&0!= R$
M6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG $L(<P!)
M"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL
M  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3"QL 40LB
M $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.< ! #G\
M/P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0
M,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8 2! = $80
M) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y$WP -Q2-
M #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W  ",.
M@C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09 #\4(  ]
M%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D ,!F* "\:
MG0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*/   @#P
M '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V&B,
M-1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ( "D?FP H
M'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00  ?4   '0^
M  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P'B  +QXF
M "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",CF0 B)*T
M(23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0  ')#  !G
M/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT *2(C "@C
M*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =**L &RG#
M !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'  !F1
M6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A ",H)P B
M*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D %BW! !8M
MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D20  6$0
M $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =+2P
M'"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2
M,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@  5DD  $U&
M  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q
M !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TWW0 --O8
M#C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\  $Q,  !"
M20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y
M-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (//  "3O_
M  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2   ^3@
M-$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K  M -  *
M0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X  4'\  )
M_P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z5   +U$
M "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(,0 "2#L
M $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[  !'_P"2
M6@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P  *ED  "!7
M   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@  4#@  %!#
M  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-_P"/80
MAF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$  !I?   2
M7@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,  %D_  !9
M3   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",:   @FT
M 'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H   -9P
M!V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z  !C1P
M8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P  ?W0  'AW
M  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '<@   '(
M  !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O0   ;U
M &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L  '-]  !E
M?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P   '\   !_
M    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0  ?4@  'U9
M  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#  !;A0
M388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T   "-
MC    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\  (U0  "-
M9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0C0  0H\
M #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";    FP
M )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&  "@60
MGW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@  -ID  ">;
M   9G   #YT   6?    H0   *,   "E    J    *D   "I    J0   *H
M  "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U30  M&0
M +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(  !JD   .
MI@  !*@   "K    K0   +    "T    M@   +@   "X    N0   +H   "\
M    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0   S58  ,YO
M  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N   $L0
M +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L   #-
MSP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@  .I@  #K
M>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_ "$ _P L
M /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0 >@#R (
M\0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_ -  _P#$
M /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P _0 G /D
M,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#? 'D W0"
M -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W /\
MKP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B .8 + #A
M #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y ,(
M@0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H /\ H@#_
M )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P )@#( #
MQ  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R *X >@"L
M (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\ E #_ )$
M_P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S "H L  S
M *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L <@"9 'L
MEP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_ (, _P#T
M    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ", G@ L )L
M- "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"' ', A0!]
M (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E
MT0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F (L +0"(
M #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T =@!V ',
M@0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5 P  PP<
M +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P )P!Z "X
M=P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P &4 >P!C
M (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0  N1   *P1
M  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L "@ :@ O
M &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D =0!7 ((
M50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@  *0:  "9
M&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "( 7@ I %T
M+P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !, 'T 2P"-
M $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB  "3(@
MB1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C %( *@!0
M #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD 00.) $ #
MF@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".*0  A"<
M 'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&) !'!BH
M10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N' #<+F0 U
M"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P  @"X  '<J
M  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^#"4 / TK
M #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0F  M$*L
M+!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30  '0Q  !J
M*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G #,1
M+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F%*D )17
M "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V  !G,0
M72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D "P4*@ K
M%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:< 'QF^ !X:
MX  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E-P  6S(
M %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89)P E&2T
M)!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9
M'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/   63<  $\S
M  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @'BL 'QXR
M !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,CV@ 4(_4
M%2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP  $TX  !$
M-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@ &B,P !DC
M.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_
M !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^  !#.@
M.C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2
M*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\ #2S_  TK
M_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"0   .3T
M "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N,P .+CT
M#2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\  @P_P"7
M2   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@  -4(  "L^
M   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *-3L "#5&
M  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U_P"430
MBE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@  "=$   >
M00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@  3Q#   \
M3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"14@  B%@
M ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+   :20
M$D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-   !#30
M0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6   AEX  'UA
M  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   540  #D\
M  E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+20  2U<
M $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0  'IG  !Q
M:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060  "E@   -7
M P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410  5%,  %1D
M  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N  !O<
M97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(   !B 0
M808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\  %Y?  !=
M<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K=@  774
M $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N    ; (
M &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:  !I;
M:(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P  5'P  $9\
M   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z    >0   'D!
M  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W90  =GP
M '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,  #R$   N
MA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP   (<   "'
M    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70  AG,  (:-
M  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.   CCP
M%H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8   "6
MEP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@  )F#  "9
MGP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6F   #9D
M  &;    G0   )\   "A    I    *4   "D    I0   *4   "F    IP
M *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV  "NDP
MKJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP   *4   "G
M    J@   *P   "P    L@   +0   "S    M    +4   "W    N    +D
M  "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&A0  QJ(
M ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$   "T
MMP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@   ,T   #/
M    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=   YI$  .6L
M  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\ - #_ #X
M_0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"! .D B0#H
M )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_ +
M_P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P #@ ZP!"
M .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$ @@#/ (L
MS0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_ *0 _P#_
M    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #( TP \ ,\
M1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y (0 MP".
M +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )< _P#_
M_P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U +D /0"V
M $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P H@"& *
MD@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\    \
M .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4 -@"C #X
MH !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^ (X B@"+
M )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M    W0   ,P
M  #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1 #< CP ]
M (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P @@!Z (\
M> "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0   +P   "Q
M    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #  ?P W 'T
M/0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J (@ : "7
M &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%  "E @
MG    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P &X -@!M
M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($ 6P"0 %D
MH0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";#@  D@L
M (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$ , !@ #8
M7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"* $T FP!,
M *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@  BA,  ($0
M  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4 #  4P V
M %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $, EP!! *D
M0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P  'H8  !R
M$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L 2  P $<
M-@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X *4 -@"Z
M #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@  !L&P
M9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K #X!,0 \
M 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:, +0:X "P&
MU  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H(@  7QT
M %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(+  S"#(
M,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW "0,TP C
M#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0  7"0  %,?
M  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K#2X *@TU
M "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0U  =$?(
M'1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H  % E  !(
M(   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H (Q$R "(1
M.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_
M !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK  !%)@
M/2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O !P5-P ;
M%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9
M_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#+   .B<
M #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CX
M%1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_  \=_P"9
M.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@  .2T  #$I
M   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1'SP $!]&
M ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA_P"7/@
MC$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0  "\P   G
M+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D #"1$  LE
M4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"50@  BD<
M (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV   D,0
M&RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"  8J3@ $
M*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@  B$L  ']/
M  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @.   %S0
M !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P3   ,5D
M #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE   'U4  !U
M5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@  %#L   XY
M!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20  -U<  #=G
M   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:  !R6P
M:5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,   M!!  $
M0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^
M=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P80  :&$
M %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9* P  20D
M $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@  !%<P
M18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P  9V@  %MF
M  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0  4@8  %$+
M  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.;P  3H4
M $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT  %1K  !'
M:0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,  %P(  !;
M#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P  5X$  %>9
M  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ   _<
M,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#  !F"
M9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL  &*4  !A
MK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V>   *7@
M !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S @  <P<
M ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".  !OJ
M;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@  'H$  !*!
M   *@0   ($   ""    @P   (,   "#    @@   ((   ""    @@   ((%
M  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_H0  ?KT
M 'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL   J+
MC    (T   "/    D0   )(   "1    D0   )$   "1    D0   )(   "2
M @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F   DK,  )'8
M  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7    F0
M )L   "=    GP   *    "@    H    *    "A    H@   *,   "D
MI0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@  *?'  "F
M[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C    I@   *@
M  "L    K@   *\   "O    L    +    "R    LP   +0   "V    MP
M +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W  "_V !3
MEP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP   +8   "[
M    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*    S    ,\
M  #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=P@#_
M_P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!# /4 2P#S
M %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T X "7 -T
MH@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_    _P
M /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .( 10#> $P
MVP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0 ,( FP#
M *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_    _P   /\
M  #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$ $8 P0!-
M +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T DP"J *$
MJ "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _    .X   #C
M    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $  K !& *H
M3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7 )D E "H
M )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P   #,
MP0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _ )< 10"5
M $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$ @@"@ (
ML@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[    L0
M *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8 /@"$ $0
M@@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8 &\ J0!M
M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K    HP   )L
M  "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T #T <@!"
M '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\ H@!> +8
M7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@   (X   "'
M    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #< 9  \ &,
M00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1 *X 4 #(
M $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"  !\
M=0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V %8 .P!5
M $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@ 1 "_ $,
MY !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S"   ;
M &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L -@!) #P
M2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X #D V0 X
M /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$   9 P  %T&
M  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ]
M #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\ S@ O .\
M+@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,  %<.  !0
M"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #( -  X #,
M/P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E .H )0'[
M "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$
M0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I
M!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)
M_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(
M #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D
M( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<
M+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03
M   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y'
M !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0
MCC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J
M%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(2
M40 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D
M ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'
M(!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -
M%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!
M  !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\
M !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH
M!QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U
M10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A
M!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G
M   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@
M:TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -
M) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F
M=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\
M &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H
M!2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0
M+(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3
M  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-
M   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<
M #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !5
M5P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z
M#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<
M   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27
M1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0
M0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _
ML0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX
M #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX
M $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP
M1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB
M   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40
M  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H
M $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7
M:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@
M$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM
M  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@
M!W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#
M;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F
M_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T
M  !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P
M 'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S
M@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
M    C    (T   "-    C    (P   ",    C    (P   "-    C00  (X,
M  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@
M6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9
MFP   )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B
M#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39
M #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@
M *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0
MN0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<
M   CH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L
M  "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$
M -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D
M6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"]
M ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_
M_    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #-
M %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0
MS0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z
M .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %,
MM !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "=
M .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8
M 0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1
M )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -,
MAP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K
M  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L
M4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K
M ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  (
ME  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X
M $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &,
M^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ '
M ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@
M9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4
M /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ',
M"@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!'
M %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\
M1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C
M  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L
M2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_
M #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @
M50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^
M $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$
M_P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  *
M $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8
M,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A
M'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $
M"P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+
M "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@
MD28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T
M  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "
M4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL
M (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D
M*04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7
M!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q
M  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP)
M !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH
M$ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V
M-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D.
M"@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G
M  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P
M:SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1
M$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03
M=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\
M & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D
M#!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=
M&(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"
M  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-
M  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<
M !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !5
M1   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?
M$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;
M   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420
M2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@
M)1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   F
ML   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP
M $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$
M "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP
M*\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-
M   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04
M   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H
M #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J
M3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \
M&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM
M   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50
M&5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%
M11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   _
M_P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL
M  M9   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@
M $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![
M:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<
M  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<
M<W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M
M;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G
M(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H
M %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@
M 'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&
M=R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2
M  !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D
M  "(    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P
M (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   Y
MB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
M    EP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA
M  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP
M'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F
MIP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T
M)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\
M  6A    HP   *8   "I    K    *\   "S    M0   +<   "V    MP
M +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@
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M_____________________________________________________P
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M]/7V]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________^X Q        "6',____________________________TEH"
M     %W,____________________________J#4          %S3________
M____________________?0T          %36________________________
M___N?44          $34___________________________\JF0O @  !"(W
M25C.____________________________Z:1K02@_8W^5I[K:____________
M___________________5LJRRS.3Z________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___ENY=W8LC_________________________________VYYG-@H  HS_____
M___________________________(?S\%     %[/____________________
M_________]F!.0       #RJ_____________________________YY,
M     ".0____________________________W&\:         !!]^?______
M____________________KT@           !O[O______________________
M____A!,           !DYO_________________________L40
M  !7WO________________________^X%0            !(UO__________
M______________]T%              XS_________________________FB
M6A,            CQ?_________________________?FUPL           -
MNO__________________________[[%]53DB$0<! A$BLO______________
M________________W[^EF9B:H*R]VO______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________X[Z=@'S[____________________
M____________\K>$5S . !VL_______________________________2BDP5
M      !R\____________________________]9_-@        !+R?______
M____________________^I$^           OJ_______________________
M____P%H            :E?__________________________C20
M   (A/_________________________G7@              =___________
M______________^T)0              :O________________________]]
M                6_3_______________________TK
M3.O______________________Z4                 /.'_____________
M_________S ,                +=G_____________________F8IA)P
M            )]?______________________^V^B54G            )=S_
M_________________________LJ==EU*/#(M+# Y1][_________________
M______________WFW=;2T-/9Y/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___OU+O6_________________________________^>XCVI++Q5O________
M_______________________DH6<T!P     \R?______________________
M_____]:".P         2E___________________________[84Q
M    ;___________________________ID(             4.'_________
M_______________L:0              -\G_______________________^S
M+P              (K;_______________________]Y
M$*?_______________________(T                 )G_____________
M_________ZD                  (S______________________T8
M             '______________________WP                   '3_
M____________________EP                   &K_________________
M____S@                   &/______________________RDB 0
M         &'______________________[FC@%<W%P           &C_____
M______________________K3KI2&?'5Q<')W@93_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________V[J=@FEIT_______________________________R)-E/1D
M   =GO___________________________]N.3!,         ;O__________
M________________VWPL            1=?_________________________
MBRH             (K3________________________"1
M Y?_______________________]] 0               '______________
M_________^<V                 &K______________________YT
M             %C______________________T8                  $?X
M____________________Z0                   #7I________________
M____E@                   "7;____________________O
M         !C.____________________ZP                    _"____
M_________________P                    JY____________________
M_R<                   JU_____________________W
M      VY_____________________^"<C'!50C,F&Q0/#0X2&B:_________
M____________________^>38TL[,R\S/UN#\________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z].\X___________
M_____________________]*IA65(+!(!A?__________________________
M__&K<3P/        3^#_________________________U7\U
M'[+________________________C=1T              (G_____________
M__________^0(P               &?______________________]5#
M             $CV_____________________XH                  "[=
M_____________________S@                  !?(________________
M____O@                    2V____________________G
M          "E____________________N@                    "3____
M________________W                     ""____________________
M_P                    !T_____________________Q,
M      !H_____________________T(                   !@________
M_____________WH                   !=_____________________]$
M                  !A______________________\D
M  !F_______________________)K)F)?79Q;&EG9F=K<'J,____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________XL6JD7EA
M=______________________________=IG=0+ P     ,<3_____________
M____________X)).$P           (_________________________2<!T
M             &#______________________^YO#P               #?B
M_____________________Y8<                 !3 ________________
M_____T                    "C____________________K@
M          ")____________________G@                    !R____
M________________O                     !?____________________
MV@                    !-____________________^@
M       [_____________________PX                    J^?______
M_____________S,                    ;Z?___________________UX
M                   /V____________________X\
M   &T/___________________]                      RO__________
M__________\K                    R/____________________^
M                R______________________W%@$%!0,!       !!@T8
MR________________________.OAV,_,S<_0TM37W.+J________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________':QO______________________________
M\<:CA&A-,A@ %:O__________________________[E\1A@          ''_
M_______________________7?"\              #OC________________
M_____]]D"0                RU_____________________W0#
M          "-____________________Q14                   !J____
M________________F0                    !+____________________
MM@                     P_?__________________UP
M       9Y___________________]@                     %T_______
M_____________PX                     P?___________________R\
M                    K____________________U(
M    GO___________________WD                     CO__________
M_________Z4                     @/___________________]@
M                =/____________________\V
M;?____________________]\                    :?______________
M_______7#0                  :/______________________<
M            8?_______________________U \1DY465UA9&AL<'9^B?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]6[HXMS6I7_________________
M__________B_CF1!(04      %+\_______________________WG588
M         !?!_____________________^5L%@                "-____
M_________________V,                   !>____________________
MG0                     U_/__________________H0
M       1V?__________________R@                      N_______
M____________[@                      H?___________________PP
M                    BO___________________RT
M    =O___________________TT                     9/__________
M_________V\                     4O___________________Y0
M                0/___________________[P
M,/___________________^H.                    (O______________
M______]$                    %?____________________^!
M            "_7____________________("P                   NS_
M____________________7@                   .7_________________
M____R1P                  -K______________________YT!
M      <.%\7________________________5N;S!Q\[5V^'F[?3[________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______XW\______________________________[,:EB&U4.R$' #+>____
M____________________UY)9*0            "@____________________
M__^)-@                !G_____________________V8
M       R]O__________________E0                     #R/______
M____________IP                      H/__________________UP
M                    ?/___________________P
M    7O___________________R4                     0___________
M_________T@                     +/___________________VH
M                &/___________________XL
M!?/__________________Z\                      .'_____________
M_____]4                      ,____________________\D
M             +[___________________]4                     *[_
M__________________^+                     )__________________
M___+#@                   )+_____________________5P
M         (;_____________________J@H                  'G_____
M_________________VT                  &;_____________________
M__=5                 $7_________________________:B,K-3]*56!J
M=7Z'D9S_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^C/MIV#:4ZY_________________________^RR@UPZ'0(
M      ![_______________________%;2D               ! ________
M_____________X,;                   'R___________________D@
M                    F/__________________I
M    :O__________________W0                      0?__________
M_________PX                     '?___________________SD
M                 .C__________________V
M ,[__________________X4                      +?_____________
M_____Z@                      */__________________\L
M             )#__________________^\6                     'W_
M__________________\^                     &S_________________
M__]I                     %K___________________^9
M         $G____________________2%@                   #G_____
M________________6                    "G_____________________
MH@                   !G_____________________]58
M      3______________________[LO                  #X________
M______________^K*0                #/________________________
MR4<     !Q,@+CY2:(3M________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________]-7)________
M____________________^M*PDG==0B@,  !*________________________
MQ7U%%P             1V/___________________\10
M    G___________________H@P                     :/__________
M________E                       -O__________________V@
M                !^S__________________Q4
M ,3__________________T@                      *+_____________
M_____W4                      (/__________________YT
M             &G__________________\,                      %+_
M_________________^</                     #[_________________
M__\S                     "O___________________]8
M         !C___________________^!                      7_____
M______________^L                      #____________________>
M(@                    #R____________________7
M      #?____________________GP                    #,________
M____________Z$H                   "W_____________________Z 6
M                  "<______________________]Z @
M  !W________________________>@L               5,____________
M_____________Z)7:'2 C9RKO-#G________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^WC___________________________2HWI8.BDC'!8.!@  G___________
M__________^L4@X                 :?__________________Y$,
M                -/__________________>0
M ./_________________S0                       ++_____________
M_____Q,                      (7__________________T\
M             %W__________________X,                      #K_
M_________________[(                      !S_________________
M_]L#                      +___________________\J
M          #[__________________]/                      #G____
M______________]T                      #4__________________^;
M                      # ___________________$!P
M      "M___________________P,P                    ":________
M____________9P                    "&____________________HP
M                  !R____________________XT0
M  !<_____________________Y$&                  !!____________
M_________^M?                   =_______________________*2P
M                ________________________RU<   P8)#$_3F!TBZ?'
M___________________________7Y_+_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KU,W'PKZZM[.PK:FH
MI?___________________]U^4S\P(QD1"0(          -O_____________
M____=@                       *?_________________N@
M             '7__________________P<                      $;_
M_________________TX                      !K_________________
M_XP                       #]_________________\$
M          #;__________________$9                      "^____
M______________]$                      "D__________________]K
M                      "-__________________^1
M      !Y__________________^W                      !F________
M___________>(0                    !3____________________2@
M                   _____________________=P
M   K____________________K H                    6____________
M________YT4                     _____________________XH
M                _____________________]9-
M_?____________________^G+@                  U?______________
M________F"H           88+45@X/_______________________ZAC=(&/
MG*N[S>+Z____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________GR[>IG96.B82 ?'AT<&QH99#_
M________________O&I(+1D*                 #'_________________
M_P                        /__________________T(
M          #<_________________XX                       "R____
M_____________\X                       "-__________________\I
M                      !K__________________]:
M      !.__________________^&                       T________
M__________^N                       >___________________4%P
M                   *___________________Z/0
M    ____________________90                      ____________
M________C@                      ____________________O!D
M                [___________________\4X
MV/___________________XL                     O_______________
M_____\Q#                    H?____________________^1&0
M            >O_____________________R= H                17___
M____________________Z'03'RPX15-B<H6;M-+U____________________
M_______7Z/3_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________OW
M\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$____
M_____________TLE"P                    "2_________________X@
M                      !F_________________]<
M       ]__________________\S                       8________
M__________]L                        __________________^=
M                    ___________________)#
M    ]O_________________Q-0                      W___________
M________6P                      R___________________@@
M                M___________________J08
MH___________________TR\                     C?______________
M_____UX                     =____________________Y,'
M            7O___________________\U#                    0/__
M__________________^'$                   '/__________________
M___87@                   /______________________OTX       X<
M+#Y2:H:ER/_______________________\)\C)JGML76Z/W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^[AU\_)P[ZZMK&M
MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4________
M_________]<%                        __________________\T
M                    ]O________________]V
M    TO________________^P                        LO__________
M_______A)                       EO__________________40
M                ?/__________________>0
M9O__________________H                       4?______________
M____QR,                     //__________________[DL
M            )____________________W0                     $/__
M_________________Z,6                     /__________________
M_]A,                     /____________________^(#P
M         /_____________________+4P                   /______
M________________I3@           D=-$YKC/______________________
M_YDY0U%?;GV.H+7+Y?_____________________________K^?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________KS+FLH9F1BX:!?'AT<&MH
M9F9H\?________________]A13(C& X&                GO__________
M______]^                        =?_________________#
M                4O_________________[-P
M,O__________________:@                      %O______________
M____E@                       /__________________OQL
M             /__________________YD(                      /__
M_________________VD                      /__________________
M_Y "                     /___________________[DL
M         /3__________________^A<                     -G_____
M______________^1&                    +S____________________*
M4P                   )W_____________________F"X
M$"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN____________
M_____________^>@JKG(V.G\____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________?7P
MZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N
M,?_________________2)1$#                     /______________
M____0@                       /__________________?0
M             /__________________L L                      /;_
M________________W3D                      -S_________________
M_V(                      ,7__________________XD
M         *___________________Z\B                     )G_____
M_____________]9(                     (+___________________]R
M                     &G___________________^A*
M     $[____________________37                    #/_________
M____________EBX              !4R4G?_____________________X'(3
M   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________^>#2R,"ZM;"L
MJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_
M________________D@                       *W_________________
MS!X                      (O_________________^U(
M         &W__________________X                       %'_____
M_____________ZD;                     #K__________________]!"
M                     "/___________________5H
M      S___________________^/%                     #_________
M__________^X/@                    #____________________E;0,
M                  #_____________________GS<              ! O
M4'3_____________________W7(4      87*D%:=92VVO______________
M_________[Q81%1D=8::K\CC_______________________________2S>'Q
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________\^_K[_?______________________[KFHG9:/BH:"?WMX
M=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_____
M_____________VD                       #__________________YL*
M                      #__________________\@Y
M      #___________________!C                      #_________
M__________^*#@                    #___________________^P-
M                  #____________________56P
M  #_____________________A1H                   /L____________
M________L4D              !@Y78'_____________________Y7L>
M   ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?______
M______________________^SGK3%U^O_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________Z
M[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A7
M5UE>97'__________________[\Q'Q80"@4               #_________
M_________^U6                      #H__________________^"!
M                  #,__________________^K+P
M  "S___________________25P                    ";____________
M_______W?!                    "%____________________HC<
M            !2N4____________________RV$"            #"Q0=I[1
M____________________]8TP       -(SM7=IF^Y?__________________
M_____\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G
M_____________________________________?______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________=SL6_
MO+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M0
M66:A__________________^G)@X' @                !6____________
M_______.4                      Z___________________T>0L
M               A____________________GS(                    .
M____________________Q%@                (,5J$________________
M____Z7\?           &)TMQFL+I_____________________Z=)      (7
M+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[___________
M__________________^N<H68K,+;]O______________________________
M____W^______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________O[*JIJ.A
MH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]
M____________________GBX&                    ________________
M____PU8                  !5!____________________YWL:
M      DT8(NT_____________________Y\_          0E2G&9PNO_____
M_________________\9F#P   !,J1&*#I\WU________________________
M_^N.-2L^46B!G;S>______________________________^^=G^4J<'<^?__
M________________________________TMCS________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8
MFY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I____
M_________________Z9! 0          !S9CC[KA____________________
M_\9E"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*F
MS/3___________________________^K4#9*87N6M-;Z________________
M_______________2AWR8L<OI____________________________________
MU,[M________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFR
MO-#M__________________________^=4T=)35%68'.*K];\____________
M______________^R5@ :-5!MBZ[2]______________________________-
M;SY?>YFWU_G________________________________NGX.FPN'_________
M____________________________X\[K____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________
M
M
M              #_____________________________________________
M____________________________________________________________
M____________________________________________________________
M_____P   /_N "%!9&]B90!D0     (# ! # @0(                _]L
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M0W,%4Y.S-*!T8R05D/_:  X$ 0$"$0,1!     #\_P"??P
M
M
M
M
M
M
M
M
M
M
M
M         G33YV/G:RR;"S=;9K]>QZ2;,>;3:O5.$XN==-8X&VOMGM7JD
M
M
M"NKMRNJO0^1U_P!>^E\9KC>^W\]BDZ:/6OL+8WS L387JPV<BLEQ,;I<M4^:
M96#:=DYVLL-PKHI-<8.TO')OG?8;#XY\Q[;9>%XN=<P
M
M                                          -M[+38[]'?;\RTIT/N
M_,XAS'H/4[#Y.\[Z[96DM5O,MEQ/H     SW,P++U-Z#R>NNNO2>.UE9[63Z
M^>/B^D[EY(\W[+8L
M
M             &SL_56+ZJ]#Y%S_ );D8--\]?&=&W?SUI?19N         !
MGF9@6;OSV//=+;YV^@PCY@^!ZOO7DOSGL=B
M
M                             !454^/I;[KENCNN_2^+U_\ ,3P/4NA-
M%ZG?9@            &59&+;OI5[KF.@\EOX]G^0G->S]'8!A[&[@
M
M                                            !LG.U=D^SO4>'\R\
MG><];L_@[R'O]R^"(;XMY/*NPJ+NH>1;^#]"  /:9>PJ+NHLMBO7^+31G6MJ
M[.YP      WOM]!AOU+Z!RGG3Y>^!ZSO7C[S/M-D
M
M                               '2>]\OA'URZ1QKGCY.\ZZYTKIW6;G
M*0 /N=KO1_EPSFFYJWX,;+S?ZM=J47M#9'37AMMFF][VMY/*_0]K*X_X4R-=
M]3<*JM[-OL58KD,58AB=5&?:AKL=#=DV,_YQ<ZW<7L.2BJS*FYKC8%-W4?'U
M_ ^B0!>+EFE^LG1N1<U\^Z7TN4?,3P75M[
M
M                        =>^E\9KCZ9^\Y5I+X\<S[-U)B^/E7  #85-W
M47U_P-[^=[FV]B=H:\JM;@[MQ]C\K>',C7_4/Z/XFU^,_!>3K?JWT7:RN.=
MW<;K/7=5K<'T9Q=K\<> <G6?6CLNQG_-[35S'Z0LLTY-UM8SOGYQI?P/I#E4
M5X%ORUD\G_'_ #M'^B+3MS'Z+ (CZ3>YYEH2[7*+7\A.;=GZ.\1,0
M
M                                        .M?1^.UW],O><JTG\;^8
M]IZGM-N[4@ !](,3;?&;LFQG_.+!:K6T\@BO$:Q-M^(NP\]^G7[JZ[T?Y9/F
MAEZC[7[RMY/+E(BX8C-O87;^/L?F%\E,[2?H$^KF%NO@?A]5O8VK:[.];E%5
MDLDT9/S[=QNN>O+&=\\OGOE:OZ\Z(N8W5   ?07V?.])9SEX>.?(#FG:.D
M
M                                             #H#<^<P_P"N_2>,
M<\?&'E_;.K;/:O50  !]*,3;?%O@/)UOUFQ.JWGWU2P]S\(+'-.3_-[*U7V;
M^DN)MOB]P=DZWZK_ $[Q-O\ #_C^_@_1'7E5K;_>F-LOE);)B^;BMW^<_DOG
M:3] 'TEQ-M\7^>+N+V!A-5O9FM:K.ZM[6\GE?EJ]A]UZTKL[I   /I)[GF>A
M<:Q\WU\O_ ]7WP
M                                                           !
MFV5@6O[H=;X#RI\;.8]IZJPW%S+J          'I/CZVX6[_ #\YO1<UAPMD
MZWZF\A7\'Z%@       1'UUZ3Q[F/A/R/0MH<:>7]OLP
M
M                            /2(?<OK7 ^5/G=XKHN^=":?T&9@
M                 %TN6J?[5]3XAR7\2^5=WZ?UG@;6^@
M
M                             ?0KVG-]-[2V&EMOSD\1TK>P  ?5S"W7
MP0V!3=U)/*;Y&YND_0=AU5O8H        5::'N;&V/RWYFO8G;/0]K*Y X@R
M-=]/       W)L]+BOTQ]YS'GGX5<C^@.L(
M
M                  ,ZR]?:?N)UC@?+7Q+Y7W+KBFIJ]@ !]T-=Z/\ +7\:
M\_0_I ^CV)M?C/HB[C=5=&V<OC>CF+AH.YC=8=AV,[YU?/C*UGUVZ+M97'>]
M;>3ROPGD:WZH2"J[\QME\F>+,C ^EEIFF_\ 1MK*XWVK;OZ%XMR-?]*_K?A;
MO\^WQRSM%^C/*8KP;8M%W3F<4W-84Y5_-/+U'VK^NF%O/SW8-5;VCRS>PN[.
M0K^#]#   ^DWN>9:$T/J/29#PAY#H.V@
M
M              ^Q_3N)\T\>>9]AMSG32>DSH   ^Z&N]'^6O&IHS6W3%Y^3
M>;I?OS]\=;Z3\GOYW=IY?]A'Z*M5ZG\=O%&1K_IATA:R^,];UV=S4Q6\'Y.M
M^JOU1PMS\(.7;V'W/V78S_F]PODZ[ZE:EKL= =76,W@?@W)UOU9^FN)M_B-\
MO,S3_<WM?'V'S,WO;R>5OC#GZ#])OW$UWH?R^?.K*U?V*S>FYK'#*K>R,^IN
MZG^:.7J/M:  %QKMR/MGU7AW(_P3X_\ 0W6UFM7ZD
M
M                      VYLM-COUYZ5Q?GCXU\P[3U2   !]T-=Z/\M?QK
MS]#^D# ZK6U*M-!]\=9Z7\GOP#V?F?UH_=37>C_+-R5>POH%KFNSN/H^UE\:
M6J:;]M.B_HFG15Z&N8W5ECFG*,PBYKO1-S&ZHZ\L9WSRX1R=;]4_L/@;W\ZG
MRYS-/]S^DK67Q?O>WD\K?$78>>_3K]U==Z/\LGR<S=)]^/I]A[CX>8S-&:Z"
MNXW6?S1R]1]K   #M;U/B-37F[;LWS/\)U/>0
M
M                 !]D>G<2YIXE\K[?<NB=1OLQ    WI;R>6M-5V.D*":;
MK[3+WY:R>3] 7<7K2_Q7BF][63RKH&[B]:7>*L>W7;R.9^?;N+US3E7T-:RN
M0-(7<;I[**:\'L,TY5E]-S7FO:[6WMOV[_/.$56]FW--DOT58II&YC]/;UM9
M/+%BFG*/I9B;;XK2Y3.=;N)V-P!DZSZT@  $^8\?;SJ_"^1/@;Q[Z(ZWMMN[
M/
M                                         R_)PK=]ONK\%Y=^*?+.
MW]9@                    $U,GKZQG?/"OB;5QU?P/HQ13%R    [Z]CS[
M2^NL';5G!/C^A[<
M                                                       ^C_N.
M8Z3H*%VXP\O[;:P          !5)HL]HNZGUS79W) B 7**K->XJQFM3;,*J
MM[,E(G          9!>QZ+[!]+XWRO\ !OD/T)UJ
M
M                   !]Z^P?//)'QIYAVGJ^UV[M0          &Q:+VG?L
MY@;[\VV@KN-UEM&B]HSXE;#SWZ;,TIN:VQV:<PWW;R>4>U\?8?,S=EO(YE^*
M&P\_^F;'IHRX          /L'TOC7+WR+YOV?H/5^OVU^
M
M                       #8^=K++]@>E\4YV^/',^S=1@          'T?
MQ-M\:,9JHS;@;)UGUAR&*\1ZGLYG"/=^-LOE9E5->!_+W,T_W*[%L9_SFW9;
MR.9?BAL//_IFQZ:,N          #L#TOC=7Y'?M6+YM^&Z?NT
M
M                           /H%[+G.GKS=Q9W$OE?<;;           /
MH%C;3Y(W^FK$_F_EZG[,_1?%VOQRV71>TKF5->N+#-.5\JWL/O'I>UE\4;LM
MY',OQ0V'G_TS8]-&7          !?;UBC^N_2./\N?"KDG?^KP
M
M                            ^U/4^&<P?-?PO2^A-?X>PO8
M !>8JQWZ[8.\_/7D45X=S;=Q.T.7[V'W)]/\3<?#C%9MYY\[LK5_83K6QG?/
M[;U%_GGY#9VC_0S8IHR@           ^V?5>'<D_!3C_ -#=94U-<P
M
M                               #[Y]A^=^1OB;RON'7(
M                   !]3N@\HYT^=/B.G;>T-J/0Y:
M
M                    7J[8I?N1UG@/+GQ>Y=VWJT               "KJ
MIDW:Y:I*ZNB1/FF6$B*IE#17/M-N[5TE-4X         [=]7X;4>*XV>X+\A
MT+;@
M                                        !OG;^>Q+Z(^VYEJ/Y;<_
MZMT2             !554RLKR,6TY+?Q[7<[ENF    "V6[E3C5C(NF*8^5=
MJ6FJ:       ;_W/GL*Z9WOFM9_*;GG7N@0
M
M           #LGT_B-9[WW'G+#P!XWH6Z@            F2\YIE8=DS')Q+
M-,F/(      !+B?6'8V7><+Q<R]RX>@     ,URL*T_3/WG,>=OBMRSN?3X
M
M                                   !]!/9\XT].FU6\;>8]IM0
M       "XUT4VRL_78S<J[=,         !;:+E3K7 V.36ZBNI     )DQY^
MS/3^+<G?"'D7T%UF
M                                                     ?2_W?+=
M&ZSP-AE_+N@]5L,           NMRW2;0S]9BU15$L           IZ9F:OP
M-GE-JMW*L     ^TO4N)\E?!GD'T)UJ
M
M        ?4'W_*-#Z/U.ZSSF_1^ESP          *RJF3M;8ZO$JNJF4
M        %)35-U3KMIEM'35.    #[4=2XER5\%N0?0O6H
M
M                      !]0??\HT/H_4[K/.;]'Z7/           V=GZ[
M%[_>L6\             "P6;]PUC@;'*     ^U'4N)<E?!;D'T+UJ
M
M                               ?2_W?+=&ZSP-AE_+N@]5L,
M  "_7K-!L_/UN+               &L,#9938;-ZO    ^TO4N)\E?!GD'T)
MUJ
M                                       ?03V?.-/3IM5O&WF/:;4
M         V9GZ[&,AO6+<               8]9OW'6>!L<G   )DQY^S/3^
M+<G?"'D7T%UF
M                                                 =D^G\1K/>^X
M\Y8> /&]"W4         3)>=R[/3X7,EY               )</6FM9N,TEP
M]  !FN5A6GZ9^\YCSM\5N6=SZ?
M
M   -\[?SV)?1'VW,M1_+;G_5NB0        "ZW+=)MC8ZO$@
M    U/KMIEMJMW*L  -_[GSV%=,[WS6L_E-SSKW0(
M
M                 !>KMBE^Y'6> \N?%[EW;>K0        "_WK%OV=GZ[%
MP                UC@;'*+!9OW   .W?5^&U'BN-GN"_(="VX
M
M                            !]\^P_._(WQ-Y7W#KD         OUZS0
M;/S];BP                :PP-EE-ALWJ\  /J=T'E'.GSI\1T[;VAM1Z'+
M0
M                                      /M3U/AG,'S7\+TOH37^'L+
MV        %QKHIMN;+58@                &H];M<OMU%=2  'VSZKP[DG
MX*<?^ANLJ:FN8
M                                                  !] O9<YT]>
M;N+.XE\K[C;8        1&Y-GJ,+J*HE@              %/3,S3>LV^:0
M %]O6*/Z[](X_P N?"KDG?\ J\
M
M    -CYVLLOV!Z7Q3G;X\<S[-U&         ;!S<#'<LR,:T@
M   &)X^3=M?86?D0  =@>E\;J_([]JQ?-OPW3]V@
M         !$ D0 $ $0    $ $0   0 1     )(0
M                         !]Z^P?//)'QIYAVGJ^UV[M0        %RKM
MTVV=EJ\1]$              /)'4VMVF76VBY4@ !]@^E\:Y>^1?-^S]!ZOU
M^VOP                              >QF>+E2LYU^;+G1'@"0B(*D "$
M"81@) AZ!* @0A($8DAZ"$O,*D(P) @**JB;J_::^HM=5$?*
M                                 ?1_W',=)T%"[<8>7]MM8
M  SS,PK!F.3B68             ##L;+O.!X>;?P  R"]CT7V#Z7QOE?X-\A
M^A.M0                              #9NOSZ6MM79FM\_$G>9A&)0DB
M@2@$$9((121""22* 0 1$$D021$!$$B!4($JRB6X]7GT&E-SJJZU5VHI$
M                                        !E^3A6[[?=7X+R[\4^6=
MOZS         /<O.T<_68K>;MJC            "S6KM9J[ V>5>(>@  [Z]
MCS[2^NL';5G!/C^A[<                              "9%3>NGV]%I?
M:8%;DT+-D-55/0PAA,49%.A"HF)>>1<Q;7=5O+(CW$H$-B17C.NZJ,F\PC!+
MW*$M$:F)A(F/6R8KPW6<T9E4Q/BCF)E?%4N7-,:='J\4URJ*NF.;T58I@TLK
MH9IFU5-<-F8.12Z8VNKJX20@
M        ^R/3N)<T\2^5]ON71.HWV8@        %1,2]G;#6XO=[EJC
M      +1;NUFL=?LLHIXF8  $^8\?;SJ_"^1/@;Q[Z(ZWMMN[/
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MCG)J9<TT%Q34:WB,OME,S=H8&13:5VVKJH
M                    ^Q_3N)\T\>>9]AMSG32>DSH          +[>LT&=
M9>%8;M<M4@      !:;=VKP7$S;]8K-ZO    N-=N1]L^J\.Y'^"?'_H;K:S
M6K]2                               !M7 V%'3Q<]X'E8M3YF%9$><C
MBNUXC5%VA,(Q ()99%5KQ2JBZ( @$@1@RRFNT8G51=P" BD 0 1$) JJ*VW]
M=FV_46SUE;9;MGW
M &=9>OM/W$ZQP/EKXE\K[EUQ34U>P          B+S=M462W\:UWZ]8H*^NB
MGB  ("@HKJ+#9OU^-6,FZ6:U=K8     /I-[GF6A-#ZCTF0\(>0Z#MH
M                           /<RV)@9<C,,3+\4M;RF2F(PJF$::8PJF
M1B28@A&"20"( 3%#U$A"4(Q$8THPJF$!$  @$!54TM3[/ J[%=L1@
M                                        ^A7M.;Z;VEL-+;?G)XCI
M6]@            "=,>*ZNB1/FF6$B*IE#17/DQ/L      -R;/2XK],?><Q
MYY^%7(_H#K"                               21@
M             @                                           #TB
M'W+ZUP/E3YW>*Z+OG0FG]!F8                      !=+EJG^U?4^(<E
M_$OE7=^G]9X&UOH                            !&1 D)(
M               !,$$1Y
M     &;96!:_NAUO@/*GQLYCVGJK#<7,NH                     $1]=>
MD\>YCX3\CT+:'&GE_;[,                        "(@    )B69:_(54
M5D@)"0                      $ 1*,4L=RK:P7[
M                           .@-SYS#_KOTGC'/'QAY?VSJVSVKU4
M                 ?23W/,]"XUCYOKY?^!ZOO@         B"HFE-IJ5U-;
MT"0  1! ()  !$$ @/ H*J'B8$(   +Q8O,[MWDG(LHH0220JJ
M            1B  0A54CJ[C6FSPWF1
M               !UKZ/QVN_IE[SE6D_C?S'M/4]IMW:D
M    #Z"^SYWI+.<O#QSY <T[1T@         !$7*FYYVMJ]C3*JO-(CT/12
M ""8",8$P   (",2A)Z3YKHGS;Z[+56QP*V1-*   OEB\S6FXEY% A&" A,@
M                     (@ 3"-L8N0UEG8*$B
M                       .O?2^,UQ],_><JTE\>.9]FZDQ?'RK@
M          !$?2;W/,M"7:Y1:_D)S;L_1WB)B         1%QHN>=V:K9T,C
M+QL3TSDVL\V?$X-K&8SE![$J2=!*DFQ+)XFQ6F8O=HEZG02T/<DN)3%+-Z;F
M-X-51DD9+]1-!C]<5^48]Z5G>)>I-'[;67"7-*  +YCWF:KJ7D64:))D   0
M! (I!!"*4$(I    ! $(I  !! (I   $ ! E'!OM9;#!0D0
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M@  #,C6MRA:<(EM/*3 ,6,]N!8Q-EGNS&1P  ! E4%/7ELRB)Q+ )IV1%*
MAD:<6LIDE,38@    A!*.#?:RV&"A(@
M                 V3G:NR?9WJ/#^9>3O.>MV?P=Y#W^Y?!$
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M,;_M9<P   A!*.#?:RV&"A(@
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M@SC(37>MIC==B,A   "$$HX-]K+88*$B
M                    #9V?JK%]5>A\BY_RW(P:;YZ^,Z-N_GK2^BS<
M     #/,S LW?GL>>Z6WSM]!A'S$\%U?>O)?G/8[$^I'@LW67'GI+&;<\;FS
M=R$(D&Q8JU-U51>XCY.KL]R]FT7_ )[<V56NOM#U6^F^@:;G+%0FFM"+YHVJ
MWTH  %?3<;:U>SHM3['"K8Q2@E$0F$4D$!ZF4$$2]3 EM2FO"-556\WB,@IF
MVS9JJZTLV%J,@2(@!((2;AUV?0Z/VVGKO( +WCWF;+J7DVD;8F0  !FAK6X0
MMF$2VE?C%;<73(#%\:,M]GCP3JDH,KA@>%2VCL6)TCATQLVU&15Q9KY#';=*
M]0)4HF9!#$[!++LAAA]AEETLJ<DA@N 2VU2%6   $()1P;[66PP4)$
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M32:4VFLK @ OF/>9JNI=^VC$$2   (2  $"1 D$1 9##%K<7BWRN(    1$
M! E$(   !5"$$</(:RSL%"1
M              %=7;E=5>A\CK_KWTOC-<;WV_GL4G31ZU]A;&^8%B;"]6&S
MD5DN)C=+EJGS3*P;3LG.UEAN%=%)KC!VEXY-\[[#8?'/F/;;+PO%SKF$1 10
M52W!K+EJ^IW.[^O=F<QU&T=D^=Q'QJ^E=E'E'V%V;  'W.Z9\1N8M+TM\_\
MRO>GWQZE\)/D5X'ZR<I:/J0  /4F9XF7*R[$S)6K=A@U48A"0D ; HJQ.W54
MW29+QFENK&+;=72@HB?5Q-'EDU8_KRNC/LAMU6!4GV2E.U_51DX1!!,IDRW'
MJ<^CT_M=966>]9(E! +YCWF:U7DJ];>J8                          0
M4HTC$R&LL_"0D0
M       $Z:?.Q\[66386;K;-?KV/239CS:;5ZIPG%SKIK' VU]L]J]4@
M$V:7T.YM;I_IEP7!F8#['VE'C678D9AY;R5?\"_J?95%AR*@!6567W2Z9\1.
M@=MX)\8N=_8CCWS_ %P  "0(Q+8>%F4^78F9XP',QI]FNT3/,PC $0 $/:4L
M1'N9>(A[@\2!  'N)9';N2,[U^1XU?M==-Q7(QYH0@ +Q9O,ZLW4G*H>J*4)
M                         !,E9# R&M<_ >9$
M                                            $1G>#5#]#OR'I:;
M??>_M6H<'W=ZN>99I^;O=\LE_-7J=BXVI2 ,QR-0^^/4OA);+>4XA\WVE\SO
M&_2(   "(25--;8^OS)%VMW),52,4Q"!!,@@0]T1[O%=F595_P!0JDIB/J!(
MB !"9AX1'&LBQ48)FXLV7-*$   3(EF^%DJJ*D4  D
M     !"(*JF.7K+'<BP
M                        +Y=PEFM9K[$<#L2.PO#WZ/"]SU2GY3]KI[MR
MUT?3V[<NJW<KYM>S\#>Z>8!]]>I?"+YF>-^DG).AZL^YG2_B5\^O*]\<6><[
M(     (@    (@EO2_Y:AT98]/7>4@      @   !)$( 2
M           'N#,Z:['A55N^>4@
M                               [*]#Q]]P>E?%3\^O*?OAJ+0>ZA]/.
M4Q2?/CJ>PJNL]%ZFQ=A^(];+Z*\9Z>=\?^V<FK^)_4>0KH(7JYAK+;S 5E5E
MZ0H:;X     B 20@  #T WK>\O0Z*L^HKO("("  (R( @     B/8\"
M                     /0Z!IN:>T-5;W!2D0     /42V!KMPV=JM^SW7;
MAEN'L5[L9:LHN)4TK5=QV-9>"PG.U+6^TTC5VV\^MEVP
M                                 -MY_E'Z0>O_ )V-;8?HWYR>1?H<
MLUO-=C^?]-:_LGPOL]'S![WR4OH+R.\4$U>_A!W?B=]U9F:V8'V:LYWY[J4K
M-8S1N7/XJU=J2JC>V*HS7.(JUOU)3=XLXYKL=_R"I^>ES&^K(  !$!"2(!!&
M);UR/*T>BK'J:SR(B B( (@ @      -ZTW=5Z:JM[2MZ/0
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M<>^VWI-^W5HO2-YZ#TS#<W5N2O9<Y<L>MYZM5VP
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MG.OV+C#W/+W(7M.:J&NT)00B(
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M8ZTY%*,0           (0>JY;;TF\=C^'Z"R'&R'S\Z/QIH#T7CD)$$
M                                     !UAO>5ON1TOXG;)S/.*6FXY
MITW2'YZ.4??SS%Y]>N9]/L_;W,?;^.0^E>7E=;\]]*YA]9YV9\2>S\>ODBF
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M^^NQ4       +K=OPZF]IT.EZ!])[*FY8\1S:?H_G/*< UM;Q\VQ::;M
M !TWHO<2^G-%[B7B>1K_ %<*+T/G)[7C,\ #I?1^V\=)Z3VLOYJ^WXI/"(20
M@",D(          +C;OOI+R_N38^LWCA_P!_RY8-MH\2D7J9&$VLC-/-VLHA
M$                0'NDZW\=[UU%Y'V;YE=6X*TWN_,O,
M                 >TO<2\J20D@ES /<P3**'B)9KD:5^C'KGYZOF;XWZ1?
M,WQGTD\) &=Y6C?I%Z_^=:TV\I^:/CGZ0*5>5%-Q]D?)^RX[^07J?&]?]8:_
M<8315(\?[/29U"(;Y]/[63] .J=NH]5Z;S7KE/Q7.:K%<;$G>*8*A3(@!(
M  A"9;.Q>?VG661[Z[)J       " AL':;J7VC[_ *G1R,'78[\[.7<4R_7>
MIT7OR     B-MZ[T/FNHNPTYL_-^Y$T@ ,ILYT,GQ\^&LL[0^O*4Q)$/"$9(
MU03+Q1*         N=J^^G?*>]+M9RG"_O\ E[!MIBH1;;IG7Z<TI&SW&0@E
M$                ! 1DZ%\SZQV]X'H[YG=4X0T=OO)H
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M>]MAYVS\GZ[WETYEM^NNGA+-/5YS?_6]M*RO;Y<OF+BOGZG7GB]>\I
M1DJ[=Q].>5=Z7FUEN#N@<O8GFXR$D!G4XN%2HF?A;(RZ$RC
M      &^/.>F=U\_Z:^7W6>!-0;GS*$'F0
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M\P     $4OHOS/MC;&F]$^?O2.4L2S\9YF4:8![BF&XKNOT_INC8[A\Q*(
M                5$$NC/*^K=F^'Z$^478/G=@V?J7D
M          !$1B6Q[&OE_I:TGSYH*NZES"%_\UUKY?3..>UZKF<?Z'U'\^^K
MV\F^<'T5[O+^P/KGTE6RZ*+9GPALM4;J\]ZJV\H?2_C,H^1_$^7;CH[$
M    /4GUW\Q[+E35??\ I'3F<;G=R^+N?\HJL#P==4^ "2-(        DBAL
M?%\):]=Y'N+G+JN10       !#,\7%U_1557/&<G)RV$RV]NO1R>W.@]8HN%
M>8\:J^9?&\[J/*4$     !)-@R>Q9?I[YSR/GR\]AY/IR^:#J?!,S@_M/H+8
M_*>AW!\/_H?TVV.AOLWW.-V#HS),X^/MCAW37$_58SQ)]/>/R3Y3<GY-M*GM
M2@    (A)U]XKI3M/PW4GSJZ;R%@6QP$*I1H@F00@SZYB8%;Z*KKB,Y.4)E&
MBDF0                 0@J=A>*]\W3H-Z^4W7_ )Y6ZY9
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MSO/.N/?<^&>**'FNI&(  )(H;%M8F!V._<OF*49&0*B-( 0  $0
M    !&(9'CY;Z><F[2^:?4^$-&;[R8(                           /4
M@>Q]2N=M0]?Z7O4G1.V]7L?E#T7-;SPSZ;DDSS!['F3S         '1GKO>2
M.]>H=IH^'^<\?J-7ZS35?B) "        J8IIU,0GU1*MZJN5U(3*OMVZ*73
M$REN5U,(J1JA[IB%;3106ZJNX7BBBTV>NY=D@1@!)MG4ZO2&IMOM-WJ8 F1
MD0Z-]5[FGZ0]3[BF^7'$_G*X8YBZ^,(      (CT)E1]Z>'Y6D>?_7?3VY,K
MMZ^CX*]1\UV_EW>T9-"80@\P      =D^)Z<ZP\?T5\V>H\?6N]02!&   $$
MR:?.YHUVI=*5;/;D:8)EZB5PHJ5M%:MM2FP1%-44%VE0U4J2JA"J!*$R4PC6
M*0        D0Z-\QZYU;X_VKY(]D^<%)5;0
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M"  0*BEKA9K]MCF5;>*X1B$)J*8        $@C!])^6]@<L^NYRX^]KS5"(
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M^>AWN8?-+V7S_48!D^>>(       "(ZD]KT>G['Z%U6DX,YOQRMQ/"PIT9D
M      !%!) 9CCX^!6&Y7EM+-R=<8M6RIMK=**FJ44-!5=NW@J+K3;QJUS5?
MZJY-!3Q-1.HHF03(FPD^:J8TJNML^1>OL;<,BLV<4N=-FQX3DYNQU4HTP
M 2;6W7HI7:_ONJT7RGX?\U7''</ C        &S-9$O[8\/S<4X#Z5Z#).%O
M;^=J[7.(ES(    (B\V<E]BN)_33YV]+Y&U;M].!,@  00KJ1BE[B648=U?<
M:XS*_KM9V.C)RZUVLB_0 0F0     $4+%D4,5S;+R@I@D3(       @/5,/H
MYS+K[EWU?.G(WL^;(20@                            BE] ^:X])D%E
M)^?_ $K9W&P7\-+B4$       B+QD9</K#W/Z8MW)_B>83="Z#S%;YH
M    3""55%$FZVK=DL%Z_D,::4*ZD:8$H(!,B(>*IC!+U,O:$(E"3P(Q!327
M*BB&U-=JM&:OV&UWC+EZ@E$    $$':_0NK46$ZK3>N$N8<6JX20@
M/H/ZO@C4>#ZMRUH>GI4R@     ])=>^,Z0Z@\GT)\XNH<D>4"0   $)E-IJ9
MMK[JX8]2%PFS33YUDZK46O\ &V^Y?5N$*Y02      0>D+5D4,+SK*$P4P3(
M       A)&#>?G_2NQ?$>]?(KLWS:\B
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M<5OJCR'MSYI]3X0TSNO+O,P                              C)"
M    "]9&7#ZT]V^G+;Q;S[DM3IS3Z"J\R(AZI      $D)(TPW]H='R)9KM[
M+=/[?:]%RJY]Y%CV,8V'A8FK+9>7B73-3<+E=FN,*>%5^,+D4]3:MT<VU9M<
MF_?N/NE+IKU5XC0DTV1?OV/['9;8(A$ADNFT^B-9Y^?OVPVK-1XF2((D
MDA('8/N>FT=HPL!P5RWBE9YD       /U2]O_+UPCYCN+XD<W^T0     &Q]
M9NGU@X_]%OE+V'AJBKH     &9X60NV-4A,@C$(Q";=BGSB[J]38#C;;<,*I
M(       "(C%+#\^TLM^T)        !"9=G>%Z&I*M>^?W1^.(1
M   [A\KU&5P]ZKETT              .[_)]6DZIV&@]<S;SQ$P    ,DL9L
M.F='[?QR%Z/G<P   Z[][U"FZ0]A[VFX6YUR2X6FFWZ!$/5(      0A7*ZV
M:+5NK3:;E?!LW+W#@.?G[6D3,Z]V[-DSO%Q-7X[<R,TRJ_>Q[U7=G^T*BW:L
ME%DY&0S[-J@JK%G'*3)R,GKL;&Q2BR+N1>Z%/+N55%ASMCM/T*NS9QZYXF'@
M=@V>RV[(MTL7Q\>HL]JU,0     J RK,V/GZ(]/[7;ODSPKYEN..8F!Z
M   /U2]O_+UPCYCN+XD<W^T0     ':'A^H-T:'V#@?I'+B)    0&18UUD^
M#=1J()!ZB'FJ7JBEF^3J]3XI1L=AT5NY=8)       "#U,)-4-?[''2ZH
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M)OH!H'T/FG.?JO*HQ    1"?%;/M9D/<"9 $4$$*I5-=NDS')UNI<'P-KN6
MC402Z7O8W!WU$S]7^?C%*:]C6^)O/Q\UVW_3388JS   (@ACF3;4V9CXO]KK
MF!^9SYO4Y?V:Z36>+_F%3F?<$    ( (CU-3ZP\;[D^4G8/G=K?9:,
M     ?<'EGU#2?$+J7R_5_;GEOT_2?,CW7#ZCZ.^*[/(X2]9RF=TCI/:R_F=
M[GB,_P"X/*_J&D^4_0."5/9_F>E2OEO[WA-1]D^:?2-+\[?9\<G_ $*\;V"1
M\=.E?.-5]E^9_25+\\/9\>G_ $:\5V:1\D.B?/=3VIYCIDK56PT'JW5V6^]1
MZSQ;J[,<"S-3'3VR\YZ[N\EU:3P1Z[DT[8V%N8=L>7Z=)^>_L>03_J3X+NU/
M\I>@<#J)T5.VO+].E?+#WW!Z@ ",FW]]ZF5]'.N]ZH?GER_B%=CMBQ-C3 D
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M_P#/-\M:<S[J=4+/"/R5IS?T!       DZY\3[M<:*'SUZ/Q<
M?5OGW?:?E/T'@9F2V<V&^M1ZSQB]_!C\[/9\<G_3[PO<J?&;V%'JK0>]E_#/
MJORS5_1_Q7:)%_LY<--[/S?KG;<^-F?4[P/>*?2.U\QZQN]A1XX]+S>;W7Y3
MJLGYB^ZX=4= :?UWCNWR?59.&96MC@>7J?5!7:;:UWH/-WMY,.'_ %/+IVV]
M=Z'SO35>I\7"B]#BWT_-)W?GD.M2/CMTGYRJLRQME#ZC>"[K3_.?VG&Y^G]E
MYST 1'U?[G],6[F#R'.YVC//^7J\^Q<;6591:MV/WK^=9?BX>L]3Y^RWA$
M  7ZU9Q_.<+#U!@&9F[DSS'Q=46*NYG&#9F9G4)E?;]Z5E61DR/4
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M<S[SQ$SK[SG19?QUZ3\XU( &VM=Z#S]#?&]AD?)CH?S]4@
M 9AG[7S]7NY_2UM^<?*>%5^-6<6;LG68.IJ6[-99[MZ^YO@8.LZ2[>N$3U
M !%$*VFU9,TUN#I7'<S+V5B5_,VQ6UV[+JS.V&Z*VY=\YUEY5)ZF8@@
M   #)=3J-+6+:;+:=/5<NJ9B@  !(DQW'L3<9QL>>    F'0/I_:4^U]OOY/
MS=XYP*NA,/" 1'H38AXFH2B(H>4DPC3#U)V-XFF@S'!II\3RE3QK[JNND3)2
M>IJ=J^%ZDV1K/3.'O>\U0J(P   DRW"OKYC5H)    1@]4TH25==JUY1FX6M
ML+UNSVZKENN[8Y3[]S,#XV!A-%S:OSHP]A]OK'%66!VODX7RHZ&O8_%/#.+G
M?6_'*:LX^@.9@?&;3=J[U!PS:S/K%WKLM7\2^,(R/I+NF;?-7#M.1]00
M  2;!UFT?0_FG6'QP[9\R((              !GV)MH9OB;3SJ/8^>]6:[C1
M  NUO(;$PMQYU+L?/^@               .C?6^\D=D]#ZM1\"<WX[<J&W;C
M?+5K'LIQ[.,X5EW\VO%NW:,7OY.4((B$D4()!&"XV[=ON-%NS8Y>OY3>K=FR
MJ9F6>_=NV<9>925UVY (U"B($Q0     "0B$VBBCR'5:O3V,;G<;NC$01,0
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M5Y*9;/-4@     (H7&;%HR'+Q=>89A;';29       $8@@P+:8ZCKI
M  !&3Z]<5[X^,G;_ )A8_DX(
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M*I1BE];>,]Y?(/L_S8P[-U0                 ",B $B)$   @     "(
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M9DPL%.VKR6![*PH;M!        02K+=3ZZ<9[T^*7=/EM;;N,
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MYMUZOU+JJ00U]LL53W",       !"J67X6>^G')^ROB[W'Y=2YH
M         5,5-QZ?;4VI=IKZD-Q45X79JTV67*LB;9?RDH(I\)F3<TTMAED%
M5*STU,7>>FC]HC[F::BI7">I]5<54%/51YO\54.OYC(-?HS#=NJR:29Z'PWE
M,1G57(_1+OOVK3<B<:^&+=-Q]/4ZFJZ358O5ZV3DEJQ@>"9V;M132G4Q+S#&
MQL#MMZY?J954U]NW:DS&O6\?DS578C7D9[XKGU"HN-$6[:U-.H;!L]GN-
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M,H"(0$ LV32P[.L$0B        .F_*^S;7TNV?,WJ?!@
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M]>AYF0     "(8CG6EDR;8A&        (=R\_P"F-<[/SKB'WG)D
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M:87#*UE')LWYOBUES\DQ;$J=E:FWQV.JIK+B;VX6:C;UT:80NU%,%,H2
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M&!;7'25(         Z9\I[)N_0^@?+KK'S\\(
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ML=2"(   (5%^Q+S*\*XBE"0          (P!"2%,,5V-E8;UM$        0
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MMHSW%7O.=$B   (",D$LEP[K),:X]6SS7(         #U3 (26+(H8GFV"0
M       A":F:8&P?3GE'9GQU[9\T,?R->\@
M            #W,OKMWKZBMO$O/.25>KM5HI\*JE133*S'%Q<!P;+RMAQB4
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M!%"Q9=#$\NR@A"91B        "(=J>%Z,FQ:?.GIG#T(/(
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M?K&2^IG(>VOE3U_Y\:MVOG1"
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MNO4,8R;2W9,(Q           AVAX7HK(,:X^:/4^$/,0
M                       (BLKNP^N/>OJ"V\1\]Y)5T/F?*:NO-NQC$*JJ
MS4N=LMZ2ZI     JAL' P=4SY4\NXC>L2C'M8;+/W??,S-J+Y=NRHS$*GS^-
M(>)P)\R_5*\[O(4OL\Z;!,4       0D]:^E9<3G]16:_:>:SU7K9"48P\JD
M8#&\:Q.QNU8GQ$*1!$ D[$]UTZCM6'@N ^6\2K(               (B C)]
M,^5=W67(I<2^\YT2       D14O-F5VQKBX6JE2E&@21D@/$E-5"UWZ%FO6U
MNNTE4H#U$$         !FV!LGTTY3V1\H.Q?/#6NRT"
M                        #N;I?8Z38>XWDKC/GW*Y\N(C&(A1UW*D
M 3#W3$+Y9M62V7;EUKJ*+;05UW&GN7*C.<O*HZR:O%5Y3#A2>,P:JJN52&]O
M^:;H&S]H$       *HA'71&UZGQ5158>PA4^P]-3*B%4^D1"RV+4W$<;'J(J
M0(D !<KM^'THZSW:V_-CCO *[3^@\I-@                 SS7[=];..?1
MKYV],Y*U3NM*0(      A!** $IM,JBF4Q(E)F%/-*75"*$)D@C$$D)E&
M     "$R]Q2^B_,>NM-;SRK@WH7'4!"
M            ,XV6X\?5/M_TE;OGIR_B5?AF#KIL0!(     ($B"0$RGU5PS
MC,R:6X:NBFK_ "6#)DYUV/G87%#Z3+K4"       "($*[R>/;8WTFW^GR;Q&
M2$%BLVI^*XN/.((   #ICUOO*;;VY]#3_,7C7SU<:6W:
M $1V/XGIKKKQG2GS3ZIQY:,FTC1           D$1!       (H02     (#
MJ+RGMG3ODO7ODOV+YS6N[CO*
M     !$?0CJW<:*YY&1YXS\+S*O\P$@       @"2$RB)\S#;/F*+!;?49M7
M+OU3+_XK!L^/^WS[W"N?2       $Q!,0RG3:G1T^U9LV';O>=%>2.+6;-39
M,?'F02"$D8 !)7W+T/I!U7N5NX0Y?Q:IYS\EX.I\@                 B)
MD2^H7)^_+?=I<&=$YHEJ$*I1@         E$0!       ,GOZCSCMG9^I47
M  0$1 ;-U>Y?1OE_7'RXZUP-J'<^6$H(0
M              1&=[+<^/J=V_Z0M_ O-.,5FO-9JI\:Q0   0","8$H! "1
M,H(55IYS[F&&\^WSZ.LVMVEH.7ZF\5_4MQ;*7;WIZF(1B8@     0D(A7XV/
MC=1;MVC$\G)S_&,7%GTE,>@   ""3JGV'0J7:.VWM/\ ,CC7SY<K?:QT
M               &3XV>^LG'?HIS7ZGQKDSVGB4J81I@2
M "IJLPSG*\]XL-K8^L;L;;T   $,FQLY]+>5=B<3>[Y6Y(]ES1X
M                                  1!+N+I78:3</H/4R>$N=\BN%-3
M3%$@  A41IA>+=%BH9FYW>FU:KU8MXC27*[O9;MR]W.W;H[C31B]BKNY9;)N
MY#GW+\*-A]AE>:397/&1\[PIU?T_;6ZDW5^;&F$4@     0(>91I<3&MU'BX
MEJP_(O9DMTBH    0RW,V7CZ'=2[9;_GCR7A-7H;S'BZ@/(
M     "(VEJ?0/J=R3Z"<<^VYRYH]5Y1*KA&                 +M<PH9)?
MU7FVT93%\?;^R0 $(+W;R7T?Y;UYH/T7C7 W1.-O"$
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M5Z69Y                      &[=%ZI]-.5]X<M>M\*Y1]AXA07B,0
M            RO(TOG&+&W]2XK! 10S/ V3Z(<TZPT=Z#R3YZ](XNIYM@
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MHW>G.NH./_:\U<2>\Y0\*4
M         $1.JK?23K_?J&KNW//$'@.4U]-13$A"91@0)(H02010A4*9$"1!
M,D0)$$R00JEZHI77%2<@UM%/5ZZQ"-JPI*,=;ZK/JFKHFRZ*(^9(I3:9A5UU
M4F1V[MHIZ,B_>,S*ER,N[-QS;7)EHS*IZ8),OR]GX^@73NST'+/A^9S.,^>\
MLKJ.W80                        &2XN<^CW,>WMB:W>.*?=<T:8WVB4M
M=),E,(34B@           0&69&E\XQ9W'J6J5]FZ[(\-T%T-YOU;YV=+XLYW
M]-X=""                                                "44+QD
M9</IQV;Z&H,(P=3ZXY\'S&NDR0$8$  "2$E=3B2Z-DS(*@   "(*Y9;H[=%>
M-'@^,2N:R?C>3BU%MN6(HE70DT2F<JJ12\J0 "9![HI5$7V2XF13Y?3M*:BV
M^?,H/4;*K[\Z9V:@TQYOQSA?F?':^P8V%Z"
M"8EU[XOI+N7P'66EM]Y7SR![3PGK!=AA)54$D8            AE>1IO.,X^
MW];X\[ZUVGX3HC5>V\X^>G2N,,.S-6
M                     ,HS=CY^FG9?H6@UYJ]'ZXZ\/S2NE4VXP5 1 D 1
MJAO'#Y)9=49'1KG9)VL^%4HP   JAG?F+5#AV'YNJQC+PYFZ)R-)>41P>*<_
MG(H\G7+!9%%SII7*\U5V=3;MV"0V;FL-<XW53F29C=Z:[#E2NU8E--Y]*9>!
M+6P-EY'H9/?W:_H6WZCU?FIO"/,>.5V)8&J]^0
M   !$>Y.I_-[K$M[>4ZMEO1'F?:M'^B\33\F>Q\C48'L->I:H $!$)$  $!$
M D0 $!-B71^CV\.G_#]+C6VZG!_0^1.<_2^(>4(
M                               #*<W8>?I5V'Z"H<:Q<"/%_A.6UUNM
MVXA&((D$8AE-'G:/>-KD=!A;U7O3&1U2\1D@D  $$-B>+PJ'3VP\Q73J3:=5
M[3>"TV=E[%G(US<S%*.(RNSHE0A?LQFK5^%FT\Y5:IM,Q?(4T5MDF;A73734
MT43JB9\2J+?BQ[S?;E^@/8?H.AUEX7Q]/PAY3E-WPK6:CWYD0
M               !LG#KL,(>M<9U%\W1I/02>Z/ ]2H=NZ+VMTU/N//- >C\
MHTOO/.,<S+*CK@4B1"%52--(  D0A,O5$MCZ[;-_^;]2Z+\QZ]2Y&##B;V_,
M(\M>L\ I:J
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M@E7V;J_8V6RW$V#/]=M&S-1N6VM/ODVDYU]+XER]ZWP"S;OS?G6=5KU2H
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MTH    #:E-WSK.JWZIT
M                "(O&1E0[2Z+UNEZ=]GT2GYU\QXFIYG\CX*IL^/BQV78\
M);=<7O<7*7-P     )(2((P(A&3S(@C!"J0 0V;MM]*ZO]ET*DSK-R)','C_
M  \WF7Q?@:S7>LT<Z732@ @                          /4F]=%=M?1'
MCKM5&#']I%NON),+7<B;Q][?'NF+Y4>XC8<5XCF<58M92^7<M>!33EVRHKP/
M7\T9KGD58;HVJWMBD1Z      #:E-WSK.JWZIT
M                                     B-@[7>>.T.B=:I=[^H]I)T'
MYOQT_7?D>)R-#8>]N?F:D$HR("")   D $0""2H *BJMN;?>HD]'^I]S39UL
M-K)T_P"+XM;]5^-X'<.;-9[:OP.UDS@@(B                       B(
M "(",G6/C[]JV7YZJL7YI+)G1+OFMFMA4\<Q^ULM/;:W7!OFF]JO3M5K96YJ
M;NL-33;V5LJ*M94Z;ADL3:,"FG++!-.08?--W      #:E-WSK.JWZIT
M                                                       #U DS
M[:[SQU?[GIE/TI[#WU/B>'@>])>?\G/T_HO,S<$U^HF>4(P(      (27"[>
MAM3<^AE;FWOJ).Z_0>KDV7&PH:1\YXWWSKY'PT_!M)Y6=EEOS5#IZSZ"X^0
M                 $0D"$ 1 0$9 "$ 1"0$%\LSXWAH+M,K2]X^9KE1M34V
M7,ID\2^_Q[E2U@;MHN:LOBJS2"N]E!BR,OV9%6J\.F,_OL,:T%7:WE9T3@
M    VI3=\ZSJM^J=
M                C F1#T-]YOGZ:Y>BZ[[Z ]3[B1O#TGKY/JNN.NM5HYF!
MZW3^\/P=;[QK$P/5FL8OJAM68RXA45UPN=W(A?LG,AE.;L/&:Y^U\;!VFZEY
MUL=O+Q+ U4=9Z?SD=)>9\?-T]H?,S\,UVJFVK&Q(W2<9LO(T]!IW']#7P
M               $R*E\M7E9$^8$8P  @ "( "4 "$D2,:3T-]>>NT>U=)-#
MHWTE%9I_<45R00HYCU9KMEXFD$!$0'L2A       !M2F[YUG5;]4Z
M                                                      1 ;TO^
M9I]'V/2U'A*ONY#9>Y]!*VKO/32]F[GT$O.=GM_&39FP\W:_E>:NY=>IF,JF
ME0V["T8^*Q[#P(XEK]5ZU]K=+[U;H_-S,/P-9[QC"P9MGQL.,J*4$ NTXS9E
MS3T&G;7H:\               "()5*6VM7L*6HHNQH*J4J8]  1A$(3$$3&(
M@"( F20$ !ZIB/F4?9X\S,8  G0\5U%?JDN6X:FV>NJ9$P@@         ;4I
MN^=9U6_5.@
M          $0&]+_ )FGT?8])42U0(Q(A"93*JE;=OKQ>O\ FJFKQ,JJCZF8
M2XIC)IB-MM6O5KLXT:>BT@"1!)"  NTXS9ES3T&G;7H:\
M#T)DRWIH]M2:RV./462Y9]D  (#-8KQR]1/BPJ:RDJ55GE6T1[]H0%^BJFL-
M5-3Z'J"4)@SJBK',$N49'*BI&*0  02R&U<E[#PLJET?M]572II
M&U*;OG6=5OU3H
M       1 0     1 ;UR?,TVCL;TM3+5 (1$  ! 1$!$!   1 !"1 %VG&;-
MNZ>@T[9]#7P               !&3:6LV,BQ7J?>-WK,P@D  0;25:_K",Q,
MJO*>DIFMPR8S'+3$KY$VK&ZXOM=3%HNZJBHXFY8A51DVQ8JP>PS$V93-=I6N
MC8DM"(  @DB65V+TFOBGSK7.PJB"         ;4IN^=9U6_5.@
M                                       !$ D0 $) C     "0-Z7O
M,T^C['I:B7,D  DA        !&2,!**075C-EW]/;M08_H;C"0 0   D AY"
M80@      #U)O/1[BFTWML"IB@   (ELA7A^/*;UFT58U;JJ:XKF7,I92*6^
M4K9C5<7^GIB/FN?4BF:N^%HNLK=:D5<VF?6"33EN,(N,4   "$2W%K,^FT=N
M=/4^0        &U*;OG6=5OU3H
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M&?TU8W@%5&2>00""2!)N35Y]#HS<ZBN\H        !M2F[YUG5;]4Z
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M0I;G$V^1$UF(5TY3LJF=8XY-.0S*9]Z9KIV+X 0"(7&F[#8.'D4NG=KJJN$
M        ;4IN^=9U6_5.@
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M5=WB;932O=KFE.A(F$J>FHDHE5LU4EF4WV\4S:=-33GNV=;ETVD]QJJF
M B-XZ?;T^GMG@5$0B5:2[A"GM]4U%S3(MD14S)2_1"0F;"F"J8W)%':T5=ZB
MJCMR*JAF)E;$^*67J9"%)-/HELW7YE+K;88%5:;MD     1&38]_QM#7;"GP
M_(LS\:R*)DJ8 'N#RAZ'D1$ $9/0\B(\CU! 0$0$4O,GH>$(P34LELW9&7XU
MV3JG9:^JQ^]8]P         !M2F[YUG5;]4Z
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MQ9GA"           VI3=\ZSJM^J=
M                 (BOHKAN'5[.FG4W(*42"44!, C$12A )D(!%" $4(B
M "4$GN:?.M,["J<2RL69Y     >ANK4[:DU;G8E73U4B$$LX58S?I4-\MK/2
MW'NHMHXK6R#+4X?;H7BS51>,]58#AU-.:54*6>4E/5-?XIB;J2NG,XQ"$R#=
M.JV%%HG=:>MEH      !$ $ $0 )(01   ! !$ $  1 0 1$9(00D0
M    ;4IN^=9U6_5.@ 1$
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MI2@
M             (@+I:NMB8.7(KHK(F((!&(2 $((B "(@ 2A(KIEX-E8M1C.
M1C^H                            R**E8J6B:4L(@    !(@      DB
ME7Q*YI8;-M+
M                      1D1**!" @D"0 0 $0  "1 $
M             3DLLBMA\VV8Q7)ED<4FB;Z$!<XGQ*/5%,1B)0F#P)@N<3XM
M$Q[]B @/8JTJ%#*XJDXK-,X*E*^Q4Q2:
M                                            $1     1  $   "1
M                            !>%2 HD,LBJEQ6::K-J:J2:F$\E"-"CW
M"9F^" A71/BDF)GJ$;RFEM2)UTA"BE*IBIG3,NC1/F1%/=T^+83J&4S"9MS\
MOBY##YMQ
M                                  "*4$
M   K4KW%3&IH9[%RFI3W,B/$V9A0H4J)EQ3*])F4J/<],NH/-E1/R:)I[9,3
M?</%OF)\Z%/[F?=6GQ3DSVB56Q,,?FFHOT5R-?U6JO*XN,/FV
M
M               "(@                         B,TBY#'YIC;%(("(@
M B "  (B B @ B( (@)@S.+D,1FB-(@
M
M                        >AD$5KHF$1 B           !$@$@CC,T*9"
M
M
M
M
M
M
M
M
M
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M.7F;FKOPA%J&XX(M/%,M0Y'!EIX<%? ]FK?%&_!/"$:R,M5K)^#0V:PALD?
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M@1<(T(ST))ZZGIHK@XCT))F7F1$$((PDM#3Z)/S(B"?1*",B21A'D:$Z$2=
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M9^=V933J2JDMDV3/J#[3+4<L@9#E$$I(NPDZ&I)&$IT[SA:E /0^_H-.W0:
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MDJDM"B&EIR$O'\,?L!,NH],BJS)$]PNVDC1X<>\O%3U(6:#H;XII9+"9C/?
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MGCT#W#I?R^(N01"0[J2DFH: _(>HT&@(QJ-1J?:1Z!#QI"'^(%VZ^-H+VO\
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M'G.YKH.$(<#R>)*2U)7EX\=SB^!RZ+HK#)G X9?!R,AXE_#Y')<:7C[RG6?
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M<1F$*U&9Q>!W$9.A^O>T!>0,M0ZCA-((] K^8)220HN(%Y$:=1H. @1Z$1:
MRU[-/#U##8U\>?(]NTTV;JH[),H^VL&>U:RAORT!^D@N)$0C2DC(*/PR+46;
M)FIF.;JD(X2[9;QLM_.G!\Z<'SIP09!OH&HU&O=G2#8173U2#L9ZHYP9!OH2
M+8RY&(1D*:R1*6Y39Z$:2,^S3N.GY]Z$URFLA>YLHOS&%'J2/17YC/B-!^:/
M4OS)_-VM^IAST3Z%^;7B-LPT$>N4Q.?&II7MY!^ 0>;X@HN'XA"349)T+Q\L
ME<#6+Q.?)^V\(D<$C(6>-@_+L/3AYA)+W?F@^(M1KW]1J.+0.IXTP(_#W5))
M1>T;#A:+]HV$()! ST#UPA!MW23-"R64J:B.7SLM8TM$@K;^E2?FN_S5/](C
M%H1<C#U:L9.7_DH+5):$D%V:]AF%GWH3/.==<)M,E9K6I&HX5&#3Y$2B"4#@
M()1YJ2>J$Z TF1EQ=JD>?":@M/EHH(1H. @A&@-)D$)T#C9.)EQSCN5,OW3'
M@)+4/M:_":]IAAO0O@,AE^XD8=#Y;7VW0R?;RI37-;=+17J'6]0XPK5!%JDE
MD6K@U6.)8XG!Q.#B<'$X.)P:K&K@6IT)4Z(BE:'WG?S]MN\:&ZF(ET3*Q+H@
MQ3C)4OW#AM1C3'<Y#MM_2I/S7?YJG^D0MOZ&(?T,H_N4>A^O.+4U\(4Z1 UI
MU4H@XHN'B(<:>[C;',D9'(Y,4_AS&8P>6[BDSA4->^1@_,.M:@TZ#CU^!,NS
M34,L@O&,(4+&3[-IEI3ZXD<HZ/MLCT$"3[EFYC<EY(/S!H)1)A%K^7PR!J#9
MGKWG?S]MVG5-*LN&1(2PEF4B232"-?R9L-PXRCMOZ5)^:[_-4_TB%M_0Q#^A
ME']RCT6>@4ZI+DISC*27$28R%'.20;,/M!EGR["[,6C\+>;RN%'Q%W ]['C/
MG'<CO$\@::=XB[##K7$#1I\$7F&F=1IIV'XQEH,KG\:L1@<UT_MW"IG-CY-'
M\R/4WGB;-!\0=E<M0U&HU&IC4QJ8U,:F#/0*<X23-'$1DF?JIM?$6@,M 2=2
M!)\G(SAK,O(NQ]DGDJAO1E+9D23A1"C)L*PU*XI.E?6F@[-!K:J&5(5<,J6=
M6@T-$+;^AB']#*/[E'HYZ,-<2G5&TJ6G4DQB2'3YBS(VE/J,-'PI[2\Q7QO;
MM93-]Q)^)R6O]I(Q6PU21:@U:][7L/L<:X@MHT#7LU&H+S[-1J-1J->S0:C4
M$G4-L: O+M,_&ERDQFWG5/KI:\H3'V[A\WD2K6-SV33PJGGJ;+V@E:FOU+P"
M\P\HS6MLB+D\1*0E"82N%.NH(PM1F%D2$MRD&;SZ&C:<2Z0/Q"%M_0Q#^AE'
M]RCT66H99))R(Y+-R/J2B\DIT-UO4U(U!%Y=A"DB^X?G22C-/N<Q?Q.05OO6
M(LA4=<60E]OP]",.1=0I!I&O9Z C!&0/LT'"- HC,)2$M&8;:T!)!_ &,IL>
M(\6K?<O?;I!IPVE0I12FK:)R'9"=5N-FE3K81Z> 7D'F]%+<2ZEK1M*/YU$9
M!IP%Y!*M3R.6IM%?8.-NW%@IYS&IJC!:@_$(6W]#$/Z&4?W*/0_4_52= 7HZ
MX"!>82"/M(8Q$X&\RG<MOXO)ZOVCV,6?+47GXG$#21A3!&%QS"63!HT!I!%V
MZ&8)I1A# 2T1 B(AJ0XAI\!9SBAM?SR%U->4%K[?PBPXT9%$YB'&RU4@C"FR
M4"+3P3\P9:D45! T$9&RG1""220A7$%&9'E:5$4<N)<Q/*=Q3R=,]0?B$+17
M%'Q:<TRS?RD2)+7H7D- 8<<T[=>S3M89-Y;+1,(R*?[I_P"+M*],YIQM<==1
M9E,:5H0_@7BF6H-!&.2D<E(Y*1RD@DD0T[F@T&OCI,7UG[QW$JKB,_N!43S@
MOJ2E]$Z*;"_@DJT-LR6=NP3K5-3*=7>4QJ/'(B4I,_&=0E296/,D591,D:4$
M%GY&86Z#\#%X7$K(I_M6'5\9_%F,LJ.8FLGG#<9>)Y))T^R3,9-:\E-37*G.
MLLI:27E]P<.L_<,Y)"XTZ:?!'Y E<(OK;C57J032U$:(-R3#Z%DLO$(B,U^9
MVKBB*L<\N+@)7HMP'YC7OLM&\J)&*,WE%E[EWXTR(RR&G. Y06QL*)SB(C&G
MQK:?)1:>#;V:8+?\\E=)5% :^X5/8G ?_ED(LHAQG- 7EX'H/4>H/4@1F.(*
M+4*28,A(/A0X?$K&7?\ 3N'=(^@IU\3! R\3A\I"/Y(B")"G- I9GX.HQBO%
M_8>U9?<YBOCID)$QNQKUP7*&Z-1(T,EGPA!<7Q:4ZF'4]\O,39B(:)\Y<QS&
M:/D%]Q,,M^--Y7^Y;6G0:][0'Y!U?"3;G$E#FIJE<)ID:A*R,<\%+U#<@G#E
M>;9^1XT1DBXU-C449:1B!^(:O*2X7!'6?"9^"8K81RW$I2PC(;0Y2_L"WJD6
M#;["XKE)<\\$YQ$1Z?%H420E7$#<+O&K0/RD1D6MHJ>O&:#FGII]Q8TA4==7
M8)GLW]=R%=[B!EJ)1ZDROEI0KA-@RXU:<)2#6&6OY6EEQ1EZJ-/&F12N$NJB
M'%;G,<UHJ-W6&DV6TOZ GB,<9#7L,P1ZC3LU'&0-TB"GM0:S$@SX(OY#/LT&
M@,NW3L).HI*SV;>369-I=<-9_8-Y2IL4.-KBKIKLGPE9+["+7XIKT/N%YCA$
MN0B,BVMESUX]CYR321)+7[C8W<_+W7V4R46,)45?=,@0D(U,T?R,),PVT7$M
M!<#+&A)=X28,B-C\REF02DC"BXAQ CX09Z]NH)9D"<,&LP3ID.>8-XQS#,>?
M9H#/0/'_ "LF6GEW#[2!C'*KB.QG%$;LIAO*^P[JC18ID1W(JZ6^U!+U[-=?
MB6O0^W70?F$^R1"38V3DY=!C9R E))+[D8A>\16M:4Q#K1MGW#]$A2=1IH26
MR2"3H"(M$IT!MD8-A()))!&0,<79KW-1J%:@M0;A$#>0/<MD/?-$/?-#WS0*
M<T%36C-Q]LTL.-F7$0U[3[2%15G-6M:8Z+VW-]1GK]BVM.W8(L*YR"NIOS8#
M$HG"/3XEKT/N6M\W"*3)<E+HL7T^Y:5&D\<O2L6[JI*22D<)]F@,%Y#4:]JO
M(%Z$8/S&G9J-.X:3&H-1$'9S;8>O$I#EL^X..2X#CN&$P]0=>@?+VQ\O0#KT
M#Y>@'$U)$1;9$N4@T6;[9,9 2@U8M.!*B4%%H. ]*Z"N8Y&C(C(R"Z)T..FX
M?V-,A-RT7..N0#@V+D0Z^Z1((G"420?9K\(UZ&#(//H93:9,IP18CDM=+CB(
M0,_N9%E+BKI;E%DW=T_-)2=#+OD%!2^$'Y> ?\H_A-MB;!/27PF"DP3"6P1!
M1F0(]2+L\QY]GD/(>0,<06TE85!21FI]D1+K40(RYJH$%$-%_<D127S<5]D&
M1&+?$TNAYE<9=?D"FBAS$OI)1:$0(R^$:]%>0L,E:C";8NS%5.-.S! KVH2?
MN= GN0G*FV;L6[FDYH46@(P?>,<7&9*X@1]])ZBWL%*./%)@<(XM!KQ#0&1&
M"(B'%H"7V&#&@T(: U#E$8+R'$9C0C$.C5;+IJANL:NKDD%,EFL_LDP9D1/P
MDV2[/%'8X:>6PJ-DBR$>T0^22(^]IX&G<T!K))2\H8C%/NGI@@5+TXZK&&8@
M]0?W0@3W(+E/=-V2+>C*2'&#;/7LT[3#I\)<&A)/0R1PFOU[JBU$U7+DF6I^
M@U!A)@P8,&0,NP@8T[#,),*,%J8I:1RR77US<%O(,OU=F3.,_LN:]P)@L\M)
MBVJ6)27L:?X?YV51\@>;$;)6W U.2LB=X@2=1H9#4^S0NW0QH8T&ICA!GH)-
MS'CB7EQF)=@[*.#3/S!78BTR$()!?=.)+7%719$W8E95*)A3(*XJAKW%$2AP
MD";00XM1Z][70[*M1))"W(QHE(='"-3,$0(AJ-1J#]/X%Z=F@(::C@T%!BZY
MH0VU";R/,E3Q%8-D:Z_99^07_P"0X1:=DYTUFPT3:9<!F44W#$J$N@DQ@AQ3
M9LWLAL,Y4I(:RIHPB_86$632P4I)CW"1[A(7.0D+N64!S)XZ _ER ]E+ZQ(L
M'I C079)P\.><$+'(T4&-/NLA9H.BRXEB1'1)39T*XX,@9@AH#T,.$$EH#&O
M>+R!!^,A\GJ!)!460R#FJ2$RTF"?2.,C!&788_@79J#61 WDI*,DY*J+$4QR
MES$14Y!/=GJ42$C7[+E6*(YNVJ%)@LFT1.D8=<)"8*3>/N2:]F2)&(1G _A3
MA!W&);8<JI#86VI'9J8U!%J&X3K@:Q^6X&</D+$?"FR$;'XK 21)+7L/[LTN
M3.UX@634Y%C0-R!+KW(IZ @7JY^8O#2#T"VDJ#U0TZ',?20^0+!U+J![)\A[
M60/:R![22"@R#'RI\P="I15. KEBJI(]6BPND1Q8VQN&Z\;A_9;BR0F?)YR^
M(T"FL36;BVEG,</5AOEI\)3*%#VK8*,V0))%X)_=J-*<C*J<R0Z#2B0F?C)*
M#\5<=7\7/S%X?H->S0$K0>H\AJ0U&H]1H0@TCTH0*%F*)E@U$*QR!3Q2+$S"
MEFKM+[*N9?+2?F?F(>K1/O&I3$]3:HDLI">PS&H,QJ-1J-1KXI_=RNNGZ\ZS
M+V)(<;0^F9C"%B?4O1C3Z:C7LT\#4:]F@T+MT"&S6</''GA"HV(PD2D1RL\J
M6)$XU*6^I?V=J+QI7$A6@82:E3G>$BT(B%,R;;?9_$&#! P8,%XA_=ZONGX)
MUV:MN"-+;DE*IF) DXH9!^G?8!EH-1KX>@:86Z<?'9#HBXNT@,16V"DVK,<2
M\B4H3+/S=F+<#VI'\?KX^@?CI>)^A(Q'J.2B0?\ ,9"#'-UQ">$M>PQKJ#(:
MCT[#\QJ"\0_O!#>4V(>8R&1#S*.\(\YJ0'HK;P>QV,X',32%XL\07CLE(522
M4@ZF00^5R 51(,)H9*@C&I"@WBBS#6+-)#--':!$2">M6&A(R0B$Z\6X';+R
M<EK<!^8T$CS/XTST!R$D/=('ND#W2![I ]T@>[0/=('ND#W2![I ]V@>[0/=
M('ND#W2![E ]P@'+00]VA13H#:SY/+.H)*$^Z0/=('ND I"3!'\&?W@9]#!!
M#RD"-D4AD,9LXD1\R;6&\GC+"+N,H)LF#!36C'O&@<YH@JS82%W<=(<R5E(=
MRL/9,XH2+DUA=J9A<Q:@:C/NN^OQ6H-1)#T\S,HSK@^7I'R] ]@@>P0/8('R
MY!CY<@>P0/ER#'RY ^7('R] ^7H!5Z![! ]@D?+T#Y>@?+T#Y<@%7('RY ^7
MH'L$#V"!\O0/EZ0<9U :GFDTJ)7P)_>!GT[Q*,@F0L@4Y9#Y@X"L5CYDX/F+
M@.P<,*F+4#=48U[=.\[Z_%$>@?<7)6RT39#0:=PST'\PU-1%Y%V:#0&1C3LT
M&@T'GQ:=[3L>8)PH[BF%$>OP!_<_3X&.G4N[I\&1:AXO/XDO,6#YI*.URDC3
MO&G4$H$6A*+R,M"3Z)\RXC,*\@H_,R\UEPA1:C30'ZK\O!DL\PH,CF%XY_>!
MH]"+X/4:=FI#4AJ)!<)ZC4AJ0U(:D-2&I#4AJ0U(:EXY!1\U_P  ST!^9(/4
ME'Y$K4B,M$JT(_(&8,_/4. S'$04?FH^(&KS\!"N2_XY_<XST!O)(<] YZ!S
MT#GH'/0.>@<] YZ!ST#GH'/0.>@<] YZ!ST I"-4RT$/<(,>X0/<('/0.>@)
M62NS3Q'I*6P<EUT^0\H>U='M70TPXA4E*W"3$<'M71[5T>U='MG1[9T>V='M
MG1[5T>U='M70F.ZD+4^V&)Q&"/7P]1%3_K> 79J#[Y=XD^8/OR2U?\<_N;*E
M$T333KP]@D?+T#V"![! ]@@?+T#Y>@?+T#V"![! ]@@>P0/8('L$#V"![!!#
MV" 4!!#Y<@?+T#Y>@>P0/EZ <-2 Q,-)EY^%H)LLR-B(21Z U$./M4K0^PCU
M[Y!*M0?8]'2X3+BXZB/4'X.@;5PO][4:F0,O+0*!=GH-/#/UT[A ^Q234]XY
M_<QQ7"49KGK&H(QH-!H#/0*/3O: S\P8T&@T!F9'H%J,CT'F),<G4P'^)/@$
M)TGE)B,:%KV$G0S+B!ZC0R"B\SU,%J1D"(S"06I@C,%Z%Z)(PGS!$9C74$'F
MB<* ^9&?@^@G(Y1M+XT]TO4%Z*1J"/4C+RX"(: TZ$KT).H4G4S]3(*+4^'0
M&CA"BU'"1!1:GP</<,P0=<Y:8&J_@#^YEBHTMPRX4*/0FC\C3J>O$/0_4U@_
M(C,>9!6H,^$*,$-/,S!GH#\S/R!D:0H_,]=5>1K5YDHR/01M$O>!H)1\UW30
MNPU>:EA0/0@I7GKH$KU-(2>H3YCR!: E$"/RU#9^6H1YEV2$\IPCU+P76R<)
MIPXZB/7M/MXM0?D1K"2T)9A1^1'Y&>H-6H,S(B/A"O7CU"C_ )E'YK!C74*/
MS)7$#[AJ))&LY2FFB07CG]S)J.)$-PEH\C)*B(<>ID9),S(S(_->@4HM.(B&
MI$%+(*T,*X06A&9D1KTU_E!&6JC(C4LC"C(CXB(U&DS5PF9:$>NA0T\3G@M_
MS/\ <))%V:$-"!^8+R[-- 7D#\P0X2[2["+3ML"U)D_Y?"D1R>(U.1@U.0L$
MZDQS$CF)',2.8D<Q(YJ1S4CF)',2.8D<U(YJ1S4CFI'-2.8D<Q(YB1S$CF)'
M,2.:D<U(YJ1S$@WDD%RT)&BY!LL):+X _N8KS(DG"6APE@RU! R!>79H-.S4
M$8U&O89:C0$G0:#0$6G8?88]"??XQ&8Y2?!27 _VF#/0%V*/0S(:Z'KYZ:#7
MS&@T&@T&@+N3S#9:)\(BU['H+;H*K(A\L(?*R'RHA\J('4D/E)#Y20^5$/E1
M#Y40^4D/E)#Y20^4D/E) JHA\J(?*B'RHA\J('4D/E)#Y20*K(?*R!59!F&A
MOX,_N:XV3A'"<;&CY#C?'$^.)\<3XXGQQ/@C?'$^.)\<3XXGQQ/C5\:OC5\<
M3XXGQQ/CB?'$^-7QQ/CD/.E'C$T7A3T&E:5<1=IGH2AH:0KS!D9&9Z&?KYD?
M\2]5:F9:I-6NIJ'"9=UTN<[]DE\&?WQ(/M$XF*X;1EVK]%&%GY:A84?F:M#4
M>IZ^>OGKH:CU/7SUT"CT[DM_@*"QP)^W#^Y^G;H-!H-!H-!H-!H-.W0:#0:#
M0:>-Z=DF*3P2^J.&Y*'.W0:=AD- 9 BT&@,M09:@BT&@T&G8M9)"YW$<>(>H
M/[+U&HU&HU&HU&HU&HU&HU&HU&HU[-1J-1J-1K][=0ZRETCK"('$>(>V>'MG
MA[9\>V?'MGQ[9\>V?'MGQ[9\>V?'MGQ[9\>V?'MGQ[9\%%>,>Q-0:BH:&OV7
MJ-!H-!H-!H-!H-!H-!H-!H-!H-!H-!H-!H-!H-/PN+LU&O<U\#7P#/N%]]]1
MK]IF"["[/4>G89 P8T!@_('V: ^YIH#!^8,&"_"XNST[?7L,&#&O8?:8,NS3
MS,@?F#!@_/N%_P#XZ:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:?_ )+_
M /_:  @! P !!0#_ /0"4HDD]>Q&0YF5>@*SNM(%GM<83F]<H,Y+!=#,EMXO
MP[==2T5AGD"()NYSJ@K([6R,L6LIAM;>25!&W +;EL'MRT%;<)#NW3Q!W!YS
M)E(MZT0]R)C(@;DQ'A"LV)I?AK:W\6L*UW+=<"*ZRO#@[=I(0\9AQ01$1>#+
MJH\L3L C.B9ALV"=?G<ZO.HSF'/!'K^&-K=QZQ%UN#(F'687*GG68K$@? SZ
MMB<5KM\9"#?3\?719K&L_P +EK)!9%N(EL5N/2[Q=1C<>L+X29!:F(NL#6T*
M+.)-6=9:LV3?X56UPQ5MW.22L@<H,';C BT[8\53X=KUMI[KC*FRCQE/AYDV
ME>'=8XQ:%(AS<:>QG,VK8OPHR7*6J9#+$S)I%-1,U:.Y"1RFV'"D(6@T&W$6
MX3,);I/PULBN9,U6$=3IQ.8)/'Q,1%O!Z"MHG(BVR2DU&FL<,/1U-!IA3H1#
M6I3E<X@NV1'1(1D6(+KSQ/.^9^$^69:BH334;]^]"A-PV^XRWS%6#G+;JW?.
MS:X5U_\ 2>L%DHSYK=:^>LZ4ID57K-1QO2'?;HCV"S58_P!.K:(B?D/<7#SV
MZKUG2U-*@OF\F4GA7W,IPW48?FIQ@1Z_A)EN5)J&Z"@=O'6&$,([M6UJ;\AH
MC3)82=@UQMU_])?JS_1KOZEJ6IU7K+5POSVC<;C,FXNQ_IUBM42)SC2CDOD5
M6>IV/]2J_+,_J=W+<2]P,*S'VQ_A%DN0HIF:>J>R&1'CHCH[T6<AE#B^-0:L
M4DF-/0TE1ZFW8(2AATVE?-$:0I263E.D\ME]QDE6/&=B?^FQ(-DTVB!)L3<*
M%*2P);Q.KA3$LI?<)Q7>S+%N(8)EO'^$-G8MU[*E2,GF5\!N"U\$Q9),BE,(
M$R9S_'S#'#@KPO)_FK7X/&>@R^_5=2,<HTU3/V(^PE]-C#>QR92VS=HQ^#NX
M&1>U;P6@X"[L.(AQ!QXY!=>VLG6S;5XQ%J'8/*;CI2:YK;:2\.^ITVC&)7:J
M25^#EI8HKF*N(YD,U""07=KOZ;WYJK72R_J+JTZ2H;;2(<'FE[-DQ+B&P<6O
M)22BL+$R)R!$AF^/9LD)D+DB%%2^"KT(-=>VLH<4EK>9)U)QD\Z;$2P46 EU
M#4%M E5Z22VV;AHKVVR^7(6<V,E@^[GE'J6 7_O6/P;W$O/<O8M3?+8_>KOZ
M:GF"-=BV@EN&XJ2LT("$?Z::LTG/3Q-Q9*'4*K$B5&6T(2=&SJS,WD:MU0LU
M&:ZL_P"21_5L?Z<'^I:^E?\ TGE&I39ZM5A:KM5GK6+,EVOKW7F4O)5S,;GQ
MI*9+?X,W]L57&PZL.QE=^N_IO?F!"=_3$5PGVRJE:S(B6"9A-NH9@N-G9.$2
M*YXEH75GK*@I935"Q_J57Y9)Z.RF3>0PT;3UKZ5_])?JS_1A/$TN9$YY0XG(
M.U]>]G-1[IC;:ZYB/P9W'M_</XU5?+HO?;EK;)1ZGV+F.+((6:#]\Z%*-1MN
MJ;!SW3"E&HTJ-)E.=(+<-9M/J:#CIN&U)6T2UFLT3'$%SU<3LA;H;EK;(SU!
M3'"*,V3BU1G6BB,.$NT61K[RDDHGTKQVP8>2^C\%[&:F$SC,15M.^PD6+B0N
MR<4#,S\#/ZSFL[=6WN8WX+[EVG*9P2N]M%^"(M0;"R[J4FHUM*0$LJ47P,N,
MF2WBDM518_@ODLA5Q9L,I91\"RT;JCY<1*;4C.7&2\D):4H*2:1!_J6OI7?T
MU^OP.>0/;RJ*P^81?P5NI_L8V!PO<2_@JI/\UHK58-9F4".3JI,XF#T1+1#3
MPNVOI7?TU^OP.<P?<0]LK#C9_!7<J=RHN P^5%^"JUZ*M&SU!5NJ*H_*1(:0
MI%BT@,+);]KZ5W]-?K\#*CE(;P:4<&Q_!7<F9S9E3$]I'^"2HTFU/0Z24,-G
M,GDLHLCD*4ME\.R6FDQ%$3EDZE90'DI;7Z_!9$DZZR;62R_!2:?S.V^T-Q8W
M"YBDKW,#\$Y3Y,-X0R;\[XE2R2#DI('+(>['NP4L@4E)A*R5\!N!'XXFVTGF
M0_P3RM_D0-N6-7/AE+)(7*"G5*\%+JDA$H)62O%RMGFP=KG_ #_!/<)[@K]N
MFM&/A#/0.2@9Z^*1Z!N4"/7P[-OFQ]M'>&;^">YKFD3 D<,+X-QPD$XZ:_@6
MW30&W"67@F6I8&?+LOP3W05_I84G2!\$ZZ2"4HU'\$E1I-ITEEX.,GRK;\$]
MTC_EP\M('P*UD@EK-1_"(6:30LEEX%/Y7'X)[I%_+AYZP/@7W.,_AF'. _ I
M_.X_!/=!/^EA2M8'P$A?"GXB.OB3W\9+FVWX)[FMZQ,"7Q0O@)*^)7Q$9?"K
MO&>A8&7,LOP3W"9XZ_;IW5CQS/0&>OQ)'H"/7O6;G*C[:-<4W\$\K8Y\#;E_
M1SQWCT3\4R>J>[E;W*@[7,>?X)RF"?;PAXV)WCR?R_%1OR]W<"1P1-MHW+A_
M@I-+Y9;>/(_+\5'_ "]W<63Q.8I%]M _!3<F'RIE3+]W'\9TM4_%-%HGNY$H
M[&R;02"_!3<J#S8N S.;%\=2>$_B$IXC[LJ04=O!HISK'\%;J![Z-@<WV\OQ
MY2-#^(BHU/NYS.]O#VRK^!G[0T^\V2QU4]FP\EY'C.HXR^(:1P%W<\G^XE45
M?\OB_9Y!J(:Q[9!#D-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-
MCD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CD-CV[85#29.-J0>GW%W+J^:
MS@EC[F+X\EK3X>,UKWI<E,9O%(BK>Q^T(L<E$X^9 ]>S0:=FG<T&G9H-.YIX
M&G81=J7%)"#)XGF^!7W$L829K.,RU5,[QS+4/-<!_",M<9D6G>S^SY3.W53[
M:-]GH3Q&Y_II(]1ZCB(@I.G89&-#"?0O,'Y#0P?D#]/0%Y@RT!>?9PGV+["+
MLT&A]BM 1&%&$EJ##2S0<U!&1?<7<>H]N_C5K\QB^.I)*)UHT'\$TT:S2DDE
MW5*))/J7D5@PREA'V>S^>8"\B+T(AJ9#^)*U"5@O0_Y01ZEQ:$1\1&>A>J5?
MRC\Q%YD9A:M 9ZDL] L<1F%>JE&1K,R"O11ZF:O/3SU,&/42/-L']Q+^I*TC
M8=9G72O@#+4.QS3\"U'-0(M._G-O[5C;:EY:/M!"N$W4<Q)#70< 6K4:>2/(
M<.@+T+^8&7"7#Y:$DC+R+\I?S _Y2).H5Y!2-0K0.!7H:-0H+]5EJ%%Y+(&6
MH4?GPZ@_,(3Q',7HG[C;B4?MGL6N?F4?X%Q@EA;)H\5#)K#;!(\!YY+*5<S)
M)\:,F,W]HQGPXQH#!I!$#5KW2(&>I$7?49&-._J-1J0U&H))J"4DT3SO,/[C
M6E<BQ8JY;F/34+)9?!+82H*BF04TI/?2TI03%,PAA*?"SR\T+ *#V3'VD1AF
M4:!ST+'&V.)L:MC5L:MCB;'$V.)L&ML$ML<38XFQQ-C5L:MCB;'&V.-L<38X
MFQQ-CB;'$V.)L<38XFQQ-CB;'$V#EH0'GS=/[D;@8[[IO!;_ (R^%-)&#928
M]ND>W2"920))%XE]<)JV,2I%7<HBT^[&OW%,M1E] JED8Y>)M6?L1]]+";&8
M]D<REJ6ZMC[.U^S-?N)9US=@RI,C&)E?/;G-?8>89&<Y>%XQ\J:^SB+4$R0-
MI)#EI'+2.6D<I(Y21RDCE)'*2.4D<I(Y21RDCE)'*2.4D<I(Y21RDCE)'*2.
M4D<I(Y21RDCE)'*2.4D<I(Y21RDCE)'*2.4D<I(Y21RDCE)'*2.6D<M(Y:1R
MDF'&N'[BY+CR+EFGM7L>D1Y")"/L',LIX1@F)<'P9$9@FE&.0H<A0Y"AR%#D
M*'(4.0H<A0Y"AR%#D*'(4.0H<A0Y"AR%#D*'(4.2H&DT^ P6INJT,UF?V,9#
M0:#4P04G4ON+EN*IMVZ"_=HW6'T/H^/RW+?;C"L.]R?P+:#6$1$I!O(2/=$/
M=CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW1CW8]T"<2X'8
MI&%(-/>8/S=\QJ1 _,:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0:#0
M:#0:#0:#0:#0:#0: O4U: E:I^XV68DBW337C] ]"FMS&_C<IS+08?A1R01:
M? &&VS69$EDG7#6- 9:$7>U"3(S/U/T/T(P?89@BU[#\NPS#+QI#S1.DI/""
M[C'J[ZZ:@OLC70>H3^7[CY+BS5RAE^9C,BFO6;1'Q4B0B.C(LO78'B>"<ONF
M@R!%J.6H&6G8:3($1F#+3OQ4\"7U\1D6@(O-1^1GJ2@:]!ZGS//T/C'#Y\7G
M_'4PGR''J$^0)>HTT"3T"CU'%J2?,:&8C.<)SD=UC\SOJ0+OZ#3LT[=/#/O:
M>$8()_+]R+:G8M&[G&Y6/N4&<-R01Z_$761L592)DW)7L9PQJI+N,D2$IE'J
M1D:W7S0:C)U#+?&<D]4I5RD.GS$=P@@M3D%PI5YA9^1GY?\ \MF#/S4C4_))
M\'GKY\/F1ZF9^>OGP&"()+S2"1H-=07F7"9!):D7H1&""RXVR[C'YG?4@7B'
MV'V%XFGB&""?R_<E:"661;=I<%;D,NC749)'LR^$F3FH:+K/%NBAP>1:*@T3
M%6UW6RXVT,J,^ D+D(,U(+EH21<#B"-"BXVU%PM]V/\ GF=NH,$9%VD#()\C
M/X!D_P"0_7M8_,[ZD"^ +OF#!=S7PS!!/Y?N7:TD>S1=;?2(9UF:2H!UF51)
M_P #/M&()6NX)F(-#/R!=%A46L[(SNH?:X#[B%FD')48)1D?NE!;IK[%.FHF
MWC0''37WFCT5)\R,N^1C4:]FO89DD:C4*+0'H%EY]\CX6^XQ^9WU(%W]1KV:
M]FO87;KVEVZC7MU&HU&HU&O@&""?R_<VUH(MF5KMHZV$6-E1G!W$28AY-#E
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M),G;AKFY%B5?"B46"19T6SC)BR,0Q-BX9RNF;J9.)_V!X?$9=F8#!E-V->Y
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M%Y#30*/4_#1Z']V_4:Z=F@L93D>16;A2HY5^X,20(MBS*$B$U($C$8;H>P1
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M-0)A"!S4#FH'-0)9I<;I(I1!S4F.:@<U YJ!SD#G('.0.<@<Y YJ!S4#FH'
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MS 'SF /G, ?.8 ^<P!\Y@#YS 'SF /G, ?.8 ^<P!\Y@#YS 'SF /G, ?.8
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MP..,Y1GN^M5DU[B..; [KXM:;T8XWE>#]%5$RF'UDY;+E7_33ELO&,ZZG?\
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MNYL+<+;>YVVL/M(T]A$#+P-IMI,BWHO^GKI1Q386..H_K,QO95.XFY62;JW
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MN7B^==4U&U<;>[6[NYIA*+;8_=/=RXV/VXG[6XWU0MI;W)Q+_8\WWVS"^O\
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M%;@6!C]?V@_7]J8_7UJ$[@V)")N&ZV[;;AUTN260XU-!P\>GG(PPW"D8_8Q
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ML*'LL*2&\BQ"D&29?,R!S7P2&WDENUJY<9<-[7MV_K(UM:8A25DQ^K5C.4#
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MQ^EI_@+ZQ7^2NE2M>N.F?I%WJK>G#=7J'WIJ>H/I&^C7_P H^IG_ /(C;_\
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MU$3565)9O0*BIP^ _&Q%?Z=HJFRQNT@X)82K&M"?ZWW%RNA1DE7MC?KQRY^
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M@R$ZI8/1?COV+,=9W<=)Q[!J4OXJZKDVT#;&<Y!+LZS]B[[J*VQ_^G[>0?\
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M/B-0($6I]W70,EHGO+/539:)VF=C'U\[F76*X[BW61FN'Y[TL_3J_P#COO\
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MFV^W]' MW)=7$JJS"\)KLCQW#LCD<6$WE+5.T3D>RRSP=",<"1RTCEI'+2.
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MC)I-<LG#B1N0?$0XB'$7PJ@7W??_ #=JV4K'MB!QU$#:60X%$-.S0:&-!H.
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M8YIVA V/&X_<HXV,.TA0L:.T]O5)*749J?113C\IVCO^Y3$.0;RG9+O\HZI
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M)1114.6?/B4YY^PY\N^EM&5O_"=A"('A=-O:-&Z'HD-;,DP&=1/NC]3S[99
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M=J@XM/SB'\PAM46@9VN/88+A<X:CV!2Q-;?^)2>-1[UXQJ*GB?M_XEQ/<<P
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M@HE04NG!82#412$&8\G5.H!SV'9F5QX[QF41,&@^M!ZC*>:E1@9Y"H%IM"G
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MCQ2:G#*+;#H-4"UT"XTG(IKZA ! I7TL-U-8,(0]9A%LA$@ FM$.F1ZCDI4
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M-'$>8 3)L 7UL,BZ?>M]?8@YAF-4U]2)R#/7T@\NVKB=GJ';I"O&AN^KOU*
MZ2"BH]+)3ZF0/$V8[1IWP3<5M1UBL:0@]M!$1I]'0,PFX E$1O$\+1E[$YCW
M=WJ$(5T6D(-%73_[#QPM\.5W_#OA8BZN@9_8HF9/5(=+&'.!Z.!\+I')8=&Y
M'#?01_ Z$<-](/J=/3.P087A3WY$<$Q8UIE/AC4X6C+VT.;YD3!A&,G"V"@.
MC.(ZAHBCB.I<8ZT&FFDYSZPZ22BKJNV=-%0*CU(PH=,=HU[((X+J6S'RGN._
MT>/,,?=($*/6,5-Y.)$$.J$*@VO+&G(@#"(%('3MPV4N,/7-2FX3*&C^)TF:
MB*!(=^GJ4.JP4.D^FZENUM6JC4AYAHFV3OEMT;LW3@AS)BT_VH/>6D$PE&PF
ML"SI!@CWIG,.\[D#4V9[/7)T<U+EB$'5U]0AU*\*6ST5[)Z$W$JC _*:=5.C
MTA%1Z<^9=\K?ZCV:U=%+MU?=U&')'FP4.0W;$8U**]JC)5:U(TGGWNE#Q53E
M%:M:X:P4[#-5&4&CUMZ89AN3?G&YW2.<* ;HS"6VG2KYI?/15WZ>CERR4$6G
MWA 9":T6FJ4>0'IH=1@4[#L,LU6Q-)I;PG11LAZ>;AMI<8>N9##;(-$-7K-%
MU5 S>L^HD@J!4>6)45%.T)X-2?D"<2G@5#L5ZZ22A)-D:4V!A-1IS(D2YD I
M=,<$TMF,WL.]#';2R1^4]QWGIAF&Y-^<;G=&]]<(#.9!!@K("#10!#HH<V/)
M$4H1ZA#J+<45\)SB8[=2=A'WA$9Q[-W5 S"%8$3GJ'?JZPT,<1(T$BO(B7DD
MWC28U#H2]U 5P"#8'.>>[S#JN%N<TZA+2KHI=+17W:>I$U9E$]JERB:T*.1.
MRIQM3LN1&"<;0H-.Q"<\R$Z[$,ZD=B)/,O*'3->*C/-6BTS#A#00G83O=,.X
MZ1THS#<F_.-SNC9A"LEQT2&\ZE?/NC:9;H]%#G0Y)UJ-O48]0<*P+P_+/=%,
MQ+"(YJ#LZF', ,3"<;,A"O6&*<'@" %$>TE7&B+M@S]ROB-W(T7=<.U##Q8
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MUVQWMCU,?,-Z@KKY0,#KFJ7:QW(M.(008&)%/Z4&LF&P.CU*+36)9Q/=%1-
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M2H.*I5(5(5(5(5(5(5(4E-0"FKPZH2OJV]3N_"8:#/O3<85BZ<XF-^SGP<X
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M2&HD(AQ +@TTY(=BI&M4C6J1K7B TJ(<-86(,-\ *(!IJR@J/U#^EO\ :O\
MF']+/[5'ZAU-_M0/U#^EG]J_YA_2S^U$?4,Q#PL_M3&/<71< 9-K.98E]I(+
M"",X1A$#,>Y8;A'QM-!J(R+%#ISA#0%A_P"/W;76G*A_CVN[U$LAI=WH$,$L
MKN]%F&(" E_%%QIO'<.K00:H=?.<[TSY6[AZ:PQ^$'7/M3M V#DDB33!1/+
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M8L,_,-W30*=C"5XQ,S3K56MW>@]PC @TNI&E0',_*.U.'XCN'6+ILIY*)%&
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MOFX9_"!J$.Q.SQU@'E.8H<V:@.@.9'H8O;$BN?842!,Y3WH#X:$'N/>B\>,
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M9A"\XT 3/KEH0Q/,P<[X?=;G^([,]*O/,-YS!?Y' 8=3!'6XUG8*K5P"'HP
MJ2O&<9JQ%R.(>;_D:#E(GKI7!>;F,1MGM7^-X.<%NZ\O#',1WQV+BPW?I*F"
M,XYO"QQS GL4F'3!N\A<1:W3$[!#:O\ (\G, W?>4F FUW%ODH#[.7'<3+*Q
M\I[*,U*OX1C:*QG'KD5YG"[8<X[0H/$,M1S'J4PJ!M4NU1#H:%)VQ4[%[%[%
M3L7BV+Q;%%SA%!V-PMTQ.8=IVJY@- M/O'.:=% J"NMXG;!G[E>=,J)]&1/)
M)7'*!(UH,:8Q0'1S U+PMU!2:-04OM'?PR6D5A!GF.$_$/"<]F[,IP<TZ05>
MP3#(>P]^M77@@]5HY9\D0("T]EJO0O.M/8*M^51Q##)6='J$0WA;GF<Y[ H-
M4_1MT5J/(7E7@4'&:O#[9_XW2^$S:=':(%7<7@=E\)TU:=:@X!P.D*.$;IL,
MQWC:HN:86B8]<_58-$3D47\(RTZN^"C"\;3/4*!O47F'K8H8(@/B-.@4#:HN
M)).E0)EZ/BH%2H5P5*2@IU_;7_&XPL,VZNY7<<73:)MU4C:KV&X.&0Q7$V!M
M$CZYU'"=H=WCN7$TYQ/=T\& G,(J8#1E/8(J.(2[8._:H, &90)B;!,^N=09
M!HMK[@HQB<\52M'I"#D;JB:5 J2 JBH#[;ES200)$&"@^#QEIUCMBH/!8=8U
MB>Q?XW YCV+C:#G 4@1F/?%<#R,XCVA<+FG6.Q2:#F([8+P'9WKP.U+P.U%>
M ZEX-H[U. SGNBN)X&8$]RXG..H>NM28-,]\5* &I3<#FGN7^,:7'L'>N)TK
M!(;.U<*F?05(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(UJD:U2%2%>:0K5>=
M(JE4A4A4C[:'-RR*DX[]A7$ ?7)W+B;#2.V"I(U=A*D\;5XVZPO&W]0[UXFZ
MPO&W6%X@O%'0>Y2!.H=JX6@9S'N7B S0]I7$2=,5)4\[1UR:NX8.=<;NMR46
MN5UXTJ7VQ.;H*52J52J52J53T>CK<U=90*5+H9*?-ET\U=?15]L79NM:.MA@
MI=)0Z>""AS)<D>B+:Q]L'9NM4];S=0CT,.A(MA]GZ0J1K5(UJD:U2-:I&M4C
M6J1K5(UJD:U2-:I&M4C6J1K5(UJD:U2$8$:U2-:I&M4A4C6J1K4NGX1!3<O$
MO$HER@"O$O$O%N7BW+Q+Q+Q+Q+Q+Q+Q+Q*U0?)1'2/ZS'H6YQO\ L[*E1>96
M*?4(\^.&8*[B4VT*/1W&4E1=,\Z'335UTPI=&1;T<NK@V0^SA*ONT<DE#I(=
M .7**%=-(Z+.K[J3RQY)<L!S)\AY9\V".&ZKH_J!7ATD5'F2YDE$<DN27.)1
M>?LX8(*/)'G2Y(<V'+!104!R0BH4\A Z(-L4!S)<HY)<IY##H0\5]'=*+'45
M%1'-BI=!#ECRCF1YT2KHH"@/LX4(5*!4%+H*%!0(4N2?+%0"'+,* Y"[HG:.
ML!#HX%0@7#(IRSR5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5(5
M(5(5(5(5(4IYE8%+[.P4:05$3ZS<9./1G+#HH*')#HP$.EF%(JE4JE4JE4JE
M4JE4JE4JE4JE4JE4JE4JE4JE4JE4JC[00*_QNE9!4[%[%[%[%[%[%[%[%[%[
M%[%[%[%[%[%[%[%[%[%[%[%[%[%!QAH67HP\*(YT>@@%-24.< *ONO@KCM'-
M',') <R7)-2YD&TE1-/W81KJ4'T*1ZE-7635]]/W90<(K@DO%L7BV+Q;%XMB
M\6Q>+8O%L7BV+Q;%XMB\6Q>+8O%L7BV+Q;%XMBF[8N,Q7"/_ ,U?_]H " $#
M @8_ /\ \ *)D%QXN&/SMCJC%3Q1H#CN!7_,_8_^U?\ ,/Z'_P!JEBC]+QO:
MN'&9I<&_S046.#LQ!W?=Y>>0 *R8#65 .+S8P1_<8-U$J&!AM;E<2XZA= VJ
M#'//_;;#:P1UE7GM.=[A':2[8N)[!K/8%Q8NIG_$IXI_2.]?\QVH=ZEBG]'_
M !!<&(TYP1NO*+0'?*X#^:ZJ<5H%L7-VWFJ&*&OT77:VR_:H8S789M\;=8XO
MVJ]@O:[,9C.*1I^[:..\ _")N/Y1/28#*BWRK0T?$[B=^GPC3>5]]YP^)Y@T
M?+&4/E"CYA\<C)?N/]H7!A@FUW$?W1AH@H#HO\K&NRD".NG:HX1<P_J;J,_W
M*_A<4*"PP<-$C'Y8JYC<8%(>(/'YJ8_->0:X_3=8^0T.HUP.3[LK^.X"P4N=
MF%.FBTKZ?EA]-IE&G$.GW?RS_$OJ8YN S)=-YT?W$:5%K;SOB=Q'14- ZC#&
M8';QF-(T%7O*NC^%W8[O&E?3=& ]Q\V_ELSM,,Z#"?IO^%QD?E=0<TCD^ZXN
M<8 4DT!'"\E,UXAH'RBO.99"OK8A(!I>^)C\HKV-RJ+!%WQ&;M%FC3'JMS&:
M'#+V&D'*$7^5-X? ?$,Q][-(YU]+S +V"4#XV9B;/A=F!"^I@.#A7:#8X4@^
MH^ZOZF,8"H>\XV-%>X5D+Z.&"&DRPVUY7&O^4;4,3S,'.^'W6Y_B.S/3S#=J
MM5XPEZV<X%THHPA*U73TG&(.J>*=/Q#(=!"#VDBQP\+A8?[3G%J&&^#,2RIW
MR'^DSST_=3/BQ#X6=KK&[35607N,;7'P,%@&YHF:365=PQ,TN/B=W#(-\^;$
MY_70IUQ!1!J5X"6<*(D,JB:+0K\)(71&$4?IZ:.U<=.CL411:5$SS*+A+.%
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MHAU7>KI7TYPVT10(C.U!QCZZ%_D,S5&"+F55*Z*UQSRDP46F60[D(1G;SO\
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MDC^KJ!ZV.=B&T0_40WM6-B?*W7>)W#[E'89]X$:Q!!A]X.;JXOZ?2(9\3QJ
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MLN22GSASY*/V(=@&DB+38X>$]AR$HX&)(/-T@^Z\4;>$Y\G48%1'48E0'/\
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M7F$.!LFH@7#DHTM[H(NAPVB)'>-*F.@PO^XS^8+%^7M"PR:"2W2X$#;!''P
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M!!$B")@@U$&A0Q"!CX4&XH^+X<0"Q]?PNB*+L5?JK%H]:%<;$=J+GF5(0#!
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M#FPT9,A]9Z^EC)%I&<5*Z! !%HK4&&E7X2[4<=\WFBQL:!WU543)?C5TP40
M6RSH'$( .6:-QS3"J-.7*@SPL!C=M-IS5>L.B&'0T3>;&V9S0-=2@(-:T:
MB\T"318.\UJ//(4#0?0,0KKO&VG*/B[\N=?[>$.)HXQ\31[V=M?X<WHV*CRG
M&QF@M<(".V(*A  &0@O]EKO$9MRPI;W552HY XO(@("!A"%$((Q<Z<C,SS]0
M'G,<3IPVFK\9R_#939"\9N/A%OL%:+WF)/H6 K43SKCYL-/X3:.T=J+'0<UP
MV6CL*(I:9M-H[Q7TTN1N&91-*&$T2:/6.5%CA!HE$UIS6T D<DU'HPUHB28
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M.Q+!+/0-OH<E%YKZB&&AXNZ:6]VE8F&)D"\WYFSVT:>EQ/G=_,5B_P#Z[O\
MY,+H@T4DP3<,4- :- @GOM<89JMG4QB"HQU(.YIC8J1K40@#RP;K43N4#2LJ
MB-@4'<@Y#TH;\)(_J[4W%'O-AI:>XCJ;OD/\J!L7U<&!);>;&@DB+:*C)0+,
M/]+O[T,1N PM<+P(:XQ&8/CF$(E'$Q@&N?>!$"(.IA Q(\,)IKV^X\$YB"(Z
MX:T&-$23 "TFA-P_A:!J$$ ?>:YNFD?RH8C1&XZ)^4B$=<.3#PWR,(F-5XET
M#FC!#%;0[%)&:)AL6(QLS .'Y2''8#R83'2-V/ZB7=J&(V@XIAFB8;%B9V?S
MMY,4?B;N*8ZW# U.=WISZFL.LD0&PZEA_/\ TE8OS#<F8U3FW=+2>PC:L(-J
M<''(&\79!/!I<6M&L'<"AC@<6)&)K@"0&YI1SG($[ P&#A,"7QF:X-!$K)SI
M1QO,3)>0V @+H#?ZKRQ/R?R-3/D'\HY,+.[^1R/S-[><_P P:7&Z,S9G63^U
M-PA6;QS"0[=7+3T\.JW H#J(<*001H3<04. .M8F$* Z(^5W$-AAS_\ 4\J,
M,LN-=QM+C%T8S#A98J,']#O[U1@_H=_>J,']#O[U1@_H=_>B]U+B2<Y,4[S/
ME TN<PL-\%PNDM=0"V<6A48/Z'?WJC!_0[^]48/Z'?WJC!_0[^]/\UYL-#FX
MKF"X"T70QCA(ETXN-?-PF_B!_3Q=B>^QI.F$MO5"U%AJYL JO70IJ/(3R0*B
M$4! J(0.1#D/2XF'F(V@]B9B?"Z&AP[VCJ;6XKVM<&P<'D-$A P+I$'/&U-'
MDBV]>XKKB^1%L7"FH'0AY?S4;H\+@(W18X"<+"(FJ$%]=YPBXSF^[$_B;> .
MELT</RAO.(@"!!K-=)%0$K:((8K3!P,0:XTQ5S'+6.(@YK_ ;8$\,#89U3I)
MQL$-<^H,)Q#708N:S+1+0$W$,HM!UB*#FF!!!!L(H*^GYOA="!,(L=JC"-8(
MAEJ7UVG"B)^.]#,R\0",C9(X'E(P,G/HE6&BF=9,)2A6L+Y@CCPO72V(R%P!
MTS7^P/IAU,'.N0/R.(;&-@(1P?*&\YP@7#PM!IA:ZR$A3&(@L)[R  X1), ,
MY*>S#Q&.)+8!KVD^(5 QY#]2)8\ .A2"*'981,<^A#ZS\-P$Q%UUPVM>,U:;
MY7RMUK#$N>>%H@TPXG3<XD 1.LE,;A8C'D/C!K@XPNFPE8@Q7M82X0O.#8RJ
MB0G^5\R6N9(M=XF&5K8W7 QGM!1=@OPQ&FZZ^XY*7.T4(!@AAMC=!I)^(]@J
MTK_6\P;H!):ZH1F6F%$Y@T3,8+Z^.[#<;0^9SM88NT@V)V&PMPVL@&WBU@<)
M^$&$ (;10OJX3VO#FB;7!T".&!@34 4T'%PXW (7VV9^1F/"-T@D6BO8KF+B
M,+32'.N&VLM<,X4/)PN711$B,XS--4^;AX58:"?F=Q.VE.L'"-%.V/)=40J5
MQ'H9*?(;RB.J$E'$MZG<-+"1H,QVIGF![PNG.V8U@[%'G7\'"Q'M^DP1:QSA
M'BE$ A?_ %\;_P!I_P#:O_KXW_M/_M7_ -?&_P#:?_:O_KXW_M/_ +5_]?&_
M]I_]J_\ KXW_ +3_ .U?_7QO_:?_ &K_ .OC?^T_^U?_ %\;_P!I_P#:O_KX
MW_M/_M6(S'8YA^N\P>TM,/IX4X. ,)&>3FWOA8XZX-[2G"T@;8[AU4/&=!PK
MYAC8J1K0 J1/(0IJ*A!9U0,LE"Z-BE)#D/2@?$"/ZNQ8F0!VHCLCUAC\< LC
MQ B\($0B0:81CH1^DQK21PN:3 $T&1@X+_(]@;:+Q=#,0!M1,9W;K!63" U4
MG)S<+Y@L3.W^=O6L/"J<X1S1B[9%.>:@3J$5$TDQ/(#E1(,E-1"IV*G8J=BI
MV*G8J=BIV+Q;%,QT*B*B)(AZE1U1K6UF!4!U-V&?>;M;[(IQ%+"'=AV$J'.D
MJ%0J%0J.9 \D!S<5_P HUWCV!-;:Z.H'OZJ04664<L JO70JO70N(ZE <L1)
M4A95 J1"BZ:AR0"GTN&?Q :Y=JQ&6L<-AZS#!Q'-%,(Q;^DQ&>4ZU XO[6#:
M&Q5_%<7&TDGU&3FC%PS!S3$&1@<QB$<+&?>:81%UHH,1,-!IZU?/N-)TGAW$
MIWXH#;/8#S($J"B.AARQ*EU,DU!'$-!A 6=48_\ $!H,CL*?A?$TC6((F%"C
M=.I>$ZEX3J4FG4IM.I W1K/>HW1M[UX1M[U-@.D]ZC<&WO7@&WO7@&WO1(:*
M,O>BUH-,*T3==^D]RB6NU'N0B#(J(Y8)[K7PU =ZPV_,=W=U8.%LT".OM=8X
M':B#6B+#Z:Q<6TM;J!)_F"8RTDZA#M/+'IRBH\E*I&M2Z8,%<BH=4BFO^( Z
MQ%8F$V0#C"55(IR*%[8.Y4[!W*G8.Y"!V#N0$=@322)BT*D:QWJD?J'>O$W6
M.] Q&L=ZI&L*D:QWIQB)-)I%B#H4E$01A8H*/*2CE>3L:.Q,;^&.LGNZL1D5
MP^@(IXL<=_IH.^)SG;;O]*#;&[23[.6Z@H\D50H0HY05'FE'EB#)042I=(2B
MXT2AU;#-@A^DD=B+FB-X-.P-[%10J%0A$5J(%2:(4#*J!M5 V]ZFT:SWJ :-
MO>O"-J\(V]Z< !,$5V*Z'!$Q",ZBJ:U#DS*!$4TM$(ER:34P?S.ZN'!1Z^W,
M-RQ?G=O/IK"'X ?U<7:GZ!J Y)(N-*BZ:AR$9$":T2%XAL1B8R*:AS3F1/+
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M=G&52N/:YAJO2ZF!D"Q#^-V_K\%)4JE4JE4JE4JE4JE4JE4JE4\E*I5*G/G
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MB-CK["HX;8:3VGK+&_B;O"<ZQI.H(]=&=#F1Y(*7)#DCR04>6"'++D,4Z[3
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M"'?;&YLI#D%N87B/D<#]SR/;=HMY;J[E-(X8(VDD8\RJH)/B&$N+K;H]DM'
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MVB6JD C(YTIQQ>;G9H)+[8W3<X2HJ3&@*S"O-V;%SSE!C8OZ2_\ ]<EQN?\
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M\YB6-0%]UJ,?_+'OW*)=_M82L$DU#Z;;**$-7SI$7SJYNG6S(<X'>?NQ$?\
M!^ZRGL *D6DYJS0,?Q2*M$3Q6JYE*G]QX1Q@LS$  "I)/(,3]^._'9VW>&^M
MC<[A-+EZ':J-8AKR4 U2TXOU<PBG#[H"\6QV9:';;9OFQUSD8<-<E 6YAI6I
MTU_86VWW9)WMK^TE6:":,T9'4U!'R'(\#EBYV;O+"C3RQ"TW6U7)H9Z52:.M
M2 2.TB;.A!7,JV+WN-W@&I[=M=O.%(6XMV)[.5>A@,Q4Z6#+6JG]QX^MGO1!
MJV79I0MA&Z]6>]7,/GQ6')NF0KGU&&#ZF^Z\W]FMV63=Y$.3RBC)!7F3)G_+
MTKD48>VV_O9WTV7TW=9Y[M))O3+N*HCF95&F*5%%  ,AX<265[/L4-Q"[1RQ
M2=XYE='4T964W8(((H0<P<>G^KUY=L:6(FUN[*\>\MV8$C4PE>36M<B$=>&1
M!K6_[D]Y4";A82]F^FI5U(#(Z$TJKJ0RY5H<P#E[O#M]FNJ>>1(HUJ!5G(4"
MIR&9QN'?OO=>>E]Z!+:+'%;DBVMEDF56%3G(]"1J-%'(IH&QLVU^LAH$[MS2
MR"\:YN#;1!1$Y75*'0KU@N>H9Y<N-GF]1\VVRW<UQ,MX+'=6OF$812FI6FET
MBM:&@K[I;]Y[77)M\E(-PME/WUNQZU <M:^<A_&%*Z2U8.]_<K1=;W8V_IVU
MS1?_ %F!U#/!_#&: \) !D&;!5@00:$'D_<<V[N+W?7^U[A,(RY%5BC'6DD;
M\E$!8\]*#,C$&S]U41+B" ;?M,+4)><@EIG'+0EI9#P9C3+6,2W]](TUS.[2
M2R.2S.[FK,Q.9))J3[;:O[S??ZP^.\?^^+__ %A\=Y'N1)_AXS6OHVNNCTD!
M^U[/DKI[/7_ Q;PV]-;[59+<:>.LR2C/IT:?%3$:=R]TW47[W$"N][-;O$D!
M<=LVA((V9@E= #"K4KE7&X=X[6RNH=VM(TCM;KTV5I9[F1M*!T<M$14ZG"1H
M=*G25XX'?OOW--9]V3(R6T,%%FNRAHS:V!"1!AIJ 68A@-% QD[C[7Z*.\,2
MTDBMMZD>^0H 6)A:9P#3SJQ4%> RQ!?6,[W_ '8OW*6MTX DCD U=C-IH-5
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MS;)9]T+F_N4W**YDF-])$Y!B9 NGLXHZ><:UK[9_4UWAF^SDUW&TNYX-FTL
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M^,8[S_W:'_6(_87NANDP>\BVT[-NUN& E4=EV0E'+21*,K4IJJ.*G AW+?K
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MY[PV-L;;<(9<_3+5AH$U.6H.F6G!^MD'48?:P'EV.\+3;;<M\Z.N<;'AKCJ
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M50*\..6#%MUJQD S 0CXP,7.[6,8-LS_ &D;4!ZH%:#C6F'@,1%P!UNJRD>
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MS=+]3M)L-#W6M=QWJ4#J-'$+:$TY"TI#C_HCA[;N=96.PP,.K(%-W<+_  Y
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M0GG Y?Q$X(.=B3B'=-KFDM[RWD66&:)BCQNAJK*PS!!S!&$[A=_7B@[YP1$
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MT>":4M;,BO5!49NKBG/EC;;+N=>7BP322&_N+QXI!%$@%-"I'&2[$T )IRY
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MPP4W&X!G'\S'UW\8&0_A$8:WV2-;9>21QVDGB%-(\C>'':WT\DK<AD8FG@'
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MV4:6MT0<@OV;$\X&:^%?(<,+F B(U*L#56 _%/+\?.,:7!4CD.(K* 5>5U0
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M3<[A2.&NI8D/5!Y\='N4>TKJ3;X:2WLP^9$#YH/XS^:OC:E%. B!+7;;&$
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M"1]K&\CL!7(T9:4\(-L_>6\W*/=3&OI*V\\'9"3YVC5 3IKPJ:TXX"("6)H
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M:L-H/1H^;4/./UJCP 8+<IS/O#7"Q5N<8U2,6/.37VE<":ZJ$Y .7 @@0"G
M\N#))R^S3%!PQ3%,9>Q7%,5]BIPUW(.L17#2,:DXKC/V.TBZLE.3A@Q2BC#W
M('FPNW3M6YVUNP:O'LSG&?)51]'%EWSMEZETOHMP1_I(Q5">EEJ/ GNNV?W*
MV_JUQL__ )AM_P#5+GW.QD==,M^TEX__ #ATH?J*N(]F1JQV%LBD<TDO7/\
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MMUA&TMS/(L44:YEG<T4#I).+'9V.HVEM# 2.7LT"U^#%M!<MI%_;3VBD\-1
MD4>,I0=)&+;>;%#)^K+L23!032*12A;+F;37F!)]C9MHW)3%<+ T\JN*,AGD
M:;2PY"H>AYJ9X@WZS(-O=;W(\1'+'J8(?&H!QO.VV*&2Y2%+A%45)["196 '
M.54@>QL6V7JE)O1VG93Q'I$C3 'F-'Q'O%H0T$^^RM&P^<@9@I\8 .-W /%[
M,'_M,?L;]&#UA<VQ(Z"C4^+&V7I!T2;4D8/)5)Y2?SQB]W-5/H]KMLBN_('E
ME0*I\(5B/HXVK_>7_L7QOG][A_JSC;N\VDFSN[(6^NF0EA=B17DJKJ1SY\V-
MC@M%+>CW:7<A R5+?[0D\PRIX2!Q.-SBD($EX]O;1 \K&57/\1&.(.]D<:MN
M>[-*TLQ'66..5HUC!Y%ZFH\Y.? 8O>Z?=3;(&>QD,,EQ>ZVU./.TQH4H.8EC
M7C0<,3=Y>^+J\\E]*EN4C6->Q2.,9 #/[37F:FN5:  ;P""-*V8\/]EC.+!E
M-"-O@((_HA[&Q%C3[2X'EMI,2_WVV^,^VW#O5,O7NI5MHB?Q(AJ8CH+-3^#B
MUV5#0R%KB0?DH*+7PDGZN&F/+PQI4$D\ ,:Y(G5><J0/8,BJ2HXD#(>XT''V
M*#C@2R 1*>&HYGX<=I<IU#P9<Q[-!@75P*'YJXSX8RX>[M>2Y5&5>C#2MRG+
MVU>7!BDR;D(P8I!0\AY_<*XAOK5M,T+K(C#D934'RC%KO%O]W<PI*!S:A6GB
MX8W/9$73#'.7A'_)2==!XE8#Q>W'?7OC)N2[@;^XMJ6MPD<>B,+IR:-C7,US
MQ]]O?_;(O^IQ]]O?_;(O^IQ]]O?_ &R+_J<??;W_ -LB_P"IQ!MUO7LK>)(D
MU&ITHH45Z:#%OW4[[-=)96UVEZAM)%C?M$C>,5+*XI21LJ<:9X^^WO\ [9%_
MU./OM[_[9%_U./OM[_[9%_U./OM[_P"V1?\ 4XL^Z'<IKI[&?:8+US=R+(_:
M//-&:%544I&N5.-<_:['8$:E%XD[#G6"LI^!,;GNX-&M[2>1/I!#I^&F#[@L
M2_.(&$A7YHS]Q#82Z;S:BHYQ7'ZP@&2*,QRC,XJ.7V;/^Z7G]6<6_>+O1!=S
MVUS<K:HMFD;N'*,]2)'C%*(>6M:98 .W;X >4V]ME_\ K&+NQVR[GFVJ8]A<
MI#));3QL,P' (R/$!@T;<S4RE[JW4OI%I)&+FSN*4,D#D@:AR,I4JPYQ49$>
MQW=V>]4/ ;U9G0\&%NIFH><'10CEQ/%MDCQ-N5Y!8R.AH>R</(ZUXT8)I/.I
M(.1.+'O9L+A+^PF6>(FNDE>*L 02K"JL*BJDC$_=KO%+:)M=Q()'@@M4'FL'
M4*[ZW4*0*$-J(R9B":[5<0J!/N+3WD[ #K,TK(M?!&B#Q8W3O?=;KL[K>W4L
MD(EN+G4D&HB*.@MR!H2BT!(RXGCB'N=WXN[:\N;2:46SVLDDBK;M1E0M(B-5
M6+ "E ND \@W#;+! ENV\P7"(H "BX9)J #@!KH!R#'>K^X'\]<6/]RO?ZHX
M[M?W^X_JA[I7&[[(Y\](;E!S:2R,?A7&W;VHJUI>F(GF69#7X47WG:V?>#<K
M6PW&.U6&[M[Z18E8JH1BK2$(ROQ !)H<QD<6<'JMELFW W;-<"TN'N*QM'QU
MEG4 $"B@Y5.7'$?<KO\ M(-O@RM+Q$,G9(34QR*M6*CYI4,1YM*4I_BW<KG8
MY+V5M;,]\(-; T)DA[1 22,RZ=;CG7$FR>K647FZ/&(XIXXRMO; BE1J U,H
M\U5!4'SCEI,._6,SI?P3+<1S5JPD5M08D\<^->.%V[OA/;;;N$D9BN[:](6W
MDJ"&*N_4*,/FL0173GQ,O>?NREC=[R5+0I8S-=MJ:N2,7>.'E!(*T7*AR!M-
MWE41FYMXIV6M0NM Q%>BN(MPL9&BN8)%EBD4T970U5AT@BN%V?UDTL-Q,?9S
M2/&7M;@$4/FAM.H><K#1S-G0#O;93[&MU&1*M+X3!6)!!6W[1E!!H1ICJO'+
M/$W<_P!7#2>CW*F.YW!E:,M&<F2)31@&&3,P!I4!<]6.[_\ ?4^(XN.^!@])
M2UEMP\6K262298VH><!JBN5<)WW@;:;>_9A*R7D_HVF0FIK;R.L9(/$A2.4$
MU!Q/W9]7%QZ9N-TABDO8P1% C#K:"0-;D&@(ZJ\:ZAIQL>X[G/';6L-VK233
M.J(BT.;,Q  \)QN>V;)O6VWEY(]J4AM[R&61M-PA-%5B30 DY</8G.\([[-N
M*)'<]F*M&R$E) O*%U,".-#49BAB_P 4[GM%W:QDR1">[%O,G/I&J.9:T%1E
MJY0<6/J_]7WHEIM<S2O>7SL88$T0L5K+,0TCLP5=3$BF0))RVRU[N[K8W\T>
MX:W2UN8IF5>R<5(1B0*FE<;Q#WCW2QV^26ZB:-;NYBA+ (02H=A4>#%_ZN^_
M,EI=;12%[>[5O2+:35&"1VD6HI(C$@,",LM0/&:^[K[AM-LLH^T-O=>ESN "
M0N3R2TRX<*].(K?;HV@V&Q+>C1OY\C-D97 R!(%%7/2*YU8X_P !]]I3;6L<
MCR6=V5+1J)#J:-]-2.L2RM2F9U4H*_XN[UW>SW5XH4M)#>DR/I&6N*W>LA
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M^\+?^7C_ ,2;/_WA;_R\?^)-G_[PM_Y>/_$FS_\ >%O_ "\?^(]G_P"\+?\
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MV\UW>2DB.&"-I)&H"3I502: $Y#ABGLV]]>VTT-M>*SVTLD;*DJHQ1C&Q%&
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MO(Q .+9+9F6.@\W%I!=Q-V E6DA!SS'+AG< D0K3RMAYM<AGK0J6)^##SP9
MJ,NG%/8@/Y0^/$?N*U%1J%1X\1SIYKC@.2F B#PGD'AP7#HU.13C2J,6Y@#B
MDB,OA'L40%CT8J4;R8$TLJ1UX*QH<=O Z2@<B&I& [CS,V!Z,=IYJ2Y4/ 8A
M1#1ZMF.7A3#1W*U9Q0L,L)EK*FHSP6C>B'@N66*3/4<V*#QXJ,L9DGPXTQRD
M#FRQ65BWAP).;#.V=348!/(?;[Q+^*ELOE+G\&-NA_&O2WDC/R^Y0^L/O]')
M;=S;>35#%FDFX.AX*<BL((H[C-CU$SU,FV>K3?MU@M=]W1?[+;L<AR(';@AD
M.488C611<Z8N?6_ZLHGEWX*'W+;U)8W2HH':P@_SJJ #&/O .J->4A1P0P-"
M#Q!]QVLN:1W!EMFZ>TC8*/KZ<;S9@5(M7F Z8:2C\WW%3R$@'!\%?95=)*ZA
M4\E*XN8(A5(E:@'@PL]]5F;-4YO#AVEMAV8;0M*@D]&>/3"X6(C5I/'+';VL
M@U $Z2:DTQID!4UH01PP+N]J%+4 Y\,1$4,!!X\>6N&123%**1LN84G+/'9L
M2TD#=8$#,= P'G0*)<Z<#7A7'HUB"K $!C0X+L>L>)Y\#G&,\5&*XK[<I7-C
M3%/=[_="*K;68CKS-*XI\"-A[,&C7MU##3H%9#\*CW^^Q;P:V%P2"2*T+"GD
MQZ;M:F:R<:M0Y,<2K#Q'%:XHK$5XT/QXHLC =!.*2.S#I)..R$C!/Q=1ICK,
M33G-<=F78KS$Y>3%6:OA-< %B0. )X8J[$\@J:TQH21E7A0,:8M;V>O9Q3([
M$5)H&!.)]PL)'6&0*  2. H<:JY\:USQJ8U/*3G@:F)IPJ>&-3L6/3QP-3$T
MYS7&F.1E',&(P%2K.3X\\?K;?JPV<)UTJ,].?3A;"QZMA;BB "E3T^TL+L&H
MEM8'K]*,'%ZG-=S@>#M#3V;;^E3XQB+Z'X3[%<+=P><IX<AP+AK4>D4XY?+B
M/=810*ZAFRH%!S&%LT-5C7/PX%IND(E"<#B'LHPEO$X8)ST-<+N4*:-("%3R
MBO[^#/Z*/2.?DKR<N&NI %+<BCV8?I#X\1^XM/I)5!7+HQJN#0)4@$9TQ+#;
M9*%(8TS.6(E4D#4"QY *\N)&L<V7)F7,$8%M>49"!GPI7ERQV2]92>H1P.!V
M(K,?.Z,,7ZT:+K(/,.3 DMA0 T*#$L,9*E<Z']_!NFTQRO4%F-*G%;F1'1,U
M"MG@ 91IDHYO8K[A0^QX_;[M=?CR0)]4.?\ .QLEI^/)<O3Z(C'^=[C+WS[X
MS1-W8VF=8Y+*.0=M<S4#!'"G5'%3SF-"_FI\YE3NEW3CMYN]DMNJ6-C&H$-G
M%32DLJK0*J@?9QBFJG(E3BY[R]X[J6\W2\D,T]Q,VIW<\I/1P &0%   ,6OJ
ME];MT!N'5AVO=9F^_P"18)V/\YR)(?/\UNO0O?\ KR[D&#;[VV4S[O:NRQ17
M )H9HR: 3$GK+_/'S?M<I/<-OWU.-G=07&7_ ";AJ?!A[>2CP3QE33@5<4/E
M!Q<;9/\ >VTLD+_21BI^+W#4.(SPK\HR/L4.&4*&1A0UP8!%H66@+>'+/$MQ
M$PDUKICTYA<L0M>$50ZCGRUXTQ-9< U>S\F-# GLHJTZ14XAO+?)9& <<U#R
MXEM "4MZ%:<G+B6_7(20D#P@'Y<44ZEXT:AP\XA^T89\V.TD-,LE' 8J>/NE
M!@1#@H]X7V\N*-=W00'G2%10_69AC9^[R',++<N/I$(A_BM[_K@6=P1/:<"C
M@$TZ#CM+_;Z2'B06_!BHLW^L^/T-_K/C]#?ROC]"?ROC]"?ZSX_0G^L^/T-_
MK/C]#?ZSX_0W^L^/T)_K/C]#?ZSX_0W^L^/T)_K/C]#?ZSX_0W^L^/T-_K/C
M]#?ZSX_0W^L^/T-_K/CM=LVZLH\TL2<^3C@VQ816Q_FT &73[78[@&M+"WC/
MAC0(?A&+T?\ *A_KJK?A]FV_I4^,8B^A^$^S3V'ALW 5C7@.;!FN#J=LRW/[
M&6,_:P=+CX\1^ ^XE86H#Q'/BC'[/E6@\>#V:&-F\[K$U&/1;%"AH0S5K6OA
MP!,:PR$!QSCEQ++;#[(KU*9XB6[HDL9.DL:<N)@06#5HPX86&)@9W#!R#7 D
MA.E@>.&EFCU2M\[ CX(N=!R8ZQJ.3'3[HHYV]O<W)XS7KT\"QH/CKC:=OKG'
M;22T_I'I_F>X_P"*.X5X;:Z:-HI8W&N&9"/-DC.34.:\H.8Q<]XN\5S)>;E>
M2--//,VIW=N))^(< ,AE[.U=Q^]^Z2W6T[0M(D.32L*A7G;C(Z+U59N _*+,
M?<=FW4MJD-HD,AY2\/V3$^$J3B_TBD5WHNTZ>T'6/UPWN%,&WD-$;AX<5Y/8
MZ,9<!R8T0N53D%!EC[>35XAA)H?.!J/%AKJ?4)W4J:'+ M[=6=>4GIQ)*L+$
MRBC9G/ M8>K;\ N6!3ACACF]U:5LJ#!E?B?=Z8VG;6&F3T=9G'*'F)D(/@+4
M\6+R*-M45DD=JO04%6'URW[-V$9-6MI+B$^*5F'P,,&<#[Z"*3R$I_FX/1[%
MK_2I\8Q$/R/PGVE<4Q3D]N YHM14]&(;^"<LJD/P!K\&%)8C3S#'9(VHTJ?<
M/![%<9XIC1$Y"\V 9&)(X8[-92%I2E!\F-3FI]GP^TZS 5S%33': @CHP:^X
M1Q^/V]AJ%&F[64_PI&I_%I@VP/Z+:01'QZI/\_%UZW?6Y?MMG<NU,PC"2+"9
MA#]Y*\K A(D(*_C,P;-0O6E[B>K.]:U[P -V<EO<WZRN4#5[,7NJ*49:B(P3
M05!"XL/47ZSX!N6V&:XUZ7DA6Y@]$DFAD!C<.M:*2 ^3 H2:'%SW([WVPLMZ
MM&C2>!IM]<(9$5UK(C-'0JP-0U!7.E#B#UV^HV[:[[JR&-KF#MO2$2.9M,<L
M,OG% Q",KEF4D'5YP&W]P>[2_P!KOI-+2L"4AB7.25Z?-1:GIR49D8[M3]PK
M![>_N+B2WN[J2XGE:<1P@ZF5W9%):K'0JC.@ &6+/UV?\34[>C;N4-K TMS'
M'''(3V("VM)I))%4R9$J$^;U6;&T>MSU.SM/W-WIQ'V9E,R0O*AEA:.1JN8W
M0,*/5E9<V):@[E>L_N[MGH_>;=Y]N2]N_2+A^U6:SGE<=F\C1K5T4]5%I2@H
M"1[2/UW_ /$7N)L-@N$2>UM.V[!#"S41YI!UR9<NS2,AJ$&I+:1=[1ZB-R;;
M]^M8W=6BEO2U<J-);W_6>-20"8]'G4+UIC>O5/ZXMM%XNT6-[VD GFB N(+B
M&,.KPNC%2K-ISTD,#3ABY[H[BJ6VZ6MS+9S+)-OJ+'-$Q1P96;LNJP(U:M/2
M1BP[\]P+F2][G[HXB7M7$KP2LI=!VB@!XY%!*-QR().1-KW3@U1;5#2YW.Y
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M!#9"E333F.M7&X=X^YJ17=_%8R7=FDBLT<I5-:BBE6.H< ",R,\!5VW8R3D
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MMFD5B[<H X>7!EC! !IGAH9$<@U4Y#Y<9</;0[)LD1FNIC15' #E9CR #,G
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M9X!4O#TKRL@\J](S%7S3D(]]GZ9^(8?Z1^/VF>!MFR1]44,T[5[.)3RL>?F
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ML=@K3LP:23@<LI')^0,N?5D13]ID&^;+*8;RW<,C#X01R@C(CE&!N%K2*_A
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MT905N;A3YHY44\_.>3@,^!AB.BW3(*.7&7[%!5S)RIB&YV20)N=Z_:,CYJ>
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MI1''P5>+.>91RG_(X;M#Z-9+4I#JZSTX%N<_ /AQI=M, X*/8S_8IKRT"QP
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M<N5F04[2,Y21D\CIQ!^ \A(PVX;218[CF:J/LG/Y2C@>E?&#@VN^6[1@GJ2
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M\^@_S,742G,0O'QUP4L(P#^,V>";F4D'D&0QQQ:?T\?YPQ:_T(^,^_@J DG
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MP#'75E'$5!&+S=I$K=1RD(V=0-*_+@&166O."/CQG[:Y=LFG+TKT@#!]W?\
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M7_!CK[A(?!$!^$XROY?^C7Y<?9;DP\, /^>,?V6]@?Z:LGQ:L:K:..8CEBE
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MRDZ:D\IS]J^]]V8Z-FTMLHX\[1C_ #?J\V$V+O$Y-KDL4[<8^96_)YC\WP<
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M!'!$H5$7@!_EQY_;[GZR]NWCNS!LS106>V6]W=WJS16T"9!PEFZ@M(9)" S
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MFC&^]\MRB:*UWW=QZ$6!':Q6D?9M(O.O:,Z5_&1N;V[12 ,C A@<P0>(.-<
M.BWE$D?Y<+\E?HDJ>G$=W;MJBE171ARJPJ#Y/W&)]TN?NX(V<CG(&0\).6!?
M7_72-VNYR>!.JH'C8C+FK^P3VMTBRP2JR21NH965A0JP.1!&1!Q)N=A9[GW=
MEED[5TV6[6.(G.H6*XCG1%)-=**H% %H*@C<MT7>]_565EM]TOD$(*UXBTAM
MV8$D$AF(.D"E-0:VV+8;:&RVVSB2"WMK=%CBBC045$10 J@9  >X1;_"OVMJ
MW9R$<L;G+R-^<</M$S5FLFHM>6-ZD>0U'@I^XQ;[%$W7N6[20#\1. /A;/\
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M&56*ZHI5;267-^]/>K8Y.VVW<]HV^]MI!\^&>YMY(V\:L#COO_NVP_KGQO\
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M)/,/8H.#K7QCW?8ZBO5MN2O\^V)MNO%#Q3(R,#S,*8W?N](Q*6LVI <Z5JI
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M<2!#(0**&( /6RY>7$6[7%PVXVS,IEBC57H*YY 5 Z5Q:[KLY,,D\L=0Z D
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M2E>;IZ<7$EZRBRX0H*5\)/'&S=^-BGGM;F&Z$+2Q)VXT,&ZC1,"M&K74:%2
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MAC]6F9/2BH<1UZQ4\H\F([2YE5)I?,0G-O ,-V]] I4T(+BODXX?=8[F-K1
M2T@:H%.?$\;ND4R2,L:5S= !1AB_BWV]':F[=D$C9Z:  #QX-SM\B21CBRFH
M&!:RWD2RUH1JX>''IS3IV%"=>L4H.G'80WD>NH !>E2>:N+%8KQ8D8J.RU9O
MUL!;^Y1&_%U5/D&>#)MUPDH'$!@2/".(QF,4-1C(XN=QD-'6-A&.=R**/+B3
M=[Y2+J^?M#7B%Y/=2IQTC ;]C+;O59Y2[<ZS2 5JT:'40/AQ#N5ODLBUH>(/
M,?VPECR8J>)QX/>-RT9U11A8?$HSIY<?JKO#,3:L0(9"*Z.2A('#P\,"6)@R
M,*@@U!'L75AMII<21D**TKT5//B/:>\^WOMUPM )]#4UUR8.M>7G-,;/WKM&
MU0PR10S25K6)FX_"<2[M">UL["W2-#R=HU2:>7&ZW6XP)+.ETRKJ!-%H#D.'
M'&^[*D8_5P.H1&N1TYXO[LQKVT3NJ,:]4:<;A<[G"LSI,0I-<LN@X[Q0[>VA
M(T<QCB%.@YYXD2ZVN:YNI0]9PK$:B*#/DIA]OC1U>.0E8WH"4R- 3X\6^V[G
M9/872NM96#@$UXZAEC8^Q<,H*=>O'KXDWG<+5K^R=5\P:BM..0X8N;W8ZP,X
M >W?4&'B/L4Q4XM^[EH[26D+(TJ?-J&J:GP=.%B4:0H  YJ>[:QRXT'E_8R2
MTG&J.5&1ASAA0XO>ZMZ2L>L/;ZA0&HY">/[+T7WP*8SY_<:G%.3VX0>'%>;'
M3[PNKU?.BAD9:"N84TR\.#<"W>%7<LTLHH,S6M#QPMQNKR7,@^82 GD !^'"
MV]NNF-10 <@]B6RLYGMYV%4D0T(8</%A.[^ZB'T0L%EN.H7*@C,9\?%BYV^Z
M8=E%:L$+',LJ]7QUPTA!$ERS,:C/A08O3>C2)I=2\]*8W.^G%(KJ@4^ 4Q<V
M@0&QN"6U4%<\L7<5X IEE++X",;O'N-.QO@54^%2,/MFV!9K5ZZ&(4E:Y<N!
M ]VWZP!+ZA1<P:@4I3$.V[LB+"CC5( -1 (YL;5=68#0VI42$GD#5KA]QV&0
MSV\P&J)J$ CPXGW[>]*SRT 5:  #P>S/>,0'$;!/I4RQ+WAO03<W#FA/,/8J
MI\1QS'W0KBO*,!AR_L9;=Y]OJL]G(K2%16J US\&(MPMS577/H/+^RM1BN,\
M4''%>3%#['5QUN&,N'L47%>3P8H>."<=;%> Q1L$XS]C+%3BHQ0X&*#CC/V.
MG&6,\5&*98RX8H>7%1BI]L3@>7WCI< @\AQ0</:Z1YV!/?R2%  #&&(4T/*,
M+;P4"H* >S7EQ4\<5Q7&>,O8KBF*8YABV[JVC5A1U,H'*"<Q7CPPEK;KI1!0
M 8&*^Q1N'/BH]SJ.7!7F_8R:QG%8YHVC8=#"F+ONAN3474)+>N50>;G]KN/>
M'N3NE]L^Z)N&WHEWMUS+;3JKS ,HDB96 89$5SY<2;1ZO^]/K WV^AB,\EOM
MFY;M=RI$&"EV2&1F"AF U$4J0.7'_P#US_\ ?^(K;OENMYWBVFW<0WVU;Z6D
MGTJQU:9Y!V\<JU-"S%:T[1'"J!M7K [JR&7:=XM(;RW9A1@DJAM+#.C*>JPY
M&!')[CO%U:NT4\6WW;QR(Q5E98F(92,P0<P1CN7W?[S=]^\NX[7=;F([BTO-
MXO9X)5[-SI>-Y2K"HX$'&X]X>Y.Z7VS[HFX;>B7>W7,MM.JO, RB2)E8!AD1
M7/EQWNL_6%WFWK?K>VVRUD@CW3<;F[6-FF(+(LSN%)&1(_8$>Q4XXXRX8KSX
M\&*'%/8SY/8(&*]& /8(Q7HP!C(8&/'[!P,5P?8J<4&*C P<4(P?;GIRQ3%3
MQ/O:B<<4Y?=B>?$^XR&A1&*CG-,L3]Y[\5EF?[,GFQ3VO.IQ4>Y5Y1@']C;/
MO=8#KVCJ9J"M44U\'/B+<+8U250P]ING^\ML_KQC?MW]8&];;L5C-W<F@CN-
MSO(;2)Y3>6S!%>9E4L54G2#6@)Y,%SZP^Z5 "<M]L"<N8"6IQ<=XO5&1>V*V
M5IM\EW#$P%[=Q,X:1 0&<49(E:G7[,%:J5)[H=P^]"M'NUGM_:743GK127,K
MW!B;IC[301R%>7C[!9C0#,DXNNXW_#C:V<MI9R&"7?+V-INVD5J-Z+#55T B
M@DDU]IF511I=K7O7W^;<H-FN*=@^\=V8+6TGUK5=,JVL!;(AAIDSZ1BZ[L]Y
M;2#:._>VQ">>U@9C;W<%0K3VX<EU",0KQLSE=2$.X8Z8=QOX/UGWGW/6FU[6
ML@37HIJFE:A*1)45(!9F(5?G,MUO_JPCNSMMM43P]W^[D=[;P9E^N\L%TZD*
M0.M)YH!I6I-MW%_XE+6TBL[F46XWNUB:W:VE)H/2H:E2FK)G0)V?%D85(WIE
M-0=LO""/Z%L=Q/\ >J_U3XW3_>6V?UXQWT_W59_U[?L"/8H<<N*5Q0<F*>Q7
MV*>P3BG1@'V#BG1@>P,>/V#@8I@^Q3FQ4XH,#!]@^W"XR\&*>QH1U+<P(K[%
M#Q]T:R:5Y9T\Y(8WD*^'2",,VUS"1D-'0@JRGI5@#[30O'E.,L9^[4&+;NG9
M$L"RF4+GD3RTZ,16, HL:@4'L4]IIY,5Y#QQ4>XTP0>3 /[&3;=<"L<T;(?X
M0IB\[H7YT>CNK0:\M2ME1:YG,>TW3_>6V?UXQ>]R?5_=[;9WUC8-N,C[G+-%
M$8EECB(4PQ3,6U2 T*@4KGR$L-[[I,0":"]OZGH%;(#&W;MO^VV=KWAM5%U8
MRW,$-]9SQDT+1,P(!!ZI9#'-'R%-0)M_6'86_H6XPS-8[I9AM0@NXU5F"$YF
M-U=70G.C:3UE/L=]^\VUR-%=KM3VL4B^<C7CK:AE(X$=K4'D.>+2YWZ".XCV
M+;+O=X(Y5U+Z1&T<,;T.6I&FUJ3YK*K#K '&[>KGOA$9=GWBUDM+@+IUJ''5
M>,L& DC:CHQ!TNJM3+%IW[[D6VY2=X+*!H8KN[W"5B>TC,<C/''V<3%U)J&0
MH#UD12JD=X;.YD9K39([/:[1&)HB1P))( #PK-)(V7/CN]ZL]O[O=YXWVK;X
M(;IK:RL-$MWH!N)JF\4L9)2SU*@FO <,77K.]4VW7VV6.Y6L#7T5_#!#(]ZF
MI9) L$LJT=!&2VH,SZRPJ=1V/O)NLC2W;=V+FTDD8DLYLDEM=3$YEF[*K'E)
M)QW$_P!ZK_5/C=/]Y;9_7C'?3_=5G_7M^P.6.MBJXIGBK<,4QEBAX8I[%5Q3
M/%6P<4Q3/%6P<"H]C+CC*N-3<<9C IC4..,ZXZ<5&*"N*\<4.#D?8IC(8ZW'
MVI.*^Q:=SMH<Q2W8US2#(K%6AITY'!O^[=W<G<85U*'DJ)",Z&O/A988TAW5
MD%5DS56Y:T.(MNWV\[8F R:5R2AJ!EXO<;V[MW[.6.%V5N8@8%OWF4:3DLL8
MJ3X0/DPTNT7"2U!&61!IR@T.+W;^]BM!<S7!D2=HV9'0@ =900.&&[V;)<*8
MY8PCI$1I8BN9Z<_9H/../#[PGW&X("Q1LWA('#$_>V^J2[D1D\V#[A1O-]RK
MSX*_L;9=[;525@=!-05ZJM6N([RV8-'(*@@U]G=/]Y;9_7C&_;OZP-ZVW8K&
M;NY-!'<;G>0VD3RF\MF"*\S*I8JI.D&M 3R8_P#RB=T?^_MO_P"NQW9[K>K*
M]BW:'NY%?/=;C;U:!I+PPTBBDX.$$-69:K5@ U588[R=Z+U&2PW3>4CM-7!_
M1H0LCJ.;4^FO*4(Y/8[X=Q=HC[;<+S:Y7M8@*F2>W(GB0=+/&JCI.+#>^_%P
MMALNXVMSM%W=2]5+?MRK1O(3YJ"6- [')%)9L@<;CZS]]O[46T%G)-8*95/I
MD^BL,4(!K(9&*CJ\%.HD*"1M/JHWGN?MS/?1S-=WUA<S0I;I"AD>8QR";J@#
M0$,@+.RCM!P.[[_/$R[;WD@M=RLY*=5J0I!,M1EJ$L;$CB RUX@G9=\MNYW<
MR?O!8;?!;;Y!+L^WFXANH(PDLDH>+7ID([19#4,&\XL&IO'<&U]3W=K?-JVN
M6.!-WV[;=J9)Y0H[8+&UN!IC:J!A(P<J2*+0EKGN;LG^&]EN=AN+NUVGT6&T
M:U2X@:;0\$!,<;U<EU4FCDUSKCN)_O5?ZI\;I_O+;/Z\8[Z?[JL_Z]OV&-..
M,\9#VQP/?1/1[3;[BXR2:V[-&/#5J;*OCQ+NVP7Z06,,!=HBBEJJ"2:D'DQ;
MWVY2=K</74U *T/, !B*RV^8VTWHB-VJURHS8J=\D_C8_P!N2>5L?[<D\K8_
MVY)Y6Q_MR3RMC_;DGE;'^VY/*V/]MR?QL7%Y=;LT\42,[QL6H5 SXX$<"M)(
MWFA 6)\E<?K&T,FWE%JFHZ68CAE\HP=N[V-&E_"QCD6Y"J6'.*T!KT8EA[LD
MG:C"#,$J8A)0\"<J\.'L5."3R^\,L6G=C;V)DE<=H%SZI-,\16$( "+3+G]R
MT-Q]Q!YL4Y_>'8R+*6_(AE<>55(^'&DI<UZ+6<_$F##&LH8"IUPR(/$64 ^7
MWW<;=(*]M$Z"O(2" ?$<7'=7<25GMI#H#954CD]F\]6'<FXL;7=+B\L[A)=Q
MDEC@"P2!V!:*.5JD<.IX2,?[<[H_]LW#_P!QQ_MSNC_VS</_ ''%O<^N'O79
M1;<CEI[78XY9I95!%%6>X2(1DBM6,3Z:4"FM5V_N'W*M$L=DVN!;>UMTK15&
M9))S9F)+,Q)9F)9B22?9N_6%ZKMS7NSOU](9KRTD@[6QGE8U>50A5X7<G4Y7
M6C'/0K,S%(]][Q]V+:R-=<MM+>W$@RRI&]M"#GQZXIT\,3G899-U[SW\:QW^
M\7$8C=T4@]E#&"PABU ,4U.S, 7=M*Z4[I]_HI([BU9Y=NW&V(6XM)7 #%"0
M0R/0"2-AI< ')E1E:+N?WH[O7VWYZ9K_ -+LY3UC2L4<-RHRH?O#F2.2IM._
M7KLW6W[PWMDT<UOM5I"RV*SK1M4LDE'G56\U.SC4Z07#!C&-QV:U*K/=V=Q;
MQER0H:2,J"Q )I4YT!\&.[7K-[S;OW:GVO9KT7-Q'9W5Z\[*$9:(KVD:DU/*
MZ^'%YZL.Y-Q8VNZ7%Y9W"2[C)+' %@D#L"T4<K5(X=3PD8[P[[ZPMPV6\M]V
MLH+:!=KGN965HY2Y+B:WA %#E0GP?L/F,<,9>UH<5 ]]4YSBN !["P7NI70Z
MHY8SI=&' @X;:]PW:Y>R(*E1H#%2*4+::XCVVP4K#$*"IJ?&<)WH[1A*D(A[
M,4TD DUX5Y?<9MMG)$<Z%&*\:'%-NAZYXNYU-\/#Q>QVVY6Z2%1YQR-/"*8,
M>R]EV(:A[(@BO2<\_8Z!P]FONNG$U[,0%BC9\_R17%SWJO%)&O3$3PH,_<JX
MJN1'#%?<".C /-C+=[#_ +5%_*QGN]A_VJ+^5C_:^W_]JB_E8_VOM_\ VJ+^
M5BB[M8$]%U%_*P->[6 KF*W47\K!OMONX7VUJ"$Q!7#4R)+9@Y\*'AC*<?57
MY,=6?^*OR8:='21E^:PR^# G$P4,*Z0HH/**X($X'\%?DPNBX% <QH7,>3$3
M).(U$B]H"BG4M14<,JCE]@0)$7C-3KUKE4\*$@_!C2MNS>!T^7$L2%HS+$Z@
MYJRD@CP@C"E_.H*TY_?=GWNLZA1(BSZ1Q4-G7PC"7<!#1R*&!'[6P/:7.Z2&
MG8QLR]+4R'EQ*+Y@;N%\^2J','XQ[M./^2?\TXO0:G^V/Q^BOL9Y <^*RRQK
M3G<#\.#KNHC3F=3AK6P;6R"IIPQ0"GN9Q4<<6_=;;V^VN6 >F>3-2GCQ'8Q"
MFD5-.?&>#[E3D/Q^XD<V.T;9;4LU231N)-3R\^*G9+7R-\N/]AVOD;Y<?[#M
M?(WRXK'LMJ#T!OEP+5=E@= S$:VD8YGG+$XAV79+4C;X6'9HC9(I-2.L:FF"
MJ6DA4<#5?PG&5I)7PK\N#;06C*S ]9V6@^' 2>U8,@H:,M#X,\9V<E.?4ORX
MTO9R:20*U7+X</M26TBPS*8VF#+U0PH6%3Q''$D$;-J:,H&!.K,4K49U\&%6
M-/-X59C\9PLZ K(K+0@GG%1QPP'+7'92WD"2+D4>558'I!((P?[=:Y<?MD^7
M 9;VV(/ B9/EP6>]M@H%23,@H/+CTC;YHYXJD:XG#K4<E02,!68 G@"?>T^W
M2BO:1L%Z&ID?$<7/=>_)$UF]$U9$J>CC^UOP8K[*]V[9R(HU#S4Y6/ >+$$Y
M)$$C+',.0J30'Q5P'0U4BH/L%FR S)Q):[9:7-Z(B5=XE&FHXT)IAKFPUJT;
M:)(Y!I93TCV+C=676+>-I-//08M=\,)/I+1J$)&6LTXX#<XK[6;^C?XCB]/+
MZ8_YJXZ!@QMP8$'/GPUY#)+)929FK$Z2<5&8YSB3>+ME4S,3J.5% '[^ ]NZ
MNOY)!]TEO)<DC1F/B%<7'>>]SCB<"($<V8\F,N&,O<J>Q7W X%KN5[!!,!71
M)(JM0\#0G&>Z6G_3)\N/]J6?_3)\N/\ :EG_ -,GRXHFYVC'F$RG\.#>6FZ6
MYB5V4EVT&H.>3T/P83<MHO2MBQZFA$(=0<S5E)SZ,$>EM3Z"?R<973?43^3@
MS-<ZR.0HE/@48$LUUUFSH$2@^#!K=M3FT)_)P-%VVFN?43^3B7>GO7>RM$::
M6$11DLD8U,HHM:D"@P]U;L8RT6M69:%<JU(/-R@X!CFC:O,PPD':H97=%"@@
MDU8<F&*Y-0GQX]+OK.*6=CJ9V&9/.:8/]@ASR/5P$BLH0HX#3AHYK*%E<%6!
M7B#D<"QVF!+>W!+:$%!4\3@2NH+K2A\'O>V[WV=5A=T2Y '$5SK7HPES":HZ
MA@1T_M:/AP?![!"&C$&AYCB[WNZOGDG"O*>J #I!-.&&W*:Y:(+(T855Y@,\
M_#B*QN9C.\8TZR "1XO8O[F D2=BR@CB-0I7%M' HJZ"1VXEF;B3B[[R0NZ+
M+%66,>9U 26ISTQ<7T&ZV^VPQN5AA/9EFH.+:JFA.6-W_6'9FZMTEB<QD%6
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M(*F2-@AYFIU3XCB7NSN#?VJQ(4 T!TGX?:Y_ ,(35FD.E HK4X2(6Y)8YT/
M<YPQBJ"IH0>CV,B,NG]EJ,XKY<9O\!QY_P !^3'G_ ?DQY_P'Y,>?\!^3'G_
M  'Y,>?\!^3'G_ ?DQY_P'Y,>?\  ?DQY_P'Y,>?\!^3'G_ ?DQY_P !^3'G
M_ ?DQY_P'Y,>?\!^3'G_  'Y,>?\!^3%(W!/-[8GIP3[-\3_ /99OS#@U_\
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MVN"YB9FDD*$.9KB8$4&5 /#CN[LWJ^L-FO(=WM+FXG.Z07$K*T4BJH0PW$(
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MEN-MV>XW>#;MTE@=(YK97F$4C:G5T7LR:L2K  '(X+OOO>U545)-[MX  _\
MO'%KM_=?UH[O+N$UQV5O#<;A96S22J^D(HGL(R2S9)3[RHT:JC&Z?[RVS^O&
M.^?^ZK3^O;'<G_=M]_7)BQ_WKN7]8/8'APWA_!AOH_+@8)Z,7&[0:G@28=N!
MF-/X,L6UY9M5))%-5/#,8V2*4GLW<*V=!0D U/@PH)0L:9"<Y_QL6?=/:Z@W
M)T$KF0M0.DXN>[VX_?VLC1NIJ"4=13IY\2;AML317"NE&$C'SFS\XD8MMQA@
M(N8U5E8R.<^/"M/:A>;!;Q?N%UY_9A&YEAV[:5TBOEPLB&JL 0>@X@VJ^9O2
M+FF@**^<:"OC]S?<-RD$4$8JS'][ #F9(2:"5HF"_%AMTDD M4C,I?B-(%:^
M3 1GE$3&@E,3:?+3"W$!#1R"JL.!]FOL[WN=GW#[TRV<N^WDT<T>R7S1O&UT
MS!U814*D9@@T(SQ7V=S]6'?)6] W&,!9HZ=I!,AU131URU(P!YF%5;JDC#=[
M/5/:[C?F NEMNO=Q#=]O"S :)K,!Y*'JEXY(GCJ*AGT:A9VWK(V;?[KT1]$+
M;Q9)L]G;]H.M((WCMXZT7K,B,YH%ZS%5,G=PW"7_ 'DW25;K=[Z-2$>15TI%
M%4!NRB!;26 9F9W(75I6_P#7/Z@X(KV7<W-SNFQZTBE](.<D]LSE4<2'KR1E
M@_:%C'KUA$/J3.W]]CL3+^K3&=GD/V1^S[/]8=AK[*G5KV_9Z.71BS]=/KZM
MX[.\VYA/M.RZTED6?YEQ<,A9%*>='&"6#T9]!32VX]W^Y6UWV\;H^X;>Z6FW
MVTMS.RI,"Q$<2LQ &9-,N7'>V\]8/=K>=BM[G;+6."3=-NN;19&68DJC3(H8
M@9D#'<^Z]7W=K>=]AMMOO4G?:]ON+M8F:5"H<PHP4D"H!XXLM@[[;5?;/NB[
MGN$C6FXVTMM,%>0%6,<JJP!' TS]@>'#>'\&&^C\N!@^#&][?>KJ20Z?**8?
MNE<L7@[0/":?-)X5\(QLML3D[HI/A8#";@SRZT*R9R-2JY\*]&)MWV*!9H[,
MK&.T("BF?.,\0;EO<*0Q;H5@81D$:JT4FA//B:F?7C_.&(2/]&OQ>U+8'3G^
MX77FQ7%<;980_>2NRKX21A[?<6TW5BQBFU4!  J"?%B'O,]1:&\BMX"1D51Q
MP\9]SVCN],Q]#D=998^1Z/P/1EAMFW5[:W26,JJNR(0#E45I@=WK7<9)K8FG
M;HR,2H-2E1E2F6'V@PHTLT9AMHE4:VD844BF?'EQ:V%Z29HXZ&O$<M/%C+DQ
MGB@QJ? 52*GIQ1J5Q5"/=QX<-X?P8;Z/RX&",7>XQR%FNB&*G@*822;[.2,B
MCCCD:XL!*Y7T.17!'+I(.?DP]HC%2R% 1Q%12N&L[9B[.YD=VI4D@#D\&(X+
MIGC:*198W2FI64UY:X.TW;NL;%266FKJFO-A85J0H"BO1[0GQ8"\_P"X90X*
M\V"#C822,[M!Y7 Q<1;2FJ'>XUB-1YLA!3+Q$8V':X^2\BU5XEBRD^Y[=WLM
M(FEBLV G5!4B/54F@Y@3A]QW">*6Y2%EC&I@X-"0-(Y:GFQ)N6[(T4<;R.H8
M$,P(&G+I.6!WJ[U72130MIM+<L=*J,PQ K4U./2]ME6:&I74O"HY,:QX\5QG
MA(6\SB<&15HT8U+3HSP;J0=9^%>0#'V0HK@U'2,9^[#PX;P_@PWT?EP/8 Y#
M@Z<=;!<\3R>X!1R8U<@_<-#\^!A)9XU=XSJ0D9J><81IT5S&P92PK0CE&$])
MC5]#!EU"M".!'N91Q52*$'';K:1"2M:Z>7'H\Z*\1^:149=&!6TARX=08[&T
MC6-*UHHH*XH< <AX' ''"U\[2<2?0;XL)R4RQ$/I?@]W'A&&\/X,,>333X\=
M&,_8K@.<AS>X5/)BIY<4/A_<-*^QX/>=#@ZO$<&X<TT9U.66/[.I5*T8GE X
MX>727BXT'$<^/2U8$#)17A[MGCJ\<2;C='JQJ6ID"2!P&%W"W-%:H9214'FR
MP0.3 'L:F\GN.@>/ '[A^H<#BO)[TH<&"/.&F9-03T"F!#"*:>(Y:X*R>:10
M@]."\0K Y)*YZAC4#7W;(XCVBWJT--<A J,CP)\6#MDP8VUP:J:9!N''R8ZH
MS/' TYG%3Q]QJ>&"QP7/+P\'[A^G%#C2>3WF2.-#@#$DH/G4R\ Q&C5![1?C
M'L,HX!C\?L5]T.+N62-"W8R9GCYIQ;3B-==2:\O'&9H,44>Y:!X\:1RXI^T&
MG[3]8\>*C%1[B=RW'5V(8+U!4YXCO;5M44BAE/0<7>QP:O2+,*9*C+K"HIB6
MUT3NT+E&*1DBHQ,+9)D[",R-KC*B@!.5?!@;G8:A"69>N*&HXXEV&S$DD\(K
M(RKU%RKQQ+:A)W>)BK:8SQ&&N-K<G0=+JP*L#X#@^ XKAO#^# +#@RD>7V&/
MY1^/W6N.KGB[C8TK!+P^B<6I6IJ&X^$^YZCBIQJ(X\/W$:'AC2<:3[B(S2C3
MQ"IY*L,)W0WQCV-P ]I(W ELBE?#PQOKBGF0?%C=8-YD2.5KMRI9":K0<P.+
MZ;9)%D6.&17*J5H=!/*!B/NOM[!+NYF:-IFR$:N0M0<A6F#;VI,DDG7EF8U9
MV(XUQN<.Z(S3-=.P*0O)E0<=(-,7N[[4HALQ"J%/-+-GUM/)QYL4QI )IPP6
M/%C7X,4\?DQYIKXL:3CEQU<QCAC/%?:Y#'#'6/L98N%YX9!_%.+8<VH?QC[G
MEP&-)X<O@Q0?N)9<1['3[@"!6D\1_C#$-Q:9;E:!9K9_RUH0#T&F-TN-U%+K
M1&L@I3-2>3&[3;E;I*ZWK!2W(-(.+Z/;H4A5H)68+E4Z#B6:6/3>R22:):FJ
ML -)YN.)>ZW>3J;I;9*2*"6.F3#D/+PQN<>^2QQ3M=,5[0'-:#HP=R[K*1MP
MMPL[A2$9ZGA4<:4X>Y9XX8X8X8X8X>VG_HG_ #3B#PO^=[EH'C]CI/[BFM?'
MBHQ4>W[.X0.M0:,*C+%!PP\\4:K))YS  $TY\-Z.BIK.IM(I4\YP4<54BA!Y
M1CL;9%1*UHHH,"Z>-3,!0/3.GAP6EMHF)-22@QV=LBQKS* /=^..(QYP\N/.
M'EQYP\N.(Q, ?YM_B.(E84(=\CR9^XY<3PQTXU'(#AT_N+5' XKBH]\5=@,%
M806/@(Q554>$XI+U1T'%2[^#4<<7^MCE\N.'PG'F_"<</A..7RG#JK,K,I -
M>%<""YF+2:V8E20,\4BZWA.*,BD<]<4GR/14XJK#QY?'[2IQ4\<%?+T?N+T/
M#%#PQ0\,5'N05CFV0]S[)3JDKP ./MJHO,IQ4#/G)KC+V6MTD4RH 60,"RUX
M5'$5]TTR#R98I:FH_*-<:)J+(#0C/&HXJ<47SC\'3B@_8R@_;9I.*'%#F,5'
MN+2#B.JG'(X!)!85!ISCW%;6/ES8]&*(/'R^Q?B>\N+;9MOD6&.*V;1VCC-B
MS9U_]&++<>ZT][=V<LZ1W5M(3,-!(JPH,LJYX0WQ:2>4TC@B :1J\R\W3B2S
M@22VNXLS#< *Y'.!7/IQO2$Y>C6^7)P&/U4(IKRY5=4BVP#Z.AL\CRTYL7>[
M6DKBV$$PFT'3+'1"6YZ,!F,0[ZLES/8KD&E.N4EGIF<N7$<:PW1M794-R8Z1
MJ3SDGDY</NEU*JVJ)VA>HI2E<CRUY.?$>WO%<6ZSMIBFF4+&QK3C7%KW>G#^
MDW:EHR!U:"O$^+%G;WP<M>SK!'I%:,Q J>C/"[5N"3/<-$)56):U#$@#CQJ,
M;'N%X;ZT-S>1B&)3V99M0 $@H:K6GBP-HW,2]LT(F70FH$$D #/B2,/M2Q36
METHU+'<J$+C\D5]@B3@>;C@)4FG*34X'.>&*5)/.?V,G>"5A:62"%E'FO*W6
M-? "/90P%0M>N&')T?MKHV*'ASXIR'%1[?36C-D, (1F>L<".H(D/)S^XEF\
MUD 'E]G>]KF&FYCOV=E/(K"@^(XA.ZS=EZ1((HAI9BS'D 4'GQ#9]VMNBO-^
M6V#=M,Q"1QEFRIJ J.//GC;9N\\,$%P\#!1;GJE1KXYDUK7&_O%FZVD! Z=&
M6+[<91JNY;Z42NV;&BJ0*\V>.\-UM9TSW-G*]Q$K#2I$3T(4>;7/PXBK_I$_
MKL7MK%$JQQV+,JT&15*@^''=NSM.OZ0\8*,<G84TJW#*N/U+<;79Q)U6#QR*
M&0J:]6KY8[N17A'I"P4DIS@G\..[U/\ ^I1?GKBR$RA@NW:EKG0AI*'Q8[M@
M\?UE'3ZZ8M?2$5PFW!U!SHP9Z''=ZX0:9&E",PR)&L9?"<9\>;%6PMNN;FA(
MZ,$\I_8R:[ASN"-$(YY&R7X<"W)+32,996)K61@*_%[#W,QI'&I=CS!14X6]
MEB['63I756J\A\?-^VRAX8J,QC+ABH]L"XK3A@1)DI2IP*J,C4>XTJ0>0C C
MN5/0RBM?)BJ\,-WC[JWOZOOY0!.&3M(Y0.%5/ _Y<<0;QWSO_3I+1@]O%'&(
MHT8&M33CF!B/O1W<O19;@L78OKC$B.HX9'ES^+%IWIW?=EN;BWHK+V 0:*FJ
MC2:#B<Z8ON\YF#)>111B+30KH%*UKGB>Z[E;DME;73=I+;RQ"11(<BRUX<F7
MX,;E;7-V]QN6Z1ND]TXY60J**,@%J3_D,)W+6Z =2K=MHR-'U<*_AQ<;$CZ#
M/;M '(K2JTK3%OW7OY"S6R 1SH-+*Z\& _!A;+<=^K9 C48H$65E!X:Z9'I^
M/%KNFVW)M=TLB##,5# T-:,.7/%CNG>#=TG]"GCE6-( BT5@Q I3,TXG$'?#
MMP$AM?1^QTYDU;.O\+&V7:3B(;?=)<%2M=85@:<13AA.]_; (EIZ-V6G,G4Q
MK6O3S8V[>FGT?J]B_9A:ZC4$9URS&>1P68^/ 6U&MB<SR#!D.<C<6/[&^CUU
M;=M@1VH" ;DDD"O+I%#[,/=:S:DUV5:>G%;?5USXP",+%&*(H  Y@/VVYXU)
MY,5''%&R/MA7\3\/N>>.U21U_)RI\6*"/6.<&F/M@4..HZGQXR]STEL^C/XL
M43(>P #0<I!J,:4\9/$_L9I<]:E=(!)IX!B>^M@6E1#V:%2"7IU10Y\:8*W'
M6N)G,TM/QF KY*8J/ARPT\Q"QHI9B>  %2<7?>BY'WY6*W'-"@R(^DQ/[<*C
M(XHV*',8JI]H/H?A]VSQJX'HQE+(O@(^3'5E<GI;%%HWA)QE&A\>/NE^MC[I
M?K8^Z7ZV/NT^MBC@+X&."QE=? WRX+S/(&K337*G/F/8JV0P1FJGEY<!5X#]
MC#(YHJ@DGF Q)?.,Y#U>-0H%!Q\OCQ2510\^$MGH48$(<R:CD.#&S4)Z:'$?
M=JU(,U]U'XZEBKUFRIR5PEM"*)&H51T#]N-#PQ5,^C&61Q1_+BJFOL#Z'X??
M'.>C%#PYL&1JT J:"IP'CZ]>;&I\SR='['+8HU&D*ZA^17K>498" 9#+&>5.
M?$EU&0>R'9Q\O7/_ *1C3= LQ\YB34DX_60%9@G9U)).FM:#RXU(:@&GLQ;?
M$C7.Z7.5O;1@DL2: L>"K7B3TX]-[[V"Q;>SJO;6[!^RU&@U@$DCI&+.3:(5
MN9[V=((@3D2_#/+C7!N^^.V&.S!&J>V82",<I95)-!RG#=Y)I0UEH#HR9Z]7
MFA>DG+X\'?=UVH)LHZSA6!F2,_/*UY!F13PX_P 3LQDM716B"J=4A?S5 XU)
M\F!N?>S;1;[/(RKVD;!WBU&@+@$FF>>6 ZFJD5!Z/VT=;%5S&*C(XHPKC6IZ
MH3\/O7/&69QS#HP3GES"N @A<*3341ABA#(V1SZ,+&%"@<@-?V/[21:(\:J'
M)RJ"<L:DP5'WC]5?"<A@6ZU*0*#7G8\_3PP:GJCA@RNU% J?%AI&J#*VNAY,
M@/P>S</, 3!ML8B)Y*L2:>4XDL;Y!)!*I5T;@0<=W;:$:8UW6V50.0!A08N8
M+D Q/#(K@_BE2#\&/1=PC66&&YD2,.*C2M&!SYB<'N;LR]MNFXJ(B@4L(X9#
MI9VIP%*YGPX[N[+;U-M'N-I&=6=0K#CC= P!'H['/HH<6;N26-O$37Z(_;5U
MACJFN*'+&1QUAY,9'W?,TQEGCJBF.L:^Q09GF&,\J\V-*\,.$%!VC?L@8W%5
M/' [*0@ \& .6#=,2\B*="\%KCM!YS$D^'!U>+ M:@@CK#\G]_VD/?KNU$;F
MYBB%O/:A2QDBU$U4#/5G\66%V#9MJOMO-R1'/=3QNG9(3UBIH,Z8VB39[::_
MDV^[AE*J&D<B*AJ:5.=..&V+;=EGL$N4:*6XNT<!%<48C)<P#EQ\&&M>[%O)
M=W4"!8T"EV9W-"Y5<S2M:#DQ<7>Y]WMQNMSNI-4MQV4@)7D7-<@,\AA=SM[.
M:SW.TF6Y@MYU(8O$0U*9'K<!TX3NO'LMW9M>%8KF>:)Q&B%AJ*D@<G/A+:/S
M(U"#P 4_;8@(K4TQEECJYXH<CC(TQQKC,8S!QQQQQQ&.(QQ&...7&0QD!C,X
MS]BC$8J,ATXZQ)Q0>R]/](WO_/''''''''''''''''''''''''''''''''''
M''''!E@:E<RN5"?P8$35##(@CCAY9&JST\0' ?"<<<<<<?VZQ_2]IS'HQD3C
M+/&8QF#[3A[.6?@QP/DQYOPXXT\&*DD^'][&7MF^FWORIP5MQJ(-"3D/+CKR
M,#^3EC-G;PG'+Y<<OEQR^7'+Y<<OEQR^7'+Y<<OEQR^7'+Y<<OEQR^7'+Y<<
MOEQR^7'+Y<<OEQR^7'+Y<<OEQJ(SQR^7'+Y<<OEQR^7&3NO@..H[$C\;/ 6X
M&DGEY/+^W*/Z7N-"!BNG'#V.&*@8R]S;Z;>_&B3S.#'Y,!$% /;F^M(A-,98
MHD1C0%I'"BOEQV\\$$J@5,<1(?I )-*X;<=F(9B'55D!%)%^:PXC/CB3<]Q;
M1#"A>0C.E!G3GZ,"2,@JP!!'*#[2/T8(5U#M-5?-Y:4Y?;0;,H3L);=Y6)\Z
MH-!3H]Q,;\#A+:8D@Y*Y'+S']N,?TO?34_';WVT:^<P(\N!&G >X+=!#)V=W
M:/H7,G3,IH.DX1WL+]))66./M;=D36YHH+M0"I.-T!E_M3PW5RS)U0KM&<EY
MJ4'CQ-<7,D@>&T[8:6H&(2O6'+B]M[":9BEG,ZR.]6#=GR'DX985JDOV(->6
MNGCA;62YE2XF1P)P:.K!SI->@@>+![H#M+:_MV0W\B9!4!!ZC<\@X<V-ICMY
M&19+U%< ^<O*#BWLTNYX+6.R$LB1/I$A[1A0_AY:8L3LEY-##N$G87"%]0 &
M>I*UHU#Q\&+/>MLN9TDAN;>.5&D)66.255;4#RT.%AFO#96_:*975@I90?-#
M$Y5X8VR;9[N1C<SI:R0,[,CH[ %L_G+7GQMD$<[VZQP22,T1HY /FUYCBV[P
M[?/-V1EAMKB!W+(R22!==#P8:N?W%HCRC(\QP!+YZY-X1^W!*_C>^G _TC>^
MV;F0#X3[C#%:1M(ZWMHY503U5F4DD#D S.+C:ILA-&5#<JMQ5ATJ:$8OK2]@
M<;B+6X@*Z<Y'[,@%><-4<.7%SML"%KE[%HU3E+=G2GAKEBZLK9)(YIK66 +,
MC1D.T=!YP&53Q&6.Q:TN1N"0%>Q,$M"ZK0#7ITT)Y=6(VDMI#?1Q2%8-)U%R
MQ*J1Q&9%3R#/$7>:U5I]TD=3N(6K&6-B-050:50>: ,\;5+;1LZ17B.Y /57
MG/-A;_LV]'%@(^TH=.KM&-*\*T.-IFMXRZ0W#-(P!(4:>)PD5JA=Q<VK$ 5Z
MJS*2?$!7&V;F8GN+"VD<RQQAF*LU KZ%J6TGF!IC:5VVSGEABO[>665H70QJ
MLBUR< TIQ-*4Q8;G;6TDUJL#QS.@KHU$Y]/@Q:[1MT$X@6XAGN9I87B4)%(&
MTCM%6I-.3!V:I])$(GI3+06*\?"#[B5Y&6OCK^W!&#$:&K04S]Z 2M0G@.)/
MB&*PA5C_ "@:XZ\I\0'R8^];X/DQ]XWP?)BB3.I\7R8+F9M)^:*4\/#%1*X\
MGR8^]?X/DQ]Z_P 'R8^]?X/DQ]XWP?)C[QO@^3'WC?!\F/O&^#Y,?>-\'R8^
M\;X/DQ]X_P 'R8ZDK#Q#Y,=4J_ARQV3'3)S$'W5^@@?![Y>_"CTAT6,ORZ5)
M('E8^XISD']KNH@D\@'$X#NS1_DJ:8XL3SDDXY?+CE\N.7RXY?+CE\N.7RXY
M?+CE\N.7RXY?*<<OEQR^7'+Y<<OEQ0U\N*9T\.*YY=.*FOEQR^7'+Y<<OEQR
M^7&I9).@$U'DPT$RT/S33(^Z=A%]X16M,A@NQ+N>5OP>QVTJ23S-E';P+KED
M/Y*C,])PMGN%A>;>TE!&]U%H1F.04-PU'D'+[-GM+(6:[$A# Y+H%<_#[-Q:
M]C+'Z.RKK=2%DU*&JAY0.!Z?<&G,$UOI=DTSIH8Z>4#F/(?9TMY>48$,I+*W
M!SSGD]TD!X$*1\7M[>RM8FN+ZZD"11+G0$T+M3@J\2<'<[Z-+FV0CM1;HP=%
M)S;-C4*,SPRQ=;UMK*SQQ=I&U05-2,^;A@,>4 X<VNGMJ'3JX5Z:>RMS=UT/
M+%"*"O6D<(/A.?ND&T+3T>2W>5LL]0) ]P"_BQU\I_:X2> P;B4=8GJ] ]B6
MRVN)[N>W8+,$(548BM"S4%:<@KA]LE#0WT:"1H7XZ#D&!&3"H(R/A]H)+A@B
MEE4$\[$*!XR:8,L<;2L*=1:5-33EYN/M_1-8[;3KT<NFM*^7VR(J,P8FK"E%
MISU_![%E:]F7]+F[*H^;T^R5K0\A'(<'6*,ITGW(N>3#.QK(YJQ_ /9W>ZFS
M>U%O:Q?DJ4[0^,EN.)-MO-0CDIUD-&4J:@J>0@C+$:;4(S(74.\N85*]8@ B
MIIPZ<6),JW%O=7,=M(LBJ'4R,%#*5H*"N8(/AQLE.:Y_,&'V3;RL<5O%')<2
MD58&0MI50<JT6M2#CT:<">P>/4LU '5P356 H""*4( QNEC.%$=G-%'$0#4A
MHE<U\9.+N>]:.!(KF2&(PJ"Q5:9G46'+S8W"TW<H)-OFT&100&C,:N&(J<\S
M7#[E'(+:W9V%LJJK%E&6IZUXFN0TY8W2\N$1;_;!.K@5*,T<0D4C.M"",JX@
MNY0 \D:N0.%2*Y5Q>=X9%C%W ERR*H.FL5=-<^C//$5[O31K/)&"8HEHBUSX
MDDDTZ:8W#?)UC6>U]**4!T_9*2M<_+B+<;N2.VO98RZK&@*9^;JU%CGE6A&%
MO+A56=7>*4+YNM#0TK7+V#$_ X,$AJ5X'G'N:W(Y"%;P$XK[:[EDS>';[=4Z
M \DA-/#3$D$HJCHRL.<$4.+E2=6F&2-:\:"2@\F%<7EV+Y8U$<XF8:6 J.H*
M(17B"N+O=-1BO8XG5FC.FCJU*CFKBP2QF>"2>_LXFD2E=+R 'CEXL3]Y=ON+
MD7UJ!-5I6*/I(JK)YM".8#%K?W#RI(MQ:Q@)(56DDJ@]7A4 Y'CAXMNDE4Q-
M JN79GH95!ZQSS&+^:%BDB6L[*PR((0D$>#%LMZ\A,D4;,R.R,33G4@XCL]D
MNKJ.VL&1[Q_2'8%SUEBHQ/( 6Y*'GQ:VBR,+=K1V,8/5+!CF1C:DM)#&)=P@
MCD --2%A4> X7;1=316@V]9'BC;2')D=<S2H\5#C;X]BNYXX+Z4Q7,<CF444
M5U+KU%6SXUIPRQ!O>U3W"S"YMXY5>9G21)951@5<D T.1%*88W=VUG:C.616
M"DKS:CYM><9\V+"/NO?RS-=W$=O+ \CRQE68 MUZD,*Y$-3HQ8(LTD*K:R,W
M9FA85.5:&F+?>-HFF$+W,$%S#-*TB,DL@0L-9)#"N5#3H]L6/ 8>Y/%SE]$<
M/VN,>BGEP . Q<7:9M%$[@=*J3B&Y%3+=%IY6/%G8YD^( >+$6[NO]JA5D5P
M:=5N(/.,3;3M$PMK6S$8N)NS#NTCC5H35511:$D@\<0[9N\HN;2\ZL$^@*ZR
M#BCA<B#E0A1RUQ=[-M]Q%;65O#"YD[(/(&DKYM33DY01BW.WWAB5;BV5ET*=
M3&50K5IE0D&G#+$M[%,LU[%V0[21  2TBJ3I6@X'%OM^U:/3[R0)&7%5110N
MY%172N=*YG$-U;W0O4#()X7B125+=9D*Z:$#.AK6F(>[FRE8[EX^WFF==0CB
MJ5! J 6)! KESXBOKRY%WMC/'%-KC59(R[!0X*4!6I%003BRVFS<6RW3-KNG
M4,J!?FBO5U-R5\F )KE;O;W2M715E1^@H I4^"O3A)XK_3"+0-I[-?,UMU*<
MN?SN.(.[>U2)#=S)VTDL@!T15(JJDBK&AIQ Y<6D=_=BZL[R18 '1%D25C12
M-&D%22*Y&G/A]AVJ:*WM$LXYY)&CUN&=W7JU-/F\H.+7NYM<BM?S)KEGD0$)
M&#0OI%!J.>D<*\<L)NMQ=>E[>K(MRLD2JZ*S!=:% ,A7,$'&W6< !BNI'62H
MSH%J*8'=[9Y%MQ'"D]Q<% [*KLRJJ Y:CI.9!'1C91<7(N;'MSFR*L@?I*T!
M'B&(=AMYULX&@$S3,@+.2Q&A"W5J *G(FAQ+#N$R75D55HI2BI(&K0JP6@(I
M0@T''V'7D*J?'G[DL/S0-1\OM+R]O04L=R$+B;2Q5)8U*$.PJ%! 4@F@XYX%
MML)2[W&8JL*(&D0:F +2%,E4#,U(Q8*9'@VZ64K=SQK72*#2":'2K'(ME3G&
M-I_5FN6[&XVKAXVDEC"]JNK4W60&G)6N-ED"DJOI-2.3J#CB[GW'5';[C';F
M.<J>S#QAE*,W!<J$5IQP;"Q+3:4UO+&*Q+S OPU'F&>-^+ @&Z@H3R_V=.&+
ML,K+6^G/6!'-SX[R6HJAG>.-6(RZULHJ.>F/U-N4LEK>VS,)4FE>,,2:ZDJ0
M"IY"N-TA[M1L?2XK@&HDK)*T6FHUYD'(5&7-B.:20))!%IDA((E#(,QH\ZO-
MEGB_;0REX+Q@&4AJ$-3+$ .1$2<?HC&\1.C:SZ?I72:FJ&E!RUQ9*X*D01U!
MY,L7(D4K6]G(!%,JCV8YDX5"MX"?<RIX$4P()V+ GJM3DYC[:/O-MJF4=B+>
MZ@%-31JQ8,G.RECER\!B3;]CM[I;N9"BR36\D21:LM1,BJ#IXT%:XN.[^TJT
MLJPA4 XNVH$^4UPL"V5R=R:,!(EA=XPY%!JE4: M>-6R&+K9H5,]Y)$[,$!.
MIW:IH.C&W);(7,6X64CA0314D!8Y<@'$XO[.T0R320.$114DTX 8'HL9FEMY
M;>X[-<V80R*[!0.)(!H.4XG&VQR"9U62*.9&B8O&P<*0X!%2*8O;2QLKOTR6
MUEC[*2"1*,R$><P"GQ$UPAVNW>7<Q!'&B(A8JY !8@?B\<+:):W_ &KMKE=[
M28EI& !9F"T_>Q9]X889)[>-&@G6)2[J&.3!14FA.=!C:6VRTG-M%?1RS2R1
M-&5",#YK@-3II3'ZP[,^C_J](^TIEJ[5SI\-"#C:YX4+)#,[.0,E!7EPL%JI
M=Q<VKT KDLZ,3X@*XL;Z:%[K;(')G@C!9M1II?0N;A3G2A\&-IFVC;I>Q@OX
M'DF>%HF10ZDT1@&I3B:4Q9;I:6SS6J6[QS,M.J"2<ARGH&+;:MO@F2VBN8)[
MF:XA>(:8G#Z%UA2Q-.0$#VM3CLH32+Y[?@&*#A^UQT'$@T\. W1GB2VD\R1&
M0TYF%#AMBWHB"6S<QH\G566/BKJQR/&A .5,\+8[?&'LDCUS7!!TZC4!$;@3
ME4TK0'&Y+?U2WOFBN(IF!"5T"-D+< 1IJ*\AQM\&W@O:V;^DS7"YI7@J!N!)
MIF!P&-VF=6$;PV>@D&AH'K0\M,"90Q6*YMI7T@DA$F5F-!R "IQ<_J_[4N82
MIC&JOVJYBE:TQMN^0H\L5M*8YE12Q5):*7H 31>)Z,(EF?2YG=$$<'78:B 6
M:GFJ*U)-,1;S*CM97-JMH\BJ6$3([,"U."G52IR'+B/8=I)N'NIHA))#UTBC
M616=F85 R&0.9Q'MV[P,UO*">V*$Q*PY&8>:>8FF+6WV"XDN=OE#^D19211
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M3%?-J>1>4X07]XFXV,BT>L21/&W.--*CHX^U$(S" ,>@\G[EY1N!%,&VF)U
M]4GE'M+M%!))AX9_SJXVC(FFY6QR'#KCCB[5%U$]EE_SBXV0*I(])<DCDZHQ
M" "?[;9\/Z=,;*5!('I-:#(=08:.Y8(LNUQ!6/"JS2$U;@,N?&V;5MC"=H[J
M.ZF:,ZEC2(UZQ&0K2@&)C3+]5PY_\_)BYCG8(TUC:B/40-9$DM0M>)%1D,7W
MIOV<%[#;R1RN"$+IJ0IJ.5: &E:YXVS;-M/;=C=QW4SQ]98UB.H!F&0+4H!6
MN+A^3]5VX_\ 72XCMMU4]A.2I<J3&IY-3#):\A)&+$]VKN2=9[B..>T#B9!$
MS4:3E9=(SKJI[2O%CDHYS@DUU,=35Y_V=\?[<Z-Q' CB,:+@=4Y*P_#BJ\/8
MHPJ.G'6%:9XTL*CF. 2,QPQ0BN Q&8X'!+ &HH:CDYL$0(J FIT@"N-=!JI2
MO+3"O(BLR&JDBI!Z,%) &4\0148[.!%1>913&J@U$4KRTP4< J<B#PP1;QJE
M>.D >SV,/7EYN;I..UG.J3X!X/V>S_;I0XJK,OT3C[PGP@8\X>3'G#R8\X>3
M'G#R8\X>3'G#R8\X>3'G#R8\X>3'G#R8\X>3'G#R8\X>3'G#R8\X>3'G4\ Q
M621ST9 ?%CJBG[NKI'7J'221E6E<N?\ RZ<"-@:M6AIEE[0O(:*.)QEQ]N(R
M>L14#H]P33\Y@#^YD">)))\-?8:+40B!:@95)Y*\>%.&%8,>S8A"I-:$F@()
MS^'#QF0B$1+5!05+%@36E1D.0C'92%@*KF">?$IA)#)$Q4UJ00,CG@11DJSF
M@(ID.).=16G#%8G96J"<ZUIR9UX]&!;H2N09B*<*\,^?_P!&#<1LP5,V4FH(
MY>-> YL(JUT$]<KQI\?DQJC=M/*I-1X<ZGX<)>$MJ52*!C3R82T#%68:LN-!
MR>/_ -&%:+6P9E4KFPS-*USI3CAHNT985B4E%H*EBPXTJ.'(1A;>,E:YEAQH
M.3/GX8-Q&S )UF!-:@9GC7DYL( : L0?(<&T!*JB*[4Y=1( KQ^;R8AD1V"*
MU"G$&O+GG\. C:A#IXKRM7@:9@8+*[%"  I-0".4'CGX?W,'0BL==2D<@/$<
M_' "Y1@5)YSS8:0"J.JUIQ!%<_)3"+3[-2')/*1P'/B24CJ-'&H/2"U?C&#H
M&IA0@<]#7$L48JSQLH'"I(IRX#Q><I!ISCE'DQU%)-0.;CR^+HPLT8K\UAT<
M_BQV2 T8@,3E05S\HX8%%J"<Z<G3B.6,$4J&/#+FIRX5@*K0@GFX4PMPBZCY
MIYZ$\1X,9 ^2GQX>4CJ&-%!RX@M7IY1A98Q4@T(RS!^3C@P("0_58G*BGCQZ
M.&$*BH#&OD.#<*"P=%1@.3220?A.(A&E4U59JTI099<<4*U2E:CG\'R8[9*A
9"E&KE4URRYQ^Y=7]TGCCC[UX_P#YS#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img116206746_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img116206746_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4*#!$# 2(  A$! Q$!_\0
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M[]+_ (4?5\-Y_@'M\S_N?B?4'_"=Z'_SUF_[]&C_ (3O0_\ GK-_WZ-?+_\
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M^_1H_P"$[T/_ )ZS?]^C7R__ ,);K/\ S]+_ -^E_P */^$MUG_GZ7_OTO\
MA1]7PWG^ >WS/^Y^)]0?\)WH?_/6;_OT:/\ A.]#_P">LW_?HU\O_P#"6ZS_
M ,_2_P#?I?\ "C_A+=9_Y^E_[]+_ (4?5\-Y_@'M\S_N?B?4'_"=Z'_SUF_[
M]&C_ (3O0_\ GK-_WZ-?+_\ PENL_P#/TO\ WZ7_  H_X2W6?^?I?^_2_P"%
M'U?#>?X![?,_[GXGU!_PG>A_\]9O^_1H_P"$[T/_ )ZS?]^C7R__ ,);K/\
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M -^E_P */^$MUG_GZ7_OTO\ A1]7PWG^ >WS/^Y^)]0?\)WH?_/6;_OT:/\
MA.]#_P">LW_?HU\O_P#"6ZS_ ,_2_P#?I?\ "C_A+=9_Y^E_[]+_ (4?5\-Y
M_@'M\S_N?B?4'_"=Z'_SUF_[]&C_ (3O0_\ GK-_WZ-?+_\ PENL_P#/TO\
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M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
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M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
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M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
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M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
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M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
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M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
MGK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH
M^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^
ME_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_
MWZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;
MS_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]
M+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'
M_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /
M;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1
M_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z
M'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_
M '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P )
M;K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SU
MF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q
M/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_
M #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]
M&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_
M (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+
M_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE_
M_A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O
M0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^
ME_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=
M9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\
MGK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH
M^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^
ME_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_
MWZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;
MS_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]
M+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'
M_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /
M;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1
M_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z
M'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_
M '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P )
M;K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q/J#_ (3O0_\ GK-_WZ-'_"=Z'_SU
MF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_ #]+_P!^E_PH^KX;S_ /;YG_ '/Q
M/J#_ (3O0_\ GK-_WZ-'_"=Z'_SUF_[]&OE__A+=9_Y^E_[]+_A1_P );K/_
M #]+_P!^E_PH^KX;S_ /;YG_ '/Q/IV3Q]HB+E3<.<]%C_Q(I_\ PG>A_P#/
M6;_OT:^9(/%6L.Y#7*D8_P">:_X5&?%NLY/^E+_WZ7_"G]7PUKZB^L9G>WN?
MB?3_ /PG>A_\]9O^_1H_X3O0_P#GK-_WZ-?+_P#PENL_\_2_]^E_PH_X2W6?
M^?I?^_2_X4OJ^&\_P'[?,_[GXGU!_P )WH?_ #UF_P"_1H_X3O0_^>LW_?HU
M\O\ _"6ZS_S]+_WZ7_"C_A+=9_Y^E_[]+_A1]7PWG^ >WS/^Y^)]0?\ "=Z'
M_P ]9O\ OT:/^$[T/_GK-_WZ-?+_ /PENL_\_2_]^E_PH_X2W6?^?I?^_2_X
M4?5\-Y_@'M\S_N?B?4'_  G>A_\ /6;_ +]&C_A.]#_YZS?]^C7R_P#\);K/
M_/TO_?I?\*/^$MUG_GZ7_OTO^%'U?#>?X![?,_[GXGU!_P )WH?_ #UF_P"_
M1H_X3O0_^>LW_?HU\O\ _"6ZS_S]+_WZ7_"C_A+=9_Y^E_[]+_A1]7PWG^ >
MWS/^Y^)]0?\ "=Z'_P ]9O\ OT:/^$[T/_GK-_WZ-?+_ /PENL_\_2_]^E_P
MH_X2W6?^?I?^_2_X4?5\-Y_@'M\S_N?B?4'_  G>A_\ /6;_ +]&C_A.]#_Y
MZS?]^C7R_P#\);K/_/TO_?I?\*/^$MUG_GZ7_OTO^%'U?#>?X![?,_[GXGU!
M_P )WH?_ #UF_P"_1H_X3O0_^>LW_?HU\O\ _"6ZS_S]+_WZ7_"C_A+=9_Y^
ME_[]+_A1]7PWG^ >WS/^Y^)]0?\ "=Z'_P ]9O\ OT:/^$[T/_GK-_WZ-?+_
M /PENL_\_2_]^E_PH_X2W6?^?I?^_2_X4?5\-Y_@'M\S_N?B?4'_  G>A_\
M/6;_ +]&C_A.]#_YZS?]^C7R_P#\);K/_/TO_?I?\*/^$MUG_GZ7_OTO^%'U
M?#>?X![?,_[GXGU!_P )WH?_ #UF_P"_1H_X3O0_^>LW_?HU\O\ _"6ZS_S]
M+_WZ7_"C_A+=9_Y^E_[]+_A1]7PWG^ >WS/^Y^)]0?\ "=Z'_P ]9O\ OT:/
M^$[T/_GK-_WZ-?+_ /PENL_\_2_]^E_PH_X2W6?^?I?^_2_X4?5\-Y_@'M\S
M_N?B?4'_  G>A_\ /6;_ +]&C_A.]#_YZS?]^C7R_P#\);K/_/TO_?I?\*/^
M$MUG_GZ7_OTO^%'U?#>?X![?,_[GXGU!_P )WH?_ #UF_P"_1H_X3O0_^>LW
M_?HU\O\ _"6ZS_S]+_WZ7_"C_A+=9_Y^E_[]+_A1]7PWG^ >WS/^Y^)]0?\
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MS_S]+_WZ7_"C_A+=9_Y^E_[]+_A1]7PWG^ >WS/^Y^)]0?\ "=Z'_P ]9O\
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M_OTO^%'U?#>?X![?,_[GXGU!_P )WH?_ #UF_P"_1H_X3O0_^>LW_?HU\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH L1_\>LE5ZL1_\>LE5ZJ6R)CN
MPHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH GM?]8?I4)^\?K4UK_K#]*A/WC]:I
M[(E?$Q****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3@X7D>2_\,\?]33_ .4__P"V4?\ #/'_ %-/_E/_ /ME'_#0_P#U*W_E0_\
MM='_  T/_P!2M_Y4/_M='[_^K!^X_JY1UKX$_P!D:%J&I_\ "2>;]CMI+CR_
ML.W?L4MC/F'&<=<5X[7L6M?';^U]"U#3/^$;\K[9;26_F?;MVS>I7./+&<9Z
M9KQVMJ?/;WS*IR7]P]LM_P!GWS[:*;_A)]OF(&Q]@SC(S_STKRWQ;H'_  BW
MBB]T7[3]I^RE1YWE[-V5#?=R<=<=:^OM/_Y!MK_UQ3^0KY;^+/\ R4_6O]^+
M_P!%)65&I*4K-FE:G&,4T<711172<P5IZ%X?U3Q)J*6.E6DEQ,QY('RH/5FZ
M*/K5&VMIKRZAM;:-I9YG6..->K,3@ ?4FOKCP3X1M/!OAV'3H-KW! >YGP,R
MR=^W0= /2LZM3D7F:TJ?.SS31_V?H_)#ZUK3^80,Q6: !3W^9NO_ 'R*V6^
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M[&=3V5O=W.9HHHK8P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )[7
M_6'Z5"?O'ZU-:_ZP_2H3]X_6J>R)7Q,2BBBI*"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W/!?_(]^'O^
MPG;?^C5K#K<\%_\ (]^'O^PG;?\ HU:4MF5'='V)1117F'I'P_1117J'EA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8
MC_X]9*KU8C_X]9*KU4MD3'=A1114E!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDVL"[I)-I;:/H 2:FMI4T*HZT]3YB_X4_P"._P#H!?\ DW!_\71_PI_QW_T
MO_)N#_XNO</^%P>!/^@[_P"2D_\ \11_PN#P)_T'?_)2?_XBK]K5_E_ CV5+
M^8^?=<^'WBCPWIQU#5M+^SVH<)YGVB)^3T&%8FN9KW+XJ?$'POXD\%MI^DZI
M]HNC<1OY?V>5.!G)RR@5X;6].4I*\D8U(QB[19]L:?\ \@VU_P"N*?R%?+?Q
M9_Y*?K7^_%_Z*2OJ33_^0;:_]<4_D*^6_BS_ ,E/UK_?B_\ 125S8?XV=&(^
M!'%T445V'&>@?!G3H]0^(]H\B[EM(I+@#W VC\BP/X5])ZO?KI6BWVHOC;:V
M\DQW=/E4GM]*^?O@(5'CR[!&2=.D ]CYD=>W^.03X!\08&?^)?/_ .@&N.OK
M4L=E'2G<^1+NZGOKR>\N9#)<3R-+*YZLS')/YFH:**[#D.C\!ZS/H7C?2;R%
M]JFX2*4$D!HW(5@>?0YYXR >U?7I (((R#U!KXDM;>2\NX;:+'F32+&F?4G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!/:_P"L/TJ$_>/UJ:U_UA^E0G[Q^M4]D2OB8E%%%24%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.@XN[.?^).L+HGP_U>X+$22P&VBP<'=)\N1] 2?PKYF\%_\ (]^'O^PG;?\
MHU:ZKXL^/D\6:JEAITI;2+-B5;&/.DY!?Z8X'U/K7*^"_P#D>_#W_83MO_1J
MUI2ARP=S.I/FFK'V)7Q7JW_(9OO^OB3_ -"-?:E<5-\)/ \\TDTFB;I)&+,?
MM<PR2<G^.L*-10O<WJTW.UCY4HKZH_X4_P"!/^@%_P"3<_\ \71_PI_P)_T
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M/UK_ 'XO_125]2:?_P @VU_ZXI_(5SFK?#;PEKNJ3ZEJ6D^?=SD&23[3*N[
M '"L!T [5QTIJ$KLZZL'.*2/DJBOJC_A3_@3_H!?^3<__P 71_PI_P "?] +
M_P FY_\ XNNCZS P^KR/"OA7K":+\1-,EFE\N"<M;2G;G.\$*.G'S[.?Z9KZ
MHN;:&\M)K6XC62&9&CD1AD,I&""/H:^-O$-K#8^)M5M+9-D$%Y-%&F2=JJY
M&3R>!7T)\,?B;:^);&#2M5NDCUQ 5^8;1<@?Q*>F['4?4@8Z17@W::*H32O%
MG@/BGPY=^%/$-UI-X"6B;,<NPJ)4/W7'L?QP01VK'K[(\0^%M%\4V@M]8L8[
M@+]QSP\?()VL.1G SCKWKBX_@5X02Z>9GU*1&)(A:X78O.< A0WMR:J.(C;W
MA2P[OH>4?";PI<>(?&5I=M 3I^GR">>1A\NY>47W);''H#7T]<7$-I:RW-Q(
ML4$*&221C@*H&23[ 5!IFE6&BV*V6FVD5K;*21'$N!D]3[GWKQGXO?$RVNK.
M7PSH=QYH<[;VY0_+@'_5J>^2.2.,<<Y.,FW6GH:I*E#4\?UJ_P#[5UW4-1VE
M?M=S)/M/4;V+8_6OK;P7_P B)X>_[!EM_P"BEKX[K[$\%_\ (B>'O^P9;?\
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MO_12U\G>)/\ D:=7_P"OV;_T,U]8^"_^1$\/?]@RV_\ 12U>(^%$T/B9\_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $]K_ *P_2H3]X_6IK7_6'Z5"?O'ZU3V1*^)B4445)04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'A+_ *!TWY'_ .*KE**/;/LON#ZA'^>7_@3.K_M#PE_T#IOR/_Q5']H>$O\
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M'A+_ *!TWY'_ .*KE**/;/LON#ZA'^>7_@3.K_M#PE_T#IOR/_Q5']H>$O\
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M_(__ !5']H>$O^@=-^1_^*KE**/;/LON#ZA'^>7_ ($SJ_[0\)?] Z;\C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W/
M!?\ R/?A[_L)VW_HU:PZW/!?_(]^'O\ L)VW_HU:4MF5'='V)1117F'I'P_1
M117J'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!8C_X]9*KU8C_ ./62J]5+9$QW84445)04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8M?O-]
M*KU8M?O-]*KU3V1*^)A1114E!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!/:_P"L/TJ$_>/UJ:U_UA^E
M0G[Q^M4]D2OB8E%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 6+7[S?2J]6+7[S?2J]4]D2O
MB84445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 3VO^L/TJ$_>/UJ:U_UA^E0G[Q^M4]D2OB8E%%%2
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7@_X?V+K&=/TF)\;BS@/+C.,DG<Y&3Z]37SW\3?' \;>((Y+42)IMHACMDD
M#$G!9R.V2 /HH[YJ:2O.\=BJKM"TMSZ7\.7R:EX9TN]3[L]I%)CTRHXKQ36?
MC9XMTC6[[39=.TA7M9WB.Z&7/RDC/^LY^M)\)/B;9Z'9CP]KDODV@<M:W)&5
MC+')1L=!DDY[9.>.GJ^I^$_!_C4I?W5G9Z@2!BY@F(+#MEHV&1]34V5.3YEH
M.[G%<KU//=(^(/Q1U[35U'3/#&F7%HSE%D$;KN(ZX!E!([9Z9!'4&O.?B)K_
M (BUS6;=?$NFQ:?>6T.U8HXF3*DYS\S'/U%?0>O>,/#'@+1UA,MNC11XM]/M
MB-[=<84?=7@_,>/QKY>\0:W=>)-?O-7O,>?=2;B%'"@#"J/8* /PK6CJ[VLC
M*KHK7NS-HHHKH.<*^I/@W_R3#2_]^;_T:U?+=?2'PH\3:!IWPZTZUOM<TVUN
M$:;=%/=QHZYD8C()STK#$*\3?#NTCR?XP?\ )4]9_P"V'_HB.N'KL?BI>VNH
M_$C5KJRN8;FWD\G9-!('1L0H#@C@\@C\*XZM8?"C.?Q,*]4^ ^D_;/&5SJ+H
MI2QMCM)ZK(YVC'_ 0]>5U[O\$]0T'0O#%Y<:CK.EVEW>7/\ JYKI$D\M!A<@
MD'J7Q]?>IK.T'8JDKS5SE_CMJ9N_'45DKYCLK5%*Y!P[$L3[9!3\J\PK:\7:
MH-9\7ZMJ"LK)-=.4*G(* X7GZ 5BU4%:*1,W>385Z7\"_P#DH3?]>4O\UKS2
MO0O@SJ-CI?CIKC4+VWM(/LDB^9<2K&N25P,D@9I5/@84_C1Z]\:?^2:7O_7:
M'_T,5\OU]B?\)IX5_P"AFT;_ ,#XO_BJ/^$T\*_]#-HW_@?%_P#%5S4ZC@K6
M.FI34W>Y\=T5]B?\)IX5_P"AFT;_ ,#XO_BJ\6^.FL:9J^H:,VF:C9WJQQ2A
MS;3K(%)*XSM)Q6T*KD[6,ITE%7N>U>'/#^G^#_#D5A9Q*L<*;YI OS2OCYG;
MU)_08 X KQS6/C_JDLS+HVDVMO""P#W1:1V&>#A2 I]1\W7KQSZ;X'^(6D^+
MM+M\W4,&J!0LUH[@/NZ94'&X'KQTS@U'JOAOX?>'KI]>U2PTRTEY.^;[K'[W
MRQYP6X/W5S7/&RD^=79O*[BN1V1O>%KR]U#PKI=YJ(Q>3VR2RC;M^9AGIVZU
M\I>-/^1[\0_]A.Y_]&M7TMH?Q*\+ZUIYNVU:RL?WKH(;NZ2.0@' ;:2,9&#^
M-?.?Q"CM%\>ZO+875M=6MQ.;A)K>42(V_P"8\@GD$D5I034G=&==IQ5F?6\Y
M(@D(."%."/I7Q%7V#/XS\+&"0#Q+HY)4X OHO3_>KX^IX9-7N+$-.UCTOX%_
M\E";_KRE_FM>F_'#_DG3_P#7W%_6O*?@SJ-CI?CIKC4+VWM(/LDB^9<2K&N2
M5P,D@9KT/XQ>(]#U3P&]MI^M:==S_:8V\JWNDD; SDX!)HFG[5#@U[)G@VD:
ME-H^L6>I6^?-M9DF49QG:<X^AZ5]=7L-EXQ\'310R;[34[,^5(1C =<JV.Q!
MP?J*^.:^C_@9X@_M/PA-I,FXS:7)M!/.8Y"S+^1#CZ 4\1'1270FA+5Q?4[#
MPQI</@_P/96=PT<2V5KYER^[*AL%Y&R>V2Q^GI7R?K>JS:YKE]JD^X27<[RE
M6;=M!.0N?0# 'L*^BOC3XB;1?!)LH)%6XU-_L^,C/E8RY /7LOMOKYFHPZWD
M^H5WM%= HHHKH.<L6WW9/I5>K%M]V3Z57JGLB5\3"BBBI*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
MQ:_>;Z57JQ:_>;Z57JGLB5\3"BBBI*"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@">U_UA^E0G[Q^M36O
M^L/TJ$_>/UJGLB5\3$HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %;G@O_D>_#W_ &$[;_T:M8=;G@O_ )'OP]_V$[;_ -&K
M2ELRH[H^Q****\P](^'Z***]0\L**** /2_@7_R4)O\ KRE_FM>\^-/^1$\0
M_P#8,N?_ $4U>#? O_DH3?\ 7E+_ #6O>?&G_(B>(?\ L&7/_HIJXZW\1'91
M_AL^/8HI)I4BB1I)'8*B*,EB>@ [FMD^#/%(!)\-:P .I-C+_P#$U7\-_P#(
MTZ1_U^P_^ABOLQU#HR'HPP<5M5JN#1C2I*:9\9:+X?U?Q%=FVTC3Y[N4<MY:
M_*G7[S'A>AZD5T4OPF\<PPF5M!D*@9PD\3-^08FO;;WQ/X+^%6GQ:.BE9E0.
M;:TC#2R$X&]R2!D]?F.<#CM70>%/&.C^,K"2ZTF9R8B%FAE7;)$3TR,GKSR"
M1P>>#42K3W2T-(T8;-ZGR%/!-:S-#<1212H<,DBE67Z@U'7T#\=O#-K-H,/B
M&&&-+R"58IY!P7C;(&?4AL?@37BWA709/$_B>PT>-Q&;F3#.?X5 +,?KM!Q6
MT*BE'F,9P<9<I%HOAW6/$5R;?2-/GNY%QO\ +7Y4SG&YCPN<'J1FMZZ^%7C>
MSMFN)= F9 ,D12QRM_WRK%C^5?3VBZ+I_AS2(=.TZ!8+6$?BQ[LQ[D]S7&7G
MQK\'V>J&R$UW.BDJUU!"&B!!(ZYR>G4 @Y&#6/MYR?NHV]C&*]YG(_L_120W
MOB.*5&CD00*R,,%2#)D$=C75?'#_ ))T_P#U]Q?UKL]'DT;5%_M_26AE%[$J
MM<1#'F*I. W?()8<\CD'I7&?'#_DG3_]?<7]:RYN:JF:<O+2:/#? NLZYH?B
M$WGA[3?[0O?(9/)\AY?D)&3M0@]AS7<>(?'OQ&U#P]?V>I>$OLUE- R3S?V=
M<)L0CD[F; ^IK,^!?_)0F_Z\I?YK7N/Q!_Y)[K__ %Y2?RK6I)*:5C*G%N#=
MSY#J:TL[K4+I+6RMIKFXDSLBA0N[8&3@#D\ TZPLIM2U&VL;8 SW,J0Q@G +
M,0!^IKZS\%>"M.\%:.+2T'FW,F&N;IEPTK?T4<X';W)).M2HH(SITW-GSTGP
MC\=2+N70F _VKF%3^1>L76_!OB+P[$)M6TBYMH2<>:0&3/H67(!_&OH36?C)
MX2T;4C8F:YO)$<I*]I$&2,CU)(S_ ,!ST-=9INIZ3XJT,75H\-[I]RI1E=<@
MCH593^H-8^VFM9+0U]C!Z)ZGQG2HC2.J(I9V.%51DD^@KN_BMX,C\(^)PUG'
MLTV^4RVZCHA!PZ=<\9!^C =J])^"'@^WLM!_X22ZB#WEZ2(-Z_ZJ-21D>[$=
M?0#\=I54H<QE&FW+E/*K3X6>-KV)9(M G56&0)I$B/Y.P(^E+<_"KQO:1-))
MH$S*JEB(I8Y#@>@5B2?85[_XK^)?AWP?=?8[^6XFO-H<V]M%N8*>A))"CZ9S
M^E3^$OB#H/C0R1Z9+*EU&F][:X3;(%SC/!((Z="<9&>M8^VJ6O;0U]C3O:^I
M\ES0R6\TD,T;QRQL4='4AE8'!!!Z$5TO@;0=2U+Q1HUU#I-W=6$>HP+/,ENS
MQ* ZE@Q P.#DY[&O8OCEX;LKOPK_ &\L2)?64B*TH7F2-CMVGZ$@CKCGU-8O
MP4\8:#I&A-HE_?>5J-YJ9\B'R7;?O6-%^8*0,L".36GM7*',D1[-1GRMGN
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M6CUJR^U)!'&T8\UTVDEL_=(ST'6K_P 8O!7A[PKIFES:+I_V62>9UD/G2/N
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M71FTT[,****!!1110!8MONR?2J]6+;[LGTJO5/9$KXF%%%%24%%%% !1110
M4444 %%%% !1110 5[Q\,?AWX5\1>!K74=5TK[1=O)(K2?:)4R Q X5@.GM7
M@]?4'P6_Y)I9?]=IO_0S6-=M1T-Z"3EJ6/\ A3_@3_H!?^3<_P#\72-\'O K
M# T4K[B[F_J]>;?&;Q%KFE^.EM]/UG4;2#[)&WEV]T\:Y);)P"!FN1T3XG^+
M=%NXY?[8N;R$.&DAO)#*''<9;)'X$5FJ=1QNI&CG34K.)VOCSX*II6F3ZMX<
MFGF2',DMG+AF"=248#G'H><=R>#Y?X8LX-1\6:-974?F6]Q?00RIDC<C2 $9
M'(X)Z5]CPR+<6T<FWY9$#8/H17RAI5I%8?%ZRLX%VPV^O1Q1C).%6< =>>@J
MJ51R33)JTU%IH]C\6?"WP9IGA#6+ZTT;R[FWLY98G^U3':P4D'!?!Y]:^;Z^
MP_&L,EQX'UR&&-Y)9+&9$1%)9F*$  #J37C.B_ /5KVR6;5=4BTV9C_J%B\]
ME&.Y# 9]AGZTJ-1*+<F.K3;:Y4>145Z;XJ^"FM>']/EO[&[CU2WA4M(J1E)0
M/4+DY'KS7F5=$9*2NCGE%QT845W7A#X4Z_XMMDOE\JQT]_NSW&<R#_84<GZG
M ]":[4_L\-LR/$XW>GV#C\_,J75@G9LI4IM72/$**[GQI\+=;\'6YOI'BO-.
M! :XBX*$X #*>F2<#&?PZ5Q,,,EQ-'##&\DLC!$1%)9F)P  .I-4I*2NB7%I
MV8RBO7='^ >KWEFDVJ:I!I\K<^2D7G,HP.IW 9Z\#/3K5Z?]GF=4S!XEC=_2
M2S*#\PYJ/;0[E^QGV/%**V/$OA?5?">J&PU6#RY"NY'4Y21?53WK*AADN)HX
M88WDED8(B(I+,Q.  !U)K1--71FTT[,917K>A_ 76+^T6?5=2ATUW&1"L7G.
MH_VOF !^A-2:O\ =6M+-I=*U:#4)EY\F2+R"PQ_"=S#.?7 ]ZS]M"]KE^RG:
M]CR"BIKRSN-/O);2[A>&XA8I)&XP5([&H:T("NR\ ?#R^\<WDI286NGV[ 3W
M#*223GY4'0MQSSP#GT!XVOI'X9>)O">C> M-LI-<L(+G:TDZ33!&#ECG.<=.
M!]!WZUG5DXQ]TTI14I:FA:?!CP1;0+'+ILUTP',DUU(&/_?!4?I67X@^!GAZ
M^M&.BO+IMV.4W2-+&W3A@Q)_$'OWKSSXB_$O6=1\4W=OHNLSV^EVK^7";*8I
MYI'#.64_,"<XYQC'U/JOP@\5:GXI\+7$FK3">YMKDQ";:%+J5##..,C)';C'
MUKG:J1CS7-TZ<GRV/FO5-,N]&U2YTV^B,5U;2&.13ZCN/4'J#W!!JI7J/QZB
M2/Q[;,J@&33HV8@=3OD'\@*\NKJA+FBF<LX\LF@HHHJB0HHHH **** "BBB@
M HHHH **** +%K]YOI5>K%K]YOI5>J>R)7Q,****DH**** "BBB@ HHHH **
M** "BBB@ KWCX8_#OPKXB\#6NHZKI7VB[>216D^T2ID!B!PK =/:O!Z^H/@M
M_P DTLO^NTW_ *&:QKMJ.AO02<M2Q_PI_P "?] +_P FY_\ XND;X/>!6&!H
MI7W%W-_5Z\V^,WB+7-+\=+;Z?K.HVD'V2-O+M[IXUR2V3@$#-<CHGQ/\6Z+=
MQR_VQ<WD(<-)#>2&4..XRV2/P(K-4ZCC=2-'.FI6<3M?'GP532M,GU;PY-/,
MD.9);.7#,$ZDHP'./0\X[D\'RG1+>*\U_3K:=-\,UU%'(N2,J6 (R.>E?9L,
MBW%M')M^61 V#Z$5\CQ6D5A\3$LX%VPV^L"*,9)PJS8'7GH*JC4<DTR:U-1:
M:/>-6^$W@BVT:^N(=$VRQ6\CHWVJ8X(4D'EZ^8Z^T=<4MH&I*H)8VLH '4_(
M:\&\/_ C6=3L5N=6OX]*9^5@,7G.!V+88 ?3.?7'2IHU+)N3'6IW:44>3T5Z
MGXD^!NM:/I[WFF7L>JK$I:2%8C'+@?W5R0W&>,Y] :\LKIC)2U1SRBXZ,**[
M/P?\,=>\8PB\MEBM=/W[?M-P2 V#\VP 9;'X#/&>M=X/V>&V9/B<;O3[!Q^?
MF5,JL(NS92I3DKI'B%%>@>,?A)K?A.P;45FBO[",#S9(@5://&2I[=.03^%<
M B-(ZHBEG8X55&23Z"JC)25T3*+B[,2BO6-"^ ^LZC91W&IZA#IK/@B'RC*Z
M@C/S#( /MFM63]GF4+^Z\3(Q]&LBO_M0U#K074M49OH>)45N^*?".K^#]16S
MU6%5,B[HIHSNCE'?:<=NX/(X]1G#1&D=412SL<*JC))]!6B::NC-IIV8E%>J
M^'O@5K>J68N=5O8M*WX*0F/S9,?[0! ';N3ZXJ]J?[/VHP6K2:;K<%Y,!D12
MP&'=[ [F_6L_:PO:Y?LIVO8\<HJSJ.G7FDZA/87]N]O=0-LDB<<J?ZCN".".
M15:M" KK? 7@.]\<:JT,;FWL8!NN+DJ2%]%7U8^GH"?8\E7L_P +/B)X4\*^
M&3IM^UU;W;S--/*8-R,2< *5)/"A>H'.:BHY*/N[ETU%R]X[FS^#'@FVMUCF
MTZ:[<  RRW4@9O?"%1^E<_XL^!FEW%F]QX:DDM+J-<BWE<R1RX!X!/S*QXYR
M1[=ZX;Q]\4=6UCQ%,NA:Q=6NDPD+;_97>$R<<LQX8Y.>#V XSR?<?AWJ^HZ]
MX%TS4M5(-W,KAG";=X5RH;'N #7-+VD$I-G1'V<VXI'R5-#);S20S1O'+&Q1
MT=2&5@<$$'H13*['XJPP0?$W6TME58S(CD*,#>T:LY^I8DGWKCJZXNZ3.62L
MV@HHHIDA1110 4444 %%%% !1110 4444 3VO^L/TJ$_>/UJ:U_UA^E0G[Q^
MM4]D2OB8E%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5N>"_\ D>_#W_83MO\ T:M8=;G@O_D>_#W_
M &$[;_T:M*6S*CNC[$HHHKS#TCX?HHHKU#RPHHHH ]+^!?\ R4)O^O*7^:U[
MSXT_Y$3Q#_V#+G_T4U>#? O_ )*$W_7E+_-:]Y\:?\B)XA_[!ES_ .BFKCK?
MQ$=E'^&SY.\-_P#(TZ1_U^P_^ABOLVOC+PW_ ,C3I'_7[#_Z&*^S:>)W0L-L
MSXY\874MYXSUN>:1Y&:^F 9SDX#D ?0   =@*]!_9_N2OBS4[7!VR6/F$YX^
M611T_P"!UYOXD_Y&G5_^OV;_ -#->@_ +_D>[[_L&2?^C8JVJ?PV8T_XB/4/
MC)_R3#5/]^'_ -&K7FGP!LQ+XMU&[/(@LB@X[LZ\Y^BG\Z]+^,G_ "3#5/\
M?A_]&K7F7P#O8X?&-]:/@-<61*$GJ593C\B3^%8P_@LVG_%1ZG\6[^?3_AKJ
MKV[E'F"0%@/X7<!A^*DC\:^5:^K/BQITNI?#;5DA&7A1;C'^RC!F_P#'03^%
M?*=:8;X2,1\1[O\ L^ZC/+8ZWITCEH('BEB4G[I?<&_]!7]:Z'XX?\DZ?_K[
MB_K7/_L^Z9<1:?K.IN,07$D<,?!RQ0,6/T^<#\_2N@^.'_).G_Z^XOZUE+^,
M:1_@GF7P+_Y*$W_7E+_-:]Q^(/\ R3W7_P#KRD_E7AWP+_Y*$W_7E+_-:]Q^
M(/\ R3W7_P#KRD_E16_BH*7\-G@OP6L8[SXD6LDA/^BPRS*/4XV\_P#?6?PK
MW[QS>R:=X%UNZBE>*5+.0)(A(96(P"".AR>M> ?!:]6T^)-I&_\ R\PRP@GL
M=N[_ -EQ^-?0/C;3Y-5\$:U90H9)I+23RT'5F R /Q IUOXBN%'^&['Q[70:
M'XW\1^&K"6RTC4WM;>60RNBQHV6P!G+ D< =/2N?KKO"/PYUSQI8W5YIC6D<
M-NXC)N)"N]L9(7 /08SG'4>]=4N6WO'+'FO[IC:SXEUOQ"R'5M3N;L(2461_
ME4GN%Z#\JO\ A'3O%>KWCV?AF2^5@0TK03M$B9XRS9 '0^YQQFI/%/P_U_P?
M;17.JPP""60Q(\4P;+8STZ] >U?2G@/P]!X:\':=91Q1I,T2RW#(/ORL 6)/
M?T'L!652HHQ]TUITW*7O'EUM\!]7U*47>O>(T^T2$&78C3N>G!=B.<=\''O7
MH7@[X9Z)X+O'O;*2[GNWC,1EG<<*2"0  !U4=<UQGQ"^,.I:#K]WHFCV4"/;
M$*]S< N22 ?E4$ =1US]*A^$WC3Q-XK\:W2ZK?R3VD=F[^6L:I&C;T ^Z!V)
MQG)ZUE)5'&[>AK%TU*R6IVGQ@_Y)9K/_ &P_]'QU\Y^"_P#D>_#W_83MO_1J
MU]&?&#_DEFL_]L/_ $?'7SCX.8)XWT!ST74K<G'_ %T6KH?PV17_ (B/L:OA
M^ON"OA^IPW4>)Z'T)^S_ /\ (K:I_P!?O_LBT?M ?\BMI?\ U^_^R-1^S_\
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MCW $D;A@]NN/RKK?%FC6NO>%]0L+N)75X6*$CE' )5@>Q!I*I.,K3&Z<)1O
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MD#C&<=*[GP'\&M*M])M[_P 2VYN[^;;*+9F98X!U"D C<?7/';'&3TUQXO\
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MC(;C-9%GXY^$NG7275D=,MKB/.R:#271UR,'!$>1P2/QJ%9PMREN_/?F.?\
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M!,];L_BWX'T?PT+72Y95:SMBMM:O Z^8RCY5+ $#)ZD^N37G=E\8_'5WK:&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB/7-4MOLVH:UJ-W!D-Y5Q=/(N1T."2*:H-23N)U[Q:L=Q\"_^2A-_P!>4O\
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MQK-KJEQJ&V>S?S+9$C41Q-ZA2"#^.:A4ZEN6^AHZE._-;4]_^,'_ "2S6?\
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M3'4FI231]EZ]_P B]J?_ %Z2_P#H!KYZ^!E];67C^1+B58S=63P1;B!N?>C
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M[H@L],M;32;J.02)<06Z\]BK8P2,'UX./I7#^&_@7K-CKMG?:EJUC'%:SQS
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K<\%_\
M(]^'O^PG;?\ HU:PZW/!?_(]^'O^PG;?^C5I2V94=T?8E%%%>8>D?#]%%%>H
M>6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %B/\ X]9*KU8C_P"/62J]5+9$QW84445)04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6(?]1+]/Z5
M7JQ#_J)?I_2J]4]D3'=A1114E!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!8MONR?2J]6+;[LGTJO5/9
M$KXF%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %BU^\WTJO5BU^\WTJO5/9$KXF%%%%24%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% $]K_K#]*A/WC]:FM?]8?I4)^\?K5/9$KXF)1114E!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;
MG@O_ )'OP]_V$[;_ -&K6'6YX+_Y'OP]_P!A.V_]&K2ELRH[H^Q****\P](^
M/1X/UG W0(A[JS@$>Q'K1_PAVK_\\HO^_@KZS;1-)9BS:99$DY),"\_I2?V%
MI'_0*LO_  '3_"O1^M4?Y6>.\)C;Z3C]S_S/DW_A#M7_ .>47_?P4?\ "':O
M_P \HO\ OX*^LO["TC_H%67_ (#I_A1_86D?] JR_P# =/\ "CZU1_E8OJF.
M_GC]S_S/DW_A#M7_ .>47_?P4?\ "':O_P \HO\ OX*^LO["TC_H%67_ (#I
M_A1_86D?] JR_P# =/\ "CZU1_E8?5,=_/'[G_F?)O\ PAVK_P#/*+_OX*/^
M$.U?_GE%_P!_!7UE_86D?] JR_\  =/\*/["TC_H%67_ (#I_A1]:H_RL/JF
M._GC]S_S/DW_ (0[5_\ GE%_W\%'_"':O_SRB_[^"OK+^PM(_P"@59?^ Z?X
M4?V%I'_0*LO_  '3_"CZU1_E8?5,=_/'[G_F?)O_  AVK_\ /*+_ +^"C_A#
MM7_YY1?]_!7UE_86D?\ 0*LO_ =/\*/["TC_ *!5E_X#I_A1]:H_RL/JF._G
MC]S_ ,SY-_X0[5_^>47_ '\%'_"':O\ \\HO^_@KZR_L+2/^@59?^ Z?X4?V
M%I'_ $"K+_P'3_"CZU1_E8?5,=_/'[G_ )GR;_PAVK_\\HO^_@H_X0[5_P#G
ME%_W\%?67]A:1_T"K+_P'3_"C^PM(_Z!5E_X#I_A1]:H_P K#ZICOYX_<_\
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M?67]A:1_T"K+_P !T_PH_L+2/^@59?\ @.G^%'UJC_*P^J8[^>/W/_,^3?\
MA#M7_P">47_?P4?\(=J__/*+_OX*^LO["TC_ *!5E_X#I_A1_86D?] JR_\
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M'U3'?SQ^Y_YGR;_PAVK_ //*+_OX*/\ A#M7_P">47_?P5]9?V%I'_0*LO\
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M!5E_X#I_A1]:H_RL/JF._GC]S_S/DW_A#M7_ .>47_?P4?\ "':O_P \HO\
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M?67]A:1_T"K+_P !T_PH_L+2/^@59?\ @.G^%'UJC_*P^J8[^>/W/_,^3?\
MA#M7_P">47_?P4?\(=J__/*+_OX*^LO["TC_ *!5E_X#I_A1_86D?] JR_\
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M'U3'?SQ^Y_YGR;_PAVK_ //*+_OX*/\ A#M7_P">47_?P5]9?V%I'_0*LO\
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M!5E_X#I_A1]:H_RL/JF._GC]S_S/DW_A#M7_ .>47_?P4?\ "':O_P \HO\
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M(_Z!5E_X#I_A1_86D?\ 0*LO_ =/\*7UJC_*Q_5,=_/'[G_F?)O_  AVK_\
M/*+_ +^"C_A#M7_YY1?]_!7UE_86D?\ 0*LO_ =/\*/["TC_ *!5E_X#I_A1
M]:H_RL/JF._GC]S_ ,SY-_X0[5_^>47_ '\%'_"':O\ \\HO^_@KZR_L+2/^
M@59?^ Z?X4?V%I'_ $"K+_P'3_"CZU1_E8?5,=_/'[G_ )GR;_PAVK_\\HO^
M_@H_X0[5_P#GE%_W\%?67]A:1_T"K+_P'3_"C^PM(_Z!5E_X#I_A1]:H_P K
M#ZICOYX_<_\ ,^3?^$.U?_GE%_W\%'_"':O_ ,\HO^_@KZR_L+2/^@59?^ Z
M?X4?V%I'_0*LO_ =/\*/K5'^5A]4QW\\?N?^9\F_\(=J_P#SRB_[^"C_ (0[
M5_\ GE%_W\%?67]A:1_T"K+_ ,!T_P */["TC_H%67_@.G^%'UJC_*P^J8[^
M>/W/_,^3?^$.U?\ YY1?]_!1_P (=J__ #RB_P"_@KZR_L+2/^@59?\ @.G^
M%']A:1_T"K+_ ,!T_P */K5'^5A]4QW\\?N?^9\F_P#"':O_ ,\HO^_@H_X0
M[5_^>47_ '\%?67]A:1_T"K+_P !T_PH_L+2/^@59?\ @.G^%'UJC_*P^J8[
M^>/W/_,^3?\ A#M7_P">47_?P4?\(=J__/*+_OX*^LO["TC_ *!5E_X#I_A1
M_86D?] JR_\  =/\*/K5'^5A]4QW\\?N?^9\F_\ "':O_P \HO\ OX*/^$.U
M?_GE%_W\%?67]A:1_P! JR_\!T_PH_L+2/\ H%67_@.G^%'UJC_*P^J8[^>/
MW/\ S/DW_A#M7_YY1?\ ?P4?\(=J_P#SRB_[^"OK+^PM(_Z!5E_X#I_A1_86
MD?\ 0*LO_ =/\*/K5'^5A]4QW\\?N?\ F?)O_"':O_SRB_[^"C_A#M7_ .>4
M7_?P5]9?V%I'_0*LO_ =/\*/["TC_H%67_@.G^%'UJC_ "L/JF._GC]S_P S
MY-_X0[5_^>47_?P4?\(=J_\ SRB_[^"OK+^PM(_Z!5E_X#I_A1_86D?] JR_
M\!T_PH^M4?Y6'U3'?SQ^Y_YGR;_PAVK_ //*+_OX*/\ A#M7_P">47_?P5]9
M?V%I'_0*LO\ P'3_  H_L+2/^@59?^ Z?X4?6J/\K#ZICOYX_<_\SY-_X0[5
M_P#GE%_W\%'_  AVK_\ /*+_ +^"OK+^PM(_Z!5E_P" Z?X4?V%I'_0*LO\
MP'3_  H^M4?Y6'U3'?SQ^Y_YGR;_ ,(=J_\ SRB_[^"C_A#M7_YY1?\ ?P5]
M9?V%I'_0*LO_  '3_"C^PM(_Z!5E_P" Z?X4?6J/\K#ZICOYX_<_\SY-_P"$
M.U?_ )Y1?]_!1_PAVK_\\HO^_@KZR_L+2/\ H%67_@.G^%']A:1_T"K+_P !
MT_PH^M4?Y6'U3'?SQ^Y_YGR;_P (=J__ #RB_P"_@H_X0[5_^>47_?P5]9?V
M%I'_ $"K+_P'3_"C^PM(_P"@59?^ Z?X4?6J/\K#ZICOYX_<_P#,^3?^$.U?
M_GE%_P!_!1_PAVK_ //*+_OX*^LO["TC_H%67_@.G^%']A:1_P! JR_\!T_P
MH^M4?Y6'U3'?SQ^Y_P"9\F_\(=J__/*+_OX*/^$.U?\ YY1?]_!7UE_86D?]
M JR_\!T_PH_L+2/^@59?^ Z?X4?6J/\ *P^J8[^>/W/_ #/DW_A#M7_YY1?]
M_!1_PAVK_P#/*+_OX*^LO["TC_H%67_@.G^%']A:1_T"K+_P'3_"CZU1_E8?
M5,=_/'[G_F?)O_"':O\ \\HO^_@H_P"$.U?_ )Y1?]_!7UE_86D?] JR_P#
M=/\ "C^PM(_Z!5E_X#I_A1]:H_RL/JF._GC]S_S/DW_A#M7_ .>47_?P4?\
M"':O_P \HO\ OX*^LO["TC_H%67_ (#I_A1_86D?] JR_P# =/\ "CZU1_E8
M?5,=_/'[G_F?)O\ PAVK_P#/*+_OX*/^$.U?_GE%_P!_!7UE_86D?] JR_\
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M'^5A]4QW\\?N?^9\F_\ "':O_P \HO\ OX*/^$.U?_GE%_W\%?67]A:1_P!
MJR_\!T_PH_L+2/\ H%67_@.G^%'UJC_*P^J8[^>/W/\ S/DW_A#M7_YY1?\
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M]A:1_P! JR_\!T_PH^M4?Y6'U3'?SQ^Y_P"9\F_\(=J__/*+_OX*/^$.U?\
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M["TC_H%67_@.G^%'UJC_ "L/JF._GC]S_P SY-_X0[5_^>47_?P4?\(=J_\
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M'^5A]4QW\\?N?^9\F_\ "':O_P \HO\ OX*/^$.U?_GE%_W\%?67]A:1_P!
MJR_\!T_PH_L+2/\ H%67_@.G^%'UJC_*P^J8[^>/W/\ S/DW_A#M7_YY1?\
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ML+2/^@59?^ Z?X4?6J/\K#ZICOYX_<_\SY-_X0[5_P#GE%_W\%'_  AVK_\
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MO["TC_H%67_@.G^%']A:1_T"K+_P'3_"CZU1_E8?5,=_/'[G_F?)O_"':O\
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M_P"@59?^ Z?X4?V%I'_0*LO_  '3_"CZU1_E8?5,=_/'[G_F?)O_  AVK_\
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M_P#GE%_W\%'_  AVK_\ /*+_ +^"OK+^PM(_Z!5E_P" Z?X4?V%I'_0*LO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,N\_P"0S:_0?S-:E9=Y_P AFU^@_F:U*UJ?#'T.:A\<_7] HHHK(Z0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH @G_U\'U-3U!/_KX/J:GH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""X^_#_OB
MIZ@N/OP_[XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (+K[L?\ OBIZ@NONQ_[XJ>@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0
M7'WX?]\5/4%Q]^'_ 'Q4] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 077W8_]\5/4%U]V/_?%
M3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M P/@K_R4/Q__ -??_M66O;Z\$_9_2\C\5>,4U$DWRN@N=PP?,WR;L_CFO>Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,N\_Y#-K]!_,
MUJ5EWG_(9M?H/YFM2M:GPQ]#FH?'/U_0****R.D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()_]?!]3
M4]03_P"O@^IJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** (+C[\/^^*GJ"X^_#_OBIZ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH @NONQ_[XJ>H+K[L?\ OBIZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=:_
MX]$_ZZ?T-:$?^K7Z"L_6O^/1/^NG]#6A'_JU^@K67\./S.:G_'GZ(=11161T
MA7&>(_AY:ZYJ+7T%XUG-)_K0(@ZL?4#(P?7KFNSHJZ=25-W@[&-:A3KQY*BN
MC)\/>'[3PYIQM+5G<LV^21\99L ?@..E:U%%3*3D[O<TA",(J,59(****11X
MC^TI_P BWHG_ %]O_P"@5ZS9Z+I36-NS:99EC&I),"Y/'TKC_BYX!U7Q]I.G
M6FE7%G#);3M(YNG9005QQM5N:] MHS#:PQ,061 IQTX% "6]K;VB;+:"*%?2
M- H_2JVM_P#( U'_ *]9?_035^JVHV[W>F7=M&5#S0O&I;H"5(&: /*/V<?^
M2>:A_P!A63_T5%5G]H7_ ))JG_7_ !?^@O6W\)O!6I> _"MUI>J3VDT\MZ]P
MK6KLRA2B+@[E4YRA[>E3?%/P?J'CCPBNDZ9-:Q7 NDFW7+,J[0&!Y52<\CM0
M!0\0^*KCP=\%;+5;- UV+"VA@+ $*[(HW$>PR<=R!7%^%_ACJ7Q!\/VOB#Q7
MXMU64WP,BV\,G"QY( YRHSR<!<#->J7GA"VUKX?P^%M7.Y/L<4$CPMRKH%PR
MDCLR@\CGN.U><:3\./BEX8M!I.A>,].BTI2Q02199<DD[5:-MN2<\-W)H X+
MXQ^!?#?@2WT6TT<SO>7'FO.\\P=RB[0I(& ,DMC YP?2OH3QIJGA.STM+'Q=
M-;+97Q*+'<*2KD8/8<8X.>,5Y?XC^ VIZKI*W/\ ;ZZEXEFN ]S>:@[I'Y6U
MAL0 ,>#MZ]AQMZ'TKQ=X*M_'GA*'2M9?R+I-DPFMVWB*8+@XR!N7EAR!D<X!
MQ@ X/6/V==%FG^TZ#K%[IDH(9%<><J$=-IRK#ZY-0?#77?%&@_$V_P# 'B'5
M'U2*"$O%*Y+LK;5=3O/S;2C=#G!P![SVW@/XN:1;)IFE^.;%M.1/+1KA29%7
MG@9C8C /'S<< 8P*ZKP!\,X?!]W>:O?ZA)JNNWN?.O)%(V@X+* 2<Y(Y8]<#
M@4 >-VO@K2/$?QU\2Z#XANKNT\ZXN+FV,+K&TCLX=5^96SE&+=NE>@_\,X^#
M_P#H):Y_W_A_^-5O_$/X66GC:>WU.TO&TO6[;'EW<:D[P.5#8(((/1AR/?C'
M,W/@/XN:O;/IFJ>.;%=.=/+=K=2)&7C@XC4G('/S<\@YR: -3X3Z%X$TO4=4
ME\'Z[>:E,8UCN5G((0!C@C$:]2#SSFO4ZYGP+X(T[P'H']F6#O,[N99[B08:
M5\8SCL   !_4DGIJ ,3Q7XJTSP=H,VKZK*5A0[41>7E<@X11W)P?H 2>!7CV
M@>&]>^,VL+XB\7F6U\.0D_8;!"4\P'^Z>#CIE^IZ# Z=)\7/AOXE\?ZEIQTR
M^TZ'3[2%OW=S(ZL96/S'"H>,!.I]>!WQHO /QE@A2&'QGIL<4:A41)G"JHX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9=Y_P A
MFU^@_F:U*R[S_D,VOT'\S6I6M3X8^AS4/CGZ_H%%%%9'2%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $$
M_P#KX/J:GJ"?_7P?4U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Q]^'_?%3U!<??A_WQ4]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK/T+4_[;\/:9JWD^3]NM(KGRMV[9O0-MS@9QG&<"M"@ HHHH **** "BBB@
MHHHH **** "BBN'\8_$O3_"GB'2-"2 7NH:A<1QO$LNSR(W;:')VG)ST7CIV
MXR =Q117$:'\0_[:^)6L>#_[+\G^S86E^U_:-WF89!C9M&/O^IZ4 =O1110
M445A^)?%^B>$H()=8O!"UPQ2"(*6>4C&0H'ID9/09% &Y1110 45Q_Q'\=?\
M*_\ #UOJW]G?;_.NUMO*\_RL91VW9VM_<QC'>NIL;G[986UULV>=$LFW.<9
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MT09]EVGCZD_6N0L+K6?@?\1;31;O4C>>';\(27!5%1F(+@$X1U.2<'!!YZC
M!] :GK^C:*T:ZKJ]A8-*"8Q=7*1%\=<;B,]15]'26-9(V5T8!E93D$'H0:\P
M^/'A@:YX!?48DS=:2_VA< 9,9P)!GTQAO^ 5?^"OB :]\--/1W!GT_-E(!G@
M)C9_XX4_'/TH [VYN8+.VDN;J>."")2\DLKA511U))X J#3=6TW6;=KC2]0M
M+Z!7*-):S+*H; ."5)&<$''N*\O_ &A/$!TSP-#I,;E9M4G"L!WBCPS?^/>6
M/Q-=A\-?# \)> ]-TUP1<LGGW.5P?-?D@C_9X7_@- '64444 %%%% !1110
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M?]!#_P @Q_\ Q-'_  FOB#_H(?\ D&/_ .)K HH^KT?Y%]R#Z]BO^?LOO?\
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M_P 36!11]7H_R+[D'U[%?\_9?>_\S?\ ^$U\0?\ 00_\@Q__ !-'_":^(/\
MH(?^08__ (FL"BCZO1_D7W(/KV*_Y^R^]_YF_P#\)KX@_P"@A_Y!C_\ B:/^
M$U\0?]!#_P @Q_\ Q-8%%'U>C_(ON0?7L5_S]E][_P S?_X37Q!_T$/_ "#'
M_P#$T?\ ":^(/^@A_P"08_\ XFL"BCZO1_D7W(/KV*_Y^R^]_P"9O_\ ":^(
M/^@A_P"08_\ XFC_ (37Q!_T$/\ R#'_ /$U@44?5Z/\B^Y!]>Q7_/V7WO\
MS-__ (37Q!_T$/\ R#'_ /$T?\)KX@_Z"'_D&/\ ^)K HH^KT?Y%]R#Z]BO^
M?LOO?^9O_P#":^(/^@A_Y!C_ /B:/^$U\0?]!#_R#'_\36!11]7H_P B^Y!]
M>Q7_ #]E][_S-_\ X37Q!_T$/_(,?_Q-'_":^(/^@A_Y!C_^)K HH^KT?Y%]
MR#Z]BO\ G[+[W_F;_P#PFOB#_H(?^08__B:/^$U\0?\ 00_\@Q__ !-8%%'U
M>C_(ON0?7L5_S]E][_S-_P#X37Q!_P!!#_R#'_\ $T?\)KX@_P"@A_Y!C_\
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M )!C_P#B:/\ A-?$'_00_P#(,?\ \36!11]7H_R+[D'U[%?\_9?>_P#,W_\
MA-?$'_00_P#(,?\ \31_PFOB#_H(?^08_P#XFL"BCZO1_D7W(/KV*_Y^R^]_
MYF__ ,)KX@_Z"'_D&/\ ^)H_X37Q!_T$/_(,?_Q-8%%'U>C_ "+[D'U[%?\
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MC_(ON0?7L5_S]E][_P S?_X37Q!_T$/_ "#'_P#$T?\ ":^(/^@A_P"08_\
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M?]!#_P @Q_\ Q-'_  FOB#_H(?\ D&/_ .)K HH^KT?Y%]R#Z]BO^?LOO?\
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M_P 36!11]7H_R+[D'U[%?\_9?>_\S?\ ^$U\0?\ 00_\@Q__ !-'_":^(/\
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MCR1SPX%Q:S "2(GITX(.#@C]#Q6%KWQ4;PO\0+3PYK&B&"QNV41:FMSE2K<
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ML$@@==BFNB^*FE^(]$^)6D>.]*TIM5M+2!8WB"L_ED%P05&2H(?(8#ALDCU
M+DOQRU+3E^T:U\/=9T^P/W;ERW.2,?>C4=_[WI7J.@Z[I_B71;?5M+G\ZTN
M2C8(((.""#T(((KRJU^/'@OQ'I\VE^(;"]L;>Z@,5P&'FQD,,,NY/GZ'@A1^
M!KN;*?P_X<^'5_J/A06[Z9;6L]W$+>7S$+*A8\DGG*\CL: ,7QA\8M*\-ZS_
M &)IUA<:WJXRKV]J>$;^Z6P26]0 <8YK.T_XX10:K!8^+?"^I>&_M'^JFN0S
M)]6W(A SQD X[^H\P^%7Q&\->"H]1O=;L]3O-9O)LFYA1)/W>,\L[@[BQ8GC
MGCFNA^('QA\%^-/"%YI/]E:K]J9=]K+-!%B*4=#D2$CN#CL30!]#*P90RD%2
M,@CH:6O//@CJ5QJ/PLTS[2[.ULTENK,<DHK':/P!"CV KT.@#D?'VI>++/3[
M2V\'Z:EWJ%W*4:63&RW0*26.2%SZ9/X&O"?$O@>[\'^-_!T^J:M)J6KZE?I+
M=S$DJ&62/ 4GD]3R<9XX%?4E>(?&K_DH?@#_ *^__:L5 'M]?.5MXOTSP3\=
MO&>KZH9#%]G>*..)<O*Y>$A1VZ GD] :^C:\'\*:+:ZI^TGXDNKJ-9/[/#SP
MANTIV*&QWP&8^QP>U &LWQUN-/EAFUWP-K&F:9,0([M\_,2,\!D4'C)X;M7J
MVE:I9:WI=OJ6G7"W%G<)OBE4$;A]#R/H>:9K6D6FO:+>:5?1B2VNHC&ZGWZ'
MZ@X/X5Y)^SE>7)\.ZUI<Y.RSO%9 6SM+KA@/;*9^I- 'M5?-'QV\0ZA?^*M+
MLI] NK2'3)Y1;7,F[;?9\HDIE0.-H'!;[PKZ7KPC]HK_ )"?@S_KM<?S@H ]
M T;QUJ=]X+UOQ!JGA6[TB738I95L[IV5IU2/?D%D7 /(S@UR%K\?&U2QMAHW
M@^_U/5'#-<6=M(SB!02 =XC)8D 'A<#/7->C>._^2>>)?^P5=?\ HIJX7]GG
M3H+7X>2WB &:[O',C8YPH"A?H.3_ ,"- &GX@^*LF@_#S3/%<OAV<->W(M_L
M4\XB>/(D.[.T_P!SI@=:[I-3MUT1-5NY([6W^SB>1I'PL:E<G)]O6O+/VCO^
M2>:?_P!A6/\ ]%2UV^I:/I>N_#F/3]9N7MM.>SA:>99A%L50K9+'@#CG/&*
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M"C:,Q-M*\#H">G'I7>^";KP!KFLWVO>&&MVU:Y!:[.YUFP2,Y1CP,@=!MR*
M.[I&8*I9B H&23T%+7 _&;5Y]'^%^J26SLDUQLM@ZG!4.P#?FNX?C0!B:I\<
MK0ZS+IGA;P]?^(Y8LAGM20K$'G;A6)& ><8/TYK1\*?%^PUW6UT+6=)O- UA
M^$M[O)#L3PH)"D,>N"H^M>=?#CXM^#/ _A&WTQ],U9KYB9+N>&&(B5R3CDR
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MU?X&_$Q[:8O/IDQ42$K@7-N3PXZX9>?Q!'0T >U_&W_DD.N_]N__ *41U1^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% $UI=SV-REQ;R%)4.017K'AOQ)!KMM@X2[0?O(_7W'M7
MD-36EW/8W27%O(4E0Y!%<V*PT:\?,]/+<RG@Y]XO=?UU/=:*PO#?B2#7;;!Q
M'=H/WD?K[CVK=KYZ<)4Y.,EJ?>4:T*T%4INZ84445!J%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 077W8_P#?%3U!=?=C_P!\5/0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<3M10 HR>3@ =:S-2\(:%J^OV.N7UCYNI6&/LTWG.NS!W#Y0P4\GN#0!X_\
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MT26-HY%5T8%65AD$'J"*RH?"GARVN_M4&@:5%<C_ );)9QJ_Y@9K7HH SI-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $]I=SV-TEQ;R%)4.017K'A
MOQ'#KMK@X2[C'[R/^H]J\LTW3;G5;U+6U3<[=3V4>IKUO0]#MM#LA#"-TK<R
M2D<L?\*\S,G2Y4G\1]+P]'$\[<?X?7U\O,U****\4^O"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** (+K[L?^^*GJ"Z^['_ +XJ>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,W6O^/1/^NG]#6A'_JU^@K/UK_CT3_KI_0UH1_ZM?H*UE_#
MC\SFI_QY^B'4445D=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 9^LZ%I7B&P:QU>QAO+8G.R5<X
M/J#U!]Q7+V_P>\ 6MU]HC\.0%\YQ)-+(G_?+,5_2NXHH :B)%&L<:JB* JJH
MP !T %.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \C^(GQ"\=>&O%3:?H'AR.^L/)1Q,UC/*2QSD;D8#M7'W/
MQJ^)MG;O<77A.T@@09>273KE54>Y,F!7T97$?%__ ))1K_\ UQ3_ -&+0!Y-
M8_'+XC:G"9K#PS87<2ML+P6%Q(H; .,B3KR/SK>\,_%+XC:IXGTRPU+PK#;6
M-Q<)'/,-/N$*(3@G<SD#\:TOV<?^2>:A_P!A63_T5%7L% !17(>+/B-I'@[6
M=-TO4+:^EGU @1-;HC*OS!?FRP(Y/8&L+6/CMX,T?6)-.WWMX8B5>XM(E:(,
M,Y&2P)Z=0".>M 'IE%9D'B'3)O#D.OO=+;Z;+ LXFN?W05& P3NQCJ/KGBN
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MJQOYQVIN&3NQU]J]3KYZ\/\ _)U&H?\ 72?_ -$U]!2RQP0O--(D<4:EG=V
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M?#?QI\'>);V*RBNKBQNI6V1QWL83>Q.  P)7)[#->A4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y[\2/^/K3_P#<?^8K
MAJ[GXD?\?6G_ .X_\Q7#5]'@OX$3\^SC_?JGR_)!11174>8%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5O3=-N=5O4M;5"S
MMU/91ZFC3=-N=5O$M;5"SMU/91ZFO6]"T*VT.R$,0#2MS)*1RQ_PKDQ6*5%6
M6YZV699/&3N](+=_HA="T*VT.R$,(#2MS)*1RQ_PK4HHKY^4G-\TMS[NE2A2
M@H05D@HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M"Z^['_OBIZ@NONQ_[XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6O^/1/^NG]#6A'_JU^
M@K/UK_CT3_KI_0UH1_ZM?H*UE_#C\SFI_P >?HAU%%%9'2%%%% !1110 444
M4 %%8GBOQ5IG@[09M7U64K"AVHB\O*Y!PBCN3@_0 D\"O)X?BQ\2/$0-WX9\
M#QMI^?EDN(Y)-X[8;<@/3G&: /<Z*\7TKXWW^F:I!IGCWPY-H\DP!6X2-U4
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MC_WV_P#\36_UNA_,CA_LK&?\^V<C177?\*ZU?_GYL?\ OM__ (FC_A76K_\
M/S8_]]O_ /$T?6Z'\R#^RL9_S[9R-%==_P *ZU?_ )^;'_OM_P#XFC_A76K_
M //S8_\ ?;__ !-'UNA_,@_LK&?\^V<C177?\*ZU?_GYL?\ OM__ (FC_A76
MK_\ /S8_]]O_ /$T?6Z'\R#^RL9_S[9R-%==_P *ZU?_ )^;'_OM_P#XFC_A
M76K_ //S8_\ ?;__ !-'UNA_,@_LK&?\^V<C177?\*ZU?_GYL?\ OM__ (FC
M_A76K_\ /S8_]]O_ /$T?6Z'\R#^RL9_S[9R-%==_P *ZU?_ )^;'_OM_P#X
MFC_A76K_ //S8_\ ?;__ !-'UNA_,@_LK&?\^V<C177?\*ZU?_GYL?\ OM__
M (FC_A76K_\ /S8_]]O_ /$T?6Z'\R#^RL9_S[9R-%==_P *ZU?_ )^;'_OM
M_P#XFC_A76K_ //S8_\ ?;__ !-'UNA_,@_LK&?\^V<C177?\*ZU?_GYL?\
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M_?;_ /Q-'UNA_,@_LK&?\^V<C177?\*ZU?\ Y^;'_OM__B:/^%=:O_S\V/\
MWV__ ,31];H?S(/[*QG_ #[9R-%==_PKK5_^?FQ_[[?_ .)H_P"%=:O_ ,_-
MC_WV_P#\31];H?S(/[*QG_/MG(T5UW_"NM7_ .?FQ_[[?_XFC_A76K_\_-C_
M -]O_P#$T?6Z'\R#^RL9_P ^V<C177?\*ZU?_GYL?^^W_P#B:/\ A76K_P#/
MS8_]]O\ _$T?6Z'\R#^RL9_S[9R-%==_PKK5_P#GYL?^^W_^)H_X5UJ__/S8
M_P#?;_\ Q-'UNA_,@_LK&?\ /MG(T5UW_"NM7_Y^;'_OM_\ XFC_ (5UJ_\
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M6K_\_-C_ -]O_P#$T?6Z'\R#^RL9_P ^V<C177?\*ZU?_GYL?^^W_P#B:/\
MA76K_P#/S8_]]O\ _$T?6Z'\R#^RL9_S[9R-%==_PKK5_P#GYL?^^W_^)H_X
M5UJ__/S8_P#?;_\ Q-'UNA_,@_LK&?\ /MG(T5UW_"NM7_Y^;'_OM_\ XFC_
M (5UJ_\ S\V/_?;_ /Q-'UNA_,@_LK&?\^V<C177?\*ZU?\ Y^;'_OM__B:/
M^%=:O_S\V/\ WV__ ,31];H?S(/[*QG_ #[9R-%==_PKK5_^?FQ_[[?_ .)H
M_P"%=:O_ ,_-C_WV_P#\31];H?S(/[*QG_/MG(T5UW_"NM7_ .?FQ_[[?_XF
MC_A76K_\_-C_ -]O_P#$T?6Z'\R#^RL9_P ^V<C175O\/M60J#<67S' P[__
M !-/_P"%=:O_ ,_-C_WV_P#\31];H?S(/[*QG_/MG(T5UW_"NM7_ .?FQ_[[
M?_XFC_A76K_\_-C_ -]O_P#$T?6Z'\R#^RL9_P ^V<C177?\*ZU?_GYL?^^W
M_P#B:/\ A76K_P#/S8_]]O\ _$T?6Z'\R#^RL9_S[9R-%==_PKK5_P#GYL?^
M^W_^)H_X5UJ__/S8_P#?;_\ Q-'UNA_,@_LK&?\ /MG(T5UW_"NM7_Y^;'_O
MM_\ XFC_ (5UJ_\ S\V/_?;_ /Q-'UNA_,@_LK&?\^V<C177?\*ZU?\ Y^;'
M_OM__B:/^%=:O_S\V/\ WV__ ,31];H?S(/[*QG_ #[9R-%==_PKK5_^?FQ_
M[[?_ .)H_P"%=:O_ ,_-C_WV_P#\31];H?S(/[*QG_/MG(T5UW_"NM7_ .?F
MQ_[[?_XFC_A76K_\_-C_ -]O_P#$T?6Z'\R#^RL9_P ^V<C177?\*ZU?_GYL
M?^^W_P#B:/\ A76K_P#/S8_]]O\ _$T?6Z'\R#^RL9_S[9R-%==_PKK5_P#G
MYL?^^W_^)H_X5UJ__/S8_P#?;_\ Q-'UNA_,@_LK&?\ /MG(T5UW_"NM7_Y^
M;'_OM_\ XFC_ (5UJ_\ S\V/_?;_ /Q-'UNA_,@_LK&?\^V<C177?\*ZU?\
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MJ:9?SQOYEM&V<*+5]N3DY. #6Y\9K2#4/BGX$LKE!)!<3QQ2(1D,K3J"/R-
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M[;X<27"X,EU?2.YP,\!5 SZ<9_$T 4=-^,^JZ)X@.C?$31(M(D,32K<6^XJ
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MOEL,D*#@<BN^\%P36O@7P];W$4D,\6F6R21R*59&$2@@@\@@\8K<HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+O/^0S
M:_0?S-:E9=Y_R&;7Z#^9K4K6I\,?0YJ'QS]?T"BBBLCI"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""?
M_7P?4U/4$_\ KX/J:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""X^_#_OBIZ@N/OP_[XJ>@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** (+K[L?^^*GJ"Z^['_ +XJ>@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,W6O^/1/^NG]#6A'_JU^@K/UK_CT3_KI_0UH1_ZM?H*UE_#C\SFI_QY^B'4
M445D=(4444 %%%% !1110!Y)\:/ ^K:S_9WBCP[YKZMI.#Y,7+LH;<K(,<LK
M<X[]N1@U=#_:(T">T1->L+RPOE^641)YD9([CD,.>Q'&>IZU[+67J'AO0M6E
M,NI:+IUY(<9>YM4D/' Y8&@#QGQK\8H?&&EW/A7P=I-]>W6HIY!F:,#"G&[:
MO)/&02=N.M>F^ ?"4GA7X?V>A3R*;GRW:=EY D<DD#U SCWQ6_IVC:7HZ%-,
MTVSLD/5;:!8P?^^0*O4 ?./PM\:V7PONM8\+>+8IK)Q=&07"QLZ[@ AX R5.
MT$, <C\*/B[X^A\>>'9+;PY;3S:/ILZ7%Y?R(8U+DE(T4'DYWDX(SP/0U[_J
M6B:3K*(NJ:797RH<J+JW24*?;<#CJ:230M(ETPZ;)I5B]@3N-JUNAB)SG.S&
M.O/2@#B?%'_)O\W_ &!(O_0%KA?A3\4+#PEX6M-"\5136%N%>?3[T0L\<L3.
M20=N3G>7Y QV.".?=Y=/LI]/.GS6=O)9%!&;9XE,90=%VD8Q[56D\/:+-ID>
MF2Z/I[Z?']RU:V0Q+SGA,8'//2@#POQGXAF^-'B73O"WA>&>31[6<375ZR%5
M]-^#]T*I;&<%B<8Z9]%^*O@:3Q1\/5TO2(U6YT]TFM(<@!PBE?+R>GRL<>X&
M:[BQT^RTRV%M86=O:6XY$5O$L:C\ ,59H \=\%_&WP]!X>MM/\4SS:9JMD@M
MIU>VD8.4^7.$4X/'((&#FJND>+=<^)'Q6LKKPY-J-GX6TT8NG;*I,1EL,N[!
M+': .H&3CJ*]9U+PYH>L2K+JFC:=?2(,*]U:I*1]"P/H*O6]M!:6Z6]M#'#"
M@PD<:A54>P' H \)\>WL_@+XZZ?XPO;22;2;J$1M)&/N_(8V /3<.&QW!_+H
M];^,^B:IIO\ 9?A);G5M;U!##;VZ0.@C9E/+%L=.^#^..:]3N+:"[MWM[F&.
M:%QAXY%#*P]P>#5/3= T;1F=M+TFPL2_#&UMDBW?7:!F@#RS]G2)H/">LPL0
M6CU)E)'3(C05S4FO6?@']HG7-1UP30V=S"=D@B)R'"$, .HRI&1W!],5[[I^
MDZ;I,<D>FZ?:V22/YCK;0K&';^\0H&3[U'J>A:/K6S^U=*L;_P O[GVJW27;
M]-P.* /$?CS%)J=MX6\5VD+W^@JF]L JNURC*6!&5#CC)'8 \X%=D?CK\/[?
M2UEAOK@LJ#;9QV;AUP.%&0$]OO8KT2.QLX;%+&.U@2T1 BP+&!&JCH O3'M5
M&U\+>'K&Y^TVF@Z7;W&[?YL-G&C;O7(&<T > >'=3U/5?VCM)UK6-.DTUM01
MY;>WD)++%]GDC3(Z@G;GH.N<8-=/\6O^2P_#W_K[A_\ 2A*]>NM"T>^U&#4;
MS2K&XOH-ODW,UNCR1[3N7:Q&1@DD8Z&G7>BZ5J%Y;WE[IEG<W5L0T$\T"N\1
M!R"K$94Y /% %ZO"/A1_R7/QY_UVNO\ TIKW>J%IHFDV%]<7UGI=E;WEP29[
MB&W1))23D[F R<GGGO0!XCXK34OA/\69?&L-F]WH6K9CN"O+(7VEUSV;<H9<
M\$<9ZFNOU'X]>![33'N+2\N+VYV92U2W=&+<<%F 4=>3D]#C/ /ICHDL;1R*
MKHP*LK#((/4$5DV_A+PU:77VJV\/:3#<9SYL=E&K_F%S0!R7PGU+QAX@T2ZU
M;Q9*OD7+[;.W:V6,[.[<#.TYVC/.%SSG)\\\/:K<? WQGJ>CZU:3R>'M0<26
M]Y&I.,9VD<\G!PPZC /3K]$5!=V=K?VYM[RVAN(203'-&'4XZ<'B@#R7QC\;
MM"GT.XT[PE+<ZGJ]Y&T,'E6SJ(V;C=A@"2 20 #SC-='\(/!MWX+\%+;:BH6
M_NYC<SQAMWEY  7TR HSUY)Y-=7IOAS0]'E:72]&TZQD<89[6U2(GZE0/4UI
MT ?.7@/Q5;?"?QEXCT'Q3#-;Q7-P'CNDC+# 9L-@<E65L@CD8QCTM_%/XBVO
MCCPQ>:3X6@GN["UV7.H7[QM'&B!L*HS@Y+8ZC^1(]UU'2-,UB)8M3TZTOHU.
M52Y@64 ^P8&F+H6D)I;Z6NE6*Z>_WK06Z")NG5,8/0=NU '%:9)KL/P)TN?P
MV0=5BTN%X4,8??A1E0#U.,X]\5B>$/CMH,FC16WBRXFT_6+=?+N&>V9EE<<%
M@$4[2<9((&#G%>MVUM!9VT=M:P1P01*$CBB0*J*.@ ' %4-0\-Z%JTIEU+1=
M.O)#C+W-JDAXX'+ T >%SW5I\3/C1HM_X0L)(K73)(Y[[4!$(]X#[\D8ZGE1
MGDY/&!7T14%I96NGVR6UE;0VT"#"10QA%4>P' J>@""^_P"0?<_]<F_D:\8_
M9K_Y%O6_^OM/_0*]M90RE6 *D8(/0U2TW1=*T6-X]*TRSL8Y#N=;6!8@Q]2%
M R: /$_%\6H_"SXM2>.(+%[O0M379=>6,>66V[U)]=RAQG .<=LUU>H?'OP1
M:Z4]U:75S>W6/DLTMW1B>V68!0/4@GV!KTUT26-HY%5T8%65AD$'J"*R;7PG
MX<L;P7=IX?TJWN0=PFBLXT<'KG<!F@#SGX+>%]:BO-8\9>(8FAO=9;=%$P*M
MM9B[,5/0$[=H]!Z$5G^!O^3E/&'_ %Z2_P#HR"O;JHP:+I5KJ<VI6^F6<-_.
M"LMU' JRR X)#.!DC@=3V% &;X[_ .2>>)?^P5=?^BFKD?@'_P DNM_^OJ;_
M -"KTJ>"&ZMY;>XBCF@E0I)'(H974C!!!X((XQ4.GZ;8:3:BUTZRMK.W!+"*
MWB6- 3U.% % 'B?QH_Y*EX%_Z[1_^CUKW:J%[HFDZE=075_I=E=7%N<PRSVZ
M.\1SGY21D<\\5?H \1_9Y_YFS_K\C_\ 9ZS?$&J/\-OC]<^(=5M99-)U2 *L
M\2YVJ54'V)#1\C.<'/<"O<M.T;2](\[^S--L[+SCNE^S0+'O/JVT#)Y/6I[N
MRM=0MGMKVVAN8'&'BFC#JP]P>#0!Y/XI^+6D^)-%N/#O@Y;C5-5U.!H 1"\:
M0*RD.S%@#E5R<C@=<\58_9Z_Y)J__7_+_P"@I7H^GZ%I&DHZ:=I5C9HXVNMM
M;I&&'H=H&>IJ73M+T_2+;[-IEA:V5ON+>5;0K&NX]3A0!G@4 >*? ?\ Y'3Q
MO_UV7_T9)6#X6U>R^&OQC\0MXPAEA:Y:4P7S1M(<-)N#C )(<9Y&2",'OCZ%
ML-$TG2IIYM.TNRLY;@YF>WMTC:0Y)^8J!GJ>OK2ZCHVEZP@34]-L[U!T6Y@6
M0#_OH&@#ROQ;\6].\1Z1=^'/!5O=:QJ>H0/#O2%HHX49<,Y+;3D \'@#J3Q@
MK^S@ZGP!J,8/S+JCDCV,46/Y&O5=/TK3M)C:/3M/M;.-L96WA6,''3A0*CTS
M0M'T3S?[)TJQL/.QYGV2W2+?C.,[0,XR>OJ: / M!\2:?\//CAXOE\0F:WM[
MMYVCD$3-]^42+P,G!4GGVK;^.DT=SKGP^GB;=')<R.C8QD%H"#7L&I^'M$UJ
M2.35='T^_>,;4:ZMDE*CT!8'%+=:!HU\MHMWI-A<"SXM1+;(_D=/N9'R_=7I
MZ#TH \\^-_@_4/$&A66L:.CR:CH\C2K'&,NZ'!)7U(*@@?7'NW0/CWX4N])1
M]=FDTS4D7$UO]GD=2XSG85!XXZ-C&<<XS7JU9%]X5\.ZG<&XO]!TN[F8Y,D]
MG'(Q_$C/84 >,6TE]\9?BGINLVEI/;^&-$=&668;3(RMN..N69@ 0#PJ]03S
MH?'K_D9/ 7_7W+_Z'!7M<44<$2Q11K'&HPJ(, ?054O]%TK59+>34=,L[R2W
M):!KB!9#$3C)4L#@\#IZ"@"]7A/@[_DYOQ-_UQE_G'7NU4(=$TFWU.74X-+L
MHM0E!$ETENBRN#C.7 R>@[]J +]%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5U#3;#5K4VNHV5M
M>6Y(8Q7$2R(2.APP(IUC86>F6<=G86D%I:QYV0P1B-%R23A1P,DD_C5BB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#+O/\ D,VOT'\S6I67>?\ (9M?H/YFM2M:GPQ]#FH?'/U_0****R.D
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ()_]?!]34]03_Z^#ZFIZ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N/OP_[
MXJ>H+C[\/^^*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@""Z^['_ +XJ>H+K[L?^^*GH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUE';2]4LKY4.&-K<)*%/OM)QU%0ZAXFT#2+C[/J6N:;938SY=S=QQMCZ,0:
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M!!/_ *^#ZFIZ@G_U\'U-3T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!<??A_WQ4]07'WX?\
M?%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!!=?=C_WQ4]077W8_]\5/0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZZP?^C%H T-0U236_@??:I,,37?AZ6:3C^(VY+?KFN?_ &>O^2:O_P!?\O\
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MK>"-I99&Z(JC))]@!7B_[.=E*=.\1ZRT92*]NHXTR<\H&8_^C1S_ (4 <?\
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M%.1'%YR,0T:NZJ2".^#CMC.:[BL?Q/JNA:1HDLGB.:&/39OW$@G0NC[@?E(
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M=JH03CKC+"@#HOBQXPN?"/PVA?3Y6BU"^\NVAE4X:(;=S./P&/8L#VK*\(?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EWG_(9M?H/YFM
M2LN\_P"0S:_0?S-:E:U/ACZ'-0^.?K^@4445D=(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 03_Z^#ZF
MIZ@G_P!?!]34] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 07'WX?]\5/4%Q]^'_?%3T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!!=?=C_ -\5/4%U]V/_ 'Q4] !1110 4444 %%%% !1110
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M?X?IX&TVY:YNS?:O?R>;>71R=QYP 3R1R3D\DDGV';4 %%%% !1110 4444
M%%%% !155M3L%8JU]; @X(,J\?K2?VII_P#S_P!K_P!_E_QJN278S]K#^9?>
M6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\ ,OO+=%5/
M[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI_:FG_P#/
M_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\ O\O^
M-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y?\:/[4T_
M_G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^
M7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+_C1R
M2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV#VM/^9?>
M6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\ ,OO+=%5/
M[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI_:FG_P#/
M_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\ O\O^
M-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y?\:/[4T_
M_G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^
M7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+_C1R
M2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV#VM/^9?>
M6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\ ,OO+=%5/
M[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI_:FG_P#/
M_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\ O\O^
M-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y?\:/[4T_
M_G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^
M7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+_C1R
M2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV#VM/^9?>
M6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\ ,OO+=%5/
M[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI_:FG_P#/
M_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\ O\O^
M-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y?\:/[4T_
M_G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^
M7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+_C1R
M2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV#VM/^9?>
M6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\ ,OO+=%5/
M[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y6O/^0S:_0?S-
M:E85WJ-BVKVS"\MRH R1*N!R?>M+^U-/_P"?^U_[_+_C6M2,N6.G0YZ%6'//
M5;_H6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-9<DNQT>UI_S+[R
MW153^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\
M\_\ :_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O
M\O\ C1_:FG_\_P#:_P#?Y?\ &CDEV#VM/^9?>6Z*J?VII_\ S_VO_?Y?\:/[
M4T__ )_[7_O\O^-')+L'M:?\R^\MT54_M33_ /G_ +7_ +_+_C1_:FG_ //_
M &O_ '^7_&CDEV#VM/\ F7WENBJG]J:?_P _]K_W^7_&C^U-/_Y_[7_O\O\
MC1R2[![6G_,OO+=%5/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]_E_QHY)=@]K3
M_F7WENBJG]J:?_S_ -K_ -_E_P :/[4T_P#Y_P"U_P"_R_XT<DNP>UI_S+[R
MW153^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\
M\_\ :_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O
M\O\ C1_:FG_\_P#:_P#?Y?\ &CDEV#VM/^9?>6Z*J?VII_\ S_VO_?Y?\:/[
M4T__ )_[7_O\O^-')+L'M:?\R^\MT54_M33_ /G_ +7_ +_+_C1_:FG_ //_
M &O_ '^7_&CDEV#VM/\ F7WENBJG]J:?_P _]K_W^7_&C^U-/_Y_[7_O\O\
MC1R2[![6G_,OO+=%5/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]_E_QHY)=@]K3
M_F7WENBJG]J:?_S_ -K_ -_E_P :/[4T_P#Y_P"U_P"_R_XT<DNP>UI_S+[R
MW153^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\
M\_\ :_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O
M\O\ C1_:FG_\_P#:_P#?Y?\ &CDEV#VM/^9?>6Z*J?VII_\ S_VO_?Y?\:/[
M4T__ )_[7_O\O^-')+L'M:?\R^\MT54_M33_ /G_ +7_ +_+_C1_:FG_ //_
M &O_ '^7_&CDEV#VM/\ F7WENBJG]J:?_P _]K_W^7_&C^U-/_Y_[7_O\O\
MC1R2[![6G_,OO+=%5/[4T_\ Y_[7_O\ +_C1_:FG_P#/_:_]_E_QHY)=@]K3
M_F7WENBJG]J:?_S_ -K_ -_E_P :/[4T_P#Y_P"U_P"_R_XT<DNP>UI_S+[R
MW153^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WDD_^O@^IJ>L
MZ;4[ S0D7UM@$Y_>K_C4W]J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI_:FG
M_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\
MO\O^-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y?\:/
M[4T__G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_ ,_]
MK_W^7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+
M_C1R2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV#VM/
M^9?>6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\ ,OO+
M=%5/[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI_:FG
M_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\
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M_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\
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M_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\ M?\
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M#VM/^9?>6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\
M,OO+=%5/[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI
M_:FG_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\
MM?\ O\O^-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y
M?\:/[4T__G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_
M ,_]K_W^7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_
M +_+_C1R2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV
M#VM/^9?>6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\
M,OO+=%5/[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI
M_:FG_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\
MM?\ O\O^-']J:?\ \_\ :_\ ?Y?\:.278/:T_P"9?>6Z*J?VII__ #_VO_?Y
M?\:/[4T__G_M?^_R_P"-')+L'M:?\R^\MT54_M33_P#G_M?^_P O^-']J:?_
M ,_]K_W^7_&CDEV#VM/^9?>6Z*J?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_
M +_+_C1R2[![6G_,OO+=%5/[4T__ )_[7_O\O^-']J:?_P _]K_W^7_&CDEV
M#VM/^9?>6Z*J?VII_P#S_P!K_P!_E_QH_M33_P#G_M?^_P O^-')+L'M:?\
M,OO+=%5/[4T__G_M?^_R_P"-']J:?_S_ -K_ -_E_P :.278/:T_YE]Y;HJI
M_:FG_P#/_:_]_E_QH_M33_\ G_M?^_R_XT<DNP>UI_S+[RW153^U-/\ ^?\
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M_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^7_&CDEV#VM/^9?>6Z*J?VII__/\
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M_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^7_&CDEV#VM/^9?>6Z*J?VII__/\
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M_M33_P#G_M?^_P O^-']J:?_ ,_]K_W^7_&CDEV#VM/^9?>6Z*J?VII__/\
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M^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\ \_\
M:_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O\O\
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M^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\ \_\
M:_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O\O\
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M^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\ \_\
M:_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O\O\
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M^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\ \_\
M:_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O\O\
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M^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\ \_\
M:_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O\O\
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M^U-/_P"?^U_[_+_C1_:FG_\ /_:_]_E_QHY)=@]K3_F7WENBJG]J:?\ \_\
M:_\ ?Y?\:/[4T_\ Y_[7_O\ +_C1R2[![6G_ #+[RW153^U-/_Y_[7_O\O\
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MUU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\
M?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%
M=511];K_ ,S#^S,'_P ^U]QR$O@+1T:,!KKYFP?W@_PJ7_A7^C?WKK_OX/\
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M.5_X5_HW]ZZ_[^#_  H_X5_HW]ZZ_P"_@_PKJJ*/K=?^9A_9F#_Y]K[CE?\
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MUU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\
M?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%
M=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%
M'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_
M ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_
MLS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#^S,'
M_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]
MQRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QR
MO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_
M $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O
M77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]
M_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4
M?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK
M_1O[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]
M=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W
M\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X
M5U5%'UNO_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511
M];K_ ,S#^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO
M_,P_LS!_\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#
M^S,'_P ^U]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_
M\^U]QRO_  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#^S,'_P ^
MU]QRO_"O]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_
M  K_ $;^]=?]_!_A1_PK_1O[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O
M]&_O77_?P?X4?\*_T;^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QQ.H^"-)M8%>
M-KG);'+CT/M5M? &C%%):ZY'_/0?X5LZU_QZ)_UT_H:T(_\ 5K]!6DL36Y$^
M9]3GAEV%=:4?9JVAR_\ PK_1?[UU_P!_!_A1_P *_P!%_O77_?P?X5U5%9_6
MZ_\ ,SH_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_
M ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_
MLS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'
M_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]
MQRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QR
MO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_
M $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O
M77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]
M_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4
M?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK
M_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]
M=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W
M\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X
M5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511
M];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO
M_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#
M^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_
M\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^
MU]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_
M  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O
M]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^
M]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?
MP?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A
M1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_
MT7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[
MUU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\
M?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%
M=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%
M'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_
M ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_
MLS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'
M_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]
MQRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QR
MO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_
M $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O
M77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]
M_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4
M?\*_T7^]=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK
M_1?[UU_W\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]
M=?\ ?P?X5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W
M\'^%=511];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X
M5U5%'UNO_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511
M];K_ ,S#^S,'_P ^U]QRO_"O]%_O77_?P?X4?\*_T7^]=?\ ?P?X5U5%'UNO
M_,P_LS!_\^U]QRO_  K_ $7^]=?]_!_A1_PK_1?[UU_W\'^%=511];K_ ,S#
M^S,'_P ^U]QRO_"O]%_O77_?P?X5/9>"M*L+V&[A-P9(FW+N<$9_*NCHI/%5
MFK.3''+L)%J2IJZ"BBBL#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH R[S_D,VOT'\S6I67>?\AFU^@_F:U*UJ
M?#'T.:A\<_7] HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH @G_ -?!]34]03_Z^#ZFIZ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH @N/OP_[XJ>H+C[\/\ OBIZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @NON
MQ_[XJ>H+K[L?^^*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#-UK_CT3_KI_0UH1_P"K7Z"L
M_6O^/1/^NG]#6A'_ *M?H*UE_#C\SFI_QY^B'4445D=(4444 %%%% !1110
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M1T_6--U9K@:=?07?V:3RIC"X<(^,[21QGGD=J +U%%% !1110 4444 %%%%
M!1110 4444 %%%<GIOQ"TG5/'5]X1@M[U=0LE9I)'1!$0NW."&)_B'84 =91
M110 4444 %%%% !15*+6--FU:32HKV"2_BC\V2W1P71<@98#IR1UJ[0 4444
M %%4=1UC3=(6$ZC?06WGR"*$2. 9') "J.K'GH*9K^M6WAW0;W6+M)7M[2,R
M2+" 7('H"0,_C0!HT5C^%O$EGXN\.6FN6$<\=K=;]B3J XVNR'(!(ZJ>];%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &7>?\AFU^@_F:U*R[S_D,VOT'\S6
MI6M3X8^AS4/CGZ_H%%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% $$_^O@^IJ>H)_P#7P?4U/0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% $%Q]^'_ 'Q4]07'WX?]\5/0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $
M%U]V/_?%3U!=?=C_ -\5/0 4444 %%%% !1110 4444 %%%% !1110 4444
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MB#P9X?\ $^GR6>IZ9;R*RD+*L862,^JMC(/Z>N:XWX1>$_%O@P:EI6LO#)I
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M[>$K#2]?T37[""*W:]N/*ND08#N"I5P.F2,Y^@]Z[GX^?\DNN/\ KZA_]"H
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M'7=SVQSOQWM;?2/&/@_6[&&.&_DG=I)57&\QO$4)QU(+'F@#WRBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#+O/\ D,VOT'\S6I67>?\ (9M?H/YFM2M:GPQ]#FH?'/U_0***
M*R.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ()_]?!]34]03_Z^#ZFIZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N/
MOP_[XJ>H+C[\/^^*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@""Z^['_ +XJ>H+K[L?^^*GH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH-_I=M9S1F^B\J:[\S=/MR#\K$$#E0< 8- &?I'_ ";;)_V+UQ_Z*>CX!_\
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M_4(VCECD=3$H)0G: H.?D'4GO0!9\=_\D\\2_P#8*NO_ $4U<1^SU_R35_\
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M-*"8Q=7*1%\=<;B,]10!HT5'!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$<YJ2@
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M $$/_(,?_P 31_PFOB#_ *"'_D&/_P")K HH^KT?Y%]R#Z]BO^?LOO?^9O\
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M^1?<@^O8K_G[+[W_ )F__P )KX@_Z"'_ )!C_P#B:/\ A-?$'_00_P#(,?\
M\36!11]7H_R+[D'U[%?\_9?>_P#,W_\ A-?$'_00_P#(,?\ \31_PFOB#_H(
M?^08_P#XFL"BCZO1_D7W(/KV*_Y^R^]_YF__ ,)KX@_Z"'_D&/\ ^)H_X37Q
M!_T$/_(,?_Q-8%%'U>C_ "+[D'U[%?\ /V7WO_,W_P#A-?$'_00_\@Q__$T?
M\)KX@_Z"'_D&/_XFL"BCZO1_D7W(/KV*_P"?LOO?^9O_ /":^(/^@A_Y!C_^
M)H_X37Q!_P!!#_R#'_\ $U@44?5Z/\B^Y!]>Q7_/V7WO_,W_ /A-?$'_ $$/
M_(,?_P 31_PFOB#_ *"'_D&/_P")K HH^KT?Y%]R#Z]BO^?LOO?^9O\ _":^
M(/\ H(?^08__ (FC_A-?$'_00_\ (,?_ ,36!11]7H_R+[D'U[%?\_9?>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+]S=U_G0!T%%9'A;^V?^$7T[_A(?^0OY(^U?<^_W^Y\OY<5KT %%%% '+3^
M=*N/B#;>-'N+P:E;QF-(@Z^2049.1MW9PQ_BZXKJ:** "BBB@ HHHH **X_X
MC_\ "9?\(];_ /"#_P#(3^UKYO\ J?\ 4['S_K?E^]LZ<_K6KJNMMX<\'3:S
MJ44DLEG:B6>./;N9P!D#MUH VZ*YGP#XJD\:>$H-<DM5M3/)(JPJ^_:%<J,M
M@9/'H*Z:@ HHHH **** "BBB@ HKQ+7_ !SXY\2?$C4/"G@>6VLUTY#YLTZ(
M2Q4J'8[P< ,P4  GO]/4O"4'B&W\.6\?BB[@NM6!;S9($"KC)V]  >,=AUH
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M'/('J)/V:;>-=&U^Y /F27$4;<\856(_]"-3?M*?\BWHG_7V_P#Z!0!<DO\
MXM^,;4ZYX;FL-$TF53)96MRJM<3QX^5CN1@"V,CE1\W<<UJ_"?X@ZGXJ?5-$
M\10QPZWI;XD*KM,@W%6RHX!5A@XX.1QUKT73U"Z;:JH 40H !T' KQCX:JJ_
M'GQT%  S,< =S,I- &_\1/B9?Z-KEOX3\*627_B*X )#8*PY&0,9&6*\\D
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MYNW2H_AE%'/\*M!AFC22*2R"NCJ"K*<@@@]17"?!UW\*^._%?@2=F"13&YM
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M^)ECK+3^,-9TJXTDP-(ZQ(H:)NRY"+CJ22=P^7KSFN2U:))OVJ]&610RBUW
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MO++XO\>>%O =JQ*/)]LO-K?=3D9/H519#ZG</7GV=$2*-8XU5$4!551@ #H
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MP)-=6$,9,,ZV%PPE#$MNR.#DDG(KTWXU^%[CQ/\ #^7[%%)+>6$JW4<48R9
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MR=A)_P!?5Q_Z3/72_M#^%;K5-"T_7K*%I3II=+E47)$38.\\]%*\\?QYZ T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V/#_ (@N-!O-
MZ9>W<_O8L\$>H]#6/77^$O"1U%EO[]"+0'*1GK*?_B?YUCB)4XTW[38[,!3K
MU*\5A_B[]O7R/1;.[AOK.*Z@),4J[E)&#4](JA%"J % P .@%+7S+M?0_1XW
MLN;<****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""X
M^_#_ +XJ>H+C[\/^^*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""Z^['_OBIZ@NONQ_[XJ>
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"+3X)&4?,510[#T.$3I_>;WKW.N>\#>&4\(>#=.T52K201YF<?Q2L=S'WY)
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MC\$"Y'L<UZ?10!PVN?"CP]K?B#3=:5[O3KK3DB2W73_+CC'EMN3Y2AZ=..P
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MB@ KC(_AIHT7Q$/C9;F__M,LS>49$\GF(Q]-N[H?[W7\J[.B@ HHHH ****
M"BBB@ HHHH **** //?B1_Q]:?\ [C_S%<-7<_$C_CZT_P#W'_F*X:OH\%_
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MJ"Z^['_OBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%:_]1;_ ,EO_LJ/K^'_ )OP?^0?V)CO^??XK_,X&BN^_P"%:_\ 46_\EO\
M[*C_ (5K_P!1;_R6_P#LJ/K^'_F_!_Y!_8F._P"??XK_ #.!HKOO^%:_]1;_
M ,EO_LJ/^%:_]1;_ ,EO_LJ/K^'_ )OP?^0?V)CO^??XK_,X&BN^_P"%:_\
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M7^9P-%=]_P *U_ZBW_DM_P#94?\ "M?^HM_Y+?\ V5'U_#_S?@_\@_L3'?\
M/O\ %?YG T5WW_"M?^HM_P"2W_V5'_"M?^HM_P"2W_V5'U_#_P WX/\ R#^Q
M,=_S[_%?YG T5WW_  K7_J+?^2W_ -E1_P *U_ZBW_DM_P#94?7\/_-^#_R#
M^Q,=_P ^_P 5_F<#17??\*U_ZBW_ )+?_94?\*U_ZBW_ )+?_94?7\/_ #?@
M_P#(/[$QW_/O\5_F<#17??\ "M?^HM_Y+?\ V5'_  K7_J+?^2W_ -E1]?P_
M\WX/_(/[$QW_ #[_ !7^9P-%=]_PK7_J+?\ DM_]E1_PK7_J+?\ DM_]E1]?
MP_\ -^#_ ,@_L3'?\^_Q7^9P-%=]_P *U_ZBW_DM_P#958L?AW;V]W'+=7IN
M8E.3%Y6S=]3N/%)X^@E\7X,J.1XYM)PM\U_F9'A+PDVI,M_?H5LP<HAZRG_X
MG^=>EJJHH50 H&  . *%544*H"J!@ #@"EKQ<1B)5I79]A@<#3P=/DAOU?<*
M***P.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@""X^_#_OBIZ@N/OP_P"^*GH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""Z^['_OBIZ@NO
MNQ_[XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,W6O^/1/^NG]#6A'_ *M?H*S]:_X]$_ZZ
M?T-:$?\ JU^@K67\./S.:G_'GZ(=11161TA1110 4444 %%%% !1110 445S
M7CGQG8^!?#4NKWB&9]PCM[=6VF:0]%S@X& 23V [G (!TM%>$:1!\5OB5!_:
MS:V/#NDW"GR$@4HS+D<J!\V",_,6&<<<&IKWP3\6/"]N^H:-XTN-9:$%S;3L
MSLXQR LFX$^V<^G- 'N-%<+\,OB+%X]TB7SX5M=7LR%N[=3Q[.H)SM/H>0>.
M>">ZH **** "BBB@ HHHH **** "BBB@ HKB/B5X;\4^)--L8?"VM?V7/%,7
MF?[5+!O7& ,Q@D\^M=O0 4444 %%%% !17@UIJ_B_P"+_B[6+71_$4WA[0M,
M8(K6P/FMDL%)VE6);821NPHXYZFYX,\1^*?"GQ4_X0/Q+JSZM;7$>;:YD&YP
M=A<'<3NP0"I!SR!CCD@'MM%%% !1110 4444 %%%% !1110 4444 %%>2_'_
M %C4]&\):9-I>HW=C*]\$9[6=HF9?+8X)4C(X%>IV;%K&W9B2QC4DGJ>* )Z
M*** "BBB@ HHHH **@OHII["YBMY/+F>)EC?)&UB" <CD<URWPXT#Q)X<\/7
M%GXHU?\ M2^>[:5)OM,D^V,H@"[I ".0QQTY]Z .PHHHH **** "BBB@ HHH
MH ***\7^/&MZMH^H>$ETS5+VR6>6<3"VN'B$@!AQNVD9QD]?4T >T45YU\;=
M2O\ 2?AQ/=:=>W-G<"YB42V\K1N 3R,J0:Z/P#<SWGP_T"YNIY)YY;&)Y)97
M+,[%1DDGDF@#HJ*** "BO.OC;J5_I/PXGNM.O;FSN!<Q*);>5HW )Y&5(-=3
MX+GFNO OAZXN)9)IY=,MGDDD8LSL8E)))Y))YS0!N4444 %%%% !1110 444
M4 %%%>;_  [^(&I>-/%GB6TN8(+>STUECMXXP2Q^9P2S'J?E'0 >U 'I%%<1
MXM\-^*=6\8^'M1T;6OL>EV4R/?6WVJ6/SU$@8C:H*ME01\V.M=O0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 9=Y_R&;7Z#^9K4K+O/
M^0S:_0?S-:E:U/ACZ'-0^.?K^@4445D=(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 03_P"O@^IJ>H)_
M]?!]34] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 07'WX?]\5/4%Q]^'_ 'Q4] !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M96:!5&27 .5P.>: /'+#4_'?Q:UG4WTG6I/#7AZU<0H8T_?,>N>,-N(()^8
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MNN/^OJ'_ -"K4\,ZPGA_X*Z5JSP2W M-)CD\F($LY"# & <9..>W6LOX^?\
M)+KC_KZA_P#0JN:+XFL_"'P0TC6[T%X[?38=L:G!D<J JCZDCZ#)[4 <=X?T
MKXB_$[3?^$@NO&4V@:?<L_V6WLD(.T-C^%E.,@C)))QZ&J>IZEXU^$'B?1AJ
MWB>37-#OI2DANMQ8*"H;)8DJ0&!&&(X/&!6EI?B3XN^/+-=3T*#2M&TR9BL$
MDP#$@9&[Y@Q//&=H''3K7!?%_0O%NE6NDW/BSQ+'JEQ<O*(X(EVQQ8"[BO"C
MG('W10!ZY\?/^277'_7U#_Z%7)>$/#GQ!\<>%=-N6\5R^'-'AM([:RALU;S)
M%C 3>V&4\[<Y+'V !&>M^/G_ "2ZX_Z^H?\ T*NS\&>5_P (-X?\C_5?V;;;
M.OW?*7'7VH \LT'Q;XL\ _$"T\(>,K_^T].OBJ6=^RDOECM0[CR><!@V2"<Y
MQUZWXK?$1O NC01V$23ZQ?,4MT;D(!U<KU/4 #N?IBN-_:$$?]J>#C&Q^UBX
ME"!/O$;HOQZXQ]33?BJ<?'+P,;I0UGNMPH/3?]H.<]L?<_K0!;M/AQ\2M8L4
MU/5/B'?Z?J4HWFRB+^6G< ['50?4!2/K5KP#X]\0:=XQD\!^-RKZCR;6]''F
M\;MI. &!&<-QR,')KV"O"/B<FWX_>"'MCMN&-MYA1L$I]H;.?;&X>XXH 3XM
M^)_$^B_%O1+3P_?W"/<6,:1VAE;R9)9))8P63.TGE>H[#.<5U_A/P%XPT3Q!
M;:GJWCR\U. AVN;)MQC+$' 7<Q&,G/"KT%<SXZ56_:3\'!@"/LD1Y'<23$5[
M?0!XOJ?B#QIX_P#'VH^&_#%\VA:7IFY+F[:/]Y(P8KD9&X9(( !' ))Z 4?$
MG@OX@^"M#N=>T_XBZCJ/V-?.EAN0_P!T=P'=U/!)(( X[U=F^*/BWQCXFO-'
M^'VF6;6MFQ$E_=-N#@$@,.0%5L' ^8G@\<@9_BSPU\49?!VLWGB7QA9I90VS
M2-:6B >:!DE"0B8!Z=3G.#0!W6C:A?\ Q/\ A+#-;:I)HVIW:A)+JT#;H9(Y
M1NV@," P7INZ/WKQCX7>#]8UWQ/KT%CXMOM*>PF7SY8 ^;OYW'S8D7^Z3SG[
MQKUCX!_\DNM_^OJ;_P!"KE_@/_R.GC?_ *[+_P"C)* -7XG:UJNG_%7P+9V6
MIWEM:W-U$L\$,[(DH,Z AE!PPP2.:Z#XK?$1O NC01V$23ZQ?,4MT;D(!U<K
MU/4 #N?IBN2^+7_)8?A[_P!?</\ Z4)4'Q5./CEX&-TH:SW6X4'IO^T'.>V/
MN?UH MVGPX^)6L6*:GJGQ#O]/U*4;S91%_+3N =CJH/J I'UJUX!\>^(-.\8
MR> _&Y5]1Y-K>CCS>-VTG # C.&XY&#DU[!7A'Q.3;\?O!#VQVW#&V\PHV"4
M^T-G/MC</<<4 6?C1XKUKPQXU\,RZ5<W978SM91S.L=PP<85U4_-Z8J[-\/?
MB5K5N-1O_B%/8:BPWK8VBLD*' (4E& XZ9VMTZG-4?BVH;XP?#Y6 *F[A!!Z
M'_2$KV^@#RGX.^-M9UN?6/#7B1Q)JNDR%?..-T@#%6#8XRK #/<$>F3F^*?$
M'BOQA\4+CP1X9U9='MK",2W%T 5D? 4MCN<;P HQG!.<50^%'_)<_'G_ %VN
MO_2FNB\>?!^77_$+>)O#FLR:3K; ;CN95=@NT,&7YD., XS],YR 8>L^#?B;
MX,L?[5T3QKJ/B!XY(_,LYHGD9P6Q\JLSY'/.,<9/:O7_  ]?7FI^'K"]U&R:
MRO9H5:>W92#&_P#$,'G&>GM7BD^N?&?P%%+>:M;P:SID(#2R$)(%4=3E-KCC
MNP('7UKUWP5XJM_&GA6TURW@:W$^Y7@9MQC=201GN.,@\<$<#I0!T%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9=Y_P AFU^@_F:U*R[S_D,VOT'\S6I6M3X8^AS4
M/CGZ_H%%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $$_P#KX/J:GJ"?_7P?4U/0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% $%Q]^'_?%3U!<??A_WQ4] !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,#9SD!1@#&,D9XS7>44 >#>'K[XD_"V&71+CPM-XBTM':2WEM&9C\QR<%0Q
M)).&7.23TIVI:1XU^,6KZ8FM:"_AWP[:N9'$Y_?.<X(PP#9(X'R@#D\\"O=Z
M* /'?V@-$U/5_#VC0Z1I=W>M%<L62TMVD*+LP,A0<"ND^+'@S4O&'AR :+<F
M#4[*;S81YI02 C#+D'@]""?3'&<UWU% 'C%M\3/B/IULECJ?PWOKS4%3:;JW
M#B-FY 8A49?3.& Z] >+OP]\%^(;CQQJ'C[Q?#%::A<KLM[--IV*550QP3C"
M *!UZY]_6J* "N4^(G@J#QWX4ETMY%AN4<36LS9PD@!'..Q!(/USC(%=710!
MX/H?BKXG>"-+A\.WG@FYU86H\FUN85=@$'"@L@8$ 8Q]W@<U"?AKXS^*-]+K
M7C.[_LF(1.MC9JN3$3T^3LN>22=QP.G!'OU% 'E_P?T_QMH=M?Z'XEC3^SK!
MO+LY'8L[>R'^*/'3/(SCV'J%%% 'DWQI\":QXC32]<\/KYNH:8QS;C&YU+*0
MRYXRI&<'J#[8->'XF?$6]@%I:_#*[CU#[GGW#.D&[UPRKQ_P/\:]AHH ^>=&
M\*>+="^..B:UK\-WJ4MVIEO+VVM7>&%Y$DB"%U! "_+Z #'0#-=Y\5OAY>>*
M5L=>T"40^(M+(:#D+YP#;E7<> RMDJ3QDG/7(]*HH \:/Q,^)$,!T]_AK=/J
MH4+]J D-ONQUP%P1])/QJ[X"^&.HVVF^([[Q5,O]L>(H9()EC;=Y".&W9(."
M22.G VC!Y->L44 ?/7A&X\>?"/\ M'1&\&76NV#W'FQRV0?!8@#<&5&R"JKP
M0"#4_C:R^)/Q"\-W5Q>Z,=(TVS031:;%F6XNY,@8('. "Q' ^A/(]^HH X7P
M)I*ZG\(;'0]9L+FW#VCVES;W$31.O)&<, >F"#_A7!:./'WPAGNM'MO#LWB7
M06D,MM);*0XSU^Z&*GID$'H<'J:]WHH ^9OB+8_$CQSIMOK%_P"';JULXIEC
MM=+MXWDE^=26D=0">-H&6 QN QUKWCQ#X7M?%O@N30K_ '1K/"@#A?FB<8*L
M![$=.XR.]=#10!X/X?U7XD_"^U?0KWPG=>(M.B8BSFLW9BJY/=5<[>X# $9]
M,"BXT3QW\6?$NEW&O:4_A_P_9/O,+.R2,#C?Z,6., D *#W.<^\44 >4_'G1
MM0U3P#I]GI&G7=[+'J,;>5:PM*RH(I1DA03CD#/N*])T='BT2PCD5D=;:-65
MA@@A1D$5=HH \8\*:)JUO^T/XAU.?2[V+3Y891'=/;NL3DF/&'(P>A[]J[?X
MIV5UJ'PSUNTLK::YN9(E"0PQEW8[U/"CDUV%% '!>!-/O;/X,6=A<V=Q!>+8
MS(UO+$RR!B7P-I&<\C\ZR/@%I.I:-X%OK?5-/N[&=M3D=8[J%HF*^5$,@, <
M9!&?8UZI10!X=/X4\6?"SQ??ZSX-TO\ M?0;\%Y]/0X>+!)"@#DXR=I /!((
MS@F+7]4^(OQ2LAX?M?"$WA[3IF7[7<7S."0"#U95)7IP%)..N,U[M10!E>&]
M"M_#/AO3]%MF+16<(CWG.7;JS8R<9))QVS6K110!X=/X4\6?"SQ??ZSX-TO^
MU]!OP7GT]#AXL$D* .3C)VD \$@C."8M?U3XB_%*R'A^U\(3>'M.F9?M=Q?,
MX) (/5E4E>G 4DXZXS7NU% 'FGBOX2VNK_#73_#=A,J7FE1@VEQ)G#OCY]W)
MP'.3WP<8X&*YW3O'_P 2_#-BNEZUX"U#6;F >6M[;[SOQT+%$<-P1SD9QSSF
MO;:* /&O"_@;Q-XI\>1>./',4=F]KM^PZ?'@[=I)7/)V@$ENN2QSQC!9\>-$
MU;6-0\)-IFEWMZL$LYF-M;O*(P3#C=M!QG!Z^AKVBB@#SKXVZ;?ZM\.)[73K
M*YO+@W,3"*WB:1R >3A035>X\%WGB?X$Z;X>8-9ZBMC R+<(5V2H =KCJ,X(
M]LYQQBO3:* /"/"GC'X@>#M!MO#EU\.]1U"2T4I#<1[E7;DD!BJ,IQTX(Z#O
MS7/?$CPS\1O%6GVOB'6=-D+B;R+71[")IFMXV4L7;;G!.U03],[< 5],44 >
M:?&*TOO$'PKVZ;IUY<7$TL$HMX[=VE /)RF-P(SR" 1WQ7,>']:^(OPYT*UT
MNZ\)7/B+3A$C6<ML7$T(8;C&X"LPVYQ@J,8QDC 'N5% 'BOAKP;XL\9?$"V\
M:^-;=;"WLB&LM/\ XAM)*#&<J WS$MR2.F.G5_%3X?2>.-'MI=/F6WUG3W,E
MI(6*A@<90D=.0I![$=LFN_HH \5LOB/\2M'LUTS5OAY?ZCJ$2^7]LA#['/0,
MVQ&4]LX8#Z5;\#> O$.I^-7\?>.!'#J/_+K81X*Q_+M!(R0H / R3GDG/7U^
MB@#Q[QCHNJW7[07A74K?3+R:P@M8UENHX&:*,AYB0S@8!Y'4]Q7L-%% 'SUH
MNE>,O@WXIU9=,\-7'B#1KT*5-J&+%5+;.55BK#<000<]?>M?79OB3\2M$N;'
M^P3X;TCRFDF$K%[BX(!*Q!3M."0H/ ^O8^W44 >:? VUOM.^'_\ 9^I:=>6-
MS!=2$QW5N\196P01N R.HXSTK@["+QE\+/'WB">R\(W>M6&HS%T:U1V4Q[V9
M?F56VMAL$$?GUKZ'HH \=^)NCZIJ7Q3\"7UEIE[<6EO<PO/-%;NR1#ST)+D#
M"\<\XKH_BI\/I/'&CVTNGS+;ZSI[F2TD+%0P.,H2.G(4@]B.V37?T4 >*V7Q
M'^)6CV:Z9JWP\O\ 4=0B7R_MD(?8YZ!FV(RGMG# ?2K?@;P%XAU/QJ_C[QP(
MX=1_Y=;"/!6/Y=H)&2% !X&2<\DYZ^OT4 >/?$[1=5U#XJ^!;RRTR\N;6VNH
MFGGA@9TB G0DLP&%& 3S7L-%% 'B_P ,]$U:P^,GC2^O-+O;>SN);DP7$UNZ
M1R@W&1M8C!R.>.U+XC\/^-_!WQ&N_%OA6U.KZ=?#_2;$R$LN<%QM)SU7*LO3
M.,8Z^ST4 >'ZQXS^(WC71KG0=-^'UWI;7D+07%Q>%E78PPVTR(@&1N'4GGCG
M%>D_#_PBO@CPA:Z-YRSS*6EGE48#2,<G'L. /I73T4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 9=Y_R&;7Z#^9K4K+O/^0S:_0?S-:E:U/ACZ'-0^.?K^@4445D
M=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 03_Z^#ZFIZ@G_ -?!]34] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07'W
MX?\ ?%3U!<??A_WQ4] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 077W8_]\5/4%U]V/\ WQ4]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ_W1^5&U?[H_*CVM#_GW^/\ P ^KX[_G^O\ P%?YG&?\+'L/^?&Y_-?\:/\
MA8]A_P ^-S^:_P"-=GM7^Z/RHVK_ '1^5'M:'_/O\?\ @!]7QW_/]?\ @*_S
M.,_X6/8?\^-S^:_XT?\ "Q[#_GQN?S7_ !KL]J_W1^5&U?[H_*CVM#_GW^/_
M   ^KX[_ )_K_P !7^9QG_"Q[#_GQN?S7_&C_A8]A_SXW/YK_C79[5_NC\J-
MJ_W1^5'M:'_/O\?^ 'U?'?\ /]?^ K_,XS_A8]A_SXW/YK_C1_PL>P_Y\;G\
MU_QKL]J_W1^5&U?[H_*CVM#_ )]_C_P ^KX[_G^O_ 5_F<9_PL>P_P"?&Y_-
M?\:/^%CV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\ /O\ '_@!]7QW_/\ 7_@*
M_P SC/\ A8]A_P ^-S^:_P"-'_"Q[#_GQN?S7_&NSVK_ '1^5&U?[H_*CVM#
M_GW^/_ #ZOCO^?Z_\!7^9QG_  L>P_Y\;G\U_P :/^%CV'_/C<_FO^-=GM7^
MZ/RHVK_='Y4>UH?\^_Q_X ?5\=_S_7_@*_S.,_X6/8?\^-S^:_XT?\+'L/\
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MKL]J_P!T?E1M7^Z/RH]K0_Y]_C_P ^KX[_G^O_ 5_F<9_P +'L/^?&Y_-?\
M&C_A8]A_SXW/YK_C79[5_NC\J-J_W1^5'M:'_/O\?^ 'U?'?\_U_X"O\SC/^
M%CV'_/C<_FO^-'_"Q[#_ )\;G\U_QKL]J_W1^5&U?[H_*CVM#_GW^/\ P ^K
MX[_G^O\ P%?YG&?\+'L/^?&Y_-?\:/\ A8]A_P ^-S^:_P"-=GM7^Z/RHVK_
M '1^5'M:'_/O\?\ @!]7QW_/]?\ @*_S.,_X6/8?\^-S^:_XT?\ "Q[#_GQN
M?S7_ !KL]J_W1^5&U?[H_*CVM#_GW^/_   ^KX[_ )_K_P !7^9QG_"Q[#_G
MQN?S7_&C_A8]A_SXW/YK_C79[5_NC\J-J_W1^5'M:'_/O\?^ 'U?'?\ /]?^
M K_,XS_A8]A_SXW/YK_C1_PL>P_Y\;G\U_QKL]J_W1^5&U?[H_*CVM#_ )]_
MC_P ^KX[_G^O_ 5_F<9_PL>P_P"?&Y_-?\:/^%CV'_/C<_FO^-=GM7^Z/RHV
MK_='Y4>UH?\ /O\ '_@!]7QW_/\ 7_@*_P SC/\ A8]A_P ^-S^:_P"-'_"Q
M[#_GQN?S7_&NSVK_ '1^5&U?[H_*CVM#_GW^/_ #ZOCO^?Z_\!7^9QG_  L>
MP_Y\;G\U_P :/^%CV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\^_Q_X ?5\=_S
M_7_@*_S.,_X6/8?\^-S^:_XT?\+'L/\ GQN?S7_&NSVK_='Y4;5_NC\J/:T/
M^??X_P# #ZOCO^?Z_P# 5_F<!/X[LY;Z&X%I.%0#()&3S5S_ (6/8?\ /C<_
MFO\ C6_>*O\ ;%KP.@[>YK4VK_='Y5I.I0M&\/Q_X!A1H8QRG:LM_P"5?YG&
M?\+'L/\ GQN?S7_&C_A8]A_SXW/YK_C79[5_NC\J-J_W1^59^UH?\^_Q_P"
M;_5\=_S_ %_X"O\ ,XS_ (6/8?\ /C<_FO\ C1_PL>P_Y\;G\U_QKL]J_P!T
M?E1M7^Z/RH]K0_Y]_C_P ^KX[_G^O_ 5_F<9_P +'L/^?&Y_-?\ &C_A8]A_
MSXW/YK_C79[5_NC\J-J_W1^5'M:'_/O\?^ 'U?'?\_U_X"O\SC/^%CV'_/C<
M_FO^-'_"Q[#_ )\;G\U_QKL]J_W1^5&U?[H_*CVM#_GW^/\ P ^KX[_G^O\
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M,_X6/8?\^-S^:_XT?\+'L/\ GQN?S7_&NSVK_='Y4;5_NC\J/:T/^??X_P#
M#ZOCO^?Z_P# 5_F<9_PL>P_Y\;G\U_QH_P"%CV'_ #XW/YK_ (UV>U?[H_*C
M:O\ ='Y4>UH?\^_Q_P" 'U?'?\_U_P" K_,XS_A8]A_SXW/YK_C1_P +'L/^
M?&Y_-?\ &NSVK_='Y4;5_NC\J/:T/^??X_\  #ZOCO\ G^O_  %?YG&?\+'L
M/^?&Y_-?\:/^%CV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\^_Q_X ?5\=_P _
MU_X"O\SC/^%CV'_/C<_FO^-'_"Q[#_GQN?S7_&NSVK_='Y4;5_NC\J/:T/\
MGW^/_ #ZOCO^?Z_\!7^9QG_"Q[#_ )\;G\U_QH_X6/8?\^-S^:_XUV>U?[H_
M*C:O]T?E1[6A_P ^_P ?^ 'U?'?\_P!?^ K_ #.,_P"%CV'_ #XW/YK_ (T?
M\+'L/^?&Y_-?\:[/:O\ ='Y4;5_NC\J/:T/^??X_\ /J^._Y_K_P%?YG&?\
M"Q[#_GQN?S7_ !H_X6/8?\^-S^:_XUV>U?[H_*C:O]T?E1[6A_S[_'_@!]7Q
MW_/]?^ K_,XS_A8]A_SXW/YK_C1_PL>P_P"?&Y_-?\:[/:O]T?E1M7^Z/RH]
MK0_Y]_C_ , /J^._Y_K_ ,!7^9QG_"Q[#_GQN?S7_&C_ (6/8?\ /C<_FO\
MC79[5_NC\J-J_P!T?E1[6A_S[_'_ ( ?5\=_S_7_ ("O\SC/^%CV'_/C<_FO
M^-'_  L>P_Y\;G\U_P :[/:O]T?E1M7^Z/RH]K0_Y]_C_P  /J^._P"?Z_\
M 5_F<9_PL>P_Y\;G\U_QH_X6/8?\^-S^:_XUV>U?[H_*C:O]T?E1[6A_S[_'
M_@!]7QW_ #_7_@*_S.,_X6/8?\^-S^:_XT?\+'L/^?&Y_-?\:[/:O]T?E1M7
M^Z/RH]K0_P"??X_\ /J^._Y_K_P%?YG&?\+'L/\ GQN?S7_&C_A8]A_SXW/Y
MK_C79[5_NC\J-J_W1^5'M:'_ #[_ !_X ?5\=_S_ %_X"O\ ,XS_ (6/8?\
M/C<_FO\ C1_PL>P_Y\;G\U_QKL]J_P!T?E1M7^Z/RH]K0_Y]_C_P ^KX[_G^
MO_ 5_F<1)\0[%Y(V%E<?*<]5_P :D_X6/8?\^-S^:_XUUDZKY\'RCJ>U3[5_
MNC\J/:T/^??X_P# #ZOC?^?Z_P# 5_F<9_PL>P_Y\;G\U_QH_P"%CV'_ #XW
M/YK_ (UV>U?[H_*C:O\ ='Y4>UH?\^_Q_P" 'U?'?\_U_P" K_,XS_A8]A_S
MXW/YK_C1_P +'L/^?&Y_-?\ &NSVK_='Y4;5_NC\J/:T/^??X_\  #ZOCO\
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M:_XT?\+'L/\ GQN?S7_&NSVK_='Y4;5_NC\J/:T/^??X_P# #ZOCO^?Z_P#
M5_F<9_PL>P_Y\;G\U_QH_P"%CV'_ #XW/YK_ (UV>U?[H_*C:O\ ='Y4>UH?
M\^_Q_P" 'U?'?\_U_P" K_,XS_A8]A_SXW/YK_C1_P +'L/^?&Y_-?\ &NSV
MK_='Y4;5_NC\J/:T/^??X_\  #ZOCO\ G^O_  %?YG$2_$.Q=HR+*X&UL]5_
MQJ3_ (6/8?\ /C<_FO\ C767"KOA^4??':I]J_W1^5'M:'_/O\?^ 'U?'?\
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M^%CV'_/C<_FO^-'_  L>P_Y\;G\U_P :[/:O]T?E1M7^Z/RH]K0_Y]_C_P
M/J^._P"?Z_\  5_F<9_PL>P_Y\;G\U_QH_X6/8?\^-S^:_XUV>U?[H_*C:O]
MT?E1[6A_S[_'_@!]7QW_ #_7_@*_S.,_X6/8?\^-S^:_XT?\+'L/^?&Y_-?\
M:[/:O]T?E1M7^Z/RH]K0_P"??X_\ /J^._Y_K_P%?YG&?\+'L/\ GQN?S7_&
MC_A8]A_SXW/YK_C79[5_NC\J-J_W1^5'M:'_ #[_ !_X ?5\=_S_ %_X"O\
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M^?&Y_-?\:[/:O]T?E1M7^Z/RH]K0_P"??X_\ /J^._Y_K_P%?YG&?\+'L/\
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M+'L/^?&Y_-?\:/\ A8]A_P ^-S^:_P"-=GM7^Z/RHVK_ '1^5'M:'_/O\?\
M@!]7QW_/]?\ @*_S.,_X6/8?\^-S^:_XT?\ "Q[#_GQN?S7_ !KL]J_W1^5&
MU?[H_*CVM#_GW^/_   ^KX[_ )_K_P !7^9QG_"Q[#_GQN?S7_&C_A8]A_SX
MW/YK_C79[5_NC\J-J_W1^5'M:'_/O\?^ 'U?'?\ /]?^ K_,XS_A8]A_SXW/
MYK_C1_PL>P_Y\;G\U_QKL]J_W1^5&U?[H_*CVM#_ )]_C_P ^KX[_G^O_ 5_
MF<9_PL>P_P"?&Y_-?\:/^%CV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\ /O\
M'_@!]7QW_/\ 7_@*_P SC/\ A8]A_P ^-S^:_P"-'_"Q[#_GQN?S7_&NSVK_
M '1^5&U?[H_*CVM#_GW^/_ #ZOCO^?Z_\!7^9QG_  L>P_Y\;G\U_P :/^%C
MV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\^_Q_X ?5\=_S_7_@*_S.,_X6/8?\
M^-S^:_XT?\+'L/\ GQN?S7_&NSVK_='Y4;5_NC\J/:T/^??X_P# #ZOCO^?Z
M_P# 5_F<9_PL>P_Y\;G\U_QH_P"%CV'_ #XW/YK_ (UV>U?[H_*C:O\ ='Y4
M>UH?\^_Q_P" 'U?'?\_U_P" K_,XS_A8]A_SXW/YK_C1_P +'L/^?&Y_-?\
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MKL]J_P!T?E1M7^Z/RH]K0_Y]_C_P ^KX[_G^O_ 5_F<9_P +'L/^?&Y_-?\
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MYG&?\+'L/^?&Y_-?\:/^%CV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\^_Q_X
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MM7^Z/RH]K0_Y]_C_ , /J^._Y_K_ ,!7^9QG_"Q[#_GQN?S7_&C_ (6/8?\
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M:/\ A8]A_P ^-S^:_P"-=GM7^Z/RHVK_ '1^5'M:'_/O\?\ @!]7QW_/]?\
M@*_S.,_X6/8?\^-S^:_XT?\ "Q[#_GQN?S7_ !KL]J_W1^5&U?[H_*CVM#_G
MW^/_   ^KX[_ )_K_P !7^9QG_"Q[#_GQN?S7_&C_A8]A_SXW/YK_C79[5_N
MC\J-J_W1^5'M:'_/O\?^ 'U?'?\ /]?^ K_,XS_A8]A_SXW/YK_C1_PL>P_Y
M\;G\U_QKL]J_W1^5&U?[H_*CVM#_ )]_C_P ^KX[_G^O_ 5_F<9_PL>P_P"?
M&Y_-?\:/^%CV'_/C<_FO^-=GM7^Z/RHVK_='Y4>UH?\ /O\ '_@!]7QW_/\
M7_@*_P SC/\ A8]A_P ^-S^:_P"-'_"Q[#_GQN?S7_&NSVK_ '1^5&U?[H_*
MCVM#_GW^/_ #ZOCO^?Z_\!7^9QG_  L>P_Y\;G\U_P :/^%CV'_/C<_FO^-=
MGM7^Z/RHVK_='Y4>UH?\^_Q_X ?5\=_S_7_@*_S.,_X6/8?\^-S^:_XT?\+'
ML/\ GQN?S7_&NSVK_='Y4;5_NC\J/:T/^??X_P# #ZOCO^?Z_P# 5_F<9_PL
M>P_Y\;G\U_QH_P"%CV'_ #XW/YK_ (UV>U?[H_*C:O\ ='Y4>UH?\^_Q_P"
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M^ 'U?'?\_P!?^ K_ #.,_P"%CV'_ #XW/YK_ (T?\+'L/^?&Y_-?\:[/:O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!EWG_(9M?H/YFM2LN\_P"0S:_0?S-:E:U/ACZ'-0^.?K^@4445D=(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 03_Z^#ZFIZ@G_P!?!]34] !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07'WX?]\5/4
M%Q]^'_?%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!!=?=C_ -\5/4%U]V/_ 'Q4] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 9NM?\>B?]=/Z&M"/_5K]!6?K7_'HG_73^AK0C_U:_05K+^'
M'YG-3_CS]$.HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+O/^0S:_0?S-:E
M9=Y_R&;7Z#^9K4K6I\,?0YJ'QS]?T"BBBLCI"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""?_7P?4U/4
M$_\ KX/J:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@""X^_#_OBIZ@N/OP_[XJ>@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** (+K[L?^^*GJ"Z^['_ +XJ>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6O^/1
M/^NG]#6A'_JU^@K/UK_CT3_KI_0UH1_ZM?H*UE_#C\SFI_QY^B'4445D=(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 45Q_Q2UO4?#GPXU;5M)N/L]]!Y/ER[
M%?;NF13PP(/!(Y%9WP;\2ZOXK\#MJ.M7?VJ[%Y)$)/+1/E 7 PH [F@#T&BB
MB@ HHKQOXQ^.?$?A7Q+H-IHNH_98+I"9D\B-]QW@=64D<>E 'LE%%% !1110
M 45P7Q.^)EO\/;"W"V;7>H7@?[/&3MC7;C+,>N,L.!U]1UKN+:0S6L,K !G0
M,<=.10!+1110 45YM\0OC%I'@B9].MXO[1U@ %H%?:D.>F]N>>^T<_3.:X6/
MQ#\=O$:)>Z;IOV&W<;E06\$0(]<3DM]/6@#Z#HKYY;XJ_$KP+>Q1^--$6XMI
M"!YC1+&6QU"21_(3WQ@_A7MWAGQ-IGB[1(M6TF9I+:0E2'7:R,.JL.QH V**
M** "BBL?Q9?7&F>#=<O[.3R[JUT^XFA?:#M=8V*G!X."!UH V**\R^"7BS6_
M%WAG4+S7;W[7/%>>4C^4D>%V*<80 =2:R/%/CGQ'IWQSTCPY::CY>DW#VXEM
M_(C.X,?F^8KN&?8T >R4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!EWG_(9M?H/YFM2LN\_P"0S:_0?S-:E:U/ACZ'-0^.?K^@4445
MD=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 03_Z^#ZFIZ@G_P!?!]34] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07'
MWX?]\5/4%Q]^'_?%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!!=?=C_ -\5/4%U]V/_ 'Q4
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9NM?\>B?]=/Z&M"/_5K]!6?K7_'HG_73^AK0C_U
M:_05K+^''YG-3_CS]$.HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\
M@A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_
M\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_
M97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X
M)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >
M]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)
MO^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ
M_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K
M-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\
M@A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_
M\/\ @A_K-_TZ_P#)O^ >]T5X)11_97]_\/\ @A_K-_TZ_P#)O^ >]T5X)11_
M97]_\/\ @A_K-_TZ_P#)O^ >Z3_Z^#ZFIZ\$HH_LK^_^'_!#_6;_ *=?^3?\
M ][HKP2BC^RO[_X?\$/]9O\ IU_Y-_P#WNBO!**/[*_O_A_P0_UF_P"G7_DW
M_ />Z*\$HH_LK^_^'_!#_6;_ *=?^3?\ ][HKP2BC^RO[_X?\$/]9O\ IU_Y
M-_P#WNBO!**/[*_O_A_P0_UF_P"G7_DW_ />Z*\$HH_LK^_^'_!#_6;_ *=?
M^3?\ ][HKP2BC^RO[_X?\$/]9O\ IU_Y-_P#WNBO!**/[*_O_A_P0_UF_P"G
M7_DW_ />Z*\$HH_LK^_^'_!#_6;_ *=?^3?\ ][HKP2BC^RO[_X?\$/]9O\
MIU_Y-_P#WNBO!**/[*_O_A_P0_UF_P"G7_DW_ />Z*\$HH_LK^_^'_!#_6;_
M *=?^3?\ ][HKP2BC^RO[_X?\$/]9O\ IU_Y-_P#WNBO!**/[*_O_A_P0_UF
M_P"G7_DW_ />Z*\$HH_LK^_^'_!#_6;_ *=?^3?\ ][HKP2BC^RO[_X?\$/]
M9O\ IU_Y-_P#WNBO!**/[*_O_A_P0_UF_P"G7_DW_ />Z*\$HH_LK^_^'_!#
M_6;_ *=?^3?\ ][HKP2BC^RO[_X?\$/]9O\ IU_Y-_P#WNBO!**/[*_O_A_P
M0_UF_P"G7_DW_ />Z*\$HH_LK^_^'_!#_6;_ *=?^3?\ ][HKP2BC^RO[_X?
M\$/]9O\ IU_Y-_P#WNBO!**/[*_O_A_P0_UF_P"G7_DW_ />Z*\$HH_LK^_^
M'_!#_6;_ *=?^3?\ ][HKP2BC^RO[_X?\$/]9O\ IU_Y-_P#WNBO!**/[*_O
M_A_P0_UF_P"G7_DW_ /=+C[\/^^*GKP2BC^RO[_X?\$/]9O^G7_DW_ />Z*\
M$HH_LK^_^'_!#_6;_IU_Y-_P#WNBO!**/[*_O_A_P0_UF_Z=?^3?\ ][HKP2
MBC^RO[_X?\$/]9O^G7_DW_ />Z*\$J_I&KW6C7RW-LWLZ'HX]#4RRMI:2U]/
M^"7#B6+DE.G9>M_T/;**S]'UBUUJQ6YMF]G0]4/H:T*\N47%V>Y])3J1J14X
M.Z84444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+K[L
M?^^*GJ"Z^['_ +XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOZK?:GJ<\VC1J2T<@!7SF.55"02 %W$@'CY<]16</A'\0O&][;W/C;7$A@C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SWXD?\?6G_[C_P Q7#5W/Q(_X^M/_P!Q_P"8KAJ^CP7\
M")^?9Q_OU3Y?D@HHHKJ/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** +^D:O=:+?+<VS>SH>CCT->NZ1J]KK5BMS;-
M[.AZH?0UXG5_2-7NM%OEN;9O9T/1QZ&N/%X15E=?$>QE>:2PDN2>L'^'FCVR
MBJ&D:O:ZU8K<VS>SH>J'T-7Z^?E%Q=GN?<PG&I%3@[IA1112+"BBB@ HHHH
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M4Z?%9>#]9\)W]I:VL<H74989%0G<6"GY=O<@'=S@4 >Q4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GOQ(_
MX^M/_P!Q_P"8KAJ[GXD?\?6G_P"X_P#,5PU?1X+^!$_/LX_WZI\OR04445U'
MF!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN4444 %%%8>D^+]"UW6-1TG3;[S[[3G9+J+R77RV#%2,LH!Y!'!- &Y1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6FL:;)NM[A,[3]Z-OXD;T(/'_P!:@#Q#P_\ \G4:A_UTG_\ 1-?0M?/7A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114D,,MS,D,*,\C
MG"JHR2:-AI-NR"&&6YF2&%&>1SA54<DUZIX7\+Q:) )YPKWSCYFZA!Z#_&D\
M+^%XM%A$\X5[YQ\S=D'H/\:Z2O$QF,]I[D-OS/L\HRA4$JU9>]T7;_@_D%%%
M%>:?0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!=?=C_P!\5/4%
MU]V/_?%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!FZU_P >B?\ 73^AK0C_ -6OT%9^M?\
M'HG_ %T_H:T(_P#5K]!6LOX<?F<U/^//T0ZBBBLCI"BBB@ HHHH **** /$?
MVE/^1;T3_K[?_P! KV>Q_P"0?;?]<E_D*\8_:4_Y%O1/^OM__0*]GL?^0?;?
M]<E_D* "^_Y!]S_UR;^1KQC]FO\ Y%O6_P#K[3_T"O9[[_D'W/\ UR;^1KQC
M]FO_ )%O6_\ K[3_ - H ]0_X3/P\/$=YX??4D34[.+SKB*1'58TPK;BY&SH
MZ]^]8[?%[P$EZUH?$EOYBG!81R%/P<+M/7L:\FU[PS'XN_:7U'2+F21;%UAD
MNU1RIDC2WC;;]"P4>W7J*]3\3?#/P?<^$M0MHM L+5X[=WBN+>!4E1E4D'>.
M3SV)P>] '<Q2QSPI-#(DD4BAD=&!5E/(((ZBN+\)?\(+_P )CXA_X1O_ )#G
MG/\ VI_K_O\ F'=]_P"7[^?N\?A7-_L\ZE<7OP_N+6=V=;.]>.$DYVH55MOY
MEOSK,^$O_)8?B%_U]S?^E#T >H>'_&GA[Q3=WMKH^H"XN+(@7$9A>-DR2.CJ
M,\@],X_$5MRRI!"\LK!8T4LS'H .2:\.>%O /[1\<N[;IWB52./[\AY!]_-4
M'Z/]:ZKXY>(WT'X<W%O!(4N-3<6:D '"$$R=>Q4%?^!?C0!V/AOQ5HOBZPEO
MM#O#=VT4IA>3R7C < ''SJ,\,/SJCKWQ$\)>&;LVNKZW!!< 9:)5:1E^H0$C
M\:Y FX^%/P#4JHBU2.W!*O@E;B9N>G!V[C_WQWKEOA=HOP]B\/QZSXJU;0KW
M6[YWEECU*\B8Q D@ H[<L?O$D9R?;- 'L/AWQIX<\6*YT/5H+MD&YHQE)%&<
M9*, P&>^*M:_XBTKPOI;:GK-U]FLU94,GEL_)Z#"@G]*\&^)J>%?#=[IGBWP
M#J^DQ:E!<JDUGI]S&R,N"0WEJ>!QM('!R/K78_&/45UCX(V^IH,)>&UN%'H'
M ;^M '67_P 4_!.F74%M=Z_#'-,B2*HCD;"N 5W$*0F00?FQP:V=5\4Z%HFF
M0ZEJ6J6UM9S@&&5W_P!8",C:.IXYXK@_AK\,_#"_#S3)M2T6RO;O4+=+F::X
MB$C8<;E"D_= 4@<8KB?B'<Z5:?'FRD\96TDGAZ&VC%N@0F,+M/)4?>42%L@>
M@&#T(!ZI8?%SP'J=PL%MXB@$C$*/.BDA!).!RZ@5VBL&4,I!4C((Z&O++SPI
M\,OB!HDFG^'Y-"M[UD_<S64:+-$>#DQ@JS<#^+WKN_">@MX8\,66BF]DO5M$
M*)-(NUBN20,9[9P/8"@#F? E]\/-,\.:O?\ A"3R]+M<S7S[;@[=J9)Q)\QP
MH_AKRK0/B%H-O\=-9\1W^KR?V1- \5M</%*_&4VJ%VE@.&["NB_9S@ANO"?B
M"WN(HYH);E4DCD4,KJ8\$$'@@CC%97A3P_HMQ^T/XATR?2+"73XH93':O;(T
M2$&/&$(P.I[=Z /8YO'WABWUC3=)FU01WNIQ1RV<;0R 2K)D(0VW R1C!(.>
M*Z2O%?C]H;6V@Z)XBTQ!!+H]PL2^4 !&AP4./1610 /[W3T]0T_Q+9WG@R'Q
M,Y*6C6/VR0=T4)N8?48(Z]J &Q^,=!E\5OX8COP^L1KO>W6)SM&W=RV-HX([
M]ZW*\7^ ^G2:G)X@\;WZ WNIW3Q1L3T7.]\=L%BH_P" =J]HH :[I%&TDC*B
M*"S,QP !U)-<5=?&#P#9WAM9?$<#2 XS%%)*G_?:J5_'-<9\<]5U+4-3T#P/
MILK1?VM(IF(8@."^Q0W'W0<D\]AZ5W&E?"OP9I>BQ::=!L;O:N'N+J!7FD/<
MER,CZ# ':@#I=+U?3];L$OM+O(;NU<D++"X89'4?7VKY_P#C]XTTC7(K+1-+
MU%II["\F%[!Y3J$D7Y!RP .#O&03U-7+"W?X3_'*ST73YY!H.MB,"!RS %R4
M7GG+*XZ^C8/7-,_:+T?2]/M]&N[+3;.VN;JXG:XFA@5'F;"G+D#+'))Y]30!
MZ3\/9OAW?2W<W@BWM!-:QK%/+%:R1N$<D@%G4%LE/?I7=UGZ9H6CZ)YO]DZ5
M8V'G8\S[);I%OQG&=H&<9/7U-:% 'CWQJ\7ZI!/IO@OP](Z:GJI'FO$^'",=
MJH".1N.<GC 7T)K9\*_!3PEH.G1+?Z?%JM^5'G3W667=CD*G0+G..,^IKA[X
M?:OVL[:*YR(HMOE$G&<6A<?^/YKZ H \F^(/P9T+4M#N+[PYIZZ?K%M&9(%M
M?E68KSL*] 3V(P<XSQ73_#&]\37?@Z)/%=E/;ZE;N8A)/C?.F 5<CL>=ISUV
MYZDUV5% '@7P!UK3-"\'ZY=ZK?V]G;B\0;YY H)V=!GJ?85Z?HWQ0\%Z_?Q6
M.FZ]#)<RMLCCDCDB+MZ#>HR?YUXG\"/ FF>)[C4-4UJW6[M;)EC@MI.8VD8$
MLS#O@!?8Y]A76?'#P+H&G^"QKFDZ5:Z=>6<\8WV<2PAD8XY"X!.2"#UXH ]>
MUW^SO^$>U/\ M?\ Y!GV27[9][_4[#O^[\WW<].?2LCP#_PBW_"+1_\ "'?\
M@?S7V?ZW[^?F_P!9\W6LJXU"?5O@-=7]RQ:XN/#DCRL3G<QMSD_B>:R_@,ZQ
M_"J&1SA5N9R3Z &@#N=>\4Z'X7@2;6M3@LTD.$$ARS?11DG\JR]#^)?@[Q'>
MI9Z7KL$MRYVI%(CQ,Y]%#@9_"O)?AMH<'Q6\6Z[XL\4J;VWAD$5M:2,=B9)(
M& ?NJN !T)8D\]>Z\>_![1O$6CH- L-/TC5H)%:&>",0H5R-P<(.>.0<9R!R
M 30!Z4S!5+,0% R2>@KB[_XN^ M.G\F?Q);.WK;I).O_ 'U&K#]:I^*O"?BW
MQ!\-+7P_%K5JFJ%52^N6+JMP@!R,@9&X[<\<\_C#9>$_AEX.TB"RU2+P\9HT
M"RS:D87DD<#+'Y^<^P_*@#K] \5Z#XHBDDT35+>]$1Q(L;?,GIE3@@'L<<XK
M3N;F"SMI+FZGC@@B4O)+*X544=22> *^<M*N_#^D_M$:8/!LT+:7<KY,R6['
MR]S(P903U&0K<<9^E=+\8+FZ\3^._#?P_MKJ6WM;HK/>[.CJ6./J55'('3)&
M>G !W$/Q<\!3W_V-/$EL)<XW.CI'_P!_&4+^M;5OXNT*[\43^&X+\/J\$0FD
MMQ$^ A"L#OQM/#J>#WK*'PK\#C1CI?\ PCECY)7;YI3]_P#7S?OY_']*\G^%
MNA2^&?CUJ^BRSR3_ &2SDC223[S1_NRF?^ E: /?-3U73]%L7O=3O8+.U3[T
ML[A5SZ<]3[=37)V_QA\ 75U]GC\1P!\XS)#+&G_?3*%_6O-]6LYOBK\<[G0K
M^65=#T16+PHY 8*0&QQP6<@$]=HX/%>GZK\+/!>JZ4UB?#]A;?)M2>UA6.13
MV.Y<$].^<T =>CI+&LD;*Z, RLIR"#T(-.KQ+X':QJ&G:YK_ (#U&X:8:6[M
M;;@<J%DV.!U^4DJ0,]SC.>/;: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *XCXO\ _)*-?_ZXI_Z,6NWKB/B__P D
MHU__ *XI_P"C%H Y;]G'_DGFH?\ 85D_]%15[!7C_P"SC_R3S4/^PK)_Z*BK
MV"@#YQ_:5_Y#^A?]>LG_ *$*^A[*T@T^QM[*V01P6\2Q1H!@*JC 'Y"OGC]I
M7_D/Z%_UZR?^A"OHZ@#AOB/X,\*^)+.#4?%-_-96U@#MF6Y$:*&(R/F!&6P!
MQR> *S;OXY^ -.18K>^GN50;0MK:. H'&!N"C\N*\W^/E[-??$;2-&U"<VNE
M1PQN),9"B1R'DQWP%Q_P'WKV/1?AMX&T^UADL= TZY1D5DGF07!<8&&#-GKU
MR* /!?BW\3;#Q_96$.FZ5=P6]I,S?:;G:"Q*C*X7('K][L.*^BO G_)//#7_
M &"K7_T4M>'?'_Q'HT_]E>&='-NPL&>6<6X CB)&%0;>,_>)';CWKV_P"ZR?
M#OPT5.0-+MA^(B4']10!X5^SA8P3^+]4O)(T:6VLPL19<E2S#)'H<#'T)KZ7
MKYQ_9J_Y#^N_]>L?_H1KZ.H ^=/@M!%:_&WQ1;P1K'#%;W:1HHP%47,8 'MB
MNA^.W@_6]3N-(\2:%:R7,U@I29(EWNH#!T8+_$ =V?PX(SC"^#W_ "7;Q9_U
MRO/_ $ICKM/B5\4=3\!>*=*LQIMM)I5TJR2W+EF? ?$BJ 1@A<8SGEA]* .4
MT;]H]X)!;>)/#[J\8VRRV;X;>#@_NWQC_OKJ/RZ_0=:^&7Q"\3V^L01QMXAA
M6-XTNP\<J[#E<#.QB"?X<G@>@KL+G1O"OC.TBO9['3-6A8?N[C8DG!ZX<<C\
M^U?-?Q-T#1O"GQ#T^T\%2R+>(8W,$<OFF"XW_(JDY.[@'!)QQZT >R_'S_DE
MUQ_U]0_^A5>^"VD0Z5\+]*>-4\V\#7,SJ,%BS'&?HH4?A5'X^?\ )+KC_KZA
M_P#0JJ? OQIIVK>#[7P\\ZQZKIZLODNW,L>XD,N>H .".V/0B@#OO&&FP:OX
M,UFPN1F.:SD&?[I"DJ?J" ?PKR?]FK4IYM'U[3'.8+:>*>/V,@8-^'[L?K7<
M_%7QI8^$_!U]&]RJZG>P/#:0C#.68$;\?W5SG)XXQSG%<O\ L\>'I],\(WVK
M7,)C;4YE,6[(+1(" <>F6?'K^5 '.>'_ /DZC4/^ND__ *)KUWQWX2T/Q;H7
MD>(+J:VLK5C.9DG$2QD C<Q8%> 3U'&37D7A_P#Y.HU#_KI/_P"B:L_M*:G?
M1PZ'I:Y6QF,D[$?QR+@ ?@&_\>H ZN#XN?#GPKI%KI%AJDMS#91+ BV]N[$A
M1@$L0%)/J#U->=_%+XO:3XU\,2:/I.E7WEB9)7NKD*H0@G& "W7U)'6O4/!?
MPV\!Q^'-.O+72[#5?-MU)N[A!,)21R=K9 YR,8XQCM7(?'C7M"TOPG%X4TM+
M5+N>Y6:6"V556%5R<L%Z,3MP/3/M0!VGP2_Y)#H7_;Q_Z425Y1X&L8+W]I75
MVGC1Q;ZA?SH&7(W!W /U!.1[BO5?@@ZO\(M%"G)0SAO8^?(?Y$5YG\._^3DO
M$/\ U]:A_P"C30!]'5\Z:;!%;_M9ND,:HIN)G(48^9K5F8_4DD_C7T77SQ9_
M\G;-_P!=9/\ TC:@#T#XZ_\ ))]2_P"NL'_HQ:/@5_R2?3?^NL__ *,:G?'-
M&?X3:J5&0DD!;V'FJ/YD5%\")8W^%=A&DB,\<TP=0P)4F1B,CMQ0!8\<^%/!
M9UVQ\7^*-1DM);-XQ%YDX$<FPEE3802PSDD+R>?>J=]\?/ MIGR;J]O<#_EW
MM6&?^^]M>6^/7B\2?']=*\277V32X9HK8$MM"Q;0XY[;BW7MN]J]YL?AYX,T
MF,FW\-Z6H7)WRP+(P]?F?)'YT ?-'Q7\=VWCW6+&^L]-GM+>")HHY)R-TPW9
MS@<#'ID]:^M[[_D'W/\ UR;^1KY9^.GB?3-?\6VMGI$D<MKIEOY!EBQL+DY(
M7'!4#:/KGTKZFG_TG3Y/)^;S8CL[9R.* /G_ /9H_P"0AXC_ .N4'\WK9_:4
M_P"1;T3_ *^W_P#0*P_V:98UU7Q!$TB"1X82J%AE@"^<#OC(K<_:4_Y%O1/^
MOM__ $"@#J9[Z73?V>8;J XE3PY"%/\ =+0*N?PSFN5_9MTBW3P[J^L[5-S-
M=_9<E>51$5N#[F3D?[(KMK+1W\0? VQTF+;YUWX?ACBW-@;S NW)]-V,UYA\
M _&%EH<VH>$]8<6,\USYL!N&V RX"-&0?NM\HQGJ>.N* /HBOFD6R>$?VGH[
M?3T\BVGNU C3A2L\8+#&>@9C@=L# X%?16IZK8:-82WVI7<5K:Q EI)6P.!G
M ]3P>!R:^=O!LLWQ'_: E\1PP2?V=:R&X+/_  (B;(ATP&)"G'^]@\9H U?V
MFO\ F5O^WO\ ]HU[1X3L8--\(:/9V\:)%%9Q* JX!.T9/U)R3[FO%_VFO^96
M_P"WO_VC7N.B?\@#3O\ KUB_]!% 'D?[2<$3>%-&N#&IF2^**^.0K(21]"57
M\A7I?@3_ ))YX:_[!5K_ .BEKSC]I'_D3-*_[" _]%O7H_@3_DGGAK_L%6O_
M **6@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6I&,5&36G<\^&%H5*DY5()N_5)]# _X0KP__ - __P C2?\ Q5'_  A7A_\
MZ!__ )&D_P#BJWZ*CZQ6_G?WLV^HX7_GU'[E_D8'_"%>'_\ H'_^1I/_ (JC
M_A"O#_\ T#__ "-)_P#%5OT4?6*W\[^]A]1PO_/J/W+_ ",#_A"O#_\ T#__
M "-)_P#%4?\ "%>'_P#H'_\ D:3_ .*K?HH^L5OYW][#ZCA?^?4?N7^1@?\
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M "-)_P#%4?\ "%>'_P#H'_\ D:3_ .*K?HH^L5OYW][#ZCA?^?4?N7^1@?\
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M "-)_P#%4?\ "%>'_P#H'_\ D:3_ .*K?HH^L5OYW][#ZCA?^?4?N7^1@?\
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MTG_Q5;]%'UBM_._O8?4<+_SZC]R_R,#_ (0KP_\ ] __ ,C2?_%4?\(5X?\
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MTG_Q5;]%'UBM_._O8?4<+_SZC]R_R,#_ (0KP_\ ] __ ,C2?_%4?\(5X?\
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MTG_Q5;]%'UBM_._O8?4<+_SZC]R_R,#_ (0KP_\ ] __ ,C2?_%4?\(5X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <5\0_ ,_CJVL4M]?N=)>U,F3$A=95<#(90R_P!T8.>YXYXN^!? NF>
MM%-A8,\TLK;[BYDX:5NW'8 < ?U)-=110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<SXV\":/X[TM+/5$=9(2S6]Q$</"Q&#C
MU!P,@]<#T%=-10!XU_PH[6&@%C)\1M8;2\%#9['VE2,$?ZW;SD_P]Z]%\(>#
M-'\$Z.-/TF$C<0TT[\R3-ZL?Y <"N@HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,N\_Y#-K]!_,UJ5EWG
M_(9M?H/YFM2M:GPQ]#FH?'/U_0****R.D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()_P#7P?4U/4$_
M^O@^IJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** (+C[\/^^*GJ"X^_#_ +XJ>@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** (+K[L?^^*GJ"Z^['_OBIZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=:_X]$_ZZ
M?T-:$?\ JU^@K/UK_CT3_KI_0UH1_P"K7Z"M9?PX_,YJ?\>?HAU%%%9'2%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 9=Y_P AFU^@_F:U*R[S_D,VOT'\S6I6M3X8
M^AS4/CGZ_H%%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $$_P#KX/J:GJ"?_7P?4U/0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% $%Q]^'_?%3U!<??A_WQ4] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 077W8_\
M?%3U!=?=C_WQ4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 9NM?\ 'HG_ %T_H:T(_P#5K]!6
M?K7_ !Z)_P!=/Z&M"/\ U:_05K+^''YG-3_CS]$.HHHK(Z0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_\ $T?5E_/'[_\ @!_:+_Y\S^Y?YG:T5Q7V;QW_ ,_UO^4?_P 31]F\=_\
M/];_ )1__$T?5E_/'[_^ ']HO_GS/[E_F=K17%?9O'?_ #_6_P"4?_Q-'V;Q
MW_S_ %O^4?\ \31]67\\?O\ ^ ']HO\ Y\S^Y?YG:T5Q7V;QW_S_ %O^4?\
M\31]F\=_\_UO^4?_ ,31]67\\?O_ . ']HO_ )\S^Y?YG:T5Q7V;QW_S_6_Y
M1_\ Q-'V;QW_ ,_UO^4?_P 31]67\\?O_P" ']HO_GS/[E_F=K17%?9O'?\
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M_/'[_P#@!_:+_P"?,_N7^9VM%<5]F\=_\_UO^4?_ ,31]F\=_P#/];_E'_\
M$T?5E_/'[_\ @!_:+_Y\S^Y?YG:T5Q7V;QW_ ,_UO^4?_P 31]F\=_\ /];_
M )1__$T?5E_/'[_^ ']HO_GS/[E_F=K17%?9O'?_ #_6_P"4?_Q-'V;QW_S_
M %O^4?\ \31]67\\?O\ ^ ']HO\ Y\S^Y?YG:T5Q7V;QW_S_ %O^4?\ \31]
MF\=_\_UO^4?_ ,31]67\\?O_ . ']HO_ )\S^Y?YG:T5Q7V;QW_S_6_Y1_\
MQ-'V;QW_ ,_UO^4?_P 31]67\\?O_P" ']HO_GS/[E_F=K17%?9O'?\ S_6_
MY1__ !-'V;QW_P _UO\ E'_\31]67\\?O_X ?VB_^?,_N7^9VM%<5]F\=_\
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M_P#B:/LWCO\ Y_K?\H__ (FCZLOYX_?_ , /[1?_ #YG]R_S.UHKBOLWCO\
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M7_SYG]R_S.UHKBOLWCO_ )_K?\H__B:/LWCO_G^M_P H_P#XFCZLOYX_?_P
M_M%_\^9_<O\ ,[6BN*^S>._^?ZW_ "C_ /B:/LWCO_G^M_RC_P#B:/JR_GC]
M_P#P _M%_P#/F?W+_,[6BN*^S>._^?ZW_*/_ .)H^S>._P#G^M_RC_\ B:/J
MR_GC]_\ P _M%_\ /F?W+_,[6BN*^S>._P#G^M_RC_\ B:/LWCO_ )_K?\H_
M_B:/JR_GC]__   _M%_\^9_<O\SM:*XK[-X[_P"?ZW_*/_XFC[-X[_Y_K?\
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M_P#/F?W+_,[6BN*^S>._^?ZW_*/_ .)H^S>._P#G^M_RC_\ B:/JR_GC]_\
MP _M%_\ /F?W+_,[6BN*^S>._P#G^M_RC_\ B:/LWCO_ )_K?\H__B:/JR_G
MC]__   _M%_\^9_<O\SKI_\ 7P?4U/7#26WCCS(]U[!NS\O$?_Q-2?9O'?\
MS_6_Y1__ !-'U9?SQ^__ ( ?VB_^?,_N7^9VM%<5]F\=_P#/];_E'_\ $T?9
MO'?_ #_6_P"4?_Q-'U9?SQ^__@!_:+_Y\S^Y?YG:T5Q7V;QW_P _UO\ E'_\
M31]F\=_\_P!;_E'_ /$T?5E_/'[_ /@!_:+_ .?,_N7^9VM%<5]F\=_\_P!;
M_E'_ /$T?9O'?_/];_E'_P#$T?5E_/'[_P#@!_:+_P"?,_N7^9VM%<5]F\=_
M\_UO^4?_ ,31]F\=_P#/];_E'_\ $T?5E_/'[_\ @!_:+_Y\S^Y?YG:T5Q7V
M;QW_ ,_UO^4?_P 31]F\=_\ /];_ )1__$T?5E_/'[_^ ']HO_GS/[E_F=K1
M7%?9O'?_ #_6_P"4?_Q-'V;QW_S_ %O^4?\ \31]67\\?O\ ^ ']HO\ Y\S^
MY?YG:T5Q7V;QW_S_ %O^4?\ \31]F\=_\_UO^4?_ ,31]67\\?O_ . ']HO_
M )\S^Y?YG:T5Q7V;QW_S_6_Y1_\ Q-'V;QW_ ,_UO^4?_P 31]67\\?O_P"
M']HO_GS/[E_F=K17%?9O'?\ S_6_Y1__ !-'V;QW_P _UO\ E'_\31]67\\?
MO_X ?VB_^?,_N7^9VM%<5]F\=_\ /];_ )1__$T?9O'?_/\ 6_Y1_P#Q-'U9
M?SQ^_P#X ?VB_P#GS/[E_F=K17%?9O'?_/\ 6_Y1_P#Q-'V;QW_S_6_Y1_\
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M_GS/[E_F=K17%?9O'?\ S_6_Y1__ !-'V;QW_P _UO\ E'_\31]67\\?O_X
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M #YG]R_S.UHKBOLWCO\ Y_K?\H__ (FC[-X[_P"?ZW_*/_XFCZLOYX_?_P
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M5E_/'[_^ ']HO_GS/[E_F=K17%?9O'?_ #_6_P"4?_Q-'V;QW_S_ %O^4?\
M\31]67\\?O\ ^ ']HO\ Y\S^Y?YG:T5Q7V;QW_S_ %O^4?\ \31]F\=_\_UO
M^4?_ ,31]67\\?O_ . ']HO_ )\S^Y?YG:T5Q7V;QW_S_6_Y1_\ Q-'V;QW_
M ,_UO^4?_P 31]67\\?O_P" ']HO_GS/[E_F=K17%?9O'?\ S_6_Y1__ !-'
MV;QW_P _UO\ E'_\31]67\\?O_X ?VB_^?,_N7^9VM%<5]F\=_\ /];_ )1_
M_$T?9O'?_/\ 6_Y1_P#Q-'U9?SQ^_P#X ?VB_P#GS/[E_F=K17%?9O'?_/\
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M_P"?,_N7^9VM%<5]F\=_\_UO^4?_ ,31]F\=_P#/];_E'_\ $T?5E_/'[_\
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M_P#G^M_RC_\ B:/JR_GC]_\ P _M%_\ /F?W+_,[6BN*^S>._P#G^M_RC_\
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M ,^9_<O\SM:*XK[-X[_Y_K?\H_\ XFC[-X[_ .?ZW_*/_P")H^K+^>/W_P#
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M_P#B:/LWCO\ Y_K?\H__ (FCZLOYX_?_ , /[1?_ #YG]R_S.UHKBOLWCO\
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M7_SYG]R_S.UHKBOLWCO_ )_K?\H__B:/LWCO_G^M_P H_P#XFCZLOYX_?_P
M_M%_\^9_<O\ ,[6BN*^S>._^?ZW_ "C_ /B:/LWCO_G^M_RC_P#B:/JR_GC]
M_P#P _M%_P#/F?W+_,[6BN*^S>._^?ZW_*/_ .)H^S>._P#G^M_RC_\ B:/J
MR_GC]_\ P _M%_\ /F?W+_,[6BN*^S>._P#G^M_RC_\ B:/LWCO_ )_K?\H_
M_B:/JR_GC]__   _M%_\^9_<O\SM:*XK[-X[_P"?ZW_*/_XFC[-X[_Y_K?\
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M_P#/F?W+_,[6BN*^S>._^?ZW_*/_ .)H^S>._P#G^M_RC_\ B:/JR_GC]_\
MP _M%_\ /F?W+_,[6BN*^S>._P#G^M_RC_\ B:M:=;^,5U" WUY UJ&S* $R
M5_!<TGADE?GC]_\ P"HX]RDE[&:OY+_,ZNBBBN8] **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+O/^0S:_0?S-
M:E9=Y_R&;7Z#^9K4K6I\,?0YJ'QS]?T"BBBLCI"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""?\ U\'U
M-3U!/_KX/J:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@""X^_#_OBIZ@N/OP_P"^*GH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@""Z^['_OBIZ@NONQ_[XJ>@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6O^
M/1/^NG]#6A'_ *M?H*S]:_X]$_ZZ?T-:$?\ JU^@K67\./S.:G_'GZ(=1116
M1TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &7>?\ (9M?H/YFM2LN\_Y#-K]!_,UJ
M5K4^&/H<U#XY^OZ!11161TA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!!/\ Z^#ZFIZ@G_U\'U-3T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!!<??A_WQ4]07'WX?]\5/0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%U
M]V/_ 'Q4]077W8_]\5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &;K7_ !Z)_P!=/Z&M"/\
MU:_05GZU_P >B?\ 73^AK0C_ -6OT%:R_AQ^9S4_X\_1#J***R.D**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH R[S_ )#-K]!_,UJ5EWG_ "&;7Z#^9K4K6I\,?0YJ
M'QS]?T"BBBLCI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@""?_7P?4U/4$_^O@^IJ>@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (+C[\/^^*GJ"X^_#_OBIZ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @NONQ_P"^*GJ"
MZ^['_OBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH S=:_P"/1/\ KI_0UH1_ZM?H*S]:_P"/
M1/\ KI_0UH1_ZM?H*UE_#C\SFI_QY^B'4445D=(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2/\ H*V/_@0G^-']N:1_T%;'_P "$_QKQ.BC^RX?S,/]9*O\B_$]L_MS2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $%Q]^'_?%3U!<??A_WQ4] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 077W8_P#?
M%3U!=?=C_P!\5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &;K7_'HG_73^AK0C_U:_05GZU_
MQZ)_UT_H:T(_]6OT%:R_AQ^9S4_X\_1#J***R.D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQ\ZG% 'J=%9WA^ZFOO#>EW=P^^>>SBED; &YF0$G X')K1H **** "BBB@
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M1110 4444 %%%% !1110 4444 077W8_]\5/4%U]V/\ WQ4] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9NM?\>B?]=/Z&M"/_5K]!6?K7_'HG_73^AK0C_U:_05K+^''YG-3
M_CS]$.HHHK(Z0HHHH **** "BBB@ HHKD/'/Q'T3P ED=6CNYGO"_EQVJ*S
M+C).YE 'S"@#KZ*SM!UJT\1:%9:Q8%S;7<0D0.,,N>H(YY!R#@GD5HT %%%%
M !1110 4444 %%%<MX7\?:5XLUG6-+L+>\CGTJ3RYVG10K'<R_+AB3RIZ@4
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MT>0;B2&41P' 'H0TIZ#LQ/.#0![\M_\ 9]&34-56*P*0"6Z5Y0R0';E@7X!
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MA6%6.-DP 4'K]V0CKV'O72?M*?\ (MZ)_P!?;_\ H% 'J_A3_D3]$_Z\(/\
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MF(]SAAGGH/I7T1IFE6&C6$5CIMI%:VL0 6.)<#@8R?4\#D\F@#B? _Q@\/\
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M7ML_T?Z&_1117EGTH4444 %%%% !1110 4444 03_P"O@^IJ>H)_]?!]34]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 07'WX?]\5/4%Q]^'_ 'Q4] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 077W8_]\5/4%U]V/_?%3T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!FZU_QZ)_UT_H:T(_\
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M[9F&B%YHO-Z(FPMLZC@,C'_@5 '?^+_B?X7\%2_9M3NWEO<;OLEJF^0#L3R
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M<=2R_O!Z9 !]: ,K7)D\5_M-6$=@=\=E=P!I$^<'R,._3IR"OX?A72?M*?\
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MWVL\@QTPG!''0MCGH:B\!?#77_ _Q;N;J'3GF\/.LL,5V9XMRQMAE)7=N)!
M4\>^* */[37_ #*W_;W_ .T:]QT3_D :=_UZQ?\ H(KR[XZ>"?$7C'^P?[ T
M_P"V?9?M'G?OHX]N[R]OWV&<[6Z>E>JZ7#);:1902KMDC@1'7.<$* 10!Y'^
MTC_R)FE?]A ?^BWKT?P)_P D\\-?]@JU_P#12UR7QM\)ZWXN\,Z?9Z%9?:YX
MKSS73S4CPNQAG+D#J17:^$[&XTSP;H=A>1^7=6NGV\,R;@=KK&H89'!P0>E
M'A'PF_Y+YXB_[??_ $<*]+^,GC6\\&>#TDTQS%J-[,(89=H;R@!N9L'C.!C\
M<]JX+Q)\,_'V@_$&_P#$O@F59C?323;EEB5X_,.YE99,*1NZ=>@S7;7O@K6O
M'_PJM-+\7O\ 9?$44C3>=B-@L@9@I(C.T@H0#CZXXH X/P?\$F\8Z+9^(_$V
MOWSRWR^=L1@\A0\J3(^>3UZ=ZT_&WPK\$>!_A[J^HK%/->^4L5M-=S[F$C$
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MBBB@ HHHH **** "BBB@""Z^['_OBIZ@NONQ_P"^*GH **** "BBB@ HHHH
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M;W\@ >ZM)-CMCID$%2<<9(SCOP*B\*_![PCX2ODOK6VGO+V,YBGO9 YC/JH
M"@^^,CL: /-/C5>7E_XN\':5K[_8=)EAAFO K?+'(\FV8Y!(.Q0,'MD^M>J0
M^#?A[X:T^.];2=%@MX4#K=72H_ QAM[YYZ<^_O6MXL\':+XTTQ;'6;8R*C;X
MI4.V2(]RK>_<=#^ KBK#]G[P39W?GRC4;Q<Y$-Q<#8/;Y%4D?4T <-\/-9L_
M$'[1&I:IIRXLYXIO)^39E0JJ#CMG&?Q[5J>+I6\"?M!V/BF_W+I&IQA))\':
MF(Q$P.!_#M1L<\'\O1XOAKHEKXTMO%%E)=6EU;PK EO 8Q!L";-NTH2/EXX(
MK>U[P_I?B;29=,U>T2YM)""5;(*D=&4CD'W% ":AXDT;2]&;5[O4K5+ +N6;
MS05?MA3GYCGCBO'?@/J2ZSXT\;ZHJ%%O9EN AZJ'DD;'ZUT=E^S]X)M+\7,@
MU&Z0=+>>X'EYX_NJ&[>O>NI\+^ -'\(ZSK&IZ8]SYFJ2>9+$Y3RX_F9@(PJC
M &XC!)X H \;DM]&\'?'O5D\7Z=:3Z3JY>6":[@66)&E<.)/F!P =Z$]LYZ5
M[!J/A[X>:3ICZE?Z'X;M[)4\PS/90A2O&,?+SG(QCKD8ZUI>)_".A^,+!;/6
M[%;F.,EHF#%7C8C&58$$?3H<#(-<';_L\>"X;KS9)M6N$S_J9+A0G_CJ!OUH
M O\ PH\0Z/XGCU*^T7P;:Z%;Q.(3<0)&OGGKM.U0<@%21R!NKFOA+_R6'XA?
M]?<W_I0]>PZ5I.GZ'IL6G:7:16MI$,)%&, 9Y)]R3W-8?AWP#I7AGQ+K.NV5
MQ>276K2-).DSJ44LY<[0%! R3U)H YKX^?\ )+KC_KZA_P#0JZ?X<?\ )-O#
MG_8/A_\ 015KQ?X3L/&F@/H^HRW,5N\BR%K=E5\J<CE@1^E7M$TF#0=$LM)M
M7D>"SA6&-I2"Q51@9( &?PH \@_YNM_[<_\ VWH^+7_)8?A[_P!?</\ Z4)7
MHO\ P@6E_P#"P?\ A-/M%Y_:7E^5Y6]?)QLV=-N[./\ :H\1> =*\3>)=&UV
M]N+R.ZTF19($A=0C%7#C<"I)&0.A% 'GGQ_L;NTF\,^*K:W,L6F7)$Y'8ED9
M,\' RK#)XR1ZUZSHWB'2M>T:+5M.O(I;-X_,+[@-@QR&_ND<Y!Z8-7;NTM[Z
MTFM+N&.>WF0I)%(NY74\$$5YA>?L]^";J[\Z$ZG:1\?N(+D%/S=6;]: +>@_
M$RY\2_%6\\.Z1!:76AVL)=[Z-B6R  2&W;64NP P/4]*]*K%\,^$M$\(:>;+
M1+%+:-B#(V2SR$=V8\GO[#/&*VJ /$_C_8W=I-X9\56UN98M,N2)R.Q+(R9X
M.!E6&3QDCUKUG1O$.E:]HT6K:=>12V;Q^87W ;!CD-_=(YR#TP:NW=I;WUI-
M:7<,<]O,A22*1=RNIX((KS"\_9[\$W5WYT)U.TCX_<07(*?FZLWZT 6-(^(T
MWB[XFZAX7TRWM+OP_#;-YM]&<L?EP2#NVLI9@HP/4\BN.^"VLV_@KQ!KO@K7
MYEL[O[0'@:4[4=@"&&<X&5"D>H_#/LGAGPEHGA#3S9:)8I;1L09&R6>0CNS'
MD]_89XQ6=XN^'/AKQL4DU:S/VI %6Z@;9*%!SMST(Y/4'KQ0!)X[\7:;X1\,
M7MW>W$0N#"PMK8N \SD8  ZXR1D]ADUQO[/NAW.E^ YKVZB:,ZC<F:(,""8@
MH"GGU.XCVP:MZ-\!?!6D7@N98[W4BI!6.^E5D!_W45<_0Y'%>FJH50J@!0,
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M: .?\#Z'<Z)^SEKQNHFBEOK&]N]C@A@IA*J2#ZA 1[$5M_ /_DEUO_U]3?\
MH5>A:MIL.LZ-?:7<-(L%[;R6\C1D!@KJ5)&01G!]#6=X0\)V'@O0$T?3I;F6
MW21I UPRL^6.3RH _2@#RW]I+4-0@T#1;&!F6PN9Y&N=O&YD"[%/M\S''JH/
M:NPT+P#\.M/\/VMY#INDW=F8@XO;M5E$@P26)?(]?ICVKJ_$'A[3/%&CS:7J
M]LMQ:R\X/!5AT93U!'K_ $KSR']GKP5%=^<\FJS1_P#/![A0GYJH;]: .$N-
M>TGQ!^T=HD^BF-K*WD2V62) J.5#9*XZC)P#WQZ<UTO[2:,?"^BN!\HO6!/N
M4./Y&NUN_A3X<GU71=0L_M.FR:/C[+'9E G#[_F#*V3DG)ZG-;_B?POI7B_1
M7TK6(#+;LP=2IPT;CHRGL>2/H2.AH 9)=6]YX*GFMIDFB:P;#(V1_JZ\O^!%
M@NJ_"+7M.8@+=WMQ 21D -!$O]:[;PA\+]%\%6NJV^FW>HRQZG&L<_VB1&("
MA@"NU!@_.>N:TO!7@K3? >C3:7I<]W-!+<-<,UTZLP8JJX&U5&,(.WK0!Y;\
M"/$=MH*ZIX*UJ3[%JD5Z\L<<[ !CM570'.,@IG'?)(SS7?\ Q2\7:;X8\$ZF
MEQ<1&^N[9X+:UWC?(7!7=MZ[5SDGVQU(J;Q?\,/"_C67[3J=H\5[C;]KM7V2
M$=@>"&_$'&*Q] ^!G@O0;Y+PP76HRQG=&+^5753Z[550?Q!H H?"?0[G1/@M
M=&ZB:*6^6XN]C@A@I3:I(/J$!'L15?\ 9Q_Y)YJ'_85D_P#145>M75NEW9SV
MTA8)-&T;%>H!&#BL'P5X*TWP'HTVEZ7/=S02W#7#-=.K,&*JN!M51C"#MZT
M<'^T=_R3S3_^PK'_ .BI:])\*?\ (GZ)_P!>$'_HM:I>-?!6F^/-&ATO5)[N
M&"*X6X5K5U5BP5EP=RL,8<]O2MO3[*/3=-M;&%G:*VA2%"Y!8JH &<=^* +-
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*[ZBBOG:U:5:7-(^_P '@Z>$I^SI_-]PHHHK$Z@HHHH **** "BBB@ HHHH
M**** ()_]?!]34]03_Z^#ZFIZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N/OP_[XJ>H+C[\
M/^^*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@""Z^['_ +XJ>H+K[L?^^*GH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#-UK_ (]$_P"NG]#6A'_JU^@K/UK_ (]$_P"NG]#6A'_JU^@K67\.
M/S.:G_'GZ(=11161TA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (+C[\/\ OBIZ@N/OP_[XJ>@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+
MK[L?^^*GJ"Z^['_OBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=:_X]$_ZZ?T-:$?^K7Z"
ML_6O^/1/^NG]#6A'_JU^@K67\./S.:G_ !Y^B'4445D=(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!EWG_(9M?H/YFM2LN\_Y#-K]!_,UJ5K4^&/H<U#XY^OZ!111
M61TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!!/_ *^#ZFIZ@G_U\'U-3T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!<
M??A_WQ4]07'WX?\ ?%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!!=?=C_WQ4]077W8_]\5/
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &;K7_'HG_73^AK0C_P!6OT%9^M?\>B?]=/Z&M"/_
M %:_05K+^''YG-3_ (\_1#J***R.D**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R[S
M_D,VOT'\S6I67>?\AFU^@_F:U*UJ?#'T.:A\<_7] HHHK(Z0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M @G_ -?!]34]03_Z^#ZFIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N/OP_[XJ>H+C[\/\
MOBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH @NONQ_[XJ>H+K[L?^^*GH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#-UK_CT3_KI_0UH1_P"K7Z"L_6O^/1/^NG]#6A'_ *M?H*UE_#C\SFI_
MQY^B'4445D=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^K_C1_:=A_S_ %M_W]7_ !HY)=@]K#^9%JBJO]IV'_/];?\ ?U?\:/[3L/\
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MYD6J*J_VG8?\_P!;?]_5_P :/[3L/^?ZV_[^K_C1R2[![6'\R+5%5?[3L/\
MG^MO^_J_XT?VG8?\_P!;?]_5_P :.278/:P_F1:HJK_:=A_S_6W_ ']7_&C^
MT[#_ )_K;_OZO^-')+L'M8?S(M455_M.P_Y_K;_OZO\ C1_:=A_S_6W_ ']7
M_&CDEV#VL/YD6J*J_P!IV'_/];?]_5_QH_M.P_Y_K;_OZO\ C1R2[![6'\R+
M5%5?[3L/^?ZV_P"_J_XT?VG8?\_UM_W]7_&CDEV#VL/YD6J*J_VG8?\ /];?
M]_5_QH_M.P_Y_K;_ +^K_C1R2[![6'\R+5%5?[3L/^?ZV_[^K_C1_:=A_P _
MUM_W]7_&CDEV#VL/YD6J*J_VG8?\_P!;?]_5_P :/[3L/^?ZV_[^K_C1R2[!
M[6'\R+5%5?[3L/\ G^MO^_J_XT?VG8?\_P!;?]_5_P :.278/:P_F1:HJK_:
M=A_S_6W_ ']7_&C^T[#_ )_K;_OZO^-')+L'M8?S(?/_ *^#ZFIZSIM2L3-"
M1>VW!/\ RU7_ !J?^T[#_G^MO^_J_P"-')+L'M8?S(M455_M.P_Y_K;_ +^K
M_C1_:=A_S_6W_?U?\:.278/:P_F1:HJK_:=A_P _UM_W]7_&C^T[#_G^MO\
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M_C1_:=A_S_6W_?U?\:.278/:P_F1:HJK_:=A_P _UM_W]7_&C^T[#_G^MO\
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M[#_G^MO^_J_XT?VG8?\ /];?]_5_QHY)=@]K#^9%JBJO]IV'_/\ 6W_?U?\
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MYD6J*J_VG8?\_P!;?]_5_P :/[3L/^?ZV_[^K_C1R2[![6'\R+5%5?[3L/\
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M=A_S_6W_ ']7_&C^T[#_ )_K;_OZO^-')+L'M8?S(M455_M.P_Y_K;_OZO\
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M'\R+5%5?[3L/^?ZV_P"_J_XT?VG8?\_UM_W]7_&CDEV#VL/YD6J*J_VG8?\
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M_OW?_?P?X4?\*^T;^_=_]_!_A75T4?6Z_P#,P_LS!_\ /M'*?\*^T;^_=_\
M?P?X4?\ "OM&_OW?_?P?X5U=%'UNO_,P_LS!_P#/M'*?\*^T;^_=_P#?P?X4
M?\*^T;^_=_\ ?P?X5U=%'UNO_,P_LS!_\^T<I_PK[1O[]W_W\'^%'_"OM&_O
MW?\ W\'^%=711];K_P S#^S,'_S[1RG_  K[1O[]W_W\'^%'_"OM&_OW?_?P
M?X5U=%'UNO\ S,/[,P?_ #[1RG_"OM&_OW?_ '\'^%'_  K[1O[]W_W\'^%=
M711];K_S,/[,P?\ S[1RG_"OM&_OW?\ W\'^%'_"OM&_OW?_ '\'^%=711];
MK_S,/[,P?_/M'*?\*^T;^_=_]_!_A1_PK[1O[]W_ -_!_A75T4?6Z_\ ,P_L
MS!_\^T<I_P *^T;^_=_]_!_A1_PK[1O[]W_W\'^%=711];K_ ,S#^S,'_P ^
MT<I_PK[1O[]W_P!_!_A1_P *^T;^_=_]_!_A75T4?6Z_\S#^S,'_ ,^T<I_P
MK[1O[]W_ -_!_A1_PK[1O[]W_P!_!_A75T4?6Z_\S#^S,'_S[1RG_"OM&_OW
M?_?P?X4?\*^T;^_=_P#?P?X5U=%'UNO_ #,/[,P?_/M'*?\ "OM&_OW?_?P?
MX4?\*^T;^_=_]_!_A75T4?6Z_P#,P_LS!_\ /M'(2> M'26-0]UAC@_O!_A4
MG_"OM&_OW?\ W\'^%=)/_KX/J:GH^MU_YF/^S,'_ ,^T<I_PK[1O[]W_ -_!
M_A1_PK[1O[]W_P!_!_A75T4?6Z_\S%_9F#_Y]HY3_A7VC?W[O_OX/\*/^%?:
M-_?N_P#OX/\ "NKHH^MU_P"9A_9F#_Y]HY3_ (5]HW]^[_[^#_"C_A7VC?W[
MO_OX/\*ZNBCZW7_F8?V9@_\ GVCE/^%?:-_?N_\ OX/\*/\ A7VC?W[O_OX/
M\*ZNBCZW7_F8?V9@_P#GVCE/^%?:-_?N_P#OX/\ "C_A7VC?W[O_ +^#_"NK
MHH^MU_YF']F8/_GVCE/^%?:-_?N_^_@_PH_X5]HW]^[_ ._@_P *ZNBCZW7_
M )F']F8/_GVCE/\ A7VC?W[O_OX/\*/^%?:-_?N_^_@_PKJZ*/K=?^9A_9F#
M_P"?:.4_X5]HW]^[_P"_@_PH_P"%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_ .?:
M.4_X5]HW]^[_ ._@_P */^%?:-_?N_\ OX/\*ZNBCZW7_F8?V9@_^?:.4_X5
M]HW]^[_[^#_"C_A7VC?W[O\ [^#_  KJZ*/K=?\ F8?V9@_^?:.4_P"%?:-_
M?N_^_@_PH_X5]HW]^[_[^#_"NKHH^MU_YF']F8/_ )]HY3_A7VC?W[O_ +^#
M_"C_ (5]HW]^[_[^#_"NKHH^MU_YF']F8/\ Y]HY3_A7VC?W[O\ [^#_  H_
MX5]HW]^[_P"_@_PKJZ*/K=?^9A_9F#_Y]HY3_A7VC?W[O_OX/\*/^%?:-_?N
M_P#OX/\ "NKHH^MU_P"9A_9F#_Y]HY3_ (5]HW]^[_[^#_"C_A7VC?W[O_OX
M/\*ZNBCZW7_F8?V9@_\ GVCE/^%?:-_?N_\ OX/\*/\ A7VC?W[O_OX/\*ZN
MBCZW7_F8?V9@_P#GVCE/^%?:-_?N_P#OX/\ "C_A7VC?W[O_ +^#_"NKHH^M
MU_YF']F8/_GVCE/^%?:-_?N_^_@_PH_X5]HW]^[_ ._@_P *ZNBCZW7_ )F'
M]F8/_GVCE/\ A7VC?W[O_OX/\*/^%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_P"?
M:.4_X5]HW]^[_P"_@_PH_P"%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_ .?:.4_X
M5]HW]^[_ ._@_P */^%?:-_?N_\ OX/\*ZNBCZW7_F8?V9@_^?:.4_X5]HW]
M^[_[^#_"C_A7VC?W[O\ [^#_  KJZ*/K=?\ F8?V9@_^?:.4_P"%?:-_?N_^
M_@_PH_X5]HW]^[_[^#_"NKHH^MU_YF']F8/_ )]HY3_A7VC?W[O_ +^#_"C_
M (5]HW]^[_[^#_"NKHH^MU_YF']F8/\ Y]HY3_A7VC?W[O\ [^#_  H_X5]H
MW]^[_P"_@_PKJZ*/K=?^9A_9F#_Y]HY3_A7VC?W[O_OX/\*/^%?:-_?N_P#O
MX/\ "NKHH^MU_P"9A_9F#_Y]HY"7P%HZ-& ]U\S8/[P?X5)_PK[1O[]W_P!_
M!_A727'WX?\ ?%3T?6Z_\S#^S,'_ ,^T<I_PK[1O[]W_ -_!_A1_PK[1O[]W
M_P!_!_A75T4?6Z_\S#^S,'_S[1RG_"OM&_OW?_?P?X4?\*^T;^_=_P#?P?X5
MU=%'UNO_ #,/[,P?_/M'*?\ "OM&_OW?_?P?X4?\*^T;^_=_]_!_A75T4?6Z
M_P#,P_LS!_\ /M'*?\*^T;^_=_\ ?P?X4?\ "OM&_OW?_?P?X5U=%'UNO_,P
M_LS!_P#/M'*?\*^T;^_=_P#?P?X4?\*^T;^_=_\ ?P?X5U=%'UNO_,P_LS!_
M\^T<I_PK[1O[]W_W\'^%'_"OM&_OW?\ W\'^%=711];K_P S#^S,'_S[1RG_
M  K[1O[]W_W\'^%'_"OM&_OW?_?P?X5U=%'UNO\ S,/[,P?_ #[1RG_"OM&_
MOW?_ '\'^%'_  K[1O[]W_W\'^%=711];K_S,/[,P?\ S[1RG_"OM&_OW?\
MW\'^%'_"OM&_OW?_ '\'^%=711];K_S,/[,P?_/M'*?\*^T;^_=_]_!_A1_P
MK[1O[]W_ -_!_A75T4?6Z_\ ,P_LS!_\^T<I_P *^T;^_=_]_!_A1_PK[1O[
M]W_W\'^%=711];K_ ,S#^S,'_P ^T<I_PK[1O[]W_P!_!_A1_P *^T;^_=_]
M_!_A75T4?6Z_\S#^S,'_ ,^T<I_PK[1O[]W_ -_!_A1_PK[1O[]W_P!_!_A7
M5T4?6Z_\S#^S,'_S[1RG_"OM&_OW?_?P?X4?\*^T;^_=_P#?P?X5U=%'UNO_
M #,/[,P?_/M'*?\ "OM&_OW?_?P?X4?\*^T;^_=_]_!_A75T4?6Z_P#,P_LS
M!_\ /M'*?\*^T;^_=_\ ?P?X4?\ "OM&_OW?_?P?X5U=%'UNO_,P_LS!_P#/
MM'*?\*^T;^_=_P#?P?X4?\*^T;^_=_\ ?P?X5U=%'UNO_,P_LS!_\^T<I_PK
M[1O[]W_W\'^%'_"OM&_OW?\ W\'^%=711];K_P S#^S,'_S[1RG_  K[1O[]
MW_W\'^%'_"OM&_OW?_?P?X5U=%'UNO\ S,/[,P?_ #[1RG_"OM&_OW?_ '\'
M^%'_  K[1O[]W_W\'^%=711];K_S,/[,P?\ S[1RG_"OM&_OW?\ W\'^%'_"
MOM&_OW?_ '\'^%=711];K_S,/[,P?_/M'*?\*^T;^_=_]_!_A1_PK[1O[]W_
M -_!_A75T4?6Z_\ ,P_LS!_\^T<I_P *^T;^_=_]_!_A1_PK[1O[]W_W\'^%
M=711];K_ ,S#^S,'_P ^T<I_PK[1O[]W_P!_!_A1_P *^T;^_=_]_!_A75T4
M?6Z_\S#^S,'_ ,^T<I_PK[1O[]W_ -_!_A1_PK[1O[]W_P!_!_A75T4?6Z_\
MS#^S,'_S[1RG_"OM&_OW?_?P?X4?\*^T;^_=_P#?P?X5U=%'UNO_ #,/[,P?
M_/M'(3^ M'C52KW7+ <R#_"I/^%?:-_?N_\ OX/\*Z2Z^['_ +XJ>CZW7_F8
M?V9@_P#GVCE/^%?:-_?N_P#OX/\ "C_A7VC?W[O_ +^#_"NKHH^MU_YF']F8
M/_GVCE/^%?:-_?N_^_@_PH_X5]HW]^[_ ._@_P *ZNBCZW7_ )F']F8/_GVC
ME/\ A7VC?W[O_OX/\*/^%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_P"?:.4_X5]H
MW]^[_P"_@_PH_P"%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_ .?:.4_X5]HW]^[_
M ._@_P */^%?:-_?N_\ OX/\*ZNBCZW7_F8?V9@_^?:.4_X5]HW]^[_[^#_"
MC_A7VC?W[O\ [^#_  KJZ*/K=?\ F8?V9@_^?:.4_P"%?:-_?N_^_@_PH_X5
M]HW]^[_[^#_"NKHH^MU_YF']F8/_ )]HY3_A7VC?W[O_ +^#_"C_ (5]HW]^
M[_[^#_"NKHH^MU_YF']F8/\ Y]HY3_A7VC?W[O\ [^#_  H_X5]HW]^[_P"_
M@_PKJZ*/K=?^9A_9F#_Y]HY3_A7VC?W[O_OX/\*/^%?:-_?N_P#OX/\ "NKH
MH^MU_P"9A_9F#_Y]HY3_ (5]HW]^[_[^#_"C_A7VC?W[O_OX/\*ZNBCZW7_F
M8?V9@_\ GVCE/^%?:-_?N_\ OX/\*/\ A7VC?W[O_OX/\*ZNBCZW7_F8?V9@
M_P#GVCE/^%?:-_?N_P#OX/\ "C_A7VC?W[O_ +^#_"NKHH^MU_YF']F8/_GV
MCE/^%?:-_?N_^_@_PH_X5]HW]^[_ ._@_P *ZNBCZW7_ )F']F8/_GVCE/\
MA7VC?W[O_OX/\*/^%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_P"?:.4_X5]HW]^[
M_P"_@_PH_P"%?:-_?N_^_@_PKJZ*/K=?^9A_9F#_ .?:.4_X5]HW]^[_ ._@
M_P */^%?:-_?N_\ OX/\*ZNBCZW7_F8?V9@_^?:.4_X5]HW]^[_[^#_"C_A7
MVC?W[O\ [^#_  KJZ*/K=?\ F8?V9@_^?:.4_P"%?:-_?N_^_@_PH_X5]HW]
M^[_[^#_"NKHH^MU_YF']F8/_ )]HY3_A7VC?W[O_ +^#_"C_ (5]HW]^[_[^
M#_"NKHH^MU_YF']F8/\ Y]HY3_A7VC?W[O\ [^#_  H_X5]HW]^[_P"_@_PK
MJZ*/K=?^9A_9F#_Y]HY3_A7VC?W[O_OX/\*/^%?:-_?N_P#OX/\ "NKHH^MU
M_P"9A_9F#_Y]HY3_ (5]HW]^[_[^#_"C_A7VC?W[O_OX/\*ZNBCZW7_F8?V9
M@_\ GVCE/^%?:-_?N_\ OX/\*/\ A7VC?W[O_OX/\*ZNBCZW7_F8?V9@_P#G
MVCE/^%?:-_?N_P#OX/\ "C_A7VC?W[O_ +^#_"NKHH^MU_YF']F8/_GVCE/^
M%?:-_?N_^_@_PH_X5]HW]^[_ ._@_P *ZNBCZW7_ )F']F8/_GVCB-1\$:5:
M0*\;W.2V.7'H?:K:_#_1BBDO=<C_ )Z#_"MK6O\ CT3_ *Z?T-:$?^K7Z"M)
M8FMR)\SZF$,NPCK2C[-6T.6_X5]HW]^[_P"_@_PH_P"%?:-_?N_^_@_PKJZ*
MS^MU_P"9F_\ 9F#_ .?:.4_X5]HW]^[_ ._@_P */^%?:-_?N_\ OX/\*ZNB
MCZW7_F8?V9@_^?:.4_X5]HW]^[_[^#_"C_A7VC?W[O\ [^#_  KJZ*/K=?\
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M#_"C_A7VC?W[O_OX/\*ZNBCZW7_F8?V9@_\ GVCE/^%?:-_?N_\ OX/\*/\
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MW[O_ +^#_"C_ (5]HW]^[_[^#_"NKHH^MU_YF']F8/\ Y]HY3_A7VC?W[O\
M[^#_  H_X5]HW]^[_P"_@_PKJZ*/K=?^9A_9F#_Y]HY3_A7VC?W[O_OX/\*/
M^%?:-_?N_P#OX/\ "NKHH^MU_P"9A_9F#_Y]HY3_ (5]HW]^[_[^#_"C_A7V
MC?W[O_OX/\*ZNBCZW7_F8?V9@_\ GVCE/^%?:-_?N_\ OX/\*/\ A7VC?W[O
M_OX/\*ZNBCZW7_F8?V9@_P#GVCE/^%?:-_?N_P#OX/\ "C_A7VC?W[O_ +^#
M_"NKHH^MU_YF']F8/_GVCE/^%?:-_?N_^_@_PH_X5]HW]^[_ ._@_P *ZNBC
MZW7_ )F']F8/_GVCE/\ A7VC?W[O_OX/\*/^%?:-_?N_^_@_PKJZ*/K=?^9A
M_9F#_P"?:.4_X5]HW]^[_P"_@_PJQ9>"=*L+V&[A:Y,D3;EW.",_E71T4GBJ
MS5G)E1RW"1:DJ:N@HHHK [0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,N\_P"0S:_0?S-:E9=Y_P AFU^@_F:U
M*UJ?#'T.:A\<_7] HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH @G_U\'U-3U!/_KX/J:GH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@""X^_#_OBIZ@N/OP_[XJ>@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+K[
ML?\ OBIZ@NONQ_[XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6O\ CT3_ *Z?T-:$?^K7
MZ"L_6O\ CT3_ *Z?T-:$?^K7Z"M9?PX_,YJ?\>?HAU%%%9'2%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9=Y_R&;7Z#^9K4K+O/\ D,VOT'\S6I6M3X8^AS4/CGZ_
MH%%%%9'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $$_^O@^IJ>H)_\ 7P?4U/0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $%Q]^'_?%3U!<??A_WQ4] !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 077W8_P#?%3U!=?=C
M_P!\5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &;K7_'HG_73^AK0C_U:_05GZU_QZ)_UT_H
M:T(_]6OT%:R_AQ^9S4_X\_1#J***R.D**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNS&CXV;>/OX^]VH [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<""UA>5E58XCLR=IR<LIXX'4X.:ZCX^?\DNN/^OJ'_T*M?X0?\DHT#_KB_\
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MI%Z.K#((]B#0!-7S1\?O^2JZ+_UX0?\ H^6OI>OFCX_?\E5T7_KP@_\ 1\M
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M^&J]% %C[==_\_4__?PT?;KO_GZG_P"_AJO10!8^W7?_ #]3_P#?PT?;KO\
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M_P#/U/\ ]_#5>B@"Q]NN_P#GZG_[^&C[==_\_4__ '\-5Z* +'VZ[_Y^I_\
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M_P#/U/\ ]_#5>B@"Q]NN_P#GZG_[^&C[==_\_4__ '\-5Z* +'VZ[_Y^I_\
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MKO\ Y^I_^_AJO10!8^W7?_/U/_W\-'VZ[_Y^I_\ OX:KT4 6/MUW_P _4_\
MW\-'VZ[_ .?J?_OX:KT4 6/MUW_S]3_]_#1]NN_^?J?_ +^&J]% %C[==_\
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MVH5^GS<^GT+I>G6VCZ5::;9J5MK2%(8@3D[5  R>YXZU;HH *\!_:-\."/\
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MS5M/DTGP_:#Y=RL %)!8(3@N[8 ST  ],'Z-BB2"%(HE"QHH55'0 < 4^B@
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MADW = 22,^O'<9Z[X;?%)/B3-?Z;<Z.EF\%NK/BX\P2AOE;C:"!T[GK7IE%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(_M*?\BWHG_7V_\ Z!7MU8?B7PAH7B^V@M]=L?M<4#EXU\YX]K$8S\C#-;E
M'A%M_P G:WG_ %Q'_I(E'Q/CNO _Q:T7X@+:27&FLHBN/+ZJ^UHV'/ RC KS
MR0>G6O65\&: GBU_%*V&-:<;6N?.DY&P)]W=M^Z .E;%U:6U]:R6MW;Q7%O*
M-LD4R!T<>A!X(H YA/BAX(?2O[1_X273UA";S&91YP'IY7WR?8"O-OAXEWX\
M^,FI^/!:/#I%NKPVLCJ!O.P1J/KL)8XS@G'>N]_X4YX ^U_:?^$<A\S.<>?+
ML_[XW;?PQ79VMI;6-K':VEO%;V\0VQQ0H$1!Z #@"@#Q?4O^3KM'_P"O1O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIR(TCA$4LS'
M  [T 7=.O9(I$A.7C9P=HZ@^U=;6/:Z8ME#&[X:=G&3Z>PK8H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#-UK_CT3_KI_0UH1_P"K7Z"L_6O^/1/^NG]#6A'_ *M?H*UE_#C\
MSFI_QY^B'4445D=(4444 %%%% !1110 45YY\7?'NH> _#]K/IEO!)=7<QB5
MY\E8P%SG:,9/XX^M=[:NTEG!(YRS1J2?4D4 34444 %%%% !1110 4444 %%
M<[X^N9[/X?Z_<VL\D$\5C*\<L3E61@IP01R#6'\&=0O=4^&6GW>H7EQ=W+R3
M!IKB5I'.)& RQ)/2@#OJ*** "BBB@#(U[PMH?BB!(=:TR"\2,Y0R##+]&&"/
MSK#TSX3>!=(NTNK3P]!YR$,K3223!2.00'8C-=G10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !6'K?A#0O$6HZ??ZK8_:+K3WWVK^<Z>6V0<X
M5@#RHZYZ5N44 %%%% !1110 4444 <KH_P -_"&@ZP=6TS0X(+TDLLFYV"$Y
MSL5B0G4CY0..*ZJBB@ HHHH ***QO%FMOX;\)ZGK,<"SO9P-(L;-M#'MDT ;
M-%<A\,O$M_XN\#VNM:D(A<SRR@K"NU% <@  DGH.Y-=?0 4444 %%%>/?M Z
MUJNBZ!H\FE:G>6,DETRNUK.T18;.A*D9% 'L-%>'1?"KXB30I*OQ+U *ZAAF
MZN,\_P# ZR_$.D?%+X:V*:_'XMFU>R@<&XCFE>4*"0/F63.5/ R#D9[=: /H
M6BN/\.^+X_%_PW?7+<^5<&UD698\CRIE4[@#UZ\CV(KF_@%JVI:SX%OKC5-0
MN[Z==3D19+J9I6"^5$< L2<9)./<T >J4444 %%%% !1110 4444 %%%% !1
M17 ?%CQ_+X&\/P_8(UDU;4':*U##(3 &Y\=\94 >K#Z4 =_17B]O\./B7J5H
MNJ7_ ,1;NTU1P)!9Q;Q"IZA6VLJCT("$?45I_"KQ[K6K:QJGA+Q6JC6]-R1(
M%"F55.ULXX)!*D$?>#9[9(!ZK1110 4444 %%%% !1110 5F:YX=T?Q):+:Z
MSIT%["IW*LJY*GID'J#]*TZ* .)L?A#X#TZY2XM_#L)D1@R^=-+* 1TX=B*[
M55"J%4 *!@ =!2T4 %%%% !1110 4444 %%%% !1110 4444 >3?M#PW<GPX
MA>W$AACU")KG8#@)M< M[;BHY[D5H?!'5-#N?AW86.F2P+>6ZL;RW! E$A8Y
M=AU(/&#TQ@<8P/0[NTM[ZTFM+N&.>WF0I)%(NY74\$$5X=XB_9U0W+W?A;63
M:,3E+:Z#$+QVD7+8^H/7K0![O7C_ /PI^_L/BW%XJT6YL;/3$N4F^S*S!\$8
ME4 +@ Y; SW[5QK:3\;_  5O-K=7VH6L>%!BE6]4@= L;Y<# [**Z[X<_&W^
MWM5C\/\ B>UCL=3=O*AG3*I+)G&QE/*.?K@GCC@$ ]DKR3Q-\?O#^C:BUAI%
MG-K4J':TL,@2$MV"M@EN>X&/0FMCXV:]+H7PSO3;NR3WLB6:.K;2H;);ZY56
M'XUD_ OP7IVD^#[7Q"\"R:KJ"LWG.O,4>X@*N>@(&2>^?0"@#/T?]HK2;C4%
MMM<T2YTE"<&82^>$&,Y8!5;\@:]5U*Y@O/"UY=6TJ2P363R1R(<JZE"00>X(
M-8GQ%\"VOCKPU-9F.!=2C7=9W,@P8W]"P!(4]"!_,"J?A3PQJ7@_X97FBZE?
M0WCP0SF)X@P"HRYV\]<,6]."* .#_9H_Y!GB+_KM!_)Z]@\1>)M(\*:6VHZS
M>);0 [5SRTC8SM4=2>*\?_9H_P"09XB_Z[0?R>N;^+>MVGB#XQ6FC:M?O;Z%
MI[Q0SLI8A<X:1@!GYL';G'\(]* .GN?VD8#+(=.\*75S;IDF26Z$9"]B0J,!
MW[]J[+P/\8/#_C6[73T66PU)@2EM.01)@ G:PX)Z\<'@\4:9\2OAEHUA%8Z;
MK-E:VL0 6.*&0#@8R?EY/ Y/)KQ_XP:GX-O[[3=?\'ZA;+J:3'[2+:)HRQ'S
M))R ,@@\]3D>E 'TEKNI_P!B>'M3U;R?.^PVDMSY6[;OV(6VYP<9QC.#7E,/
M[0NF-X7.HRZ+*-2DNFM[?3HKC>7"JAWL^P;1\^ ,$DCZX[#4]7.O_!+4-6*A
M7N] FE=0<[6,#;A^>:\Q_9NT*VEEUC79D1[B$I;0$J"8\@ER/0D;1QVSZT >
MA?#CXH_\+ N[VU&A7%@]F@:5S,)(U). I.%.XX8]/X34/C3XT^'/"%_)IJI-
MJ6H1Y$L5O@)$W]UG/?V .,'.*W_B%K!\,>!-<UJU"Q7B6X1)E0%@[$(A]\%\
M\UY=^S_X+L;G3;GQ7J5LMQ=O.T-J9<.$4 ;G _O$DC)YX]^0">T_:0M_/A_M
M+PK<VEO(1^]CNO,.WN0"BY[=Z]?\/^(=,\4:/#JFD7*W%K+QD<%6'56'4$>G
M]*DUK1-.\0Z5/IFJVL=S:3##(XZ'L0>Q'8CD5\^_"R:Y\$_&S4/" N&DLKB2
M:WPQX)0%XW/^UM&/^!&@#VSQIXZT7P)IL=WJTCEYB5@MXAF24@<X'H,C)/ R
M/45Y<?VDD+O(GA&X:S4X\[[9S^(\O /3O65\>TEL/B-X>U74+9[S1UACS >$
M?9*6DCSTRRE>??VKTW0/BYX!UBW2WAU6#3\I_P >]ZGD!!CH2?D_)C0!<\#_
M !.\/^//,AT]I;>^B0/):7( ?'<K@D, >_TR!FG_ !'\=?\ "O\ P];ZM_9W
MV_SKM;;RO/\ *QE';=G:W]S&,=ZP](^%>E6WQ"'C;1-76*U=C)'9VD2F([E*
MOALD%3DG  P3QT%9?[1W_)/-/_["L?\ Z*EH ])\+:Y_PDOA?3M:^S_9OMD(
ME\G?OV9[;L#/Y5PGC/XYZ#X5U.XTNUM9M4OK=BDHC<)&CCJI<YY'0X!P>.M=
M%\, S?"S0 C;&-D &QG!YYQ7@GPO\4Z1\/\ QAJZ>+K*8WKMY0NS'YCV[JS;
M\@_-\QQR,GY1QSD '>67[1UB+I8M8\,WMBC=6BF$I [':RIQG/\ ]>O8-&UG
M3_$&DV^J:7<I<6DZ[D=?U!'8CH0>0:Y/4-5\#?$WP]/H\6M:;</=(R0!V"S1
M28^5UC;#Y!(^O3UJ[\// P\ Z%+I:ZI+?I),9MSQ! K$ ':,D@' XR?UH ZZ
MBBHKF86UK+.V-L:%SDX' SUH \#UZ1OB'^T/9:,<2Z5HK_.H(*_N\-)GZN%0
MCGIV[?0-?._[.:/J'B?Q)J]R3)=&) \I7DF1V9OIDIG\*^B* .;\?>)?^$2\
M$:IK"%/M$46VW#=#*QVKQWP3DCT!KR3X2>!%UOX5>(YKI09]<W0P22+NP(\[
M7R?^FN2?]P<^C/VB?$#W&HZ/X5@G1%_X^KC<X"[F.V/<>V &//\ >!KU#P]X
M@\#^'/#UAHUIXKT0PV<*Q!CJ$.7(ZL?FZDY/XT ><_L[>)66/5/"5X95G@8W
M4"29^49"R)@_=PVTX]68^M>\5\M^)]<T[PG\=XO$6B:I:76G7,L=S<-9RB1
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MSQ%_Q]0_[G]:QJV?$7_'U#_N?UK&IO<F&WW_ )A1112*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*XBG?>  Z @-Z<T_Q/Y'_#3_ (8\K;O^Q#S<?WL3=?\ @.VF_%M0WQ@^'RL
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MDEA]WG@8Q@FM#Q6GCWX1S6.MMXPN==T^>Y$4T-WNP3@MMVLS!00&Y4@\5I?
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MD=]I!!'XCG%=8RAE*L 5(P0>AKPK]G%65O%BQL3:"> 1 /E<_O<D?AMY[X%
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M \%28MS],]/?->C_  U^'-I\/M'FA6<7>H73!KBYV;00/NHHR<*,GW))/H
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M#_"@#F:*Z;_A'K3_ )Z3_P#?0_PH_P"$>M/^>D__ 'T/\* .9HKIO^$>M/\
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MM/\ GI/_ -]#_"C_ (1ZT_YZ3_\ ?0_PH YFBNF_X1ZT_P">D_\ WT/\*/\
MA'K3_GI/_P!]#_"@#F:*Z;_A'K3_ )Z3_P#?0_PH_P"$>M/^>D__ 'T/\* .
M9HKIO^$>M/\ GI/_ -]#_"C_ (1ZT_YZ3_\ ?0_PH YFBNF_X1ZT_P">D_\
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M0_PH_P"$>M/^>D__ 'T/\* .9HKIO^$>M/\ GI/_ -]#_"C_ (1ZT_YZ3_\
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M#_"@#F:*Z;_A'K3_ )Z3_P#?0_PH_P"$>M/^>D__ 'T/\* .9HKIO^$>M/\
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M4 <S173?\(]:?\])_P#OH?X4?\(]:?\ /2?_ +Z'^% ',T5TW_"/6G_/2?\
M[Z'^%'_"/6G_ #TG_P"^A_A0!S-%=-_PCUI_STG_ .^A_A1_PCUI_P ])_\
MOH?X4 <S173?\(]:?\])_P#OH?X4?\(]:?\ /2?_ +Z'^% ',T5TW_"/6G_/
M2?\ [Z'^%'_"/6G_ #TG_P"^A_A0!S:(TCA$4LS'  [UU.EZ6MDF]\-.PY/]
MWV%26>EV]BY>/<SG^)R"1]*NT %%%% $%U]V/_?%3U!=?=C_ -\5/0 4444
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M+:T&"8LC 8X)"X7Y0.3R2>:]?HH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@""Z^['_OBIZ@NONQ_[XJ>@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6O
M^/1/^NG]#6A'_JU^@K/UK_CT3_KI_0UH1_ZM?H*UE_#C\SFI_P >?HAU%%%9
M'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 9=Y_R&;7Z#^9K4K+O/^0S:_0?S-:E:
MU/ACZ'-0^.?K^@4445D=(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 03_P"O@^IJ>H)_]?!]34] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 07'WX?]\5/4%Q]^'_ 'Q4] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 077
MW8_]\5/4%U]V/_?%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!FZU_QZ)_UT_H:T(_\ 5K]!
M6?K7_'HG_73^AK0C_P!6OT%:R_AQ^9S4_P"//T0ZBBBLCI"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,N\_Y#-K]!_,UJ5EWG_(9M?H/YFM2M:GPQ]#FH?'/U_0**
M**R.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ()_P#7P?4U/4$_^O@^IJ>@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (
M+C[\/^^*GJ"X^_#_ +XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+K[L?^^*GJ"Z^['_OB
MIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH S=:_X]$_ZZ?T-:$?\ JU^@K/UK_CT3_KI_0UH1
M_P"K7Z"M9?PX_,YJ?\>?HAU%%%9'2%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\ ,X[_ (6-I_\
MSY7/_CO^-'_"QM/_ .?*Y_\ '?\ &NQV)_<7\J-B?W%_*CGH?\^_Q_X >QQO
M_/Y?^ K_ #.._P"%C:?_ ,^5S_X[_C1_PL;3_P#GRN?_ !W_ !KL=B?W%_*C
M8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*_P SCO\ A8VG_P#/E<_^._XT?\+&T_\
MY\KG_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\ ,X[_ (6-
MI_\ SY7/_CO^-'_"QM/_ .?*Y_\ '?\ &NQV)_<7\J-B?W%_*CGH?\^_Q_X
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M?\+&T_\ Y\KG_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\
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M_P#GRN?_ !W_ !KL=B?W%_*C8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*_P SCO\
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MN?\ QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_P" 'L<;_P _E_X"O\SCO^%C:?\
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MQKL=B?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_ //E<_\
MCO\ C1_PL;3_ /GRN?\ QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_P" 'L<;_P _
ME_X"O\SCO^%C:?\ \^5S_P"._P"-'_"QM/\ ^?*Y_P#'?\:['8G]Q?RHV)_<
M7\J.>A_S[_'_ ( >QQO_ #^7_@*_S.._X6-I_P#SY7/_ ([_ (T?\+&T_P#Y
M\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_
M //E<_\ CO\ C1_PL;3_ /GRN?\ QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_P"
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M ([_ (T?\+&T_P#Y\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\
M/Y?^ K_,X[_A8VG_ //E<_\ CO\ C1_PL;3_ /GRN?\ QW_&NQV)_<7\J-B?
MW%_*CGH?\^_Q_P" 'L<;_P _E_X"O\SCO^%C:?\ \^5S_P"._P"-'_"QM/\
M^?*Y_P#'?\:['8G]Q?RHV)_<7\J.>A_S[_'_ ( >QQO_ #^7_@*_S.._X6-I
M_P#SY7/_ ([_ (T?\+&T_P#Y\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?\
M@!['&_\ /Y?^ K_,X[_A8VG_ //E<_\ CO\ C1_PL;3_ /GRN?\ QW_&NQV)
M_<7\J-B?W%_*CGH?\^_Q_P" 'L<;_P _E_X"O\SCO^%C:?\ \^5S_P"._P"-
M'_"QM/\ ^?*Y_P#'?\:['8G]Q?RHV)_<7\J.>A_S[_'_ ( >QQO_ #^7_@*_
MS.._X6-I_P#SY7/_ ([_ (T?\+&T_P#Y\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ
M'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_ //E<_\ CO\ C1_PL;3_ /GRN?\
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M_/E<_P#CO^-'_"QM/_Y\KG_QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_X >QQO\
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M_/E<_P#CO^-'_"QM/_Y\KG_QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_X >QQO\
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MW_&NQV)_<7\J-B?W%_*CGH?\^_Q_X >QQO\ S^7_ ("O\SCO^%C:?_SY7/\
MX[_C1_PL;3_^?*Y_\=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?^ 'L<;_ ,_E_P"
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M .._XT?\+&T__GRN?_'?\:['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_P#/Y?\
M@*_S.._X6-I__/E<_P#CO^-'_"QM/_Y\KG_QW_&NQV)_<7\J-B?W%_*CGH?\
M^_Q_X >QQO\ S^7_ ("O\SBIOB%82!0+.Y&&!_A_QJ3_ (6-I_\ SY7/_CO^
M-=CY:?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_ //E<_\
MCO\ C1_PL;3_ /GRN?\ QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_P" 'L<;_P _
ME_X"O\SCO^%C:?\ \^5S_P"._P"-'_"QM/\ ^?*Y_P#'?\:['8G]Q?RHV)_<
M7\J.>A_S[_'_ ( >QQO_ #^7_@*_S.._X6-I_P#SY7/_ ([_ (T?\+&T_P#Y
M\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_
M //E<_\ CO\ C1_PL;3_ /GRN?\ QW_&NQV)_<7\J-B?W%_*CGH?\^_Q_P"
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M ([_ (T?\+&T_P#Y\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\
M/Y?^ K_,X[_A8VG_ //E<_\ CO\ C1_PL;3_ /GRN?\ QW_&NQV)_<7\J-B?
MW%_*CGH?\^_Q_P" 'L<;_P _E_X"O\SCO^%C:?\ \^5S_P"._P"-'_"QM/\
M^?*Y_P#'?\:['8G]Q?RHV)_<7\J.>A_S[_'_ ( >QQO_ #^7_@*_S.._X6-I
M_P#SY7/_ ([_ (T?\+&T_P#Y\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ'_/O\?\
M@!['&_\ /Y?^ K_,X[_A8VG_ //E<_\ CO\ C1_PL;3_ /GRN?\ QW_&NQV)
M_<7\J-B?W%_*CGH?\^_Q_P" 'L<;_P _E_X"O\SCO^%C:?\ \^5S_P"._P"-
M'_"QM/\ ^?*Y_P#'?\:['8G]Q?RHV)_<7\J.>A_S[_'_ ( >QQO_ #^7_@*_
MS.._X6-I_P#SY7/_ ([_ (T?\+&T_P#Y\KG_ ,=_QKL=B?W%_*C8G]Q?RHYZ
M'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_ //E<_\ CO\ C1_PL;3_ /GRN?\
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MB?W%_*C8G]Q?RHYZ'_/O\?\ @!['&_\ /Y?^ K_,X[_A8VG_ //E<_\ CO\
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MS[_'_@!['&_\_E_X"O\ ,X[_ (6-I_\ SY7/_CO^-'_"QM/_ .?*Y_\ '?\
M&NQV)_<7\J-B?W%_*CGH?\^_Q_X >QQO_/Y?^ K_ #.._P"%C:?_ ,^5S_X[
M_C1_PL;3_P#GRN?_ !W_ !KL=B?W%_*C8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*
M_P SCO\ A8VG_P#/E<_^._XT?\+&T_\ Y\KG_P =_P :['8G]Q?RHV)_<7\J
M.>A_S[_'_@!['&_\_E_X"O\ ,X[_ (6-I_\ SY7/_CO^-'_"QM/_ .?*Y_\
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M_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\ ,X[_ (6-I_\
MSY7/_CO^-'_"QM/_ .?*Y_\ '?\ &NQV)_<7\J-B?W%_*CGH?\^_Q_X >QQO
M_/Y?^ K_ #.._P"%C:?_ ,^5S_X[_C1_PL;3_P#GRN?_ !W_ !KL=B?W%_*C
M8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*_P SCO\ A8VG_P#/E<_^._XT?\+&T_\
MY\KG_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\ ,X[_ (6-
MI_\ SY7/_CO^-'_"QM/_ .?*Y_\ '?\ &NQV)_<7\J-B?W%_*CGH?\^_Q_X
M>QQO_/Y?^ K_ #.._P"%C:?_ ,^5S_X[_C1_PL;3_P#GRN?_ !W_ !KL=B?W
M%_*C8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*_P SCO\ A8VG_P#/E<_^._XT?\+&
MT_\ Y\KG_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\ ,X[_
M (6-I_\ SY7/_CO^-'_"QM/_ .?*Y_\ '?\ &NQV)_<7\J-B?W%_*CGH?\^_
MQ_X >QQO_/Y?^ K_ #.._P"%C:?_ ,^5S_X[_C1_PL;3_P#GRN?_ !W_ !KL
M=B?W%_*C8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*_P SCO\ A8VG_P#/E<_^._XT
M?\+&T_\ Y\KG_P =_P :['8G]Q?RHV)_<7\J.>A_S[_'_@!['&_\_E_X"O\
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M_P#GRN?_ !W_ !KL=B?W%_*C8G]Q?RHYZ'_/O\?^ 'L<;_S^7_@*_P SCO\
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>H!^E)SH6TA^/_ *A2QBDKUDU_A7^8M%%%<IZ1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img116206746_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img116206746_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 3B"@\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBO'O@+_ ,>6N?\ 72'^3U[#45(<DG$JE/G@I!1114&@4444 %%%% !1110
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M0-J__7PG_H)K.KA?9QYKFM+%>TGRV/6Z***Y#K"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8FO*DURGV'I>IV>LZ;#J&GS>=:S F.3:5R 2.A /4&K=<E\,/^2<:-_US?\
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M*7@][%+MM5\M&;85:"0LI]"%4XZ''K@^E?.,>B:M+8&_CTN]>S'6X6W<Q_\
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MA/4HKL^%H[1$1E$_V>T,&2<[<Y5<]ZCU3XB>%M%U*;3M1U0P7<) DC-M*<9
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M(P(# >@(;/X>_/L.M?\ ("U#_KVD_P#037)4I^SGRG93J*I#F/C^OJ'X8?\
M).-&_P"N;_\ HQJ^7J^H?AA_R3C1O^N;_P#HQJ[<9\"]3AP7QOT.MHHHKS3T
MPKX]U;_D,WW_ %\2?^A&OL*OCW5O^0S??]?$G_H1KNP6[.#';1/7O@QH>D:I
MX?U&74=+LKR1+K:K7%NDA V#@$@\5Z1+X+\+S1-&WAW2PK<$I:(I_ @9%<-\
M"?\ D6M3_P"OS_V1:]2EFBA4-+(D:DXRS #-8UY251V9OAXQ=)71X9\5OAYI
M^A6::YHZBW@,@BFMLD@$]&7/TY'Y5Y9:W,ME=PW4#E)H9%DC8=0P.0?S%>S?
M&'QMIEUI \/Z;<QW4[RJ]P\1#(BKD[=PXW9QTZ8.:\8@ADN;B."%"\LK!$4=
MR3@"N[#N3I^^<&(454]P^Q+.X%W907(4J)HUD"GMD9Q4U065O]DL+:V)R8HE
MCSZX %>+?%OQ_<27TWAO2IFCMX<+>2H<,[_W ?[HXSZG(Z#GS:=-U)<J/2J5
M53CS2/0-:^)_A31)&BDU'[5.K;6CM%\PC_@7W>/3.:Q8?C?X6EDVO;ZI$,?>
M>%"/T<FO$-!\.:KXEOOLFE6CSR#EVZ)&/5F/ Z'Z]LUUFH?!OQ78V1N42SNR
MJ[FAMI27'X,HR?8$^U=CH48Z2>IQK$5Y:Q6A[MH/BC1O$UNTVDWT=QM^^G*N
MGU4\CZ]#6O7QU97MYI5]'=6<\EO<PME70X*D?YZ5],_#_P 91^,= $\@1-0M
MR([J)>@/9A[,!^8([9K"OA_9^\MC>AB?:>Z]SK*Y'6_B7X6T&=[>XU#S[A#A
MHK9#(1QW/W?UK'^,'BFZT#P_;V5C(\-SJ+.IE3@K&H&[![$[E&?K7A&AZ%J'
MB+5$T[3(/.N'!;!8*%4=22>@JJ.'4H\\WH*OB'"7)!:GN/\ PO'PQOV_8]6Q
MG&[R8\?7[^:Z/0OB)X9\0W"VUGJ 2Z<X6&=#&S'VSP?H#7D;_!#Q2L!D%QI;
MMC/EK,^[Z<IC]:\_O;*[TJ_EM+N)[>Z@;#HW53UK58>C/2#,7B*T-9H^Q:XC
MQ[XRT#3M'UC1+J_\O49K"5(X?)D.2\9"_,%QR3ZU!\*?%\WB;P\]O?S>9J-B
MP1W8_-(A^ZQ]^H/TSWKC/BOX-U_4?$E[K=K8>9IT-JKR3>=&,!%);Y2V> /2
MN>G22J\LW:QT5*K=+F@KW/(J^@?"7Q*\):9X1TJQO-6\JY@MD21/LTK;6 Y&
M0I!KY^KJ[#X:^+=3L(+ZSTGS;:= \;_:8EW*>AP6!%=]:$)I*;L>?0G.#;@K
MGU#&ZRQK(ARK ,#Z@TZH;1&BLH(W&&6-5(]"!4U>0>R%>2?'C_D#:1_U\/\
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M]GE;&5##E5(Z$=ZOZ-XIT77[&XOM-OEEM;<D2RLC1A,#)SO XQSFOGSXL?\
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M$LK(T83 R<[P.,<YKY\^+'_)3-7_ .V/_HE*Q=/U/5Y](;PUIJRO'=W'FO#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&G$CE4F(]CY;#^M.F[8>Z[,517Q%GW1]*JJHH50 H&  . *%544*H 4#  '
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M%H?_ %YQ_P J^4Z^K/ ?_(A:'_UYQ_RKKQOPHY,%\;.BHHHKSCT@KR3X\?\
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MAE0?52I/_H0K5I?6OZ[&*;^J_P!=S@?!%UI=CXRTV[UIPEA"[22,4+@$*2O
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MSEK!F'X2)_C7=_&32)=2\#FXA4L]C.L[ ==F"K?^A _A7 ? S_D=KW_L'/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJDB V^G1ELD @R,"%&/IN.>V!ZBOH6N3^'OA%_!WATV5Q)#+=S2F6:2(';T
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M6MVUK9:]J%K9.SVL-S)'"S=2@8@$_A7IOP+T7SM5U#6I%^6WC$$1]6;EC^
M_P"^J]>I/E@Y'CTJ?-443V^*)((4BC4+&BA54=@. *?117C'M!1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWKTNGB:ZG[L=A86@X>]+<****Y#L"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXQK[.KQC_ (4'_P!3+_Y(
M?_;*Z\+5A"_,SCQ=*=2W*CJ_@]_R3JS_ .NLO_H9KO*P?!_AO_A$_#D.D_:_
MM7EN[>;Y>S.XYZ9/\ZWJYZC4IMHZ:2<8),****@L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 0,I. P)],TM>(_#RXGD^.7BJ)YI&C53M1G) Y':O;J "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#PWX=?\ )=O%G^Z?YBO<J\-^'7_)=O%G^Z?YBO<J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHKD_&GQ#T/P5:DWUP);UQ^YLXCND
M<]N.P]S0!UE%>*_!KQ;KGBKQKXFGU>XN OEHR6;NWEP?,1A5/0X'/K7M5 !1
M17D'B/Q-XD\8^/9_!WA&^%A;6(S?WZ_>![@'J,'CCO[4 >OT5XGK/_"<?"HV
MVKRZ[-K^A^8([J.YRTD8/?)Y_P ^]>IWWB:PL?"4GB-WS9+;?:1CJ01D#ZT
M;-%>(Z!8>/?B5:MXAG\2W&AV,K$V=M:DK\H/!..H^O6MCP9XL\0Z-XVE\#^,
M9X[FX=/-L;X8'FKZ>_0^_!H ]6HHHH \-^'7_)=O%G^Z?YBO<J\-^'7_ "7;
MQ9_NG^8KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\/RKT*B@ HHHH \-^'7_ "7;Q9_NG^8KW*O#?AU_R7;Q9_NG^8KW*@ HHHH
M**** "BBB@ HHHH **** "BBB@#XBU7_ )*+?_\ 85E_]&FOK?2_^0C#^/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >&_#K_DNWBS_=/\Q7N5>&_#K_ )+MXL_W3_,5[E0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%$X<Q_WJIZA1116QQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X;\.O\
MDNWBS_=/\Q7N5>&_#K_DNWBS_=/\Q7N5 !1110 4444 %%%% !1110 4444
M%%%% &3XH_Y%75?^O63_ -!-?)'PL_Y*1I7UD_\ 1;5];^*/^15U7_KUD_\
M037R1\+/^2D:5]9/_1;4 ?7VC_\ '@/]XU?JAH__ !X#_>-7Z "BBB@"EK/_
M "!+_P#Z]Y/_ $$UYIX-_P"1FM?^!?R->EZS_P @2_\ ^O>3_P!!->:>#?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'AOPZ_Y+MXL_W3_,5[E7AOPZ_Y+MXL_P!T_P Q7N5 !111
M0 4444 %%%% !1110 4444 %%%% &3XH_P"15U7_ *]9/_037R1\+/\ DI&E
M?63_ -%M7UOXH_Y%75?^O63_ -!-?)'PL_Y*1I7UD_\ 1;4 ?7VC_P#'@/\
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M0WA1C%-DJ"?WII__  @.A?\ /*;_ +^FNF50B!1T P*6M/84_P"5&#Q^)O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $(#*01D'@BO"?"^K)\(_'.LZ)KXEATC491/:7A7* \]<?7'X5[
MO534-*T_5H!#J-C;7<0.0D\2N ?49'% 'B_Q+\9VGQ!BM/!?A%CJ,MY,CSW$
M:GRXU!R.3],FO7H(K;PMX55,,;;3;0DA1R51<G'Y4_2_#^CZ(&_LS3+2S+?>
M,$*H6^I YK0DCCFB>*5%>-U*LC#(8'J".XH YWP5XUT[QUI$VI:9%<1PQ3&!
MEG4!MP /8GC#"N$_:'U&2W\$VEA&"?MUV%('^S\W\P*]5L-,L-*@,&G6-M9P
MEMQCMXEC4GUPH'/ I+W2]/U/R_M]A:W?E-NC\^%9-A]1D<&@"#P]8)I?AW3K
M&-0J06Z( .W%9?CZUURZ\'W@\.7<MMJ<8$D1B(W/CJO/K73    # %% 'D_@
M?XQ:')X<@M?$^H&PU>U017'VI2#*0/O<#J>IK N[A_C!\3M*DTVVE_X1[127
M>[D3 =B03CZE5Q]#7K]_X4\/ZI<_:;_1-/N)R<F22W5F/U.,FM&TLK33[<6]
ME:PVT(Y$<,811^ XH GHHHH \-^'7_)=O%G^Z?YBO<J\-^'7_)=O%G^Z?YBO
M<J "BBB@ HHHH **** "BBB@ HHHH **** ,KQ."WA?5 H))M9, ?[IKXP\)
M:XOASQ58ZJ\7FI YW+G'# J3^ .:^XR RE6 ((P0>]?%/Q%LK;3OB%K=K9PI
M#;QW3A(T&%49Z =J /L70I!-I44J_=<;Q]" :TJR/#/_ "+UG_UR3_T$5KT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT7_H(KJ+3_CSA_W!_*N7D_U-M_U[1?\ H(KJ+3_CSA_W!_*@":BBB@ HHHH
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MVC1I6BEB.4<#/U!KF?\ A6S?]! ?]\UZ#16,\/3F[R1VT<PQ%&')3EH>?_\
M"MF_Z" _[YKCM8T[^RM3GLO,\SRSC=CK7N->.^,?^1GO?]X?RKCQ5"%."<4>
MUE..KXBLXU'=6/5]+_Y!%E_UP3_T$5;JII?_ ""++_K@G_H(JW7HQV1\W4^-
M^H4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** /#?AU_R7;Q9_NG^8KW*O#?AU_P EV\6?[I_F*]RH **** "BBB@
MHHHH **** "BBB@ HHHH *^,/BC_ ,E.U[_K[?\ G7V?7QA\4?\ DIVO?]?;
M_P Z /J&3_4VW_7M%_Z"*ZBT_P"/.'_<'\JY>3_4VW_7M%_Z"*ZBT_X\X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ROQWXM\?Z/XFDM/#
MVA?;+ 1J5E\O=DD<C/UKF?\ A8/Q;_Z%7_R#7>ZW\3[?1?'UGX4?2KB66YEB
MC%PKX5?,( .,=LTGCWXHVW@34+6TFTJXO#<1EPT3X"X(&.A]: .#_P"%@_%O
M_H5?_(-'_"P?BW_T*O\ Y!J]_P -%V'_ $+5]_W]'_Q-'_#1=A_T+5]_W]'_
M ,30!Z'\/]6U_6O#9NO$EC]BO_/=/*V[?D&,''XFNIKFO WC"+QOX?.K0V4M
MHHG>'RY&R?EQSG ]:Z6@ HHHH **** "BBB@ HHHH **** "BBB@#PWX=?\
M)=O%G^Z?YBO<J\-^'7_)=O%G^Z?YBO<J "BBB@ HHHH **** "BBB@ HHHH
M**** "OC#XH_\E.U[_K[?^=?9]?&'Q1_Y*=KW_7V_P#.@#ZAD_U-M_U[1?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC!#?[HJG=6KVDHCD*DD9^6@#JP0P!!!!Z$4M5=-_Y!\/^[5J@ HHHH ****
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M_P"@E'_WRW^%'M:?\R^\/JF(_P"?;^YFY3)9HH%W2R)&O3+'%8W_  F/A_\
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M **** "BBB@ HHHH **** "OG+]I7_D.Z#_U[2?^A"OHVOG+]I7_ )#N@_\
M7M)_Z$* /0?@/_R3&W_Z^)/Z5Z/=?\>LO^X?Y5YQ\!_^28V__7Q)_2O1[D$V
MLH'78?Y4 <]I?_(2B_'^1KIJY.UF-O<I*!G:>AKJU.Y0WJ,T +1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQOXDH?#WQ4\+>
M+;U';28BT,TF,K$Q4@9].N?PK1\=_##6_%7B:34[#Q$UC T:H(1NX(&,\5RM
MQ\ _$-W"8;CQ8)8SU5PQ% 'N]I=V]]:QW5I/'/!(-R21L&5A[$5C>,M>TWP]
MX7O[S4YHTB,+HL;GF5B" H'?->16?P)\1:4I^Q^,!;*?[FY145W^S]KFHRB6
M[\4I<..C2*S4 =O\#])O-+\ [[R&2 W=R]Q'$XQA#C!Q[XKTJN8\!^'-1\+^
M'/[.U/4SJ,XF9Q,<\*0,+SZ8KIZ "BBB@ HHHH **** "BBB@ HHHH ****
M/#?AU_R7;Q9_NG^8KW*O#?AU_P EV\6?[I_F*]RH **** "BBB@ HHHH ***
M* "BBB@ HHHH *^<OVE?^0[H/_7M)_Z$*^C:^<OVE?\ D.Z#_P!>TG_H0H ]
M!^ __),;?_KXD_I7IE>9_ ?_ ))C;_\ 7Q)_2O3* .5O %OY@   _05U$?\
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M*NFZ<DCLP$E'%0;[F-\-ON7WU%=]7AT5MJD&?*MKQ,]=L3#/Z5)MUK_GG?\
M_?M_\*XJ6)]G!1Y3W,9E:Q%9U542O_7<]MHKQ+;K7_/._P#^_;_X4;=:_P">
M=_\ ]^W_ ,*T^N_W3F_L/_IZOZ^9[;17B6W6O^>=_P#]^W_PHVZU_P \[_\
M[]O_ (4?7?[H?V'_ -/5_7S/;:*\2VZU_P \[_\ []O_ (4;=:_YYW__ '[?
M_"CZ[_=#^P_^GJ_KYGMM%>);=:_YYW__ '[?_"HI;C4K=@)I+J(GD!\K_.E]
M>_N@LB;T51?=_P $]RHK#\(WD]]X<MIKAS))RI8]3@UN5VPES14EU/$JTW2J
M.#Z.P44451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1J1CC Y_SZ5ZK0 4444 %%%% !1110 4444 %%%% !1110!X;\.O^2[>+/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR/\ A1_PEN@_]!*+\C_A7"_\*^UG_IA_WW1_PK[6?^F'_?='M\1_('U'+O\
MG]^*_P CNO\ A+=!_P"@E%^1_P */^$MT'_H)1?D?\*X7_A7VL_],/\ ONC_
M (5]K/\ TP_[[H]OB/Y ^HY=_P _OQ7^1W7_  EN@_\ 02B_(_X4?\);H/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/I6=7^&_0NG\:,W2/^/MO]RMNL32/^/MO]RMNL,%_"-L5_$"BBBNLY@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# O?!^DWUT]P\3J[G+
M;&(!-5_^$$T?TE_[[-=/16RQ-5*RDSDE@,-)W=-7]#QWQ'80Z9K4]I;Y\I ,
M9.3R*]6TG_D$VO\ US%>9^,_^1GNO]U?Y5Z9I/\ R";7_KF*[<:VZ--O^M#R
M<IBHXNO&*LE_FRY1117F'T(4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "OG+]I7_D.Z#_U[2?^A"OHVOG+]I7_ )#N@_\ 7M)_Z$*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '&_$;_ ) UO_UV_I4'PV_X\;W_ *ZC^0J?XC?\@:W_ .NW
M]*@^&W_'C>_]=1_(5PO_ 'H]Z/\ R*7Z_J=S1117<>"%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_7M)_P"A"@#T'X#_ /),;?\ Z^)/Z5Z97F?P'_Y)C;_]?$G]*],H *YK5?\
MD(2?A72U!/9V]P=TL08@=>E &3::M(K10NBE.%R.OI6[7**H6_"@8 DP/SKJ
MQTH **** "JVH?\ 'E)]*LU6U#_CRD^E9U?X;]"Z?QHS=(_X^V_W*VZQ-(_X
M^V_W*VZPP7\(VQ7\0****ZSF"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#RGQK&R>)KAG4A752I/0\5!%XLU>&)(H[L!$& ,=J]7
MFM;>X(,]O%*1TWH&Q^=1_P!F:?\ \^-M_P!^5_PKTHXVGR*,X7L>!4RBM[:5
M2E5Y>9W_ *U/+_\ A,=:_P"?P?E1_P )AK1Z7G_CM>H?V9I__/C;?]^5_P *
MXOQ_:V]O'9^1!%%DG.Q N?RK6C7HU9J"I[G-BL%B\/2=5UF[>O\ F=%X4U:?
M6-'\^Y"^:DAC)7C=@ Y_6MRN3^'W_( F_P"OAOY"NLKS\3%1JR2/=P$Y3PT)
M2=VT%%%%8'6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,RJ,L0/J:6LG7]&.MV
MD< N9+?9)OW(>3P1C]:4FTKI7+IQC*24W9=S!^(KJVC6X5E/[[L?:LOP-K>F
MZ5:727UTD+/("H8$Y&/85#XE\*'1])-V=0FGPX78_(YS5:T\"ZI>6D5S')"$
ME0.N3S@UYLW5]MS*.I]-2CA?J7LIU/=;WV\^IW?_  F/A_\ Z"<7_?+?X4?\
M)CX?_P"@G%_WRW^%<5_PKS5O^>D'_?5'_"O-6_YZ0?\ ?5:^VQ'\AR_4LM_Y
M^O[U_D=K_P )CX?_ .@G%_WRW^%6K#7]*U.8PV=['+(!G:,@_K7GTO@#58HG
MD:2#"*6/S>E9WA/*^*]/&?\ EH1_XZ:2Q-522G&UQO+,).E.=&HVXJ_3_(]D
MHHHKO/GPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 >&_#K_DNWBS_=/\Q7N5>&_#K_ )+MXL_W3_,5[E0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*^C:^<OVE?\ D.Z#_P!>TG_H0H ]!^ __),;?_KXD_I7IE>9_ ?_ ))C;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHR@# X_E70VO_'I#_N#^5 $M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!DZS]^'Z&K&E?\ 'F/J:KZS]^'Z&K&E?\>8^IK@A_O<OZ['9+_=T7J*
M**[SC"BBB@ HHHH **** "BBB@ HHHH Y/Q1X3GUJ^2[MIXT<($99,XX[C\Z
M\^N+:2QU![9V!DB?:2O3(->VUXYKO_(QWO\ UW;^=>OE]:<KP>R1\OGF%I4[
M5HK63U/88_\ 5K]!3J;'_JT^@IU>0?3K8****!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!EZKX>TW671[V#>Z# 96*G'ID5G?\()H'_/M+
M_P!_F_QKI:*S=*$G=I'1#%UX1Y8S:7J<R_@7051B+:7@$_ZYO\:\ZTM%C\46
MB+PJW8 ^@:O:9?\ 5/\ [IKQC3_^1KMO^OP?^A5QXJ$8RCRJQ[>55ZM6%7VD
MF].K]3VFBBBO0/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M KYR_:5_Y#N@_P#7M)_Z$*^C:^<OVE?^0[H/_7M)_P"A"@#T'X#_ /),;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9
M?]4_^Z:\8T__ )&NV_Z_!_Z%7L\O^J?_ '37BEK-';>)(IY6VQQW6YCC. &K
MAQF\3W\E3<*J7;_,]MHKG_\ A-O#_P#S_P#_ )"?_"C_ (3;P_\ \_\ _P"0
MG_PKJ]M3_F7WGD_4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"BN?_X3;P__ ,__ /Y"?_"C_A-O#_\ S_\
M_D)_\*/;4_YE]X?4\3_S[?W,Z"HA<P-.81*AE'5 W(_"L3_A-O#_ /S_ /\
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M4?\ ";>'_P#G_P#_ "$_^%'MJ?\ ,OO#ZGB?^?;^YG045S__  FWA_\ Y_\
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MI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\A/\ X4?\)MX?_P"?_P#\A/\
MX4>VI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\A/\ X4?\)MX?_P"?_P#\
MA/\ X4>VI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\A/\ X4?\)MX?_P"?
M_P#\A/\ X4>VI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\A/\ X4?\)MX?
M_P"?_P#\A/\ X4>VI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\A/\ X4?\
M)MX?_P"?_P#\A/\ X4>VI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\A/\
MX4?\)MX?_P"?_P#\A/\ X4>VI_S+[P^IXG_GV_N9T%%<_P#\)MX?_P"?_P#\
MA/\ X5KV.H6FIVPN+.998CQD<?H:<:D).R=R*F'K4U><6EYIEFBBBK,0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "F/+'&</(BD_WCBGUYY\0OAK<^-]1M+J#6I; 01E"J9^;)'/'TH [[
M[3!_SWC_ .^Q6#XSUK2--\(:K+J5S#]G:UD0H7&9"5("CW/2O+?^&?\ 4/\
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MNON/,_\ A7.H_P#/U!^M'_"N=1_Y^H/UKTRBCZG2[!_;6+[K[CS/_A7.H_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ K@_B-UT[_MI_P"RUWE<'\1NNG?]M/\
MV6NO _QX_/\ (\S./]RG\OS1I^ ?^0 __78_R%=37+> ?^0 _P#UV/\ (5U-
M1BOXTO4VR[_=*?H%%%%<YVA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\1O\ D$6W_76H/AI_
MQZ:C_P!=4_D:G^(W_((MO^NM0?#3_CTU'_KJG\C7"_\ >U_70]^/_(H?K^J.
MZHHHKN/ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \&^)\=[X&^*>F^/;>U>>RE"I<E1T(785]B5Z>]/\
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MMXL_W3_,5[E7AOPZ_P"2[>+/]T_S%>Y4 %%%% !1110 4444 %%%% !1110
M4444 %?.7[2O_(=T'_KVD_\ 0A7T;7SE^TK_ ,AW0?\ KVD_]"% 'H/P'_Y)
MC;_]?$G]*],KS/X#_P#),;?_ *^)/Z5Z90 4444 %%%% &/KWW8/J:ET3_CT
M;_>J+7ONP?4U)HA'V5AD9W=* -2BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH R=9^_#]#5C2O^/,?4U7UG[\/T-6-*_X\Q]37!#_ 'N7]=CLE_NZ
M+U%%%=YQA1110 4444 %%%% !1110 4444 %%%% !1110 5P?Q&ZZ=_VT_\
M9:[RN%^(RMMT]\':-X)[ _+77@?X\?ZZ'F9Q_N4_E^:-'P#_ ,@!_P#KL?Y"
MNIKR#3/$VHZ3;&WM7B$9;=\RY.:N?\)SK7_/6#_OW_\ 7KIK8&K.HY*VIY^$
MSG#T:$:<KW2/4Z*\L_X3G6O^>D'_ '[_ /KUW?AK5I-8TA+F9%64$JVWH2.]
M<M;"5*,>:6QZ6%S.ABI\D+W\S8HHHKE/1"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/B-_R"+;_KK4
M'PT_X]-1_P"NJ?R-3_$;_D$6W_76H/AI_P >FH_]=4_D:X7_ +VOZZ'OQ_Y%
M#]?U1W5%%%=QX 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'AOPZ_Y+MXL_W3_,5[E7AOPZ_P"2[>+/]T_S%>Y4 %%%% !1
M110 4444 %%%% !1110 4444 %?.7[2O_(=T'_KVD_\ 0A7T;7SE^TK_ ,AW
M0?\ KVD_]"% 'H/P'_Y)C;_]?$G]*],KS/X#_P#),;?_ *^)/Z5Z90 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@/\ KJ/YUU1Z5RH_Y" _ZZC^= '54444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &3K/WX?H:L:5_QYCZFJ^L_?A^AJQI7_'F/J:X(?[W+^NQV2_W=
M%ZBBBN\XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_B
M/][3O^VG_LM:G@/_ )%\_P#75JR_B/\ >T[_ +:?^RUJ> _^1?/_ %U:O2G_
M +E'U_5G@4O^1O/T_1'44445YI[X4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=3V(_P#K=#7D'@7X&:YX7\4Z=KEQKMBKVDFYHX(GDWJ1M9<G;C(+#/;K@]*
M/4O'VJ7FB^ ]9U+3YO)N[:V+Q2;0VUN.<$$'\17S'_PNWXA_]##_ .25O_\
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MH **** /*?&__(S7'_7-?Y5Z/HO_ "!;/_KD*\X\;_\ (S7'_7-?Y5Z/HO\
MR!;/_KD*]+%_[O3_ *Z'S^6_[]7]?U+]%%%>:?0!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'C/BO_D9;_P#WZ]AM?^/2'_KFO\J\>\5_\C+?_P"_7L-K_P >D/\ US7^
M5<.%_B3_ *[GO9M_N]#T_1$M%%%=QX(4444 %%%8/C3Q''X3\'ZEK3@,UO%^
M[0G[TC$*@Z'^(B@#Y;^,GB >(/B7J3QN&@LL641&>B9W?^/E_P /SKZ@\!^'
MQX7\#Z3I!0++# #.!G_6M\S]?]HFOCG0O#^M>+]8>RTFV>]OG5IG#2JI(!Y8
MLY ZGU[UU/\ PI+XA_\ 0O?^3MO_ /'* *'Q'T5_"7Q*U.VMOW2+<"ZM2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'AOPZ_Y+MXL_W3_,5[E7AOPZ_Y+MXL
M_P!T_P Q7N5 !1110 4444 %%%% !1110 4444 %%%% !7SE^TK_ ,AS0?\
MKVD_]"%?1M>3?'[0+"]\"OK,L9^VV#HL+@_PNX!!]N<T 0_L^Z_8W?@Z71HW
M(O;.4R2(1P5;H0>_0UZ_7S=^S=_R,6L?]>Z?S-?2- !1110 4444 !Z5RH_Y
M" _ZZC^==4>E<ID+?9)P!)DG\: .KHI 0P!!R#2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% &3K/WX?H:L:5_QYCZFJ^L_?A^AIVGW<$-KLDD"MGIB
MO/C)1Q4FW_6AVM-X=)&I15;^T+7_ )ZC\C1_:%K_ ,]1^1KL]K3_ )D<OLY]
MF6:*K?VA:_\ /4?D:/[0M?\ GJ/R-'M:?\R#V<^S+-%5O[0M?^>H_(T?VA:_
M\]1^1H]K3_F0>SGV99HJM_:%K_SU'Y&C^T+7_GJ/R-'M:?\ ,@]G/LRS14,5
MW!,VV.0%O2IJM24E=,EIK1A1113$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >4^-_P#D9KC_ *YK_*O1]%_Y MG_ -<A7G'C?_D9I_\
MKFO\J]$T"6.;0[1HW5P(P#@]#Z5Z>+_W>G_70^?RU_[=7_KJ:5%%%>8?0!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%']KZ;_S_P!M_P!_11S1[A[*I_*_N+M%4O[7TW_G_MO^_HH_M?3?^?\ MO\
MOZ*.:/</95/Y7]Q=HJE_:^F_\_\ ;?\ ?T4?VOIO_/\ VW_?T4<T>X>RJ?RO
M[B[15+^U]-_Y_P"V_P"_HH_M?3?^?^V_[^BCFCW#V53^5_<7:*I?VOIO_/\
MVW_?T4?VOIO_ #_VW_?T4<T>X>RJ?RO[B[15+^U]-_Y_[;_OZ*/[7TW_ )_[
M;_OZ*.:/</95/Y7]Q=HJE_:^F_\ /_;?]_11_:^F_P#/_;?]_11S1[A[*I_*
M_N+M%4O[7TW_ )_[;_OZ*/[7TW_G_MO^_HHYH]P]E4_E?W%VBJ7]KZ;_ ,_]
MM_W]%']KZ;_S_P!M_P!_11S1[A[*I_*_N+M%4O[7TW_G_MO^_HH_M?3?^?\
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MK%M,]R)$0LI&,B@#2TW_ )!T'^[5JN4$5THX64 >YJ;3IY5OHAYC$,<$$YH
MZ6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_&C_A#/$'_/@W_?U/\ &O8**/J-/NP_M[$?RK\?\SQ__A#/$'_/@W_?U/\
M&C_A#/$'_/@W_?U/\:]@HH^HT^[#^WL1_*OQ_P SQ_\ X0SQ!_SX-_W]3_&C
M_A#/$'_/@W_?U/\ &O8**/J-/NP_M[$?RK\?\SQ__A#/$'_/@W_?U/\ &C_A
M#/$'_/@W_?U/\:]@HH^HT^[#^WL1_*OQ_P SQ_\ X0SQ!_SX-_W]3_&C_A#/
M$'_/@W_?U/\ &O8**/J-/NP_M[$?RK\?\SQ__A#/$'_/@W_?U/\ &C_A#/$'
M_/@W_?U/\:]@HH^HT^[#^WL1_*OQ_P SQ_\ X0SQ!_SX-_W]3_&C_A#/$'_/
M@W_?U/\ &O8**/J-/NP_M[$?RK\?\SQ__A#/$'_/@W_?U/\ &C_A#/$'_/@W
M_?U/\:]@HH^HT^[#^WL1_*OQ_P SQ_\ X0SQ!_SX-_W]3_&C_A#/$'_/@W_?
MU/\ &O8**/J-/NP_M[$?RK\?\SQ__A#/$'_/@W_?U/\ &C_A#/$'_/@W_?U/
M\:]@HH^HT^[#^WL1_*OQ_P SQ_\ X0SQ!_SX-_W]3_&C_A#/$'_/@W_?U/\
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M./-):&U#,<-7GR4Y7?S->BBBN<[0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN2CD:&8.O#*<C-=?6?J5M +2601('QG<!S0!'IFHRW4K12@9 R"*U*Y_1/\
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M:D+!DWB>/1T,6WU#F,C'OFNK^&_QUU#5?$%KHGB:*%Q>.L-O=6\15A*QPH<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU='7!@/@?J=>+^)!1117><@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '(_$'_D#P?]=?Z55^''^HU'
M_?3^1JU\0?\ D#P?]=?Z55^''^HU'_?3^1KTE_N+]?U/GY_\CB/I^C.XHHHK
MS3Z **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.GO7N?@SP7I/@?11IVEQDLQW3W#X\R9O5CZ#L.@_,GHLCUHH **** "BBB@
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M?YGKM%>1?\)3KW_00F_[X7_"C_A*=>_Z"$W_ 'PO^%']FU.Z#_6"A_++\/\
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M9_NG^8KW*@ HHHH **** "BBB@ HHHH **** "BBB@ KSKXY?\DHU3_?A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X;\.O^2[>+/]T_S%>Y5X;\.O\ DNWBS_=/
M\Q7N5 !1110 4444 %%%% !1110 4444 %%%% !6+XNT"S\3>%K_ $F_#^1-
M'DE#@J5^92/H0*VJAO/^/*X_ZYM_*@#XT^'\0@^*&CQ DA+W:"?;-?:-?&/@
M;_DJ^E_]A _S-?9U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!0NK.2:_@G7&Q,9S5^BB@ HHHH **** "BBB@ HHHH *0_=/TI
M:0_=/TH YVS_ ./R+_>KHZYRS_X_(O\ >KHZX,!\#]3KQ?Q(****[SD"BBB@
M HHHH **** "BBB@"IJ-N]U:F./&[(/-36\9BMXT;JJ@'%2T4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% $<_\ Q[R?[I_E7D?AK_D9++_KI7KD_P#Q[R?[I_E7D?AK_D9++_KI7I8'
M^%4]/\SY_./]XH>OZH]@HHHKS3Z **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^T7T^[RXOLLR;MJECRR #@$\FM#QW_R3SQ+_ -@JZ_\ 135\P?!+_DKVA?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A;.@[-V?,E^[Z>4^?TS0!O?&SP-J>C>(+SQ1<3VC6.I7FV&.-V,BG9GY@5
M'W3T)KFO WPSUGQ_!>S:5<V$*VC(L@NI'4DL"1C:C>E>R_M(_P#(F:5_V$!_
MZ+>L_P#9H_Y!GB+_ *[0?R>@#V[3K=[33+2VD*EX84C8KT)"@'%6:** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0>XV '_@1KYV\>:/-X+^).HVUIF 6]T+FS94P%1B'3'8[<@?53]* /M&N?\
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M=G=!XL_PB1<D#VRI/XFO*?BWX%TOP%KUC8Z7/>317%KYS&Z=68-N(XVJO'%
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M0_\ 7HW\Q0!\O_"W1-.\1_$?2=)U:W^T6,_G>9%O9-VV%V'*D$<@'@U]&3?
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M3]GV0I\30H P]E*IS_P$_P!*^JZ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMXL_W3_,5[E7AOPZ_P"2[>+/]T_S%>Y4 %%%% !1110 4444 %%%% !1110
M4444 %(RAU*L,@C!%+10!\7_ !.\/6OAGQY?Z?9N[09$J[^2-W.*^L_!/_(B
MZ!_V#X/_ $6*^8_CC_R4^^_ZYI_*OISP3_R(N@?]@^#_ -%B@#COCY_R2ZX_
MZ^H?_0J\N_9Q_P"2AZA_V"I/_1L5>H_'S_DEUQ_U]0_^A5Y=^SC_ ,E#U#_L
M%2?^C8J /I^OEC]H;_DI,7_8/B_]">OJ>OEC]H;_ )*3%_V#XO\ T)Z /8/@
M5_R2?3?^NL__ *,:O1Z\X^!7_))]-_ZZS_\ HQJ\'^-O_)7M=_[=_P#TGCH
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MFTU G>"]I>PC:)0"-R,I)]1E>1@B@#[ J&YNK>R@:>ZN(H(5ZR2N%4?B:P?
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M74<\!E(..3QFJWA[X>^%/"MU]JT71XK:XP1YID>1\$ $9=B<<=* /D>QGOO
M/CJ&:ZLE>\TJZ!>"4%0Q4]N,\CD''<&O8_$_[0%EJ^A3:5X<T?4&U&^C-L&G
M"CRRXVY0(6+MSP..<=>E>M^(?!'AGQ4=VM:-;74N OG$%)< Y WJ0V/;/<TS
MP_X!\*^%I?.T;1+:WG&<3',DBYR#AW)8#GL: /E?X63#3OBMH/VE3&PN_)97
M^4AF!0 ^^2!BOHKXQ^#KCQAX(>.P3??V,GVJ%!UD 4AD'!R2#P.Y JW/\)/
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M_:(\+ZKJ2:5K5A:RW-O:QR17(B3<8@2"&('./O9.,# ]: .N^!7_ "2?3?\
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MD\E?7]?"&B:WJ/AS6(-6TFX^SWT&[RY=BOMW*5/# @\$CD5UY^-'Q$G4PCQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK?#OQ@M\EL4NK9FAN;6=2NY<_,A[@\=>Q Z]* /MJOEC]H;_ )*3%_V#XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!X;\.O^2[>+/]T_S%>Y5X;\.O\ DNWBS_=/\Q7N5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_AI32/^A>OO^_R4GPNL67XM>,&FM"(BYV%XL*?G/3(KVO[);?\ /O%_WP*
M/%?^&E-(_P"A>OO^_P E'_#2FD?]"]??]_DKVK[);?\ /O%_WP*/LEM_S[Q?
M]\"@#Q7_ (:4TC_H7K[_ +_)1_PTII'_ $+U]_W^2O:OLEM_S[Q?]\"C[);?
M\^\7_? H \5_X:4TC_H7K[_O\E'_  TII'_0O7W_ '^2O:OLEM_S[Q?]\"C[
M);?\^\7_ 'P* /%?^&E-(_Z%Z^_[_)1_PTII'_0O7W_?Y*]J^R6W_/O%_P!\
M"C[);?\ /O%_WP* /%?^&E-(_P"A>OO^_P E'_#2FD?]"]??]_DKVK[);?\
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M^R6W_/O%_P!\"@#Q7_AI32/^A>OO^_R4?\-*:1_T+U]_W^2O:OLEM_S[Q?\
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M^_R4?\-*:1_T+U]_W^2O:OLEM_S[Q?\ ? H^R6W_ #[Q?]\"@#Q7_AI32/\
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M\-*:1_T+U]_W^2O:OLEM_P ^\7_? H^R6W_/O%_WP* /%?\ AI32/^A>OO\
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M\/;.)?AWX>$ML@D%A#N#1C.=HZUTGV2V_P"?>+_O@4 >*_\ #2FD?]"]??\
M?Y*/^&E-(_Z%Z^_[_)7M7V2V_P"?>+_O@4?9+;_GWB_[X% 'BO\ PTII'_0O
M7W_?Y*/^&E-(_P"A>OO^_P E>U?9+;_GWB_[X%'V2V_Y]XO^^!0!XK_PTII'
M_0O7W_?Y*/\ AI32/^A>OO\ O\E>U?9+;_GWB_[X%'V2V_Y]XO\ O@4 >*_\
M-*:1_P!"]??]_DH_X:4TC_H7K[_O\E>U?9+;_GWB_P"^!1]DMO\ GWB_[X%
M'BO_  TII'_0O7W_ '^2C_AI32/^A>OO^_R5[5]DMO\ GWB_[X%'V2V_Y]XO
M^^!0!XK_ ,-*:1_T+U]_W^2C_AI32/\ H7K[_O\ )7M7V2V_Y]XO^^!1]DMO
M^?>+_O@4 >*_\-*:1_T+U]_W^2C_ (:4TC_H7K[_ +_)7M7V2V_Y]XO^^!1]
MDMO^?>+_ +X% 'BO_#2FD?\ 0O7W_?Y*/^&E-(_Z%Z^_[_)7M7V2V_Y]XO\
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M_P"A>OO^_P E>U?9+;_GWB_[X%'V2V_Y]XO^^!0!XK_PTII'_0O7W_?Y*/\
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MD?\ 0O7W_?Y*]J^R6W_/O%_WP*/LEM_S[Q?]\"@#Q7_AI32/^A>OO^_R4?\
M#2FD?]"]??\ ?Y*]J^R6W_/O%_WP*/LEM_S[Q?\ ? H \5_X:4TC_H7K[_O\
ME'_#2FD?]"]??]_DKVK[);?\^\7_ 'P*/LEM_P ^\7_? H \5_X:4TC_ *%Z
M^_[_ "4?\-*:1_T+U]_W^2O:OLEM_P ^\7_? H^R6W_/O%_WP* /%?\ AI32
M/^A>OO\ O\E'_#2FD?\ 0O7W_?Y*]J^R6W_/O%_WP*/LEM_S[Q?]\"@#Q7_A
MI32/^A>OO^_R4?\ #2FD?]"]??\ ?Y*]J^R6W_/O%_WP*/LEM_S[Q?\ ? H
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MTII'_0O7W_?Y*/\ AI32/^A>OO\ O\E>U?9+;_GWB_[X%'V2V_Y]XO\ O@4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT>7R7<GYI%!QD^I!&,^] 'I5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%>6_%'Q5K UG2_!7AJ;R-3U/F6<=8HR< @]LX//M0!Z=Y\.
M_9YJ;O3<,U)7D%S\";,:8\UMKNIG757='>O,<E^H!]!G\:Z7X8:IXAN?"CQ^
M*;6Y@O+-RGG7$94RH.C<]3P>: .XD:-4/F%0IX.X\4V$0A/W'E[?]C&/TKPW
M3K*_^,_BO5KC4-0NK;PUITQMX;:"0J)6'7./SS[@4:_I-_\ !C5M.UK1]3NI
M_#TTRP7=E.Y<1J>X_#H>N: /=J8\T49 >1%)[%@*YWQ?XKB\.>"+O7X\2;80
MT"_WF;[O\\_A7FWA;X6R>--%B\1^+]6OY]0O@9HD28@0*3\I'X<XZ#B@#VX$
M$9!R**\=\%:GJ_@KXBR^ ]9U*2_L;B,RZ=<3$E\]=I)]@>/4<5[%0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UG1/O,H^II/.B_YZ)_
MWT*XWQQ\/$\:W5K.VMW^G_9U*[;8C#Y[FN'U?X-Z;H6DW.IZAXVUJ*UMD+R-
MN'0=ASR?:@#VM9$8X5U)]C2D@ DD #N:\+^!?AO4YKZY\47-[>'3BK06<5PY
M)E&1\Y'MC]:T/&VI:KXW^),7@'2=0FL+"WC$FHSPDAFXR5SZ8(X[DF@#U^'[
M-N8P^5N/4IC)_*IJ\3\3?"^;P1HTOB+P=J]];W=@//EADE+),HY8D?3)QTKT
MCPEXK@\1^";;7VVKF$O.J\[&4?,/Z_C0!T3R)&,NZJ/5CBE5U<95@P]0<UX/
MX>T>\^-.K:EK>MZC=1:!!.8+2RA<HK =R/H1D]<\5-J%KJ/P:\4Z5<6FIW-U
MX9U&86TUO<R%O))[C/3'7/L10![G134=9(U="&5@"".XIU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%8?C'7'\-^$-3UB.,226L!=%/0MT
M'\Z -EYHHSAY$4^C,!3@0PR""#W%>&>"_AL/'V@Q^)O%NKWUY=7I9XXUF(6(
M D#&/ITZ"K7@V^U7P-\57\!W>IS:CIMS%YMHT[%GCX) SVX!R.G2@#VJH5-J
MT^Y3"9?48W5Y?\6/$FK/K&D>"?#]RUK?ZJ09KA"0T<9.!@CIT;)]JJ7_ ,$(
MM/TF2[T'6]2BUV)-ZW!F(\YQS@^F: /8:1F5%W,P4>I.*X?X5>,9_%_A0R7[
M+_:5G*;>YQ_$1T;\>?RKA[IM1^+GQ%U/1UU*YLO#6CGRY$@8J9W!P<^OS CV
M% 'MZ21R#*.K#_9.:=7A?BKPG??"6&W\3^%=2NSI]O*J7EC-(60HQQD ^YQ[
M9!KVC2=1AU?2+34;=@T5Q$LBD>XZ4 7**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *8\L<8S(ZK_O'%4=?U>+0= OM5G&8[6%I&'KBO%?!
M_@_4/BS;R^*/%NJ71LIY&6ULH9"J!0<=.P!&/?&: />E977<K!AZ@YI:\0NH
M]2^#GBW2E@U&ZOO"^IR^0]O</N-N_;;GIUS] <UW/Q0\8R^#_!LE[9%3?7#"
M&V)Y 8_Q>^* .PD-JTBB4PF0=-V,BIJ\;T?X*IJFCQ:CX@UK4Y->N(Q*TZSG
M,#$9P/7%7?A?XAU:P\1ZKX#\0W9N[K3QOM+AR2TD>><D]>JX[]?2@#U?I3%F
MB=MJ2HQ] P->3_$S7-8UGQ=IG@'0+N2S>[42WES&V&5,GC(YZ#/OFJFM?!H:
M#HLVJ>%]:U&WU>T3SR[3'$Y7D@C\/I0![-17(?#7Q:_C+P=;ZA<;1>Q,8+I5
M&,2+WQ[@BNOH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H)P,
MGI2.ZHC.Q 51DD]A7A7Q!^*]YKFGZII'@RVN)8+:-C?:B%*B-.A"YZ?7\J /
M=$=)%#(RLIZ%3D4ZO/?@C_R2?2/K-_Z-:JWQ?\7:AHEAIVAZ)(8M6UB;R8Y1
MG,:9 +#T.2/UH ]'\^(OL\U-WIN&:<\:2KMD17'HPS7D0^!5LFE>>FO:DNO[
M-QOO.;E^N/IG\:V/A+XNU#6]/O\ 1=<D#ZQI$QMY6)^:0 XR?<$8SWH ]%)2
M-.2JJ/P H22.091U8?[)S7B>H/J7Q7^(^H:#'J-Q9>&](&V?[.^TSOGOZYYZ
M],'UJ#Q9X.OOA3:P^*/".J7?V6V<"ZL)Y"\;J3R<?S].U 'NM,>6./'F2*N?
M[QQ6))XJLE\$-XHC.ZU^Q_:E'K\N0OUSQ7E'A+P1=?%.TF\4^+M2O&AN96^Q
MV<4I5$0=P!TY]/0T >Z!@PRI!'J*6O%-*FU3X6_$BQ\.W>J3WWA[5R!;M<,6
M:%S\H&3TYQ[8YZU[70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUHN(UR/3S<U[57BGB]T\3_'WPWIMG()%TH)-<[>0K*V\@GZ8_.O:Z "BBB@
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MC^E'Q]C5OAE,Y'S)<Q8_%JH_ +4(H_#>I:!+)B]L+URT3<,$. ./JII/C[J
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ML@-S8,\$R'JIW%AD?1A0!@_M #RK'PU<I_K4U)<$=>F:J^/&-U\8/ D$O*;
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M]PZ<A#@G'YX'XU[50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5XI\5[VY\7^-M(^'FGRD1NZS7Y4\A?O<_1?F^M>TR.(XW<]%!)_"O$
M_@\O_"1^/O%7BR8^83.T,#'^%2>,?\!P* /9=/L+?2].M[&TC6.W@01QHHP
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M% 'J/AYS)X;TMVZFTBS_ -\BM*JVG6QL],M+8]884C_)0*LT %%%% !1110
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M CR >?4,I'\J@^#[L_PKT+=_#$P'TWM5+XVZS#IGPVOK8R 75\4@@3NQW G
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MGJ&JS1LG]HWKR1ANZ#H?S)_*O6* "BBB@ HHHH **** "BBB@ HHHH ****
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M% '">#OA?IWA;5)M8N;RXU76)>MY=<LHQCC_ !KNZ** "BBB@ HHHH ****
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M77:AI]KJNGSV-] D]M.A22-QD,#5FB@#R0_!.6T6:TT?QCJ^GZ7,S%K-&)4
M]NO/XUW7@_P9I7@K238:9&<N=\TS\O*WJ3_3MFNAHH YSQEX)TGQOI0LM3C(
M="6AG3AXF]1_A7$'X*2WKPV^M>,=7U+3(6!6TE<[2/3KQ^%>M44 5[&QMM,L
M8;*SA2&V@0)'&@P% JQ110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JEJ^K6>AZ5<:GJ$OE6ENNZ1\9P,X_K5VJ
MFJ:99ZSIL^GW\*S6LZ[9(VZ,,Y_I0!QG_"Z/ O\ T&1_W[;_  H_X71X%_Z#
M(_[]M_A5C_A4?@?_ * -O^5>,> /"6AZK\8M>T>]L(YK"W68Q0MT7#J!^AH
M]@3XR^!I'5%U@%F( 'EMU/X5OWWC+0]-\16V@W5WLU&YQY46TG=GIS60OPE\
M$(ZNN@VX92"#CO2:UX>\'WGCW3]3U&\V:["4-O#]HV[L'CY>] ';455U#4;+
M2K1KJ_N8K:W4X,DK;5'XU2U'Q5H.DV45Y?ZK:P03+NB9G^^/4#J10!KT5D:+
MXHT/Q$&.D:I;794998W^8#UP><57U3QOX8T6[^RZAK=I!/G!C+Y*GWQG'XT
M;]%5;#4;+5+1;JPNH;F!NDD3AA^E6'D2*-I)'5$499F. !ZDT .HKFI/B%X1
MBNA;/X@L1*>PDR/S''ZUT%M=07ENEQ:S1S0N,K)&P96'L10!+1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img116206746_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img116206746_3.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" )-!>0# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y&_X(&_\
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M .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\
MZ/4^(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H
M]3XB?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU
M/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^
M(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB
M?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_
MX)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@
MGL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">
MP_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#
M_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_
M (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\
MB:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")
MH_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC
M_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^
M((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@
MBOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*
M_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]
MD_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3
M_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*_9/_
M .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]D_\
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M (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\
MB:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")
MK]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FO
MVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;
MJB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ
M* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH
M _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#
M\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q
M%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7
M_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^
M((K]D_\ Z/4^(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@
MBOV3_P#H]3XB?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*
M_9/_ .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]
MD_\ Z/4^(G_@GL/_ (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3
M_P#H]3XB?^">P_\ B:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_
M .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\
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M (FC_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\
MB:/^((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")
MH_X@BOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC
M_B"*_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^
M((K]D_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@
MBOV3_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*
M_9/_ .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]
MD_\ Z/4^(G_@GL/_ (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3
M_P#H]3XB?^">P_\ B:_;JB@#\1?^((K]D_\ Z/4^(G_@GL/_ (FC_B"*_9/_
M .CU/B)_X)[#_P")K]NJ* /Q%_X@BOV3_P#H]3XB?^">P_\ B:/^((K]D_\
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M (FOVZHH _$7_B"*_9/_ .CU/B)_X)[#_P")H_X@BOV3_P#H]3XB?^">P_\
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M!(GFLSA7B8'DGD, >*^UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-K=;=ES;,1_%%.DL1]T- 'K5%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ."K_P"S9\-=+M]+\':;X7;Q!I&B6,8CM[&?4?#9N+A(HU&V-3(Q(5< #
M%?HU_P $I_\ E&?\!?\ LD^A?^D45?#OP:_9%_;9\1?\$\_VV_VHOVGO@?>:
M+\7OVDM%UF[TKX:Z.OVZ]L;.'2GM-/L0D&\R3% JA!ESA<@,2HX_]D3_ (+0
M_MT_LS?LM_#W]GS5?^#?W]J'5;CP3X/T_19]2M_"6H1QW36\"1&14.GDJ&*Y
MP2<4 ?LE17G/[)_QM\6?M%_L^>&?C3XY^!_B+X;ZMK]C]HO?!/BRW>+4=);>
MR^5.KHC!L*&Y4<,*]&H **** "BBB@ HHHH **** "BBB@ HHHH *S/%WA;0
M?'/A;4O!7BJPCO-+UC3YK'4K23[LT$J&.1#[%6(_&M.@C/!% '\:/[5G[.O[
M2?\ P0/_ ."H]M=:(MQ]H\"^+!K?PX\174)$.NZ6)#Y+MCC+1'RID!.UBZ\C
M!/[K_ ;_ (.]_P#@E1X_^$MKXL^-NL>+? 7BR/3PVI>%9O"USJ >Y"G<EM<6
MJO&Z$CY6E,1PZ[@OS8^[?VW?^"?O[)W_  41^$LGP<_:P^$MCXCTU6\S3;[F
M&_TJ;'^NM;E,20OZX.UQ\KJRD@_ESXY_X,F/V/\ 6/$<E]X!_:_^(&AZ:W^K
MT^\TFSO9$^8G_6_N\\8'W>V>^  ?EK_P7/\ ^"OOB_\ X+1?M0^&])^$G@?6
M-/\  ?A4R:=\/?#,T8DO]0NKF1!+=RQQ%AYTICA18U+;%0 $EF)_I,_X(K?L
ME_%O]BS_ ()Q_#OX*_'KQ1JNI>-&T]M3\21ZMJDEVVFW-R?,^PJSL<+"I6,J
MIV[U<KD'->;_ /!.'_@W._X)U_\ !-WQI!\7O!GA34O&WCRU4BP\5^-KA;AM
M.R,%K6W15AA<_P#/0JT@Y"NH)!^]J "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H[C_4
M2?[I_E4E1W'^HD_W3_*@#^+_ ,$?\CE\1/\ LI6K_P#HQ:*/!'_(Y?$3_LI6
MK_\ HQ:* /V*_P"#(O\ Y-.^-7_91+/_ -(%K]NJ_$7_ (,B_P#DT[XU?]E$
ML_\ T@6OVZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBORH_X.>/
M^"PFI_L,?L^Q_LI_LZ>+KBU^+GQ$TZ5Y+S1[AENO#VB@-YUX&3YHI7"LL; @
MJ%D<$; : /U7HK\D_P#@S^^//QR_:!_81^)'B?X\?&CQ9XXU*S^+DUK9ZCXN
M\17.I3P0#2[!Q$DEP[LJ;F9MH(&6)QDFOEZ7]HG_ (*/?\'$7_!4'XF?L^?L
MD?MNZ]\#?@S\,7N1:ZQX9N+F.6X@AG:VAG9;6:"2>6YD5I K3(D<8/5E < _
MH-HK\0_^"'__  4)_;F_9X_X*D^-O^"+O[?_ ,:;SX@S:1]KA\*>)]8G::Z$
M\$8N$Q-)F66*>V;S%$A9E/?'%4?^"N_[>7[>'[;O_!7?0/\ @C!^P)^T!>?#
M'3[=HX/%GBK1II(+J2X-N;JXD:6(B41P0 8CC9"S9RV", '[E5\X_P#!7/Q9
MXO\  G_!,'X^>,_A_P"*;S0]:TGX4ZU>:;JVGR%)K::.T=PZ,.5;CAAR.HY%
M?D9\+/VH?^"C/_!!O_@KEX"_8?\ VOOVQM=^-_PE^)DUG%'KWBB:=IX4O)3;
MK=H;J::6!X)\;X_.D1H\XPQ&W]9_^"SG'_!)7]H[)_YHSX@_](9: /S+_P""
M<?\ P1N_; _;I_8C^'/[6VM_\%J/C=X=N?'&AF_FT6UWW$=HWG21[%D:[4L/
MDSDJ.M?M1\'O!&H_#'X3>%_AIJ_B^\\07?AWP[8Z9=:]J"XN-3D@@2)KJ3D_
M/(4+MR>6/)ZU\M_\&]O_ "AA_9^_[$MO_2RXK[*H 1FQ7&:Y^T3^S_X:U>XT
M'Q'\<_!NGWUK)Y=U9WWB:TBFA;^ZR-(&4^Q%=I7X/_L;_P#!*3]C/_@IW_P5
MT_;R_P"&NO VH:U_P@_Q"T/_ (1_[#K,UIY/VQ=3\_=Y9&_/V6'&>FTXZF@#
M]I#^U+^S+_T<9X#_ /"NLO\ X[7YH_\ !OU^V'I&M_&O]K^+XX_M.V-Q9VOQ
MJV>%5\3>,(S''9YNN+7SI<>5]W[GR]/:O2A_P:C_ /!&+O\  OQ!_P"%E=__
M !5'_$*-_P $8_\ HAGB#_PLKO\ ^*H ^Y#^U-^S*!G_ (:,\!_^%=9?_':Z
M3PAX\\$_$#3&UKP!XRTG7+-93&UYH^H17,2N!DJ6C8C/(XSGFOSW_P"(4?\
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M89C(E13E<$@8Z4 ?2E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YJ_\ !1OX[?\
M!2?XQ_\ !4[P5_P3I_X)U?M;Z?\ "3R?A+=>,?'&O7W@G3]:C*M=^1;(RW<$
MA1B48 (5R&).<"O7?V'/V6/^"Q'PB^-R^+_VWO\ @J'H7Q;\$C2YXF\)Z?\
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M7WAG5_%O[.K6NHV<MK<B.S"L8Y$*-@]C@FO)_P!A7_@GU_P<Z_\ !.SX&?\
M#/'[./B3X#P^'/[;NM5V:U)]JF^T7!4R'>5'R_*,#'% '[A45^47]D?\'>/_
M $-_[./_ ( BC^R/^#O'_H;_ -G'_P  10!^KM%?E%_9'_!WC_T-_P"SC_X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_.O]M#]ESX<_#;_ (*X_LN?M#:!
MK/B>;7/&?Q(UF+5K74O%%U<Z?$J:#<8^SVDCF*W/RC)103SGK7Z*5\3?\%!?
M$?A_4?\ @HE^QOH=AKMG-?6GQ,UPW5G#=(TL(.@W6-Z Y7\10!]LT444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%_IC:?>:E8ZE>S-);,ZN8R)YW7!9%.0,\=: /HRBBB@ HHHH **** "BBB@
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MA<Z7#.WBRZ^.NG>'6%TS.)+?[)<6DKD( A\S=AM^ !M.0#Z:HKX9_P"&YO\
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MTY_X.J?V7=O_ $1OQ)_Z1ZE7ZE$XZT (H(&#2T9STHH **** "BBB@ HHHH
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M?V'/^"RUU^RG^UM_P47^(GQ2CU?X7W6N?#NWUFXD.G:S;B6..X\^&2:0V]W
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M8L[6>%6FB.)$VSQH^03_ '<>E 'I5%%% !1110 4444 %%%% !1110 4444
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M<_!]O9:E-X$_L^\G\36B176S3;T/Y;F3#[20#M)P2,T ?H)17 _\-6_LN_\
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MXUZ/\3-?^#OBS0_@IXEL=%\:7OAF_M_".L:I"9+:QU1[=UM9Y5"L6C28QLP
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M_P"WYH.K>)_V<;F:Y_X1UO"_A&QC6\TZ5]T%W%<[%,ES!GRW@>:,$CD#<KD
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M@/X#^,K.WT_6)+GQ!J7BBRC6.QN)U2-YY#;R2*EM;Q>8[2,RL^<! < _9?\
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MF+X/CLM-NK?^U5F%U]J)^T7$V[RS%;_=VX\WG.1CZ<_:-^(-G\)OV?\ QO\
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MX)?_ !W\6>"O$VHZ-JVG_#/5)M/U72;Z2VNK640G;)%+&0T;@\AE((- %/\
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MU\WPTTTFQ!P-TLCN?4L37Z'5\-?L _\ *9?]O_\ ["OPQ_\ 44% 'W+1110
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MR^(G_92M7_\ 1BT4 ?L5_P &1?\ R:=\:O\ LHEG_P"D"U^W5?B+_P &1?\
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MTG3X[:+=Z[8U S^%7M0TVRU:QFTW5;.&YMYHS'-;W$8=)%(P593P0?0U:HH
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M!B2/?L;@<J>!7RW_ ,&]W_*&+]G_ /[$MO\ TLN*^RJ "BBB@ HHHH ****
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MCG_^4] 'V57S;_P6+_Y12_M%?]D<\0?^D,M</_PTE_P6]_Z1>_"/_P 2.?\
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M/6$T_P #:*S"XOEE2^BD9=JL?W<;M(>.B&OLS_@G#_P43_;]_:T^,VI?#_\
M:G_X)>^+O@GH-GH,E[:^)M>DE,-S<"6-1;#?&HW%69NO1#7B?[5HV_\ !U3^
MR[M'_-&_$G_I'J5?J50  DC-%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_V9OA9X@\9_&7]EGXE:;J'[27[36O>)M.\/V_AM9;CP?I]W9V\<$^M*)?\
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M;XBO(Y[7P7X7NF6PTM5ACC,<(%PO!*%S\HY<U^@U?#O[3?\ P<1_\$J/V/\
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M/B33TO=&U:R?='<0MW'H0<J0>000<$&OE[_@K+_R5_\ 8U_[.VTK_P!,&N4
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MV^%>N?&SXS^+K?0?"_ANS-WK6L7BMY=K"&"[VV@G&6 X'>OE?_B(B_X(T_\
M1]GA/_OW<?\ QN@#[4K\GO\ @UH_U'[6W_9QVJ?^C)J^C3_P<1?\$:<_\GU^
M%/\ OW<?_&Z_.?\ X-]/^"L/_!/G]DN+]H\?M#_M+Z)X7_X3+XX:AK7AG[<D
MW^GV+R2[9TVH?E.1UQ0!^]E%?%?_ !$1?\$:?^C[/"?_ '[N/_C=>A_LO_\
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M&X?_  1>^)/C/5OB%XY_8MBU#6M<U&:^U6_E\>>(%:XN)7+R2$+?A1EB3@
M=@!7W%10!\+>&?\ @VR_X(H>#?$^G^,/#/[$EK:ZEI-]#>:?<?\ "=>(&\J>
M)PZ/M:_*G#*#@@@XY!KZS^.O[.WP,_:;^&=Y\&_VAOA1H?C+PMJ"J+K1?$&G
MI<PEE^ZZAP2DBGE9%(=3RI!YKMJ* /F7]D;_ ((\_P#!-/\ 85\;3?$S]EO]
MDOP[X;\13(R+KD]Q=ZE>6ZD898);Z:9[<$<$1%,C@YKZ$\8>#O"GQ"\,7W@G
MQYX8T_6M%U2U>VU+2=6LTN+:[A88:.2*0%74C@JP(-:U% 'R+\(/^"$O_!([
MX$?&"/X[_#+]ACPC9^)K>[-U9W-Y)=WUO9S9W"2"TNII+>!E/*&.-2A *[<#
M&U_P6ENK>R_X)*?M&37$FQ3\'==C4[3]YK.15'XD@?C7U!7S'_P6BACG_P""
M2W[1R31AE'P;U]L,.XLI"#^! - 'PS_P1D_X+K?\$G_V9O\ @F!\'/@1\<OV
MP]*\/^+/#/A=K77-'F\/ZI*]K-]IF?87BM71OE8'Y6(YK]:/ 'CKPI\3_ ^B
M_$OP)JZZCH?B+2;;4]%U".-U6YM)XEEAE <!@&1U;# $9Y /%?GM_P $)_V%
M/V,/B9_P2.^!OCSX@_LK> =;UK4O"+2ZAJVJ>%;6>XN9/M4XW.[H68X &2>U
M?HKH&AZ/X7T.R\,^'=*M['3].M8[6QL;6()%;PQJ$2-%'"JJ@  < #% %ZBB
MB@ HHHH **** "BBB@ HHHH *I^(_P#D7K[_ *\Y?_0#5RJ?B/\ Y%Z^_P"O
M.7_T T ?CG_P:V_\F:?&+_LY;Q%_Z;]*K],*_,__ (-;?^3-/C%_V<MXB_\
M3?I5?IA51)D%%%%42?"/_!KK_P >7[7W_9U&N_R6OU6K\J?^#77_ (\OVOO^
MSJ-=_DM?JM69H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (PRM?"/_!*_XC^/?VD[OXY?&_X[_M1ZHVK:AX^UKPBO
MPOAOHK2U\"V>GW<\$#PPX!6YGA9+AKA@2XDCR3L&/N^OQO\ VAH/V7/^"@G[
M07C;XL?!/_@A9\1OB_!H_B2XT#7/BGX3^)"^$(-?O[-VAG&(]0M6O5C93&7<
M/R"#C % 'UG_ ,$@?'OQ'LO%?QR_93\0_M#ZQ\7/"_PA\;VFE>#_ (@^(;[[
M9?SPS623RV%S=CBZEMW.TR$EL, W(K[= P,5\O\ _!+;3=1\'_ Z^^&<7_!.
M2^_9MT?0]2VZ3X9O-<L+\ZGYB[Y+KS+.:7+;N&:5B['GFO9OV@?'/Q<\ ?#J
M75O@9\'O^$X\37%U';:;HLVL1V%NC/G,]Q.X.R%,9;8KN<@*I)H [JBOA/7_
M /@GW_P51_:"U2;QE\?/^"O&N?#_ .T?-:^"_@;X-M+&PTT==GVR[\RYNCZM
M)CIQ@' T/ WP,_X*]?L<7O\ :7A[]K+1_P!IGPA&V;SPK\0=!@T7Q%%'_P!.
M>HVI\F:3 ^[<IACP&3J #[<HJGHM[<:EI%KJ=WILUG-<6Z226=QCS(&902C;
M21D'@X)&1Q5R@ HHHH **** "OC/_@HE_P G_P#[%_\ V4[7?_3#=5]F5^=?
M[:/[*/P2^&'_  5Q_9;_ &D/!NAZM#XN\;?$C68O$5Y=>*M1N;:94T&XV^7:
M33O;6Q^4<PQH3WSDY /T4KYC_P""T1_XU/\ [07_ &2W5?\ T0:^G*Y?XR?!
M[X=?M!?"KQ!\$_B]X936/"_BG2YM.U[29+B2);JUE7:\9>)E=<CNK CL: ,G
M]G/7-%7]GOP&K:S:@CP;I>1]H7_GTB]Z[+^W]"_Z#5K_ .!"_P"-?(]O_P $
M%O\ @EC;PK!;_L[:K''&H6.-?B7XB"JH'  ^W\"O#/\ @IS_ ,$=_P#@GS\!
M_P#@GU\8/C)\)O@[K6D>)?#?@._O]#U2/XD:_(UK<1QY20+)?,C8/9@1[4 ?
MI6=?T0CC6[/_ ,"%_P :_([_ (..HK']F:_U?]L/PO/&-+^+7P-\2_"?XB?9
MY@5>5K.XO-&N' .-PG$T&[J?-B7HO'TI\$_^"'7_  3-\5?!KPCXFU_X#:Q<
M7VH^&;"ZO;AOB5XA4RS26\;NV!?@#+$G@ 5R'[;_ /P;G?L#_&']DWQYX$^!
MOP8OM+\<W/ARYD\%ZC>>/-9NHX-4C0O;;H[F\DB*M(H1BRG"NQ'(!H ^QOV'
M2?\ ABOX/_\ 9+?#_P#Z;8*]2KYW_P""4W[0'AW]I?\ X)[?"GXE>'=&CTMX
M_"-II.K:+'N']F7UE&+2XML,2R[)(6 #$L%QDDU]$4 %%%% !1110 4444 %
M%%% !1110 445\[?M/?MJ?&WX!?$M? WP_\ ^">OQ6^)]@VFQ7/_  DG@UM.
M%F)'+@P?Z1<1OO7:"?EQAQ@]: /HG-?%_P"PJ<?\%7/VU,_\]O /_ILOJD/_
M  5!_:G_ .D-7[07_?S1O_DRO ?V<_VDOVV/@[^VE^T!^TEKO_!(GXY7&D_%
MB3PRVBV=M)I'GVO]G6=Q!+YN;O'S-,I7!/ .<4 ?J517QF/^"H7[4HX/_!&K
M]H+_ +^:-_\ )E>[_LI_'[XA_M#^"]0\5?$?]E[QI\*;JSU0VD.B^-VM3<7<
M?EH_VA/LTLB^7EBG)!RC<8Q0!ZK45Q#%<0M!<1J\;J5=&7(8'J".XJ6B@#\X
M?BCX%\9_\$.OBQJO[3_P,T/7M>_9=\9:TU[\6OAWI<37<GP_O9F'F:]IL(RW
MV-CS<6Z9V_>4< #NO^"D'Q$\$?%GQ)^Q!\2_AIXIL]:\/ZY^U1HMYI.K:=.)
M(;J"3P]KC)(C#J"#_C7VYJ%A9ZI93:;J%I'<6]Q"T5Q!-&&21&&&5E/!!!((
M/45^+/\ P46^"4O_  1N_:7^ /Q-A^)0M?V29OVC]/\ $+>%;Q6GF\!:Y_9N
MJ1R16.,M_9\T4\TQCY\IH % #'< ?M=15#P_X@T/Q;H-CXJ\,:S:ZCIFI6<=
MWI^H6-PLL-S!(H>.6-U)5T92&# D$$$5?H *XW]HO_DWSQW_ -B;JG_I)+79
M5QO[1?\ R;YX[_[$W5/_ $DEH \9_P"",G_*)?\ 9P_[(QX>_P#2"*OIBOF?
M_@C)_P HE_V</^R,>'O_ $@BKZ8H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "@Y["B@G'6@#\\?VQ/^"57_!03XI_\%#KK]O7]CG]OWPW\)+R3PW:Z
M)_9__"N1?2WUG'&NZ&^9IA'>+YN]XV>/?$'VJP &/-_BI_P1S_X+(?&WX]^"
M_P!HGXL_\%:? ^NZM\.;J6[\%Z7>?!E?[,TR[D38UTMJER%DG"\+))O9?X<5
M^C7B3]I3X"^$OC?HO[-WB+XK:/:>//$6DW&J:-X5DNO],N;*#_6W 0?=C7!^
M9L [6QG:<>"?L]?\%NO^"<'[4'[3MU^R3\'OCJM]XNCNKFUT_P"T:;+!9:M-
M;_ZZ*TN' 2=E'. >1RN10!Z+^Q3\+/VX_A;X<URR_;=_:C\._%#4KJ^C?0[[
MP[X)714LH F'C=!*_F$MSNR,#BO<J** "BBB@#\[/VL/^"7/[</PW_;A\2?\
M%$/^"2'QR\"^$_&'Q!TNWLOB5X(^)5C<2:'K4L*+''>!K9'DBE"*I(51N<%B
M?G;.C^Q7_P $MOVNK_\ ;2M_^"D7_!5']H/PWXZ^)FA>'6T7P'X7\":?+!H'
MAFWDW&5XO.57ED8N_P [*&^;DG:@7] J* /SE_; _P""9/\ P4/\$?MWZ]_P
M4+_X).?M%>!_"WB+QYH=IIOQ&\#_ !)L[A](UIK;"PW):".1Q(J]"%5A\P#A
M7<'I_P#@FU_P3-_:T^%W[57BS_@H=_P4D_:$T'X@?&+Q)X<B\.Z3:^$;.2'2
M?#NDJXD:VMO,2-F!< Y**3RS;F8FOO.B@#\M_$__  2Y_P""N'[&?[2WQ.^*
M/_!(G]I_X6V/@7XM>(9/$&M_#WXL65V;?2M4E7$MS:M;PR_,V!S\H90@</Y:
MD?07_!)[_@FU\4/V((OB-\:?VGOC;#\1OC-\8O$$.J?$#Q59VGD6V(%=;>U@
M3"XBC$CX^50 V H  K[&HH _*+]MOQIX1^'W_!T1^S'XI\=>*=/T;3;?X.^(
MEFU#5+Q+>&,M:ZBJ@NY"C)( R>2<5^E_@GXZ_!;XFZG)HGPX^+GAG7[R&$S2
M6NC:Y!<R)&"!O*QN2!D@9Z<U^3G_  5:_9,^ 7[;W_!QK^SC^S?^TYX$/B3P
M;K7PAUN74]'&J75GY[017\\1\VUECE7;)&C?*XSC!R"17W;^Q9_P1J_X)P?\
M$\OB5??%_P#9 _9W;PEXBU+2FTR\U!O%VKZAYEJSI(8_+O;N5!\T:G<%#<=<
M$T ?4:?=I:1<#@&EH **** "BBB@ HHHH **** "BBB@ HHHH **,T9H ^._
M^#@''_#FG]H3'_0AO_Z40U\H_L$_\$_OV#?&/[%?PL\5>+OV)?A'JFJ:AX%T
MVXU#4M2^&^ESW%S*T"EI))'@+.Q/)8DDFI/^#F3_ (*]_LA?"G]D3XE?\$]-
M$\5_\)5\4O&6A#3[K0]!D69= 0R1RM)>N"1$PC0L(N7P5)"J0:^;/V/_ -M[
M_@LKX4_9:^'_ (;^&/\ P25L_$7AVQ\)V,.BZ\WQ(LX#?VRPJ$F\MGRFY<':
M>1FJB*1]U_\ #MC_ ()U?]&#_!7_ ,-7I'_R/1_P[8_X)U?]&#_!7_PU>D?_
M "/7RW_P\ _X+F_](7['_P .E9?_ !='_#P#_@N;_P!(7['_ ,.E9?\ Q=42
M?4G_  [8_P""=7_1@_P5_P##5Z1_\CU\Q_L=_!OX0_ W_@Z#T_P9\%/A3X;\
M'Z.W[/MY.=)\+Z';Z?;&5GCW2>5 B+N.!EL9.*K_ /#P#_@N;_TA?L?_  Z5
ME_\ %UQ__!+WXK?M/?&3_@Y*L?%?[67[.47PO\4#X$ZA"OAN'7(M04VZO%LF
M\V,D?-D_+G(Q4R'$_>JBBBI*$?[M</XF_:5_9Y\&:[<>&/&'QT\'Z5J5FP6Z
MT_4/$=M#-"Q (#([AE."#R.AKN&Z9S7QE^T=_P &_G_!)7]K;XV:_P#M%?M!
M?LJR:]XR\3W27&N:P/'FNVOVF1(DB5O*M[V.),)&@PB*.,]230!\S?\ !K1J
M%AJ]Q^UUJNEWL5Q;7'[1-Y);W$$@=)$,;$,I'!!'<=:_6>OR'_X-/_ WAGX:
M>'_VJOAUX*TW['H^A_'N>PTNT\YY/)MXH2D:;Y"S-A0!EB2<<DU^O% !1110
M 4444 %%%% !1110 4444 %%%% !4=Q_J)/]T_RJ2H[C_42?[I_E0!_%_P""
M/^1R^(G_ &4K5_\ T8M%'@C_ )'+XB?]E*U?_P!&+10!^Q7_  9%_P#)IWQJ
M_P"RB6?_ *0+7[=5^(O_  9%_P#)IWQJ_P"RB6?_ *0+7[=4 %%%% !1110
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MXX?MQ?!G7/"EOJ,3>)-+T;X8SVMY>68/SQ1S&8[&(Z,00* /MRBBB@ HHHH
M**** "BBB@ HHHH _%?_ (+(_M)?$#]DG_@X1_9Y^.GPQ_9TUWXK:UI/PCUB
M.U\#^&[CRKR^$R7T+LC>7)@1JYD/R'(0].M?:'_!.?\ X*G?M)?MN_&/4OAA
M\8/^"87Q"^"VG6.@R7\/B;Q9JAFM[F59(T%LH^RQ?.0Y;.X\(>*\-_:M_P"5
MJG]EO_LCGB3_ -(]2K]26Y&* !?NTM%% !1110 4444 %%%% !1110 4444
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MWP/X9\<?$+QAK=K8^!_#5UX>_M&\LVN[A84ED91FU@9\$EV 8(3@XH ^!?\
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MY1+_ +.'_9&/#W_I!%7TQ0 4444 %%%% !1110 4444 %%%% !1110 4444
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MT?LD_MQ_MD?&_P"-_P 5=6TWP[\8_'FE:KX#NK?PI>W+WEM!)JID9XXHRT)
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M%*_5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCXI?$3P)XZMK:?4KK3[:ULHM-FM%FLY+6.!%"^8A8R*PR'4CD8)^X* /R?\
M^"I-]_P3F_:<^/\ K'P1^&7_  3)^(OQJ^/GA^Z6&^\7?"?19/#<VAWF-R?:
M_$+^2A*\$,WGQJ2>5;-5_P!G/X2_\'%?[$WP%USXU^./CIX1\?:'H5N]]I_P
M5\<:E<>(->^PHFYK4:W!$K278V[5!$Z,3C>.*]6_8F^*OA'7O^"KO[36M_M-
M_M+W6B>.O!_BA= \ _"O5/$$6GZ;#X3DM+6XAU:&T8K]JFN)3)YDWS% B9QO
M%7?^"8'B+PWX;_X*+_M&_ ;]F;XWZEX^^#.FV.DZ[YUWXA;5[7PYXGO9KIKS
M3K2\9F+(R!9&AW/Y151E=V& /NGX;^*+WQS\/M#\;:CX=NM'N-8T>UO9])OD
M*SV3RQ*[02#LZ%BI'8@UN4#/>B@ K\^_^"[45U\1M0_9E_91\3Z]J=G\/_BS
M\?-/T7XCV^F:M+8_VKIZQ/(+"66)E<13/PRA@25&.0"/T$KS;]J#]DK]GC]L
MWX9-\'?VEOAI;>)_#_V^&^AMY;J>VFM;J(YCN(+BWDCFMY5R<21.K#)YY- '
MRU_P0,U'5]-_9\^,'P3CUS4-0\+_  M_:-\2^$?A_)J5]+=/#HD$-C/# LTK
M,\B1RW,\:DL<! N?EQ7P;^Q]X=T?X*?MY> OVW_VH?V7OASXOD^/'[1GB+3?
M OQ2\#_&B[U75-$O99[AK2.>RM)VTZ2W6%2GR&5TV_O1&^U6_7;X=_\ !/C]
MD7X2^!O _P -_AG\*YM$T7X<^))->\*V>G^)-1C\K49%D62XN&%QNOF<2N6%
MT958D,02JD<S\-?^"2O_  3R^$/[0_\ PU/\._V9],T[QLNH7-_:WXU2^EM;
M*[N#^_N;:QDG:TM9GR=TD,2,<GGDT >H_M)_M%_#?]E/X2:A\;OBRNM'0]+F
MMXKK_A'_  _=:G=;II5B3;;VJ/*XW.,E5.T9)P 37Y\?%;_@HY^S;^VW_P %
M(/V1_"GP-C\:+>:+\0-:N[[_ (2CX?ZIHT?EMHER@V/>P1K(V?X5)('.,5^H
M@5LY)KXU_P""B8_XS_\ V+_^RG:[_P"F&ZH ^S**** "BBB@ HHHH *^2O\
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M_%S]D7X!_MQ^+O@5\'_@);Z;8>(]6^'%PUMJ^NZW=(9BBW,;)(BQA"K .%&
MI5MQ*])_P3R^)/[9_P"PS_P4WUC_ ()4_MA_M5:M\8_#/B'X<_\ "7_"?QUX
MI^?5$CMY?)N;.ZF8F260!2Y+L^0NX,"Q4:'_  1:BET3_@H_^WYX7U:;_B9+
M\;+.^:%EPPMKBVD>!L?W2O0]\55_:UM+KQ!_P<H_L[Z=H,FZXTOX#^++K5(X
MX\D6\L<T,9;T!E(Q[C'>@#R?X2?#K_@H)_P7<^+'Q:^/NB?\%*?B-\"?@WX+
M^(U_X0^&_A[X3ZE)I]QJ3V*J)KVXFADC:6-FD7&YFRP; 0(,_0/_  1F_:0_
M:PL/CM\=/^":7[</Q@_X6!XX^"NIV%YX?\<RVZQ3:[H5\C-%)(%ZR1LH5MW(
M,@&YL;JR?^#7K;:?\$[?%'AN[GW:AHOQV\666K1]&BN%ND8JP[':ZGZ$50_8
M^MYM8_X.7OVHM>T:5FL-,^"_AVQU/RU^5;N2:&2,,>S;(Y,#N,^E ''_ +;?
M@GP9\0?^#H?]F/PKX]\):;KFEW'P=\1-<:;K&GQW-O(5M=192T<BE3A@",C@
M@&OTO\$? ;X&_"_4Y-=^&7P8\*>';Z:$PRWFA>';6SE>,D$H7B125R <9QD"
MOR*_X+$^(_VQO"__  <+_L[ZY^P1X+\'>(?BA'\(]9&@Z5X\:9=+EC,=\+@R
MF&:%\B R,N''S!<Y'!]:/QZ_X.WA_P V>_LE_P#@7JW_ ,MJ /U*'3K17EO[
M'&N_M8>)/V=_#^L_MN>$?">@_$R9)O\ A)-+\$M*VF0L)G$?DF665^8]A.7;
MYB>G2O4J /#_ /@IO_RC:_:$_P"R'^+/_3/=5\M?\&VOPF^%WB+_ ((U_!_5
M]?\ AIX?OKJ:SU S75YHT$LC_P#$PN!RS(2>/>OJ7_@IO_RC:_:$_P"R'^+/
M_3/=5^6__!#?_@O3_P $N/V/?^"8?PU_9Y_:!_:*;0_%GA^WO5U73!X;OY_)
M,EY-(OSQ0LARKJ>">M '['?\*,^"?_1'?"O_ (3]M_\ $4?\*,^"?_1'?"O_
M (3]M_\ $5\3_P#$4-_P1/\ ^CMY/_"/U3_Y'H_XBAO^")__ $=O)_X1^J?_
M "/0!]L?\*,^"?\ T1WPK_X3]M_\17YE_M=^#_"/@S_@Z)_8NM/"/A?3=+BF
M\!^,FFCTVQC@5V_L351DA ,FO7/^(H;_ ((G_P#1V\G_ (1^J?\ R/7YN_\
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M2'3O)D/F1?9[F!O-\T1#EB-I;C."/CW_ (7U_P ';O\ T9[^R7_X%:M_\MJ
M,+_@UJTW3])G_:ZTO2;*&UM;?]HB\BM[6WA"1Q((V 55 P !P .!7ZSU^0?_
M  :77GC^^\(_M27GQ3T^PL_$TWQXE?Q!:Z6S?9H;PP?ODBW,Q\L/N"Y8G&.3
MUK]?* "BBB@ HHHH **** "BBB@ HHHH **** "H[C_42?[I_E4E1W'^HD_W
M3_*@#^+_ ,$?\CE\1/\ LI6K_P#HQ:*/!'_(Y?$3_LI6K_\ HQ:* /V*_P"#
M(O\ Y-.^-7_91+/_ -(%K]NJ_$7_ (,B_P#DT[XU?]E$L_\ T@6OVZH ****
M "BBB@ HHHH ****  XQS7Y;?L"^!_#OQO\ ^#B3]L'XW?$S38=6USX::9X;
MT'P3->1^8-)M9K5O,\G=GRV/E')'.99.FXU^I-?EG\9?^".G_!5/1?V\/C%^
MV#^P;_P4F\-_"NS^+FH64^K:3<>!8=2F9+: 1Q*[7,<B@@F0_(%SOYS@4 ?J
M9@8QBOS-\,>!?#/[/'_!SM<6?PHTBUT?3_B]^SO=:KXRTVQA$4-WJ5I?Q!+P
MJN 967(9L<[F8Y))K%G_ .">O_!RS;QM--_P77\*(B\LS?"'2P!_Y*5UG["G
M_!*'_@HU\+O^"A^F_MY?M[?M[^'_ (O7VD^ ;[PQI\.G^#X],FBAN)8Y!_J$
MCC*AD8G*ECNZT ?I!1110 5E^+]";Q5X5U3PN+KR/[2T^>U\_P O=Y?F1LF[
M&1G&<XR,^HK4HH _/_\ X(9?\$-/^'+Q^*/_ !E%_P +*_X65_8G_,D_V-_9
MW]G_ &__ *?;GSO,^W?[&WROXMWR^C?\%8?^".?[,_\ P5M^&VF^%OC'?ZEX
M>\2^'6D?PKXTT$(;K3R^"T;(XVS0L0"T9P>,JRGFOKKIT%% 'Y+?L>?\&JGP
MW^$'[1?A[]HS]L[]MKQA^T!?>#9;>3PGH_B#1WM+.U\AMT*3">\NWFC1OF6)
M6C3/56'%??\ ^WM^PA\ /^"CG[..J?LR_M&:)<7&B:A,EU9WEC(([K3+R,,(
M[J!R"%D4.PY!!#,I!!(KVH#' %% 'XM?#W_@SK\#Q>,=#TC]H/\ X*/?$'Q]
M\+_#-X\^@_#?^PS9);(6W>4)WO9XT5NDAAMXBXS@H3D?>W_!67P7X7^&_P#P
M1F^/7P_\#:+#INCZ+\"M;LM+T^U3;';V\>G2(B*/0* *^K\#TKY?_P""UEC#
MJ'_!)']HR"?=M7X0:Y+\O]Y+1W'ZJ* .4_X-[3_QIA_9^P/^9+;_ -++BOLN
MOP7_ ."5'_!L;^P=^V5_P3T^%?[3_P 3?B-\2K77O&7ATWVJ6VC^((HK6.3S
MY8\1H825&$'<\U^X7P>^&>A?!7X2^%?@UX7N;J;3/"?AVQT;39KV3?,]O:VZ
M01L[ #+E4!)P,G- '34444 %%%% !1110 4444 %%%% !1110 $X&37/_$'X
MH?#?X1^'&\7_ !6^(6A^&-(258FU3Q#JT-E;K(QPJF69E7)/09R:Z"O*?VPO
MV,OV>/V\O@U/^S_^T_X'D\0>%;F^@O)M-CU*>U)FA;=&V^!T?@]LX/>@#\T/
M^#2_XR?""V_9]^)OPPN?BKX9C\3:S\:-8N='\.OKEN+Z_A$0D,L-N7\R5 B.
MVY5(VJQS@&OV%!R,BOC?]E;_ (()?\$NOV+/CQH/[3'[.O[/=QH?C+PW]J_L
M?4Y/%.H7(@^T6LUK+^[FG9&S#/*O(.-V1R :^QMV%P#0 ZBOSNL_^#AWX"^*
M_P#@K/8_\$LOA=\);[Q'--K#:3?_ !"M]>CCL[:^2%Y)HD@\IFE$97RRV]06
MW8&!D_HC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!X[^U_^V]\$_P!A_P )Z7XS^.%GXJELM8OVL[,>$_!]]K4H
MD5-YWQV<4C(N/XF &>*_-'QO^T'_ ,$1_&N@_%7PN+#]I/2]-^+6OV/B'4-/
MTKX7>)HX=#UVUD:5=5TU#9D6ETTA1W9<AFB3C@Y_8YXDD&'0'ZU\6_$#]F7_
M (+5ZMXUUC5?AY_P4A^%>DZ'<:A-)HVEWGP/:XEM+<N3'$\OV]?,95P"^T9(
MS@4 5_\ @BY8?LDCP'\0/%7[-GCSXN^,=8UKQ/#<^.O&GQJT"[L=8U6[%NJP
M_P#'Q;6ZM$D2A1Y<85>>Y-?;F>,U\=_\$J_C)^UYXL\2_&;X%_MP?&'POXJ\
M>?#7QC:V$G_")^%SIUI'8SVB3V\RL78R^:K$D,J,C(RX88=OL09[T ?D_P#M
MQ>*[S_@I!^T_XZ^%OP7_ ."'W@?]H.Q^#>N?\(OX@^)'C[Q[;Z QU1(HYY+"
MW)A\R1(1.I.9",RY"*#EOJ'_ ()3^%_VEOA?X<USX2?%7_@F3\/_ -G/PEIL
M4,_AZW\"^/K76%U2Y<LLWFK#$C(RJL?SN6+9QVKP[XM_ O\ ;K_9>_;*^*GQ
M7_9\_P""D/[//PS\/?%+7(=<D\ ^//#KR,+E;=+<WS W<;?:)4CC61TPC^4A
MVY!)^@O^">'Q+_:G\8^,O%6A?M)_MM_ SXK-:Z;:S:;IOPCTAK6XTXL[AY;G
M==3;D<!57A>5;DT ?5U%%% !1110 4444 %?G9^VG\>_$/CC_@KC^RW\&;_]
MG+Q]X?L?#/Q(UE[7QUKEC:)HNNEM!N,K921W#S.RYY\R*/[IQGO^B=?&?_!1
M+_D__P#8O_[*=KO_ *8;J@#[,HHHH **** "BBB@ HHHH ^%_P#@I!Y'[*O[
M='[/?_!1*W9;729M8/PO^)EYNVI_9.JR9L)Y3TV07V#DX"K<2'/ K[G# G%>
M0?MZ_LG^'/VX_P!CSXA?LI^*)(X(_&7AFXLK&^D7(LKW;OMKGU_=SK&_')"D
M=ZXK_@DO^T[XK_:L_84\%^-_B<DL/CC0X9O#7Q"M;C_6P:YITAM+L2>C,\>\
M^[\<4 ?2M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\:_\%9?^
M2O\ [&O_ &=MI7_I@UROLJOG7_@H=^Q5X^_;-\/?#=_A9\=/^%>^)?AG\2K;
MQCH>O'08]14W$-C>V@C:&1E4@B\+9.?N=.: /HJBOC7_ (8]_P""N7_26C3?
M_#,Z?_\ '*\&_P""F4__  5\_P""??[#_CO]K^Q_X*8Z3XDE\&V]C(NBS?"/
M3X%N?M%_;6F"X8[<"?=T.=N.] 'ZAUQO[1?_ ";YX[_[$W5/_226OF7_ (8]
M_P""N?\ TEHT_P#\,SIW_P <K/\ %/[#G_!5WQ?X:U'PEKO_  5BL9+'5+&:
MSO(U^#>GJ6BD0HX!$G&58\]J /1/^",G_*)?]G#_ +(QX>_]((J^F*\S_8Y_
M9ZA_9+_92^'?[,5KXD;6(_ /@W3]!75I+<1-=BU@6+S2@)VEMN<9.,UZ90 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%(V,9(H ^2/VJ?^"OWP=_9
M*^-6I? [QA^S/\=O$5]I<-O+)JW@?X4WNJ:;,)H4E CN(AM<J'VL.JL".U?*
M?QT_;'\;?\%1?VP_V;?#7[(/['7QE\+7?P[^*47B3Q=\1_B%X"GT.VTO11!+
M%=62/,=TOVA2 R ;?D3(8XV[G_!3O]N/]N'X@?%W]I#X!_L5?&>W^%NB_LO_
M  1N/&/CSQ5'HD%]J6M:I)I+ZG:Z;;"=6C@B\@1[YMI<%VVX*@U9T']N/]MG
MX&P?L9?M'^/OBU9^+/AC\<]%T'P7XZ\-WVDQI?6?B"[AGGBUF*= &?S21%)'
M@(HB0@?,Q !^G]%%% !1110!^/'[5/\ P2$_X+A_$_\ X*C>(O\ @HC\&_VC
MOV?8Y+.XEL?A;8^-X[_4&\.:2C8@\N"32Y8H+HK\[R(6(DD?:Y&#7T-^R#\%
MO^#C+PQ^T-X=US]M3]K_ . ?B/X9P3R'Q-HOA#19X]0N8_+8((F;3(0"'V$_
MO%X!^E?H#1CMB@#\Y_VY/^"4'[<K_MIZE_P4*_X)0_M=>'OAKXZ\6:';:7X^
M\,^---DFT?7%@P(;AS'%-^\5. K0MR.'4,PKJO\ @F/_ ,$LOVB?V??VA/%G
M[>?_  4&_:;L_BM\</%VAQ:)'>:+8M!I>@Z6C"0VMKO5&96D .?+B  ^Z2Q-
M?=U% 'Y:_%C_ ()!_P#!4C]FO]IGXB?'#_@CS^W!X+\%>&_BQK+:SXJ^'_Q&
MTJ:2SL=2=2);FU:.WN068XY\N-@, LX5:^CO^"4/_!,_Q+^P)X>\<_$'XX_'
M2X^)GQ>^+&O1ZO\ $;QM+:F&.YDB5E@MX4))$4:N^"<9W'"J  /KRB@#\J?V
MRO$>@>%?^#I+]F'6_$VNV>FV<7P=\1"2[U"Z2&),VFH@ LY &20!SR37Z;^'
M/B;\-O&=ZVG>#_B!H>K7$<>][?3=6AG=5SC<51B0,D<^]?C_ /\ !7W]CCX+
M_M[_ /!P_P#LZ_LP?M VFI3>%==^$>M2ZA'I.H&UG+6\=]<1[9 "1\\:YXY'
M%?;?[ /_  0[_81_X)I_%G4/C3^S!HOBBWUS5-%?2KI]<\2/>1&W:1)" C*,
M-NC7GZT ?82  D"G4B'Y:6@#P_\ X*;_ /*-K]H3_LA_BS_TSW5?%_\ P;J_
ML9?L??%#_@D%\)?'/Q+_ &4?AMXBUJ^M=0-YK&O>!=/O+JX(OYU&^66%G;
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M* "BBB@ HHHH **** "BBB@ HHHH *CN/]1)_NG^525'<?ZB3_=/\J /XO\
MP1_R.7Q$_P"RE:O_ .C%HH\$?\CE\1/^RE:O_P"C%HH _8K_ (,B_P#DT[XU
M?]E$L_\ T@6OVZK\1?\ @R+_ .33OC5_V42S_P#2!:_;J@ HHHH **** "BB
MB@ HHHH *_*#XZ^)OVQ/^"NG_!6'QA^QI\#_ -HK6/A/\%_V:;S2;GQUJGAM
M?]/\2:Y*WGQV['(7RE,+HJ'Y?W4C,'+*$_5^OR2^)7QF3_@AK_P5_P#BM^T?
M^T)X:U8_L^_M06^EWDGCK2].>YC\.>(+1'C,%V$!(1S).X8#[LRXSL>@#],?
MVF/@3H_[3OP"\6?L^^(/%^N>'['Q=HDVFW6L^&[I(;ZT208,D+R(ZJX]2IK\
M\_\ @EQXA_:M_P""='_!1;6/^".G[2GQWU+XI>#=:\$R>+O@OXRUS<U_;6T,
M@CGT^9B2>%RV,E5*$K@/M'T)JW_!?7_@CWH_A#_A-I_V\?!,UKY>];>WN)9+
MAN,[1"$W[N.F.M?.'_!.[XD>*?\ @J__ ,%?-9_X*E>#OA]KFA_!'X<_#F;P
M;\+]4U[3VM9O$MY<RJUU>HIY\H 2*!SP4)*MN0 'ZIT444 %%%% !1110 44
M44 %?,O_  6?_P"42_[1_P#V1GQ!_P"D,M?35?+W_!:RT^V_\$D_VC(1/)'M
M^#^N2;H^IV6CMM^AQ@^Q- '+?\&]W_*&+]G_ /[$MO\ TLN*^RLU^%?_  2<
M_P"""NL?M0?\$Z?A3\?8/^"IG[1W@E/$_ALW2^%?"/C1K?3=._TB5/+@CS\B
M?+NQZL:_;#X3> G^%?PJ\,_#&3Q3J.N-X;\/V>EMK>L3>9>:@;>!(OM$[_Q2
MR;-[MW9B: .DHHHH **** "BBB@ HHHH *^+?^#@7]JWQK^QU_P2D^)WQ5^&
M'B^^T'Q9>6]GH_AG6--NF@N+2ZNKF.,RQ2*0R2+%YS*0<@@5]I$X&:_,?_@X
M*TV+]H/XX?L??L$.3-;?$;X\6NI^(K/:&\W2=-"S71VDX.(V?J".?P(!\Y_&
MG]G'_@N5I7_!->7_ (*$_'__ (*V>)OAOK7@/X>V^LZ7\-?#MBRPM%'#%@:E
M=&4/<W4I 9_.68!Y&7@96OU8_P""<?QR^(G[3G[!'P=_:#^+=A%;^)O&7PYT
MG5];%O%Y<<MQ/;([3(G\"29\P+T <#G%?*G_  <W^+=:D_X)S:?^S;X-F\O7
M/C5\3M!\$Z2HZDW%QYKG;QE0D)SV&>:^^_AMX'T'X7_#K0/AIX6LEM]+\.Z+
M:Z9IMNO2*""%8HT'T5 * /S1_P""[GP[_:#\8_'[P;>?"'_@NAX%_96LHO!Y
M2Z\)>*OBH= FU>7[5*?MR1">/S%QB/?@\QD9XKX;_P"%&_MO?]+C'P;_ /$D
M&_\ DNOU^_;\_P""+7[ W_!3+XB:+\4?VMOA[K&L:QX?T?\ LO3)M-\375BJ
M6WFO+M*PN QWNQR>:\&_XA,/^"*O_1#O%7_AP=1_^.4 ?=/[*]IK.F_LP_#?
M3_$?Q7L_'FH0> ]'COO'&GZA]K@\13+91!]1CGR?.2X8&99,G<) <G-?&_\
MP< ?\%-?&7[%GP&TG]FW]E_S=0^/7QJNAH'P[TO3E62[LQ.ZP/>I&<_.&<1Q
M$C'F,#R$(K[C^$OPP\)?!'X5>&?@Q\/K.6WT'PCX?LM%T.WFF:5XK.U@2"%&
M=B6<B.-06/)/)K\X/^"J7_!NCX^_X*.?MQV?[;O@7_@HEJ_PHU;3/#=EI6DV
MFD^"9;RXL#!YV98;N/5+9H]YF?Y508RW)W&@#\O_ -BO]A;4/^"=7_!R-\"_
MV:O$?B>;6/$%KINGZIXJU"2;>)-3O-+EGN C=T5W*@GD[<GK7]0E?R>_&#_@
ME5^T!X*_X+S^&/\ @GIJG_!1GQAJWC+5+6QDM_C?<:==C4[,2V+3*JQ'46E.
MQ1Y8Q=+P>PXK^I[X3>"]4^'7PM\,_#W6O%=QKUYH/A^STZ\UNZ5EEU&6"!(F
MN'#.Y#2%2Y!9CEN6;J0#I**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_)SX??LR>)_P!N7X__ !JN?@-_P5 _;@L_
M#_@GQ!=6\>L:3XVMK/P_J&J!Y#/I.EM)!EA;L%C+$[%W %N#7ZQU^;OAOX9_
M\%=/^"9NJ>-OA=^R-^SU\,?C)\(=9\8:KXG\+7OB#Q]_PCVI^&VU"X>[NK>[
M,RM'/$EQ)(ZLF&VN<D<*@!V/_!"/1/V?M ^#WQ T[P-9?%*W^*4?C3;\;H_C
M=J277B@:QY"&/[3)&JQO"82IB:,;67)RQR3]XU\H_P#!,3]FWX]?#R'XB?M1
M_M5>+/"NI?$;XT>(;?5M8L? MPTVCZ19VT M[2SMYFYGVH&+R'.68X) %?5H
MY7F@#\"/V^_V9_V>?B/X_P#VW/%/Q_\ A1<>*/V@O GQ(TSQUX3L]6M;B0W/
MPWMAIY1;,$>4T'-\DV,D@*#G:<?7G_!%6Z_85T7]O;X_>%?^"9&D>&[WX0ZI
MX/\ #.OW&M>&[4F'3=8F^TI)IJSM\VPQJ)?LY/[EQ(,+N(KL/&'QY_X*6_MR
M_M6_%+X>_L!?\*I^'/@GX/>(&\%^(/B)\0M EU;5-;U98(;FZM+>W0A8[6,3
M0YWGYBRL"<E5[;_@F!\6/BQX$^,GQ%_8$_:9^!_PP\)^/O!NGV/B6/7/@_I/
MV'1O%.F7KR1K>&WV*T-RDD6R16SG<I7C- 'VM10#D9%% !1110 4444 %?G9
M^VCXZ_:-UG_@KE^RWX.\?_ S2]%\"Z;\2-9;PGXPM_%"W-QK#G0;C>LEH(E-
MOMRW)=LX]Z_1.OC/_@HD?^,__P!B_P#[*=KO_IANJ /LRBBB@ HHHH ****
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M@^''B#X3>/M+%]H/BC1+O2-:L6D*_:+.YA:&:/*D$;HW89!!&:^)5_X-E?\
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MJ.RQJ#SFOMC_ (2/P]_T';/_ ,"D_P :_,C_ (*7?L9?LMR_\%?/@O\ &O\
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MM+?1=)NM0BBU+5A\7-/G^QP,X#S>6J9?:N6VCDXQ0!]<T444 %%%% !1110
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MB,GK7Z^U^17_  :B>-?#7Q%T7]JSQ]X*U1;W1];^/L]]I=XL3()[>6$NC[7
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MB#QW5W)"WES2QS#<IP8@1@@$ 'ZG4444 %%%% !1110 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ J.X_P!1)_NG^525'<?ZB3_=/\J
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MH **** "BBB@ HHHH ,XZU7DU+3XG,<U_"K+]Y6D (_6K!YKX"_:P_X-LO\
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M_P! G]D__OJ^_P#BZ /U.HK\L?MO_!WA_P! G]D__OJ^_P#BZ/MO_!WA_P!
MG]D__OJ^_P#BZ /U.HK\L?MO_!WA_P! G]D__OJ^_P#BZ#>_\'=P'_()_9/_
M .^K[_XN@#]3J*_#[]B#_@HO_P '-G_!0+2_&FK_  "TC]FOR? ?B^X\-Z]_
M;FGWEL?ML)^?RP)FWIZ-QGTKW/[;_P '>'_0)_9/_P"^K[_XN@#]3J*_+'[;
M_P '>'_0)_9/_P"^K[_XNC[;_P '>'_0)_9/_P"^K[_XN@#]3J*_+'[;_P '
M>'_0)_9/_P"^K[_XNC[;_P '>'_0)_9/_P"^K[_XN@#Z!_X*]_\ !/7XV_\
M!1:X^!/@7P-XG\+V'@OP+\8K'QA\0K?7KRXCN+RVM8VCCCM$BMY5EDVSW'RR
M/$N=O)ZKJ?\ !:K]B#X_?\%%?V&-0_9)_9[\7>&=#NO$7B/2Y/$%YXHOKF"W
M.F6]P)Y(T^SP3,\A>.(JI55.WEAQ7S5]L_X.[O\ H%?LG_\ ?5]_\72_;?\
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ME_$S7&U/1[74HI+JS!T&YP98E8O&#D8W =: /N6BBB@ HHHH **** "BBB@
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M^._$FOZY%I]K\0_V=-:6^L;20G'FS1/&_DE2,L%G8KSP,<@'['T444 %%%%
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M(OB]_P %1$T"XM=2C^",/PV^&-FT;)]BU1].%UK3PAN5/]H/';JV <0/R0U
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M9%_\FG?&K_LHEG_Z0+7[=5^(O_!D7_R:=\:O^RB6?_I M?MU0 4444 %%%%
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M*^$]5U**TUSQ=HOQ,L93IMLQPT\B1Z9')<!1SM,@)]17Z<T4 %%%% !1110
M4444 %%%% !11D8S10!^*O\ P67^$?[3'QQ_X.#_ -GGX;?LB?'^/X8^/+[X
M1ZP^D^,IK$W"V21I?/,OECKOB5X_;?FOM#_@G%^Q;_P58_9T^,NI^,?VXO\
M@I%:_&#PO=:#):V/AV'0&M3;WAEC9;C<>N$5UQ_M5\O_ /!2;]H'X*_LP?\
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M+!>^=:$HHF7Y_+/SIT;F@#V_4=1T_2K";4]4O8;:WMXR\]Q<2!(XU R69CP
M!W/%31R)(BRQNK*W*LIX(]:_,'_@XQ\8_M>>+KCX'_L-_ &Q\#-I7QL^(EA9
M,VN:Y?VU]<75A<+>/#*MO ZIIQ5(1+*K-+E]HCV\G]&?@\GQ3B^%N@0_&VT\
M.V_BY-+A'B&W\)SSS:;%=;?G6V>X5)7B!X5G56(&2JYP #J,\XHR,9S7Y-_
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MQC'4]:^X:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "F22)&IDD;:JKEF/0"GU2U^*6?0[R"'[[VLBK]2IH _('P)X=_X*<_\
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M?&#QIX='AWP]X1NEOKO0X+?4+>[N+R_2++:<L443J_GB-E5F)&U6(\@_;-^
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M*XF4OL4,QR>]):_#;_@Y6L+75+*Q_P""7/[&L,.N3)+K4,.CZ>JZ@ZR"57G
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MT&59-#UK5H[6XNM.=6#AH)9+\O"0P# H001GK5/XB^'?^#GOXOZG::Y\6O\
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M@ HHHH **** "BBB@ HHHH *CN/]1)_NG^525'<?ZB3_ '3_ "H _B_\$?\
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M -N'5_@9J7A+QWINAK\)OC5IOC;4EU*WDD-_;VT4R-;Q[/NNQE!!;CBOJ*@
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M"U^W5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_AL_]CS_ *.O^&O_ (76G_\ QZOC#_B%2_X(P?\ 1O\ K?\ X65[_P#%T?\
M$*E_P1@_Z-_UO_PLKW_XN@#[/_X;/_8\_P"CK_AK_P"%UI__ ,>H_P"&S_V/
M/^CK_AK_ .%UI_\ \>KXP_XA4O\ @C!_T;_K?_A97O\ \71_Q"I?\$8/^C?]
M;_\ "RO?_BZ /L__ (;/_8\_Z.O^&O\ X76G_P#QZC_AL_\ 8\_Z.O\ AK_X
M76G_ /QZOC#_ (A4O^",'_1O^M_^%E>__%T?\0J7_!&#_HW_ %O_ ,+*]_\
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MW"!V+;1@$\G.!CJ/^&S_ -CS_HZ_X:_^%UI__P >KXP_XA4O^",'_1O^M_\
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MO_!&;3X_B]^U_P#MG?MJW*"0>)OC1'X-T6=LEA8Z';>6=IR1M,URZ\=XO84
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'AO_  4D_9#\/?MV?L._$C]EO7D59/$WAN5='NF7)M-3
MAQ/93C_<N8XF..2 1WKY:_9:_P""IH\ ?\$$IOVT?B>Z-XN^%?A&]\-^(--O
M&P[>)-.8V*6T@ZY>80L>Y63=7Z+U^/OQB_X)>?M<:M_P5&UK]F_PQ\-9+C]D
M_P"*'Q4T3XN>,-461/LEKJ5G;S+=Z6R;@2;FYAM'8;<;(XQW- #? WQI\=_\
M$3_^"6?P,^%]QX@\)Z+\<OVD/%SZAXB\9?$[4$M=)T._OE%Y?ZEJ4CR1@_9X
MY88RA909&ZX&#8N_^"J_Q)_8:^(OP_\ %/C?_@LY\%/VL_!GB_QEI_A[QEX8
M\._\(W8ZYX<6[?RQJ-BFD2[KFWB<CS%E1CMQ@KDFOIO_ (+5?L$?%3]K;PW\
M*/CK\ O _AOQ=XX^"'CO^W['P-XNCC;3_$VGS1B.\T]S*K1H[A(65G4K^[(Q
MD@CR*U\ _';]JSXD_#WP1\"O^"./A7]G/2[+Q%:ZC\4/'WQ*^'OAB\=;&'YI
M;#2X(5F,TDS?(MPXB,?RMM'(H \P\(>"/VT?B=_P<._M<_#_ /9%^/&E?"^.
M\\(>$I?%7CRZ\*P:U>V,::?#Y$-G:W)\AGD=FW-*K!40X&2"/HO]@[]K[]LN
M#XH?M0?L2?M7?%?2_'7BWX%:19:IX:^)6G^&[?39=7L[^TNI83<VD($"31/
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MGX,^%OQ@N]&\/^)X_AGI.K:JJ!<Q:;%%+$L'D(J[WFF669C,H5E"G.[\9/\
M@EZO_!/7_@HM\ /VQO\ @EW^RA'9^&9M0NO"?QI\*^#HU1&T:\"@:@Z22#=Y
M#XEX.285&#FO5_\ @CG^S9\=/@!\7_VLM>^,GPUU#P_9^.OV@+S7/"=Q?;-N
MIZ>UNBK<1[6/RD@CG!]J /'/ W[1W[;/[87_  3%_:T^ 'QD^.>GZ)\4/@CK
MFM>%-6^(_ASPG:R1^(+*UM5N7<V<P,,+W-N7A<HJ^7YF^,*RBO!/A_\ '/\
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M'[2WP8\1?!3XQ>&K#5?#^OZ3<6=];ZA;K(B*\97S!N^ZRYW!A@@@$$5^3?\
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MO;EYY7<1 +U;:..B@5[A10 4444 %%%% !1110 4444 %%%% !1110!\X_\
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M52H^8]J=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %1W'^HD_P!T_P JDJ.X_P!1)_NG^5 '\7_@C_D<OB)_V4K5
M_P#T8M%'@C_D<OB)_P!E*U?_ -&+10!^Q7_!D7_R:=\:O^RB6?\ Z0+7[=5^
M(O\ P9%_\FG?&K_LHEG_ .D"U^W5 !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4$9&#110!XUI/[%/POTS]N;5OV_I/$?B"\\8ZI\/;?P;'IMW=0MIMAI\-
MT]R&@01"5)7DD<L3(RD,<*.M>3>*/^"+_P"R[XK_ &F;C]HJ]\??$.&POO'E
MMXVU3X8VWB*)?#%_XB@CV1:G+;& R^:!@X698RPR4)KZ^HH **** "BBB@ H
MHHH IZWI&G>(='NM U>V$UI?6LEO=0MT>-U*LOX@D5\9_ +_ ((3?LF? 3X@
M^'?%:_$[XH>+M!\$V>J6GP_^'_C+Q-#=:'X8@U!'CNH[2*.VCEPT<CH/-EDP
MK8%?;%% 'QS^RI_P1,_9;_9/^,GA?XQ:#\2OB9XM_P"%>V-]9?"WPSXX\41W
MVE^"H+PC[0FGQ+!&XW*%7=,\K *,$$9K[&HHH **** "BBB@ K!^)/@BR^)W
MP^USX<:CJ]]I]OKVCW&GSWVFR*ES;I-&T;/$S*RJX#9!*D XR#TK>HH ^<=5
M_P""7O[,.O?\$\]+_P""9_B*UUN]^'^C^';32;&^;4$BU2-K9E>&\$\4:*MR
M)%$F]4"ELY7!(K6_8F_8$^&?[#]KXNO_  O\1_&GC?Q-X\U:'4/%WC?XA:M#
M>ZKJ<D$7DP)))###&$C3(55C&-S$Y))KWBB@ ''%%%% !1110 4444 > _MP
M_P#!/+X1?MV#P7K7C3QUXT\&^*OASK<FJ^!_''P_UB.RU32+B5!'+Y;S131,
MKH K*\;# XQ7DEM_P0C_ &3M ^#WA7X<_#OXI_%+PKXD\(^,-1\4Z;\5M!\5
M1)XEFU:_01WMS-/);O!(9HU1&4P;0J+M"D9K[9HH \I_8Z_8_P#A'^P_\%K;
MX'_!O^U+BR74+G4=3U;7K[[3J&K:A<R&6XO+F7:HDFD<EF(51V   %>K444
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MPTT'XP_"_P 11ZMX;\4:1;ZIH.J0QNJW=G/&)(I5#@, R,&&0#@T =%1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<?ZB3_ '3_
M "J2H[C_ %$G^Z?Y4 ?Q?^"/^1R^(G_92M7_ /1BT4>"/^1R^(G_ &4K5_\
MT8M% '[%?\&1?_)IWQJ_[*)9_P#I M?MU7XB_P#!D7_R:=\:O^RB6?\ Z0+7
M[=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% $=Q/#:Q-/<S+'&@RSR, %'J2:I)XM\*RNL<7B;3V9CA56\C))].
MM> ?\%?\_P##K[X\?]DSU3_T2:_*3_@EK_P;R_\ !/O]LO\ X(X>!?VI-;T#
MQ-H/Q<\0>&]6OK?QQHGBN[C:SO[;4+R*VF6W+F$!1!%D!03@D$,=U '[U@Y&
M117Y _\ !%S_ (*=?MM^+_\ @C-XM\0Z3\#-:^.GQ>^$?CZZ\$Z+I=OJBQRZ
MQ&L4$T%S=3R<[(1.Z,1EW6%!D,Y8=5\,/^"R/_!0#X/_ /!2OX=_\$\/V]_
M7P+U*\^*VDI)H^K?!K4=0:3PS>,)A]GU&&[N)?-97C"LJF'C+*S@X !^JE%?
MG1^P%_P65^*WQ-^$W[4#?MV>$/"/A7QY^S'K6J)XBL?"UI=6]G/I]M%*T4X2
MYN)I#O:!\,' <,FT#//C$O\ P7]_;0\!_P#!.+X-_M+?&/X0_"O1OB!^T/\
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M^R'\:M%TWP7X!\4?'SX-ZG)I%NVAZPL?AWQ)*_G+:7L<Z.R^1(]O,=T;;'5
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M@DZ+#)+HWB29&FEU%KAHO,EB,<L$8B9BG[DG8"Q)^>OCU\#OBU\<O^"46C_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>>***  KNZ
MTW8*=10 W9W4T;.>M.HH 3:>[4GE^].HH ;Y?O2[?EVFEHH 0KQ@4,NZEHH
M0* <T!0.:6B@ HZ]:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J.X_U$G^Z?Y5)4=Q_J)/\ =/\ *@#^+_P1_P CE\1/^RE:
MO_Z,6BCP1_R.7Q$_[*5J_P#Z,6B@#]BO^#(O_DT[XU?]E$L__2!:_;JOQ%_X
M,B_^33OC5_V42S_](%K]NJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *CN/\ 42?[I_E4E1W'^HD_W3_*
M@#^+_P $?\CE\1/^RE:O_P"C%HH\$?\ (Y?$3_LI6K_^C%HH _8K_@R+_P"3
M3OC5_P!E$L__ $@6OVZK\1?^#(O_ )-.^-7_ &42S_\ 2!:_;J@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "H[C_42?[I_E4E1W'^HD_W3_*@#^+_ ,$?\CE\1/\ LI6K_P#HQ:*/!'_(
MY?$3_LI6K_\ HQ:* /V*_P"#(O\ Y-.^-7_91+/_ -(%K]NJ_$7_ (,B_P#D
MT[XU?]E$L_\ T@6OVZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+4_]'C77_A-Z=_\ &*/^(FK_ (+4_P#1XUU_X3>G?_&* /[!J*_CY_XB:O\
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M-=?^$WIW_P 8H_XB:O\ @M3_ -'C77_A-Z=_\8H _L&HK^/G_B)J_P""U/\
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M?_&*/^(FK_@M3_T>-=?^$WIW_P 8H _L&HK^/G_B)J_X+4_]'C77_A-Z=_\
M&*/^(FK_ (+4_P#1XUU_X3>G?_&* /[!J*_CY_XB:O\ @M3_ -'C77_A-Z=_
M\8H_XB:O^"U/_1XUU_X3>G?_ !B@#^P:BOX^?^(FK_@M3_T>-=?^$WIW_P 8
MH_XB:O\ @M3_ -'C77_A-Z=_\8H _L&HK^/G_B)J_P""U/\ T>-=?^$WIW_Q
MBC_B)J_X+4_]'C77_A-Z=_\ &* /[!J*_CY_XB:O^"U/_1XUU_X3>G?_ !BC
M_B)J_P""U/\ T>-=?^$WIW_QB@#^P:BOX^?^(FK_ (+4_P#1XUU_X3>G?_&*
M/^(FK_@M3_T>-=?^$WIW_P 8H _L&HK^/G_B)J_X+4_]'C77_A-Z=_\ &*/^
M(FK_ (+4_P#1XUU_X3>G?_&* /[!J*_CY_XB:O\ @M3_ -'C77_A-Z=_\8H_
MXB:O^"U/_1XUU_X3>G?_ !B@#^P:BOX^?^(FK_@M3_T>-=?^$WIW_P 8H_XB
M:O\ @M3_ -'C77_A-Z=_\8H _L&HK^/G_B)J_P""U/\ T>-=?^$WIW_QBC_B
M)J_X+4_]'C77_A-Z=_\ &* /[!J*_CY_XB:O^"U/_1XUU_X3>G?_ !BC_B)J
M_P""U/\ T>-=?^$WIW_QB@#^P:BOX^?^(FK_ (+4_P#1XUU_X3>G?_&*/^(F
MK_@M3_T>-=?^$WIW_P 8H _L&HK^/G_B)J_X+4_]'C77_A-Z=_\ &*/^(FK_
M (+4_P#1XUU_X3>G?_&* /[!J*_CY_XB:O\ @M3_ -'C77_A-Z=_\8H_XB:O
M^"U/_1XUU_X3>G?_ !B@#^P:BOX^?^(FK_@M3_T>-=?^$WIW_P 8H_XB:O\
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M'C77_A-Z=_\ &* /[!J*_CY_XB:O^"U/_1XUU_X3>G?_ !BC_B)J_P""U/\
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M\8H _L&HK^/G_B)J_P""U/\ T>-=?^$WIW_QBC_B)J_X+4_]'C77_A-Z=_\
M&* /[!J*_CY_XB:O^"U/_1XUU_X3>G?_ !BC_B)J_P""U/\ T>-=?^$WIW_Q
MB@#^P:BOX^?^(FK_ (+4_P#1XUU_X3>G?_&*/^(FK_@M3_T>-=?^$WIW_P 8
MH _L&HK^/G_B)J_X+4_]'C77_A-Z=_\ &*/^(FK_ (+4_P#1XUU_X3>G?_&*
M /[!J*_CY_XB:O\ @M3_ -'C77_A-Z=_\8H_XB:O^"U/_1XUU_X3>G?_ !B@
M#^P:BOX^?^(FK_@M3_T>-=?^$WIW_P 8H_XB:O\ @M3_ -'C77_A-Z=_\8H
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M^5?Q^_\ $35_P6I_Z/&NO_";T[_XQ2M_P<S_ /!:AUVM^V+<8;C_ )%K3O\
MXQ0!P'@C_D<OB)_V4K5__1BT5SW[-&N:EXE\+:UXCURX::]U#Q-<7-W-G;YD
-LD<3,V!QR2310!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>eldn-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-28T09:32:44.3655+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.eledon.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:eldn="http://www.eledon.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100060 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlans" id="DisclosureGoingConcernAndManagementsPlans">
        <link:definition>100070 - Disclosure - Going Concern and Management's Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments" id="DisclosureShorttermInvestments">
        <link:definition>100090 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1" id="DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1">
        <link:definition>100110 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill" id="Role_DisclosureGoodwill">
        <link:definition>100120 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100130 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100160 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureRestructuringExpense" id="Role_DisclosureRestructuringExpense">
        <link:definition>100170 - Disclosure - Restructuring Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisition" id="Role_DisclosureBusinessAcquisition">
        <link:definition>100180 - Disclosure - Business Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables" id="DisclosureShorttermInvestmentsTables">
        <link:definition>100220 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100230 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables" id="DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables">
        <link:definition>100240 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillTables" id="DisclosureGoodwillTables">
        <link:definition>100250 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100260 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100280 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100290 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisitionTables" id="Role_DisclosureBusinessAcquisitionTables">
        <link:definition>100300 - Disclosure - Business Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" id="DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Going Concern and Management's Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail" id="DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail">
        <link:definition>100360 - Disclosure - Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2">
        <link:definition>100370 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetail" id="DisclosureShorttermInvestmentsAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Short-Term Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" id="DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail" id="DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100400 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" id="DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail">
        <link:definition>100410 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail" id="DisclosureGoodwillAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Goodwill - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail" id="DisclosureGoodwillScheduleOfGoodwillDetail">
        <link:definition>100430 - Disclosure - Goodwill - Schedule of Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail" id="Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail">
        <link:definition>100450 - Disclosure - Commitments and Contingencies - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail">
        <link:definition>100460 - Disclosure - Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail">
        <link:definition>100480 - Disclosure - Income Taxes - Summary of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail">
        <link:definition>100490 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail">
        <link:definition>100510 - Disclosure - Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100520 - Disclosure - Income Taxes - Schedule of Significant Components Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail">
        <link:definition>100530 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail" id="Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail">
        <link:definition>100550 - Disclosure - Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" id="DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail">
        <link:definition>100560 - Disclosure - Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" id="DisclosureStockbasedCompensationAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail" id="DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail" id="DisclosureStockbasedCompensationSummaryOfRsuActivityDetail">
        <link:definition>100600 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail">
        <link:definition>100610 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100620 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="eldn-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="eldn-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="eldn-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="eldn-20231231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="eldn-20231231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="eldn-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:href="eldn-20231231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlans" xlink:href="eldn-20231231.xsd#DisclosureGoingConcernAndManagementsPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="eldn-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments" xlink:href="eldn-20231231.xsd#DisclosureShorttermInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="eldn-20231231.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1" xlink:href="eldn-20231231.xsd#DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill" xlink:href="eldn-20231231.xsd#Role_DisclosureGoodwill" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="eldn-20231231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="eldn-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureRestructuringExpense" xlink:href="eldn-20231231.xsd#Role_DisclosureRestructuringExpense" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisition" xlink:href="eldn-20231231.xsd#Role_DisclosureBusinessAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="eldn-20231231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eldn-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="eldn-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:href="eldn-20231231.xsd#DisclosureShorttermInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="eldn-20231231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables" xlink:href="eldn-20231231.xsd#DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillTables" xlink:href="eldn-20231231.xsd#DisclosureGoodwillTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="eldn-20231231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="eldn-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisitionTables" xlink:href="eldn-20231231.xsd#Role_DisclosureBusinessAcquisitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails" xlink:href="eldn-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail" xlink:href="eldn-20231231.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#DisclosureShorttermInvestmentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" xlink:href="eldn-20231231.xsd#DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="eldn-20231231.xsd#DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" xlink:href="eldn-20231231.xsd#DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#DisclosureGoodwillAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail" xlink:href="eldn-20231231.xsd#DisclosureGoodwillScheduleOfGoodwillDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" xlink:href="eldn-20231231.xsd#DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail" xlink:href="eldn-20231231.xsd#DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail" xlink:href="eldn-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRsuActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail" xlink:href="eldn-20231231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="eldn-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2" xlink:href="eldn-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" xlink:label="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCreditCarryforwardExpirationDescription" xlink:label="eldn_TaxCreditCarryforwardExpirationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" xlink:label="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DescriptionOfBusinessTable" xlink:label="eldn_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DescriptionOfBusinessLineItems" xlink:label="eldn_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyStockIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NOLTrueUp" xlink:label="eldn_NOLTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementMember" xlink:label="eldn_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidClinicalExpense" xlink:label="eldn_PrepaidClinicalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1ExchangeAgreementMember" xlink:label="eldn_SeriesX1ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConversionAgreementMember" xlink:label="eldn_ConversionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveFederalAndStateIncomeTaxRate" xlink:label="eldn_EffectiveFederalAndStateIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:label="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RegulatoryMilestonePaymentsObligation" xlink:label="eldn_RegulatoryMilestonePaymentsObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCreditCarryforwardExpirationPeriod" xlink:label="eldn_TaxCreditCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" xlink:label="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXNonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="eldn_ScheduleOfWarrantActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AtMarketOfferingProgramMember" xlink:label="eldn_AtMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" xlink:label="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AreaOfOfficeSpace" xlink:label="eldn_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxLiability" xlink:label="eldn_DeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ArmisticeCapitalMasterFundLtdMember" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_WarrantsExchangedForSeriesX1PreferredStockMember" xlink:label="eldn_WarrantsExchangedForSeriesX1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_FeeDueForMilestonesAchieved" xlink:label="eldn_FeeDueForMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementInitialClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnnualLicenseMaintenanceFee" xlink:label="eldn_AnnualLicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccreditedInvestorMember" xlink:label="eldn_AccreditedInvestorMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementThirdClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementThirdClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsRightOfUseAsset" xlink:label="eldn_DeferredTaxAssetsRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" xlink:label="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreferredStockWarrantsMember" xlink:label="eldn_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AggregateNetSalesAchievement" xlink:label="eldn_AggregateNetSalesAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" xlink:label="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxReconciliationPermanentItems" xlink:label="eldn_IncomeTaxReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" xlink:label="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccretionOnInvestmentDiscounts" xlink:label="eldn_AccretionOnInvestmentDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PublicFloatMinimumBalanceToBeMaintained" xlink:label="eldn_PublicFloatMinimumBalanceToBeMaintained"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_LesseeOperatingLeaseRemainingTermOfContract" xlink:label="eldn_LesseeOperatingLeaseRemainingTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementSecondClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementSecondClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXOnePreferredStockMember" xlink:label="eldn_SeriesXOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="eldn_DeferredTaxAssetsDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" xlink:label="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NetOperatingLossCarryforwardsExpirationPeriod" xlink:label="eldn_NetOperatingLossCarryforwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NoncashActivitiesAbstract" xlink:label="eldn_NoncashActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RisksAndUncertaintiesPolicyTextBlock" xlink:label="eldn_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PercentageOfCumulativeChangeInOwnership" xlink:label="eldn_PercentageOfCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonAndPreferredWarrantsOutstandingMember" xlink:label="eldn_CommonAndPreferredWarrantsOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedSeveranceCurrent" xlink:label="eldn_AccruedSeveranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedFinancingCosts" xlink:label="eldn_AccruedFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RemainingLeaseTermAbstract" xlink:label="eldn_RemainingLeaseTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_StateIncomeTaxesNetOfFederalTaxBenefits" xlink:label="eldn_StateIncomeTaxesNetOfFederalTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract" xlink:label="us-gaap_TableTextBlockSupplementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockWarrantsMember" xlink:label="eldn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandSevenStockIncentivePlanMember" xlink:label="eldn_TwoThousandSevenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DiscountRateAbstract" xlink:label="eldn_DiscountRateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" xlink:label="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OticPharmaLtdMember" xlink:label="eldn_OticPharmaLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TimeBasedVestingRequirementsMember" xlink:label="eldn_TimeBasedVestingRequirementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxReconciliationStateTaxRateDifferential" xlink:label="eldn_IncomeTaxReconciliationStateTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_InProcessResearchAndDevelopment" xlink:label="eldn_InProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OtherInformationRelatedToLeasesTableTextBlock" xlink:label="eldn_OtherInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsLeaseLiability" xlink:label="eldn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_JefferiesLimitedLiabilityCompanyMember" xlink:label="eldn_JefferiesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OticPharmaIncMember" xlink:label="eldn_OticPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="eldn_ConversionOfPreferredStockConversionBlockerPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RemainingMilestonePaymentsForFirstLicensedProduct" xlink:label="eldn_RemainingMilestonePaymentsForFirstLicensedProduct"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenStockIncentivePlanMember" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" xlink:label="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_FiveHundredMillionAggregateNetSalesMember" xlink:label="eldn_FiveHundredMillionAggregateNetSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXConvertiblePreferredStockMember" xlink:label="eldn_SeriesXConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" xlink:label="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" xlink:label="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" xlink:label="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AmortizationOfOperatingLeaseAsset" xlink:label="eldn_AmortizationOfOperatingLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" xlink:label="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CormorantGlobalHealthcareMasterFundLpMember" xlink:label="eldn_CormorantGlobalHealthcareMasterFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OneBillionAggregateNetSalesMember" xlink:label="eldn_OneBillionAggregateNetSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" xlink:label="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedClinicalCurrent" xlink:label="eldn_AccruedClinicalCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_JeffriesLimitedLiabilityCompanyMember" xlink:label="eldn_JeffriesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ContingentLiability" xlink:label="eldn_ContingentLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfMilestonesAchieved" xlink:label="eldn_NumberOfMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New aggregate share limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Total Number Of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award total number of shares authorized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series X1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X1 Non-voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series X1 Non Voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X1 non-voting convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anelixis Therapeutics, LLC and Otic Pharma, Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign operating losses carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled/Exchanged</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Exchanged</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants or rights cancelled or exchanged.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net valuation allowance Increased (decreased)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquired IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, in-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Preliminary Estimate of Fair Value of Assets Acquired and Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts payable, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable, accrued expenses and other liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCreditCarryforwardExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards expiration description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCreditCarryforwardExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCreditCarryforwardExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of specific clinical development milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Specific Clinical Development Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of specific clinical development milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Under RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 382 limitation on net operating losses and credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Section Three Hundred And Eighty Two Limitation On Net Operating Losses And Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, section 382 limitation on net operating losses and credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares weighted average grant date fair valueof stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business acquisition, date of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Effective Date of Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NOLTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOL true-up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NOLTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N O L True Up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NOLTrueUp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NOL True Up.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with conversion of X non-voting convertible preferred stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Conversion Of X Non-voting Convertible Preferred Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with conversion of x non-voting convertible preferred stock shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Country [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, number of shares initially reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, number of shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidClinicalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidClinicalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidClinicalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X1 Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series X1 Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesX1ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X1 Exchange Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants available for exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited / Canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Canceled In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, forfeited and canceled in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited / Canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions from tax positions taken in prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Provision (Benefit) for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled/Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cancelled/Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable for exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants or rights cancelled or expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants to purchase common stock shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock warrants exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Losses before income taxes:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConversionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConversionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveFederalAndStateIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveFederalAndStateIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Federal And State Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveFederalAndStateIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective federal and state income tax rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease asset obtained in exchange for lease liability:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Asset Obtained In Exchange For Lease Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease asset obtained in exchange for lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RegulatoryMilestonePaymentsObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RegulatoryMilestonePaymentsObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payments Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RegulatoryMilestonePaymentsObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payments obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash, maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Restricted Cash Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash cash equivalents and restricted cash maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination, likelihood of settlement, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Likelihood of Unfavorable Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts and Jobs Act of 2017 Change in Tax Rate Income Taxes Expense Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act of 2017 change in tax rate income taxes expense benefit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancellation of common stock in connection with exchange for preferred stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cancellation Of Common Stock In Exchange For Preferred Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cancellation of common stock in exchange for preferred stock shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of pre-funded warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock in Connection With Exercise of Pre-funded Warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with exercise of pre-funded warrants, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X Non Voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series X Non-voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series X Non Voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X non-voting convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease asset, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Warrant Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Activity Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AtMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AtMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AtMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office of Chief Scientist of Israeli Ministry of Economy and Industry [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Of Chief Scientist Of Israeli Ministry Of Economy And Industry [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office of chief scientist of Israeli ministry of economy and industry.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flows Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Franchise Tax Board [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited / Canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Canceled In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, forfeited and canceled in period, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armistice Capital Master Fund Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armistice Capital Master Fund Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armistice Capital Master Fund Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options Outstanding and Other Equity Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, shares converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_WarrantsExchangedForSeriesX1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Exchanged for Series X1 Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_WarrantsExchangedForSeriesX1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exchanged For Series X1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_WarrantsExchangedForSeriesX1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Exchanged for Series X1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2023 and 2022; 24,213,130 and 13,776,788 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_FeeDueForMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee due for milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_FeeDueForMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fee Due For Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_FeeDueForMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fee due for milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement Initial Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement Initial Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement initial closing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Or Rights Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants or rights issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual License Maintenance Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnnualLicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock and pre-funded warrants, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock And Pre Funded Warrants Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre funded warrants net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reductions from tax positions taken in prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of available-for-sale short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern and Management's Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Substantial Doubt about Going Concern [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions from tax positions taken in the current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccreditedInvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accredited Investor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccreditedInvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accredited Investor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccreditedInvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accredited Investor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assumed and replaced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value, assumed and replaced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Or Rights Assumed And Replaced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants or rights assumed and replaced.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short-term Investments Classified as Available-for-sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards, not to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement Second and Third Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement Third Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement third closing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reporting units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reporting Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right-of-use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time-based and Performance-based Vesting Requirements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time-based and performance-based vesting requirements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AggregateNetSalesAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reaching of aggregate net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AggregateNetSalesAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Net Sales Achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AggregateNetSalesAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate net sales achievement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Payments Under Noncancelable Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options assumed in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock exchanged for X and X1 non-voting convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Exchanged For X And X One Non-voting Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock exchanged for X and X1 non-voting convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unaudited Pro Forma Combined Financial Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recorded during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccretionOnInvestmentDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion on investment discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccretionOnInvestmentDiscounts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion on investment discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccretionOnInvestmentDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion on Investment Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccretionOnInvestmentDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion on Investment Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PublicFloatMinimumBalanceToBeMaintained_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public float minimum balance to be maintained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PublicFloatMinimumBalanceToBeMaintained_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Float Minimum Balance To Be Maintained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PublicFloatMinimumBalanceToBeMaintained_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public float minimum balance to be maintained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_LesseeOperatingLeaseRemainingTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining term of office lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_LesseeOperatingLeaseRemainingTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Remaining Term Of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_LesseeOperatingLeaseRemainingTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease remaining term of contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementSecondClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement Second Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementSecondClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement Second Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementSecondClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement second closing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Gross unrecognized tax benefits at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Gross unrecognized tax benefits at the end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series X One Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X One Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Depreciation And Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets depreciation and amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Under Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination, likelihood of settlement, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Likelihood Of Favorable Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax examination likelihood of favorable settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NetOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NetOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NetOperatingLossCarryforwardsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued in lieu of making a cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Principles Of Consolidation Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and principles of consolidation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Anelixis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anelixis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anelixis Therapeutics Incorporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anelixis Therapeutics, Incorporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liability:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in measurement of lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board of Directors Chairman [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NoncashActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NoncashActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NoncashActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense, recognized over estimated weighted average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertianties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">RSUs vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, vested and expected to vest, outstanding, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, vested in period, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PercentageOfCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cumulative change in ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PercentageOfCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Cumulative Change In Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PercentageOfCumulativeChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cumulative change in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Irvine, California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonAndPreferredWarrantsOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Preferred Warrants Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonAndPreferredWarrantsOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common And Preferred Warrants Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonAndPreferredWarrantsOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common and preferred warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Terms [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options, weighted average remaining contractual terms.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Outstanding Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options granted outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedSeveranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued severance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedSeveranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Severance Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedSeveranceCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued severance current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average number of common shares, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic weighted average shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Long Term Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Long Term Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty long term incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of pre-funded warrants exercised for common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Pre-funded Warrants Exercised for Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pre-funded warrants exercised for common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk and other risks and uncertainties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued costs associated with PIPE financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Lease Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining lease term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_StateIncomeTaxesNetOfFederalTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_StateIncomeTaxesNetOfFederalTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Income Taxes Net Of Federal Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_StateIncomeTaxesNetOfFederalTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State income taxes, net of Federal tax benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common and Preferred Warrants Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TableTextBlockSupplementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Table Text Block Supplement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Components Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandSevenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2007 Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandSevenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seven Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandSevenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seven stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discount Rate [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in operating lease asset and liability due to lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Operating Lease Asset and Liability Due To Lease Modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease asset and liability due to lease modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties associated with uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancellation of common stock in connection with exchange for preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cancellation Of Common Stock In Exchange For Preferred Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cancellation of common stock in exchange for preferred stock value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OticPharmaLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Otic Pharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OticPharmaLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Otic Pharma Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OticPharmaLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Otic Pharma, Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Issued But Not Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses Other Assets Accrued Expenses And Other Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses, other assets, accrued expenses and other liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TimeBasedVestingRequirementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time Based Vesting Requirements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TimeBasedVestingRequirementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time-based Vesting Requirements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TimeBasedVestingRequirementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time-based vesting requirements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issued upon conversion of each share of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock issued upon conversion of each share of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxReconciliationStateTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxReconciliationStateTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State Tax Rate Differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IncomeTaxReconciliationStateTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation state tax rate differential.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Settlements Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options assumed in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Israeli Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Israel Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of available-for-sale short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of one-time milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Guarantees, Commitments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options, nonvested, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Outstanding Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options vested outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of pre-funded warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock in Connection With Exercise of Pre-funded Warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with exercise of pre-funded warrants, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses Other Assets Accrued Expenses And Other Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses, other assets, accrued expenses and other liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in warrant fair market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Warrant Fair Market Value Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, change in warrant fair market value, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected life of option (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life assumption using simplified method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating business segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Long-Term and Short-Term, Combined Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Long-Term and Short-Term, Combined Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_InProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_InProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_InProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited / Canceled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Information Related To Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other information related to leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies Limited Liability Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies Limited Liability Company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Short-Term Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OticPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Otic Pharma, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OticPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Otic Pharma Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OticPharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Otic Pharma, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConversionOfPreferredStockConversionBlockerPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock, conversion blocker, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConversionOfPreferredStockConversionBlockerPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Preferred Stock, Conversion Blocker, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ConversionOfPreferredStockConversionBlockerPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred stock, conversion blocker, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RemainingMilestonePaymentsForFirstLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining milestone payments for first licensed product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RemainingMilestonePaymentsForFirstLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Milestone Payments For First Licensed Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_RemainingMilestonePaymentsForFirstLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining milestone payments for first licensed product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 2021 Warrant Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Two Thousand Twenty One Warrant Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Two Thousand Twenty One Warrant Exchange Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_FiveHundredMillionAggregateNetSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of 500 Million Aggregate Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_FiveHundredMillionAggregateNetSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Hundred Million Aggregate Net Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_FiveHundredMillionAggregateNetSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five hundred million aggregate net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Or Rights Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments Measured At Fair Value On A Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">RSUs vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, vested and expected to vest, outstanding, number.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X Non-voting Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series X Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SeriesXConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BVF Exchanging Stockholders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biotechnology Value Fund L P Biotechnology Value Fund I I L P Biotechnology Value Trading Fund O S L P M S I B V F S P V L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biotechnology Value Fund LP, Biotechnology Value Fund II LP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification obligations amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Current Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity distribution agreement maximum value of common shares issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Distribution Agreement Maximum Value Of Common Shares Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity distribution agreement maximum value of common shares issuable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Outstanding and Other Equity Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with conversion of X non-voting convertible preferred stock shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective date of lease amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Effective Date Of Lease Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, effective date of lease amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development tax credit carryforwards for federal and state</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AmortizationOfOperatingLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AmortizationOfOperatingLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Operating Lease Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AmortizationOfOperatingLeaseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of operating lease asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workers' Compensation Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Loss Before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for which cumulative change in ownership annual use net operating loss and research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period For Which Cumulative Change In Ownership Annual Use Net Operating Loss And Research And Development Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for which cumulative change in ownership annual use net operating loss and research and development credit carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CormorantGlobalHealthcareMasterFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cormorant Global Healthcare Master Fund LP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CormorantGlobalHealthcareMasterFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cormorant Global Healthcare Master Fund LP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_CormorantGlobalHealthcareMasterFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cormorant global healthcare master fund lp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Burlington, Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, grants in period, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OneBillionAggregateNetSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of 1 Billion Aggregate Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OneBillionAggregateNetSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Billion Aggregate Net Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_OneBillionAggregateNetSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One billion aggregate net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average number of common shares, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of U.S. Federal Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ALS Therapy Development Foundation, Inc. License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A L S Therapy Development Foundation Inc License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ALS therapy development foundation, Inc. license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedClinicalCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedClinicalCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_AccruedClinicalCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement Second and Third Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement Second And Third Closing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement second and third closing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Range of exercise prices</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_JeffriesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jeffries LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_JeffriesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jeffries Limited Liability Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_JeffriesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jeffries limited liability company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ContingentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ContingentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ContingentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, equity instruments other than options, nonvested, weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Purchase Price Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eldn_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestones achieved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Common stock number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares of common stock sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, number of shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with PIPE transaction, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rental expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PreFundedWarrantsMember" xlink:to="eldn_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" xlink:to="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TaxCreditCarryforwardExpirationDescription" xlink:to="eldn_TaxCreditCarryforwardExpirationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" xlink:to="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DescriptionOfBusinessTable" xlink:to="eldn_DescriptionOfBusinessTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DescriptionOfBusinessLineItems" xlink:to="eldn_DescriptionOfBusinessLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" xlink:to="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TwoThousandTwentyStockIncentivePlanMember" xlink:to="eldn_TwoThousandTwentyStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_NOLTrueUp" xlink:to="eldn_NOLTrueUp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SecuritiesPurchaseAgreementMember" xlink:to="eldn_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PrepaidClinicalExpense" xlink:to="eldn_PrepaidClinicalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SeriesX1ExchangeAgreementMember" xlink:to="eldn_SeriesX1ExchangeAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ConversionAgreementMember" xlink:to="eldn_ConversionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_EffectiveFederalAndStateIncomeTaxRate" xlink:to="eldn_EffectiveFederalAndStateIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:to="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_RegulatoryMilestonePaymentsObligation" xlink:to="eldn_RegulatoryMilestonePaymentsObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" xlink:to="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TaxCreditCarryforwardExpirationPeriod" xlink:to="eldn_TaxCreditCarryforwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" xlink:to="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" xlink:to="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SeriesXNonVotingConvertiblePreferredStockMember" xlink:to="eldn_SeriesXNonVotingConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ScheduleOfWarrantActivityTableTextBlock" xlink:to="eldn_ScheduleOfWarrantActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AtMarketOfferingProgramMember" xlink:to="eldn_AtMarketOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" xlink:to="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AreaOfOfficeSpace" xlink:to="eldn_AreaOfOfficeSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DeferredTaxLiability" xlink:to="eldn_DeferredTaxLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ArmisticeCapitalMasterFundLtdMember" xlink:to="eldn_ArmisticeCapitalMasterFundLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_WarrantsExchangedForSeriesX1PreferredStockMember" xlink:to="eldn_WarrantsExchangedForSeriesX1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_FeeDueForMilestonesAchieved" xlink:to="eldn_FeeDueForMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SecuritiesPurchaseAgreementInitialClosingMember" xlink:to="eldn_SecuritiesPurchaseAgreementInitialClosingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AnnualLicenseMaintenanceFee" xlink:to="eldn_AnnualLicenseMaintenanceFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" xlink:to="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AccreditedInvestorMember" xlink:to="eldn_AccreditedInvestorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SecuritiesPurchaseAgreementThirdClosingMember" xlink:to="eldn_SecuritiesPurchaseAgreementThirdClosingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DeferredTaxAssetsRightOfUseAsset" xlink:to="eldn_DeferredTaxAssetsRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" xlink:to="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PreferredStockWarrantsMember" xlink:to="eldn_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AggregateNetSalesAchievement" xlink:to="eldn_AggregateNetSalesAchievement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" xlink:to="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IncomeTaxReconciliationPermanentItems" xlink:to="eldn_IncomeTaxReconciliationPermanentItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" xlink:to="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AccretionOnInvestmentDiscounts" xlink:to="eldn_AccretionOnInvestmentDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PublicFloatMinimumBalanceToBeMaintained" xlink:to="eldn_PublicFloatMinimumBalanceToBeMaintained_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_LesseeOperatingLeaseRemainingTermOfContract" xlink:to="eldn_LesseeOperatingLeaseRemainingTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SecuritiesPurchaseAgreementSecondClosingMember" xlink:to="eldn_SecuritiesPurchaseAgreementSecondClosingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SeriesXOnePreferredStockMember" xlink:to="eldn_SeriesXOnePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="eldn_DeferredTaxAssetsDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" xlink:to="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_NetOperatingLossCarryforwardsExpirationPeriod" xlink:to="eldn_NetOperatingLossCarryforwardsExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:to="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AnelixisTherapeuticsIncorporationMember" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_NoncashActivitiesAbstract" xlink:to="eldn_NoncashActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_RisksAndUncertaintiesPolicyTextBlock" xlink:to="eldn_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PercentageOfCumulativeChangeInOwnership" xlink:to="eldn_PercentageOfCumulativeChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CommonAndPreferredWarrantsOutstandingMember" xlink:to="eldn_CommonAndPreferredWarrantsOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AccruedSeveranceCurrent" xlink:to="eldn_AccruedSeveranceCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TwoThousandTwentyLongTermIncentivePlanMember" xlink:to="eldn_TwoThousandTwentyLongTermIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:to="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AccruedFinancingCosts" xlink:to="eldn_AccruedFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_RemainingLeaseTermAbstract" xlink:to="eldn_RemainingLeaseTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_StateIncomeTaxesNetOfFederalTaxBenefits" xlink:to="eldn_StateIncomeTaxesNetOfFederalTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlockSupplementAbstract" xlink:to="us-gaap_TableTextBlockSupplementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CommonStockWarrantsMember" xlink:to="eldn_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TwoThousandSevenStockIncentivePlanMember" xlink:to="eldn_TwoThousandSevenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DiscountRateAbstract" xlink:to="eldn_DiscountRateAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" xlink:to="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" xlink:to="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_OticPharmaLtdMember" xlink:to="eldn_OticPharmaLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" xlink:to="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TimeBasedVestingRequirementsMember" xlink:to="eldn_TimeBasedVestingRequirementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IncomeTaxReconciliationStateTaxRateDifferential" xlink:to="eldn_IncomeTaxReconciliationStateTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="eldn_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:to="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" xlink:to="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_InProcessResearchAndDevelopment" xlink:to="eldn_InProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_OtherInformationRelatedToLeasesTableTextBlock" xlink:to="eldn_OtherInformationRelatedToLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_DeferredTaxAssetsLeaseLiability" xlink:to="eldn_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_JefferiesLimitedLiabilityCompanyMember" xlink:to="eldn_JefferiesLimitedLiabilityCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_OticPharmaIncMember" xlink:to="eldn_OticPharmaIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ConversionOfPreferredStockConversionBlockerPercent" xlink:to="eldn_ConversionOfPreferredStockConversionBlockerPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_RemainingMilestonePaymentsForFirstLicensedProduct" xlink:to="eldn_RemainingMilestonePaymentsForFirstLicensedProduct_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_TwoThousandFourteenStockIncentivePlanMember" xlink:to="eldn_TwoThousandFourteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" xlink:to="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_FiveHundredMillionAggregateNetSalesMember" xlink:to="eldn_FiveHundredMillionAggregateNetSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SeriesXConvertiblePreferredStockMember" xlink:to="eldn_SeriesXConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" xlink:to="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" xlink:to="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" xlink:to="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AmortizationOfOperatingLeaseAsset" xlink:to="eldn_AmortizationOfOperatingLeaseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" xlink:to="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_CormorantGlobalHealthcareMasterFundLpMember" xlink:to="eldn_CormorantGlobalHealthcareMasterFundLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_OneBillionAggregateNetSalesMember" xlink:to="eldn_OneBillionAggregateNetSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" xlink:to="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_AccruedClinicalCurrent" xlink:to="eldn_AccruedClinicalCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" xlink:to="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_JeffriesLimitedLiabilityCompanyMember" xlink:to="eldn_JeffriesLimitedLiabilityCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ContingentLiability" xlink:to="eldn_ContingentLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eldn_NumberOfMilestonesAchieved" xlink:to="eldn_NumberOfMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXConvertiblePreferredStockMember" xlink:label="eldn_SeriesXConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_InProcessResearchAndDevelopment" xlink:label="eldn_InProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="eldn_InProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXConvertiblePreferredStockMember" xlink:label="eldn_SeriesXConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXNonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_15"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXNonVotingConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AmortizationOfOperatingLeaseAsset" xlink:label="eldn_AmortizationOfOperatingLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NoncashActivitiesAbstract" xlink:label="eldn_NoncashActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" xlink:label="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccretionOnInvestmentDiscounts" xlink:label="eldn_AccretionOnInvestmentDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" xlink:label="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxLiability" xlink:label="eldn_DeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eldn_AmortizationOfOperatingLeaseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_NoncashActivitiesAbstract" xlink:to="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="eldn_NoncashActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eldn_AccretionOnInvestmentDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_NoncashActivitiesAbstract" xlink:to="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eldn_DeferredTaxLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:to="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureRestructuringExpense" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RisksAndUncertaintiesPolicyTextBlock" xlink:label="eldn_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eldn_RisksAndUncertaintiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract" xlink:label="us-gaap_TableTextBlockSupplementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlockSupplementAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:label="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" xlink:label="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" xlink:to="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OtherInformationRelatedToLeasesTableTextBlock" xlink:label="eldn_OtherInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="eldn_OtherInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="eldn_ScheduleOfWarrantActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockWarrantsMember" xlink:label="eldn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreferredStockWarrantsMember" xlink:label="eldn_PreferredStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ScheduleOfWarrantActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_CommonStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_PreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DescriptionOfBusinessTable" xlink:label="eldn_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DescriptionOfBusinessLineItems" xlink:label="eldn_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_DescriptionOfBusinessTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="eldn_DescriptionOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_DescriptionOfBusinessTable" xlink:to="eldn_DescriptionOfBusinessLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementInitialClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccreditedInvestorMember" xlink:label="eldn_AccreditedInvestorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementInitialClosingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eldn_AccreditedInvestorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eldn_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenStockIncentivePlanMember" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OticPharmaLtdMember" xlink:label="eldn_OticPharmaLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OticPharmaIncMember" xlink:label="eldn_OticPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" xlink:label="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" xlink:label="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" xlink:label="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="eldn_OticPharmaLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eldn_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="eldn_OticPharmaIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandTwentyLongTermIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportingUnits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Goodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_TitleOfIndividualAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="eldn_SummaryOfSignificantAccountingPoliciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonAndPreferredWarrantsOutstandingMember" xlink:label="eldn_CommonAndPreferredWarrantsOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eldn_CommonAndPreferredWarrantsOutstandingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidClinicalExpense" xlink:label="eldn_PrepaidClinicalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="eldn_PrepaidClinicalExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedSeveranceCurrent" xlink:label="eldn_AccruedSeveranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedClinicalCurrent" xlink:label="eldn_AccruedClinicalCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedFinancingCosts" xlink:label="eldn_AccruedFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="eldn_AccruedSeveranceCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="eldn_AccruedClinicalCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="eldn_AccruedFinancingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" xlink:label="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_FiveHundredMillionAggregateNetSalesMember" xlink:label="eldn_FiveHundredMillionAggregateNetSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" xlink:label="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AreaOfOfficeSpace" xlink:label="eldn_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OneBillionAggregateNetSalesMember" xlink:label="eldn_OneBillionAggregateNetSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" xlink:label="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_LesseeOperatingLeaseRemainingTermOfContract" xlink:label="eldn_LesseeOperatingLeaseRemainingTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_FeeDueForMilestonesAchieved" xlink:label="eldn_FeeDueForMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfMilestonesAchieved" xlink:label="eldn_NumberOfMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RemainingMilestonePaymentsForFirstLicensedProduct" xlink:label="eldn_RemainingMilestonePaymentsForFirstLicensedProduct"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RegulatoryMilestonePaymentsObligation" xlink:label="eldn_RegulatoryMilestonePaymentsObligation"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnnualLicenseMaintenanceFee" xlink:label="eldn_AnnualLicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AggregateNetSalesAchievement" xlink:label="eldn_AggregateNetSalesAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ContingentLiability" xlink:label="eldn_ContingentLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="eldn_FiveHundredMillionAggregateNetSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_AreaOfOfficeSpace" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="eldn_OneBillionAggregateNetSalesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_LesseeOperatingLeaseRemainingTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_FeeDueForMilestonesAchieved" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssued1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_NumberOfMilestonesAchieved" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_RemainingMilestonePaymentsForFirstLicensedProduct" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_RegulatoryMilestonePaymentsObligation" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_AnnualLicenseMaintenanceFee" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_AggregateNetSalesAchievement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_ContingentLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:label="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RemainingLeaseTermAbstract" xlink:label="eldn_RemainingLeaseTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DiscountRateAbstract" xlink:label="eldn_DiscountRateAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_RemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_DiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="eldn_RemainingLeaseTermAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="eldn_DiscountRateAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveFederalAndStateIncomeTaxRate" xlink:label="eldn_EffectiveFederalAndStateIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NetOperatingLossCarryforwardsExpirationPeriod" xlink:label="eldn_NetOperatingLossCarryforwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCreditCarryforwardExpirationPeriod" xlink:label="eldn_TaxCreditCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCreditCarryforwardExpirationDescription" xlink:label="eldn_TaxCreditCarryforwardExpirationDescription"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PercentageOfCumulativeChangeInOwnership" xlink:label="eldn_PercentageOfCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" xlink:label="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_EffectiveFederalAndStateIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_NetOperatingLossCarryforwardsExpirationPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_TaxCreditCarryforwardExpirationPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_TaxCreditCarryforwardExpirationDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_PercentageOfCumulativeChangeInOwnership" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_StateIncomeTaxesNetOfFederalTaxBenefits" xlink:label="eldn_StateIncomeTaxesNetOfFederalTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxReconciliationPermanentItems" xlink:label="eldn_IncomeTaxReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxReconciliationStateTaxRateDifferential" xlink:label="eldn_IncomeTaxReconciliationStateTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NOLTrueUp" xlink:label="eldn_NOLTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_StateIncomeTaxesNetOfFederalTaxBenefits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_IncomeTaxReconciliationPermanentItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_IncomeTaxReconciliationStateTaxRateDifferential" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_NOLTrueUp" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="eldn_DeferredTaxAssetsDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsLeaseLiability" xlink:label="eldn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsRightOfUseAsset" xlink:label="eldn_DeferredTaxAssetsRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_DeferredTaxAssetsDepreciationAndAmortization" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_DeferredTaxAssetsLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_DeferredTaxAssetsRightOfUseAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" xlink:label="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccreditedInvestorMember" xlink:label="eldn_AccreditedInvestorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXOnePreferredStockMember" xlink:label="eldn_SeriesXOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ArmisticeCapitalMasterFundLtdMember" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_JeffriesLimitedLiabilityCompanyMember" xlink:label="eldn_JeffriesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1ExchangeAgreementMember" xlink:label="eldn_SeriesX1ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXNonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AtMarketOfferingProgramMember" xlink:label="eldn_AtMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_JefferiesLimitedLiabilityCompanyMember" xlink:label="eldn_JefferiesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConversionAgreementMember" xlink:label="eldn_ConversionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" xlink:label="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementMember" xlink:label="eldn_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="eldn_ConversionOfPreferredStockConversionBlockerPercent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CormorantGlobalHealthcareMasterFundLpMember" xlink:label="eldn_CormorantGlobalHealthcareMasterFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementInitialClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementSecondClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementSecondClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementThirdClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementThirdClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" xlink:label="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PublicFloatMinimumBalanceToBeMaintained" xlink:label="eldn_PublicFloatMinimumBalanceToBeMaintained"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eldn_AccreditedInvestorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eldn_ArmisticeCapitalMasterFundLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_JeffriesLimitedLiabilityCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SeriesX1ExchangeAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXNonVotingConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eldn_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_AtMarketOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_JefferiesLimitedLiabilityCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_ConversionAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ConversionOfPreferredStockConversionBlockerPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_CormorantGlobalHealthcareMasterFundLpMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementInitialClosingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementSecondClosingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementThirdClosingMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_PublicFloatMinimumBalanceToBeMaintained" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockWarrantsMember" xlink:label="eldn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_WarrantsExchangedForSeriesX1PreferredStockMember" xlink:label="eldn_WarrantsExchangedForSeriesX1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eldn_CommonStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_WarrantsExchangedForSeriesX1PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreferredStockWarrantsMember" xlink:label="eldn_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_PreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TimeBasedVestingRequirementsMember" xlink:label="eldn_TimeBasedVestingRequirementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyStockIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" xlink:label="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenStockIncentivePlanMember" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandSevenStockIncentivePlanMember" xlink:label="eldn_TwoThousandSevenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" xlink:label="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="eldn_TimeBasedVestingRequirementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandTwentyStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandSevenStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandTwentyLongTermIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementMember" xlink:label="eldn_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ArmisticeCapitalMasterFundLtdMember" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eldn_ArmisticeCapitalMasterFundLtdMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXConvertiblePreferredStockMember" xlink:label="eldn_SeriesXConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_InProcessResearchAndDevelopment" xlink:label="eldn_InProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="eldn_InProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXConvertiblePreferredStockMember" xlink:label="eldn_SeriesXConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXNonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" xlink:label="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" xlink:label="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXNonVotingConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="eldn_ScheduleOfWarrantActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockWarrantsMember" xlink:label="eldn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreferredStockWarrantsMember" xlink:label="eldn_PreferredStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ScheduleOfWarrantActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_PreferredStockWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DescriptionOfBusinessLineItems" xlink:label="eldn_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DescriptionOfBusinessTable" xlink:label="eldn_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eldn_DescriptionOfBusinessLineItems" xlink:to="eldn_DescriptionOfBusinessTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_DescriptionOfBusinessTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementInitialClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccreditedInvestorMember" xlink:label="eldn_AccreditedInvestorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementInitialClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eldn_AccreditedInvestorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eldn_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="eldn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenStockIncentivePlanMember" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OticPharmaLtdMember" xlink:label="eldn_OticPharmaLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OticPharmaIncMember" xlink:label="eldn_OticPharmaIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" xlink:label="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" xlink:label="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" xlink:label="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="eldn_OticPharmaLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="eldn_OticPharmaIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandTwentyLongTermIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportingUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonAndPreferredWarrantsOutstandingMember" xlink:label="eldn_CommonAndPreferredWarrantsOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eldn_CommonAndPreferredWarrantsOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnelixisTherapeuticsIncorporationMember" xlink:label="eldn_AnelixisTherapeuticsIncorporationMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eldn_AnelixisTherapeuticsIncorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" xlink:label="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_FiveHundredMillionAggregateNetSalesMember" xlink:label="eldn_FiveHundredMillionAggregateNetSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" xlink:label="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AreaOfOfficeSpace" xlink:label="eldn_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_OneBillionAggregateNetSalesMember" xlink:label="eldn_OneBillionAggregateNetSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" xlink:label="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_LesseeOperatingLeaseRemainingTermOfContract" xlink:label="eldn_LesseeOperatingLeaseRemainingTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_FeeDueForMilestonesAchieved" xlink:label="eldn_FeeDueForMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfMilestonesAchieved" xlink:label="eldn_NumberOfMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RemainingMilestonePaymentsForFirstLicensedProduct" xlink:label="eldn_RemainingMilestonePaymentsForFirstLicensedProduct"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_RegulatoryMilestonePaymentsObligation" xlink:label="eldn_RegulatoryMilestonePaymentsObligation"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AnnualLicenseMaintenanceFee" xlink:label="eldn_AnnualLicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AggregateNetSalesAchievement" xlink:label="eldn_AggregateNetSalesAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ContingentLiability" xlink:label="eldn_ContingentLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="eldn_FiveHundredMillionAggregateNetSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_AreaOfOfficeSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="eldn_OneBillionAggregateNetSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_LesseeOperatingLeaseRemainingTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_FeeDueForMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_NumberOfMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_RemainingMilestonePaymentsForFirstLicensedProduct" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_RegulatoryMilestonePaymentsObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_AnnualLicenseMaintenanceFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_AggregateNetSalesAchievement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eldn_ContingentLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveFederalAndStateIncomeTaxRate" xlink:label="eldn_EffectiveFederalAndStateIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NetOperatingLossCarryforwardsExpirationPeriod" xlink:label="eldn_NetOperatingLossCarryforwardsExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCreditCarryforwardExpirationPeriod" xlink:label="eldn_TaxCreditCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TaxCreditCarryforwardExpirationDescription" xlink:label="eldn_TaxCreditCarryforwardExpirationDescription"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PercentageOfCumulativeChangeInOwnership" xlink:label="eldn_PercentageOfCumulativeChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" xlink:label="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_EffectiveFederalAndStateIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_NetOperatingLossCarryforwardsExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_TaxCreditCarryforwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_TaxCreditCarryforwardExpirationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_PercentageOfCumulativeChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" xlink:label="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccreditedInvestorMember" xlink:label="eldn_AccreditedInvestorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXOnePreferredStockMember" xlink:label="eldn_SeriesXOnePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ArmisticeCapitalMasterFundLtdMember" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_JeffriesLimitedLiabilityCompanyMember" xlink:label="eldn_JeffriesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1ExchangeAgreementMember" xlink:label="eldn_SeriesX1ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesXNonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesXNonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AtMarketOfferingProgramMember" xlink:label="eldn_AtMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_JefferiesLimitedLiabilityCompanyMember" xlink:label="eldn_JefferiesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConversionAgreementMember" xlink:label="eldn_ConversionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SeriesX1NonVotingConvertiblePreferredStockMember" xlink:label="eldn_SeriesX1NonVotingConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" xlink:label="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementMember" xlink:label="eldn_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ConversionOfPreferredStockConversionBlockerPercent" xlink:label="eldn_ConversionOfPreferredStockConversionBlockerPercent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CormorantGlobalHealthcareMasterFundLpMember" xlink:label="eldn_CormorantGlobalHealthcareMasterFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementInitialClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementInitialClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementSecondClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementSecondClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementThirdClosingMember" xlink:label="eldn_SecuritiesPurchaseAgreementThirdClosingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" xlink:label="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PublicFloatMinimumBalanceToBeMaintained" xlink:label="eldn_PublicFloatMinimumBalanceToBeMaintained"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eldn_AccreditedInvestorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXOnePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eldn_ArmisticeCapitalMasterFundLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_JeffriesLimitedLiabilityCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SeriesX1ExchangeAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesXNonVotingConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eldn_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_AtMarketOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_JefferiesLimitedLiabilityCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_ConversionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ConversionOfPreferredStockConversionBlockerPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eldn_CormorantGlobalHealthcareMasterFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementInitialClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementSecondClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementThirdClosingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_PublicFloatMinimumBalanceToBeMaintained" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_CommonStockWarrantsMember" xlink:label="eldn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreFundedWarrantsMember" xlink:label="eldn_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_WarrantsExchangedForSeriesX1PreferredStockMember" xlink:label="eldn_WarrantsExchangedForSeriesX1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eldn_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_WarrantsExchangedForSeriesX1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PreferredStockWarrantsMember" xlink:label="eldn_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" xlink:label="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eldn_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TimeBasedVestingRequirementsMember" xlink:label="eldn_TimeBasedVestingRequirementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyStockIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" xlink:label="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenStockIncentivePlanMember" xlink:label="eldn_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandSevenStockIncentivePlanMember" xlink:label="eldn_TwoThousandSevenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="eldn_TwoThousandTwentyLongTermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" xlink:label="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="eldn_TimeBasedVestingRequirementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandTwentyStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandSevenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandTwentyLongTermIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_SecuritiesPurchaseAgreementMember" xlink:label="eldn_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ArmisticeCapitalMasterFundLtdMember" xlink:label="eldn_ArmisticeCapitalMasterFundLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" xlink:label="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eldn_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eldn_ArmisticeCapitalMasterFundLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="eldn_InProcessResearchAndDevelopment" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_InProcessResearchAndDevelopment" xlink:label="eldn_InProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eldn_AccretionOnInvestmentDiscounts" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eldn_AmortizationOfOperatingLeaseAsset" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eldn_DeferredTaxLiability" order="8" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" xlink:label="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccretionOnInvestmentDiscounts" xlink:label="eldn_AccretionOnInvestmentDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AmortizationOfOperatingLeaseAsset" xlink:label="eldn_AmortizationOfOperatingLeaseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxLiability" xlink:label="eldn_DeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" xlink:label="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eldn_PrepaidClinicalExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_PrepaidClinicalExpense" xlink:label="eldn_PrepaidClinicalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eldn_AccruedSeveranceCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eldn_AccruedClinicalCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eldn_AccruedFinancingCosts" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedSeveranceCurrent" xlink:label="eldn_AccruedSeveranceCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedClinicalCurrent" xlink:label="eldn_AccruedClinicalCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_AccruedFinancingCosts" xlink:label="eldn_AccruedFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eldn_StateIncomeTaxesNetOfFederalTaxBenefits" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eldn_IncomeTaxReconciliationPermanentItems" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eldn_IncomeTaxReconciliationStateTaxRateDifferential" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eldn_NOLTrueUp" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_StateIncomeTaxesNetOfFederalTaxBenefits" xlink:label="eldn_StateIncomeTaxesNetOfFederalTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxReconciliationPermanentItems" xlink:label="eldn_IncomeTaxReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" xlink:label="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_IncomeTaxReconciliationStateTaxRateDifferential" xlink:label="eldn_IncomeTaxReconciliationStateTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_NOLTrueUp" xlink:label="eldn_NOLTrueUp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="eldn_DeferredTaxAssetsRightOfUseAsset" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="eldn_DeferredTaxAssetsDepreciationAndAmortization" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="eldn_DeferredTaxAssetsLeaseLiability" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsRightOfUseAsset" xlink:label="eldn_DeferredTaxAssetsRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="eldn_DeferredTaxAssetsDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="eldn-20231231.xsd#eldn_DeferredTaxAssetsLeaseLiability" xlink:label="eldn_DeferredTaxAssetsLeaseLiability"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" name="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_TaxCreditCarryforwardExpirationPeriod" name="TaxCreditCarryforwardExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AccountsPayableAccruedExpensesAndOtherLiabilities" name="AccountsPayableAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_SecuritiesPurchaseAgreementSecondClosingMember" name="SecuritiesPurchaseAgreementSecondClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AccruedSeveranceCurrent" name="AccruedSeveranceCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" name="IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_SeriesXOnePreferredStockMember" name="SeriesXOnePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_RemainingLeaseTermAbstract" name="RemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_EffectiveFederalAndStateIncomeTaxRate" name="EffectiveFederalAndStateIncomeTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_WarrantsExchangedForSeriesX1PreferredStockMember" name="WarrantsExchangedForSeriesX1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_PercentageOfCumulativeChangeInOwnership" name="PercentageOfCumulativeChangeInOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ConversionAgreementMember" name="ConversionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AggregateNetSalesAchievement" name="AggregateNetSalesAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_AccruedFinancingCosts" name="AccruedFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_ContingentLiability" name="ContingentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_RemainingMilestonePaymentsForFirstLicensedProduct" name="RemainingMilestonePaymentsForFirstLicensedProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_RegulatoryMilestonePaymentsObligation" name="RegulatoryMilestonePaymentsObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_OneBillionAggregateNetSalesMember" name="OneBillionAggregateNetSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" name="EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_OticPharmaLtdMember" name="OticPharmaLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_TwoThousandTwentyLongTermIncentivePlanMember" name="TwoThousandTwentyLongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" name="EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_SeriesXConvertiblePreferredStockMember" name="SeriesXConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_AccreditedInvestorMember" name="AccreditedInvestorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_SecuritiesPurchaseAgreementInitialClosingMember" name="SecuritiesPurchaseAgreementInitialClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_DescriptionOfBusinessTable" name="DescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" name="SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_NumberOfPreFundedWarrantsExercisedForCommonStock" name="NumberOfPreFundedWarrantsExercisedForCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" name="CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_AccretionOnInvestmentDiscounts" name="AccretionOnInvestmentDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_FeeDueForMilestonesAchieved" name="FeeDueForMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_OtherInformationRelatedToLeasesTableTextBlock" name="OtherInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" name="OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_FiveHundredMillionAggregateNetSalesMember" name="FiveHundredMillionAggregateNetSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" name="PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AtMarketOfferingProgramMember" name="AtMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_DeferredTaxLiability" name="DeferredTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" name="IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_TwoThousandSevenStockIncentivePlanMember" name="TwoThousandSevenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" name="LesseeOperatingLeaseEffectiveDateOfLeaseAmendment" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" name="IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_StateIncomeTaxesNetOfFederalTaxBenefits" name="StateIncomeTaxesNetOfFederalTaxBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_PrepaidClinicalExpense" name="PrepaidClinicalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod" name="CashCashEquivalentsAndRestrictedCashMaturityPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_CancellationOfCommonStockInExchangeForPreferredStockShares" name="CancellationOfCommonStockInExchangeForPreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" name="IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_CancellationOfCommonStockInExchangeForPreferredStockValue" name="CancellationOfCommonStockInExchangeForPreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_LesseeOperatingLeaseRemainingTermOfContract" name="LesseeOperatingLeaseRemainingTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" name="IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="eldn_PublicFloatMinimumBalanceToBeMaintained" name="PublicFloatMinimumBalanceToBeMaintained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_DeferredTaxAssetsRightOfUseAsset" name="DeferredTaxAssetsRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_TaxCreditCarryforwardExpirationDescription" name="TaxCreditCarryforwardExpirationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_JeffriesLimitedLiabilityCompanyMember" name="JeffriesLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_InProcessResearchAndDevelopment" name="InProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_IncomeTaxReconciliationStateTaxRateDifferential" name="IncomeTaxReconciliationStateTaxRateDifferential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" name="IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember" name="AnelixisTherapeuticsLlcAndOticPharmaLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_OticPharmaIncMember" name="OticPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved" name="NumberOfSpecificClinicalDevelopmentMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" name="ALSTherapyDevelopmentFoundationIncLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember" name="SecuritiesPurchaseAgreementSecondAndThirdClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_AnelixisTherapeuticsIncorporationMember" name="AnelixisTherapeuticsIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" name="OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_NetOperatingLossCarryforwardsExpirationPeriod" name="NetOperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ArmisticeCapitalMasterFundLtdMember" name="ArmisticeCapitalMasterFundLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" name="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" name="EquityDistributionAgreementMaximumValueOfCommonSharesIssuable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember" name="TimeBasedAndPerformanceBasedVestingRequirementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember" name="TwoThousandFourteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_NOLTrueUp" name="NOLTrueUp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_JefferiesLimitedLiabilityCompanyMember" name="JefferiesLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_TimeBasedVestingRequirementsMember" name="TimeBasedVestingRequirementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_SeriesX1NonVotingConvertiblePreferredStockMember" name="SeriesX1NonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_DiscountRateAbstract" name="DiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement" name="IncomeTaxExaminationLikelihoodOfFavorableSettlement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" name="IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_CormorantGlobalHealthcareMasterFundLpMember" name="CormorantGlobalHealthcareMasterFundLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_AreaOfOfficeSpace" name="AreaOfOfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_SecuritiesPurchaseAgreementThirdClosingMember" name="SecuritiesPurchaseAgreementThirdClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_SeriesXNonVotingConvertiblePreferredStockMember" name="SeriesXNonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ConversionOfPreferredStockConversionBlockerPercent" name="ConversionOfPreferredStockConversionBlockerPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_SeriesX1ExchangeAgreementMember" name="SeriesX1ExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AmortizationOfOperatingLeaseAsset" name="AmortizationOfOperatingLeaseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="eldn_NoncashActivitiesAbstract" name="NoncashActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" name="PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" name="IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" name="PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_DescriptionOfBusinessLineItems" name="DescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" name="BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_CommonAndPreferredWarrantsOutstandingMember" name="CommonAndPreferredWarrantsOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eldn_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eldn_AccruedClinicalCurrent" name="AccruedClinicalCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eldn_TwoThousandFourteenStockIncentivePlanMember" name="TwoThousandFourteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124994208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELEDON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19900 MacArthur Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949) <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,813,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,607,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KMJ Corbin & Company LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125528752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,612,000<span></span>
</td>
<td class="nump">$ 56,409,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">46,490,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,027,000<span></span>
</td>
<td class="nump">3,109,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">56,129,000<span></span>
</td>
<td class="nump">59,518,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset, net</a></td>
<td class="nump">365,000<span></span>
</td>
<td class="nump">739,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">32,386,000<span></span>
</td>
<td class="nump">32,386,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">186,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,066,000<span></span>
</td>
<td class="nump">92,793,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">967,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">383,000<span></span>
</td>
<td class="nump">363,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,545,000<span></span>
</td>
<td class="nump">3,912,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,895,000<span></span>
</td>
<td class="nump">6,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,752,000<span></span>
</td>
<td class="nump">1,752,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,647,000<span></span>
</td>
<td class="nump">8,610,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2023 and 2022; 24,213,130 and 13,776,788 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">326,586,000<span></span>
</td>
<td class="nump">287,034,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(243,191,000)<span></span>
</td>
<td class="num">(202,865,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">83,419,000<span></span>
</td>
<td class="nump">84,183,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">89,066,000<span></span>
</td>
<td class="nump">92,793,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember', window );">Series X1 Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember', window );">Series X Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060128609104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,213,130<span></span>
</td>
<td class="nump">13,776,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,213,130<span></span>
</td>
<td class="nump">13,776,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember', window );">Series X1 Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">515,000<span></span>
</td>
<td class="nump">515,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">110,086<span></span>
</td>
<td class="nump">117,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">110,086<span></span>
</td>
<td class="nump">117,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember', window );">Series X Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,422<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,422<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060207522560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 30,312,000<span></span>
</td>
<td class="nump">$ 27,080,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,688,000<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,648,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">43,000,000<span></span>
</td>
<td class="nump">88,428,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,000,000)<span></span>
</td>
<td class="num">(88,428,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,674,000<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(40,326,000)<span></span>
</td>
<td class="num">(87,966,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (40,326,000)<span></span>
</td>
<td class="num">$ (87,966,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (6.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (6.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">24,619,197<span></span>
</td>
<td class="nump">14,285,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">24,619,197<span></span>
</td>
<td class="nump">14,285,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124518768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Series X1 Non-voting Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series X Non Voting Convertible Preferred Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 163,995<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 278,880<span></span>
</td>
<td class="num">$ (114,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,306,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,070<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_CancellationOfCommonStockInExchangeForPreferredStockValue', window );">Cancellation of common stock in connection with exchange for preferred stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_CancellationOfCommonStockInExchangeForPreferredStockShares', window );">Cancellation of common stock in connection with exchange for preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(550,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and other comprehensive loss</a></td>
<td class="num">(87,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">84,183<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">287,034<span></span>
</td>
<td class="num">(202,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,776,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,970<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares', window );">Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,730,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue', window );">Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value</a></td>
<td class="nump">33,017<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">33,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares', window );">Issuance of common stock in connection with conversion of X non-voting convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares', window );">Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,884)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue', window );">Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares', window );">Issuance of common stock in connection with exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue', window );">Issuance of common stock in connection with exercise of pre-funded warrants, Value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock in connection with vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and other comprehensive loss</a></td>
<td class="num">(40,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 83,419<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 326,586<span></span>
</td>
<td class="num">$ (243,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,213,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,086<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_CancellationOfCommonStockInExchangeForPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellation of common stock in exchange for preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_CancellationOfCommonStockInExchangeForPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_CancellationOfCommonStockInExchangeForPreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cancellation of common stock in exchange for preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_CancellationOfCommonStockInExchangeForPreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with conversion of X non-voting convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with conversion of x non-voting convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with exercise of pre-funded warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with exercise of pre-funded warrants, value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124200336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,326,000)<span></span>
</td>
<td class="num">$ (87,966,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AmortizationOfOperatingLeaseAsset', window );">Amortization of operating lease asset</a></td>
<td class="nump">374,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AccretionOnInvestmentDiscounts', window );">Accretion on investment discounts</a></td>
<td class="num">(1,203,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">6,545,000<span></span>
</td>
<td class="nump">8,153,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,954,000)<span></span>
</td>
<td class="nump">654,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(2,600,000)<span></span>
</td>
<td class="nump">2,081,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(363,000)<span></span>
</td>
<td class="num">(367,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,527,000)<span></span>
</td>
<td class="num">(28,424,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available-for-sale short-term investments</a></td>
<td class="num">(78,287,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of available-for-sale short-term investments</a></td>
<td class="nump">33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(45,287,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet', window );">Proceeds from issuances of common stock and pre-funded warrants, net</a></td>
<td class="nump">33,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">33,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(51,797,000)<span></span>
</td>
<td class="num">(28,424,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">56,409,000<span></span>
</td>
<td class="nump">84,833,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">4,612,000<span></span>
</td>
<td class="nump">56,409,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NoncashActivitiesAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock', window );">Common stock exchanged for X and X1 non-voting convertible preferred stock</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification', window );">Increase in operating lease asset and liability due to lease modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable, accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AccretionOnInvestmentDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion on Investment Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AccretionOnInvestmentDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AmortizationOfOperatingLeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of operating lease asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AmortizationOfOperatingLeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock exchanged for X and X1 non-voting convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease asset and liability due to lease modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NoncashActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NoncashActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre funded warrants net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122652352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (&#8220;CD40L&#8221; or &#8220;CD154&#8221;) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;). The Company&#8217;s lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. Unless otherwise indicated, references to the terms &#8220;Eledon,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;we,&#8221; or the &#8220;Company&#8221; refer to Eledon Pharmaceuticals, Inc. and its wholly owned subsidiaries, on a consolidated basis.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 14, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Eledon acquired Anelixis Therapeutics, Inc. (&#8220;Anelixis&#8221;), a privately held clinical stage biotechnology company developing a next generation anti-CD40L antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. The Company maintains its corporate headquarters in Irvine, California and has research and development facilities in Burlington, Massachusetts.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126136048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern and Management's Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern and Management's Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Going Concern and Management&#8217;s Plans</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company had a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">243.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, as a result of incurring losses since our inception. Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. The Company expects to continue to incur net losses into the foreseeable future in connection with its ongoing activities, particularly as the Company expands its clinical program with tegoprubart, continues the research and development of, and seeks marketing approval for, its product candidates. In addition, if the Company obtains marketing approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company has financed operations primarily by net proceeds from the sale of preferred and common stock and warrants.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain institutional and accredited investors (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the &#8220;Private Placement&#8221;) shares of common stock and warrants in a series of three potential closings. On May 5, 2023, the initial closing occurred and the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,730,168</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,421,350</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and additional common stock warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,151,518</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or pre-funded warrants in lieu thereof). The Company may receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in tranche financing in a second and a third closing, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million assuming the exercise of all common stock warrants issued in the initial closing of the Private Placement. See Note 10. &#8220;Stockholders&#8217; Equity&#8221; for further information regarding the Private Placement. Due to the contingent nature of the exercise of the common stock warrants and the second and third closings of the Private Placement, accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires the Company to exclude them from its going concern analysis. If these events do not occur or the Company is unable to secure additional capital or is unable to do so on acceptable terms, it will be forced to significantly alter its business strategy, substantially curtail its current operations, or liquidate and cease operations altogether.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023, the Company had cash and cash equivalents and short-term investments of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">51.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Additionally, in view of the Company&#8217;s expectation to incur significant losses for the foreseeable future, the Company will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company&#8217;s access to, such resources is not assured. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, management believes that there is substantial doubt regarding the Company&#8217;s ability to continue operating as a going concern through at least the next twelve months from the date of this filing.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122639472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are prepared in accordance with GAAP. Eledon, a Delaware corporation, owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (&#8220;Otic&#8221;). Otic owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company&#8217;s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company&#8217;s foreign subsidiary are not significant to the consolidated financial statements.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant intercompany accounts and transactions among the entities have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months or less</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all of the Company&#8217;s long-lived assets were located in the United States.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products will require approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company&#8217;s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reportable Segments</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments under GAAP are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer and the Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business segment, which is the development of products for therapeutic medicines selectively targeting critical pathways associated with the underlying molecular pathogenesis for patients with severe inflammation and autoimmune diseases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired under the acquisition method of accounting. Goodwill is not amortized but is evaluated for impairment as of December 31 of each year or if indicators of impairment exist that would, more likely than not, reduce the fair value from its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company performs its goodwill impairment analysis at the reporting unit level, which aligns with the Company&#8217;s reporting structure and availability of discrete financial information. The Company performs its annual impairment analysis by either comparing the reporting unit&#8217;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#8217;s fair value from the last quantitative assessment to determine if there is potential impairment. The Company may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#8217;s estimated fair value was significantly in excess of the carrying value of its net assets and it does not believe there have been significant changes in the reporting unit&#8217;s operations that would significantly decrease its estimated fair value or significantly increase its net assets. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies. Key assumptions for these projections include revenue growth, future gross and operating margin growth, and its weighted cost of capital and terminal growth rates. The revenue and margin growth is based on increased sales of new products as the Company maintains investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including timing and probability of regulatory approvals for Company products to be commercialized. The Company&#8217;s market capitalization is also considered as a part of its analysis.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s annual evaluation for impairment of goodwill consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reporting unit. In accordance with the Company&#8217;s policy, the Company completed its annual evaluation for impairment using the quantitative assessment, utilizing the market approach and due to declining market conditions, determined that the fair value of the reporting unit was below its carrying value. As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">48.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of goodwill impairment, reducing the goodwill balance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill impairment was recorded for the year ended December 31, 2023.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which the carrying amount of an asset exceeds its fair value. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments of long-lived assets have been identified during the years presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-Process Research and Development</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of in-process research and development (&#8220;IPR&amp;D&#8221;) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (&#8220;R&amp;D&#8221;) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company&#8217;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, incentive stock options, restricted stock units and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company&#8217;s net loss position. Basic weighted average shares outstanding for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> include </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,776,270</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">509,117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, shares underlying pre-funded warrants to purchase common shares. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the shares underlying these pre-funded warrants can be issued for little </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(an exercise price per share equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share), these shares are deemed to be issued for purposes of basic earnings per share.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.3%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.34%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.040000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,326</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,966</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.64</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.16</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,619,197</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,285,254</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of diluted earnings per share excludes incentive stock options, restricted stock units, and warrants that are anti-dilutive. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary as of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.247%;"></td>
          <td style="width:1.44%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.937%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.44%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.937%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding and other equity awards</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,909,155</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,012,035</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common and preferred warrants outstanding</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,577,332</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,127,121</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,486,487</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,139,156</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. The expected dividend assumption was based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units (&#8220;RSUs&#8221;) are measured and recognized based on the quoted market price of our common stock on the date of grant.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. We assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. We have provided a valuation allowance on our deferred tax assets as of December 31, 2023 and 2022 because we believe it is more likely than not that a majority of our deferred tax assets will not be realized as of this date.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company evaluates the accounting for uncertainty in income tax recognized in its consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positions </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">where it is &#8220;not more likely than not&#8221; that a tax benefit will be sustained, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued any liabilities for any such uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or processes, if any. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likely of being realized upon settlement.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. For additional information, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 9. Income Taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements Issued But Not Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126073728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4. Short-Term Investments</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The objectives of the Company&#8217;s investment policy are to preserve principal, meet the Company's liquidity requirements and safeguard invested funds. Short-term investments consist of U.S. government securities and U.S. government agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. Investments are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of short-term investments, which were classified as available-for-sale securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.98%;"></td>
        <td style="width:2.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company's available-for-sale securities have a stated maturity of less than one year. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t hold any short-term investments as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122627712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial assets and liabilities are recorded at fair value.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies fair value measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted market prices (unadjusted) in active markets for identical assets and liabilities.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. These fair values are obtained from independent pricing services which utilize Level 1 and Level 2 inputs.</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. Included within cash and cash equivalents on the consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.095%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.095%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124675104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract', window );"><strong>Prepaid Expenses Other Assets Accrued Expenses And Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock', window );">Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6. Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.36%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other liabilities consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses, other assets, accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses, other assets, accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122625440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7. Goodwill</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company determined that the sustained decrease in our market capitalization constituted an indicator of impairment and as a result, a quantitative goodwill impairment test, utilizing the market approach, determined that the fair value of the reporting unit was below its carrying value and the goodwill was fully impaired.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded an impairment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">48.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022 for the full write-down of the goodwill recorded as part of the acquisition of Anelixis. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment was recorded for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,648</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125603712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space under various operating leases. Total rent expense for all operating leases in the consolidated statements of operations and comprehensive loss was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,197</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Irvine, California, that expires on  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as amended.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 4, 2021, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,138</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in Burlington, Massachusetts, that expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 20, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if a contract contains a lease at inception. Our office leases have remaining terms of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and do not include options to extend the leases for additional periods.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities as adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental secured borrowing rates corresponding to the maturities of the leases. As we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding debt nor committed credit facilities, secured or otherwise, we estimate this rate based on prevailing financial market conditions, comparable company and credit analysis, and management&#8217;s judgment.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our leases contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce our right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we do not currently have any lease agreement with lease and non-lease components, we elected to account for lease and non-lease components as separate components.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have elected the short-term lease recognition exemption for all applicable classes of underlying assets. Short-term disclosures include only those leases with a term greater than one month and 12 months or less, and expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less, that do not include an option to purchase the underlying asset that we are reasonably certain to exercise, are not recorded on the consolidated balance sheet.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.68%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Includes variable operating lease expenses, which are immaterial.</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information related to leases was as follows (in thousands, except lease term and discount rate):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.367%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.466000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.486%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Cash Flows Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows from operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset obtained in exchange for lease liability:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining lease term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.95</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.95</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.64%;"></td>
        <td style="width:2.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.52%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grants and Licenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ALS Therapy Development Foundation, Inc. License Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2015, Anelixis executed a License Agreement (the &#8220;Agreement&#8221;), which is an exclusive patent rights agreement with ALS Therapy Development Foundation, Inc. (&#8220;ALS TDI&#8221;) for certain patents and &#8220;know-how&#8221; of ALS TDI. This agreement continues until the licensee terminates the agreement with ninety days written notice. The Agreement requires license fees payable to ALS TDI, subject to the achievement of certain milestones and other conditions.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first and second milestones of the Agreement are the dosing of the first subjects in a first toxicity study in non-human primates and the dosing of the first patient in a Phase I Clinical Trial, respectively. Both of these milestones were achieved as of December 31, 2018 and 2017. The fee due for the achievement of these milestones was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each. During 2018 and 2017, Anelixis issued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million worth of its common stock in lieu of making a cash payment. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milestones achieved during 2023 or 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Agreement was amended and restated in February 2020, and a first amendment to the restated license agreement was executed in September 2020. As amended in September 2020, the remaining milestone payments for a first licensed product total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In the event that the Company develops a second licensed product, the Company is obligated to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in additional milestone payments.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the milestone payments, the Company is required to pay ALS TDI an amended annual license maintenance fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million beginning on the earlier of January 1, 2022, the Company&#8217;s first sublicense, or change in control, as defined in the Agreement. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million annual license maintenance fee in each of 2023 and 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the Company shall pay ALS TDI fees based on reaching certain levels of annual net sales of any product produced with the patent rights. A royalty in the low single digits will be due on aggregate net sales. Upon the first calendar year of reaching $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate net sales, the Company shall pay ALS TDI a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the first calendar year of reaching $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion in aggregate net sales, the Company is obligated to pay ALS TDI a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lonza Sales AG Inc. License Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2018, Anelixis executed a License Agreement (the &#8220;Lonza Agreement&#8221;), which is a manufacturing know-how rights agreement with Lonza Sales AG Inc. (&#8220;Lonza&#8221;) for the use of certain processes and know-how related to the manufacture of tegoprubart. The Lonza Agreement continues until the later of the last Valid Claim (as defined therein) or ten years from the First Commercial Sale of tegoprubart, as defined and subject to the conditions therein. A royalty in the low single digits will be due on aggregate net sales of tegoprubart that is manufactured by Lonza or any other third-party or licensee.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">eGenesis, Inc. Collaboration Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, and subsequently amended in January 2023, Eledon executed a non-exclusive collaborative research agreement with eGenesis, Inc. (the &#8220;eGenesis Agreement&#8221;), under which eGenesis will gain access to tegoprubart for eGenesis&#8217; ongoing preclinical research and development xenotransplant studies of human-compatible organs and cells for the treatment of organ failure. eGenesis will pay Eledon for supplies of tegoprubart based on the number of study days per animal needed for the eGenesis preclinical xenotransplant studies. The eGenesis agreement continues until September 2025, unless terminated earlier by either party.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Matters</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company&#8217;s results of operations, financial condition or cash flows.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts associated with such indemnifications have been recorded to date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> contingent liabilities requiring accrual at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126115536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9. Income Taxes</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss before income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses before income taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,159</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,326</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,966</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision (benefit) for income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.88%;"></td>
        <td style="width:3.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.68%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to income taxes under U.S. tax laws. The Company is</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to an Israeli corporate tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in 2020 and thereafter. The Company was subject to a blended U.S. tax rate (federal as well as state corporate tax) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its review, the Company concluded that it was more likely than not that they would not realize the benefit of a portion of its deferred tax assets in the future. This conclusion was based on historical and projected operating performance, as well as the Company&#8217;s expectation that its operations will not generate sufficient taxable income in future periods to realize the tax benefits associated with the deferred tax assets within the statutory carryover periods. Therefore, the Company has a valuation allowance on its deferred tax assets as of December 31, 2023.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will continue to assess the need for a valuation allowance on its deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.913%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.783000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.422%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,473</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal tax benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,097</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">728</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NOL true-up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,085</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the years presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross unrecognized tax benefits at the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions from tax positions taken in the current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">914</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions from tax positions taken in prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross unrecognized tax benefits at the end of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,636</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,664</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred income tax assets have been offset by a valuation allowance, as realization is dependent on future earnings, if any, the timing and amount of which are uncertain. The net valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from December 31, 2022 to December 31, 2023. The net valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from December 31, 2021 to December 31, 2022.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#8217;s deferred tax assets, and the timing, likelihood, and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a valuation allowance has been established.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, available to reduce future taxable income. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also has state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Both the federal and state net operating loss carryforwards incurred before 2018 begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if not utilized. The federal net operating losses incurred since 2018 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million do not expire. The state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2035</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had Israeli net operating losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which carryforward indefinitely.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal research and development tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. If not utilized, the carryforwards will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has state research and development credit carryforwards or approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, which will begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> if not utilized</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Internal Revenue Code (&#8220;IRC) Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% occurs within a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact the Company&#8217;s effective tax rate.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s ability to use its remaining net operating loss and tax credit carryforwards may be further limited if the Company experiences a Section 382 ownership change in connection with future changes in our stock ownership.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the Company files income tax returns in the U.S. Federal jurisdiction, California and Massachusetts. The Company&#8217;s tax years for 2018 and forward are subject to examination by the Federal and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest and penalties associated with uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded any interest or penalties in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060219510576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10. Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> authorized shares of preferred stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share:</span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> non-voting convertible preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">515,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares designated; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110,086</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">117,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued and outstand</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ing at December 31, 2023 and 2022, respectively; and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series X non-voting convertible preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares designated; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,422</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,204</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued and outstanding at December 31, 2023 and 2022, respectively.</span></div></div><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or X non-voting convertible preferred stock (the &#8220;Preferred Stock&#8221;) is convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55.5556</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, at the option of the holder at any time, subject to certain limitations, including, that the holder will be prohibited from converting the Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total common stock then issued and outstanding immediately following the conversion of such shares of Series X Preferred Stock or Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock, respectively. The holder of the Preferred Stock is entitled to receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to-common-stock basis and without regard to any beneficial ownership limitations) to and in the same form as dividends actually paid on shares of the common stock. No other dividends will be paid on shares of the Preferred Stock. In the event of any liquidation, dissolution or winding up, the holder of the Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Preferred Stock were fully converted to common stock, which amounts shall be paid pari passu with all holders of common stock. Shares of the Preferred Stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of either series of outstanding Preferred Stock will be required to amend the terms of the such series.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Equity Distribution Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 31, 2021, the Company filed a registration statement on Form S-3 containing a prospectus and prospectus supplement (the "Prospectus") under which the Company may offer and sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of its common stock, from time to time, pursuant to an open market sale agreement with Jefferies LLC and by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the &#8220;ATM Program&#8221;). Pursuant to the &#8220;baby shelf rules&#8221; promulgated by the SEC, if the Company&#8217;s public float is less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of specified measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement, including pursuant to the ATM Program, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the Company&#8217;s public float.  As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, due to the SEC&#8217;s &#8220;baby shelf rules,&#8221; the Company was permitted to sell up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock pursuant to the ATM Program. The Company will remain subject to the &#8220;baby shelf rules&#8221; under the Form S-3 registration statement until such time as its public float exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. During the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were sold</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Prospectus. This Form S-3 registration statement pursuant to which the ATM Program is registered will expire in May 2024, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock may be sold under the ATM Program after that date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Warrant Exchange Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 21, 2021, the Company issued warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">298,692</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in exchange for warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,376.456</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock previously issued as part of the Anelixis merger. These Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock warrants were replaced by Eledon for the outstanding warrants issued by Anelixis that were not settled upon completion of the merger.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Exchange Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 11, 2022, the Company entered into an exchange agreement (the &#8220;Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange Agreement&#8221;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, L.L.C. (collectively, the &#8220;BVF Exchanging Stockholders&#8221;), pursuant to which the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchanging Stockholders exchanged (the &#8220;Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Exchange&#8221;) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">550,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,899.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Securities Purchase Agreement</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2023, the Company entered into the Securities Purchase Agreement with Purchasers, pursuant to which the Company agreed to issue and sell to the Purchasers in the Private Placement (i) in an initial closing, (a) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,151,518</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share, or pre-funded warrants in lieu thereof (the &#8220;Pre-Funded Warrants&#8221;), and (b) common stock warrants exercisable into an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,151,518</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants in lieu thereof) (the &#8220;Common Warrants&#8221; and, together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;); (ii) in a second closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,202,024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants); and (iii) in a third closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,252,530</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 5, 2023, the initial closing occurred and the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, or net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting offering costs, in exchange for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,730,168</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,421,350</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The Company may receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon sale of the shares to be issued in the second and third closings, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (&#8220;Registration Statement&#8221;) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The Registration Statement became effective on June 2, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Conversion Agreement of Non-Voting Convertible Preferred Stock</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 16, 2023, Cormorant Global Healthcare Master Fund LP provided notice to convert (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,782</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X Non-Voting Convertible Preferred Stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting Convertible Preferred Stock, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,883.586</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">437,977</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Exercise of Pre-Funded Warrants</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 10, 2023, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">501,197</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which were issued in conjunction with the Securities Purchase Agreement. On July 14, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">501,197</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 2, 2023, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">653,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which were issued in conjunction with the Securities Purchase Agreement. On November 6, 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">653,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,564,302</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants were exercisable into common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the warrants to purchase common stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.074%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Roll Forward of Warrant Activity</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Private placement warrants</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pre-funded warrants</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrants exchanged for  Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">preferred stock</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337,822</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">509,117</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,692</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,145,631</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,151,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,421,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,572,868</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154,197</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154,197</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,489,340</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,776,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,564,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,207.419</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants exercisable into Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock which are convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,789,301</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.52%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:41.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Roll Forward of Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Convertible Preferred Warrant Activity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,207.419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed and replaced</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,207.419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124927984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11. Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Plans</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 21, 2023, the Company held its Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s 2020 Long Term Incentive Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company&#8217;s common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares so that the new aggregate share limit under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,460,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 26, 2033.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,381,857</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,476,372</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the granted stock options subject to the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customary </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">time-based vesting schedule. The remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,905,485</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options granted are subje</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ct to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the second and third closings of the Private Placement as specified in the Securities Purchase Agreement. Further, for the performance-based stock options granted to senior management, upon such second and third closing, a full or prorated amount of each closing shall vest based on the percentage of funding received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative to the total funding opportunity represented by the purchasers' second and third closing subscription amounts. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> specified clinical development milestones were achieved during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2014 Plan was closed to new grants following the approval of the 2020 Plan, and therefore, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares reserved for issuance under the 2014 Plan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The number of shares reserved for issuance under the 2020 Plan and ESPP was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,093,742</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,077</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes all option activity under the 2007 Plan, 2014 Plan, 2020 Plan and inducement grants:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.020000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares<br/>Issuable<br/>Under Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,213,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,267,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,644</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,218,033</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,026,451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">862,631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,381,853</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest as of<br/>&#160;&#160;&#160;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,476,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,065,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that had exercise prices that were lower than the fair value per share of the common stock on the date of exercise. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> aggregate intrinsic value of options exercised during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.471%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:19.384%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:19.384%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life of options</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Estimated dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The per share weighted average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.76</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">espectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the RSU activity, as follows:</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares<br/>Issuable<br/>Under RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total compensation expense related to all of the Company&#8217;s stock-based awards for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 was comprised of the following (in thousands):</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.68%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,491</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation expense related to non-vested equity awards was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over an estimated weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122742368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 12. Subsequent Events</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 30, 2024, Armistice Capital Master Fund Ltd. (the &#8220;Exercising Stockholder&#8221;), exercised Pre-Funded Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, which were issued in conjunction with the Securities Purchase Agreement. On January 30, 2024, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the Exercising Stockholder in accordance with such exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060207652848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are prepared in accordance with GAAP. Eledon, a Delaware corporation, owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (&#8220;Otic&#8221;). Otic owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company&#8217;s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company&#8217;s foreign subsidiary are not significant to the consolidated financial statements.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant intercompany accounts and transactions among the entities have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months or less</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertianties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all of the Company&#8217;s long-lived assets were located in the United States.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s products will require approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company&#8217;s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reportable Segments</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments under GAAP are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer and the Company has determined that it operates in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business segment, which is the development of products for therapeutic medicines selectively targeting critical pathways associated with the underlying molecular pathogenesis for patients with severe inflammation and autoimmune diseases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired under the acquisition method of accounting. Goodwill is not amortized but is evaluated for impairment as of December 31 of each year or if indicators of impairment exist that would, more likely than not, reduce the fair value from its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company performs its goodwill impairment analysis at the reporting unit level, which aligns with the Company&#8217;s reporting structure and availability of discrete financial information. The Company performs its annual impairment analysis by either comparing the reporting unit&#8217;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#8217;s fair value from the last quantitative assessment to determine if there is potential impairment. The Company may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#8217;s estimated fair value was significantly in excess of the carrying value of its net assets and it does not believe there have been significant changes in the reporting unit&#8217;s operations that would significantly decrease its estimated fair value or significantly increase its net assets. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies. Key assumptions for these projections include revenue growth, future gross and operating margin growth, and its weighted cost of capital and terminal growth rates. The revenue and margin growth is based on increased sales of new products as the Company maintains investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including timing and probability of regulatory approvals for Company products to be commercialized. The Company&#8217;s market capitalization is also considered as a part of its analysis.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s annual evaluation for impairment of goodwill consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reporting unit. In accordance with the Company&#8217;s policy, the Company completed its annual evaluation for impairment using the quantitative assessment, utilizing the market approach and due to declining market conditions, determined that the fair value of the reporting unit was below its carrying value. As a result, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">48.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of goodwill impairment, reducing the goodwill balance to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2022, and accordingly, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill impairment was recorded for the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Long-Lived Assets</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which the carrying amount of an asset exceeds its fair value. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairments of long-lived assets have been identified during the years presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-Process Research and Development</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of in-process research and development (&#8220;IPR&amp;D&#8221;) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (&#8220;R&amp;D&#8221;) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges may occur in future periods.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitalized IPR&amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#8217; products could result in partial or full impairment of the related intangible assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company&#8217;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company&#8217;s prior period accrued estimates for clinical trial activities through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, incentive stock options, restricted stock units and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company&#8217;s net loss position. Basic weighted average shares outstanding for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> include </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,776,270</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">509,117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, shares underlying pre-funded warrants to purchase common shares. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the shares underlying these pre-funded warrants can be issued for little </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(an exercise price per share equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share), these shares are deemed to be issued for purposes of basic earnings per share.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.3%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.34%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.040000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,326</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,966</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.64</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.16</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,619,197</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,285,254</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The computation of diluted earnings per share excludes incentive stock options, restricted stock units, and warrants that are anti-dilutive. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary as of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.247%;"></td>
          <td style="width:1.44%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.937%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.44%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.937%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding and other equity awards</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,909,155</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,012,035</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common and preferred warrants outstanding</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,577,332</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,127,121</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,486,487</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,139,156</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. The expected dividend assumption was based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units (&#8220;RSUs&#8221;) are measured and recognized based on the quoted market price of our common stock on the date of grant.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant judgment is required in determining the Company&#8217;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. We assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. We have provided a valuation allowance on our deferred tax assets as of December 31, 2023 and 2022 because we believe it is more likely than not that a majority of our deferred tax assets will not be realized as of this date.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company evaluates the accounting for uncertainty in income tax recognized in its consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positions </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">where it is &#8220;not more likely than not&#8221; that a tax benefit will be sustained, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued any liabilities for any such uncertain tax positions as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or processes, if any. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likely of being realized upon settlement.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. For additional information, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Note 9. Income Taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Issued But Not Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements Issued But Not Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and principles of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126115536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the shares underlying these pre-funded warrants can be issued for little </span><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">consideration </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(an exercise price per share equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share), these shares are deemed to be issued for purposes of basic earnings per share.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:64.3%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.34%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.040000000000001%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,326</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,966</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.64</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.16</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of common shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,619,197</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,285,254</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a summary as of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.</span><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:63.247%;"></td>
          <td style="width:1.44%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.937%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.44%;"></td>
          <td style="width:1%;"></td>
          <td style="width:14.937%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding and other equity awards</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,909,155</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,012,035</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common and preferred warrants outstanding</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,577,332</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,127,121</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,486,487</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,139,156</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124940000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Short-term Investments Classified as Available-for-sale Securities</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of short-term investments, which were classified as available-for-sale securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.98%;"></td>
        <td style="width:2.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124682032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Table Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Instruments Measured At Fair Value On A Recurring Basis</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. Included within cash and cash equivalents on the consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.095%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,277</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,246</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.095%;"></td>
        <td style="width:1.641%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.245000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125256208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract', window );"><strong>Prepaid Expenses Other Assets Accrued Expenses And Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.36%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.06%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other liabilities consisted of the following as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,003</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses, other assets, accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122613088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,648</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125800944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.68%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(a) </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Includes variable operating lease expenses, which are immaterial.</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_OtherInformationRelatedToLeasesTableTextBlock', window );">Schedule of Other Information Related to Leases</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information related to leases was as follows (in thousands, except lease term and discount rate):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.367%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.466000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.486%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Cash Flows Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liability:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows from operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease asset obtained in exchange for lease liability:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining lease term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.95</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.95</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Payments Under Noncancelable Operating Leases</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.64%;"></td>
        <td style="width:2.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.52%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_OtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_OtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126372832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss Before Income Taxes</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss before income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses before income taxes:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,159</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-U.S.</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,326</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,966</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Provision (Benefit) for Income Taxes</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision (benefit) for income taxes are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.88%;"></td>
        <td style="width:3.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.68%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision (benefit) for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.913%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.783000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.422%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory federal income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,473</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes, net of federal tax benefits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,097</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">728</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">986</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NOL true-up</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">452</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,085</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">179</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the years presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross unrecognized tax benefits at the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions from tax positions taken in the current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">914</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions from tax positions taken in prior years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross unrecognized tax benefits at the end of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,636</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,664</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060121999248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the warrants to purchase common stock activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:32.074%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Roll Forward of Warrant Activity</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Private placement warrants</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pre-funded warrants</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrants exchanged for  Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">preferred stock</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">337,822</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">509,117</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,692</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,145,631</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issued</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,151,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,421,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,572,868</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154,197</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154,197</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#d2effa;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,489,340</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,776,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,564,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_PreferredStockWarrantsMember', window );">Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,207.419</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> warrants exercisable into Series X</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Preferred Stock which are convertible into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,789,301</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.52%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:41.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Roll Forward of Series X</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Convertible Preferred Warrant Activity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,207.419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assumed and replaced</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,207.419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125716096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes all option activity under the 2007 Plan, 2014 Plan, 2020 Plan and inducement grants:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.020000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.66%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares<br/>Issuable<br/>Under Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,213,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,267,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,644</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,218,033</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,026,451</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">862,631</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,381,853</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options vested and expected to vest as of<br/>&#160;&#160;&#160;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,476,369</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,065,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.54</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.471%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:19.384%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:19.384%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life of options</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Estimated dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the RSU activity, as follows:</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares<br/>Issuable<br/>Under RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of January 1, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited / Canceled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards</a></td>
<td class="text"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total compensation expense related to all of the Company&#8217;s stock-based awards for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 was comprised of the following (in thousands):</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.68%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation classified as:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,491</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060123764704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 14, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember', window );">Anelixis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Date of acquisition</a></td>
<td class="text">Sep. 14,  2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124512928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern and Management's Plans - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40,326)<span></span>
</td>
<td class="num">$ (87,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(243,191)<span></span>
</td>
<td class="num">$ (202,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,213,130<span></span>
</td>
<td class="nump">13,776,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember', window );">Securities Purchase Agreement Initial Closing [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common warrants issued</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember', window );">Securities Purchase Agreement Initial Closing [Member] | Private Placement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,421,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember', window );">Securities Purchase Agreement Initial Closing [Member] | Accredited Investor [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common warrants issued</a></td>
<td class="nump">$ 45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,730,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,151,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrants to purchase common stock shares</a></td>
<td class="nump">15,151,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,151,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember', window );">Securities Purchase Agreement Second and Third Closing [Member] | Accredited Investor [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common warrants issued</a></td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eldn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eldn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eldn_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eldn_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125240912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Reporting_Unit </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod', window );">Cash, cash equivalents and restricted cash, maturity period</a></td>
<td class="text">three months or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating business segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | Reporting_Unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,648,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,648,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding | shares</a></td>
<td class="nump">24,619,197<span></span>
</td>
<td class="nump">14,285,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit', window );">Tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax examination, likelihood of settlement, description</a></td>
<td class="text">The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement', window );">Income tax examination, likelihood of settlement, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Common and Preferred Warrants Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding | shares</a></td>
<td class="nump">5,776,270<span></span>
</td>
<td class="nump">509,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember', window );">Anelixis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember', window );">Anelixis Therapeutics, LLC and Otic Pharma, Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Ownership interest percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=eldn_OticPharmaIncMember', window );">Otic Pharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Ownership interest percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and restricted cash maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax examination likelihood of favorable settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act of 2017 change in tax rate income taxes expense benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482669/740-10-15-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eldn_OticPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eldn_OticPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124648704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,326)<span></span>
</td>
<td class="num">$ (87,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (6.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (6.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares, basic</a></td>
<td class="nump">24,619,197<span></span>
</td>
<td class="nump">14,285,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares, diluted</a></td>
<td class="nump">24,619,197<span></span>
</td>
<td class="nump">14,285,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060207652640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">33,486,487<span></span>
</td>
<td class="nump">8,139,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Options Outstanding and Other Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">14,909,155<span></span>
</td>
<td class="nump">5,012,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eldn_CommonAndPreferredWarrantsOutstandingMember', window );">Common and Preferred Warrants Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">18,577,332<span></span>
</td>
<td class="nump">3,127,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eldn_CommonAndPreferredWarrantsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eldn_CommonAndPreferredWarrantsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125529872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 46,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">46,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">33,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember', window );">U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 13,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060122607456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 46,490,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124349920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail) - Fair Value, Recurring Member - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 4,246<span></span>
</td>
<td class="nump">$ 9,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">46,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">50,736<span></span>
</td>
<td class="nump">9,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">9,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">33,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">13,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">9,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">9,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">$ 9,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">46,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">46,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">33,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total short-term investments</a></td>
<td class="nump">$ 13,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060207554016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PrepaidClinicalExpense', window );">Prepaid clinical</a></td>
<td class="nump">4,128<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,027<span></span>
</td>
<td class="nump">$ 3,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PrepaidClinicalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PrepaidClinicalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060218054320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="nump">$ 1,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AccruedClinicalCurrent', window );">Accrued clinical</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 2,545<span></span>
</td>
<td class="nump">$ 3,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AccruedClinicalCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AccruedClinicalCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060125257120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,648,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember', window );">Anelixis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eldn_AnelixisTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060121984608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Goodwill (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(48,648,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060117416080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th">
<div>Nov. 04, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_LesseeOperatingLeaseRemainingTermOfContract', window );">Remaining term of office lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Indemnification obligations amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ContingentLiability', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember', window );">ALS Therapy Development Foundation, Inc. License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_FeeDueForMilestonesAchieved', window );">Fee due for milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in lieu of making a cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NumberOfMilestonesAchieved', window );">Number of Milestones Achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_RemainingMilestonePaymentsForFirstLicensedProduct', window );">Remaining milestone payments for first licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AnnualLicenseMaintenanceFee', window );">Annual License Maintenance Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember', window );">ALS Therapy Development Foundation, Inc. License Agreement [Member] | Achievement of 500 Million Aggregate Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AggregateNetSalesAchievement', window );">Reaching of aggregate net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Amount of one-time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember', window );">ALS Therapy Development Foundation, Inc. License Agreement [Member] | Achievement of 1 Billion Aggregate Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AggregateNetSalesAchievement', window );">Reaching of aggregate net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Amount of one-time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | ALS Therapy Development Foundation, Inc. License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_RegulatoryMilestonePaymentsObligation', window );">Development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Irvine, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Burlington, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 20,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AggregateNetSalesAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net sales achievement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AggregateNetSalesAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_FeeDueForMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee due for milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_FeeDueForMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_LesseeOperatingLeaseRemainingTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease remaining term of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_LesseeOperatingLeaseRemainingTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_RegulatoryMilestonePaymentsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payments obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_RegulatoryMilestonePaymentsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_RemainingMilestonePaymentsForFirstLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining milestone payments for first licensed product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_RemainingMilestonePaymentsForFirstLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483119/928-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=eldn_FiveHundredMillionAggregateNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=eldn_FiveHundredMillionAggregateNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=eldn_OneBillionAggregateNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=eldn_OneBillionAggregateNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060233007712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060217074272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating lease</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract', window );"><strong>Operating lease asset obtained in exchange for lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_RemainingLeaseTermAbstract', window );"><strong>Remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease</a></td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_DiscountRateAbstract', window );"><strong>Discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_DiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_DiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease asset obtained in exchange for lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_RemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_RemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126834656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of operating lease liability</a></td>
<td class="num">(383)<span></span>
</td>
<td class="num">$ (363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060232990608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Losses before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (40,525)<span></span>
</td>
<td class="num">$ (88,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S.</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (40,326)<span></span>
</td>
<td class="num">$ (87,966)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124915776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060117640848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_EffectiveFederalAndStateIncomeTaxRate', window );">Federal Income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net valuation allowance Increased (decreased)</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards for federal and state</a></td>
<td class="nump">$ 3,202,000<span></span>
</td>
<td class="nump">2,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards', window );">Period for which cumulative change in ownership annual use net operating loss and research and development credit carryforwards</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties associated with uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties recorded during the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PercentageOfCumulativeChangeInOwnership', window );">Percentage of cumulative change in ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 68,900,000<span></span>
</td>
<td class="nump">56,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NetOperatingLossCarryforwardsExpirationPeriod', window );">Net operating loss carryforward expiration period</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards, not to expiration</a></td>
<td class="nump">$ 68,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards for federal and state</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_TaxCreditCarryforwardExpirationPeriod', window );">Research and development tax credit carryforwards expiration period</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards for federal and state</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_TaxCreditCarryforwardExpirationPeriod', window );">Research and development tax credit carryforwards expiration period</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_TaxCreditCarryforwardExpirationDescription', window );">Research and development tax credit carryforwards expiration description</a></td>
<td class="text">As of December 31, 2023 and 2022, the Company has state research and development credit carryforwards or approximately $1.5 million and $1.2 million, respectively, which will begin expiring in 2030 if not utilized<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israeli Tax Authority [Member] | Foreign Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign operating losses carryforwards</a></td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NetOperatingLossCarryforwardsExpirationPeriod', window );">Net operating loss carryforward expiration period</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_EffectiveFederalAndStateIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective federal and state income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_EffectiveFederalAndStateIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NetOperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NetOperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PercentageOfCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PercentageOfCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which cumulative change in ownership annual use net operating loss and research and development credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_TaxCreditCarryforwardExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_TaxCreditCarryforwardExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_TaxCreditCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_TaxCreditCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126763744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="num">$ (8,468)<span></span>
</td>
<td class="num">$ (18,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_StateIncomeTaxesNetOfFederalTaxBenefits', window );">State income taxes, net of federal tax benefits</a></td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(2,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(972)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_IncomeTaxReconciliationStateTaxRateDifferential', window );">State rate differential</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NOLTrueUp', window );">NOL true-up</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">9,460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_IncomeTaxReconciliationStateTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation state tax rate differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_IncomeTaxReconciliationStateTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NOLTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NOL True Up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NOLTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_StateIncomeTaxesNetOfFederalTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State income taxes, net of Federal tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_StateIncomeTaxesNetOfFederalTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060233041328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 18,089<span></span>
</td>
<td class="nump">$ 15,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">3,202<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research expenditures</a></td>
<td class="nump">10,567<span></span>
</td>
<td class="nump">5,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">2,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">36,828<span></span>
</td>
<td class="nump">27,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_DeferredTaxAssetsRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="num">(7,682)<span></span>
</td>
<td class="num">(7,787)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(7,769)<span></span>
</td>
<td class="num">(7,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(30,811)<span></span>
</td>
<td class="num">(21,675)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (1,752)<span></span>
</td>
<td class="num">$ (1,752)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_DeferredTaxAssetsRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_DeferredTaxAssetsRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, in-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126813920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at the beginning of the year</a></td>
<td class="nump">$ 2,664<span></span>
</td>
<td class="nump">$ 1,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions from tax positions taken in the current year</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions from tax positions taken in prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at the end of the year</a></td>
<td class="nump">$ 3,636<span></span>
</td>
<td class="nump">$ 2,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060112100080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
<th class="th"><div>Jan. 11, 2022</div></th>
<th class="th"><div>Sep. 21, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 06, 2023</div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,213,130<span></span>
</td>
<td class="nump">13,776,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,564,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet', window );">Proceeds from issuances of common stock and pre-funded warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember', window );">Armistice Capital Master Fund Ltd [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NumberOfPreFundedWarrantsExercisedForCommonStock', window );">Number of pre-funded warrants exercised for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXOnePreferredStockMember', window );">Series X1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares of common stock issued upon conversion of each share of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,789,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,207.419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXNonVotingConvertiblePreferredStockMember', window );">Series X Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember', window );">Series X1 Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,000<span></span>
</td>
<td class="nump">515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,086<span></span>
</td>
<td class="nump">117,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,086<span></span>
</td>
<td class="nump">117,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,564,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | September 2021 Warrant Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series X Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares of common stock issued upon conversion of each share of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.5556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series X1 Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares of common stock issued upon conversion of each share of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.5556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | September 2021 Warrant Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired', window );">Warrants exercisable for exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,376.456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,489,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Securities Purchase Agreement Initial Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet', window );">Proceeds from issuances of common stock and pre-funded warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Securities Purchase Agreement Initial Closing [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,730,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,151,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,151,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,151,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Securities Purchase Agreement Second Closing [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,202,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Securities Purchase Agreement Second and Third Closing [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,252,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Common Stock [Member] | Securities Purchase Agreement Initial Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,730,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Pre-funded Warrants [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | Pre-funded Warrants [Member] | Securities Purchase Agreement Initial Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,421,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member] | Series X Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ConversionOfPreferredStockConversionBlockerPercent', window );">Conversion of preferred stock, conversion blocker, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Common Stock [Member] | Series X1 Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ConversionOfPreferredStockConversionBlockerPercent', window );">Conversion of preferred stock, conversion blocker, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member] | Series X Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ConversionOfPreferredStockConversionBlockerPercent', window );">Conversion of preferred stock, conversion blocker, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Common Stock [Member] | Series X1 Non-voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ConversionOfPreferredStockConversionBlockerPercent', window );">Conversion of preferred stock, conversion blocker, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_JefferiesLimitedLiabilityCompanyMember', window );">Jefferies LLC [Member] | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable', window );">Equity distribution agreement maximum value of common shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_PublicFloatMinimumBalanceToBeMaintained', window );">Public float minimum balance to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_JefferiesLimitedLiabilityCompanyMember', window );">Jefferies LLC [Member] | ATM Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_JefferiesLimitedLiabilityCompanyMember', window );">Jefferies LLC [Member] | Maximum [Member] | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable', window );">Equity distribution agreement maximum value of common shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember', window );">BVF Exchanging Stockholders [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | Series X1 Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,899.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember', window );">BVF Exchanging Stockholders [Member] | Common Stock [Member] | Series X1 Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember', window );">Cormorant Global Healthcare Master Fund LP [Member] | Series X Non-voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember', window );">Cormorant Global Healthcare Master Fund LP [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="nump">7,883.586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember', window );">Cormorant Global Healthcare Master Fund LP [Member] | Common Stock [Member] | Series X Non-voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="nump">99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember', window );">Cormorant Global Healthcare Master Fund LP [Member] | Common Stock [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="nump">437,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ConversionOfPreferredStockConversionBlockerPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock, conversion blocker, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ConversionOfPreferredStockConversionBlockerPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity distribution agreement maximum value of common shares issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NumberOfPreFundedWarrantsExercisedForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pre-funded warrants exercised for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NumberOfPreFundedWarrantsExercisedForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre funded warrants net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_PublicFloatMinimumBalanceToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public float minimum balance to be maintained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_PublicFloatMinimumBalanceToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesXOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesXNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesXNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eldn_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eldn_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementThirdClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementThirdClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eldn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eldn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eldn_JefferiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eldn_JefferiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eldn_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SeriesX1ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SeriesX1ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_ConversionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_ConversionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124017248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">21,564,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">15,489,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">5,776,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_WarrantsExchangedForSeriesX1PreferredStockMember', window );">Warrants Exchanged for Series X1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">298,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">1,145,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued', window );">Issued</a></td>
<td class="nump">21,572,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised', window );">Exercised</a></td>
<td class="num">(1,154,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">337,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued', window );">Issued</a></td>
<td class="nump">15,151,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">509,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued', window );">Issued</a></td>
<td class="nump">6,421,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised', window );">Exercised</a></td>
<td class="num">(1,154,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember', window );">Common Stock Warrants [Member] | Warrants Exchanged for Series X1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">298,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued', window );">Issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eldn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_WarrantsExchangedForSeriesX1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eldn_WarrantsExchangedForSeriesX1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060233054400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">21,564,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_PreferredStockWarrantsMember', window );">Preferred Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning Balance</a></td>
<td class="nump">50,207.419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced', window );">Assumed and replaced</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending Balance</a></td>
<td class="nump">50,207.419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights assumed and replaced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eldn_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eldn_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060111905392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Milestone </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,026,451<span></span>
</td>
<td class="nump">1,267,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares weighted average grant date fair valueof stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved', window );">Number of specific clinical development milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation expense, recognized over estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=eldn_TimeBasedVestingRequirementsMember', window );">Time Based Vesting Requirements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember', window );">Time-based and Performance-based Vesting Requirements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,381,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,905,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eldn_TwoThousandFourteenStockIncentivePlanMember', window );">2014 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eldn_TwoThousandTwentyLongTermIncentivePlanMember', window );">2020 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,093,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increased number of shares</a></td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized', window );">New aggregate share limit</a></td>
<td class="nump">14,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of specific clinical development milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award total number of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=eldn_TimeBasedVestingRequirementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=eldn_TimeBasedVestingRequirementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eldn_TwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eldn_TwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eldn_TwoThousandTwentyLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eldn_TwoThousandTwentyLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060124337680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Issuable Under Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">5,218,033<span></span>
</td>
<td class="nump">4,213,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">11,026,451<span></span>
</td>
<td class="nump">1,267,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited / Canceled</a></td>
<td class="num">(862,631)<span></span>
</td>
<td class="num">(263,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">15,381,853<span></span>
</td>
<td class="nump">5,218,033<span></span>
</td>
<td class="nump">4,213,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest</a></td>
<td class="nump">9,476,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">4,065,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance</a></td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">2.10<span></span>
</td>
<td class="nump">3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited / Canceled</a></td>
<td class="nump">8.07<span></span>
</td>
<td class="nump">12.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="nump">$ 10.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest</a></td>
<td class="nump">5.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">$ 8.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (In years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, balance</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060220671872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">90.50%<span></span>
</td>
<td class="nump">83.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Estimated dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060233040880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares Issuable Under RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">4,065,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">$ 8.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares Issuable Under RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs Vested</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice', window );">Outstanding, beginning balance</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 5.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice', window );">RSUs Vested</a></td>
<td class="nump">2.47<span></span>
</td>
<td class="nump">5.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice', window );">Outstanding, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, equity instruments other than options, grants in period, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, equity instruments other than options, nonvested, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options, nonvested, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, equity instruments other than options, vested in period, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060126834912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,545<span></span>
</td>
<td class="nump">$ 8,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,054<span></span>
</td>
<td class="nump">$ 4,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140060117807248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 06, 2023</div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,213,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,776,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember', window );">Armistice Capital Master Fund Ltd [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NumberOfPreFundedWarrantsExercisedForCommonStock', window );">Number of pre-funded warrants exercised for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Armistice Capital Master Fund Ltd [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eldn_NumberOfPreFundedWarrantsExercisedForCommonStock', window );">Number of pre-funded warrants exercised for common stock</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eldn_NumberOfPreFundedWarrantsExercisedForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pre-funded warrants exercised for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eldn_NumberOfPreFundedWarrantsExercisedForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eldn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M? 4OIB@5"Y*M\DD[,R8E2_./2X*AJ:D-X/LY8W*WH'903A2[^1]02P,$%
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MKI,<;M63E;;?+[;$M]"VQ$6.!=7J'W0+H)I;OB-6<3E98U;J?:%#86#I@I9
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MGM_<YG@L Z$-\/\UY^KXH ?H#GK+?P%02P,$%     @ T8-\6!\[:YO-!@
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M)3!45%1''=6=5;NI#\<9SEQ9]4)Z*>56)H1^G7 C>$YIL4\[' $WPB3[OX?
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MFAS)R7&2:%2U&-+.FG#-%A6Y0?(:OUDMS$BPP.-)F#@$XD![]!#Q]S'MH1=
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M1OO2P7N=8[X/T"-2+;-TP^PV/8IXCUD7AH,.I/UT> 1OV$8Z#'C#5_!VPNO
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M2!KN:"3\#0E.Q5/)I@*2()<N,PW[L-(Q(-%I*4AB5U$MR'\Y/IWW: -YM\C
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MA-K H7W 9/KZU>AH^.X%DI.6Y.0E]/^2CQ>!=M/\U7B$PS[LL0+74@N=2:%
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MZ:7'T!]PXX^N>SBKM\HBC$[A_Y#J87#?37FWO-$:I07>;F.NJ+P82Y!J!>0
M*U52G1)R31YNCDX55DL*W)TLCT4=!D^$I!#5&)HQ3\\'7Y'K]C0/O*-S&NRH
M"&D:S66.< (CEM)WS)+>FI-*(N<EI,.8C8$-XSCKC2WQ>)Q!G":#=X?2F$3
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MG%<J?(3_<LP-;$BXQ=;I:(P:7Y>LG']^<SF;/GGFQ.]MN:0'P7NC6T4_C_G
M%;**T1R!P_9\A"PV%K_UG&B0/;#095>EHD]0#B<<GU#:(UGU'32OLE-76P0P
M!07X'K;("4HRW*)M(CY7IF*T60IN(6T.O7N#!(2<8AOR=.R"@EI$JNQ;)V9Q
MTB9,XM>*$UL$!Q_!49)6@+"LC?5,UZ^L:9<K7G: D'3AI*C 1=;00;FS$81<
M6A4%B1$Q685,3*BQFE.VTV6+#\%3EL@14)52[,#]5=YJKKE!YH;5"6#_MM*
M#8"83F@MF;S:!K#G8J)C!@6Q7Z6'4&)CFI,<+^%0(4 0M*G2#_I#&#$MMA(D
M[M])RG**X.S[CQEBS%&F"K6Y%2QP0FJ+5*.MN;]0MZKFQ)'+&*2<2A?!3RHR
M#1MC-XKBK$\=W3(7H*[+1PW4XU>F0S:K1+(!!?1$.J>4BUP.C'-B8X&[+,=Z
M<-$G$QPH '1@_3IO>==GI,GQF3F"D =.YI)@)]-R]<$Z@]'6K2U6?,)*[><:
MWKY1T<6D@Z/.H99"648HYVIE"XYSM(:.(>EL&63;JQ_G"#$-E3/4.X5JI >+
M'/^3LC:*7)#R?X5&UHF'7).BM(5&W:.G1_^&GX>FYX@+1"H.CW;3+.4M\5 ^
M0NEY/IGP_V=']/UM4(CC>ID1LYNW(A\$]95&E4HRZCJY&]R8PCP4&_KTT#+G
M>))@(]V=(HQP I55/2N'V@B 9%\B#[E+SD\MH)Y2X&OI5N*:3WC;L7/$CREY
M!O^HB6C&>)E*_!JGMR&;=C9(!<3V:4^C!=%;\#$+:^H]A3T09T\NZ?_+)WMV
M") R<X)..!O"PW^6JA<R#IZ::',VFSTC^N?G1S_E>K/3WMZFR?C;B]A53//'
MHS=]_>[MF8W/OQ7_2'^N6T^=:2Y)0HN%L%80DJM#N.&"F+XE#X5X!ZICBAO$
M#X=P8V/"Z: 2<ZMP;5$H5882@;)TV"5#C0R_7% H^H)O''$#<'9Y>11Z0)1@
MNF[KW8*+%KQ#Z* 4V_K0L"A**^*AN!"/CCX>+MCZU>;9Y5D@$=.,6%,*A6\<
M* RSN4$>^W# !^2+M/'NU1T6OJ<\&$K^=^A(R%O%U;M/%%JL7&_1N=VHRJP9
MV]>P><F.,2+G'Z<=XBKGO;<-NJHM'&QZ,1)7C:KT+:(QHES!VI 'MCPD&Q$[
ML\FS_)2_3Y\]2I%#<X\*P%<M=\=K (_P1W'?[>;=O\S_PW0L;7CS-AW*R$E!
M.IP4-!27?V[,YF1E-G$]&292H)"L^_P4/(]HJ13#ARJDI*""X'&H6:G4IN<[
M4@#L"J8JY19!T%+5W%""P.80^#L-6O5'RTUKI$S-KR-,LG,AE$;N4&*W\]^I
M%XGE&II?K6YRX$HBURAW'#ID%:3F8KQ73(?C%]JZT$VA;C=4-7>[8F/0<4B>
M24]*XPB.\?= (O+$ Q,9GWETO04!U?FVW-(O5 >M6E3FJ/BY&7#)@0\2A=6T
MXEH8-#]RAGXK7J- T.3_/U/Z&5&YMU9<[57;L7@%.2,1K.Y)$[)H4%5) 0:+
M=@8:T\LX7)D^B=J!><LVU_>[FMX_ V0?(,1.\FB'QCIC\0:]%F0;G-!S+.T<
M=9[#G1O$"Y9$>\<=%Y[AF.(S::/2JJ7?:OF9ZY20DF+\8MYMK!O0P_6!D.0O
M$T?(H\;VYDF=M3?=:">V$#SWXIQUK>86Q3>%"!JK<#>>L$1;F$"$9]Z7<"T'
M1^2H K*?4 6D8<ULPKUHXF#OUU$DGA)*EK(+XYSM(UOQ\!+ ,]2@@#M*  _$
MXT[G8PI\1!4J:F+=UQ]?E2$*T40H>LLNU>&XBRK8>:67J18"8Z)=TZ<'R*L7
MV=0$[VZNLR\(\Y56Y Y^;]G>X3&BY+-C *$8W!FVH7XJF8:4R?UG$< /B-&H
M<II9G:NE;EC?L;!%?@48:10F_B4;QD08#LX&[.06/$>+>.2(X!<+(.B!IV^F
MXKEBJ1:I1AK$H>'\KI94S>^P^06Q=)/GK3LCU>O64IRD0F2H3K>BOJJO10[/
M>8)AB2 7AS'\5@26,/\+S" /""<K%9]M,Q+#7VK:*6'P0*B?%^$&PIJMK/PV
MJ0*%D:!HB;Q0ZB4%B T$AW$X6I'\2RB+<->=.A:_I"E9L %"*#" \BA47XM.
MA ?B8C+IA2)]D."7]".IM#OQNCZ U0"LZ47?][Z"/8J3\Z]@[I C_G4VSR9]
M-M^9YD\I/K$AK[Z_IX+JAZOIY=^IH\)1]U93-.5J%[+P(9ZGFN:.DNH0[P_[
MAPUJ)VZ&G>K7%(!JH7B<0"[3G3:<'W4\\6:OEF9MV[FTT75WY#I<7O%D(<TF
M)0#QJT3_C.PO=8U&M@L/7/WKYA$%$JJN0I_#C1GMO68TT0T3]>CP0Q)_AZU!
MN.%B:%AA=553.NW_Y)0[?(24 [OV-%B*^39JC-(9T!PJ.;_2MCQ98]>6)QVQ
M'!T+];U"JJ<I*-OW-?HH.3?ABNINA%*\CI([I(TP&.LEWQ3<*5Z.Q'>5*L/@
M*2&9*KNNL"^Z0_E.Q,$F-#D8PG&'TS[TTT^'T!]ZS^ #>1WK>LD3PX(@RJ;K
M:9;OV.+BF(Q@DZ4AKUE;5:2BLN.5)A"]MN-6H6Q'F^76%8UGJ:2-TW,N:$]X
M'NTU-\)V*=-MH*JJKH?U-##+UP.T2BRDKF#E\8XD%*&BDFFSHRF'WL=+3C]$
MO6G9EE@2ZFWN.= \@A'4VI2 5!GO/CASIP/[XA^6,KAMWG!W8S1 U 69JF);
MI!:IS/4"0*TT YDA3&.])<Y_+]$AV>$5+]^LP)T(FKK4TJ;;+!JTR;"?S)T'
M!<%W8Y8M.&"0A\B-:W7R,3CT#<^2*W:?Z,.=BW*KBC9-KU-D"U/B;LRL%@L^
MICE8YP!';;5[03SJW6[DF,(%4)XH4:U7JKK1"]@CA)Q8E#8TSZ)]K0U!>0Y?
M:^* <^>.U84KUG27&;#8&[*S#O*(G4=_U*5REHVW4;TK[8VT-%_0,>S3K8,N
M0U>T!"0LN-)#I@<E6M:)NEV'%QR"!X?VJ<>5)AA14J$ZLY"4>S29ZL94= VR
M"#,H-F@4H8:;S%6L <G[W;!BG[<^766%*[2Y0H:@Y>$:#K8<:H^NT6DM3PLS
M?'B6S%O[)342!MW0,D2+W;FGYE9XH)14@X3N^P>S072QP^-)GC ZIIK8+KL7
M$*+P22^Y^[SWC \F3SNE<P:X\ZG,="U5$+M08UU%0>, VYMX(3Q\*>.:\RM5
M311H\7=?$":6*H<B[?:#,1E;$>AC2<(5KBWA(\@T^T /+U+QQF$/$.YN^:8^
M#\="V(20=0PI?"6F.;T"P?,P5:'CHVIYS V7Y N0E+H#LC@O4K;I+RDDP;1_
M(Y!N.,O4@7?J;,Q=&@B(XBZ>I( O@:6[W_H0XT.O\9SV7L-"G;/DE\UH; #;
MAS>R\M/\/MM5>(VK6QY>AGL/V-%;#Y5:8.MD_.3B.%23Z8LW:WZI:VZ\-S5_
M7"FHR=("_+XPQJ<O=$!^R^_E_P!02P,$%     @ T8-\6"Z/5SEE#   +R0
M !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULK5I;<]LV%G[7K\"X:2>9
MH66)NCN7F<1NNIYI4X^=[L[.SCY )&0A(0D5('WIK]_O'( 4I5"VV^Y#8EZ
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M*$4A?MLV!'O$CBYTR<[X&T"W3W>I3R-_W#)K@,ZV8NPCYV+7GUZT718A!W0
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MXPU>M[!36]G6@P/'IVL;O:*0E'J$_S(815$015%GF%%.+TFH ;A;'RR!=_!
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MP&9<:J_'$^^M>-VTZ-CLY%OPXD"1?V'Q!*UFVX?7APH YWY).Z;*8[Y=O6A
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M:*K# _3[HB6$H!\P0?A725[\#U!+ P04    " #1@WQ8D[8:3PD$   2"0
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M6"W,-[G_#=M\',%4"NV^8=_:AAZDM3:R:)V)0<'+YI>]M^?P?QSBUB%VO)M
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M7F5Q/L>%!I,C: NIH:9R*_'#'BOM:@0RO-O8W0SV3"EFB9+@8(W M:XM6ZE
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M/$KK8/83(?1N8A,T/XWP'U!+ P04    " #1@WQ87[Z(3YP#  #8"   &0
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M=<^_9WI%I0$",X+V>Y<7 >BZC]8+JTK?NY;*4B?TTYS^>J!V!V@_4\KN%BY
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MA_\$H)T![F^4LMW$!>C_,I9_ %!+ P04    " #1@WQ8&,Q4Z5D"  !K!0
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MD@!3*XG36!93*1.$53B_%9MC2.%E8H0YWF+:&"8B-V$IZ7L_%S/.6[9;,#4
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MXI&%XD*++/\3_U9H+9+\XQ)8!-(,P._G0NC-A7%0/3@R^1]02P,$%     @
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MFLPE9QD#3=Z2/>.9+$O,PJ*@"LC=EYIM* =A--D"+L!SQNL<<K*$C-8:B"F
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MZ)5J.LQF8F3EFK2E--CRN6&!73DH:X#?5U*:W<1NT/7YZ?]02P,$%     @
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MDVGDXGW #P%;LS<F3LE2J0<WN<T3&KB"0$*&CH';SP:F(*4CLF4\=IRT3^F
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MQ02#RPM*='LBVPFJVC?U4J$](GY8V$L,M NP^RNE<#=QYZ2_%M,_4$L#!!0
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M&;@N4/-KQN2^HV^ ]L)/_@)02P,$%     @ T8-\6,Y3-Y?- @  (P@  !D
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M-+X193/%5QRD"<#YE1!ZWS$/1?._(/H'4$L#!!0    ( -&#?%BI?>N4CP(
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M$J^IOA'5-VCT#"U?)JAROZBJ;8>1A[*UTH(U8!,!([S^XL<F#SN ?OP*(&P
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MQS[Z4*EJU.UAVH,#-V#5V,QV0O?O=VT(3=N4[F$OP;Z^Y]QS;_ A::2ZTR6
M(?<5%WKJE<;4%[ZOLQ(JJL]D#0)/-E)5U.!6%;ZN%=#<@2KNAT$0^Q5EPDL3
M%[M6:2*WAC,!UXKH;551]6<.7#93;^3M S>L*(T-^&E2TP)68&[K:X4[OV?)
M605",RF(@LW4FXTN%K'-=PG?&33Z8$UL)VLI[^SF,I]Z@14$'#)C&2@^=K
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M^K2DFC#^&2)^6RW1IP^?T0?$"O2X$Z4"8S5U-< ;!#=M0+_6H/X%T"5-KU"
M?T:^YP<6]\7[W?VW[BZ4K*V;W];-K^(%/ZP;6C*5<J%*2=%?-VNE)2S-OVT)
MUA'']HBF7Z_5GJ1TYD!#*BH/U)E__ E'WA=;NO]3L#?)!VWRP5#T^>^PO<!&
M(HEFQ19![@JE1,H7V%6.1-IGMXX851'-WG*8X\1+)E/W<)Z5Q2KT Z^U>H,[
M;G''@[@/4  BTUVU3#-Z@+UK#SN11AIF+X6ES+05N8X:GL$$L'HZQ'TCWY^,
M[<!A"QP. M^DJ2P)K_NJF3XK8=@;?!R''4"+3>C;^:*6+WI?0>DSR F4#]:^
ME2_JC8V],(H[A'VKT(\NE#!N$>-!Q)46Z=/(;/ 9@DX%3$6,;M@HX_X\>TFW
MC'TC/XDO0"8M9#((N:30G"DCM:#!7)-<2,W^N4B:].L9X&X/68S"26@GG;2D
MDT'2.PJ51+S9XE]L;)/>L!/<(>N;X'AB!\/>2<"\0;1'H0DWREVKDNEI4JF2
M56.\_EQ'B9]T0"UF?IPDR076,['%PXUC#A4CL1F54,V*T@J)>Z./DF[3V(QP
M?(GP)&MX4#A@Z_E>,E/'V_N'CR3??UE:"?W^X#'4L<MH,XO/4GD+>9(?/*P_
MEBGGI].'%3BPD43=UK&:3:(+S8-/ H2'%>B.*G6-#H273:]S.#Z3(J56UKZD
MC&!#PMUNLMGY.(HOT9[4!P_+CY'W_U3<L*?:L!3#WFKXD5F-ZYX=9LV7Q&]$
M;EFA$*<;\/.N8@@CZ\-Y?:/%OCK?KH6&TW)UN8,/&BJ- ;S?"*%?;\R1N?U$
MFO\+4$L#!!0    ( -&#?%A)2OCI  ,  %((   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;*U6R6[;,!#]%4(-B@1H(TNRY22U!7CIDD. ($M[*'J@
MI;%%1")5DK*3?GV'E*QZD9T><K'(X<SC>\,AQX.5D$\J!=#D.<^X&CJIUL65
MZZHXA9RJ<U$ QY6YD#G5.)4+5Q42:&*#\LSU.YW0S2GC3C2PMEL9#42I,\;A
M5A)5YCF5+V/(Q&KH>,[:<,<6J38&-QH4= 'WH!^+6XDSMT%)6 Y<,<&)A/G0
M&7E7D[[QMP[?&:S4QI@8)3,AGLSD.ADZ'4,(,HBU0:#X6<($LLP (8W?-:;3
M;&D"-\=K]"]6.VJ94043D?U@B4Z'SH5#$IC3,M-W8O4-:CT]@Q>+3-E?LJI]
M.PZ)2Z5%7@<C@YSQZDN?ZSQL!'CA@0"_#O!W [H' H(Z(+!"*V96UI1J&@VD
M6!%IO!'-#&QN;#2J8=R<XKV6N,HP3D?7/!8YD ?Z#(I\)'<0"QZSC%&;9#$G
M8U@PSAE?$,H3\IDG9CC*1<FU,NN/7&+,@K,_D!@8#. P9[AX.@5-67:&L(_W
M4W)Z<D9."./D(16E0C U<#4J,#S<N&8[KMCZ!]AZ/KD17*?*$(%D&\!%Z8U^
M?ZU_[!]%G$)\3@+O _$[?M!":/+_X?X1.D%S'('%"UX]#C)E*LZ$*B60GZ.9
MTA(K_E=;RBK$;CNB>06N5$%C&#IXS17()3C1^W=>V/G4)O>-P+;$=QOQW6/H
MT5<IE"+E9D%I3,1L75!4$YT"SM<5B>5G#"] 95MBJMU"NYMYS9:1'X;=@;O<
M%+SOY'7#R\9I2TBO$=([*F24),S<'T7F4N161"%4;=+T";BY!X9Z7$H)7!^4
M4.W3VV!WV?=W%+3X>-UV 6$C('P# 85D0EKJK5<YW./5V6&^[^%?>.W,^PWS
M_EO4$.!;]DKU]/<*(PB#<$?!OM-6B542W(WG.0>YL%U+D=B\H=5+U5B;QCBR
M_6#'/L:&6?6W?S!5M[VA$B^%(AG,$;)SWL>DRJJ#51,M"ML$9D)C2['#%)L^
M2.. ZW,A]'IB-FC^1D1_ 5!+ P04    " #1@WQ8$8AF/1,:   GW0$ &0
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MRU%-HYI!-8MJ#M4\I85]H,[-=<YZ,FOL(EU<:%S[:%8.U<16"PZ]1\/^:._
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M@6H2U12JY:BF4<V@FD4UAVJ>TL+BKK. ?6(IPI<?BT2M1!+?S<:M PT:HII
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M<@,L!E$,T-^O.%<O-T6 YA>#^1=02P,$%     @ T8-\6#X#//OI @  J0@
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MAG1-5-WYZHF1E6L>#])0*W+#G/XLH+(!M)]):9XG]@7MWX_X#U!+ P04
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MO3)TA=;D?[@TX%=N#6_.W!*P7GK\7G]X'*]3J;#G#<^$ZW QP-;::\W<3J\
M)1H.SM%L$CA4=VPO[Z]E[N"594OK6L0L[CV4:6ROTV_-VP)M8,O;H7VW%(:Z
MM48J![XR_:5 ,=M26?0AU=NJA[TVG=O1^ZGN;4V#=H I&N-;PM7F%BB#I8+T
M>D,58%[TFL5$LHUIUQ9,JN;/#->J/P>N!=3W)6/R9:(7J#K^Z!=02P,$%
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M'1ZK.:R(8EL]I'%?"%%DU>(&: Q,;2 _7Q>%>%Y1SWTT#S<M_P-02P,$%
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M9#/X#/*:]OVJT@YGDJS";L_?$,Q%!YF4,J.R#1/ZZZ'1@-,<[$@VF\-5E54
MH%)EH1L9([-2$.-AS6@:6G9*.;^#)\3/?$=[F6_MJ2D(T3:UH:9I96P']+?5
MK/:V;.]%NE[%'DOU9:&7(TP?:H7>2IJSI>DO\]8 IA[BZJ2J^.HS9S-14+OX
MHP..!F3-\^:E9$\Z&I3*5 ]0Z7N/5"HVW1[Y+4EU3Y=J74[+'/?</4'/_S;/
M,RJH)'S;M*[]MYSE%SN.^J]EV3Q5]@T[/3:O_;=NLG<*)N-3,'D2-9F<@LGT
M!$SV7^VI>;S)Z"02&;Y)DT%S7-LZ$^Z<"-M1#T[>0_\'G/'Y)J@W63"NF&AZ
M<Y9E5#P[&&IY12;Z#](=?3T_HSE9<'7?@D-_T_Y.,[8HTG;6+22BF;5I?X/E
MA7%[[->QF,CHDF;CIBMG$]/T=$-';3Y V$=NS,>-8!R+N1' L#B8 XQC65B<
M_VD]";H>BV'>$B>2H)P$Y5B6"QF;+Q;'S4GUQ[W2-(VB.,8R.AX['8RQO,4Q
M_+C5,&_ P.) I+_+-;[;>(4<K@-L3P]5"+92O!*QE>*Y!L2=-V"DJ7NWL3C
MP'8!JQV([XX#->7F1!'L*N8-NX-Q)$TQ!&K17:-QC&0GAJ][?["[)(K2U(T
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MZAU_J?=8/O=YO/1\K_$[]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#!!0
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M?\KZ9.WZKW^RZ.]Y:^KN/9\-?[)<O0)02P$"% ,4    " #1@WQ8!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( -&#?%@11\5&[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -&#?%B97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MT8-\6 0-;!+#"   -#8  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -&#?%AW)&MIU 4  )H;   8
M          " @081  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #1@WQ8J<FO07 #  !$#P  &               @($0%P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ T8-\6$7#D0GN P  ] T
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M965T."YX;6Q02P$"% ,4    " #1@WQ8,;="C5\?  !R70  &
M    @('^.   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MT8-\6!77PBK%!   0@L  !D              ("!DU@  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #1@WQ82.%,PAH%   J#0  &0
M            @(&/70  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( -&#?%C67[V #@,  !@(   9              " @>!B  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ T8-\6-][Q1)6 P
MJP<  !D              ("!)68  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #1@WQ8D$DU,<$.  #Q)P  &0              @(&R
M:0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -&#?%@N
MCU<Y90P  "\D   9              " @:IX  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ T8-\6 0JNQ96#@  YRT  !D
M     ("!1H4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -&#?%@><->KNP(  $ &   9              "
M@?O$  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ T8-\
M6%^^B$^< P  V @  !D              ("![<<  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #1@WQ8,_1[HBX#  !Q"   &0
M        @(' RP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( -&#?%@8S%3I60(  &L%   9              " @27/  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ T8-\6+]12:XS!   G@H
M !D              ("!M=$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #1@WQ8<<';10T&  !N$   &0              @($?U@
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -&#?%@/VR#>
M!P0  $,+   9              " @6/<  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ T8-\6&:*IFZ6!0  G@X  !D
M ("!H>   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #1
M@WQ87[DQ80X"  #A!   &0              @(%NY@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -&#?%@X;%>P8 4  %,C   9
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M970S-"YX;6Q02P$"% ,4    " #1@WQ8^[<^-34"   B!0  &0
M    @(&Y_@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M -&#?%A4CU!KU 0  "\A   9              " @24! 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ T8-\6+HLS:V^ @  _ <  !D
M             ("!, 8! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #1@WQ8SE,WE\T"   C"   &0              @($E"0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -&#?%BI?>N4CP(
M $4(   9              " @2D, 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ T8-\6!Y+SE&/ @  XP8  !D              ("!
M[PX! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #1@WQ8
MVGW?F64(  ""5   &0              @(&U$0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -&#?%@O7A3+;0(  -X%   9
M      " @5$: 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ T8-\6%AZ="Y. P  60L  !D              ("!]1P! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #1@WQ8<DO7O/D"  !1"0
M&0              @(%Z( $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( -&#?%B88M;_D@(  .\&   9              " @:HC 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ T8-\6)&FIQ19
M @  OP4  !D              ("!<R8! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #1@WQ8;522J#T'  #?,P  &0
M@($#*0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -&#
M?%@+IU(;TP,  $,,   9              " @7<P 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ T8-\6+M0M9P"!   +@T  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( -&#?%AQN/_ZZ@4  !0E   9
M  " @3)> 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MT8-\6'5Y!E=R!0  1!T  !D              ("!4V0! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #1@WQ8]?_^'#@#  "*"   &0
M            @('\:0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( -&#?%@=\D7&J ,  /T/   9              " @6MM 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ T8-\6! WS>1! P
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M96QS+RYR96QS4$L! A0#%     @ T8-\6+:C?Y6N!   ?R<   \
M     ( !\WT! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -&#?%A9=@'X
M]0$  #@C   :              "  <Z" 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( -&#?%@7R,P;VP$  -$B   3
M  "  ?N$ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(   >'
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Going Concern and Management's Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlans</Role>
      <ShortName>Going Concern and Management's Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1</Role>
      <ShortName>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Going Concern and Management's Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail</Role>
      <ShortName>Going Concern and Management's Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail</Role>
      <ShortName>Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Short-Term Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Short-Term Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail</Role>
      <ShortName>Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Goodwill - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail</Role>
      <ShortName>Goodwill - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Goodwill - Schedule of Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail</Role>
      <ShortName>Goodwill - Schedule of Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Commitments and Contingencies - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Commitments and Contingencies - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Summary of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Schedule of Significant Components Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Significant Components Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="eldn-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="eldn-20231231.htm">eldn-20231231.htm</File>
    <File>eldn-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img116206746_0.jpg</File>
    <File>img116206746_1.jpg</File>
    <File>img116206746_2.jpg</File>
    <File>img116206746_3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="477">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eldn-20231231.htm": {
   "nsprefix": "eldn",
   "nsuri": "http://www.eledon.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "eldn-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "eldn-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 235,
   "keyCustom": 63,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 34,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2023": 6,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 155,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 538,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 477,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:AmortizationOfOperatingLeaseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness",
     "longName": "100060 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlans",
     "longName": "100070 - Disclosure - Going Concern and Management's Plans",
     "shortName": "Going Concern and Management's Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments",
     "longName": "100090 - Disclosure - Short-Term Investments",
     "shortName": "Short-Term Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1",
     "longName": "100110 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities",
     "shortName": "Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill",
     "longName": "100120 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100130 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100140 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "100160 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "100190 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables",
     "longName": "100220 - Disclosure - Short-Term Investments (Tables)",
     "shortName": "Short-Term Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "100230 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables",
     "longName": "100240 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities (Tables)",
     "shortName": "Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillTables",
     "longName": "100250 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "100260 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "longName": "100280 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_f448875a-e2e2-4f12-b2e3-7d76a53fa08d",
      "name": "eldn:ScheduleOfWarrantActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f448875a-e2e2-4f12-b2e3-7d76a53fa08d",
      "name": "eldn:ScheduleOfWarrantActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "100290 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
     "longName": "100310 - Disclosure - Description of Business - Additional Information (Detail)",
     "shortName": "Description of Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_9e831537-98aa-43d1-a911-7e2bb6a241d8",
      "name": "us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9e831537-98aa-43d1-a911-7e2bb6a241d8",
      "name": "us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
     "longName": "100320 - Disclosure - Going Concern and Management's Plans - Additional Information (Detail)",
     "shortName": "Going Concern and Management's Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:CashCashEquivalentsAndRestrictedCashMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:CashCashEquivalentsAndRestrictedCashMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
     "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail",
     "longName": "100360 - Disclosure - Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail)",
     "shortName": "Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetail",
     "longName": "100380 - Disclosure - Short-Term Investments - Additional Information (Detail)",
     "shortName": "Short-Term Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail",
     "longName": "100390 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_85108846-892e-47c8-9754-3c7dfc301d1c",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85108846-892e-47c8-9754-3c7dfc301d1c",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "100400 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail",
     "longName": "100410 - Disclosure - Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)",
     "shortName": "Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock",
       "div",
       "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock",
       "div",
       "eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail",
     "longName": "100420 - Disclosure - Goodwill - Additional Information (Detail)",
     "shortName": "Goodwill - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail",
     "longName": "100430 - Disclosure - Goodwill - Schedule of Goodwill (Detail)",
     "shortName": "Goodwill - Schedule of Goodwill (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_c5d1f09a-750c-4e0a-996b-ec8c451d166a",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "100440 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail",
     "longName": "100450 - Disclosure - Commitments and Contingencies - Components of Lease Expense (Detail)",
     "shortName": "Commitments and Contingencies - Components of Lease Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail",
     "longName": "100460 - Disclosure - Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail)",
     "shortName": "Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:OtherInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:OtherInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail)",
     "shortName": "Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail",
     "longName": "100480 - Disclosure - Income Taxes - Summary of Loss Before Income Taxes (Detail)",
     "shortName": "Income Taxes - Summary of Loss Before Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail",
     "longName": "100490 - Disclosure - Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)",
     "shortName": "Income Taxes - Summary of Provision (Benefit) for Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "100500 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:EffectiveFederalAndStateIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "eldn:EffectiveFederalAndStateIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail",
     "longName": "100510 - Disclosure - Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate (Detail)",
     "shortName": "Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail",
     "longName": "100520 - Disclosure - Income Taxes - Schedule of Significant Components Deferred Tax Assets and Liabilities (Detail)",
     "shortName": "Income Taxes - Schedule of Significant Components Deferred Tax Assets and Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail",
     "longName": "100530 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_c5d1f09a-750c-4e0a-996b-ec8c451d166a",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "longName": "100540 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_170abf46-8a87-4bdf-bc25-11d52fb87c8e",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "eldn:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail",
     "longName": "100550 - Disclosure - Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Activity (Detail)",
     "shortName": "Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_157cedb9-5047-412b-85f9-6fbe8216f23c",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
     "longName": "100560 - Disclosure - Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)",
     "shortName": "Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b49914b8-f522-4af4-8c0b-fb6529f0205e",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eldn:ScheduleOfWarrantActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
     "longName": "100570 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants (Detail)",
     "shortName": "Stock-Based Compensation - Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_c5d1f09a-750c-4e0a-996b-ec8c451d166a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted (Detail)",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail",
     "longName": "100600 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb8475f5-4660-40c0-8142-92caed57a7c8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail",
     "longName": "100610 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards (Detail)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_57551459-8811-4b71-9e9a-189290d077cf",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a4dbd612-6707-4d02-a493-3e3587d5b602",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "longName": "100620 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_a35f913d-d756-40df-9f78-a4912c356455",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1",
      "name": "eldn:NumberOfPreFundedWarrantsExercisedForCommonStock",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ALSTherapyDevelopmentFoundationIncLicenseAgreementMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALS Therapy Development Foundation, Inc. License Agreement [Member]",
        "label": "A L S Therapy Development Foundation Inc License Agreement [Member]",
        "documentation": "ALS therapy development foundation, Inc. license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AccountsPayableAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AccountsPayableAccruedExpensesAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued expenses and other liabilities",
        "label": "Accounts payable, accrued expenses and other liabilities",
        "documentation": "Accounts payable, accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r629"
     ]
    },
    "eldn_AccreditedInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AccreditedInvestorMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accredited Investor [Member]",
        "label": "Accredited Investor [Member]",
        "documentation": "Accredited Investor."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AccretionOnInvestmentDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AccretionOnInvestmentDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion on investment discounts",
        "negatedLabel": "Accretion on investment discounts",
        "label": "Accretion on Investment Discounts",
        "documentation": "Accretion on Investment Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AccruedClinicalCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AccruedClinicalCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical",
        "label": "Accrued Clinical Current",
        "documentation": "Accrued clinical current."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AccruedFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AccruedFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued costs associated with PIPE financing",
        "label": "Accrued Financing Costs",
        "documentation": "Accrued financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other liabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional services",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "eldn_AccruedSeveranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AccruedSeveranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued severance",
        "label": "Accrued Severance Current",
        "documentation": "Accrued severance current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r503",
      "r672",
      "r673",
      "r674",
      "r750",
      "r769"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r298"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AggregateNetSalesAchievement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AggregateNetSalesAchievement",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reaching of aggregate net sales",
        "label": "Aggregate Net Sales Achievement",
        "documentation": "Aggregate net sales achievement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r342"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AmortizationOfOperatingLeaseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AmortizationOfOperatingLeaseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease asset",
        "label": "Amortization Of Operating Lease Asset",
        "documentation": "Amortization of operating lease asset."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AnelixisTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AnelixisTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Anelixis [Member]",
        "terseLabel": "Anelixis [Member]",
        "label": "Anelixis Therapeutics Incorporation [Member]",
        "documentation": "Anelixis Therapeutics, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AnelixisTherapeuticsLlcAndOticPharmaLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AnelixisTherapeuticsLlcAndOticPharmaLtdMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anelixis Therapeutics, LLC and Otic Pharma, Ltd.",
        "label": "Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member]",
        "documentation": "Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_AnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AnnualLicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual License Maintenance Fee",
        "label": "Annual License Maintenance Fee",
        "documentation": "Annual license maintenance fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "eldn_AreaOfOfficeSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AreaOfOfficeSpace",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space",
        "label": "Area Of Office Space",
        "documentation": "Area of office space."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ArmisticeCapitalMasterFundLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ArmisticeCapitalMasterFundLtdMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Armistice Capital Master Fund Ltd [Member]",
        "label": "Armistice Capital Master Fund Ltd [Member]",
        "documentation": "Armistice Capital Master Fund Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r119",
      "r138",
      "r169",
      "r178",
      "r180",
      "r215",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r381",
      "r383",
      "r403",
      "r477",
      "r540",
      "r629",
      "r640",
      "r713",
      "r714",
      "r757"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r124",
      "r138",
      "r215",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r381",
      "r383",
      "r403",
      "r629",
      "r713",
      "r714",
      "r757"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "terseLabel": "Assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "eldn_AtMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "AtMarketOfferingProgramMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering program.",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "ATM Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r223",
      "r476"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r223",
      "r473",
      "r681"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "eldn_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis Of Presentation And Principles Of Consolidation Policy [Text Block]",
        "documentation": "Basis of presentation and principles of consolidation."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BVF Exchanging Stockholders [Member]",
        "label": "Biotechnology Value Fund L P Biotechnology Value Fund I I L P Biotechnology Value Trading Fund O S L P M S I B V F S P V L L C [Member]",
        "documentation": "Biotechnology Value Fund LP, Biotechnology Value Fund II LP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r623",
      "r624"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r378",
      "r623",
      "r624"
     ]
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business acquisition, date of acquisition",
        "terseLabel": "Date of acquisition",
        "label": "Business Acquisition, Effective Date of Acquisition",
        "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r10"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unaudited Pro Forma Combined Financial Information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r379"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r75",
      "r76"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Irvine, California [Member]",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California [Member]",
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_CancellationOfCommonStockInExchangeForPreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CancellationOfCommonStockInExchangeForPreferredStockShares",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of common stock in connection with exchange for preferred stock, Shares",
        "label": "Cancellation Of Common Stock In Exchange For Preferred Stock Shares",
        "documentation": "Cancellation of common stock in exchange for preferred stock shares."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_CancellationOfCommonStockInExchangeForPreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CancellationOfCommonStockInExchangeForPreferredStockValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of common stock in connection with exchange for preferred stock",
        "label": "Cancellation Of Common Stock In Exchange For Preferred Stock Value",
        "documentation": "Cancellation of common stock in exchange for preferred stock value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r116",
      "r602"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CashCashEquivalentsAndRestrictedCashMaturityPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash, maturity period",
        "label": "Cash Cash Equivalents And Restricted Cash Maturity Period",
        "documentation": "Cash cash equivalents and restricted cash maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r135"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r72"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability:",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash paid for amounts included in measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r120",
      "r121",
      "r122",
      "r138",
      "r158",
      "r159",
      "r161",
      "r163",
      "r167",
      "r168",
      "r215",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r269",
      "r270",
      "r273",
      "r276",
      "r284",
      "r403",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r528",
      "r549",
      "r567",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r652",
      "r669",
      "r675"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r167",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276",
      "r282",
      "r284",
      "r497",
      "r498",
      "r499",
      "r500",
      "r618",
      "r652",
      "r669"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants exercise price",
        "terseLabel": "Warrant exercise price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Warrant Or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants to purchase common stock shares",
        "verboseLabel": "Common stock warrants exercisable",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assumed and replaced",
        "terseLabel": "Estimated fair value, assumed and replaced",
        "label": "Class Of Warrant Or Right Number Of Warrants Or Rights Assumed And Replaced",
        "documentation": "Class of warrant or right number of warrants or rights assumed and replaced."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExchanged",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Exchanged",
        "label": "Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Exchanged",
        "documentation": "Class of warrant or right number of warrants or rights cancelled or exchanged."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Expired",
        "verboseLabel": "Cancelled/Expired",
        "terseLabel": "Warrants exercisable for exchange",
        "label": "Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Expired",
        "documentation": "Class of warrant or right number of warrants or rights cancelled or expired."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "terseLabel": "Number of shares exercised",
        "label": "Class Of Warrant Or Right Number Of Warrants Or Rights Exercised",
        "documentation": "Class of warrant or right number of warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued",
        "terseLabel": "Warrants issued",
        "label": "Class Of Warrant Or Right Number Of Warrants Or Rights Issued",
        "documentation": "Class of warrant or right number of warrants or rights issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants available for exercise",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r53",
      "r479",
      "r527"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r249",
      "r250",
      "r589",
      "r712"
     ]
    },
    "eldn_CommonAndPreferredWarrantsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CommonAndPreferredWarrantsOutstandingMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common and Preferred Warrants Outstanding [Member]",
        "label": "Common And Preferred Warrants Outstanding [Member]",
        "documentation": "Common and preferred warrants outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, number of shares initially reserved for issuance",
        "terseLabel": "Common stock, number of shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock exchanged for X and X1 non-voting convertible preferred stock",
        "label": "Common Stock Exchanged For X And X One Non-voting Convertible Preferred Stock",
        "documentation": "Common stock exchanged for X and X1 non-voting convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r672",
      "r673",
      "r750",
      "r768",
      "r769"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value",
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r528"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r528",
      "r546",
      "r769",
      "r770"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2023 and 2022; 24,213,130 and 13,776,788 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r481",
      "r629"
     ]
    },
    "eldn_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]",
        "documentation": "Concentration of credit risk and other risks and uncertainties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r106"
     ]
    },
    "eldn_ContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ContingentLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Contingent Liability",
        "documentation": "Contingent liability."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ConversionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ConversionAgreementMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Agreement [Member]",
        "documentation": "Conversion agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ConversionOfPreferredStockConversionBlockerPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ConversionOfPreferredStockConversionBlockerPercent",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock, conversion blocker, percent",
        "label": "Conversion of Preferred Stock, Conversion Blocker, Percent",
        "documentation": "Conversion of preferred stock, conversion blocker, percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares converted",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares issued",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares of common stock issued upon conversion of each share of preferred stock",
        "terseLabel": "Shares of common stock issued upon conversion of each share of preferred stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r60",
      "r83",
      "r279"
     ]
    },
    "eldn_CormorantGlobalHealthcareMasterFundLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "CormorantGlobalHealthcareMasterFundLpMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cormorant Global Healthcare Master Fund LP [Member]",
        "label": "Cormorant Global Healthcare Master Fund LP [Member]",
        "documentation": "Cormorant global healthcare master fund lp."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r265",
      "r271",
      "r423",
      "r604",
      "r606"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r671",
      "r749"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r671"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current income tax expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r367",
      "r373",
      "r671"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r671",
      "r749"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt, Long-Term and Short-Term, Combined Amount, Total",
        "terseLabel": "Debt outstanding",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Short-term Investments Classified as Available-for-sale Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r748",
      "r749"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r671",
      "r748"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income tax expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r92",
      "r109",
      "r372",
      "r373",
      "r671"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r97",
      "r361"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r478"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r748",
      "r749"
     ]
    },
    "eldn_DeferredTaxAssetsDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Deferred Tax Assets Depreciation And Amortization",
        "documentation": "Deferred tax assets depreciation and amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research expenditures",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "eldn_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign operating losses carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards, not to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "eldn_DeferredTaxAssetsRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DeferredTaxAssetsRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "label": "Deferred Tax Assets Right Of Use Asset",
        "documentation": "Deferred tax assets right-of-use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development tax credit carryforwards for federal and state",
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r747"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "terseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r747"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r746"
     ]
    },
    "eldn_DeferredTaxLiabilitiesInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquired IPR&amp;D",
        "label": "Deferred Tax Liabilities In Process Research And Development",
        "documentation": "Deferred tax liabilities, in-process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_DeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DeferredTaxLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income taxes",
        "label": "Deferred Tax Liability",
        "documentation": "Deferred tax liability."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_DescriptionOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DescriptionOfBusinessLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description Of Business [Line Items]",
        "label": "Description Of Business [Line Items]",
        "documentation": "Description of business."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_DescriptionOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DescriptionOfBusinessTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description Of Business [Table]",
        "label": "Description Of Business [Table]",
        "documentation": "Description of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r300",
      "r331",
      "r332",
      "r334",
      "r626"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_DiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "DiscountRateAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Discount Rate [Abstract]",
        "documentation": "Discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647",
      "r649"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority [Member]",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r156",
      "r158",
      "r161",
      "r162",
      "r163",
      "r165",
      "r394",
      "r395",
      "r474",
      "r487",
      "r608"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r158",
      "r161",
      "r162",
      "r163",
      "r165",
      "r394",
      "r395",
      "r474",
      "r487",
      "r608"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "eldn_EffectiveFederalAndStateIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "EffectiveFederalAndStateIncomeTaxRate",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Income tax rate",
        "label": "Effective Federal And State Income Tax Rate",
        "documentation": "Effective federal and state income tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total",
        "terseLabel": "Income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "eldn_EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInWarrantFairMarketValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in warrant fair market value",
        "label": "Effective Income Tax Rate Reconciliation Change In Warrant Fair Market Value Amount",
        "documentation": "Effective income tax rate reconciliation, change in warrant fair market value, amount"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationSectionThreeHundredAndEightyTwoLimitationOnNetOperatingLossesAndCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 382 limitation on net operating losses and credits",
        "label": "Effective Income Tax Rate Reconciliation Section Three Hundred And Eighty Two Limitation On Net Operating Losses And Credits",
        "documentation": "Effective income tax rate reconciliation, section 382 limitation on net operating losses and credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation expense, recognized over estimated weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options Outstanding and Other Equity Awards [Member]",
        "terseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r112",
      "r128",
      "r129",
      "r130",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r166",
      "r216",
      "r217",
      "r286",
      "r335",
      "r336",
      "r337",
      "r368",
      "r369",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r420",
      "r490",
      "r491",
      "r492",
      "r503",
      "r567"
     ]
    },
    "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity distribution agreement maximum value of common shares issuable",
        "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable",
        "documentation": "Equity distribution agreement maximum value of common shares issuable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r401"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r401"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments Measured At Fair Value On A Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r95"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r398",
      "r430",
      "r431",
      "r432",
      "r616",
      "r617",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r402"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r288",
      "r293",
      "r398",
      "r430",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r288",
      "r293",
      "r398",
      "r431",
      "r616",
      "r617",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r430",
      "r431",
      "r432",
      "r616",
      "r617",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring Member",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r402"
     ]
    },
    "eldn_FeeDueForMilestonesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "FeeDueForMilestonesAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee due for milestones achieved",
        "label": "Fee Due For Milestones Achieved",
        "documentation": "Fee due for milestones achieved."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r267",
      "r282",
      "r391",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r486",
      "r613",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "eldn_FiveHundredMillionAggregateNetSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "FiveHundredMillionAggregateNetSalesMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of 500 Million Aggregate Sales [Member]",
        "label": "Five Hundred Million Aggregate Net Sales [Member]",
        "documentation": "Five hundred million aggregate net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Country [Member]",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r551"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Goodwill, Total",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r228",
      "r472",
      "r615",
      "r629",
      "r701",
      "r708"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r241",
      "r615"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r230",
      "r240",
      "r615"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillScheduleOfGoodwillDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairments",
        "terseLabel": "Impairment charge",
        "verboseLabel": "Goodwill impairment",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r229",
      "r235",
      "r241",
      "r615"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r615"
     ]
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification obligations amount",
        "label": "Guarantor Obligations, Current Carrying Value",
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r646",
      "r647"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Impairments of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r78"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r79"
     ]
    },
    "eldn_InProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "InProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "In Process Research And Development",
        "documentation": "In-process research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-Process Research and Development",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r374"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r67",
      "r101",
      "r169",
      "r177",
      "r179",
      "r181",
      "r475",
      "r484",
      "r610"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r374"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses before income taxes:",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r246",
      "r552"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r552"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r345",
      "r353",
      "r358",
      "r365",
      "r370",
      "r375",
      "r376",
      "r377",
      "r502"
     ]
    },
    "eldn_IncomeTaxExaminationLikelihoodOfFavorableSettlement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IncomeTaxExaminationLikelihoodOfFavorableSettlement",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax examination, likelihood of settlement, percentage",
        "label": "Income Tax Examination Likelihood Of Favorable Settlement",
        "documentation": "Income tax examination likelihood of favorable settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax examination, likelihood of settlement, description",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r91"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfProvisionBenefitForIncomeTaxesDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "totalLabel": "Total provision for income taxes",
        "negatedLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r110",
      "r154",
      "r155",
      "r170",
      "r351",
      "r371",
      "r488"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r347",
      "r348",
      "r358",
      "r359",
      "r364",
      "r366",
      "r496"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "eldn_IncomeTaxReconciliationPermanentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IncomeTaxReconciliationPermanentItems",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Income Tax Reconciliation Permanent Items",
        "documentation": "Income tax reconciliation permanent items."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IncomeTaxReconciliationStateTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IncomeTaxReconciliationStateTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State rate differential",
        "label": "Income Tax Reconciliation State Tax Rate Differential",
        "documentation": "Income tax reconciliation state tax rate differential."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total",
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease asset and liability due to lease modification",
        "label": "Increase Decrease in Operating Lease Asset and Liability Due To Lease Modification",
        "documentation": "Increase decrease in operating lease asset and liability due to lease modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r668"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance receivable",
        "label": "Insurance Settlements Receivable, Current",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total short-term investments",
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IsraelTaxAuthorityMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israeli Tax Authority [Member]",
        "label": "Israel Tax Authority [Member]",
        "documentation": "Designated tax department of the government of Israel."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Shares",
        "label": "Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Shares",
        "documentation": "Issuance of common stock in connection with conversion of X non-voting convertible preferred stock shares."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value",
        "label": "Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Value",
        "documentation": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with conversion of X non-voting convertible preferred stock, Shares",
        "label": "Issuance Of Common Stock In Connection With Conversion Of X Non-voting Convertible Preferred Stock Shares",
        "documentation": "Issuance of common stock in connection with conversion of x non-voting convertible preferred stock shares."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with exercise of pre-funded warrants, Shares",
        "label": "Issuance of Common Stock in Connection With Exercise of Pre-funded Warrants, Shares",
        "documentation": "Issuance of common stock in connection with exercise of pre-funded warrants, shares."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with exercise of pre-funded warrants, Value",
        "label": "Issuance of Common Stock in Connection With Exercise of Pre-funded Warrants, Value",
        "documentation": "Issuance of common stock in connection with exercise of pre-funded warrants, value"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares",
        "label": "Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Shares",
        "documentation": "Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, shares."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value",
        "label": "Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Value",
        "documentation": "Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_JefferiesLimitedLiabilityCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "JefferiesLimitedLiabilityCompanyMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC [Member]",
        "label": "Jefferies Limited Liability Company [Member]",
        "documentation": "Jefferies Limited Liability Company."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_JeffriesLimitedLiabilityCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "JeffriesLimitedLiabilityCompanyMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffries LLC [Member]",
        "label": "Jeffries Limited Liability Company [Member]",
        "documentation": "Jeffries limited liability company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_LesseeOperatingLeaseEffectiveDateOfLeaseAmendment": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "LesseeOperatingLeaseEffectiveDateOfLeaseAmendment",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective date of lease amendment",
        "label": "Lessee Operating Lease Effective Date Of Lease Amendment",
        "documentation": "Lessee, operating lease, effective date of lease amendment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Payments Under Noncancelable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "eldn_LesseeOperatingLeaseRemainingTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "LesseeOperatingLeaseRemainingTermOfContract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining term of office lease",
        "label": "Lessee Operating Lease Remaining Term Of Contract",
        "documentation": "Lessee operating lease remaining term of contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r138",
      "r215",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r382",
      "r383",
      "r384",
      "r403",
      "r526",
      "r609",
      "r640",
      "r713",
      "r757",
      "r758"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r98",
      "r483",
      "r629",
      "r670",
      "r698",
      "r751"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r115",
      "r138",
      "r215",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r382",
      "r383",
      "r384",
      "r403",
      "r629",
      "r713",
      "r757",
      "r758"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Category of Item Purchased",
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Burlington, Massachusetts [Member]",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r295",
      "r457",
      "r489",
      "r518",
      "r519",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r599",
      "r600",
      "r612",
      "r618",
      "r625",
      "r630",
      "r715",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r295",
      "r457",
      "r489",
      "r518",
      "r519",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r599",
      "r600",
      "r612",
      "r618",
      "r625",
      "r630",
      "r715",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "eldn_NOLTrueUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "NOLTrueUp",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL true-up",
        "label": "N O L True Up",
        "documentation": "NOL True Up."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss",
        "terseLabel": "Net loss and other comprehensive loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r74",
      "r102",
      "r113",
      "r125",
      "r126",
      "r130",
      "r138",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r160",
      "r169",
      "r177",
      "r179",
      "r181",
      "r215",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r395",
      "r403",
      "r485",
      "r548",
      "r565",
      "r566",
      "r610",
      "r639",
      "r713"
     ]
    },
    "eldn_NetOperatingLossCarryforwardsExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "NetOperatingLossCarryforwardsExpirationPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward expiration period",
        "label": "Net Operating Loss Carryforwards Expiration Period",
        "documentation": "Net operating loss carryforwards expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Issued But Not Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_NoncashActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "NoncashActivitiesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash activities:",
        "label": "Noncash Activities [Abstract]",
        "documentation": "Noncash activities."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_NumberOfMilestonesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "NumberOfMilestonesAchieved",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Milestones Achieved",
        "label": "Number Of Milestones Achieved",
        "documentation": "Number of milestones achieved."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating business segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "eldn_NumberOfPreFundedWarrantsExercisedForCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "NumberOfPreFundedWarrantsExercisedForCommonStock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pre-funded warrants exercised for common stock",
        "label": "Number of Pre-funded Warrants Exercised for Common Stock",
        "documentation": "Number of pre-funded warrants exercised for common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_NumberOfSpecificClinicalDevelopmentMilestonesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "NumberOfSpecificClinicalDevelopmentMilestonesAchieved",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of specific clinical development milestones achieved",
        "label": "Number Of Specific Clinical Development Milestones Achieved",
        "documentation": "Number of specific clinical development milestones achieved."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office of Chief Scientist of Israeli Ministry of Economy and Industry [Member]",
        "label": "Office Of Chief Scientist Of Israeli Ministry Of Economy And Industry [Member]",
        "documentation": "Office of chief scientist of Israeli ministry of economy and industry."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_OneBillionAggregateNetSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "OneBillionAggregateNetSalesMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of 1 Billion Aggregate Sales [Member]",
        "label": "One Billion Aggregate Net Sales [Member]",
        "documentation": "One billion aggregate net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r177",
      "r179",
      "r181",
      "r610"
     ]
    },
    "eldn_OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "OperatingLeaseAssetObtainedInExchangeForLeaseLiabilityAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease asset obtained in exchange for lease liability:",
        "label": "Operating Lease Asset Obtained In Exchange For Lease Liability [Abstract]",
        "documentation": "Operating lease asset obtained in exchange for lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r628"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less current portion of operating lease liability",
        "terseLabel": "Current operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating lease",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r415"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease asset, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r628"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r628"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r629"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_OtherInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "OtherInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Information Related to Leases",
        "label": "Other Information Related To Leases Table [Text Block]",
        "documentation": "Other information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r699"
     ]
    },
    "eldn_OticPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "OticPharmaIncMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Otic Pharma, Inc. [Member]",
        "label": "Otic Pharma Inc [Member]",
        "documentation": "Otic Pharma, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_OticPharmaLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "OticPharmaLtdMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Otic Pharma [Member]",
        "label": "Otic Pharma Ltd [Member]",
        "documentation": "Otic Pharma, Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of available-for-sale short-term investments",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r132",
      "r184"
     ]
    },
    "eldn_PercentageOfCumulativeChangeInOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PercentageOfCumulativeChangeInOwnership",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cumulative change in ownership",
        "label": "Percentage Of Cumulative Change In Ownership",
        "documentation": "Percentage of cumulative change in ownership."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for which cumulative change in ownership annual use net operating loss and research and development credit carryforwards",
        "label": "Period For Which Cumulative Change In Ownership Annual Use Net Operating Loss And Research And Development Credit Carryforwards",
        "documentation": "Period for which cumulative change in ownership annual use net operating loss and research and development credit carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "eldn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r269"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r528"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r269"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r528",
      "r546",
      "r769",
      "r770"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, value",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r480",
      "r629"
     ]
    },
    "eldn_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock Warrants [Member]",
        "label": "Preferred Stock Warrants [Member]",
        "documentation": "Preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_PrepaidClinicalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PrepaidClinicalExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical",
        "label": "Prepaid Clinical Expense",
        "documentation": "Prepaid clinical expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses Other Assets Accrued Expenses And Other Liabilities [Abstract]",
        "documentation": "Prepaid expenses, other assets, accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities",
        "label": "Prepaid Expenses Other Assets Accrued Expenses And Other Liabilities [Text Block]",
        "documentation": "Prepaid expenses, other assets, accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r699"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuances of common stock and pre-funded warrants, net",
        "label": "Proceeds from Issuance of Common Stock And Pre Funded Warrants Net",
        "documentation": "Proceeds from issuance of common stock and pre funded warrants net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common warrants issued",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of available-for-sale short-term investments",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r682"
     ]
    },
    "eldn_PublicFloatMinimumBalanceToBeMaintained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "PublicFloatMinimumBalanceToBeMaintained",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public float minimum balance to be maintained",
        "label": "Public Float Minimum Balance To Be Maintained",
        "terseLabel": "Public float minimum balance to be maintained"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r287",
      "r295",
      "r326",
      "r327",
      "r328",
      "r433",
      "r457",
      "r489",
      "r518",
      "r519",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r599",
      "r600",
      "r612",
      "r618",
      "r625",
      "r630",
      "r633",
      "r711",
      "r715",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r287",
      "r295",
      "r326",
      "r327",
      "r328",
      "r433",
      "r457",
      "r489",
      "r518",
      "r519",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r599",
      "r600",
      "r612",
      "r618",
      "r625",
      "r630",
      "r633",
      "r711",
      "r715",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "eldn_RegulatoryMilestonePaymentsObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "RegulatoryMilestonePaymentsObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestone payments",
        "label": "Regulatory Milestone Payments Obligation",
        "documentation": "Regulatory milestone payments obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r421",
      "r422",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r545",
      "r547",
      "r572"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r421",
      "r422",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r545",
      "r547",
      "r572",
      "r756"
     ]
    },
    "eldn_RemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "RemainingLeaseTermAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Remaining Lease Term [Abstract]",
        "documentation": "Remaining lease term."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_RemainingMilestonePaymentsForFirstLicensedProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "RemainingMilestonePaymentsForFirstLicensedProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining milestone payments for first licensed product",
        "label": "Remaining Milestone Payments For First Licensed Product",
        "documentation": "Remaining milestone payments for first licensed product."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r265",
      "r271",
      "r423",
      "r605",
      "r606"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r344",
      "r765"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureRestructuringExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Expense",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r247",
      "r248"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r85",
      "r482",
      "r493",
      "r494",
      "r501",
      "r529",
      "r629"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r216",
      "r217",
      "r335",
      "r336",
      "r337",
      "r368",
      "r369",
      "r385",
      "r387",
      "r388",
      "r390",
      "r393",
      "r490",
      "r492",
      "r503",
      "r769"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r628"
     ]
    },
    "eldn_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertianties",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "documentation": "Risks and uncertainties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of one-time milestone payment",
        "label": "Royalty Guarantees, Commitments, Amount",
        "documentation": "The amount the entity has committed to make for future royalty guarantees."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities",
        "label": "Schedule Of Accrued Expenses And Other Liabilities Table [Text Block]",
        "documentation": "Schedule of accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Purchase Price Consideration",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense Related to Stock-Based Awards",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Provision (Benefit) for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Components Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of U.S. Federal Statutory Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToStockBasedAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r615"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureBusinessAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Preliminary Estimate of Fair Value of Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r82",
      "r84",
      "r85",
      "r120",
      "r121",
      "r122",
      "r167",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276",
      "r282",
      "r284",
      "r497",
      "r498",
      "r499",
      "r500",
      "r618",
      "r652",
      "r669"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of All Option Activity Under 2007 Plan, 2014 Plan, 2020 Plan and Inducement Grants",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r745"
     ]
    },
    "eldn_ScheduleOfWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule Of Warrant Activity Table [Text Block]",
        "documentation": "Schedule of warrant activity."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SecuritiesPurchaseAgreementInitialClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SecuritiesPurchaseAgreementInitialClosingMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement Initial Closing [Member]",
        "label": "Securities Purchase Agreement Initial Closing [Member]",
        "documentation": "Securities purchase agreement initial closing."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities purchase agreement ."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SecuritiesPurchaseAgreementSecondAndThirdClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SecuritiesPurchaseAgreementSecondAndThirdClosingMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement Second and Third Closing [Member]",
        "label": "Securities Purchase Agreement Second And Third Closing [Member]",
        "documentation": "Securities purchase agreement second and third closing."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SecuritiesPurchaseAgreementSecondClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SecuritiesPurchaseAgreementSecondClosingMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement Second Closing [Member]",
        "label": "Securities Purchase Agreement Second Closing [Member]",
        "documentation": "Securities purchase agreement second closing."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SecuritiesPurchaseAgreementThirdClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SecuritiesPurchaseAgreementThirdClosingMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement Second and Third Closing [Member]",
        "label": "Securities Purchase Agreement Third Closing [Member]",
        "documentation": "Securities purchase agreement third closing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r515",
      "r516",
      "r517",
      "r574",
      "r576",
      "r579",
      "r581",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r619",
      "r633",
      "r716",
      "r767"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r182",
      "r611"
     ]
    },
    "eldn_SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2021 Warrant Exchange Agreement [Member]",
        "label": "September Two Thousand Twenty One Warrant Exchange Agreement [Member]",
        "documentation": "September Two Thousand Twenty One Warrant Exchange Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SeriesX1ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SeriesX1ExchangeAgreementMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series X1 Exchange Agreement [Member]",
        "label": "Series X1 Exchange Agreement [Member]",
        "documentation": "Series X1 Exchange Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SeriesX1NonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SeriesX1NonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series X1 Preferred Stock [Member]",
        "terseLabel": "Series X1 Non-voting Convertible Preferred Stock [Member]",
        "label": "Series X1 Non Voting Convertible Preferred Stock [Member]",
        "documentation": "Series X1 non-voting convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SeriesXConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SeriesXConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series X Non-voting Convertible Preferred Stock [Member]",
        "label": "Series X Convertible Preferred Stock [Member]",
        "documentation": "Series X convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SeriesXNonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SeriesXNonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series X Non Voting Convertible Preferred Stock [Member]",
        "verboseLabel": "Series X Non-voting Convertible Preferred Stock [Member]",
        "label": "Series X Non Voting Convertible Preferred Stock [Member]",
        "documentation": "Series X non-voting convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SeriesXOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SeriesXOnePreferredStockMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series X1 Preferred Stock [Member]",
        "label": "Series X One Preferred Stock [Member]",
        "documentation": "Series X One Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited / Canceled",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Canceled In Period",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, forfeited and canceled in period."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndCanceledInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited / Canceled",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Canceled In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, forfeited and canceled in period, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Outstanding Weighted Average Remaining Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options granted outstanding weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, grants in period, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance",
        "periodEndLabel": "Outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Under RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance",
        "periodEndLabel": "Outstanding, ending balance",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, nonvested, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price [Abstract]",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options, nonvested, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "RSUs vested and expected to vest",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, vested and expected to vest, outstanding, number."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "RSUs vested and expected to vest",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, vested and expected to vest, outstanding, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs vested and expected to vest",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSUs Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Vested",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award, equity instruments other than options, vested in period, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Vested",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Outstanding Weighted Average Remaining Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested outstanding weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualTermsAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (In years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Terms [Abstract]",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options, weighted average remaining contractual terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increased number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Assumed",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period",
        "documentation": "Share based compensation arrangement by share based payment award options assumed in period."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Assumed",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period Weighted Average Exercise Price",
        "documentation": "Share based compensation arrangement by share based payment award options assumed in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "negatedLabel": "Forfeited / Canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited / Canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted",
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares weighted average grant date fair valueof stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options outstanding",
        "periodStartLabel": "Outstanding, beginning balance",
        "periodEndLabel": "Outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Under Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Range of exercise prices",
        "periodStartLabel": "Outstanding, beginning balance",
        "periodEndLabel": "Outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (In years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New aggregate share limit",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Total Number Of Shares Authorized",
        "documentation": "Share based compensation arrangement by share based payment award total number of shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r304",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of RSU Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life of option (in years)",
        "terseLabel": "Expected life assumption using simplified method",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Shares",
        "periodEndLabel": "Ending Balance, Shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r666"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r136"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_StateIncomeTaxesNetOfFederalTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "StateIncomeTaxesNetOfFederalTaxBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefits",
        "label": "State Income Taxes Net Of Federal Tax Benefits",
        "documentation": "State income taxes, net of Federal tax benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r120",
      "r121",
      "r122",
      "r138",
      "r158",
      "r159",
      "r161",
      "r163",
      "r167",
      "r168",
      "r215",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r269",
      "r270",
      "r273",
      "r276",
      "r284",
      "r403",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r528",
      "r549",
      "r567",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r652",
      "r669",
      "r675"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r19",
      "r112",
      "r128",
      "r129",
      "r130",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r166",
      "r216",
      "r217",
      "r286",
      "r335",
      "r336",
      "r337",
      "r368",
      "r369",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r420",
      "r490",
      "r491",
      "r492",
      "r503",
      "r567"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r515",
      "r516",
      "r517",
      "r574",
      "r576",
      "r579",
      "r581",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r619",
      "r633",
      "r716",
      "r767"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r166",
      "r458",
      "r495",
      "r514",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r550",
      "r551",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r634"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r166",
      "r458",
      "r495",
      "r514",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r550",
      "r551",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r634"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Outstanding and Other Equity Awards [Member]",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued in lieu of making a cash payment",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Common stock number of shares issued",
        "label": "Shares of common stock sold",
        "verboseLabel": "Common stock, number of shares sold",
        "terseLabel": "Issuance of preferred stock in connection with PIPE transaction, net of issuance costs, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r85",
      "r497",
      "r567",
      "r583"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "verboseLabel": "Number of shares vested",
        "terseLabel": "Issuance of common stock in connection with vesting of restricted stock units",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r85"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfAllOptionActivityUnder2007Plan2014Plan2020PlanAndInducementGrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "terseLabel": "Stock options exercised, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r61",
      "r85",
      "r310"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r77",
      "r530",
      "r546",
      "r568",
      "r569",
      "r629",
      "r640",
      "r670",
      "r698",
      "r751",
      "r769"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r137",
      "r268",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r283",
      "r286",
      "r392",
      "r570",
      "r571",
      "r587"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r425"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r426"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest percentage",
        "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions",
        "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern and Management's Plans",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "eldn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flows Information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Table Text Block Supplement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TaxCreditCarryforwardExpirationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationDescription",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforwards expiration description",
        "label": "Tax Credit Carryforward Expiration Description",
        "documentation": "Tax credit carryforward expiration description."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TaxCreditCarryforwardExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationPeriod",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforwards expiration period",
        "label": "Tax Credit Carryforward Expiration Period",
        "documentation": "Tax credit carryforward expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "eldn_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit",
        "label": "Tax Cuts and Jobs Act of 2017 Change in Tax Rate Income Taxes Expense Benefit",
        "documentation": "Tax cuts and jobs act of 2017 change in tax rate income taxes expense benefit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TimeBasedAndPerformanceBasedVestingRequirementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TimeBasedAndPerformanceBasedVestingRequirementsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time-based and Performance-based Vesting Requirements [Member]",
        "documentation": "Time-based and performance-based vesting requirements."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TimeBasedVestingRequirementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TimeBasedVestingRequirementsMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Based Vesting Requirements [Member]",
        "label": "Time-based Vesting Requirements [Member]",
        "documentation": "Time-based vesting requirements."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r755"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r267",
      "r282",
      "r391",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r486",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand fourteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TwoThousandFourteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TwoThousandFourteenStockIncentivePlanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Stock Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Stock Incentive Plan [Member]",
        "documentation": "Two thousand fourteen stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TwoThousandSevenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TwoThousandSevenStockIncentivePlanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2007 Stock Incentive Plan [Member]",
        "label": "Two Thousand Seven Stock Incentive Plan [Member]",
        "documentation": "Two thousand seven stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TwoThousandTwentyLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TwoThousandTwentyLongTermIncentivePlanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2020 Long Term Incentive Plan [Member]",
        "terseLabel": "2020 Plan [Member]",
        "label": "Two Thousand Twenty Long Term Incentive Plan [Member]",
        "documentation": "Two thousand twenty long term incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "eldn_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Stock Incentive Plan [Member]",
        "label": "Two Thousand Twenty Stock Incentive Plan [Member]",
        "documentation": "Two thousand twenty stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Securities [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r620",
      "r766"
     ]
    },
    "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Agency Securities [Member]",
        "label": "US Government Agencies Short-Term Debt Securities [Member]",
        "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae)."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r766"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Agency Securities [Member]",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Gross unrecognized tax benefits at the beginning of the year",
        "periodEndLabel": "Gross unrecognized tax benefits at the end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r355"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions from tax positions taken in prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "terseLabel": "Accrued interest and penalties associated with uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "terseLabel": "Interest or penalties recorded during the year",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions from tax positions taken in the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions from tax positions taken in prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax settlements",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r104",
      "r105",
      "r107",
      "r108"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net valuation allowance Increased (decreased)",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetails",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common and Preferred Warrants Outstanding [Member]",
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r635",
      "r636",
      "r637",
      "r638"
     ]
    },
    "eldn_WarrantsExchangedForSeriesX1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eledon.com/20231231",
     "localname": "WarrantsExchangedForSeriesX1PreferredStockMember",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantsToPurchaseCommonStockActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exchanged for Series X1 Preferred Stock.",
        "label": "Warrants Exchanged For Series X1 Preferred Stock [Member]",
        "terseLabel": "Warrants Exchanged for Series X1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average number of common shares, diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r163"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
      "http://www.eledon.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average number of common shares, basic",
        "verboseLabel": "Basic weighted average shares outstanding",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eledon.com/20231231/taxonomy/role/DisclosurePrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and related expenses",
        "label": "Workers' Compensation Liability, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-6"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-7"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482669/740-10-15-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483119/928-440-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0000950170-24-038091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-038091-xbrl.zip
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M0?3C04K5Q&199THY/UV0TWEI(,[/JPRG=N&O"EF[M7CPHT@F7A(3$RB?,&9
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MAV_>.W3[<:#G/2N=]S3#)6C"=*9']*@+#/EQ]/QQL.RR8&\/EROFOLLULVZ
M(>#E T[W%EP0CLBY8>3<':%S.- ICLJT^GJ4"%475Y5!WQQ^?H;W.6^;]XT8
M^BPPU&,CB&X81'\;070X("J/YGEIJB([,?JHJD62'&%\,)ZQW@>B?EF^W#G
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MZN>7%"8T";J?KT+FNE!'^*(?7X'+0;C;[C3'CT1FA?JZB04[1(:R20+-5^O
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M_^>;WP[V#]\XG]^\??/YS8>]-P?/N'KZ_G?+?[>Q)U_Q>",QMKCULNSHJ9'
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M%5XM<VDQ%7',F_]%6!975RV[%Q8"1>.IP"VS(SD=C+:>#I$ZA]E8ZS(R\-,
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MBFN6SLRS6_[3(3J?\DPLS-4EGAP;1-+O.'&NJ\T'#QTMBZA#W\1\%2H_UC[
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MW<0' C0%AFV%(ERPGBKON&C*COM>R9=4FB.RL@^FX, BB,S=NRT3+AQGW^6
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M<;]]^NJ85[NMN%X>G*B$_JI3BQ[6XRJVK1%%T^?7(AGL^^!FAS=_>[V7;+8
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M"RB.8.[JLMKP:L,LUA&2+')O+U[](4VV#)RHDUUI84\!MSQG;!#;:'*A[(#
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MX]M3V76B6BQK>BBK(A)VRRYWP8XUBA:(.'CF[9K4PJIK\HO?OSC,4:"\7;=
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MLK]KBT6:J$"LI-]9<LOH:N6R%?3.W5S)7$ 23M8'%N,QNZD7DO_ZY D4*G1
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M;*P*^9Z[_Q\L:7'0MDY*T1-""T8@SI%:>"EMT);;N+XRU87Q-MJV3#!S58=
MXQ$< J8T!(F5V'H/(WQA7(\'YK9%N-7*QL]7[H>'Q6$5U$%KID(Z(_ RQGGX
MA>T*GLFD(QRM_*$V%3,*)NE_R^[H.BESE]CEY\B#(Y+6UL:_SGL4X18"$J.7
MO31;F0QM;L(=VGU5E[>^DIO2Y"I4L+KQL.@CAG@DUJ-#N<%KA"I>J^^_+_(3
M;_RDRI?IOTYP\LU#P]+"3=W&U]QLF;9Y1JJ$QY4]08;CWL2/+)D22+2W0UGI
M'"Y8>TM<^,GV\B3\ 61G93=YHBQY'-"+U_EM]*0V^TRO'Y(:,EX]VB&G_ TV
M&^ND7=L=Y'[!H*I.7%F&4_JHB?@/2[RP7$S77)NU5N36W*KR&@GW<NH'\J!-
M7KFW&TV"+4$>)3Q[T'V3K2E#$LS2Y8TB6:')JUST"LQ<9*<$?JGNF (/-TZV
M_H3I]$_\[OA35B3T0^)YS\.T43NK^+'8#>SM O48>ZK:X/I+T_KO[HYN-B-M
M@4"L+>P.$[6.=/FS:_,HR9+>\\FOI[P>H[O>R)ZF3!_3'1HZX;8=0X\RN/&;
MS0]"-BAL<Y%,:N;ZE5#&D&G@6E>FZM7.=\>&>>L;!THOLDU1\G:[K9HMAP<(
M/Q[:T=GL;L/#L8\30)4_'E7 T+9!,1[\,;IQO1F<>\.MO#4$4?>UO]C,X)#*
M&3%A$N7+Q6#K\;9?73B_XSDL]>[$X1P+:"$4>RD-*<,!?[-HY6;@A:MJZ>Q-
MB-"GGO<!]W[5^R@U/M_TU'IP+TX>5.6L(-->GLK>>(WB@N"^4_?HK\DGV8+I
MZ?NT8/B^EJX5\\4Y,RR#3BCY!';O33O2;Q#QEA&*5@,-XY5'XI*X=N6$\JXJ
MEOJ@1O6^8I1_YRCX ![%E%=+2PFL[< '2,HHI0PIAB_BPT,]L88]8_O12TH#
M4WSEMH"(43"&9+,P&HG>\;YYQ"'F=Z/S3:D IR<%$UJV@UM;BLF.9#CB=JPL
MQ/+!_++="S;RVW >70>[R^;#;GSP0O/!93@B/2.\&[1*W:2>\N(5,M->_BL&
MLI DTRT,O;'S8-H*;H2)AO,*K#L+GY%,O6R<H%O\M_NFK?;0Z.44OA4'R=,Y
M3"#94H SNNZUJPFE7T@4QB%/>&'PY_![D/JR5M@HMDF()GC VX@ K#M!^Y&Y
M!&(75CZL,: \BM^G"P'7:Q050V$DY;+0>U#5-)L=ASI+KBV4CGF8F.J9SRLG
MCI1K\[G+Z0?RSHOBJ.79-S+/Q)1<'M=N$9\%'D_W,S>;EX'WQ>Z;Q6)5S9<E
MD/-=OB] F0HNT[(?E+HQ*AD%43:7K:@JD<C<E7=2@Z'E;FEE4Q5M/.F*A?_0
ML?"_7;'P*Q9^Q<+K(^OP4G!YF1S=Y[S7,,%KB\9BB$L [D;5G(.HDNG5W%&7
MC0!OLU'/8Y9:?*U""B+%TX<8Q7/EQ0#$'?<Q!D><_^39E[_Z1-7*]$]?ZY'.
M@4TG8GE3#676)(#(,L3.AKXIP8M82*D"&+"*XM'VCJ7$16_>A2.>O&_S9TIE
M4?;*-J_SNCF4V>;[9W_(-D]/=/IN/CJ#QB'?_6THNP!4^Q,4$^E_OW.W^7&V
M^4-+"7]3;;YADL77])7M5@*(_Z3;?]/E-YNG595&-!H(,HTOQ70ZYO&\*O9J
MQ5SH2*6=;2*$[)9BE5V1S/L+*IW#<!=+/6([?7%():!$2UUG48K;YMP.6WK_
M"]D$A_IDT$4+2_KJRZ=/ G%D8J06#*O.G!I*M%%Z67\U:;/(%?+RU;=_?/7T
MJY\8IMVA6DN[0I>X&\X4IL05^_SFU[_[_*>?+;_YU1?_Y\)'VGZOOWN*M=G\
MU]?K\DR7Y_F?__+TU>OO7V_^Z]6Z/-/E^?/W7W_[_[WXKW5IIDOS[/G77S][
M_O*[=6VF:_/-__KJVU??O7BVKLUT;5C!Q Y"*49LZ7C;*T*$F_,H9B ,:] \
M;*%$PJP!A6C=#E5?GJMQW'/?M&^X"@31T*KH*7RKI)CUIMS7Q<4?HEU3#;&Z
MP;4[7!2@$VB\6LVENHAV=*$Z.\KRO'1K6MX;5:SRRHA+'G/T],-/"I@>CI.2
MHN'3KU^[H.C5TR]?/'OZEZ=B\MGFU?.O_]=?7KWXEO[\^2_QYQ=??_^_O_WZ
M^?LTR;<OI?KP;3OTW+/B=I8@9?]0DM%0C/>BJ<MN\S*Y+'WW*;1Z:)4F__!M
M&_\:?Z(;^OOE5- W_O=W5M_,-G]I+@ P)(D'?>1,#TD_C R$A9$ 1'B&791^
M#D_U[-(WM-T*_9M6E>S<)HSI&5Y+NC 9KZF^42&XYMT:_B)60!_QGOEV2!CE
M&\91B#)#0%ZW(/V3 <^B8M5QIF11DA]7,K:\;EQ_*$;=?FX/Y-R8Y#Y60#AD
MDD(>BGODY*V@=+F1D([/BS7P=P,S<&\- 9G2#Z@-3E)=8R5MI^@MCP0*1A!"
M5:,SK*'3FD/AA5:*Y0NWZ*U"T[MU$C$SB@8H ZGR7E'3(C-?HR.D,E=@]_N8
MS?./H[406J#0&U(J3%%!Z(^^DSU>13T:;&R90>#AZQNE?.#C >_F4N1@@_"G
MM(QD<3>VW,E_"^BZ%]?@4*8YL2#0D1Q7Q^(20$=,@+YGK,1(>J(XE<-)[M=W
MF5:CB4;SC>/-</&;"O$EG;UX@,!YC#\APN2R]Y.VZK5*5Q3JBS4O+O$&Q)I(
M9TH?3$A5ERJYB?ZDU\7J>CK51_J4H\)CIH@J_-,,'F8,L@LAD'>3!BC8?%.@
MX"??<07&H/CR8$Q"%C< 813&:@T7@1*4>/*X7**@2(\FU5%LVOP$V5S:#">0
M#;2N;CLZA&XVK_4CL1%)2UU=,(APZPT"]\$!!3^XLAGXS>:NF@GD9D>KV#+6
M8H+6&1?KV1])[WL,\PJW8#II*6;,+(ZO,*@&Z*X=R@#(:PM[L7\;:+/)?*=K
M(?.+!:Z0@U915ZP+<CGA+J;V0D]N6 4CY&DA_VO4^H=FPH.6H1]]SQD0WR4;
M1BN(37WQ]CPJS]CB.&4D5B+[E)G[9-[A%7UT%7T$B O'&2P<E! ^)SS//)D^
M= IV(?N?[O 2!$4*EDR$7!6+R9CBLA9<II%)7_G% [_8>^YKI' 8&Q+A[&,<
M7@5R1$ Q$[C$OL"IVQ4/S70\<L13P@@N9TVOZ6KZ@BA$C9 -]=,&S=#HE&P"
M7!DJ?<A(LZZ/_(KB)0VMF4-X<>^#[2"T07Z8(:;+B$VO6^6@=.C0T1(?Z=RA
M%>BE:<=WJBAE"?#P,1T^UJ>E^Y&36\[]KG_PQQ%HY>4>RZ+"EFSN12TZ8.)#
M]\P\F=D1=U&21T4D*11'OK[CK"1ZW@3DPFXOO(Y]^BZ"L&:J9^+8*++PHO2C
M81^&I",>>-.L@X/4U!CH3;,L6HRA47?J?%1<5[S=K&; :FF+8S-7H+M+J"F3
M,8S/TJG">N!0-:>5WCN% T/=^[L =H_R*3Z66?VE:NYQ>B:3!MZA61CO=/#H
MLV2_ C;V?T_G[=#6AM@M*>'LV,@?<Y M0#]Z7SYB"J=)?PGZWHK7?ZLC:_FL
MX@0=UU$=Z->]@*FECUE2P'UFB=@=1:9<$=TV0[]P/#&A,RL+,[CN<E8?<Z(S
M#MORV3>O.;2A__(5]P4#VT4&7(97[I&QJ=_)DXL&S\*/J=4]M^T95:2,'L@=
M7Z;NUZ9CA.^/;P'6G&"-14B05H3W,#!]"$Q[%9^A"_=R?_BR.ED\Q 1M.EV=
M ]U=+F<#ZM*ITJ*QVT!ND=>G-Q.HZ5!H]IQS^3C7"6_S.4,AWSX 6:2(C96+
MK_A5NL<-44B;5>3,K0!CA1^,+N61BI&>%Q+ /5>*9FPE.3^2*=16$VA^;*<_
MS6^8#[;DV.3L7.A[FLK[78UD$GEKA=XK.23N:T4Z?NA(Q]^M2,<5Z?AS(!T_
MS%B CE^D:<Q.>Z(X&?.MW)WIY%,4$$C$2?ZX9(?MG'H&S>]\GSOX.I+%6HI%
MQ]S-3^!:)6:;<-(-?:C 6B)@(1V^,'0(,183 (XGI'AOOQ6"B9VD+:9BG-2>
MW>%PE[<7JP>'TX"^!1+,LCMU."(1@G-48Z>.!N]QPJZVDV?VYSE*D9"!CU\;
MZM-;B3G3AJ(%0^25,Y$2'8RCE94(V8U=4-!1_JB8/$REZ:UP#ACN!6W$4U.C
M**9M'GELN<Y%18\Q@1I+\9A9(@,='YNA1V*LH2XHCR>H%@Z,@TJ2 HG^K8_C
MA[KI6BBY+1-&T)WMR/&A)\J4_[4>VHAK%B,'9EF;1$O)&&N@/)5>65"BU*'0
MT27#P.]6(F.?@H3B1LRA*H33>=?($&:B.VT+_HA3D6_(OA"><;L[."*4)OIN
MMN0Q38^SV4TS7W6 E>5GR>;QLGWR+V4'[AN D$HV[6C61?-I*7(DR5!0(Y_/
M6Z(CLNR(OI0)X:04U#/I(EE:+$SF36LY=2SBT5//F?'(04KQS>H['.KS]*A2
M^NZT"Z65%G5MM(VXN79H=DS)%5H=1M 5[)M^)W>%8/HGC2?Y38 C;BK04SIB
MAJ[8#>UH8_+ GK75&C_1.V[;"5@;A?%=G,6322L)5:[.&V>;O9Q#"A#AK.T^
M;_>A:A2M(M,$.-AF61_HV53W?5IY&AF,$.G$$5U4Y2M)>]1SJKX\.6V^ W\L
M3FRS= =.TM-0W=(S+P8PV9U2*]".UV.0'!LOG"LTA7I?QD>U-E;)+BY"]=!1
MGOK4&VA<!E#(H&BSS5MZ13:SQJV?H@VM6B[PU=!>U:E-9PKZSTGQC1D#'K$S
M3' ,)SF2DPJ#L,ZB1E#V?A">7EJ]!XH#$CH\:=DUA_Y>Y@_S/OB06S"05AP,
M")BCIXCDW$>_-O2EF[3-PMRCS"Y/7%L6Z!K"F]V#W4?(_/1'K0)IM5?>VF4G
M';&H%(&J\]3CRMAL/[ESN=U1!:H=W7_B?M;6U-76U$MUDR!GE&9$E=]W0]G'
M[OM@G2 Y'Z5 JY0$KL1E5["!TF!<B[0B5]$]C[<]9./KG!8<9?87?,%N.MJ]
M+CHNFT[.U*1XVQ>=4JPO]5-H^QX'NI')^%,Z_)YKPS^,!>%62B;52*+=3G"U
M#X*VY)MYG;)QB$88SF0SNUV5EZ<N*GK-/$'CH@QE$RWKOPZ2&=YK7?>JI:*
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M7FRC4M%LJ 4*M1'S+04R[D&,-WD"HYW/UW/N@_$&4V10&!+0!SSY3OV*5OE
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MM3#R-H41$VLU XN##G/O;@I:5\TV9Z,IN9L?.YC_^P?"Y4=<(GF:)#7<U8%
M\$(1*H;#"=8EBW-7:*2UV,P,I0P@,\T,DN&,,>?:BY#[QN_%ILO0^7-'/.S"
M%-HDA)P0'*5D\*$]A7IV[$Z]55XX-W7_D+EE5LD/P7?P- BQD0SI@,S%A=_6
M4>0DCL':"XD<)W\/?N;A>WSG&USQ'>\%W_'+%=^QXCM^.KYC#3V69O2M S,N
M2+A*?U*+&/G ,;E=F-NZ3YWC(XXF7+IJPZZ^U(W3W$?>\Y/CKG[%63^G2D%K
M+GU!,2 9ZA 9&#5Y-OZ!T,>?ISR?-&%G7K84"_[\Y=.$+]BE3'QR<*Y"EU,
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MYLM"M9 NG6L?XPD$#*BLC7FOA%.H; ON3<MLIO%IZ['=8CV5E>]-,T,U>;%
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MUT&=8/W,\MCTS;$9._V[U*<+UQ]0+((6FR_K5N][U N-W.X]M68AS@1&3LM
M6VSDA_X&[9J(4JJ3!?007AQ4FJQ[0L4GE9(:^A.3L$(D-!;60INABP_JKO53
M_R>NE!);O=-_T#3IH2L+B?>;F<@68!JP3J+JP89L@W_.P&287\HMVI("?+I<
M%ZH$JR9LZT3Z"]70#<PM8JK!P(*M0N\7/%V@B2RNZUW2RER\7146-6DWQ2/=
M7 U$TRLO;,0S99J5U%Q$D:>>T!]5_>^*65/U.-%P Y,;G.O]OJ8>ZJT"AJE9
MQ;A\=5U1.3>O=VT<)YAIY0RLU!HO*IF#-N(9!@U7+OR*? ^IUJL5:2CM6D-Y
M 3LIW1;E$L]4T3)G2#'ES^EO(_>ZG08,,L-6B6'>?' :1%=$*:),X8('7D-;
MG"Y+IA)\PZFBTZ#Q,BAOJ\52'4G(X<+F)*AQ5>!6M$73#%R;,(Z"(&<0$%1X
M,\MJAMY?&2:X,@LH[3Z(@KNT>(MU\XW'3]%M0..P_!;J[I.[X"5W3!_5,.J4
M'V<AG9Q.J2$(Z::W<G!I1;96K34E9I69R2_EYCB*+]S0_U^W("4I3X$V?:;/
M9%%#V93Z)WMU%6,-WM! B8U#;.[QRQN *(3_08],5XC4O5\4@05]^C-+P\O[
M6QIWN>A^"9,98 W]"SJ+6#X5K#J.E(>C:3*-!( 50$/BFP&5>VJ">=?V6<*N
MBYHWEV>[-'L^[3SN6I^+CDW*I!HI45L!.M X=@.RV<E,2E7*MA 6VA^XIL_E
M<D\5[;-'2Z2ZNGRS:OSRG1K0%/NX,,I=V*73DLLO*4HZ8ZL(4S>:1HZN1,Z!
MFY)>MEKI+*;9N=F7B7W?(C]"KLYO--W')5>GN2YO6=FP,_,%& .9+/F!1KN4
M-0F")8?1Q2Y%R;(&76!4?8\TRT@O^LB^/C??=,^EX 0=_*:@=[3(^]*9IL-T
M>,2$I7\+7&#YV6068;1'W4VP,;QA'H&_V-)WE_? ^5Y<^QSJ7*-G(C@"P?V$
M]@<3:C;]:C54TT:1\^M2R$Q[.B]&0)%'V"X%L9_\V)N"6R9B*L2??Y+ ]D7X
M;JSZXHIK7P8@Y>2=76!#MQ#?!0;X?V4<P?32(CV.,)J3G^R& 0*/<#S(#O5=
MU"3: UY&L#[1GG'CQTNAH_QN7[DQ+J@8?%.G3C!LI](K'JPPX$32;R'>>Z4Z
MJQ5G0?4F@BK?8USFT@5GBX[14PQ0PKJA7GWEYKM,=!;,H(I7:R]Y >^>@Y9D
MJ6[TI\:P0BYRX*:LQ'*!*[J*$Q9G6/?,&5:]$JH%=B8915AU%*'#*$)&$3X+
MBK"2SL"R-331M$F:Q_9+U<_;XC<Y<;-DN0]<WC6&]AQ+R08-+1]+N 3;BM;R
M<\42G9;M=.!/EU;#8OV&;?DB,)UYJ(T11>66*""_3PU>PMW1M91Y<LNG@BS&
MLNNM>)3'ZH%$#']@&2G*;.D]D-[-F>URIH,K*ZL+"(KO82!CTU*Z;K.EF'6=
M!^0F:9[[RM^W<*]Q"I:WI%A;!EF^<'U/]P^5IG7/0@=V%I3#4&])%-K_6O6>
MT<LF, ]6/JDVZ5F:F3HO:UQQN'4J?;R%,DK(1<4)E;>AC*4.W'B^IP:BO>ZE
M9S&.X0:3##?&FV.^]BRR3=H6?)/83&Z2Y@ :S-H6V=IO9W_/:S*@F="]L3SM
M"FM1\98%_M]9A._3_<3R(R8W*@GKVTW,AY2X_C&#S4U@S_[^Z?N9^/I1?#W]
M\.WH^\G7+]P&ML"?T';#3XIF&O]#!;,^W-$6J]D!EFD4!-$5+:5D\75UB,3L
MWC36>1V<I-QY_>[N8^(UK2]1EL OR9O#APONBSJ+=]KJ^SJ+2)QBK=D?J('B
MH [=+(W>C<''D#&-!>8!AXZW[P6TPA]2RO&=^I33Z;0[OYH'L(N NTCD8:+@
M,=+P("9-HW>_PN_# /)]S*6?^ 2(N#XTS^N;X"XOYPY]#DMIC9Q?]1YGS0U.
M>WC[]=NN==N#_L%C'V[@AV&-?>RS6%GP?A_^S[=IO"HR>C.+B^C8G?RX(/CK
MGC914_J_=U<@DFI[?*@VR?C#>L-U4]I6P*A*A=<I\!HC,=J2C5@??%A+P /V
MB:EW3V*?E[A[&\!'D@:R@%?^\FKXZG8RM>4R8VP/%JD@!*(P:YT-L_X8EV83
MY] '42[(?X[CM_^WO#X^3E)N8:'2Q4[/"B:RZCQ,=;IWJ$ZCYK11Q+( UV].
M:T0LNX1L%I[1+#3/)<2P"/M^K".L([?J2)=UA'6$=62SCOPB_N'&/B* 65-8
M4UA3-FO*KZPI6]KQ44[NYI9O BR83K:ZY0/VW!-SN%6-W*;8?56YTO B/P1R
MN$W#]/+YT1<,$14"_IR44Z;4AB!1$\AE*:[EM#:,7);B6DYKP\AE*:[EM-:*
MW(=O0V[-/-W<<901GO3&^Y3*6]V7E.%\])+R6SNW0$9?>MORT,HR=TG@?9A5
M#VNSYI5A9!>YR_._,6*XQ3FUP]0\0>Y[G5;/N3/)8/.D;T^<*S'7K-*LTK=/
M>G>_U1EUJCSI+Z;2O"2S_EJGO[U6M\<K,JNO#>0VS+EZ@M96VXF^GYG^]07R
MI!R@6,_[WU7]0%5.P(.[=-^=RSNS^6Q0+2*7#>K]#6IK.!KQ7%=FKEF3ZSR[
M3]/D_0X')'@!MH%<5MO[SO7K)FQIWK#R5FA.67GO.]>57FY?-!K!<(G'1".B
MR+OR@T#X\X7KQXR4>(J&W7T4I<ZF]D$'<:IIC*FF:?=%!"8_B5-GD;%#(-AD
ML,EX-I/1'[6&_>U%/]EBV" /;#'88CQ?N*89)H/#.FPHV% \Q5#L.5M,QE3:
M2NP>S]+=1@2I6\4(TO<(VW-%-XH#L.%FP\V&>_V>L-?JU-]T\YZ0+09;C.U8
MC-&HU>_6?DO(%H,M!EN,;461!DTP&1Q%8D/!AN))4:259L&--1*[@2$])F9D
M?U#H4Y3H)NY%ASVVP15"[C7,%7^2H[7=:,[.%?TEG"@[9IUUFG5ZO4YO.=["
M.LTZS3J]XZ3+=N,A=9YK=J]K,Y655]LM1B>L785W U^I9^3A:SJ3L?##2327
M+1%*/LY4)7UANWCOXI"MX7Z?I[HR4\V*7.?9?<J^9%CIZ@P-FVA6XSK/[I/6
MXVZURZQP=(&UMG%:V]\_J/)$,[#AI<,+7V0J @0W8/G6232'!V8R3/Q+23^S
MF5PA6".":*AKT%./1!9UVUU\EQ=EXT#N$HBVI:KX#^#2@P!KZ_E4>:O]NM]I
M];K#QW(UAZ)M1_KL1[8Q_)7-$INE%T"-[+<.AFR6V"RQ66*S9(U9ZN^WAOT[
M\:D-L$H<X6)CM"UI8!OT,!3/G:GJ!MB?+43KX+\NT$%_6F%B5KY]Z^?NJW#W
M)&YTU_>V'A1\ +'J5GSSH9_"1R?W:UC]OFA8+3ZL%-*Q8;!BTS25JQ8-VKU>
M[]=;2A<-;9ZY>\U3J;%X7O (06>Q=!/IB5]Z[:Z MP=^%(II%(MT)L4U/"XD
ML BG>2+G8QF+GM,2W4ZWUZ)8LAO#M32ZZ^YN6WR'.\SGQ)6;B$7L ]> 'N%E
M$M\Q PL.CTP"/T03N7;$K=)C5WXZ@PNPMH1P]_&WKXF(IN*70;MC"&FIEF5A
M\6$_% L9)U$8RD#$,G!3B4'Q)%7/.@436F98!8]FTO4F41:FZZAQP;"[ 0PK
MFDX3F8KQM7"!A.*[21I-?NR-Z4W(.J"'3AGJ#^\7'PZB*^ #S&PV=2=I%F.-
MJO(82_09$O04+.+(RR;FK3DGTQB&!B\$5L$?B6;+TNA :I(L6"J'15_KM'OF
M:^V'&SRG)A:OW 'O:*D#'ML\NVS>YEZ%A5R#=DD2>+B&QJ5L[I)-]H[>2*:L
MP6I@6B^<K&N]T#!)PR7@&)? \!K,\"2Z".%UL)#V1^UAOI*"";VXV:_B/@LL
M+)E?HO(SN,K@=V*\^SXK=(,%54'J3S2D_DL!J;=A< VVSJ@SOW1+GF;9,8M6
MST&L=Q-7W#D?@PLR2?6#PDV2:.*34T0.HO8J\]M@,4#7!CZ7@:_I)LH[IC_D
MOS/_T@U@J HLD<RB.-V#Y^;P^"4\/*=+-=.]*P6A&4>!MXTI_G3RM[^?O#_Y
M_C_BZ,M[<7QT>O+]Z)/X]N'LZ]^_'7\X>SA?=B3HCV3+_<W &0C@1'G9GWR0
M/,]/KYMK&?XIA1>),$K%S 5?#1=5=P';F4O0+KVK49H'2CZ7\00W- GH*BDJ
M/1+"=C$6%^3_H?;'\.\03 ;5=-&OH$>2XAFP&5F,6]@$J/>GL%F"A3;4@"FX
M,8$;)%D*_&-!&RM\&%U)>!M8(Z3 #_.=(MR)CQ>UA?6+C,V _\*F7&)$3$PS
MV-O)MBA(+UX+"[WT-1^6",$?##$P6L_WR)ZE,Q?,I31[9I&%0*<B%/:K?H#7
MHG'J^N'SKX3W7?<\_S+7_D#^W/-\H!I9? CCR>;A.\]/%H%[?8A7Z:T:[==I
M[P_\\-V_LB3UI]?F"W3;'MCC>P9*G>[C]:0(:;\\&P?+F&W@(G%SEF,B%^Z%
M5'#'/7<*PSQT@ROW.GGWZNTJVV_R%"B:#9:LSK)A<,4LEM._O/I3&DW.\4,/
M9P&]U4-'EL(?AQF8M3CP0YG/MQ_B/_?&033YL16O@]0-[.RQ^JG /+KP_[.!
M);FOYPA,%_)A[TK[-))C>9$%;AK%9L'0F_]BG8#7DPE?8S8C=.!2Y1ZB+0\"
M=QSI<($;QVYX(97/1ZYD.O-C3T7Z9$)VFU:/, 7G5"U!\ Y837S8X+D3/X %
M7>@5RT]Q24J*)7_B+M _V.@G/FC%?XHIV]W,'1$CU@268:V:N=[CG'-X(XG!
M3Q_#G3 QOPR<MI.',,7W2.#4MT@BBDIO:O[&4H9BZH<N+/9>:><QOJ95'5X[
MD=+39>)P.2</!#X);)E*<B2,Z$4ZX-L2]%/YYBN2K!0DZ,@#68'/8]RXA9N9
M2Q^X!K?@X)0SH$+$N7-1]E/N="V0D11Y&$MP(H!_.E@?NS[LG=S\XT88X28C
MH;@=PYPDWCX%"[W"KI9P@W0691<S^K1[Z?J@.5KBIZV<9!T?H2:$^^]@XB83
M=$O2J"62;#(K?S A#PAV;S!P#U@SP4@'>%#(&9 B5VDBD!+XX.-HCP=WC!*?
M3;)QD@)3T"W$Q"GL\^2%2R^@H9O!E3VVPDF#;:8K+B(59X>YCT/2;B43%+ '
MU4\$"!E)%>X><:#SA9(=&LK<)<?LDCS!,;F648P.C>+&%48<LP#<,?#&C$72
M? MDB1%)%(7(]QFHXU79PBAY:(N3,)\Z4A7\L'$7LX7>(9<F]Q>G4TJ)X,RF
M('X3E!B2=*0:?G1% FMRZ.G<@+)U$Y Q8N&4IO,T!A4$^D\#L 4X'3B-XW]I
MG]6=S&!J\/8$1@I2BHF.=<D<& JP$LA4FGR)WAX**SHBJ$+@Q\-T@X:[,:8T
M?'#! WQ<W0ZCIVG5C^&8?2.4*MM3)KX_: ]RVFG2\%DD1O[$Y2$AE00%1%E%
MK?VGUDZ0JB2#T2"_*-GCDW#=Q1%*#2F9A-6 Q!FM22ZN9>)SG30J7)J!)?XG
MN1ICRB@ASM(C^IVK0S=W&Q)!GTYHO$ M;B;@%KWCB"9H5>!=5[C@@0"%)(XP
MFS 6-"%KK$1$5@%>D$2D"1/<&:G'P!HGK;+9 <HFRNB4+!<(,Y@/$'+4@7$&
M%*)1H#B]O+ANE949;H5AP+XE4/$:I0U+E@B&$]#^&>>!S"^%ADJV'3X674BT
M%6WQ$=X&?[2T#8>EBG)G_GQY28 9!E<4GD7MFLS0$<CU&'\*)0IJP1NTD6C7
MQ%S*TO#@2JA6C*B4V$S2S/-75!V_%NIIU2:WS/J51X$.=%U^NO-%((GA>CY7
M')(DFP++?6198&(,^?M1<HPQW*"I*.7R(EK$V1B\'J)B(2/XIG*(CCZ=T1]1
MEBXQP]B5%HX);\#I](SB+4"FR<,"UP4=?31^6:#6;IR"TQG.7]<E8J_7C<'U
MX'YC>I)\+&2T2?+*NW+0#!_<0WIUP00U"&4/ S0\^)U+6.ZC+"D91I+3D!Q"
M97W(S&<QF(:U%./\J3CFTI-H'8,@NA)9LKP$E=S2$M_;XK^B*PQGM/0*!UJ#
MVK1D46@!O>O#1@^+E08^GR7K]18YF^) ZQ^]O'^8[K/.FHMC]$*_*9,]7]I%
M-BY8]Y7$%KWC:Q FJ?8SP!T_*?S%&]VUP$S-?!!9G7A= BC$=R%56BMPB.+W
M /R\?,<']H1TH[B\A+3 NPQBHK@%?[W0:6/PWV*$>2B\15M->I:H)6P#84@V
MYNDF^%K8*J"-@P5%>PE7,TF.W,*ES2!, _ZEUV+]AK8]0;DF;4#_*4W$U>RW
M:#I+F!^-C E57%(M-.0EA&JW '/N7_H8#FBIN, D"]P8_1M$&> K7;UWRD4=
MS/U%[,YU1*%8V%JE16LF-VN$V5[!5N\'*$7\0ZHMC(E]P/K8VA#N6-D[^-,B
M*KSA311NULORS?>U-(W:_[^Y0RW'8)0&YDPN 9>68O.M8B2K.D^<0#B'/\[2
MV_!(S1#=&XZ.WDZL]TO*&WK7NW1-7L.+LXM\!M)93'OZ=;Y@BWRI?$+075:2
MLRX IT3'4[[.W7$X>K?^%DCW1-$185AN#]9FE!CMW"PB9("O].C&6_0GRW8:
M_?_;DB^T6\,+Q;:%-.NV,(EA$_*; AY3B0(* _#D."V8GA1.F7E4[_(QV#,)
M,G*)<Y)PKU-$(&EOHXE7KJ=Z4P(K"]B8I?"DPB.68AQJZ.6@R!HRB%A/@D)Z
MZ _.4==Q<J.X/+[#S5D;K1G4"+2G]&PY9;/LYJS-U\  X_0=J=,>J,H\.<2
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M[/&=\E5F95-Y)KT"8L(@R>94\T,OYE@3C^I^3+&TC3ZI>?W =@KB-3DH49;
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M4WCG1!DT@/HBAF"IS9+.SV]ZR":^@D.<S3%BJ7F(V8D,NV+HYDSKNCZ5U:]
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M0D0 LJ]+3>'TENX[R(]WY5ZKIQ)TW,1KO?,Y_GKV57R,W;F\BN(?I@LLX>W
MX^EVG)Y-6;<;*X<^.XT_7ZAT4T[+D^*<3PS.E-Q>W5%..[TT=TLL)X\?=@6^
MZC<SS7^GAFQIV1O$^5PG;F,Y<3/$V=(Z,8VE5*BIL>^"^5*-79/"B!2(:QA>
M"?M#%J(,#"HWW7VX%A#0(LEP2^'#"^BS\T4 9D\DD>$&6D1PEX%&&,M4=?16
MUU3/>3=(J2&O\GU)<EW"U6Q#2W6CODCWO:7,95(,1[7E76;_O=_>9.NZO)LI
M&[GHIMU=V=6X&QL6/VQR<1MEQ*/)<W&$U@4/0+B3"0AVK#$9 0;3KF2N ^O
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M;7#L.XH<@JV.U4_)$K!J-K DS[L%2M<HH)$/TKM\XM5P<6B';I9&[\91#+-
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M]9%4C^&+_MI1[+O!1MZ(ZO-F*RBS_D&G/]Q1M;"/43P7T52<A)Z<A_X4>$N
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M+&%T= 7L-]/?;/IKE/-FCC!'F"/,$4;;,EUUHXL]'+9,+!$L$<P1Y@ASA$N
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M>3=$MSG#7=1W4P4#G($J&% 4=_L02"\*Q>G,C>?PN8QFH%S@[=3- O')3]-
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M9[.<LZ&<!A:\05+J@!BGZ2?#H]MAC!>DX$$NG*#VS*J"EMP*[Q5LA:T=P!Z
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M-'6[O=E6MN][H"(?8TUPH6+P[Q+5)-8@8_,<11<NBSPBII&DQ3#Y9JNFZ_^
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M51@QS@F2P6'DI,'!,2\,TVM#32I%#^< G0"= )T G=M<;JFP"B(W$@5G-(H
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M0-:J=)*H8T@R15"0 1>RX-Z+A>.=5].<[ZD\YXF-;AZYY;!3? <60 ! =Q=
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M!.Z[&+B#%N^H6#LUW)6GGYIQE*GJ>'K%9?)1\Q6$S47FKXIO5F=NHD<]K^(
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MWO1K>$0T.V4[XP9-VP8D)W$<?_>5W@'ITVS9/:5"K21LRJ=SWE[ LU?&@.Q
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MA%?34\>5#ZWOP@3_94RGW9VR[YH0&<ZP:1]-BS_6ZFQ,AD5_EAR2J.PM)+2
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M&O]J=6%U.GNB3![+2?!IYZ%#W^!9K7:,PCB$ACPDU-(6B]HZ@N2P$/T%=ME
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M3%9U*"/??.K3')Z?#/U3 U46O?W_MINH=\'WJWF/P/1G"[]A4$SM1;9##7:
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M0+5#2V(X0UT78I]/PK0 $V>:*KQZ^,G/01]=BA#21C)?0"_\.DEG22,&IE<
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M].[7MYOUT(&*T(_:A^E.B57)TGJN"5>NA#&:0!05',8H=06\7NFX<9C,G):
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M+.BN)2B'8#)5&/6NB0=&*RLA5%VK-89[E=9EA/!?+E8%K/T] 3D]9H?(@C8
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MARELMNN6AQ<#N.](MY_;Z;],D:"@>/4?.:CMDAMJ]02!J9N$M@T+_-4 -S"
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M_],6GC9I_A$FY_ FH(II.TNCB/,9X-SXY.%Y(.W@D04,L\>5AX]XX;:5_]S
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M/H*_;TF NVK@ELHK(1V)P@.T. D"7'-)'*RB<J$$M:ZZ3$;:>@F*(D!+916
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M-,0%7<.L8TV4+#T1+M!:X'F2W#A0VF_YZ+N=]6$CSBR)^\XG8_/\ G= M;N
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MT4QG[<&AM VU\Z;TA%L#8A?AR%@.LI<;5QG%8G0;N4]6>F&JJD8H1^PSCEB
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MQ;L6^X>?P3&2?>"@F"XMT!@!9UK&7Q.4XMEQOK7G:PECUG +,13KKWP$8[)
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M<.X^I"XO 5S&(7KCQI_=Q;RC_?K3=WX:+_[\/_[TW=GBX_C/_S]02P,$%
M  @ U(-\6"^T! X_50$ 54X4 !$   !E;&1N+3(P,C,Q,C,Q+GAS9.R]>7/C
M.)8O^O_]%'@U+V:RXLFY5??T,LL-><OVC&WYV7)6]:UXT4&3D,TNB%1SL5/S
MZ1\.-H(45Q$$*:<GIBME"3S  4#@K+_S[__[VYJ@9QS%?AC\QP^?WG_\ >'
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MM4F*;;*!(8=N03FT(SJV(Q@<RD;W=O::M=%GE_EYFH!/S=FR=O>!AZ-KJD4
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M<:)D>^VLRR[GRF9C6D$U(]V-$RTBYA#WF)='%BBK-H2V>7B\0,GUQO$CV.L
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M3EK"ZE29=-L3&")PCX7+!ED)87 7@@)>JC<T/&':*)H^$-\])Z&3" "W8X>
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M-XY/]6X!T:[Y<:L<U<T/#AV6=8HW])3W9='D^1IBPOZG+$ZV^_,'^W)J)BO
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M71./&<7*L\_SOP]5AR\/Z, D%_B6_G/JK^A\@0*^4Y1X+Q(C>G/BE*6;9<4
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M_3QN&:=\4FJ+<D[E#QR W:*WO6),.P7S[F<O1Z7GI,T35E,2J)8I(-B4Z,D
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M=PF5:O_\N#&,,*[%2E4ENPE%U;>&#='FT?'4Y[R4(BU_IY!DC[VV$0I=J4Q
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M][&MXCK#<*RG+ZD.F$1)@&G"F+:3M#8(@Z3K:@ZN-,#KPIG<18OM>:,IV@I
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M2:,J.IUCCTH8A%5C9W9I(0\!0%6OS%=.5\HDD%\8#0BG/!Q3T@ZG2F!)S@
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MI,#68I<MQ&/0?[56HGL83HM'C+:0$A'<$1T-JZ3.DRLG^@W3UXV>8?1EN8E
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MH'R([=T64'$F03JR'FW!)]9&AIE(J:P,$[.'86Z<0]+ FKS(K&5@!Y K\QB
M6QS \?CU&9]B-P(4D9@.-"5@<8*#[";RPXB#7]&V-V'L,_M9/RGD%GNIR]-(
MV:$%XLA&DJ9__88#!D<%?:,MG;7!A2VK<U+(6->ZYI""HO,9DMTCU3V?+S8
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MC7- 2@9O20PW".YATEKTNF!/1K*C[06&,I+Y3%DG>."[0 !E&4NL]*3 6C.
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M4#8$2S@*LM3B/ A2A]SB31CU.A!5Z49.$'&*4^> C#%XO:*:B"*\<:)%Q/:
MQV!/92$9(PY3IMK,T,:)T#,0/T"^JK)^#YLKDF/HCC-$B4/<$R<OL+!5#:#!
M4P/7&Q)N,;[#T;/OXG)S*+UHN4F!Z88Q4ZWTWR&6]3I,_HJ36U4[@>N95'T4
M7T&[7KG?N<(,;"\</3"#IZL;1C&WELV0UCBD+PD"&\":S?"+M'TZPO8Y+.3!
M8<QTB<%9&9(S6_,,J0%*.P&,B'Z;H"U.4#:HF:SH"^Y:;6!6[/D/S?;\API[
M_E<^^X$'9E>PBBQ#^$K#["R8^5714UGNE%XG 'G8:Z]+1XB8:I DL!@/U"A_
MMI"5>K@3.8#OY&NV#F?:.L#7.3S7$L=*5I]7XXO5ZAU\!=TG[*7,9;EWS/@2
MW$6]7+5B$!"\PKI 35'AQ]M<P]R2H%_9@(;WEXXU=:0P:^$*M=G'];'T0\\:
MQ(M<.=_\=;HVD7@I2%D)<^DU;'V?'\R@B=WQ,@/0K1__!L"$]X&+HX0>AZR2
MJ[DH>T:?G<Z\!]]A/1P<3Z2<'4'<9E3]8"P63'@9JZG>B3T['HBF@>L3#OI/
MOSB)L+='];A<)=?5"G.4/\TN=@OI+?G>9NP'WN%,1']:<ER9X[\41P7X<CFA
MP^&DD#'18Q'MB2<5M0]OLX('[.HW<\KF^ ;1)/-5,<F8>]QD%#/]?;1:BO8F
MJ$1@J^0:W6K%'H109C-%:N[]/17)(\NPHC90N=IW"ZG!L9](XP77[36UGEFM
M^IR9\YN+DUFY"*N;'^B[&+' [A7+%(P3W;9@Z>R<W#06X?I+[&+?VYP0<[O*
M6E4U7O$(BIMF20LBM<);!*HJ&FUP'<(1P_]D<'E]=,WRTFNL!*/6C2W-NZ1J
M21:A))):\U_HZ:UL[\C5/,7\7YZH0GDX^^8^P:+#+<ZO]SXG%@1(<7HLYJRJ
MZ,WW/6'2X5%1)48+/N--> 9G[LM"@C&W*JLW]IT<](\SI,:-Y,"YP,:'/G@(
M$+WE(X= E3)O[0<^N'1!?A3QN_U-#*(#-D?Y+JR!;@_"(VED3X9 6S%6# [Z
MTON2'P_HZ.N0?M<)SS[9G7A;,$??ZY1/ .2(11D,"ZLV',QG9_^;T4RNV[O[
M4;R7KVI2=4=F@]NLWFM6";6ZU*!6I9-SKCLYE]S)F:M9.5+NV*M:VL+IQI>N
M))S%R?NJ8ZV=*&^ '.ZK%N>:KZUQF,'IAM*37?-.SE"H>[)WPF1D\3\X7]WA
MSL4&PRY52JELD]*3FZJC0C"\6&\@BYPR#;4U^B46R4A^@ $71%\1IYV-V[E!
M2$&<JEIJ'(@/9&C3MY6W?VB00'8K?ATT.>]@YVF<R^Y"(@J^ZEMMB/4:^P;S
M9?&B\6XJMG8WJK8IU9_2=4J8R>*$F9\N@L5+0-__)W_3J]J:ZH)I/ZH3S?P8
MRGX.D5>RPR94P,G8Y!W N[HX9#8+;TR751UL"^MI%><^5?W7R5D4A=%)&$5<
MI3XGSF/?)(N2K!?$ND%9/^A7Z&FXN*ED$_WM9-[+[!8]^P$&,S;Q5V$4^,[P
MT5[[C5I:W>>7%^>+V^N+N3U_^SQ(?,\G*>SDS,9X]HWC= &D'EQQJ<S(.G,B
MB!^(94*%D4"%NW2]=J*M;J5CMX[F2*!W1@3WA( />\"ND]+[ G#HF!<AAAWI
MQPC8.9+\O/Y9+(EFT(>B6XWE8#B@H38<>$@.*,MCL1CN &?:"=2[BK#3%XSY
MA!76I80&QUON,V)B<[ <#I"]5SS!<H7I&>Y)&$O-8-+?Y25>7Y%)R3O*2LWJ
M1BDKKJ$!N28YAN>OG^$BOF.VTAO%N')@:8:IP>U.IZ)W)JI - 9@YBD3C3F@
M*D;_D)F14IY<+8[@#BO(808UTY)U#*MKG##$TBA\]NDE=;R]CT$-5F7OS&)#
ML#"%%8.X2&.NFV8%>"W@1=CCFF2Q+QR[5G0%JOV[>\[[CUIU0?M@$\/94EKF
MJQG941W2R- [JAAOL1/%@[U5!SZQEDV+'=;N[:VP;F=L:V;<,2I&:A5=;143
MX.U08P1$+=/N.;D3+J#Z6J;,\J$E^*IW]-O/97XMJSG.*88>Q:IJ^E.7@VUP
M7:LAGK07$F1C.*DMC$C#/%9$!#LYX@?&%&F[9L/6<G7=**6Z,H87 X(7.1IS
MKYJ[G"2*)<U#8(#DQZ[((4'O$'@H%M MK@-R.=W!C[C"A<*QF@6NA&Y%@SP>
M=\^5DGT<R2,]4(C0,E96H/T^0"\'S7(>*X*1V+W2! ZV=NT=-,]EE@&UUKD5
MSH?P'?YJZS?ZCCB:X9[SSO)(/*R_@>]X=F(M7\+E4YC&M./E"SU2MI=A\ A"
MXD4 #GYZ>]V0?0OGY'?[YX^?/R*@S@T_BCZ"#NQX!(9D5M_FC-77P98XI&D7
M2/:!>">O>"T+]R\PGTCF$\X\ >9!S8 R7H+Y#>UP\"N9:8'@</)YQO*E'^"+
MY/]G[TV;(\>1!-&_0NLU>Z_'3%7=63,]/;WOS8?0E:4>989,4E95[WPHHTA$
MB%,(,IJ',J-^_<)QD" )\ @>0 1EN].E#.)R!^#PV]%ND-\PDZFE49W_AG$=
M.O#T.7#' @G; (W&CL'=B":TWE!?AHV8Q@+3S8@@=S/=Y!.:*:#ZB!+DQAX$
M+5\35AU'>SA]7/ACJ8>&I3!APU,)4YI B)>31VM/ !_N!IJ)VLPL^SMG"!]B
M=$OC4H4+@7 _AM2E4N3AH"3].4>H"H,5;L$L*:D<17C2",!5V!\*V'/7D9L2
M['+PZDG#7JT(<.3^3VO N8HH?Q-S;SV6*PHRGQ$J0!_:J?/CE19 W2+I$AR8
ME](+]MQK\LZ='VZP"BWK,EI6%;2L:NGX!#V=BY :057-3:MRDEB6-R<6)XD9
M(6)#:?UR]_+A>6MS1_6Y4LX.6CHVM6I%HES9 D>)NHA%<G'&+'=)DNW8;^-E
MIROY+!<3.)RS)1?4]7[[CK0B'1-N]J2A7<#K?HI\@H@T(HP3"*0@Z8 K>)$:
MJ2C86C&8GC>"<1VW#>FR2PABF2NXK5K:C_G\P)GMF,4"$/0%VS#8!![9M97G
M0:@JU.$#XD@(TR@: !%V )FNB\F<8C9'3#>+,#T'^'BQD%<-^D7(22)AP"TP
ML.<SSA3*E4"]<%X8PLL&G6LIC"NAY<-9P"P=]R2 P>;@$&3\'B4)0KE?[#UD
M+!-I_@Z<C";7PU)H4DN' U9S2.R-:7HT[C1RLO#QK6/#7TB.Q72&"R>?XP)>
M[Q?D0,;)J8'-<PM?$<GRL&'Y7$=Y0HI4PHX\]JS*UW&AP_8 UO6,_@.Y\?/7
M:*#UZB\G#LY1-^_"@=D<,MWD"6>90\=#'&W("FFRV5N$DA%==O;2T$["DM-.
M3D?'!0N7(9)'=6#8BZD]>FK"[3B,=B'ESD@^AL-0%])G7/[ D&*6W6?0VS9+
M;FX34(IK-DZD]"R9E#A)R*U]-$_C&%23IDYTW"2)O(!5VZ/),.\>;@J[JOV0
M50AG812EH]F_?HWW8V'9IMLTK=4C=YVG# .XE8QAK"]"$)B DTX=?# >&+@*
M 1V1N?_,% 8V'C#5.CZ*;9E>VU_H1B4MZ.,4M4\D_<X*8Z$^YBX2!^=+Z!/R
M3;K^E;IO79 _/_Q;_J?P9 -[R%WH9QY[_:D&><92*),@2:4A+NG)'\W4/&$Z
MP)2F+.;1[BBAJ8EOD0]!!E(QF,&\*#BP0:A["I/DZ80W;"+XE<A'TQ:^F1)<
MF6V5@OH)9P.^1.N-PZ>8I<+/E(!6=;KZK;U5;.WTY"Y[2= _,_ 7>AM##,F'
M<^AXLTHCW UD#*=H>W+$C )<R=>?#70:"\=FUEQ^OIZR_1[3YW4@EU9]J)QB
MY!G=(8O'6V19(>1-52=H&CNZ;,P#N34*J2MPGO$%"#Y;#4O[4JSG3!"CX&XZ
M &^@M)OD0C<B366<W%PW>3 ,BLQA)P8!-K!X*=$7G5 \G2/O0?XBGQ8\JATY
M45#4&==8%17A(SM[[,U@1SU%I,H\KF^C0((- 5&-_X)P:U'X9^0XOC__E5\;
MPR%NHX(HN$0YIH].<(:P-H7R)11F48EIUB@^7MNP4M%PQ=P6B+@WN"3ME2CI
M6*]"Z'(W!I J>>G,6<Q;T\!<C84S5<9R=,AP_XV<](9>!PGU!X1**V,80\1X
M3CQA*M'15HXKBZ;U9F8R?(RQ_@H=+"%_'KZ)B9LC^+@P?H.G0 %K+9K^A@^'
MH,0LL9'F\V!1%J^NYR![J3KH<SL(CW<#INXN3.,@3 */$IP/@_:1&UE0,?IR
M$"&4,U) @C9#WLNA*7 A#UF0%@?EA/GRIGT9P-7YAO!-Z4&2]&K94X:<$C9Z
M*>CS0I$RY;0 Q%; UNQW]-G=H>L(+./CNA1=.#"R\]]L[,DE769I@SIOS($*
M AHR@E3N$TINSB7:1+%LD2,K0TDZ+-/1E^^?9BHR. MH?$NY ?6/,.>_")<P
M,:U3S.N\T(E+!M<+1TP^;4'@6CWXLI<Q?7HE-?OA.D//$?WT*?*IP0! &%1K
M1]1W+Z529[XEE%VA_#P6"W#\#($;,FNPDQ9QCHC"%1R)Z0%9%3]MQB:5#!0'
MAZP""KNR!I_.'%G5.M(":3X:Z81-&M!U%;T1IGF,)#<PD+4KQ=(B9S2OBGQ7
M#Z3-*]G70@%[162Z;03A@^ /(;[[QSWF\C[ E-_1I%=B4$GM"[7%V+RT$CR9
M.6\U>5#33+C $AJ>CT##;$P/5,Z$O$O?@F,=;/@(Y#R3,::W/3(Y6%/;1<79
MC$)6V*R3I\>:#SI< JRQB,V%AG.;GH#5PV,A[FKT2%\:S#5SG._1@&!3,(@S
M^B6,D1=MP^!WZHTBO!#S,_N 0A?3#&ZA?Q<2O!/ZP#WSAY@IY&E++I@7\N'-
M)^=>R&QZA\\_D_EB3@PI8E," 36M,E8@I!*LDJ>LH>Z=^R@)Z+4^(^3@\4[.
MM*X/D*D;8Y'PJ- >W84WWUB9W-LHSKT^Z:<13&#%I'(&;6[CA"()(2]92X\+
MXBNA2<6*VG73YY6;#3M8@9CUIJ1S@^+,8E+P]I=<<=GWZ8UKLZ&CZD?3<EZ:
MSH?S!@N8WG/<S>,_0'&XWCS';IBX]! /%VE@]#SNX_1 P0HH)I<RZ(E=IX'W
M\.K&._<^]8>[VL!P#AMO'H>3$=:/ZTLG8YW,\BND0 +C N"8_F(K*R,Q<Q9E
M$R3GGV1X^EQZ-Q2FMC, 4V%,S(V$DAUQ[N2Y=TF2P?M2>="N<A[D9\*"D'^]
MD5VB[]XO'SY'X4]1RDI6D9_3X 6CD5DDL:HN[)&7+PY:__+!":/PNS>Z0/Z-
MKK#Z,E[,P#'8@UQ<P:N"NRI6Y<"RG&)=T)K@]7.!5VEQ!A@Q>]!:U?U/?VPG
M9NA 7<+-P ?!U (;-(BH\_$*_AU&M!T";&+Q>55M;H6] O^O^#"<=1,#LJ"B
M+'V-*%!SQ:V, @^V I3/Z*N4Y3&.P@C4.=2GGCW=(Z;5?D0>JJ2Y+$WH ,$A
ME.$R2PEU)@W]:#]#RMBI4< WFDRC!]U$M0$!?_GA8+Y ;">&;/9#E3_A!;<"
M.O+IP(2KX)1]INZ,@<-IQ>_3;).;CWY:L+5LUVIRL"A+1Z;?NX$OJJ1(KKQ<
M#2R^B%3T<@3N&*26+R"OTW+AE+V A8I??)>J&LP0E6P.1UB-GA)VZLA9J9 S
M7R$#(YBJR ("8R@_4*QR@<L/E,MQAN0#Q9K@8C73!SDQ,S1-10*^49%',YR4
MS=^#\]><)!050SW+UD(=W6!XM<5^\O).4*%RO?G"O=G6+V!&A#I>D@5"D[%U
M6!A R7_MC*#DFTQG_"[:?/<E=VD4LX+P?B.;6*H>D/G<4Z/E,DO(@A)"Q/Z9
M!<QH3/^,T9%.X/(6B\$=:?0+1XQ_<J#A+E!-;H4!9<0]VKJ811$<X^M5\NV#
MH1PVEL5+QO75SN2CQI-:NO@N3-*8/L<# ,A'<XKA)@:$Q5D'.V:,X Y^CX@>
M5RKW#E<%P>@.,T (!T)Y@IE"R4<'$1?0??=R=M!50^0+*-\XE+$TQ_1<(R9L
M['K#TX6L8_I\#LZT04<%8X-(\;6&VFADY+DR;HP'%I8AB@J(HID@*D+B;G8H
MWI(#\C&.OH)59+=WPT&\("?H8ER'#>SPD4\$(&P2EF:K<SW2M5:3JQSIBI*[
MD)6:H3Z6Y:#706Z-VVU,WG":HU)$JKZ)8F51.3)XAD)E%F)+&(G&CQ &Q6_(
M*PC-%BE<I!G3&$EEO?"7?1061M9AZ>"XLK%F-F7FC8S,5+&7(M=[99I77HMU
M#J?(&=%3TJ"\(T=7757GA%"Q-C D%1-.^4BMR*WV:;0!=@<%U><#.3"2M4O&
M<ZY6Q'DRA_5'1,Z]%^" $ENJGX-?R7^N@PTY#N"SY>+AR;<A_XKC2T.>,GA\
MOR3_^_(\7,])/\ ?UV<"=SU,EV?==N(R_ F%GWZH[OL,V0*2+ 8/HB>4IBP9
M< ). ,$;2 LCY.7))P"H^; G"12NPB,-[A2CSY:^1Q_=>GG0Q+<.U0;:&,H[
M*K"X#<Z9M(J/"+1_7IK%$*\;^H\(0S 7+\X1H 0R=>&(G,1Q,F27YA,VIG,
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M_]^R*)0//IO)M4A2STC>)2)<#<HI*J%U\(AY\'R2WX-M2*-_QG%&RW8[-S[
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MI8IMW"G,'_R5Y\$-3![< ZR,FXDYX5?9H>NL;-\1S --[N<5V: @E9D:LN*
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MP\!'0)T9LNPH9H#1(#&>BEN%V3'&M0)!A$6DJW'Q V'IB?S/1)6&U#E-':P
MJ>RF'(64JF\T!L6^7L^]AK,"'9(YO$/4F+ZU%<!\>?H8$5H3 J6ZBN)])&S
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ME TML>Q<(4C.B.]"'WW[+U3R;]8VL@+[C6Q"(4Q=N< =7!ZJC$-G4T'W(:U
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M/N/I"#8W;@RB7R*,=1W26XPQ@Q5(JZ>,S[DK[OS1(A%V[&T%L+1R$I$#:.H
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M#&0Q;:@II&IH!0@:OI2LTB=BBT?SRW""WR_[X"@#6X&B<34I'V.-E7R"::Q
M'SO[A-G-D-\M3W1S#RN JI<S_!REJ&-L7>?.5H!:$TT+)3(Y8G(^34+;4L*@
M_ _RTN>H2*[9Y$YP]*!6H*9O-4PK2V#60@RX#V@HWST>=."OPT=@T"#;$VE
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MZ46=:IU]9[Y4\&=_A,?=PRDV9E$G?JA)D&_ 7\[0H[Z:GC+;[0@K0= 2;,.
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MGLXX56LV<JX_/OX5:1EX+N8XJRRFJ:4Q!-)-+6\UWUP-*ALZ&#20\WTMRN&
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M;;4*G,2U*QF'VGJADU 26@K"LJ&251 $_)LKQ8V.&=>!NHJ@>_G;HKRG=KU
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MWT6':A8@F]4]W/;%F_=Y:0?8>A<E^(5R26IE![<#G!V26]- 0QO:-&#NP&3
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MOW*"V"<,,!U3CY?VP@K*"&IWHUB^4BU&\CY['&OMF(,4F*9F*J06F'R!%K9
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M R0H:?92K;2RY%AW[Q*78/ P.BFY12FA2#1O8QS\KX JPI!F"7D^[W&[J2X
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M!H+MZ#LG3B],^ D-%8N837R&.@&\TMPZ[W[J!$].DH+X/@N]Q]2C"QF1;D;
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MV^-7<>FL+W RC:">/YJG J7[/W7HOZ/[#SJU%S54@?\<)Q_<3>10)LSA6P&
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MZ]S$DJ.3*!)W[&2=;?0,D'@AN4K"T2I%6G@"Y-:"H0#"%$LE07>/<#@*\Q%
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M1"5^Z!!P2B&2J4F1R9A,><TVYH*)D+.4QD\C0&'"^A*'#K \1Z8,)B55)[R
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M:Y.S7K?]#Z8S=J)$BGM?IMSD,*=R,N'*MMAID71&*ZA00%N%M3?(; 29_A9
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M93>X3M.\:C__J=.T+^G_!5!+ P04    " #4@WQ84IRG*$@%  "9'P  #P
M &5L9&XM97@S,E\R+FAT;>U9VV[;.!!][U=P4[1( ,N6Y"1-)3> ZSC88+MQ
M$+M ]VE!B93%+46I)%7;^_4[I.1+G%LO26-C$P1Q9 XY9X;GD$.JD^J,'[]
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M>.986L6W4L7S[_-U.UMB\$IEN!GLZ/4O1V>G9[WNZ&QPCBX^7@X_=L]':#1
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M8]?4[BX4J=6*-ZX2-!6L3AX#O2;\JSYM@%D14UY3/UE9X+'6UWBK\B]X$ZC
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M?.7Y4+_)DEW;%[.P&AOF#'+7-75EH7Q[NS>0JW=4T=/W)3]\V7'E_N7>EVR
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M+[2&M?$-7Y70\X6N8OZL$QQLX1X MC5TM.6PY(#3@!4@#N@#$,"?<P1S:#/
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M&=D\UH)D2;0BGB59$VV(MD0[HCW)(=:1[!3O3'5)<$T\EWP^E;,N9+EG>^2
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MY%ZFTK&US<EY=MD^11N9KS(5Z2L9I6DZ:/O4HF2R'P]C-$G&[F$B@JZC8YV
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MR0)>&E3FJH4I$F<M''V4UY>1LZ4ZKYE\FH.:Q0#1]7>SPS_"'MQT"L=Y5?9
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MN;9-!Y#167=KR7X/TG&5D4ZT%'P9SL@_Z5V)GOQM^FAN^:Y/] ;:,P @5&,
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M"*HM>$69L#;-/14?K=/'%(O+/1&5,1Y7_/_P:!=^525_'\"OJ* B!A:*@(J
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M-W,\_<\UFMB7G=_79W+LK!<U6+$3Q]7J<16R=X8B#]<PN%!64,[:O5G2N.M
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M\B717;5L<C2)S CL/4VP[JFN32?,[!B3?L7_;NDB'2),:="7W2+XU-Q.64+
M5XV$+";4&1^NI!(J=$F3'8FW&4M[L_!->Y?57, W#>JD:7CQ[E'2?#RSXUE9
M(+ZY19LLPK]NW+Q)2UA21UIIC3^CR[7X0<QA3&F_)MQ7?L/X34 #[A'^Y%/
M,/P!7@MT6DDY]QU,E_B26X!8&?R4NPS)7M[#_82*'\^P=.S*M@\""V2QT8KW
M%94J>,V;B5Z'&^:&8J85PSEBS/U$*XXE=F_P7/8!'&[99TX%[MAXDE(3%[2^
MY560;AHN<XFD;_SK'!W9&FMBWR O+X*S_<B1":M90V1T4"(+0=8O2V5]),O&
M,]%CBJ#E/.<S)T-?SYG-'N3)V"%L $;(XK"2"_',5\S#.[*8>&9T8",S@/'
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M'U7^:G039%WVN9% R+6$3P/A4..6K;NQ,(A?9I<7W,<9V1$#-\[J[WP*>PP
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MX!W]]40=8$0>)3J.04B;A6_*0B6S!1]WV8GX_!?1ED(OWD]_H\"%E^G\@G^
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M8YLW+$FSV/<\[)+:R3X(NEY.F% IY>_:M9)IP$TM"/)!4$K#>Y 6G%L+S&B
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M_K0%VZ&;!PHOJM54@"7ILU2G(*=C0I5QT'^"_11SX=/=T^0,^,F%"Q2WX&P
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MWYT#/%MYL*,L[2-\?]O$T .(92V/YIZ 3Z[GF&P5'9,(VL,HZ\L^5U^BGJR
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M9T23U3$9/L+CJH8HFK!=9>/C+10J+SI^%BY2.9LUB5C2\=<B8X6>M1[P*\*
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M;N=5T& "R[1*B""?:;N>OA*VM#HJ>R]BF^!U?@?:C: KCL?R@:YER_&[T_1
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M5CQ4'[*\P. HQOOH:1MR*,8VM%_^J[IEY6N+/M9F9@>4R@SWE[8 *O7G_76
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M_96CX'^S)O+(@C%KBSE_4\D7&#=D.Z/5K"39W6 RVU76[17)CI!ESO%@T61
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MMT";WG"R_SFGWX3K1(A7] G-H<63U9&6J>E$>9QN(*I2[*98[[N(/UX(.JY
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M+P!Y68MKHV/R<-/JF[+GX??I"!%?B'KI,8]D<A=GQ[55C 4U2PYK&8MK_;H
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M1S&GKE3?+&!';CM3KT4G)4^I$R//PO$:+'S75RQ?]?^WQA?6@?=M%K+_,']
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M7KJ"QCUG6: XSE^*S@!\!2LY!+!.M*CX%!@A7IN4"KZ49H7:0H?D'JY/X2M
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MS:CM! XU3\2V 2L;Q(*E0+=E4V4#<,AT/_,S.-XP?,51D*&=X/\;&J=\Z,R
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M+ZU1U1"K_=S(+KS-54V,PU#;2LR"TH5AI@MF)GVLT<7D7+I,GV 09BW6INK
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MPQ3@-CB"^%7]6>(CZZ=%21U8ZQBP]$^Y%^N8[&06EQLF;XG5\=\K@-!@T1F
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MP5B4=<AG$0EH5[?O8J68E,/JY*58T<ZKD.NX%^OXB&X".GN5$Y]@3GGB7D2
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MU+55R"C*-LIC%TK^8^1QSXR\;2F_^=GE_!C^.GAKUEEO080_5V>_/W:4G7,
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M84Y=M3,7M9Z2O>D@9B7EZS6E."LR;_D.@A7YZP .=[]'I,=S3H$/V7$1YZ.
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M5C IPI4/%%$5'3D<;1,WMU''*&[14,7M-61%IXRD[1(1M5UE)%V[D*QOG6]
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M?22^CG_BWT5X+#GO]5AZAO1(VCR.GPW,73/ _^!\"#VR#**,UD.LY0Z(=="
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M6"D0^)5));R2X"!F472(=V%*.*D@/]*KX&@4ON!,%*[PNM(K]V\E*?-.Y'A
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ML;! /1363I7"CCD\V+^8!MHK"*"_S@U,-SF!]39;<-QI"9C=IH#=:P3$_?I
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MJ0D)6AJ0I7T 2@[OA]HC^^#,D;W0I?,KC<=0J/)F%"JK"X6*NZ.."O\Z2RT
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MOYE]L/UH\=GVC>47FQ?67VV';?[=_S:X[)L"!*W90#%<"-Y6*X&"W@A>N)V
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MT".NI2XO7&HPP\XGW8;0Y]R?H:^Y/T$/N/>A1SUN.;_'7G+]@+N ^8!K<?N
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M!"Y3A[#EJA"S7!E2!!0A>X4\E C*0IV@-*P5DH)>K$]X*>"A0P*Z*3>PS'C
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MI"N5FM^1[9+55N2>WE+%2E[;Y!/?W.4?LV938&33MJ#PIJ.<\*:_\*^OL87
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M&,I$\)4G0C!NWRB\%_'X/!+Q>239\G])<!&:B_42?Q49+/,T+$[I87"&^OW
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MKJ*DE%I25.M<6+#6+3>_UR,K;YB9D3?ME9Y[S"LM[R_L#2LM[QLS+0\\T_/
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MC="J2R04^P<O"IT51)Q96<2>U23X/#0A,A_:<C$>.O&X/O+D<W[DO\SQ48B
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M_2J3-ZY0L]^X'3FM9K_AH9K=^O?JMNN(ANT(T1S/@59<B[T *W'\!['_/>C
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M_3+A:?O54B?M-DD=M]LM?<SNN,P1^VLR!^V?R>ZS_R"_VYXH[+(GBCN1'3]
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M=?8OHVOMWT+7W'^*KKGO(5USSWN&QF["',\0YL_#_!F+ !J&_SX#VHACL!7
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M;P-^'G)/!'^?"_! $N"A#, C98#'V@!/3 ">3?JV4?\#-T<O\87\$A_^KSH
M7F/!7^,$>X-!;X[_0_FZ;V= ,=AW?\QV/('Y9P!T+P H_P(@=0V =PM ] X
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M_1\@NO<C\ODO9F._V^;C\P"S<[#/"6L @C< >(P"V&_#?,S51557W0<@>Q!
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MFUSLT#K-,?9S>SW7A#I>CWQM(A74SJ-V<AL0TTGO2=OJUZL$KSYM>/0;PGW
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M=!\4"MS7"C*/"2'/XYB0ZWF5O"[D>'Y-_A2R/>53Y)#GJ7DQ:/H>F/% 8'4
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M$T3G##6Q2JNYNHIOK<3[Y91JCA+.>E;1?@S^##[54O@-?)\A[3I2@0N9_LX
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MWGO1"GF>39G3J,8$)'M4MV_]9Q -. SW&"#,-$6BM9@$; E^S- F2_%CUDA
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M&5!FY+0RK*N5;MTFA_4,I5D/*]5Z1"G6'RK9^EL>/P1?>O8"K8)O,MZ;FG>
M)E#+ZPK\<?->";X4X4NA+5 N:[@*K!;E6>W*M<8KVYJJ+&NF,JWYRK"5RFFK
M4;JM50Y[GU+M$TJ)6JGDJ*U*C#I="=&'%!]]J^*B'U-<U&O@0\5'?:4M<,S!
M.89,ZB7E:4VF_GFL!&ZN%?.>"W_R^5QNM)^RHT*4%6521I15SJ@8.:(2E1:5
MKM3H'*5$%RDYIE)),4U*C.U10NR8XN.6*S9NBV+B&7'C+U%4_"VRQS\J>]PK
MX'U%Q7WEV8^TU%B'(AWO DVIM(&Q]@**\:> ]W+Q)9O/9>*+,RY0CKAPI<99
ME!QG5V)<G!+B4T&FXA-<BDLH5VQB@V(2NQ2=-**HI%G9DS?+EGR*K,D7@YL5
MF?R(+,DORY+T=T4F_<MS%LYB^ 9(MSI  REY)8^EQMH+_N3Q7A;(P!\'GTU)
M\E-24H@2DLV*2[8J-CE&,<E)BDYQ*BHE3_;44ME2:V5+ZY U;4B1CJ6R.#;*
M[-@##LKDN$$1C@?!"^ O,J5]JM78GX2O'[G:"FI!.2@&^?B3S7L9P($_*2"!
M:[&.0$4[(F1/M\B6'B6;,T%69YHBG=FR9!2#*IDS6F3*7*2(S&F%9\XK+'.G
M0C//54CF-> ^!6<^I^",MQ22\4^MP/X8?#W(LV90#=S !7*=QMH/^2Y(!8D@
MENM1F0&R984J,MLL2XY-YIQ8F7)2%)&3H?"< H7EEBLTMU$AN3T*SAU74-XJ
M!>9M5T#>?OGG72F_W'LP_@R/?Y9?SD=:!L\P4KF3E+,!5(!BD']T_0?.-)#$
M\WBN1R/A;+D!BLP+E<EE4KC+JE!7M$)<B0IVI2O(E:N PA+Y%];*S[AYHA"M
M633GW<!=2*)>>#D@^7:1,;G^!#[28FPORO;N1:H%9: 0Y'(M$Z2#%)# M1AD
M@JV _-\5('-1B,)*3 HNM2B@U"X_M]&1:2PWCKK1_FXT7EFK]WC3,K1F&=JF
MC,S 32[M1@24HKM+R1Y+/]($MGNQW80TK#JZ!XC7.<CW#-\:5"+78I'1=F1;
M)#+!7.JO\/(0!55$R+^2 ;V*P;2:@:8ZT;N9JIHOU*"M:M"[GK68:8" J$'[
M5U\"R!BJ?@3^2 ?X2,.4JQ/[]9Y[P*@RD,^U+.!P>=>@XHJ) 22T%;/F"C1(
ME;^":H/E5\>$5\^$TA#I'=B-A>5FZJ*9NFCF2\UHJV9C4P'BM1E-T82 :4*X
M-)*U-2)&&EX''VD196OEXS5'UX!XG0N</$^AS/%N^.&U5DDF3(;52T$43RU,
M[*UHRS8FUW;\Z*0NNJB+;@:2;H*WF[KHKO#>8--M'+U*3'21(761K762M78\
M G['=S]2-QR-H/*8-: LGJ>5$P,T:50-_/7&^@\:G.8-0+HRB6,3K=T;Q"2+
M'_WX,4";#!H3+P/["(/)"'4Q0B%&^/(P[3&\&! 30\3EX-5\'KV[Z!7PH=K@
MJ:OT[@,JAC>'QW0D66(=?8#R6GWK/R'H<W],D<1@ QCK(:/X,88?X_@QZ=N7
ML@0_EL9Y%\"7YGN/I9[!P SML60>H/$67\9GZ9]39-23?U<3Y:P&9;Y]0!FX
MG4R98Y"G5G@CX T:\'$>78.A2*0G1K+G3?J,?2DK2+Q6X<<:XZP48F,#;;(A
MPWLSXGJ,KL?Y=7QX[0G2/#&QQMB/0O]<]98:&@A/XUXP'K.:B0%<9KJ1E:^$
MPQLX[N,T^&A2_;_]*/*MB5 G6]'\VXG3$RW>,V-/2O(>4K;;.#:<L6(G_6,G
M']YQ%I]!N)_P$)]_1?74M9MVSN4C#LH<1YFM8][]-_[+?)Q'UU^.W8OBV8?B
M2\:-_2'_.:^$I'@_">DY^'$!?AQ,]1X6=@&->S[&S\7@.:B'<\CF#S!6[7]&
ME=2WJ\]['U8"9;8N@7^YY#?O*]_Q/KZ3?#S[]-T>E*/GQ!KK!$?/;34VJE_A
MYSVO]7KZR\WTE9OH)S<1[#=2R3=0N.NV2->>RV?H'U<_I!+C+!ZXDXP]."MH
M?X82ORT^WI-]G ?TW3Z48^_).?:,DJ-GMA[1=_LUC WD#U,?CS+I/TJ;/$+
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ML%B IP#OR@U^]>>ANS>P^ =V#V=^=_SA1R0<?\"^BP2+ V!Y&)W@<S>#7]4
M?D0#^#+8]Z($8 ?O!D_"#AS6T+>UK@Y]<FV 2:.#P:N!/;P*?#L%<,A@P$I@
MD(I@P B@XWCP7P[0L(&>"7YF(=2+Q2#(W7=0?/&O>L-7S&+'BRS@6YG OS.
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M;E'9#KV]'7D "I__P.Z@P,*;F=W+&[;DG>E>#H^$EJG>P!D%Y0T"#06-!DV
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M\ R"-O?';+RU>X-_H+M]6-O^\TQ.//+O6$@Z\N_[6FG=SLJ3. @;Q@@/YJP
MQ@8/QF<)-)@##63M0Y B &: 5U<@05Z"?AZ]"KL'&<8?UF8L]H/EP&"QB(O=
M=3ZYFP2+@U"[ZWER-TDHYH*$<T+@,1"*3SSY/ETL+F'N';X?U0;SQ H#O@R,
M;01;Z*$"#<"KBI%QZ\/GH**@[EY8F\]TVQ7;]&/QGB?Y(%BNRY,XR)-S.%A=
M3V(N3\[&8,D#6"X(=ID"YLQB#G4KC(\.[%X06/1:8+UHA$;7P?,C" VLPAKT
MW__T>KYWG[[](R*C!D8/&A(S=-B(D:/&C!TW?L+$%R=-GC+UY5=>G3YCYJS9
MK\^=-W_!FPO?>GOQDJ7O+EOQWLKW5Z_Y8-WZ#1LW;]FZ;?N.G;OW[-UWX."A
MPT>/'3]YZO29<^<O7+Q\Y>KUV+CXQ*3DU+1T'(%((E-I&9E9V3EY^06%14Q6
M,8=;PA>4"L42J5RA5&FT.H/19+98;>4.I\OCK? %*JNJ@[5U#8U-S:UM[3<Z
MNV[>OG/WWL>??/KY_2^^?/C5U]]\]X_O?_SG3X]^>?SK;W^@/?WG6?O_?][^
M7L]A+>Z'-7D M'DPUNCAT.K16+-?P-K]$C1\&M;RU["FSX&VOX$U?A'6^G>@
M^<NQ]J\" ZS%++ ),\&'8(-=F!'V8U8X F8X@=GA+&:(2V"):Y@I$L 6*9@Q
M\)@U*& ..F:/7,P@#+ (&S,)#[.)"(PBPZRB!K/H,;N488:Q@V7<F&G\F&UJ
MP#CUF'5:,/-T@'UN80;Z""ST&6:B!YB-O@4C_8!9Z6?,3+__@9X]=F4.UN_/
M]X:ULM?_' S_A]=/[/5_,-C_G<7^WS79GUOL_]%@_\->2*]>SSWW_/.]P09]
M^V%6 #-$#1@P$"PQ:/#@(6",H</ '"-&@D%"%@&3@$W *& 5, MFEY!APF/I
M?U@F9!BPR]IUV%2"F;1KS[X#AXX<.W'J[/F+5Z[%)2:GX8@46F9V;@&#R>:4
M\$M%,%VPV:(W0!-#+?P?#0R/B="@P!H)K81F0CNAH=!2:.IGGT-CO_@2FOOP
M*VCP-]]^^QT,DN]_^.%':/=/CQ[]_/,OT/9??_OM]]__>-;^KF#$V"_JHA=]
M63OXP*VJZ-R@[75EH&RCT6TX82]7)_A,4G+0("(U:06D-E4)N5/!H=R2%]/N
M2%GTCR3,K$]$C-S/_ZZ>,3QC>,;PC.$9PS.&9PS/&)Y6G<!POW[@PB_J@*%Z
M8&ZP?+8B8-D #,<=(089.:@7DYHTI<#  P8NY9:LF'I'PLZX)P(&?E'VIW]7
MP##F4V"X7Q]]H*MF0&[0/E/AMZXSNHW''#9UO-\D(P5UP* &!B4PR(%! @PB
M-NV>@$7_F L<?U<=P/!1PX"%GS5$'^BL&9 3=+X&#&M-3N-QAU6=X#?*2;5:
M8% !@P(8I%SR31&'<KNTF'JWA$7[B,W,_/CO"F.XU1BU\)/&@0<Z@E$Y0==T
MA<^VUN0P''=:, 99F$$)##(>J4-<0KY9RB'?YA53[G#8U'M%,"[^KF[41HSI
M:HIZ\T[3@/WM&(/[%:77NLYL-YQPEJD3 @9@T "#O)38)N&3.H0EI"X^EW2+
M"QPLX"B <?%WU5X;,;H3&+I:!NQOK8W*J7:_HG);UYMMAI,NDSHQH <&E9C8
M)"LEMHKXQ!L"'K&SI(38Q08.!G#DP1SYNVH#AH[FJ 4=+5'[FFNC\BI=TU5.
MR\8RJ_Z4RZA*#&B!02$F-DJ$A-92 :&]A$_H*.81.HN (Q\XLCG4VW]7K741
MH]N!H;TU:E]C,++ YYRAMELV6<KTI]P&8% #@PP81$)""Z\4W\81X-N9P%$
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MU39&C*IIC5SB;XD\:_&/$*FM*TP2T[[R4OT%-U^;5%&BQON9*EQEOA)?G:W
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MA6(02AFQ5BPA-/)$^&:V$-]:6(IOR_E7_('20>33._#\O!MX :/]:?6+,WK
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M+Z166'-I@;),>K69FE5K).76&_"%C?HT5I,^M:19G5+:+$\1-8A3)'5/(]2
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MNTD%#B>NR.5(+78[DG@>>X+(:X]3>*UQ&J\Q3N/1QFO=R@2]LR<"AN=0T<O
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M4Y_DULM)09& V)9?3+N3Q>)TT0L$+1FYXGI:MJR&EJFHI-%5OHP,C:<G0J7
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M>NI'&:FTFV12?AN!7MR<GL-O2"D4UR8Q9<$$CK(ZCJ^NNB[25EZ3Z0)75?K
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MXF"A3 BL72: />N]0&X;#4[O)8#Z(1SH';,&$WD+L#QE"G:GC<!!21\(*GI
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M4XB'ZV0@CS4B#/!]Y1L>.,"+"7_.3HI^QDJ/>^*1D_B(49CRD%Z6]H!:E?[
M]7S&?<K%S/N4:YDWJ=<SK]"N95ZB7\N\X/9W$((VA*$-X6A#*-H0;B8'4;;J
M$.UH^BN*C/L4P7"="/'V>A,H$KP4A@:_X$>+>[D)L4_8:8F//+-3'[@7IM]W
M*\WJH5=GWZ,VY-RC7L[MIEW-O>)V-?<2JIEQ-;?!_>\@%-W;AZ,-$6A#&-H0
M:2H'<=;J$(<S_15#Q'V*HE$G(KS8KT,$PL' X-#G?I'13WWB$QYYIZ8^\,K*
MZ&$69-]U+\V[XW8N_PZ]J> 6K:/P"J.CX*)[1V&31T=A'>H<LZ/@;R ,;8A
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M'B[/Z&(-@E2T(DA.-X+$/4>0,%@H(8)ULSFP;0$=]BXGP)&U]G!B(P94MIJ
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M:?.&^LQNE'K??HS6C7T[(Z"NE@3R%BEP/C '7$XO 7?-]< RV@ELJR/ <E
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ML(WX7-3H\EQ42WXNJJ+T"<LI?7XS 0^T@8XV4/?- 9^CBR$8G?_%ZELA6O\
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M0O<202ZC7I3%N.Z?[OY<E.31)XQG]@MB/0?X,9Z#O"C/E]PHSU?>TT%O^1)
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MU<7C<CKX2%X;O\AK(?ZGH;4 B^@^:#M(^6< 2J\ 9%!^S . ,.K^@2@%WJ@
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M0V17[OZH.;F7HSOR7D2VYV-$:SZ&S2K D)8"#&[.Q\#Q,(K.0#IE%XD#5DK
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M#+^7-DRO5WR6^RMOMLOK8"&GUS'"#F]21;AO"D1MWDX6MWK;*&'QKEO*[-V
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MY#: X & XVN@7  K% 8SE (C6H<^JH$VZH Z&H$*FC,4T8XAATX,&10PI#"
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M(?7Q!'G*D'R'#,DWY/6/%M/Y;Z?\.LHO.4#Y=.U1YP%\?P9PO@9@_0> T1T
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MM,^F-^B,[>J@FW8K@CZW6Q9\WVYIL+!=$BQLB/7B/JP>(R;*'K6WOZ;^^['
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M9*TP>Y*+VGXDZ[Z=^FN6\5I8!<Q>"]1M8 XVTW]NH_^G30O>JXNI^TPQ9=]
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MAK?IP^G-I=?U^*#1<.%A ;SI +Q%S_\V%\?O:A>EVK^8XD/P ^T7$7?PP<P
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MVX=32DN<0=UHQNK//^)#/SZ$%GG@1<"2OMSX&J!_@S[\)GWV+7K^6_3\MTV
M%ZV)(_#R4"Z&N#!]C8NRU[D(>9TWGC=XP;W!2?4&D_GF54(#_^:?1/S-PO6\
M%K<!Y7MY'6@_AW4*"*#N*.JZ7P$&7 ?,GP4,7P!4+U+[5?(?\C9YA^-X3\W%
ML#$7Y!; 1P. 3V@0/N,"\0OFXTO>A+_D#?@K3OJO.*GO'B8\R=??D;^(>$2K
MM@?$6F<? V*I'<!X1S'>P=2UHZ[I2X#Z-4#V%C7?)Q^13XEV/\H7_7V)KW6
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M%2]$B2!F4\>D^*53%+W<29'C'HH8GZOP\5"%K8A3Z(HTA:S(U[P5E0I:T:S
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M(]BR$%L&?6=H@:^+>OU\U#,G6%USH]0Y-TGM_IEJ\R]0:T"YF@/JU!30IH;
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M7.ZQYD+N!P]:<R(/6W,BEZ=(3^"3)XU;2P@"GYUGV:QK7"/_8_K%<S3H<\<
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M1)JB(_(4%5&FB(@&A4=V*S1RD>9%KE5PY#X%1IZ3?^0#FAOY,OA(_A%F!8#
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M9$ O\K$-;K6P12T,5ZNB.MP7J(?\0"!K#>%[N$TQQ*SH#+_Y##RWYF%:J;5
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MS]X@D+(C*#N.FJ90=B9#:0YE5Z/<FGA$'8;U4LIO2=F=\9+^O!MC?7IM<]F
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M/0?QM=BV#[TGOS]^6#T3Y;ZXR&VXQ&UXQ!VXS#5B]XNPB3/H<1)['&/ .L+
M<8B!Z@"\;A^#Q1Z<>1>L?CL.M14GWH3SKJ?6:[ACI;R.ZSZSUEN=?3%&ST&H
M)PVKXVQ5[D.M07A5;^;#5C>SD[WPNUVTR6YX_V[X]C:8RR;T6,>$L9I!>R6,
M3S'9I0PDBQF\7F+@LNU%Z8.L8735*=1W$=UV*^_.(?MK:_Y#Y3[4_@]UPFTO
MH-Q(I?*.ZBZNNM<RO1LL$&?L9@06R@VD>T3*'/28B1[3\8^IUM7\!=BSF*&B
M'N4WP1M:,WQTH8[]J.,H6F:6#$+C,EJCO[QOW7>B\AXJ!]%!ST.<TMU=R5XH
MOZ_!4,O21F.+D>)F/8MS)!QS!*QH*'H,IET&PJD&P/[4>9Q]]?,X>\'$>S"!
M=&-0[<K_.W-71]JD Q9J3PNUPUO:XF'JR<]J#XC*0ZAS*/;)?^X!&:H/37WT
MX;&[.%*>!S #7Q!,V9&4'4^Y*92;B<0<:I]'V85X:#V\HRG_VB&C%UX[ H^9
M)0V1T@ OJH_7UQ/;_H_R,R@VZ/+'ZK+55*"F!34EJ>&Z.;9HAG\VI4V:XAO-
MQ(^R@]$_DK+C*#N9<C,H-P<KY%%V$>769TIOP;O.UBQ139G$5+^45MO+M/^F
M=?]'OM[3U>LBO?YJ*NBJRU;3A9JNU)\KU)\M:F.+VG#N6K1)+?2HC1[%$H*,
M2,J/H_QDRL^@O!S*S<=;:^,IC:0REL^EE7)HU4IX5$5\LZ+UM)OOK:<09>NC
MSDS=_JK^*O]1JLM5?ZY1H8H*':J)/7"1JHP95<436)#ACXP0RH^D_#C*2K%F
M'[*XFH%6Z5BF K9(LYZ@.H1O9X)U:'L</+*N@$O61S]E Y4#:D\(TMC>%A*I
MW$=5WJO0285NS'B4[@3<@!$99N"-G #DA"(CBK(2*#--DM!&K0Q)P&+Q6#2.
MEHVEE6/P]&CK$X=>YN[WK*.O.A$I1C3K4M#N3"LM&-+K$8[5="5D<[6%JNE<
M2R4D24&G9'&@?!?*]P FX(4<7^0$(B<,.3'\2Z+<#,JOC'4*&5$:2C@>&T9[
MA.)Q(?2/8$:<8$95]60LM3,R! Q$1D=7VQJ86BK_ BJ"=)#,M01"]UB^CW&Q
MEVA'9XFV=Y,H.P-R/)%C08X?<H*1$X&<.,I,XU,E>G%UM"O!4BUIM1[<-1*-
MYX,M]/+SX$MK5EZ=5-67\MLBKX'!MEQ;A>@9(,6H\AYP#:Y'@G /.PES=Y)0
M5U<)=?:0$">CA#B:)=C11P(= T"8!#A&B[]CLO@Y9HFO8S7Q<:PMW@[-Q.+0
M5;P<AHG9?K:8[3983X3V9(;PE.?659(]D=_2J,X](<R&IE0$:2 !Q' M H2"
M8*.=!!H=)<#@(@$>;N+O9@ F\7.SB*^;G_BX!8NW&Y9Q2P#IXD4P;'8K%D^W
M)F)RZRQ&MR%B<)TI'JYKQ=WEB+@[ORWN3C^(NZ,F79'?%!FU%#U1:U^\;+1-
MY5XB02@(0I\ 3SOQ,SF*K\E%?(QNXFWT$&^#42P&LW@9?,1L" 3AXFF(%Y.Q
M@AB-E<5@+!8/8V-Q,W825^,@<39.%R?C:G$T'!0'PQVQ-WPC]AZ:]<^1C9!3
MB-Q<"SP#)(!HB\J[4'\0 'S-\'ZSDUC,+N+EZ29F3W<QFPQB,IG$Y&D1HZ>_
M&,RA($;<S2GB9JXDKN8:XFQN*$[F]N)@+A,[,\&@&<[K20QG(M@Q$;&8F#.0
MWP!Y!80YE?0<4!R(Y',(".0[/^#CY2 6+V?Q\G(5L]E=3&8/,7IYB,'+*!X6
M+W&W^(J;)4A<+9'B[)TH3MY9XN"=+_;>:L,^0:HW(X W,Y&%V,F"#EYO@N^!
M)JTHORXR\]0Z(&AS,HA1^1\0Q'5_X.-M)]X61_&RN(C9XB8F8 0>WN[BYF,4
M%U]/<?;S%D>_ ''P"Q=[/V(V_W0 6?!7!T<R^ODS _E-! 3 ONC@^R\*_A&]
M-.N^M%K(K4+HFZ[G@*+T_$\@\$,7;Q]LX.TL9F\7\01&'Q?Q\'45-S\W<0XP
MB$.02>R":+ @/UO"0BV8"(8\!D-*@R$,(?"\X)Z 8#68(#6( #B0:"G@9W1C
M[N1GA<C-4?NO@F@'$!'X>_['UP\;^#J)EZ^C> *CGZ-X^#N)6Z"S. >YBGT(
M@T@8CAU!HT9XVWX< 9^(3-)S,34!1"FB&R".#5\,B!;"T"&42%(]PSO0MAXI
M.\2V!RL&A/$Y"%W\T</'WUXLP!Q@)\9 ._$(LA?7$ =Q"G44^W &TD@&F&@Z
M>"S.'8<MXE1"+\RVD2>>6#Z>62<.KAG7"3 JQQ*EQ.SE-T2.4433D9K44>N1
M^$F&O@XH"H2B1R!Z^*$';B9FWANYYL&]KMSG2#7MHIE08AGDX]$CD<$TQ6 ;
M6-*\;095BVK2(-!I^$0:,W"J.E1@,/=!5I(A0$GW?LO#%$70)_6]8'$@@L\A
MZ!& /!]@YKT)N1Y\YT*Q#E!8)@E^#U*8Z-(<;!-+%FU242WNPQ:5:,1*X;9#
M;BI!HBNIC0U$(Q4AI]E$:ID0L0RBR/1?K.MAJNMK@9)C;/O 5 XH&#W\@!?O
M35QS1ZXS5,V>)F:2Y'?6B=0VJ:K)M;*::-$CW]VVT;*&VG2I-A[&V@[\50>M
MJLT%^?AE'OVS&I%3%2+HRC]A +@_9:>#1+4/BY^$(S, ?2RQMOR/.W*=E-QT
M?1+_+0<#H(_6O 1N)\6T36WT*$&/!B;; 5CUPVV;KM3#CTKJ,PA 9.NHAXXR
M1A2?IC,\L>X)JJ2OPXE/M.T%"];7 )F0ZXY<QRR]KE7T@*9 _G,]2CWYP]H0
M.UL0H,XI:4L_::O.BXVU/9"\%3]HR5C5G(BI&62YB3JG]I'U?-JL=%L:3ZW#
M"4.N7P6U!PSYU->ABAY,U=1E_C'_TD1L:U%4\/7?^V1ZHD=?@^V ^+XX5%\*
M[TT%>O*C'HQ5W?")SA#8CN]8G]&303U3:+(HM0]+K<&I;-M_95]3;'F?\OQ+
M^9H0E7M1ZU#^.Q=2OBY$K0FQYD'08S(^.IF^.I'&'4_A8ZG$&-IC)-';<*+Y
M(9=$!OXH&=0WCO8-H7TMV-D#%[:OIP>V+729G71YO759_WTV2?ES@]4?9O_C
M#%/T6(5OK,0_E]'@2Q"PD*AYP1""><:J.;3'S,\D&;^*4/N@J+.1=K5OILO]
M8QYDB"Y/R5(Y%Q4(JPWY:GU&^9J0\CR(^D-U^;D=BKP<<;&="W*(3G8 6^Q%
MR XJLXU"MM!'-]R6:/PJ0)U#TTP_ U@M\.ZOVW2L+G.6+J_\G-1U8EN;\<<\
MB")KY6M!%'E3>0E%8M49'6_15]Z@3>[@^#>I\%4$7:3P<RA]]J1U.O'BDDMW
MO<XJR)V@UU7E013Y7*O7K?QL$.OS@.7WM2#EYZ2J_3"*0)?G0-1"!K6QP9K8
MH$V^Q3^_HO$_IZ$_0]@G"'A?*?^?_]DY.#HYN[JY>QA-GEX6;Q\__X"@X)#0
M\(C(J)C8N(3$I.34M KIF5G9E7)R*U>MEI=?4*-F47&MVG5+ZC5H6-JH2=-F
MS5NV:MVV7?L.G3IWZ=J]1\_>??KV&U V<-"0H<-&C!PU>NRX\1,G39XR;?J,
MF;/GS'UA_HL+7EJT>,FRY2M6K5ZS=OV&C9NV;-VV8^>NW7OW[7_YX*'#KQP]
M=OSDJ=-GSYV_<.G5RU>N7;]QZ[7;=^Z]_L:;_WKK[7??>_^#CS[^Y,&GGSU\
M_/D77W[]S;????_#CS__\O39<^W_]K]_ZO__>?WM[%6-7525#=39K"KM2ZT#
M5;7#5+VCJ7B\JGF*JGH&=:^H*E]%U;XZU2]4]:^# >HK"S16)FB!#=HH(W14
M5NB&&7HI._17AAB,)88K4XS!%A.4,:8J:\S"'/.4/18J@RS%(BN52=8IFVS&
M*-N55?9@E@/*+D>484Y@F3/*-!>5;:YBG)O*.G>5>>YCGW>4@3[$0O]6)GJD
M;/051GJBK/23,M.OS[7^/89FJ'9WL 9@_^T,_\OG_\_M)79V]O8.#H[8P-G%
MQ=75#3MX& Q&3.%I-GMA#6\?[.'GCT4"@[ )1L$JF 6[8!AE&:MI;+;Y+^-8
M;8-IZC=078F>U*9=ATY=NO7HU:=_V:"APT>-'3]IRO19<UYX<>'BI<M7KEZ[
M?N-FNHOJ+0=>II+6.OY7%6UUM%92U9)J4D\J2DVI*G7]]P-J^]E#ZOOX<VK\
MY5=??4VEOWWRY#OJ_<.//_[TT\_4_>FS9[_^^OR?^FN;8YVU3>DF;4N5 &U_
M8;1VO%ZF=K9Y\?/S'=I\>Z'[P$_.]9O^YK&!RZ\?&+KC_,[A1TYN&77NR/IQ
MU_:OGGQWYXI9[VQ>NOC!W\4_.ORCPS\Z_*/#/SK\H\,_.ORCPY_688NNPU9T
M.% 8I9U A_/-BI]=:M_FF\O=!GU\J<^,-\Z4K;SVRN!=Y_8//79\]X@+![>/
MN;%SXX1[&]9,>WOYBA<^_+NPZK 9';95\==>1H=3]3*TB\V*?[[2KNU7-[H.
M^OAZ[YFO7^J_ZLKI@7M.'AY\[."^8>=W[AAY=</FL;>7KY]T_\75L][]N_A-
MAQWH< @=SM3+^/5RT^(?;K1M^\7MSH,_?*WGK-O7^JX^=V; [L-'!KVR:_^0
MLQMW#;^\8MNHFPLWC;\W:]VT^W\7VE9=AYWH<+@P4CM;+^.7:TV*GMQNT^;1
MOSH-?N^-[K.N7>^SZOC9_COW'AUX>//!P:=6[1UZ8='.$5?G;!US:^JF2??^
M+JPZ;$&'W57\M%=J1CZ_4)+^X\TF15^_T:K-IQ]T&/S&6]UF7KC1>\7!\_VV
M;3M>=F#-X8''EAP8?.:%/<,O3=\Q^NJ$K1-N_EUHV]!A*SKLJ>RG':L9\?12
M287O[C8N?/QNRS8?/V@WZ.;;W6:<O-5[V9Z+?3=O.#5@[[*C98=?/#3HQ,S]
M0\].VC/RXIA=XZ[\76C;8I0.1FU?95_M9,WP'Z^45/CJ?J.:#SYNWOJ=S]H.
MO/1NUVF';_=:O/5RW_6KSO;?\=*)LOVSCPXZ//70T./C#HPX/6+?V'-_%]KV
M&"=M&SJ\7-GG^9F:84]NE*0^?+>TX,.'35O??=2V[/3[72?OO=MSP?IK?58O
MN=A_\[PS93NGGQRT;\*Q(8=&'QGQRM!#8X[_76@[T&%[!:-V.-?[YPLU0K^X
M4S?YHX\;%+S]59-65[]HT__(AUTF;'NCY[R5M_HL77"E_]J9%\LV3SXW:/N8
MTT-W#S\Y8M^@XV->_KO0=J+#3G0XEFMY<J5&\"=OU4VX_UG]@IM/&K<\\U7K
MOGL^Z3QZW3L]IR^ZU_?%.;<&+)UZ?>"J<5>&K!MY:=C&(1=&;AEP;NSVOPMM
M-SKLJ^#Q]$RNYZ/7:OB_]5&MA.M?UJ]Q_N=&S0\]:=5C\\/.0Y=^V'/\O+?[
M3I_V9MG<"?<&+QA]>]BB8;=&+AUT8\R*?M?'K_J[T/9&.VJ'4]V^N5S)\.X[
M>=XW'M5*.OM#O8+#6FGC'3^VZK3RJ\Y]YW_6:^BT3_J/F?#!H(FCWALZ9=@[
M(Z</?FO,K 'WQ\_I^\;D>7\7VOYHQU].ISA_?*^"R\T'5?W./BE./JC5S=NF
M-:R_YM>6K1;\T+GS]&]Z]Y[P1=F 48^&#A[VV8AA@SX=/6+ O\>-ZOO)Q#&]
M/YXZ]N]".Q3E\/A:E/UK'\>[G/NF2N#!YS63MFBU*J_4&A0OU%J43G_>I<7X
M7_JT&_'CP$Y#OA_6M>S)R.[]OQW;L\\W$WKU^GIRGQY?3>O[=_'#N6"[>^][
MV9W[*L[CT+,J05NU_/CE6E'6/*U>WC2M>?%8K7.]85J?TH':P";]M&'-^CP?
MU:+7KV-;]G@VH56W9Y/;='TZO>W?Q;U;[G+A"XO]H:=QQFU:I<#E6M7HN5J-
ME(E:2?9(K6F505K'ZOVTWH6]M++B[MK0VEVU$76Z:&/J=M;&EW34)I5TT*;6
M^[O0UD8Y::M3#=J:7%]M6XTP;7_=9.UPTVK:*^U+GQ[NT?7+@V4C/MHU;-;]
M36.6WUPY8<OEEZ;N/S=OYM%3,^>>/C9EP<4C$Y9>.SANW:T]HS;=_JOX1X=_
M=/A'AW]T^$>'?W3X4SJL18<=!6':R^APM$DU[7B[TE^.=>_VQ2O]1WZX;\B<
MU[>-6G5][;@=%Y=..G1ZP;13Q^;.NGAXQOSK!Z8LN;-WTKHWMH[?</>OPJK#
M&G18E^.C[42'@^AP'!U.MFWTRZENW3X_T6_4!X<&S[N[>\2:JYM&[SZW:OS1
M$TLFGS_RXHRK!^;,O;-GQN+[6Z:L?FO]Y/6O_U5HZW0=UJ/#KH)0[7"=9.UD
MXVK:F3:-?CG;M?OG9_N,?N_HP/EW]@];?WG;R'UGUH\Y<73EA%</+IEZ:]^B
M>:_O7+#TK76S5KVS8N:Z-_\J?M-A SKL1H<C=9*TT^APKDVCGR]TZ?[X8N\Q
M[YT:\.+MPT,V7MHS_.536T>=>67CA"L'UT^_M6O5O-<W+EGTUHH%J]Y9_,+:
M^W\55AW6HL-&=-B##J^@P]E&U9Y?;-WHQ\N=>CR^VG/LN^?[+[AU8M#FBP>'
M'CJY;]29P[LF7-ZS==JMS>MGO[YJU8*W%B]?]<[\16OO_U5HZW4=-J'#ONHA
MVC%T.-^HZM/+K1I]?ZUCCX>W>HQ]YTK?A3?/EVTY>VSPH<,'AI_9M6O,Y4W;
M)MQ<M6G:O47KYMV?MW;YV[-7K;W_5V'581TZ;*GDK>U'A^-U$I]?*JWZT[66
MC;Y]K4./3^]U&_?6K=XO7;[8?\NQXP,/[GYYR.F-NX>_NF+;Z!L+-T^X,WO#
M]#>GKEOPKZD;5KWY5_&;#EO1X65T.%D[\=GEAE6_O]FB],O7V_?XY*TNX^[>
MZ;7P[*5^FUZ&<V\Y-/B$RH&\I.= IFR:=&_<ACEOC-FX^/6_"FU#I$V';94L
MVL'JP=KIV@D_7VM8Y=N[S4L?O=.VQP<?=!YW'=Y]_'+?#;M.#=B[[LC 5Q8?
M&')FWI[A%Z?M&'UU/&TR<LN,V\,VS[_S5V'587V*A[8#'0[G!_]ZKG;"]S<:
M5O[R7\T:/OBX=??['W4:<_'U'O,/7NVS=O/9_CN7'RL[^.*AP<=G[A]V1N5
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M"#EG#6'GK("I9@EL=7/@(T5I_&EMG5-1E;>F*F3#7U.28-OL*-BS.!0.K0B
MD^L\07V+*QCL< #+W3;@O-<*L/LMP.>@.?@=,H5 )/)A$Z >-@;ZD?,0?M0(
M6$CL/PX$*R=!%/(9%7EP'HB1:U:RZEK(T-L)F1;'0>ZL RF>5A^E1/>7L;2
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M29"W6.%MZSS4Y9LS4<VO5D\I^[I_818<7R,%E1U1H'&("?JGJ&"I1@07;1_
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M!(/W3*K5&SK+Y66PT/-I@-1OU#>-_, SEW;/O90Q[%;/ONER(?**XS5>E^,
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M(@K%&D:AJ#!5@0#S%#&P6,D.5DPV@PW3#&#'#"W8/^L<*,\Y V?FG@#U><=
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M!Z9CED_-GIF/F8^:OS<;L?AB/%Z _FG8.AG0NZ:"S[X9$'!D+@2I+(9@G15
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M DX;B."D\N\]"(8:/WCK"(&/F2CX."P!%DT*F/XKP2MV-="SY,"C3 &HC1O
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M[?(=M._P&2>W^YQQV,*^[["%,VVSQ1_,MO# L"T0]##M7P%=$N\#;NZ?[9V
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MXY-W4&*21]VBDB?=(I,?N,:DSI#CTL$Z(0/,$C/!^%?@)X(@FHA>X.:[741
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MFF3Z8D#4^,5Z,:.7!\E-,</GK\0,GWX7,_P#17^T?CG ,KH/>^D,MNRC_.,
MN92?^ M &/7PP#<"X/M! CP_*H';1QW&^:,IR^&3+<OVDPO;ZK,7Q^+S5*[I
MEPBN\9<$'H.O6;QZ7TOY=+XV\FM]F\NO^6V9@,;W30+JWX\*JN%M0;5OKP54
MOW[]+\OI/IQ/9[!USW_R$ZX!A-P"\'X$X(9\X(RBX(!R8(-J8(EZC"F:,D9H
MP])')Y8.NK.TT(^MCM/8JAC+5L)TC@(6<^2PGBN#<[C2.,@CA1MY)/$@^9E'
M A__E_Z- &V[Z?P=^RL__CI T&T ]P< D]\!Y7+  H7!!"7  .5!E]:AA3J,
M&AHQRFC.** M(X?.C#1ZLB0Q@"6&X2Q13&2)8"Y+"*O9@MC!%L!%9(3-C]O9
M?'CXO\RB>Z#Z".6?I_Q? :;>!7!]"&#]%, , 0R)#O*"!HJ *HJ#(LJ"+"J!
M%*U%'+5!% T9$31CA-&&$4 GA@\]&2Y.91B,8@#322EI9 '.)4O(\']!8Q,6
M6E#_MS%BH:TIO5JST=*9@V9^/&@2R8N&Z7RH7\J/>@T"J-LIB+K]9) ,"Z'.
M>K*-["%'R7DAU+U)O_>8O"%?" J@W@2Z_PM3RK;69Z$=<3!FH;TE&VTG<]#:
MAP<MPGG1+(4?38H$T*A6$(UF":'A/+)$& U7DE&RF>P21H-#]'J&7"</R2OR
MF:#0=R,4^O8W0Q3\$9H;,&A'_7_\&<#X=V.<3-GH:,_!R9X\:#>-#VT2^=$J
M3Q MI@NA>8LPFLVET2\D0Y/0;&02FFX@V\D^430]0:Z0>Z)H]D+TN]FG25_,
M<-(G\M$,13[\V_L?H)4N@Y.U&'319*&;SE_?2W&WX:"K&P^Z3.5#QU@!=,@2
M0KMR8;1MG$2?QD719KX86@^0E>)H/4JV2*#5;G*$_"3QU>J.Q"?K9Q+OK3](
MO+%&B5?6*/YRG V*O?B+Z$1H-YZOQJ"'*H->ZBSTT6.AKR4'?9RYZ.G'A^Z1
M NB:)HPN19/0:888.K:*HV.WY/?)"Z6^35XF]=5AM?1GAPTRGQS&9#XZ')!Y
M[W!:]JW#;[(O'9[(/G-X+_O$ 64>34:9AY-1^H$C2MUW1,D?H:,Z@^[*#/I0
M_PZ@UR!M%@;3?@0Y<#'0DP_]I@FB=Z((>N:*??&HE/CHWBCUWFVVS%O7>;)O
MIBR1>S5EA<(+E[4*SUVV*#YSWJ/TA_-QY<?.5Y7O.S]2N>OR5OF6RW>E&U-0
MX5=7E+_FBK*_N*+,C]!%A4%OZKF!LLR?WP$(UV!A).U'!.U'F"LOA@0(?@J*
M%GD7D"'^RK]8^KGO#-D_O%L4'GO-47KHV:]RWV.IZN_NP^IWW#=HW';;H7G3
M[;#6;VX7M/_E=E_[LOL;S0L>W]7/>:+J62]4/NV%BJ>\4>%'Z$ZY_M*43_T_
MDM811VM*H/,9;\[^%N?(\S[:1^!E1-BD)V')$@]"\F3O!E4HW@IL4/G-?Y;Z
M-;\>S:N^B[0O^PSI7O19H_>3]Q;]<]Y[#<YXGS(\Z7W+\)CW"X/#OE]U#_JA
MU@%_5-\?@*K[ E"%*$^$7I0[E7ION!A@O!1@,NU)FB;S/<V(]3;5EOLLR8W_
M04*PR.W8.,GKD9GR5\*+E2^$5JN?#6G2/ATT6_?$U'GZQP(7&QX)7&%\*&"=
MR0'_,=-]_H?-]OA?-M_I_]AL+/"CT;8@U-\:C#I;0U!S2PBJ_PA]J?M/H_SQ
MSI=,W3]3AGJ7"O,^1Y=YFF/.OI?EQ/M;NK_PY>1(R7,)*0HG8_-4CT:7:QZ*
MK-7=']YBL">LRWC7M#[3L9"EYMM"ABVV!&^RVA2\UWI#T!F;=4&_VZP->6NQ
M)A2-1\+18"0"=8G6CS!  C"<^EX"=>\,ZK^Y$O"E4 Y>%*DS]XH,6;\6VG,O
MYGH+G<H,E3R2EJ"P/SE3;7="D?987)7^UI@&HTW1[:8;(KLM1B,66JT)'[)9
M'3YJNRILS'Y%V#&'H; ;#H/A+VT&([^;#T:C\=(8-%@:B[H_PB":013UO122
M0^LH%(5WI1+PJ%P>;E1H,1?+K3DGB]V%#N4'2>[)B5$8RTA5VYR6I[,^N<Q@
M;6*-R>J$)O.5<;,ME\?.LQF,&; ;B!YV6!2UV7%!U &G_JC+3O.CGSK,C_MB
MU1>/9GT):-27B/H_PA#:@UCJ>^G\@/D"\+Y4"%Y4BL"=:G&X4J,*IZLM.(<J
MI@CN+@V0V%88J; A-TEM37:6SG!&D<'RM$J3P=1ZBR7);=8+D^;:]B4L=)@7
MO]RQ.WZ]\YRX/2Z=<>>FS(Y_Y-R9],FV,QDMNE+1E!AVI?T3AHWO _7N+!YX
M6\P#=RMYX-<:?KA6)P3G&I3@:)TI>T^-L\"V2C_Q]65A\B-%\6HK\M.U!W/S
M#19GEYDLR)QA,3^CR;HG;;;=G-3YDV>G##JU)Z]U:4W:X=J<=,JU*?G>E.;4
M#PXMZ6C5FH%FK9EHW)J%1A-A!.U!$@>^Y[+A7AD#OU9SX7(]'UR8*0 GFN5A
M?Y,1>ZQA,O_&&=[B(U4A<LO+8U0'2E*T%Q;F&,S/+S;ISJNRZ,IIL.[(:K=O
MR^R9W)RQQ+DQ??64^O1M;K7IQ]QKTN^XU6:^FUR7C3;U.6C1D(LF/\(H03H+
M#+PM +A5"7"EC@/G9_+ Z58^.-PF"[M:#5B;F^WYUC9XBJVH#9(=F!ZELJ B
M2:NW+%-_3DF!24=1A45;0:UU<WZ+?6/N',>ZG(4N-=FK7*NR-[M79!]V+\^^
MX5Z9^\:I*A]MIQ>@974AFM;\ &.H=Z<#/*3N?;V:^DXC&TZU<N'H+![8.UL*
MMG7HLM:UV_*N:G877=H8*+N@+D*YMR9!LZLJ77]619YQ2UFI>6-IC75=<9-=
M35&G8U5AOTMYP7+7DOR-[D7Y!ST*\Z]Y%!>^<BXI1KNR$K0J+T6S'V'<^%D
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M<MEJ'Z=S5#ZV<Y0_+>(J?AKE*GP^R)7_?),K_^DU5_[#-Z[<>_R'I>/WP$:
MF91?1OD99P"B+P,$7 =PO05@>Q_ Z@LO4&4$8Y0& U0!/>K\6F@$&F@)JNC
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MKPH9,%P1,FPT%+S99#!XO^E \$73Q<%/3!9-^ZR_* RU%X:C!E%;&($J$V$
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M0WNPD>K@"LI?,$![0-=>3W6LE'IPYA: 6.JB0;L9\-DK#-Y[Y<!SGPYX[+,
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M7YX#H1=/0>C95Q#Z _^AG_+;1_]Z!I6WE_*/4CYE>U"V'66;_ *@=0- Z0Z
M[%,62'\0!,D/8B#V409$/RJ#R"<M$/YD!(*?K8#_BS/P?O$%SM<(8']+!];W
M"H!O'81NLJ^TN5\ODF?D*_GV/SHH?\;X,[!] (ET[2'G -PO =A0MB%EJU.V
MW'T B2< HI\!1) 'A%$(!% 4>%$2."@/#*H"H XQ)?;$ _[\@(CTACS^'R3Z
M\]D#K0-IT'B"W/^'.LHOI/PD^JUI%P#<?@:PIFS]NP J#X#F3-FT="'*YT<
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MW;O]T+E[ MIW;Y$OH?WBG]!Y0?H_#%"_E_H=!X$Z6O,B6N+42]2GK@]UG6X
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M9;W0/V6;L'7* 6'SE-/"QJG7A0U3WQ363;LOK)TNB6O(:M*C05#S<":'O3G
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M*ST+'RH\"Z1AO/(EN9IKC,%I6H"#U-^Q@.U 2])-VNO8#UB6O$KZ3L8EMLP
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MB.4N;\C*7'\42UVE84I&<9'$>ZSS'>I?I?\^PRG_2*AZ_P?7=_RLC[%9Y6*
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M$U A@U>Y"AX5%G"OF 2WBAF85SD7KI7N<*GTAW-5.)RJ$C"W*@NSJTK@6-4
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M5VA&]&;UQQQ07\P9]<;>K:EQ3X.W-"7^/YH<;_H1<?17I%]/Y%OF8"Z5DNJ
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M\BCD39#JC9#FC1#%#9])ZTUF[(?^;=MLV0NTT-@+M(NVL(<^::^4OT]* N'
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MGI!]Y]VRZWR&Z]_ET/&-'-M-9MS4:SF7=]=<J# 49#E4?1CT#]$FY] >^*P
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M,>@8%'D3O'X$2C2_U[(79U(W;1+;RK$E!^J8A"V1=5)@M;U\JUSE7>4EK^I
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M &XXIC\1K'\@>-[ D:_!9G_++XTS.(S]+[^RZC;F(/[G_\>&[V2G_\#O_JT
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M\PZ,JPILJ!+<[A48)_-VOP+L^AD:YPDJ\!#*W0?G9O9_,)FY"Y0Y!W*@<1V
MO0;"K,4HD'KPNZ_@$1_![=Z3CBC?$V7W!C_MBW('DD?0XP'TN _&=0>#12GW
M5H,4<->I,,5<2%T&6>MAHEV-WT1Y"BY?A]R YOJU!K&1TH'9!_$!MJ@BLI"G
MC-_2@:QVY"ZQ)27@N==(-W(93.8"]#C'O1-T",H>"@DCT$QQ<(-Q*#\%;C$=
MM5^ 9EP%]]D,+0K0M-=)/BS'G$'9VFP/QHIF.C!K ,QGCQ\19EE+DEP%K[H
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M&4 <1".('0(O&[%T8BVVD%B);2"6XH>(A?A-8B'QGEA(-G#S%DQI66:$++2
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M!7LA<.'E(;#%8$SN(;*_]J0,8O:DP!:#T'D&H3T&]>1]\&@@"@T"N0\"L1L
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M:</V?OS3-]5OGO&__T2RYP>PUNT(X=?B"AM O:BEWRT20KT,]F<!J)>'TU@
M9W[ 7A:@+3_@G@@-$*8,9<8J@F+6;"TIOQW' E#'5;)8 .IUTAD)&K"#'_">
M-4BMIJHQ@@;0!&,##:#?-SVEETD&4X"&1>+\ #I@;*@,XP?0 6-#PT5O?@0+
MT' )3$E6P\C&W2]\W-S- L](E;V@1\?6] ^DRIM7SI\J/%*P;_>.K5OHS0?E
MZ0'NUH::BE(_1WS^%WM)+)\F_'LL6;L7"!G/+X+E]*0[/\"/!6C##YC'EL'_
MDN0D&\!?C6I-%H!:':![!2$;^0$Q+ "U&KR(!:"X?0$+0''[!_HT(( ?T$#/
M[<2= DR@ 724LYU:?R!J%."%%UT$!:#WS+ !I?1Z\7<:L;D#/^ 6#6A8^7/
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MTGZ1THQ@2-F'SV7=KICCWOA4U+CWV%6GV"S@7!3S%E79K-O0:9NO"-I 5;G
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MMT]?.-EJXI=5>U^'^FZ,FXV.&7<HL?# \F]W%)W]'68L*55ZE6&G=O29A4Z
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M>V43)M?K&;!2.#-]"*NK[]P5%CS<5"[Q4O HGM"YGOHR@#V.,\Y8ZI_4(&+
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M*SI_\NAU6[I&QD[V8-(W/<-/ 37BI6MWU>..\=YH[?DEKSYK AW.DFOLJ:=
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MD??RMQ,.[_[PFD!EF'7YI"M:OR[OI3\ AU'%@[9UVI*:UO-,!IM\!V9.:FY
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MSB:XORP^ %^*C '_#=JFT*M=8DV"JW)D;&+S!1I 9PX,P-:-H4H37JVM"Q.
M1(D,-J8JS)(.#EBNI:96DEZ1<TMU'4[D5B_*2^:S2<XHR%5UK@TF9[X:VJ.S
MLC<IL/36\O.T%8[ 5S(M:=[P;^1LDWD&0^3D?Z#)U^3EW.+0,TU/8$MPW)=7
M\Q[29I.$G$ES\@=#K%.TJJIW>^3^T$'0HU2[,C8Z,H7SA^F_?OJU5L"6,VP,
M *SQF']G-U]8: D42;P+]2<," 9P%GW*RL/0Z\(#FU)7_'&?2DFH- 6AU ;;
M71BZ,YI;SN'&-2\3]&*O6KKJ+U7PC#GX;!4L3>^3%%1G_<X\=L%I92:G/]UW
M.6=6ITKUC9 'H?&F+4S0>'"Z*L.B;9DM7;UH=\S'0N7!K0UHE[$/YU7JSY=N
M3WRRXFI-9#[5EGJHP=!29=7F7\[,Q65D=TSGGHU2L7]H*Z["O\;1]FLRYWY^
MTOX2CPE)X[?00VWW-"IY!8BNG*DFB(OHS?.DP!/.G$^J@C$!P[D,HLGV&P[F
MM.'3:[;TK".@]<SOF;HO#D"11\F*_B_&#9R@]9/0RC!WN\B98O(K\-[)Z+SW
M^&325$%U+\G-.5(*TTD^!G;IC%<K5,VG"QM/VGLPGF<SQ! &L+P,]E>OE*N>
MX65)V9CJE)%2I J6YHVXY5E2 :M\-@NOF0$?@4;M-.<^"5"B$[\;U/4WPZ*5
M"_9TDP9N#?$)#EKMQVD;:VTX@^YPBP]W O!RCST:\NK@OH^H$[9%S_>PB3\V
MM2#D1_IV^M_/$B 57+$.].O]<AV99%[-YR*"^'&=. '(K*8^D=(GPUWK3"C[
M][WBT[WN'>H?2G0K^@T9#H_68,#[(HU@@W40*FZ@N+H;EGEK%(5LT U1-QW7
MYAN+^@P-[&)C(@FN>UZ]/./=_&RM$%]PK^>V^JM+#P;.U=S$GY9-:<Z^W0?U
MT[X&RBE_F08XFK>%:3/M50O=4[#OI[5T R>@J@GZ4$;[Q)V8-^R_DF-=5+G>
MZ5W1*MX=;IOUMCK.!BY;%Q3JLQ:B=6\_U1Q12#W2?ERZS'?#-[S%?:W<FL6;
M[L82+]6(?M0 ]^%>B3"C4^D[KB&G7;1H"BQ6.VP$:;:84&SLR>+N,*RIY,;+
M\["]_<M&-<RH,%YK;*K:1J6]T9$N5E#WI>"B91-GYM."FH$[&R6JHN^^5DQL
MGA=5CR$G(7S_!B(O*TO*2TC/0!+ G7)-IZ?]SEO:W,GY_DP?78=XV"X%^Q2Q
MA'U'^7&5@2M*UQJZZ=4C)^062C7QW(W/U3=AP6Y74+6E=-W9SI3\KA<]X&8"
M>G8S!24,?D7'-:]];JK0OC^D_NXK8[\1%&O(;=)T?><44#MZ3>\' ! <C)2D
M&4@G7VY$^GM+GB?J2#_(O[E WU:GXL^#MMJHNBOL02]-Q,C QV[DL%KRC*,9
MN%K:55@R[M7#(NSHXII545&\K7>5N8:-@>\):3"9"O/8#:_R]DM:X#-/80T.
M*X\H'H/#UIN%_WK&!ZYB--="WM3@*CSOBH[B-1V0R@1TV8KO49J?D2[5:%OH
M)["25=VPG)N0FV"\IK:!#>_$+[0JK^C& ]^9VX:?*D7DS54FM@M#CXIT0-.J
MI9K::BUMR@G+PY::5B6SV7F$LI $+ 7RFA'ACF3BHFV#75AEQN:@_13M2"9S
MI27>5_X*]^P4/4BXO1]+K^&.7#$+E#;%!X)%VE>.Q2Z/'Z0X1*94<'E\&K>S
M%>S>>I62:!5F.)B7+A>U7@6*/^L\,UI>4&*!KN]YB<N:(QI;QVX_E508J-72
MUIL2/$ +>1'B 354ZKA:%-A,,32]]JL89.O2D'NCF6#"$/(BSRBBJ5R@-EE;
MJ]*.,X<P]RK4NXY*F)]5;6P&Q<E8.'IU8^3EH_%*PO<  G4?8H@J,'C[:T-S
MZ.BY*B6 >&>08+>VFE2=Z%(VB"/2]M<)XL[$']-P:H7TVMQCD6H[<"ORGG'T
M&;[*@2G)??4,1.^U!ARHWK6TS>\=*Y1V(MH>)B<75BOU?HT.^>G=@SX%W)E+
MA7N'/69I#;7.@ZVT?RB?KM4(7?"&KI,1:K-]>,WG'RPE]6!"X-,Z$O^W6Q@O
M[ZBTPA["/8$2+OQE_)?IA_]L GNTYNCD,]K<TY8Y;^6M/$UK%FI(4+8$N+^N
MFQV))*)L@)F0 LCI47P3GE2NH^+A?B\.^:^" 9#76W.:H$<\J=MU,WZP$34&
MCS*'_NB)LM<_:B?JGPD,%F6S\XM1UF'?U=;#\[BB*P7CQEBJ]$>H/X,J3+Q$
M0+C)_#_Y&K)'*@IR-,:%0!+=9^MA9K.2D?'*N<H3ICL?*M:Y9_D_-<P(IB"U
MTC?+M1-YAI;B9T$F+%!.5<M$-1EY=V9D5;VV0][,.-JJ<S>9JYK5PU.:,LZ<
M4NHU/3XC_1U;G;QYRII*TB< O.+&:H6/[6ALS3:KT,+Y8?, FI'5FK<K4248
M]"^?)$@WMFOS1$>.^#TM'M+X/#H6W-$#29JG4V]2WE,C^U OPWLNK?.HEO]X
M!AMYTLKM7H#R;<RJ'#5;*Z'ER!D1:AZ8L9AI0_$P_1'55^_C43R-4>;F+]C#
M<)EI+@\Y(XHXD.@5KPL',BY#,.*%'I]]L/PE_ S3#:> /,&^_KZ:H%GG_U4>
MPIN4ZH16/RV6CJDCQ<+.)D^?C)09!T!*C\L P"'#QYLAOZ<@3#U*'A\FW$V"
M@_:HA7 Y+)X"*.!KKB>I_5J,%#YG-AI-*B7MM?342B959ARW[##!JCK8"4>F
M$J%*]FMZ13>Y4FL-M>Q/=GN@>%P 0)&*XZ%5-"BJJ$I[%E6#"*NEL+FNKN==
M8U-6O$^=\:Q-(=$=W#O]9"%VRT7TV."60+UH_B""@QYF4QB:)&_V&H";I7C5
MOVR\0OA66WO&&<996]ATVF24H>0<TP&WT?D^"S4//_Q3 Z1[P/$!=9C)X@L/
M(^29C,%9@;@M2#ZIR9EU:<^86=$X6R/X&VX8F$\>=JID!U@'MG#J*;# ,4U<
MYOU=O'9*Z?&%U1VF17GE\XX.=VR$T -Y)/4:*K>Z+WVXGP5/QJBX?B-(G#^=
M^OD17HY3@O^NH<!?T<4A_=,'4A( G;(8Q7<!T7Q-A(5+<_QVO%)89:H[. 8>
M3GZEIV?2F"B&GB@:@/]$@MVN5YR&*Q&48V!*73(G]7VV^?W[\"< ,F99:7[*
M+,)XM=M\XKI7:X>>?3>S7SL:<W?"5\3GN"7CE_0I<"(\4]F;-&LQ4^H]B8R*
M<UO(^*R0^ _\8/H@B&M3EW2G^&'\\&8_S?R)V6Z@L!=%M&W%K$3$>9H3]@^H
M@4+;R#B6>NJS&?AG8^M"W:#5]&W%[!^V27-/_8$QH&[,C6KV4EG4;9UZSGSK
M^O:&KP8P^!"Y8Y:'F[!(1Q8C@F,G0J<^R-2EKW$V.KR#QB<2?'[\@_(P55_]
M?2,'Q3A\ZS>RP;BWPF(B'A+>)[WP/I#(7??AGJ+H_21[J0CP[K?V0I07T\NV
M<ZJ/VBL,6P#_H1%XN&["%2$]\.U.0\XT719=L.T=NS,T*?#&$?:/+L\A9G@X
M56>O\Q;N]&#-P&U=0M)(";:D1QJN;&WZ M&<-<GET?KIYO49Q''(H%XBM@&
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MZNIR%4-IVRY8'W:;BQ;C EC'',\I&3ZA.60$J?[?=VNSG'090^'^(?^7I !
M^@-76 QXLR<G1 3ICZ6;%JKB'#W#2555+L67!19,YC$_BF9RB,'?@Q<3BP0_
M\K&FRN=1SU+K!WNE>^93BX3TLI>56,Y-ZIFM;JFI&N;.%2\<T!L#_S2"&@Z=
MH4E>Q]].<"55ZNF>'#"][9?YM'\-W_\"82CYI>7A02GDS0SD)HCP)D" V*\]
M!M[#?R1O-E]=?%.'-R8E7/2GEP[DY)ODYUC+/[F3OT)A_<&,)!^Y[61"[JF.
M/[WD?P!X,XF< $1$RE]>XI.F4(K\Z<P)&#[&&@;C<[O47F?S^%[J\+;@9V,T
M/;FSV#TF5$A!':G,3D),6,0_PA#13<KIL=D;2Y08.,>0$RNKU;&A?];>_PR8
MO_# !/SRW?]\/Y9G:VJPX:@U]/F]%M"R)6@Q=0'6H!@G[342I T145OB)B\5
MLH_96I \$SXO(Q:A5AP!F6;?G10RDQ3\*L04O(^OT&6Q_-#&+(Z>YO2_P_ ?
M(.*/X%'_# QJGWL50%:6U<[0Q&MVBI[%5)6/<N$IV$,7D,2B:T'V?71N#>7!
M'.NC!"S?[MXV$Y]=]7O(M586]N:X59(>%JJ?=5&[I#/7#ZV2L\;&[NV%?[W#
MOP>P?Q:2C9Q#INGI3M'5,J3DI+"DL+\FGY"2/E4EAWT[LK[)AI_#^1=V5?M?
M@!<^O%8S-2;&?R % X0AC>'@I/M;3*S_'_Z_!>B/2P!$&%@ S#/ (^ "5DY1
MZJM&*"Q;4\2S"$56C_2.,A,3\41PV@OV^G9TC,5&)S99-7C]5[6!!0&(KRYH
M.T<& U%&1;<C2<I?8D%3'3ALNST5I&'JC#AENS9XJ=:<"8'9+=B/ +2W&L*\
MJ\:T(AH+FI(L[!Q !\H!!*\;U4/B&/*MDWH*LVIS[!$MQIKJWKR>!_: -Q=;
M6B:H?72+KS&1W1["_>& WM5*"&^EJ#1Z&A0KV!](NC;S9EQOG,H4&V,UT@@;
M"DFZI)(WS36WBAUUUP_'Z"9>!;=WE=SM6#+70P7%F,Z26E$OCYRF1"0"5:_5
M:E2><F*#YFMS!J\!BPD$1RVM=@,D(9RU2CIT\[F3GRQM#R_=2;2!R9FZ8"]P
MAIRB0SX,.K G)#E^F3+40]S+JB$<!CU?E#E?RC*;CXXT%,G8'@C3"J8<D+W&
M]U0H2:%0Z(PS:24)OL"[*\.Q!,W*.YLSR]U':B-)*P/S*:6T\BG.R?FL)+N*
MF9*C..6!W<]S")79E*29*'Y:RY_;U5I7,JEUHX+#KP81)O<SMU[(9P^<@GWP
MK6]D8R=*>M]='<W6'PRY&2S*G8G;3"PY]K@YEDAO*^<\ @2RAK%[J@9!'W"Z
M"K5D:1\!4%E_#ELJR2&11 H_'<.RGX;'@G%G'Q1C7(:_1X SM)1TWG I#8_3
M;;EG&,MS%@8'YA)7L-JP,\'F0HJM-EA QMO1QGF.P"]R([F.B0XC&V8UO 6$
ML5T.M39HI!/*[#;<TUT&AZ![T233!^%@UH\5IL$*DWT0-N?E&ZH^0<7\5/-,
M=!+"YFO90:L?@8^ YV%U>$=R-OA/7M-SOQ[K6<XB-;WF:'/#1N:?+]8Y?ZYY
M&K1C7ANZR6JS=:AAB]*OL^!UD6RH?S!3H)->UUBDAVMZ9F*']T 4@*;^*HL*
M^U0C5_7:S,_,2VY"ZJ$XT;@P,5_@$0#880QB<0HUPR?A,L/WCA*X?BI@?P3@
M^4Z+7".8J6$G>'Y%0ED5,O[.>EK&?YLOYRN')L/!Q1 <(Y;HMR:AP&]S8J+5
M3*RG?F3P0-A=<LNTHG._TS(ES$;6D;K/*KM&G="3G?O3-*GH[85Z.51#38%S
MCU;(JRC?"J-R.YD"]VR(A?L10.D_\@C8BCR@.">MI7H9F>@_C-V:5SA$X]F
M5D<3>$QQ6)ST$W5&.WWG3+876=A/>ELZF[5_^T7>1*6K+OMI&=,6Y=R=ABK8
MHAAQ8DC5:GK[4_(OX97_E$KIL#$B(+\;>!B\,-KQ))(U__;&\Y@-JSUBX=[]
MD]S8,S_4M:3E@DJ:^_G[?6MZ=J;7:D-J;Z>D^)#@=9]1)O[Z@6.2)B.CHPRI
MET>2I4Q>I,6TPA[2X$61X)9%-J=GM<T;[26029<;G<?*4YMH&53-6U2S-VZ>
MK*WL]'#2I!L>?&:$=4@E+1L8!8;7]< +/M:#)+Z0?P0$WB@0\[ /MN[\1$\U
MF!:$H8TB&&A#?KW==;*1%"7<Z:4EUXQ5D59R@U,9'!F^P5M X#KQ=DX"\1+]
MYYNV&F%V7Z'G6"EC)G,DM?[?M>I9FOV9D@9COZO%#M%YO@ "B5:I%[A2TN@]
M+B6,=$@@0EEP$4.;@Z/KCDTW#"&2V\(ILMLR-W2R,SFE ]Y9?(;E]?F8_:HA
MR6&_^$\SO6K::EM)]S9?_ &G:\-Y8V'@&MT',_FC AVUQ7H0HV-:^6D\E5TP
M9SYA?HDIY<"**#1A[[M&G_K;<NJ$!^P8PZ'V(U2V'ZI^_>3:JVEH+MJ)C8H2
M-V#15-I]5M4H;^.C@#Y6IQF1"?/O>$'+[!Q:'I0_D2:X1E.@KW.$\.FXX/N0
MK!)6BW-4--[F07WT?;_IE^U5LG0*B+;Q>:9!6[X'ZW[8"&024&<2C^],SB3"
M^2X(;>@E_*Z,*%7#/FM#LSJQ6$96(]U17O-&SR(6,58T*87HZ6H<X7VS_3FC
M3N[%LBFPK \0+$=#R$D2Y/YP^20)#S)_;MD?*QT?!:02P?)KV&!5)@&:U3>>
M\WY(JZ$/BS37_K##/E3?QWEZ#)^%)KFO9B)77K*[[K&LXDMC/H@/K G]6#G3
M_HFTAC(EI9M!^0"'--%&=K%OL,XDI>6#T0Y_^IR7:MMN]R1&LHA\>EVA#D'7
M/3LW^G!V#&\ET/7%6?YV-"CV5<ZL$?:>5<6QT#R[ENM)RFK:B[.4Q'JEGM.%
MAY4G0[!]O(YZ*C-JN)%P0T?TX\@_IG_[IO 1P...:BIAU#Z>=$,7,K@M71U[
M].TT31#G5(FXY'@:4RRPCB#VNSIRTK _<_1P_$;>)4N8ZJ[!PF':\) 1;=4C
MX)F-N;?VV4+K[D\!-Y 1)IDNKCM.Y%A"VO"ZR]$KH;.I5BW6#*LE[:BE&^5U
M(B/,:R?>]&0F"^^&GQ-^((+G;+/HSC?7Z+&.?R0[;7PG,=X;F7_/+ L)=C\E
MR.)/1=?HO__SM\J!<4\)NN/WG5:^DQ?>G=P(07;6.KZ]79:.?,EBF^T;_2Y&
MH7';&;N'A ?M<9H3/R?22*?P N,D%RM#*@.*YCN=:LO2Q7+2[+'""7R[0^E4
M]5MCM# %G 7AE)Q2NOAW8/ /OO60GA.-%)YGW0N,B\7^+'T_+B;[@ERH"Q[;
MT'(39;RJM9-F!'\79;Q![5#4TTKP-6K?YW *>$)2RX5U)'.84?1C9GS34=#9
M\QK_?KEHZB_![4%.72)JT=)?G^S\D+HBVKSBK&_FR58E$PP<ZUNPN(',L(@U
M::4!;P NXD34!65F<R:4(2CL@A*2 L&$)XVBK.6\HWP8"*.9I*4@E\63CO_(
MCTDC$BLFBB=[)7WF?<PD&=#I3QFH;OH 0QS0,/#S6?] 0.;G!ZV694&HSFGI
MT;.7^?CZA?[A<3R<2#.8&#H@Q,OG^_Y#*+>Q874/'9_]PS.#!D5FLV6#RP+P
M1&0]P;5(9Y2>0%AY<=E4*OC;%TRO7U8 WV=2^?9UE_.-KFAYX[8]:X@F>P%N
MU6R6?2$ ^DYHNZSF04<N=)9IM,2^X81@!HRL&NA2[UZL= 2;^8XB9(2)TO2J
MA9/UXY N6:6Q-$Y0TQ-^VB!?IP=;"P?*#\DH@.'72'R6R9'!HLITAB^I-(NW
MZK_MK=36 HVQ.MF^6?F7<7GX5PC/D1Q$DQ (H6<*SST?(Q#B]+&ZF5S+[;CM
MUNZKC+WL3-B0[K_;^.'TL_$1H.]?P>EA]7W-@XBJV;8F.?)8BL+I:#YIQC&K
M"QP5P/]Q7&6GB+ $(5<86%"G_G6 <5JK?W6/..A5O6(:CZ:TX<E"-&>A)C*'
M:W59&2[?RB?YJC"21?X?O2%LCLL4%F>< S9A.PL>7UGJE.0]3^:OW+]KY')L
M\XMD.KIH\942]<:8]+.9IE:/O-EF='G)%_G_5L"C3[059_Y3N+$V!;G<>>AS
MZ0=#<X720R)0J&J2&9'1LVP.<J*9N)T\%S6^8J*9&) T%P4T?E1F^T\*)MZF
MRP8*>B.V3*%+](@Z%A\]AT2C6IF*9D]8<1*@(03]3QDB+UA9QG31^IUE?;];
MS>&&(OO)!AUUN9L';^(=U#2*3=R.QAI1>N=T8=NZV+=20OKQ9Q>Q*7D^GRFV
M]DA89&Z]I(>GA S_F\+-N"O^%^KE" 6W\0??P$_F^U+42M30\N,O!,4)\";Z
M/G"R_?LG2+J!.GF;I9H_^K('< Q+^0O*TQ)PG%).:WGG<BD&P]];5G9@.)D%
M2F/G<\;HI%+,?Q(M=-.-?Y?B9&&^F*U6*R@^"5XUGF7/$?2N:6<THLQ*9:E^
M>B:*2/:0L.S<Q\I[;8$R+ 0WN-V8.[1[V8<R-9EY4TT> ?0;Q_L&Z9)?BC@F
M;%;2/SDI9J>Q#.G>4M:RG[&KD,_@[^JW,[F12Z?@@B,'8F\ULB@$9:TG&$::
MO)Z]_&A>)$RA*S#W2A!97K]'N]DB<[-RF/#LAB#:F^MHOIOB!@X1_:=_$\X5
M<Z>!W8BWJ][ZL!F^]2E.8L4XMZE4GOT)I;/GG?M++TB]P(4<XD![XDPYG%^!
MOE36EM!^K%C(P\$EXCF\H?\C0!X^EO(6,Q[B=&O]$=@:S4_YA+;\K4>D9*@@
M3*E*+HHP%W'!3@4TEN)0]BSS6.ZANITEV"!_P2!T#?_*9L$/,_CY(T!X.;%H
MRO4V/%NQ,!:41B"=G=4E%;:9I+DN:ZMOKC!?@&!Q.9(@M-^::$-.L"_#3LZQ
MSC&OD04ACF#A<D>4>4C*?\AHCN40E,HU[/6,)_$)"#J<_Z1::=;U"- (N!KZ
M?4N1%I1&W^XC4I%[SB-AQ"ZX1T#6L3X*3W;))Q8+6:4^O&3U(DJ)&[RX5XF.
MK&=D]'-48G;LECOOS#GWY8J9$LS&BX2FF:09 ^*V,.1D6I#X"<!2P(S78R_S
M 1="/X.4OB*\KU.9KJ9?1YJAO&2^BXP^_H/;".)*HS#1,+C6<=-5 5=6G/#B
M?^\(F3!_$+[P\J23%[_F)0XR3K%\-VHPE(_MR9W ]KK.0VP,.D9<F'F3ST$?
MB5'F#&&_]Q4/HTH,+GV5/)VW;NC+F.B].Z7Y55)]V+*&47-0OS$RHFTOQ'^C
M:9_S<+ZQ4@FFL^B"G$G,/S5-AG*?$ZU0)58BRZ,[<I569EW;67LK]E;-*^CL
M9)^+(/J);Z-2N:J5]KFJ13.@WP5/&9M5ZR(1L#[#?68HVJ?PI*$8\AVT(IP1
MI.Q=8]D7QF5XAMCH*&]^O*Q*I^WV,#4C[,WA1ENZ$5.RQJ]FX8Q;3>);E%ZF
M0&!BF.0J.0RKWMR$Y*5I?B+;+>UAAU^L7NX_P:+C>R$XB&E2(7=@HUL"NEK9
M?N&.4J/A[)H[R)F9:[@_K#8]2/41R$6N%)SX_</EI)#X#&<&$M)$_";7X1.2
M\-GW)7$%.M0)RTFW)LE%TV+S1C6(F)Z#YT9?.8NF[)8&;"DH4^-T]*>>)RL@
M#V[3\KG3=6P,NW=QK#&6"DHZ\3OH#H1+S;[]9(W+:)K"K"$,%)5QJ$/A?/5L
M3XF:M!I@:$COU;)T)1L^BC:@1P;$R):769?9>#K69=;)>L3#PER O -.<1ND
M-F1]<7)D/?%]3T>/>#29L]K[W'>J59V<!HO/2DR;<CSJR-EZ>$,QUHG$PYQ>
MD/WU+*P*QP2=OMS]H!EH4T$M>DX?5!>*TU>DIAA4UDFAH$:X55C_)'4#.QM-
M1:V5.C[/)V9^E[E 9B8],GGISTAV-GE6_?OH/.MPR]T2*7T^_'Q8= XDI"6^
M%;1E^OO(W0K&#_QPSW6"#\)])0$,171LY-4G8G[Q_#E<4$!GQ^JJHR,O+Q'1
MB_^W @(B(F8\ZTRL^[YDC;SHB3Y?<#$3,EE^(1D+23=)%19S[C1Y*;O$-4H]
MF-/#Z80%1U!&)WO7(<+:K H2==VQM[ (ROPJU<9&8OPC46[&YCKF0V(9=ICB
MQY:(7I%W9A+R]LSS5"^27(C8/W&;\D$DU$NL+8:JT\#I\\8".<HF+ZVXRN;\
MX8T3'P$L7_JWUO%W21JC!MR9(]YOVP:BC.JSEHV)QLZQBUJHR=!P>E!PHUDH
MT'+$][ARWKUB:7*K1PX\M*:+BP3-C%MO:PS5X6Y>TWV5=7U)F_HU'[3:HFY2
MQ-P)A=A=>9;=*)*-*[VQ$P5-<'MA4LX O1(,,XY>%RXLM:>LH1_FDDJO3,BD
M+INDI+(N)"3+N@JSS7>KZKN2@\6"/#8^8$:!4'!E?K"_]^@275_SZ!K@BVV+
MV[(9#2[ZPKL(7P"O/]/S>F&J;<M4FWC2E*9P)X])0#)YTGF60 RJ'DU]Q;%I
M5XK>O%F4*'=H>X&L%3 NAB3,KB)[2_H0OSM?Z"=H>O+!"3\&H4H[B@).%O[M
MZ<!+'.P XVH98AQL!J2WKX,PW!$]@AKSDKLOQVI =K($'A]0JGO!P*^G ]YK
M1]3-H6M%,_,!IF:ILH55^EW')"E>W62QJ$K#)#YT\IZJNRNNTOVZ,B;YM?#]
M[$2)@<: -')XW2<]1A-7L:8@JDWU^MP@$66< E^F,]=]2O1VS6#@ ZD%4R.^
M+SK-L1";TS&07<[?JIJ;W"SGKD[E57Z5QG/GH7=?[0H5\TT:\ID(GE&H*.YB
M9Y(-(2F]'U9)W$6KDCW;@L]56J@R2'1BA;Q ;#2S"/::HP@EEC<>3CT*9;<
MXB;E!=;TP@VEDY1FS-0TP#IW1)5_0MN,3R3X9#QA)D^'7;T"=)Q+5*O&1WN>
M79[+"?&@1JFYZW0:XMCNVCO$9>/&Q\R7=F"+U[:%Y#.KF9(-[Z'3I>U <!HJ
M!CVOI[K,S)2:*].'8]SJK:!I.A$1,SY)NH(.;.0%)\L99;V2UF5)/ESU9R1>
MON=EKW&FW5HBW<DJ"D#Y#0X_^L<,=74&2*Q5\ZC%F"H%:]HLN22-XFEG]AO5
M2:ATBD<"+NG'>@>E81<'S)8:$Y;,4.K'24T0JP>R4BG$G65[^X'Q!,AZE+VD
MR6IQ$ISPJ&%6X@-/3^LKFR_%:+!?J!*7K5,DAF@V$#\91)0L=S*@\:>H7[]L
M:M Z\-%GSZ668WQ+CY5S%LV-5B%<;\CAWN7YBOSC:P2OG)+D@<)/:V34N0%A
M,F#2=553]"UK=I8W5C)#&L8'*5^1'6>XCO$> 7?'=61V".SX:(BW:@I2GRQ$
MXC&;G@ECVJT9QPIB,^4J6^0:KKT;^YDD??WRA)!1HW':_K,#SN:<@&U[(K_7
MANI 6FN,4K7DCS%ETLN^G'AR6S7P5[WM[D7TJPO,\)UTVW0J&_POETY2!6$0
M%A[,^K&-^XA'P.[F(V"V[Q'PT>%'KX:S>7HFGW5DLX4Z:#WOZT"J;:9C<D.L
MUJ)#:L$!OFU-EH+1F;N&%]%@>8]BA=IA/#'[)OT+_@_=3F'AF .X9P_XL63&
M$B/5QE(7HD96%S@:F]%*"+JP]R'J8IOG08;+E)!XX$MYAB5PYA+8FD-EU*HI
MI*\V8B?!%W,!%-9*+K[K+_:=T$[IE<7+C:YG\AARF@FJP:T0*1)HP\C(>)NQ
M^"/@H-E@H &]#^,LF)'SC$3AP2U<;!S_'5OC4/PRQ[,O/'>:),L&]3:QVCA
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MW<%G;A8NW_I+40,HH\#2Q<D9FT6\L=L;5- PFND-Y0'Y#Y#HH:BB"M.Y;S_
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M-8FR_,6F!@.-]YC3J@XV$D/U J<M$_U\+._X:"[88O>W2++P8R0BBS;/L5]
M*94K+$3LYQ@I=4<5&FB5WTP)"^@FZ]GOUD;'/ *<ELFBNJ[5"@:NCIJK*O&B
M0%S'F/!<BX6_7]C:+,^ @)1\P[2*T$218</U^![L# $@WF&;_/7WS\L.P#_T
M62-'5FBOM7F;#[6TS7CKAJDT>$%0;/ICEC'B"E1.83@YNTN1SDU?[M">=C.[
M>^0[ I0'/2XX*+8+Z'6%6]*J#XG13^>6)B2!'[_$UHWGEM4Q5<#C7Y H]>@)
M2_V2%YJ<(RK09E*#$.UTVC#X(M)R<&>3TTZLT /JH]>LU'9OL4Q/<BRE8C0:
MQ?"#,<E,88-D=DA8B/V4\-UQ@JU*O4U\W)!ZK+;IGB<NFU[4$?K5N+^*P2/
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M<W0"^A,>UT$P5C>F&]2>CN@7F<>AP ;"P>7KDKVGF!8#)<@TI7[G3<SFBF<
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M*=H1\&?IG0+/*;%=NE_$?C@2&'FA_T\ #<FL]S"I;N'T:QC+C/_@>(:<C9J
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M7&,]H0] _>C?QA,/4)-_U;/+:9\3W3+"(0QRHN/[Y24$LM" R1DAMCRC>18
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M!0:-/"P+]V:=$06(5-J,@S>DIXPW4%^R-<1;__3_ZKM34\J)_<T_ V**K^^
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M#44V\EX\E:C''(!B\!>A;J@ L@)/%A$F2Z@L<]*=A\-40B?=@_,Y9X=95D
M%"].QF@J1]BXW=J&N%_+IURZR<L)7NGD\O[X?2R=L;AEOW2ODT@83R.D0PV
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M)?U7*^?-Q(?[&X\_:"U+O+M'ZF&H"UH)=S:[9.@NN1CA,!8S56/[6ZH2$[6
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M*5R,RM]3?OWWE6-/_W\(I.0"Z,L[\C>CZ%]BPZ,@,0RI)=J/P,=C8S/S+A0
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M6XVK4QI. 0U$<L-2W6E-[LS@>(_5 P1Z\$A+S%+XY+*C=657'Z<T8]<$TN$
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M=^1-@.6C1E:1CUV(->>Y'U<;6BHVRT [800?.L;%;CR+@UR/Q>PW^V.W.&E
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MPRF@#]F3G@^40T-1N.4BPO\UO?G_GFBOD<@,--Z]_51045AX9%SQ>*2*K>B
M':^&,_H*%;6O7B!J='"(5LIF0(][> 9#"S36:L?^4))K?+136/<*9;\=_3R9
M+N! &;6,D'<K9/8\F?K_QO3\.T,%<V(9 %MC:7=5[K3?3"<1N:6.UAKE.NI\
MZ>9[<?P_/(,3=. 7>M*LRB7=I);"ZKG]UIX:ETKE[R_Z@4L_.#IQ1$P\6:Y\
MBR9*^:OQ>J,W0QUU^7TKJA_-40%Z#6<7R!I.D*$9<5N?>D4A<[;(S[@D0022
M]^_UP9+HQ9]02[A412Q:M32OQ9)1@A#X* VC]ZED92VYYO4=%$XTUUB5%FUS
M],)EJGZ: \SL> ET1H:YN-LX-96E3MXZUPKW?3N?MP"2C@<(UD]6/-OY4?GZ
M,0(\H33[B&)H+]CHJ;?!VU6#RS#Z_4D5Y4.DHD#1>.S!35='<<N\3@E1E@4R
M+_4BH&"<^H>JRGA[TB-<<_>)[P1>(IV-96QFZ9<^ADL$SJ;K"D;&=I]N"\+2
MFLSCM',ZK3",4DQ;7 9YH#K.C?R7UA;:E@:)4WLVPQMTBX.:] #W8-]:8$!H
M6[^84[(SL_E"R2@X-;4&_B[?E=M2&@D7RV5&!6C!)_]53IH7O3CLG8-&F"M=
MFUCG-J,^:QQ""=/VHH+!O710Q%K5)P,:L "I-4Z3&KM%LTIP"-UC\BO4;:1;
MEH]H4.X!S<TS#?7G"<$$6_^*!G9MQA2IP>)AGP.\SWH 3ZE?W&1_ZPV65%QE
M]M@\J\B=*B=, _KN<+Z8.4J1U:ED%%,\:N0WPX!WO8!>TZ-.*S?#A#:(2,&%
M2 7S\7!*IX+20BA-O>=H59Y;]W)PH.JY89\,_X"V-.SY0#<?;:(QO\SBR]QS
M09=7 ;;2!8W%$3;5@?0OU#I[4/R$W:&;5VT#5<%8!.!HQ.VQOK1]7AO_S6\L
M<UTCF7XJ[LCDK4[A7%[B#.UHZM?AKLFO'R)^BB4O5 X$&37D4WI)B,=M?6^Q
M+BL]HCYWOV7RI_D# '-JQ(\RK;1;$(<8)M=<&L=G"F-U,L1%S3?SHL<1TC3\
M$5:L.%_\;LT=L4F_66OKGD@IT9LED^Z5RYK@\%VRGB,(*7/I^UYN;:0<X2^7
M\5<H5)9_3.? "Y;!^^&#8]@DQ4Y,[)J7-+U?D2K@9=W;/8+S L^R.7YQ)N;@
MNS$^5NEF?K4./1T9GU54A@5L38M14\44]1Y3J3F(Y?9P<CDL^GN0,6S#32OF
MP&:ZT4#1D&8_<V"Z(Y6X'3/029$GB#"*OR=%$C!2#%^>MO)/DS>C4W3JOG1=
M7](4-W[ZX719/'P\M[_*L@#'_^EC-V/M_B/[Y)@C]<GJ=Q?=&=2Z!IZ[7V@C
M58].<M6\U],G\PY!32F9ZM#FYASRQ2M-''D<(YSJYM6\A!EN-K^_.EV/A:\N
M%PPPW+!R]QT[IQ5XU(0Z35U%+.=(,@PXJA@;>7;HA_V20LR[IO@:)L_ "D:N
M,TA=V-"02=L3"$G!V5 +F/L! >+M(:FD'.A3&GGEB!6@"?J_0I6$5PX^VKY"
MG1)<"T!COT+]^%7NU:]F08V2Z;*1$B7.'>[+8(RYJ[7(JS+"A-I@)!DS@_*D
MRA$S!3M>2VK'C,4;/6R>6GA&E4""*?H*5;&Z_Q!G\S;?5A@76#@7>H6:I-YJ
M" 4^%;(%$4O6[\Z.EPZIA@G=.T886,ZGO)]N)':F^)FZB'KNQ/M<\O \O/AE
M8\3)UVO2<3W8%'0B('9'N57;#& R?33Q?N</BE1MNN#HS'9*Y1MQ;T@KI'D^
M.$3B7-X@^X)V6N]YA5K@1#-@P'*R,V_5H5R'-2N@"/A37]GG3+K[>:3SD69I
MO:U=8I?W("?3D23.BA"N1D=AEQ=QY?H:/?ETJ>+8\&5!=Y]]U.8Q4Z<%]<->
M/+7AY">@(H>?K08Y7K@4BT(![*15)=D 87^^E)_6R>5!,N0F(]5I#UGQ%6H_
MV>?^EOF?!GP?Q"#*)FZ_58#VO9U!3C#N\Z&*NMQ4QXX!N/:47NY !Z5Y:JBM
M6K2WA2#@@.*E/3+V#VAI=,,N3VC 3F22\_W(_$3CX&=#_A$VDV[V%05U9AH6
MHYG?.4.9>6BF$228]]JI Y\SJ^+!QK3E,3IQG3KT&D<.".",:N\VG<A7**!7
MISW'B,<E*,?=DC_7(=&8TYK#L'CNOA-\HB6>Y+#<C*/1,CVGYQ<*LM)+)\2>
M= (Y,3-$<_18X4SPS"T\5T>TM)M;46[[02;":F!N#\DWU51UG(XYQ*/D^BQ_
M41<N#PYS4/'VEEZ=_+&$M;?V=_KQ_?/.CJX5Y?(JR/C4P=^.;P)'219NOLBD
M/0W88\>@;R+EMK-*+<=IX1G6GY:@:4HARTMB7F8R:P=:L9,9?B0 X=*@^CQ/
MM3LRF##/1QBV:"9,0BR6*GRWXS-Z4D.3X98&7J':[ <?7]K]^?K]Y$DO"//D
MMBE%GO'HRK+J78BRK),9B76%1XF2P;5O<R7_TYNBPUN>EG%COG#L\G9P=QCJ
M0[3"""6/SQQH#O22W*#')UKT#4?&+^WJ5#"M4U[:CNT98#6ZZ<F[57SHE86S
M*%29VUZ2 W+VY >1;'<J9+3DT6T>X&:N8ADVS8NM"\R95IH6D]3@MX)JFG6?
MKU;59_ATBN>UM8QSQP1'Q%46"7=F]7"=>7@."BL=@0^#>\O?W:KH$"_M&3FD
MC:H)X\\)RW@B7J&JN+'=D8<_1XZ,5&/R1+ !>%O-J8N35"L;TM.8H\'W6*(Q
MXF5#QS9;.K)CE:1SHTM:E)$K_=U6<NF_1 ()EKX.-= -.SCOGF@7&B^YWIBQ
M$?H4JCWLE>3I?SPI7VU-]!QU?QP0X)RW\GZS!8>\(2>R!*V9)DP#;'6M=JB4
M0VM7353'SK8P:H#1*4%-_0&M_4E @["%5^>'AC'P_FZ>T!"9V$T"NY,&[<WY
M^3WJC\2T@)\]2\-\J0E+=K,-'=VJ,A71+96F[NL&[JH_+:4]51U5C3LY="YP
M$NV.T65[@1=&<QL<,[]4$"0)AR5NE,1K8A$)\E.$X[^M#[-RV853A!3+U\2B
M$A3@V^ZPH&+F"5@S3=M2X'#%Q@/B8X[RHPS)*5L,^G110":VZU,_0%OS,F4)
MER=37+(CKCQ$)O\?!L5.0/*RU$"O3I=@4&45W:_] O'X[\N%BC$+&F,-=N5-
ML^><^*7:/>:K]=5QCK2-[W]7<K)<&C5(H^_+H\^C5C$=7[8>DN4YZA^<'L"/
MBB=?B<Y:9<13CCA!#&^-@D[FT99KB%I%!)R4!)QBD?[ZCLO7WK&<"VHE%W"2
MP#K*#SJ9@E[.97YL>I,)]CHF]SK^J';");1K2W>\:#O3XI8\VS(]5B\RJ&';
MF?Z-B.LGORV4QP;4_>B[RV3H72:X\1]HZ;^)N'_RVT-Y[/P?@3E_(NZ\EUK9
M7<5>X7(9:X^PPS+G#[O]W<@1%4?S8\06T]3R)$EAKG^D,?"(TA-RP&F1A],4
M^)FD@*UC/+&JO7&^O/&@]%<I_7U-956",FU^9/GZ*1]_XTTCXB(=N&NVNU?Z
M%<J4**!X]O?L43Y9A ;J9UJBL-NH?*MD_6MH?9T&KG(Y5DAD[\2<3"/F,)W-
MH<;;U4+*G#W\9-Q@7<4!/T8'?-7H^ &G9E$XY&#6(.GG8HKYW!])8)^>L:?_
MKQ0U)[N3@CM^7;@SG*0GKF=W-CSGJ.ZWP;^)IF>T&#,W_$CUONTL^BH"O')H
MX4)X_Y/J567ZQ$<>GBH;T;V+')@)B>1008>D@&C[? ]V W'QNPW_E4@,NA:Q
MX3PDKZS+!5M3:4.IW:7VV.5'4,SPF<=TD>W7EH!YQ.6[WAIMJQ'4>JGZ+T1R
MW8M#RQ0D8X>]11M_7!K4=;*4=IH<OOPN6(YHR&IH7$[XC(,FC.\M/\,P>0W0
MN-H)PX#UICU0U"%<K6A/[ ?2MA#,-:7H3.A^[VFNN#-9//5U:'>'6$VI'JL]
M>TIU#JU@^<F-2K\0>&6W(C7O;X!F#-D=$V.?KRIKF$IGIN9/,O ,)4\G#1IQ
ME><:)9OILP=XM+KW0^,^Y?>##:-G( B+?:&"& ^^!99;CI@B! <TOVF+6X40
M#GA^^P$DFH08%>M+N7B/PT8^W[]PFQ&: ,*X47M_W.,,M0A8CM#-RPR@/B9,
MP2EYUW/F5:*F">BH(AY2'9)?];7+6$6\7S#?^A9_*H>;-W7W>6:E5W:)0&P8
MJ7Z:K'70^0 [7&[)4J H,MF.,'O+DV_O%4KFA%]4AV:1ZD#\LQWAN.D7WFU4
M(N4T:\-/3BTK75:@QH'R-"R=%>L2]7O>-M'B7UTLM%-:X$+;'PIN\NTV(ON4
M+")>\=5U, Z-0=F"<VUV+>V>]!N(: [ED<52^_Q,5?NZYS&&X!M#73H;_.$\
M-[+J"<%L)J]WB#P%2^-+86K[.8@M\]BLH >=*#]]/;0:=\=0S;5%']QD#7&?
MNC0!B];:%M^%7^5%<0MQDX83>5P#1N(JIN[)#-W;S4/Z&0P;<V=1>"B86LN;
M_?NBLPI8L:(KN\L:^/.?3+#=*<1:S:78I3U_6]$-)$^Z^BI&BR1IP=?&^Y6-
ME>\GB$),1#695_+WRB*3*'X-QB0?G5"D8UE/@]I_-!9D"5.=" CI2+ZL07"!
M/ O[C3>13^$@_LV)1>DG,N;*)1J969BHYKKVKU9CAUA*A0#Z\6HGS!+RXCJ
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M=8<5!RG1Q"1N-Z90R-+:,-C5<.@,(>9*R#_<SJ!D'_O%-*U[-!B6*.((T]I
M"+&JS]*B;4R!@SC6V:!'0!L_+/\?LJ+9(CG^TN.(HG&G'2=,,W_8^9GGZTXA
MZ+'O(-T6.B)8H@O,&FH>E:<_N)0&+\2T4+3[)!<WJWNC'"$:'E1JO5_XK%Z@
M>C4D)[=%2/M@9]K!?TVU\UOJB(H\HJ&E$5P.4K?6CGB0JJUS"BQ"\E$ANKL8
MIZE\7KG"3!PF35:YR!91-2(U=PX5IT0C+<J7G]/+(WY[R530HM,E,U-GM]=T
M+/2W<Z^X6AW]C!".GHEUHG4E(>Z'>&RSD>M&/EA?T5HK &"&4M.#='*<2S3%
MLL:=][85"8+<OMI"VN:,8IO86 6+CET'=*)<Q;1?<7K2P#XIPO9Z=4]T!JIA
MT\D=U1$D)O4Z>+8W5.@31<OHSDUJV0P(64D<2+KL/R=>/QMS18\*L]:V%=0_
M?:U-,72L7I-FVRUQ.I=[?F7,2*;2DMG6A)DO_8&_U/0#G#8KH27)3\$KMY^R
MZT>@>GE5I_3@:T\=!T>2;8#8Z;UO3D+!*B4%UZ7(7':"Y3%0>J7NNUS3JZY;
MPL'C^VIN( 3.YI\!R6845'?KM#>+^Y0O[^K3,VSG[2YK+PMVX7=UH:FK<LWI
M]S"]JH B]BL(3.6UN:2C %8^&^?J,#/?GJN:Q'QCZ(THM9]+XHI]ZD>T/AQD
MCT68D+U+=%0JQS*BSJ^R29Y5VFAAWF*I$7GF$I[+3!\[JQ;B"RJGKH0-+KI)
M+=[\H,-4P?+W55/F1,TXR1&^,#O?I*;*;A/QT>$H_E$5(:N'S\3SMJ-N<:%U
MB+BS)#=QT;OU^_5%@H3MA>:'7BZK=F@W(JC*R91%7TNQ$R2DGY8OS<BCHG7'
M:1(!'%M6=J_(O,$Y6Y7CMU]"Q#KIB0O>*I7.A-'VBZK[I4?_R-A(SY[36O]C
M).7E=:D;D.!-K9FL.N")DO=C^$Q:DE%N4SK11L^2G%VGJ-QQ"A]O\O!8S?/5
M9AC=MN?(_\0TV5D5Y%8--0=X;_[J'K'W$=&Y? &KQ,DXBDVGTH8<CI:B]$$M
MY;;?@+/M@W[4A+:LH\PFJC[. 6:^3IL!E(6ULGJZSBONJ^Y=75;KD88D[93V
MWTPGZ,)=6_6,\,^=^ 7%I6:AB1N3V4X; ;@BGCE=O_ZHMW^K_+*/%E&[W_Q*
M)+EMTD14%WKAW>A^Z3JY0H:84ZKHJ/N*A=<T[,54_#UTK#(F/>N[?0W,(?":
M"@]+DUK:.$5(HX>7$I"YG5+/&DBP$1KR8^A%*[M@$Z=M58$5C=ESV)#V75._
MF)^K#<B'I]:NRJG0/C"A;M2T5W!<72XNZ[= YL]BRQ&?)G*O*P6>8=3'>L[;
M+X=I5(D%G'\ AFZ..CJB#8W="_5M0_R)Y>[!D8^1]RVGFT(KE"0:H)T#/E$?
ME?KX"(XY5ZV)QQA;Z<FL?B:[ .+351F-QQ==G_>*IX?)X].HJ_W':,I%*'C[
M!%H V5PO,L:F!3]0P[]KK^O+2 M7S'"ZYE5E-P1-4?N=:%Q5:(0YE'KO7KP4
M _H!ZEW%,+[&H>OTY]!*<V$ZQ^[Q #P4Y]@%9T=MNI*[A;;UR==='1/@;%!4
MNY'I>1G[W#H0'_%A&0&#_""K7:'M#>)N-#TI#&@E&ZVEYH;&:='U76_5 KGL
M_40D#JWT.S7/*L+LR\SP<VY;FQ8ADGDHU8?CKAB):RV%"4]A@P/6G^;ZG1]7
M"G:;8+Z(H2'6U,CWG-.'9]6($3:?CTYZ;>!!Y*XC-J>0>:\L P[K\)96DH,S
M?^C'GN>6$]) 3%IC]-;VI>6E0SY$81HHNROU5:WA,Q9+_4I"2WIK2P_EWZBX
M\N-8DD"D=AC?U7]*A;EB*9LZ7"I]CA=K\0EJ^G>S$<GV#;='V8[$3E'1@:0V
MF#V9KN!Q&M@GY00^6MU(K0Z9ZR@YYY-]7%EA9;H)$425EP_3!UE%RPGV0V.R
M@!"),"R^JK6$1IGV'X)WW.!W); 9,S D@R-N1U3FG3VR_]2<WA=B>WP+KH:V
M50A-NQ0MQ,,"K^]>?O]1ZVBUJC18M!/@FIO-:981DN/?R- M 4\J^'?#N8S&
M1O W*\&P\4_/ 60C^3\;5&!Y=1==Y:ITG@1Y#GIS'N6BYD/FG 3,>%#:O(OL
MY0C:8TXJ;SW)JR.OFBH[!D[_'WV)B]>/^GO4?NMJ2^TG0*_]JF#L(^;".3$M
MHVYI>QK)2\KK$"Y@I<G8\L%O<0N9FHLI__O!_+,SW)ZVL6XUST ](=@YUM:;
MI>57%6E0T->^UT5VI"0ZWKH*WWFBV L_^':HOYVQ/^Z61M,CQS1A/TV6@P-=
MQ?9+Z>%V<F#MH"DF&\_E.)_C$%AG<UPX+>N,0M%PQ6WQ(F40?5HPYNJ?63%,
M5#$$D\.T76(&JJI';Y[YC_^U7WZ!H=E*GN?"^=P#DTBRG>TA8[/XA.L+A5+.
M."?A0HGV!SX+&>&L/D]=-NIP41F@]XMYY7_3C.8V/73Q!X4$/JW;OMD8&#ZY
M1,TB8HQ((Y8GA[?5+XY%C3VF6&)Z[BSCEVJ=A+,S"ACHW_P2&COL:.D[1405
M=Z?8&9 B]F7Q']8E"E86U]5T/^%2.OW9R()U]:S1%G^--CC"]^_J_7//]_Y?
MLV.I# -2I7@U8Y8T9_^3$9YOC?VV>E0)F/DY"1I]25G^JM\8\5M:M'7+?WYZ
MK?;^8"?@]H@>50\:K?OY.,XT3>@LZ;DLLC :]NHK%0*_I,5(H>O%O*E0X.4O
MJ3#[3=&E%:,Q(%3T%.SO94G4E.>Y?/V,D2(J/7=!K:9SN*29JH0E]N!V-U?<
ML!WHVJZW_T?ULVQ9/\E>B^?T?I?O'$4>V_[FW-LMO5D&C=\60[ZC96UHA6_0
M+.#0")NJ[S]D^1$J-79L%!6 6!^EU4=6><B2(<TR&T]"CL$%:8M2@@FE?Z4N
M?N857>^+@<FVFKQ' !M3U=KXPZ>2BY=%0@L_&68<,#0$?DC4(ZO$+,0RD7_>
M"%141#'E6[^NCGY]2O6,=XH7'2$R3?B5+5J.MCP62)6C&A#\.B%K,DS1+J".
MBUJTI*TZ547LH%?F94A$[,*EXZN.Y9#&PD:)6@.+WZ.;\XK+KNT2M>LWURLB
MP*$I5R_7;Q1E#N]!9Y/^_>^Z(CNPI:W6A&'I^AKY @BL@F&6X1@LKOR7E3?,
M8ZPVV[.;H@$OYM0UM[ZK!PDU^(A<0?=)I=CR93JZOEC(&Z:HBU:=<C0#)T<=
M)YU_L.=;KI0=5(.FUN,-\]/&)V<+3@+]I50+Z"C=TFP;3F]KZJDS8\RN.Z7R
MF$!>7%JMOH5DGV%\!I]&[,P (YT9CMM_W@Q5;&VU^#\P:QA5^WHI[1CO[A!T
M?8RJ%)U9-<!6_$YD:=*=+6K\1B8>K*=Z'"X3+)R,@^T]C /4Y)IVV2R(%)43
MDNZC1 UAWEBT/^2H?#L_F2\6=2%KO8VU,PY@:;Z/(Q^GO&Z[(*DI&",;8K2^
MH,[/(;T(C].O.FF&4>Z1OCYOO4TTE3\39#H]X&,Z/S C67"L9&&U'S5AI1$4
MYGE[L:!/]89/_Z+:7GQ;?XI3/6J=8K%K\P+/2A\0<O8!$V>@]M83+9(G<XID
MXEGD%)1CD@DFHF59_VH+[+YQLEF<27,QKO_7.H,FJ8VT(D+E_I?:M.#)D.\\
M)Y#!I1>W&6L]&T5<T52KT6MFL-1E^R(PL?#T"6,V0/;0NBQ_HTJU]-=#ELJW
ME,\WX7(D4>K^E S=\)%'=6,WOF6IBH4!.0:+A&Y;?*%7&N.)MW),T\*S*61=
M#B/?.2&F F15!CNY@S49Q$KBI?"-.GDOIF^^XUP4[$/T]'I$6>6#V[:'$,8W
MNEE?ME+2 :,$>@W(;G!!XL('.]OFV,;<7%.B9:8#.3D<_)'5/C0.?$OD+B:J
M.]P*621'3/B$87.;'I80?\^W#FT#[W7)5715[P90WGPY/4J.1.B/UD5D\5"B
M1+"^A9]2?%]U!EGGJ3QA1,7LB)"+//[I_L?_4+H-_?&&41!%>]\?IK+S\7%R
M87"(?6MKWMO[1"!V8GA,-NRC8WVB?;^WP"P^IF8<9* 5[BDX;'.:'2/VA"&@
MQUEH^(5.]3=L2UM+70]6VN3&TI_?U6H;PT.\GQ2E>D5K7ZFZ6Z:;/D F5!DH
M$M.E^RO@N8Q2T*OZ.'NCNRGQI1R9?^@C;,N[.M=^HH)>W]2^O_7/ M^1P^KO
M@>M 7I[;,>YA7JJA?>Y=*7NNGZK.G-](E*?T#]^6,!%N<3(MG#S:$EM\Z+)+
M+C7_M=46*I&8*:@?R&8L7M]=?BVM7@H-USU^8+0AD>#1-H2)9*%M_]B(U]RO
M;GIU^-0OC=-WS[10HR&@08539Y< Z=VNP ^KZ.#.:,-#4T<0I6K:P79&*;LK
MH"9EKDSZI9YZLN#.,2*5<UY?CY@7 !)@573",U,%O1]MT(IBI2GA(B-F$+11
MQM-VS4[@%(ZL*1<&9MI1[++L9U/YRE"V*\F6>;S?<_SC!/]J5V=CK/^M?YCK
MM"O@WFBMOS]LL:<L;-,-IQ37+5^L4CINV^3WS34F!P-+'Q^_XY*BL*#0HW7\
MV!4WO%]<CV!A,"!B&+B3-GIO$21JQ? @D8F6%37UY;?_=D^@G6NLWTE.[)*;
MCU,!3"Q>,@%0SY;63CNM1,$[D-1S,_#U:29E7Q>$VPRM,+L?K>1AJ',L?H+'
M$%=*JNFAWX</N83="? @QZMJB"H@A!CHD=6>H9OC[6=,QRHUBYXQ[.Z6X1))
M7#BL$R(7'!6L2^2D=F% E@ _": +?"6C?+_Y_--B&*2?=""[/(^.5(?1]=G>
M:6O_UKX311X 04'I2L@%)\\]J;&F#&H5>RB 3\C/E=F5==(:N$7+_K&=FZ:0
M)CL:P53JZF D]=4[.WK>X  ];,-??T7L5MTJ6!C40/70/-H9HUIS.4NB19K@
M1J9YQF5/3[@G3.5?T]6&,H.M(Y?LB^K+Q49)9OZ=3<R-9>01?J'XKBO:/8EQ
MVJG>(2=!F.K9=&QW\5?:!<WM+YCR/O+,468 SO-C[[/%KL+=Q2-#\<SFO%!6
MIL>!"ZXG#&I_MB)D'_T-/@ZL^6A<T.T9$Q;+O"FKCJ7%A#=FX)<W6YS4"_RQ
MP?(R'YS@,X9X#JIMK8MD,)N:L,<OE+OJU %M(NW*8F($K4?T9>?OXZ#+N8DE
MEZF8)0BM^).EFA*OP.N? O&2<7W .6B7P[K$2^7#S2>,LK/GU]QQCZ)C:B'#
M)-7]C>T/XNBRTOS:K_[S#-!K9G^ID3D(@(^F[U,]ZZ81R;QJ>STRD\R68RJP
M9F+'1CPB +_?SPFJ!*(C"+=%#HBE!GN.B!N]R<;_MI(_4C#!7R,;T^48Z ?@
M\7O97^LGQ=OE4@R^K&L*V^FF?\*8O/W]A!'OK?\X,>]@RK/?DW?:[M_C,R="
M;4P=U-S9F6/-WK+X,+LRE@!&Q-P!$B[DEP#+>>H/8+$UU][;)XQR++++[0O@
MHQSZP('GMII_%*1.7SG,4KG[ZN):GDFHMI)WBH^*.<S[8CQ%_E5DB64?K'_Q
M54X,X7)L;3!M['!B*O/*O=6%+VMH#]W_7G^!DCH +!TX8^PH)E?A271$_RU0
M5W%=^U\'9XH#:";=(.,WN;U7%'M]]_GS=0)>Z=9(>,V#R@R:/*C5!/]NV[TI
M^)J0LF#B7)LHQ-4R7Y2)VZNB)X_YH E!W"B:"W<^T@RB#6_MIB7\R1ELB#EW
M91"V4?#UQQB][M3U5:1".: P>_T!\/N.._</]#F+K<>:@:-E2V!OS"34*S)M
M\/C(NX+Z=?:'II751O924^MI:SE'-KI:2;.>-#2\?.KVYV#I\@:3S<G0"0T!
M<;<CZVI/D<#N:? +5Q[J:_0_">8B8=T/NMD9"/R8^=3J?7G.WQGG+B;G>7VU
M]-=#2G('*PZ;,XQ;N:]5&.]D49$K'=V=2"GLS^I1H 7#%O&$(RUX[>,?6UJ=
MZCA/CS[AS7#(+#-:Q6AM\_%(S?^W<LT:=;$-=V8[NC1!N0+<DB\/,$O]\\D1
M_BTK)D8C*8Z3PX<%CN*LNM:X'ZK@MV2XP8:H2?%U>=((E%O[!L8TS$JT$RZ0
MAIP1VDN]1JDK'W%=R5%Q:[,?>>?.T.%U^[,]89C?&<C=[BY]>\)8D)TC>&R_
MK##N!;7PGAU 9'I@:P]>ASI/&/N%SE'_I^4\YKB.JX/3,KPJK, !7E8_O(>S
MT(-0/D6X9KO]E-LFG>E.RTMA4'N?3" [&2\W@FCMA"&$C JZ^)^+B_F[Z;5!
MKH#"W;DC4=I9=Q+*FSZ9*>-#HIN$HX[K8E()L$FW]HM\QLT:'6#&]GEX&^)K
MFBL^3O)A#U./>!]%QL6%RB/''N"^\8+F"0/L'QI>%F1!ASHM7-[\\;)%ZBIJ
MV_\)0^?[G:.V10.MFD(_UP&7KQAO?D>^WN:Y2/H"L;/C'QD5Z_8'\YHHN\N0
M)0!?CE%OUH-W0BNJGF;DK7S%8EZ@Y<V% M4M?G]8DIB*Q$/;T">PC:!JT KL
M0<-L);,ASC#/A[[0ECP+ WGD!U^*R\ME6=*<JAL0 P,%I$"U9]QAS$.!BF-[
M'E5YJ4$M^XQ-0_6^?DX;1ZL7[9VB,B)N%UI,%CGE=H(<4@$P?#S_GHJ":N@$
M>ZL4OL._0+3Q+3USPS)M_?*MQ3$X1FE$*M<6_)@YX)=XMD/^0N 3]T , 9^-
MRYASG4SZYX%4]3$O+;,A'MN,QC&3[1K/>0D7BDX:!$X\3^4S)<4.1W3Q2*?#
MZ(Q&X"DF)U?"!7DYF#(\9;L_45]I[8R,GU@$6RW7*'_SY99D6-=-@=B<@\0P
M5$^3K=R)K&3:FR!O,^MQ_A%EK7!EC$W?T:;S,-<;A:XCD?/A_W97^95@18,]
M]#]&?6QZG;';<;"G5(AVF>2/H)R+?VP/^(M/CVYC*>YW'Z2)>>2_ST3JFBH7
M4NJL"2TTE1"<^IFU#4P:1CU.[&Z6T)8/^Z*;ZJ6RF@0;H1+Z%$8!<[S/Y3R.
M\;H1N2&_AJ^&2O.\7$X*$D_;;L@01]T9>X=U5E$'6L?;63L?)KXT:54\80S(
MX(1ER)84GAP1ETO1VV9?X)F>26.M7_;,%V=R#M]Z_X16Y:S&097&5UPG.YT;
M5G?^^E6RY.]Q=*^U]ONQ;(0; FEA5>7QM,.&2E#L"#\ HL=*1(A"7LQ75\J9
M&E(\V!K(F<P1S(LH7"3H_ \PE*]G^2RK7L5,FO'><K2^FG4@=#JC2O[TC0VG
M;84:@(DG]%GZ%WNB0@G\:TS>/SEC"S^12YOP51]RU;-@ 368R_;B>]FN;MR9
MP!255\)OA"F?J2:(O-8F_+/RQK%]X"\)L\R&9[A,KX9%&72,0$MF=8OV+LEI
MZBH=<KU5UAY)\(Y5CK5_RR:Q<#Z'D\@&*5HZ2(8LQTY4C(<=)6+(_:V"C]W[
MJ=0LPP>>^UH3N?N\B'_J\Q<@) @IQ(\K!)S/R>_+G2-/E>15?P&XL]M5:XSK
MSZCB:ZFI^56\MBQMS<XRPZ;V'T8R&K;41X;K24O9/_C&Q3"QQD^\+JZ# =[0
M<8[6V\SE2KS5+=]LZ8)MO(,#ASZ.->DUX=KK@BRG'NM,=&U4XQ!WOI@=I3.'
MFR5$=UN'@BR#UTPV;HNQ_CKP"E5^WZ)9H"LZ[.PL[M="&+ONBZ/K7%(;FU7S
MA$&KW,-Q@TDEE@DZ4;;5?C$883/*UQS4C1(]G=V"BVKK&<.>,"Y*O$D(("$S
MJD\8\\!9^HM<[U_>$QWO.IQ6GLET(L%8@XV#ETP@7+"-+_R?R:R6,6X%&5E@
MK4=H'W"$)B$:44P.(&S]JN@J=49;,\'A2:,WN(97YXRMCPZ,*TM(1%,67:SS
MV]F6LI?&XE>5><ALA9R=__M%T>OX P6? %CF[!4T6SSQNI3\6^I [P]JVO2#
M6F9H-H^JDT;GY92JCUUTT)GU:'2)""4VU1DT.TL?@CTV3@G6A93,-@P5NH]!
MF^[&CW_D%##([F9'\*/"?5)HB+CR8L&;ZY3/!%0I8H3L:*+"HL)1/(QI&3Y'
M)Y58VM*U;QVZ[8_(Z$/K.L6R_S+](+^LL-65'<+;_57[]NYN&Q!$)/GP\F$C
MNPS;3PA;*,C3/3WS2.LEF(.Z]LNP?"O7:[TG#$_^.N#.J37%1>@ON,J4&+1/
M^@?(7#H69$Q-Q-Q(7;&:VTK^=EG[MK##[ D#M@(3?,*HO*OXW) ;YM-R?:1W
MX<5=I\F:RA,TD4F4H_V,='^=<,\G50NW)H/1@NJZ5$8KT)_9O[_DG7UO0%<M
MV,7G<DK3<'7L]1KRWD@1]YS"7N6[S6FC*"&MDX:X'95\OCZ%6AMOA05$4.8E
M\XLE]:CX9D:OPU3>S$Q0!W;O$\;XU*L)GY-1(>82H*'74EJ:>ZE%3_DJP.7]
M_OKW!8DQ\I"\,!U+R]=?3ND4>9B"'._NM 7T&WEFD;.2DU"KV\R.+3F4Z '!
M;4+G,SE5ZCI$[MJLT?96@.CJ^7Z$]?G+[U(!_>AIX/3#%X1TML9!Z-([.?A*
MIPB?H^]^[)5URQ7#YX8V:(/%!;2WGB9=-\%$=ZA/G%EY[1':"B!>?K[?&2#B
M5F^QXYJY$'HF*1KGX7:E3HL28B\T3.8)'B#/#!1P1CX_$3[]%B":S*(L7G==
MM@\R%^S2QT)J]-B'KA?ECLK*O2__A5R%[UGV8:^.A&[<63S'EC>O'J?P559(
M;=:Y@,VSC< &F2@%N:&YY/F-AAN'FU40%E7&]"J$\\S?@'<(<[> <$E#[#T2
M%8M/L78H?73G\'\3B*!AV8+<2RGC[.4\GM5TL68H,SSECDO"_26; @G"154)
M;;^+ UC@Y2<^)B^S6:TG#.VS.3&*5=XBH8F"]"<,/S'7L)6'9?JK,+]GDG]6
M>E\NX!\1->)7NKNFE#\.'GZC]*%NB70/+%H:S<2IL&C(J+_#:ADDAN$O58Y-
M/"):7?!G7,@IC,9%R!(MQS=]\8R$1ZU0HDLRDQN7S$,:6'4X,"2E?829W\:-
MM&4H0V"%@9:XGJ?S>4[P^:G ]K> 2-2V9 ;[EF13:=0O:Y,V;#5-E=,1:=9P
MION5"-ZN;7JPLID1^OV)?1CUM^@3NHRVNX 0!KD6XWXYUZ.HP_SCAZ8>^A:_
MOLO1ZU"X%0&":_W./EC.M3[J,.'XH?&O2>S_-?WME7Z=VGK52'3NQU2MM<-
M#M=!IX$]?#^>D\BA)9 N_&--='DY\%;_SGFB,H7ZH5E)P[B?JRF^Z4-/&#7C
MCYOMI@_;I^KQG7HE[^1X!_,!F ]Q4.IZ!6S#"&43-3- O].ZS#^$EUE*42^
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M#"3M%-V()"$ZBWUU(3B=3S/":*R8%$GCP:SL$(WN$'YM[V"*JS;<'TGK/9[
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M<75=R%*19&#&XC)Z8M"M"6XTJC:&WNT;)%XP"BX9;JT.VV/T_G^BAG _Z&&
M_ASK1!]O!*SSNY&QYESOD)49I5_51&3NUQAW8Y0"$G2*.')*S.? 9S$V-+[/
MLL)7<#BSFC:U5%"G9ZWNK$Q^_['^Q8!]58Z@H"[]S\"(<ET79]T196<Y>ICW
M2.2=N(7^SAISD="=7]E]?*U 8A&[_Z]8\X!]R*JU;E[5(#-@R$R<=.WTY0Y7
MM>5W'W_F8C4N>O.RCWHSRR(\'(],EE/OX]"3!/04"ZUN0F,\S3\^]P2I]I!\
MAQ<,N;K*W*W&2,V&S(89SGD;RO$AKP\ETU%5K8S52,G+5IIEV>8S5S\NR%ZA
MZ)"'6ETM7[6@YB]^,& -S?Z$422C]6N;'V:CF&SDD-X.0B6J_W;9D,WR,_27
M]W=8WC_J#(;Y:Y(CJWB+/.D+MGM*K"+?*I2[GEU .& MA,/)][C?C[W?N"Y'
M5W@!\N&0'OS\'%^Z"#Q%N':'R',AH6M<AR]:^DZ& &+JNE4:I.FE>L7"X62N
M9UC2=NY7U3,4-:8$P1\7UF+[9F5]KFP0KLK]RM$M6'Y@1I?3>1O0<1 W6]]8
ME"PY,S@S]R.7>?C7)9'_YY;2%)VRK\PSH1P1@:M/&!XJ#QB636QY&>LFO(3*
M4/%U/F+.81"I^P7I3&4ZP.<4[KE%4][I6TC[H)JZ[1<]B#QDY>TU^O%&P<8/
MZ_()@WWD$Y.]2  M21YH^)Z)\94/D 8P]S8K9PP)<ZI@/)B^^T 7_K[NW_%H
MM18; 8W&0!T^OL\+[V>U7A\R7;"U*<5LCLJ$KM877)C7V-S$%Y?[>!3.7E%$
MY=M3'RPK5A3X$M$_UO^K5&GC296*74RZHI]-0FH!T [G?"$Q!^4BUQ0N5"ZY
M5I%]T<R@Q:DV]R;/JMUQX'\\\VW1#,_G;](4Q"A(Y:?A?9(0Q/GW[.VMK11:
MV+AU6_XR(8 NOKS:T8UOT^Y7:].,&X*SNF6[BXE*1:1[@ 6IG%]%O=*;7K2(
M=^A;&&;@_'W#-/[)09CJ'G/5&KR;67@M/@%"[2:BR=Z%@5 BM%P[LJ<_@@7J
MLXV:134#5 KN#08:DE_15<D]GQ;=6#+=NE3.8!N.WT6I$_)ZS<(05=;N#HPN
M]GNK>=%+9T"Y.0^J(&WR=V 1\P&?!>2B!T0F*$0I/\>6^7ZJ6]O@80N5,WS.
M+U;"\V"<5-CO@FBY@=5V_@@7Q=0W[:0.O23TV'19C,%_RSHHKS)12"\2W%O>
MTU!.UEBTT*I;#[Y796V":W9P$^56R4QIB.*.TR/N/#(EPK?XFJC09![@;C <
M;/6O($PYJ:).,2TF85#78RQ^PKF$A=A0@FY.:7N3;7C3B[E3AE?%>ZQE<CI'
MF[#":0VY2W1%Y ?FTN(#JX7H6<C%7=#R@2J-/BR;,\2C(#L%FC1-I]=XP9Y,
M<J^Z P,0]+FCR\NWO"NZRP#5KMPKC"C-@-]VPE*;T:01QF^ -3U8,.64+?M-
M5.(2"X>Z#X<QR:IB%DJU]-Z*D9.B5+4S5JL(K--<EM+8HE]><7X@>VAA%Y>=
M-?$BV+(^[,QK&-@C4F[0>TGO"UB.33A!D&SI%EKK+@M>HRJ4AI-&AKQ^+JVT
MI[9E#)P>&#4%B(DJ;ZWL+X:Y)2&"?Q]@/V$\8> _8JYO)&Y<*E@$X_G0_?N$
MD>92(:.2Q<=0;\?(,IP2V"X9Y-&O+<*BG)JAK/5,#G>P&&>?K=;*]$.V*\R:
MU65FZA?R[K4@=6L6$UE94T[[J:P4_A@W?Z[K<\FZ9<F0HR6#/OV$RG1"9]+M
M$_?-O/(/,2Q^Y#$RFQ2)+-:YIM;^WKA4U14K.]*1[Q]Z&2J0J1XA!T!X[VSJ
MO'JBA[F,U/8.AU->NV>P&-=:)KB=C)%?93X[*^CDY8!",Q\714!6Y2\K/>#)
MC7 O05JVY,G6]GW;>12V:G),U&/%Q?$%MN[;$@ T)CNX7%^ZBYN).#D',&3#
M\H(6-6DQPCVU.0Q4WM-"X/PEE..C]?Z^7PWP.T:SK>H'YB<<"!73LJ,#5R6C
MSQ?:(<7AM(5I4PB+]O!6PVY%-[^1Z3(J\"R:A056$QB*E:TXQ>%7XM9CR'X/
M[E+9_AR@.N*"Z++9?RAAK,^72.MM^"QJ0:VMT=X>.&/_X H_W-+DQ1-2%\W(
M%4_1]_J8C38:8]?#[GU-4RU&SE)]I4?=$;_.Z((?49$F<@!SEN[-EW]V8"M*
MUV4-];RXB+*3/('1XQX,_[A@/("YK,H;;+1D_L/-6ATB=&ZH7"@P,I6=$"H>
M6>+@E^BP,/59MHFW9J4VSU*Z=5."\-W41J5<:]!M?ODV/,$V0\+N 8J@H/;"
M"O6#=\F4KP'0SB)W<8UW>;4];<TU,<GO)AN0XF6?_=2;7LC=QW:",^'VG^09
M['T]JW._.G(&WQW$+%7C+!E([KPG&U3WM3L(U+&OO/QDD8/WCW.JX@*"7C3E
M79W]FQM8DA_1.&UI&1:]QZ]O% OO=^2^.J8M]_^X>'9^R#O[0I0/I&7;WF,R
MSV21NU5GJ2[7<.D74"/::\^R8FG_=W^S'<SRXB1-61!L./W7V$L#<9F>-T\Y
M?J0.,&YM\!NJ(/.P&T[:*I?=\M[L9&'I_MF;/5Z-KJ*'I%B&[,W2?W'Q4!=S
M+9..(2[58!9O2>?4G]6L5M7XGKO_(H;83D,F2.1@H;/HE"J)3XC57#>-@_.E
MJ<"[REV"U,FW/L3QM';]Z=X<K[)S!)$FG^R7>7?F#S?A<^%'?4-_T#L;$@%O
MY_H=+__S3%?,;,V5[4_N9\VV=$0JU.-([8PJ5>\F.?E>B>WR*$R_U574;$K&
M$%/&.,KXR%COQ89!B>G#")AAL>X <B#2YH.H;=D;+5&//1"3Z@\DL.P]I0(S
M[!%,_61ZS2L$5I'5L<5SCZYNO+8V;H.]1?N];-A9ER1M(\.4LUHB6+B$R%F9
M1:#Q8E[E1NZ#$"!:[W:6I$W]]WU#Y7GQ_,L<% _Q[THK,44HC"C%Q!N']CYN
MI"-^M4\LTB 3M?P?!V VV2$MI-;?.Z]TVX;'&[!KYO*>,)P.3OSLY ,9OT\3
MWHO0_YV!SE<+\[%V@,ML3>#L\*ES/.</OZO'*7?#?I&[-$OY+X^^0M8MU.G/
M/9VOW%STO1$3O)+CY)_)GC<1_LF <#:JE*95QP?&JTX<EM' SU9E7CF;M9OR
M9&@0:4Q\TL.E=\PZI:)04/-6:4A_L^Y(EJSH^B5V730K!\%M1=PPYNJ^+(E/
M;-%)G;'P\F(LX_2?AT1$K!/ <.Y%ATU5:\UHT2Z"GN[@U)S1!S?3%,!*,/L'
M*=?JWI;_\S:T:U3[S2\.]T^($A@/':9IAI]/P:30 MJ7(7-QG2S(KRT]-\&T
MHU-Y9<GR/SI*8SV*SM+.Z6_^6"W0VJW>Q#NW1R>["6;[@0BIY@3VKEF FEW!
M/2QD#(PG 60D#S1!9PLD$,3N00D3?7KBRLKF#!]ZS+6 6:DTG=/UL#54./#
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M^OK#R"28,& >KWJ38<U\DQF_JW6A F9MM:@N=_&X[RS:%WQX_+Q?*- 511<
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M;K;5_G^(W,VV^AM7ZTPFKN7TVB<DNJY_7H3Y^C\OPC286K*TPC^5;(N-XR(
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M_+I\)[ZDM]^X9T)JRXAT]<,5U \[2PWS6Q;FB"[Y5ZM_#OMN[N],.R(JS:Y
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MO]22A##.1H%3 P[[9X;AM\5/2'^! 7N%#/O #Z:_GY!\-+(<-=V%<& F2;?
MFOW@E^2V.ZX_,>-OC==2,CIOG%16-9U '/7DR'#17ZL!"@T^/G$/A[(S799\
MAD@'#%X? \YAN9GG3#Y72@_H3TBYG7]?SD+G^ZY#Y ]#D_8?09>4X^)L&;F9
MP>)%MDVOS@XUK26UTR5]D6]I6V*NAZ@:T"XDE)()<ZFI-<2+991Q$L R7^(+
M4!34) 0D_U/2WI*HJA7,M&@ER8"]R'1QTU73QZJMAO/,FIUU9!FJM[1FV'?H
MC<MF['E)8F4*U5-&73%E>-OV'756/W=9$#1$AXAIRAO3S]?-"Z"OL;,NE80W
M$XPO01Y%-M]^_;TNIQ(54\O1P(^&WI3ZCK[)@K)A/^WQY:VVS?7 \I'-PX_%
MNDOY?6ZTE='CPAT.,_UFBTK,]C1PF_C%U8I00-R*\=[*O;/UQ\#$QR*?+C7B
MXYE=IY)UX=TI3")5*!R4E3-[K)3ED35'GXXHS0\ZGY_EN$>^ #PAI3U$%7!3
M&T3<%.$:R<),"X.R-G3\F3#2SJ)+\;#YQC:WJG)1K9B7TCZ6)WBDI\(L21YA
MJT!HUNF=6Z"8D_,@?.SZH;6+LIEHD^I7[8=YJD)W"V]"B3,7_T3>;&8L0T%;
MC4BZG:!7K:G,#8&I=> (Z35;8M-@*J'BX-^!P@C60?WE0?G!G_8:C\S[K7R3
M? -N\8H-50_1G?LLCD&W@2OB?__ =8;9<"MD7..)'CP%J!%;G'TS=4RZ(EP!
M+!S?%V$IIHAUP4H^ ,?O96'O^Y$-B\:U)1':*(LIV.>T@$=8R-M*]MKV$L#"
M(JTY-H?&5^J&%I,,TL2#"E==%B1R@VP?(J+!5F6T./Y:P;]I<0W>#=659="P
MKW.7U&EJ4Z2RM/2J+%\3-HU!I7[TVM?U13.C025+[3M2):-FC?-^ 4W? <='
M[%D* 1?<7?54]WX[V)IO=7&\8.RT1=>JER"A+^=&[N$'_NZ!S8,2;D8^XOJY
MHM\H!J0+!UR;U)4XN?R'E+FVAIGH(.HM;M<YGO;)!%1SQEK-$=LT*WT.$;]/
M]0]Y?R]))L/F N'R8GS1FH=#@ 19XV9BBPP>#L+><?:Q)Z1F-@/"<CG? 19J
M%3/-]YK;D\Z4;#PG'2B9L>/-KA*G(V%[7YZ0<"]/,"XP64+N7[%A@&Q0OU*,
M?!FAK/?^^)#4'>S'&<+CPL?R.J;/ -^BJOS&5GTX54)=3]&>I"0?M)*NH'@6
MZ\F8PJ,"4(B8-;*67U#&C6E).M^?H=QG_J$[&T5GJO,A?SS6?"E' GO=V?ZW
MVRM'0+9$(%S4MT;0 =J605TLWW,\&[.8+]48S"4O#QL*>>1-EAQY3P0*532U
M2T_QT-#N,QY^5 <Y/#3USBS;<= (]UNKM_6%E-KO&U95F6MJ:)C@1$Y-OQ3%
MP=07&0"_8O/GH#F4:(GN/-Y-2)S583R/\:&Y7!$2,][,%QP0;:B&&5D/".M@
M&P=+'=$H3>'2ZO794ZEZ%!4XXT+S^@',(\6XEJ3Q63^C]A1^Q@5S\12H4"J+
M3/SFD2'I*\]07 AEV:LH"Y7KV01M/))RA[4[[?"$*#H<C996;")88Z;]FC[U
M;0A[ZSLRV[+/]1)O[;+\^9A9PL*T.+BAH1*<N+"U5J];_TF3D8V3OHO!=?!.
M.5>=OF$&QY:AVWHL.\V9=DZ5&<6D[$=/J<7T&<O<Z9_T1X!A @LD!M@PW=':
M')?D7<W,6-GX0;HT:+Y969B8B^:X,U%A=WVF^2AW?J-$S*%._,XX"@4Q2F0[
M#WI?WQ]@F8E<[3HLL]7+5#T>#U71XXECLN.GR/S&6BKT)=:!2R%X?YLKUCN0
M@ZY,&FZ]9-@Z=,1DF< U5F;G.JY!%B[86H1J)]:4PE1$//XE'$(#3)>E_!@G
M:D;FWR-P$^)R_G9S!V?P_P$>Q!RQFSZJA"QPL$,B+BH6G[,N.Z2D7-=#8,<+
MK0!3NSC.!&R@9/V"%ZN\2I=!O!+?^<R+-:AIB0%CP[-ER0CU'$7"D9 UL[S7
M@8EV>P):1XK5V="$K61.7-S7(E4M T;<1NHYN+$/-9Y@X,1?O/9%I"6VG2F.
M\\>5Q)"B?X2BR=\[*>O3D'=*M$POG,4R\B;967.T9R;2,?6):*W+2:5.3<O)
M&_ H2D_;^\&)C!29MBOL^*8,V=[:2DJ0O)L,"^&ARL?\ORCH5EBXD4/BZ QX
M2V; T<6$)Z3&PR>D.R*'R85X._D/.1&]NR.RJ/5+2<MUC_.V8OE+5F73XOEI
M-C_./T@E4UB%<["P<E/^_.'\ 5)@X30+DP;;-$S:E<U+S#?/^+[BHA9DC4\0
MB2BS88@Y"-D@E_?%G0H(WY$3I3Z6Q^D('.=)_#ZG7#P<-\[MZ\@_[3V2D_#E
MN[:2,X"\CTG"42R @@:WDM2E/"D[&OE=/$SRBM)VWZEK,=D*8Y,5M&$BZXH<
MXR=35VD#@+XSB3\3KB./W[LR$-5<#E_H"X]$6.4?06(NRO^9I=MD.7I:7B;R
M4;PI]HF;NC6<C(R7*+DT#:61]LML9 KT?KS3#9-?$S"]Y0<UIK3=B-'L$%OX
M5RTS9_IVVO[#+]0F"XLS011)O H\?6LNQ"]H.7U':^J#1E>2]DC/ [(+)_4^
M/#196/=Q\91EU\3=Q72;"]U5L%/?*? [HD#!H-XM-C8C_/<8ZS]+!V,9#ZA8
MT.MU%/5!EZQSNNN\Q6SM=JJ<S%&/BEJ\[G%*D:8VPMLMVZXU3)5L#/Z5&%'G
MLPN'>[CH[\+I5W(3CZ28P0X&E;8"TOO'!R$UU*A*.0*6F+2>DMO5]E^;HL*G
M?+!S=":>D.H\/YW1@#I&B^3;DN<:Z,<?R17G%INLI$(LU;A(QIJ2(4IV'2/%
M+G(&1JI6/;'O^()&Q/ZREI+_+57 #:>>;I8D^2/VD?=KL:;6R<]<5\*(/J>?
MY=JC]F,9$08=M]22].8GG[KUZC>CG(;I0X<\#39UDU\0MF)W#E]MW<K<KYIS
ML\YRM-O\\-QA402:]\7[NL!&>61K'9> ""C#K[6.Y'N2PR""6'V,_0F*MK;.
M^.T'Y5OG)$7O3&^H-2RYN\<2/-1+W460F7[4Y! S)<P>QFY^:8%#)6>?AS>.
MQ487X-@_97[82E%*''.'VJOG*R(BPIUDKF-4)TN1OY'TCJ1E]8C7J/A3V+LX
M2/A(I<T3TH(?O\B\P:"#PP=AY8S)@6!E6<XJ*#74\S?=HK;V9'!<2PR6L@B\
M2480]79_9;1WJLVF"W1"G^'G[[*KC-69*E>%4SYL(Z5@-M[/Q$@[Y-A[A=(
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M)F0<6$3AZ+VAOWO^K/\WH/ 9.'D&/@DZO0<D-RU_;=1R.SL<ZEH"^3V$MSH
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MXR%Q)H;YH'BA\-;@4_Y^/4>KSALUH(*\RRB(GR[I8()TU3R'Q9TNGL)%$#V
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M]:C:'M -5Y")-!V@$$DGE5(T]BY@C(1.*\6F*U*X)A'5N4:.&+?P014EOUY
MO3"?3F7DRWBBI\9^!^D=MV/R39I_0YI\/B?:*?LO*-]%I?X>87%AY)O$_A88
M3F'_A?(H^3QD+:G..N+E0,%.D,_L_D\,O9V[UHK<68Y;IOL+]8\'U8=3%L!8
MW0@) VJVZ^?MMNJ/E\9[%$#MENYGI"?E_I-CS#K:T8-4HPPOAX66[3Z[%^_
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MO7^=(%-P+)K]17;R5[3_KT\<;[5>?V;B6(14)BLHU?#L_7L\T49W1";/1KD
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MJQP"6;"=C,8^ #%ZC,#-K<9M#?2@><V-4:0]D!V6$T7L_<QU\I9Y6$9".Y!
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MA*W?_]868D**B++#Z:"0LB"45#];>#A@,6T339%ZKN (%3EX4^UZ1W$P&2J
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M;F)8/- $QFKWQ58ZN3]6!2A?^65A>>:I,DOJKJ$TH755LB-,3B>% VVTK4]
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MLPSY0M-P,L6@A8;<V#@'LJ?!#C$_ S7C[U.');(J^N"O/0?G"J=DC6?:86@
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M9)P=-O_1 >JR0)V5*X4SK.P7?N+5A\/8D^(O;VZQ8\2&D7[?&3-&OAF4<VI
MYJ VYC@['[_L N"]_L2_CPY\G[.$.6I])(F,I#"+3$L![8+J;K1^I[8?$TI1
M4E95Q68R6]C]TGM2A<="JM'!!7>=%\%I5$\*_@-XOWM@E]Q0US4HL:0 #ISK
M&V!U:*X3>FAX'V@8$MX5+W_:^@N@TJ-2?T?5*KHDD19D;>1*=FU)<6IC:M_*
M;#]_V#['8CSOVGFHGW4$&_!K)"O WV-YVF;=[? $I;<CF:]X5=4/24C(^W&+
MR.R\)6@_C>.9Z E+#%Y^9FD8L^V#\>G"WOX#V C_:? '\)#!HO*N-C'D#V#V
MROH/P#AJ<./_GBT&T[+@9=W=_?S[93XLA(W/:(H#/Q+&D"S<WP_O@\LP$S--
M0:+UGA)V@")VQEN Q5.:F5:O=T$EIO=+<02,%E84DKAF9O6.+P!.6LD /VW=
M7?X!^/X!9(8_^0-HTR5\59E_9"4K-#WY8SL^BHD9A=51FA/E @OEAGD4]*J"
MXHZV\Q3!+ O8+-.<A.*@*"W!WQ,/J+=6OQLFX&W;5?PS<R3_&N._MF-[;174
M0?.>(=CC*F\#8'VB./QA1=;8E6_? 7+GM!$WFR@:_AVS>96OFZQ%'DM>K"9
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M^O@O\:Z>M-C8D>,/5\&]-TMUPXH2BGM=XE@W=%"[HO^IB[R1NOZM0.ENEA<
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M6T/)VXOBYR7C@M!!JX ^DEIJ.-LNW<_!MZ2*HKIQ$5@V070<+ 9-QQ]X*KK
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M',@9J6K[#V;7$67AV[:%7\'0N-+$%_IL%X$+5WZAT@**E<R,12T]V KVQ-$
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MP>$?CB/S*$3>G2OAU1>5'%1KEB'497L&H:QA\&TP11N S5Q>&15YC?VJ$X/
M G1*O65<)[PY@AD!4A4O#4-DR1[3L/1ZN;9\J4UO7=HR/_+W/A!\GSJI,EH=
M]U/<3$1G^ZGUOIWP![M\_Y<*FZ29TT?5.I=O7N:N!*L0N)O8W HI>6Z*9TDW
M@6MK]K9U5D5;+UK459$&>V\3+%Z643#F:'#\DS,OTEO&9U-61'P-DW/B("SW
M2;;+@.?1L<?\N.OGRU? S\N=3M,+$@GJLZIGP\>Q%O9Z;H-*SCWAE5P,_,K
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M2-4-!_GM7AX#DS)\7CA5_:<>ATZ]:LB:XY9=SE:&IR)F^US%AX&3KVG )?A
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MO.$#39_?Z759$6O3.<4=GIZB(?]!:/1F)EKW"GF^@SZL;^TNL4F'./"H(S2
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MF>R/&<S#*9H2WK4V3B6PQ]B=2T$R)0SM4>I*-NSPJ#&<='SJM+#/38,N@=]
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MLX:2+MM'5544\-'Q>CD4-YV6FV01?K\9LWJ,P75XUOY_O%8&A$=9@VO5T3Y
M^'7<K6*/Z)+W'N0A2,+A\]X6Y#HX,.RIA'-6U+Z6V3)G$?U=W/Y;(=8)ZX,+
MV[H*:CVSX_$7Z@#9;"FA2?>@D6U#?9N!'K-E86?O&1L.+^1V!&;DM+%I8?OO
M&2?N6P5_ <[*I:I;YV)26/H:\&7DU:L?N"5N?G$>N>@+7I"I*)%JT4OFLFGB
M_?[$37ER;N=^J:;Z]-7-DFB$_O!=X$?FTTS,G91.XXF ]S,.D'0SSU\'O'J)
M_KK5(=:V_):F%>OJJR';&?7.SMOGV>KT=];SV*SA\0$:-^,&?7\!L7M&SAW.
M_56>"M9WY%FM\R(ER"<T4$PI?IQD4S_/GX8/F\0S-N[R6F,3=#FZY"@G2/D:
MI?:B,]N8(Q>NDZBLBV+:#$X5!M\)+/8)S%AU3F(AE]IVK?FYZE^,($I;?SIK
M+VTSN )"KU+1,-H<SN4HW!ZWC!?4-X+---G7Z//MI^>TO"KA5U(?U'W_ BY
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MW448(R_V:(_DH?/(YW%.90<\>F;S.EO"!10>+4Y%49D] &&M.ZT9L[?,&XD
M:4CH&:I_&/2,/<7<[W-PYJ[.Q8D]+',^7&D41.88KQ\.*4S]Y98U#(X6VBE%
MU8+0>CSU90/R3Q7Q9<X.$M5E%GN34'H\QIJ/,CY!O!DW1CT3O+:J\B@B*X3J
MS1_1?F_)-5/*#B3=-O!W+95J3/$OVD2_\J@K0#\857GT\,9_M#3=I VT]TU>
MDNY3(:RT.:6Z&G:-R%O,7.K%AI*]VNXEDMO$:&>=Z-/<.!Y\LE*L>-!DJUHJ
MJ,L/=73K'#&I=W<A555%223D !F2<0;QLUQ%=6-S&LL$\#AXY$85#*RU!!'
MC#0[>B)WIVP//M<YH-1IUX')^9+0"I\UPK<-0,VV[C$\%W;R/%-%(I5T=#I9
M6!S!!%"#A9HCI=""".C"]P=_E'ZRM03:NYS<<J9^5?&.51@LOFGBN(O67W;B
M+=U]S<0[C:+DM&\Y>8<ZGDH#\PU@WG:91-MMW&LUO+^,K<*C\8&JL.0@C%SO
M?>66."^M1_\ #RPZTK-YT8Y2!Q!I0'B5!)%1S>X)9;?$\]Q(=*1QJ6=CS "I
M.$O^^LWZNMC0^CQT>=ATG-4_C'G48$7=RRCADI1IV&N9O"[5-.@4',,%-QN
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MV32R[;<+VD,DBT(J?-)X5'_HYA6N*<N(WVNV9H6DT&0Y*O*2QYO\N;#;IO\
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M8=JX9 7-"$53QYB>4@<<27=QF\C%V/2QJ?=JC%__ ,._K=N43<K"W,NVWLS
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MKJ6)#U0>?'1[E'M*ZDV^&DM[,/F1 ^:#^,_FKXVI13@(@2UVVQA  &2I&@H
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MZ<5QTXI[O_B3?8Z[)9.*(PRN)1F$Z57BW/DO*:2;I?G3%&**HXLW(JCG/[_
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MSY>7EXCN3WAG&WE]<4MS*>T:(-U?\LP#3IU8?:;^5KG:KPM+8W4I >5: MJ
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MH9@7-'P+6C&']BLI,1'1,[(E6(^67#'F=73TA$:V:*U)"1=+25P_CI8\IX?
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M6T+\2,2IYE=Y^P 4 K%5Q^?7J_;53?^6'O^)(QAQO@*:=.DJ*:5T_%^%YC?
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MFAT!-)G.]GO,6G%D3BL.7*W#2%&*H,GA!>:Y6\>6O%66[J'%&& ,P$2 &0C
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M[,=6/?> G<A,KPA8">X'!W_+L]BB/O,PR>"0\R\=GD\Q_9A1<02"PX2Q9!(
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MNJMDYD]L>($KM4-D3A<>=HA@M:_6[V@6N+277($'( VLM3BAC'E?)F'LS[Q
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M%@CSM*O)XH[67+$)-P6-)7$D*^UVY>^RNZRQPG6'O-KUI684P6/EJ\M1=)M
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M:X@/P'+ZXP8B[]9UP]W+8A*CVR!NX\3VF>E+_X#KY32']5W[83$.\PN@0S]
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M ^$&Q-L#N#D?A58@<BO#N+"(E2J7+,9PI#BM&:+H/D&KG5EV6VXHHZI;V>S
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MW/?>K'DS\V/^[5/UU:Y]UJG:]7W[K'6.YGG1-3=D.27]U*E,@<6^\$ K,3%
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M0$%@##A;XY)%_\^8];:_O[,S)=_:J?)B\M5/LUX;522%>G#Z $*#G_Q;H8%
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M'H,5MDA&%E:1"CTCA/S3@+GR.%]?>_V 4,Y;)SGIL"L/J&& ?SJ]EZZLUDE
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MH_ 5>-E9#<_K],^!Y#]=&/606T[-%5)I::L)<,97SC'^@9R.G@[:33Q^A7+
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M,FRD>53M*E]LDN!V66=3I4C7.($+(=Z)(G^:1O/__E.6LY]J02=?5X3O=L^
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M^/LA6=C6( T0)E=<&,X_.AJHX-7$YX7&X8Q&Q@H/]JZ1;0]4:&FG36HDYKT
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MO#?O_,7;KY(QH5JP;[_\BW^T[+)@77O:1#7"1.Z%6N"7O&>+ZMMRL_@?,TB
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M1[J\Z@)'X1JY['.Z"_0,1>)MB(JB?KGQ<'Y?P TZF)X.7TDDN-PXURXSDOR
M%MHTBH6(W&2:?_NV?<H0R+(WJG? <ZYU FU38)5HS31$5]-F$VLZU"=A&H_;
M^;W-@G4R7X=46>K()RGZ$CI^;66%J(.\#@_CL;2RPC$D'I <"2@:C?SGPW"
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MPQDY[UNR./$L246^VSR<3O7$OX$'TI\%I#8<Y;EEN9QHE^]^'91;M-[Q3"7
MR.J3^@R"&B[](7<'C1=M!;^1_[BP:%N&S'/BUI:89YXP*U%M>,JK?7[4\;2!
M)#-RT]38V896VE*I]J\$H8UJ)6L/?O^$U4(85]-_GYL6MM\O>ZG#@4[",?_(
M.>KIJIZO]K=C$>9J2XN^XOKH\JRF+],P7?8Y@^-> IV00% :*(OHL)G%$1+"
MWXQ?*^5Q8ZK%]<M;,^.O-08_?!.(!94^1P,\!#=EX*FV*YK\29)<4PNE! ]U
MX'7'/IVB33D=+@VV'M8?G7(T8-W;AHXDRTE9< ==_/RG.(\IJ8X>NQ68BAB'
M9 7( ^3[*;?+@3:E!GQ),BEP1^8\KB?>Z_:^U_I2^1/ZK']CUC?YX+0Q'L.-
MP\VG<T/.+,9'*T;#[(8M7C)/0>!"AJ41$W9!Z! \G2-KWZ9GL!L5K>W]S;8"
M*FX;T=FP6DMJD\R'G*:^*!0+64G7:8>4+,V)Q1K>#"J7M-B]2TIK5N+%F@5=
M6KU"7FEBEZ9.$_Y4QX>$D;J8B,WE8_E@)D]8TEG5*"6#53-.>%.\NRW5.=]7
M'$D" E\1MKJZ7F51=C[VI--"B!.BM#^0G?3.\N:@A@ W$N@X]N-Z)_-& OKW
M]*ZT&\38"!9H8VHE^N=SK+OT@I;H_WFV-/^%P[_C#6"G^P;X9XBA.[$9RU H
MO]G;U7-*._[HJ6;80A*6IRQQ8\K#4O2[-I:\[*LXF=CTRK><)S;ITE;AT"!Z
M8D.>9>7#O>DU_O%#AF^/^";RW&NZS05?"A[9[#V7C^?S)_H7/#?M\U5%4J*]
MRGN]FEJDLG2^J"9/$"U/,K16PH?A>#B-<BS8:UD6&E2KX? P\"+S%=O]8AL4
MVRQ,W<%GH$S1 F:8=7*CW4(7KVL.TCSY,]>ME/G*<&"H;N/W+G@@!O%X!"42
MOII"2Q?-$"/*0Q=FSPR\W6V\S7<J&K>\>%VAYW(4*+V7W3^L-<-W\ [AAK7Y
MUXK1W-"J^",0W5]7$R)1!B[>1<2)%1[S=N]>U>?)#O:45P'XQ;CV([;+.FU"
MQQ?"-8\1!/_RQHP>FPN,<IU3PDO'KG_O#$ZB-YM$/>!&UR9<Z"^J"Y5V^IC9
MD1+;=R=^%<NLF<9^[ 'WL7).P<!8K&OKLF'TR/0KS#(K+-:NLI#/W.O%=".[
MVCV-GCU1,UA4 MUMC51%Y-3Q#<!KZH^P.??R_M5VY%PM<O''+RG.$2F2Q5N$
MT;U*E'+<$5/2"4M0!4I\LB+;9P4HI'C>/475@+EAMR?-*E7J#; 0L6TEY6%$
MY;VGO]'Y?HF+<ME<N5'!^E*)YNHH/(#Z,-R$=SX+#CJL)2.\F)7S*^7"\O(.
M5NJC%+BO.I4Y5N9,"-Y6JGHGH-4E96(AS3>BM(9R^P_Y37NO_Z4! XK1/^ J
MH:9W/J/UZ8B?UY!(HT@BA\%/Y78M=2L$ @!:HZJDK/OX&HCW&HIB-N[<YK^
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MG;T=SSH=_%* )TN7DR'@/GMG$(PAC>]PB#!70F(&<VPR-,SA %4BZ2J%#9,
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M_HWI<R.C3ZVQIKP*CWY6SG8&J9W3@]E8I/7R2ODWNR4C(GGO":9@@,[RT6Q
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MWTO1T8N#J7(S@H.IX9>HQ=<FL?W\D;^D'H MO%G1,PE6X3RAZYC:L'=/4JB
ML\#$8/GWR@@>%#EPZ'1**RO^%AO89,52_J,>=KR5(Q]F15"4&$3,&40<LY08
MP!(9(](=+6%19^7 >#A:0@+D'.BVUJJPP?IOLRA!_[Z1Q[R[@RVKK4,=\YB-
M%L]X3K.9W*#?9E/@JY:'=D_7V:0=?1F%(3'J&@:.R<Y]K%M;^F^+O-1P)7:_
M6'F4:)M#:-NZ8SFQ^M$/W4(,GL"]5'R^W'T&.<@BFJAE/9V:*]1;@"=^4L$$
M%KY&KVX]N8-U,;9LL25F=W']O#AD\W?7U1^G8:!$6Z5.6>LRZT\&TB1#[HZ&
MJ5@3\4F5@H=Y2@;"IQY,M57T-D9%WTI=!5L/3X;]_$; 3LUM&669XJ.C+5 #
MO0=?E]<4S])B2@\;T/!CH[6S/[#UXAS15])F6K3RYQQ&JQ,:YS:7N*9.6BNF
M#$("29R#7_A^7PL/3U*4F?I&FJ,H'&5AU6H>,U:Q&QYL!C73G:Y C!; >2 S
M="F/OYHNQ\WLQ?2NXV^2L4DT+[D3+YJ:[:2B$@K??HQ&RFR0.;WW1U-;BU!"
MU>.>VE7N&WBA;VP$&$8=IA,+S_;%9I&1PHSC8-7+WZMQ&YB KU:^8_#\H;2"
M.:\'NCVKHBCI&[NPSHCLC.N-#67JAH+'>"J!FIWT$AGJ*%LKYK%$))3\=QL/
M]DXQOP+U379:IL6EB:TFLX(KH'-YGS>ZYS#?&0ABXNOG5:K6QUNLMHZ^WEJ=
MV\(AE$OI]&U;DM0=]7V3N\PF84H$S>0)#'FTYG)N;TP^X(*PF+XHB^/[M,X-
M156_)HG4C5S6J#*-D<5RU")+JA4\@G>Z!92^EPB:% -SP[FJ728[7N3!K1O#
MN5HXP!AB]*Q[NS_FW4E&N*<82+3EO/0WT.[E-\#3-^.\CJ;W#";=GJ5U[E0E
MA;?FW2:W+Y9DPEUF:XNX!G3;9&*S<<0_P3OG7TDL;,4Y,:-)1HW11OU]&K4&
MM^J<;&1^#@B6PSCL.]PZ:+[0Y$E-! (Q7.45:8@MS>QUB=#_&@UM3]L"[0P3
MV%35PWO3/HWI\FMKVO5$CLT\.Q3NQ\2-<NS')#A@Q"Q%(,HF?ZOLKXJ#2'<L
MEI"+L]%TJL]/@HSIF'K8=J!7M==GSW]$WT<H+?*)[FL*XOP!#Y..^5^_\,M+
MX3CC@Z.*I9!;N: 91 F]9-N]A/JA(^M]'<-19[P6/FZ/C;:[N3\\];-C?4&L
M)N]L*JL@=&'1LQE]UWP9'$:2^&8L7* "M=8Z[[SS3OWD#7U#'EN6GD8T?!E7
MYM;]B?2]T2-'-\\'TK13TI(')3Y=]!B&<:1*D4.VW"G] C*Y=L=B&NF5P>^1
M'TCQA,.$ND6!,8O5<DN$+VO?$YOU*7%GP^1!]<@(-Z8.[61/;:(0*09<2TN4
MB"X+WT!!O:MLQXG6'>8HMFD--B[N8FR#6_,NKS OV1=T[R.=14"LI,DPNCJG
M$OT[KZ%V.*K6WX%C2A8KS?4WC6V&)0=4[3L?!]1:5PE"RG&5B)0>8/W4>KX\
MEN4<'NRU]DLSD&Y?V]^!]68O&7IGW(C6!LW$ARZZ"0EPCE)M])SC;!9\X]LZ
MKZ-/0AZ.6R;2=O!PG;2)H*D2E6>V![V92NX-K;P<K1_:!H_]-!CX9E$% +[@
ME[83B.SAB#10M4EX7?M6!*?S)'Z%UN-O3N6M6:B0>0Z)^66(1'QQY2V4U6U1
M7SCNE5F5@[P?,.^::,=>*FAQ*]*897!?:4B)9[M'E/>T3ICZ#F:C$6J4JRJ1
M3V)2.Z9W8,TIKSQJ CHL8Q(&-BQ-BX_&Z$;O 0CH/P3\[*0(U *!9] QHYX4
ME"\'BVEB/C.X$57EVPA'[C\XW%:'_!Q5&^^#%U;PL'3UU<?7X_F:8TE"02Y\
M&MCV_UR7PFT,>ZPA\1C$AOY8=WL]<Y1V2XJNY<+FZ]46;%)VY>GI<-K!+W$<
M?$45M'DF[!]_Q1T*&7&C(Z%0L";@ITKB".-M_%0-076C*T[<&YT1][4!4WC6
MRG :>U#$E\;T6DWFI [JBS,D56B2(<"@$D,$"D_L:=+X09^8ROKZGR@B?P!/
MBO$%^1HL[.;1L]!S4!+JC1SL_.?HI2]<UXM52T 5@9*^NZII\'")4\1'2OZR
M'L0H360Y_KUN;X 2<\5YYK%9,T59WA<+)"NTC>5DI:S5L"F(C!U<>3/A#SSN
MV5.WU-X6D^3A+/BQT%KOE*4$Q>O>T)'VYBK8Z@5%T[(-=[ L38G9K&(106<>
MS#V44NG+=\P[J %IW^-EA ";5.5EA@P-L#15E@M8CK4K6XIE6<#/85VOG?6A
M)*=/D.S!8S/4H;AF7X<XF?/7Y%JBE:0@[QO@?3,QBR%!$7JY1OC?%02([)V)
M4\#%EF3?' T3+*G!*U:UX!,<7>9)&D)E59**KX@CF8.F&U'%^$$<"&+G6RB"
MT^LVJIOCAAWW/L]@L .5RJ5D297(["O'9VGA.&93\9!QK"#S9UG"J-NJ2'JF
M4-?1D@'5AX058[1Q$_U:.=&"M=P$$65,DKR*_3!0*SYZ/B&)5 5'6Q>Y0O!?
M\IFA:3@VQ\:HZ,-J/-LCWN31/XB)<J6&I"$H9#MM7VTA7OJ6*GP 4['8C$^B
M[((<H+#'4AD19*$/+A#+"-),/+:#8KF%D+F,'/+CBZDMI^R8J!@D9IH(B=+<
MRGZUSGQL@>ZFK>4MZ8Y-*0]KE1I>J#LF''G\F' ,4+<[66=K6#$PZJ75(X*_
MK*-PBACH$9E"3.$UO41L'5]1QC_:-X)LG6$N6#T# 0UAOU/QA#Q3FH,U!5T$
M&%$!-R;8.CP*\N,Q[JQ(=0)B)^RTCRX>W@TL=J@T-2+T_U=EYQW4A+/M\1!Z
M: :I(9101 @@H9G0)'200.@0$.E5E"+=0A&$0"BA%P'I74 00E%!>C<4I4I'
M$!""8D']/;WOW??NO>^^/][,SIS=/=\SL[,[>W;.'SN?+S_+U+X?SNAN;U^,
M[3I]?)57> 9CP?S9X]@M]JV2;\W9K<NB>FHSQQW!^B8VU<43.0NB\P<5+])O
M=<:9U4#TA"4A>18[QDC?1-]YC\:K&9[E[9UZ5)S]/$G9LJSV=WA\'/;MAD."
M@+0$8+9[B(*,9:!"O2<*X1]"^A+AW[%T6#8K/>@F)!;&K3C$3.&Y-K$RX:,V
M078C1:\$P1+[M,QR!=JHIA\<=D5(+^<[<.*WPTK\(3"GJFJA@, UZ=(3$6S,
M2]HKOO$,]1A$ELW>#AZ:+*<P"-E )/4,0OT'P<DB4%WD1C8OLRN=/'+R;2D8
MG_306+FO !MQR>03X>./XS^J_ZO1V4 RQQHLQ(\<M6>9Y822D6&NWD^G^^BI
MC@K^^']V#'[JKD2\']#>D#K.&7 \,Q:8L/V*>/D-L?T#N6%")VF@+K@RX##_
M/#^"4DGK.U#"PHABDU&FR%Y)SY+WN,4X>"D;^MP^X)O_Z-;_ISM0(O^/(^,/
MJ\@]%?8K?*JT[1"#K4W*KZ72[PX;FG3P2JA:,D\5S^C2XF[;"XCH"1+Q319,
M"SC=_DZ&*0S8E&B[:.#T0/"MP5NJYPR++0;!L.\:HN1VWT%W6,Y#2ULJCK1[
M/JPBZLCTP"4[;=G'80P3&;S31:5 _2')E^?T+JJ3K^@R6&,/%*W'M\I1=UOX
MY![LB[6%V10I%T^9ERX9W7JY)ETA&D,D0;L&3S<$R5^FS8\7W_E"OHTQ4%9U
M"^C;I:>TQ#U"/+]SR]T>JX@I6^/?OT0VL'5):6USQ=ST+.[$@M()4[SW6U4O
M6TL-SX(.>(?#JM$;?6^XY?0%^(S?>GG3P>!ST/;NML8\=PD/^;KDSX[+1;#-
MM2S.FJNG0F^R.D+7?%U)F3(7](!^GGL]$^D.T?2)]!W4+<]>M+E>IEQ 8\^%
M$R:%UL8)%2IAO%Q79ZP!WT9'6*7WR8>ATB[-[$-IZFFP Q[L+P&<<]]^=KH6
MZYJXDU_L9P!=.+&U%'M\Y#P9OBCC80 CM25;>#':NA MK6;8I%FY>)^P9+[P
MK+"V MFB3[3.9X:ZW,CWZ$PCC.WZB#+O#[W?I[KQ*^!-$9\K>.+T Y1=?QQ<
MFLJ6[^"2>//HX&1\GM?I67O44K.<@="UVZH\WCM?N.(I22F(E^S?/J2'ZAWT
MP+^N?/>[0K[\?)Z4RO;@+ F!TR4KKRR@+&D^6[F)IJ( 8^L;WODP!3>M@%I_
M*WY)3]U+]9<<_=L3[>)!NQ-Z^T.T8:\L_+;Z)Q:!7*0(+H)Y1IN'8:A/EDQ=
M/5%_.V_.!CA&X&5]/17VTLV\SRVYOUY&=S65<]^(?:JC'O"F$L.X-1N_<-6+
MY9._OA6+N&E 7TU:G[N.B= D."1O%G>7K&?>'EO+Z^*L2(OULA#PI%;U-5O4
MG4AS$"$!/EL7G#C=.E/ZY.\H<G#Q]MX!#[D+KD6H\ D=+;O,3):EB86$%HA:
M55WK'Z\]1QM>*T>\HV'-Y[[M')'(Y 4=A3KEU"H"G\=6^XKG0%R\KCV;"'/"
M_UJQ=?.\QNS=+!W@QR+11\[HC]OQ]16=JZ4>E"]N(&CO3*_V-[QN0R.C;L(*
MM[V<0C-$S>C(*CJX=&,C_KQ*LK9PN+DT+?[X*.90+(S79^/)00\/ @)IX9A<
MB32<$8]<-XEW;HRU^0MP$;+Q1.*8BN+RT6[U&^(+X>A.3HG1WIWK%YAR\PV^
ME60<'?5K-Z@675#__(LM73#\+P#]<$KW_9C-P97+/;^#^/X>=#;P5=WH[L8=
MP0OJQ\]_*T/_*)/+ZE2U-@<M:K\&#+H.&A7T"0;=BZ;O^9C] J0&>^UR:;3<
M0"C,Y@P?F'K?IR->E$+5MZKR5.^;I%>RE E*="-[-/FZ#.I.^^^R\U^Z$O^0
M+/I9[K17W#Y:)VU-X_/^*:U4NZ87GS?=?(66F_HQ;932$0R^N\99+\<CT]=9
M:/5#8-!7TD!U/"/X2(;D>H58*D_V>Q81&[N]0L;J?C'UU'5)Q2XI"J!']^</
MI&+S]O6UJ(GO.2=?[2_A3N4&W^_7UL_$IIO%U0A@D0)%?EYCY^UV@S'R%7'*
M81K;J@_GR2L.IE',9<UM]*H[Z<NB]%$@O?Z#@_UZ9Y_$#]5 '?8=#0Q3*U+R
M6)P^\#E!QC<U><:NE%Y'7&F<H)DTR=P4U.U;5W?<OZ [2XO1G\R/HQ; LD(7
M=@^J;N^M.>1%P -#KK%)8?&@SV5^,6NHLS(^S>G7FVUA=E*?@1I? "\2^>]4
MGK8;K,K>%.-W#N^F?ILUZI-PN-/F^)0&9LF#GWJ*M2J(;K_;C)UZIQNM&_OU
M/8J.QK6W."GEX0*C#(]PEB7-21.(/BG/<13J"P<%<64J*FQM;QS\/&]ST/+A
M]6A%RY/L16%)>;H+=1(ZE6KWZ9O<?.:S/Y$Z)5/RI_<SZ]E@T(?T-J42Y+M#
MI,U7*I"A[;K[@-.0B.JG$::W?+@WJXVGO@[?1*;[=LV($!^Y*KA)>H,*-1E&
MP14S(G+<V(\R3F;=S@#AB@)E?V>C6O];08'\+8G"54%RLM@1J^AH4C3;0SXQ
M5,-]6:=33%>=OUT_-)L]S8I.<\$2/=*"FXE)T2U@W!=0NZH("/+#6$86"^&Q
MD8@.FPD./0\%TSX-15B)M>)Q>B+I(P[)#L^%Q?<6-UE6>)@ZC8X3>J=#+HHN
M;D^Y8C4\Q[S7XJLGY>W5MZ#1"\N/8IMK:KE,LRKK0_,V%;8(9,H:^-9ICW([
MY\5QJ*:.B/)4M%R#4&<&@*+;H+%F!L_T#UOAY4*$ .V;)6,JFJPQ@>\G574B
MNA5\5-.BG1,\$^V_$@T4=BLNLU"""!ZMGTHRZ$WF)>#V/]H3_3N)*C[S+C*U
M$&#NMXY6+M06#AS;U6YI.[LBH?FM8VJ*W#KZ%G&%.H8FKCQ4P/_0)P#%8'5T
M'G_F0W(=7UL\F%6F'H8I'$VSHR_6*,LU[M!@U[<,9BMX17#'Q<28X5C_L.!+
M68K@B0M.Y9%5>R 8YSIH_>/M&>?N9'$KSXD\Y59)5&TB35/N*C'B#)FG77Z[
M*U( %=IT)2SX+#'MKC?-K)=-Z:YPS?#V5+(CPN>^'Z4LT=^'AQ%F64:L4G/@
M!&R&KJTOEF4:88"UV>[AO!8"39.(Q&^/G8EB=?MU<D(/1,&K_<TK70^&.6Z,
M)0_U33_21R9/NG9T)"_TI'T4)/-'!<[95/51 ';$AT5<SQ)%F();@A$QLU(\
MV[I*92VI V)+0LD:+(HP)]-5Y+66:QC.XL4Y/;P2&9K+'ZA0=8S=N)7BW%F(
MO%2.L!\4R=7AL#;[,&/Y= /G-WKN5H3%%R;9WX^;95@N63O+4I?6/I6%5=LL
MQR4D>"ZX%.5J!3(\\5;W#1NX\[8QI>,+9>Q-"'AQE'J(,F"9 UP.3^TEG9MY
MWQ\M1=:L]1&Y[.YI8[&%@SB_"UVXD*/Y118=R$QNB1^6BF)B<?TMQ4Z7+G*I
MT@EL'@=FOX9>\4D*E]AZ21W9W[_@_EK[D-ZP&AFW:3%Z&Q=F<^SADJLN1)\(
MOGGX8N&QE8Z?U^Q-H9,D3,O!>28?.P1/>_Y3U@,1 NZ\I86IIX'0<9^*^\>+
MI):NO1[UR(9FUHMK 4);FAP!;[@CE-[Y<[9F=LF2TIO9A+S@VS/3Z1G@Q,"V
M%9[,F]*9V9J/C-RP]3@W370E<Y/TOKG4FZ9@K98T $T+OFP7QTK/=79OMG3Z
MHR@CK[^E#H?,IH6UX8[AMC_+;/=4M\:0>.RZCMC5H%S0[F-J9<A<SL/.? F;
M0P?U%:]'00SKU5B-*MH$&M#69/R3)S(Z*V\GH>8^!"O]T4;L:CD5+@V+1C8O
MW%BRDYY6ZJS$CD3=\WQB;1Y@/1QY@637W4UNO6V9*5A<#++X"I]^4 C_*9NH
ML1"A>*+89E9 ^G&(C.F,L$A@61I>-)"*Y =;X&N(D@-Q!1I;_64A7YSW)B@Z
MD?3:MNQ6"F8*7K0&PB1(X-HI?XUG_0'[!&HSK71N[=%R>*O"MZ[B]3>=^?;X
M-R<72!YI5(P\"I?*L-ZH72A\4.K"!_^@W8CP9NF18?;:DJ>T<[& (6M9],"R
M!X .7LWO6C41Y2T1M7Q0J-,&[DU?LN=@'6D8JZEBQ26GY]+<=G'CYA;>'FQ#
M-4L."9;54PG XH/YPN8FZ"*-IN6 $U?!CYF"O '50WG0JZQK<M=L.:WP9G@B
M73VH$0>4T&2A%W1ZDUI3)'!OL_''E*+@I9:N[FY:J1 84T)+DT66XD6MQBJL
MAAEC\48A[;->LX_^.36]\1!M2 Z0S#%LP3RNWQ^=*\#286NX/ EYHU],9GQ,
MK@N0SD0-*!7-YFUU\A%J'Q+*LF2[:_9FEEWI"C(;E&R!Q-I=19'T*N3ZX=U!
MB^"SI.!MU$CAF*I31NEEVI$'5@5^-Z2N8LH5NYKP?5TO7[#HY7@0OC8*\55=
M-+ET>GLML7%DU&YWT@8\/IE,P>$?/]H@V"1US(U(HG939A8SFG$KB_*,9EX.
MLGUY>X:IOQ-\^S+L<.;&71EXI+=H';$%YZVXC1ZR<!N/WR9J$-%<N3"A!"VA
M,<^3VO&LT!>^S.6K78Z\^M[G9D;/4:>!Q05+$%W:[Q<F*W>O7:BH\D*/VMO"
MH\O0_.C-46YA';C=_!"-N62*.RH]5K,MLBA0,A1LQ"#N_+*PUCP]Y\SS;/Q9
M=4:P\,H>%08#:7(<GABQV1I]Z8QYX=+684=*+1E6[$H3Q37/&.&+=S?0N/6-
MSC/#EN8Z&)959B%*W=Q>BLDM(.1"$DV"4T@2B@-2;EHL'3K;S-,Q_]A<;3--
M15;#N#*XNOC]P%+6D'U_NZW^&EK!(I4+%4#5M_YKXC5SN@'U QU.T>E('H%$
MWCR[,-]#%<7Q'"WA3EKJ!"$(JWG"P"(TVL.2>'%;-R%QH*<W=15L)I&X>)4/
M_L(H:\[F3$(H[>+8@[ Q8!%8L9>_87EKJ0\\$!]O4YM*Y4R_?MR[(%;_%\#[
MH,$ZPB#!BP=@FR-])8+K[EH<KW@; <(X)R:SQ[/9HV/P&#7EXN7;3 [TY?P4
M,"Z5IN"F*:ON$SFS6X[X_NJI>LKW;I$#B:R&V8DB%@;DPDXLDZB\"HI:C#;,
MKQ%7'<*M]$0#3IQ(,HD'K0]\]W3X<"-JN)"AQWW&J_R3S$V.'4-!.J7<9X0.
MAP&FKP(&A5P):5K5"KI4U<87,OJS=KUNG.#*.P?EI96+B0'0RF+G1>_%U5SI
M$E)T1&X#+#0NIT ]=HZC26&3ALW'/'GDO/[SB'M4>%;!UD%T7XP)*_5MCP3I
MLA-172UC=X[?E7FX,..-I8$4<4NW%'Q'T]#Q8\"6T=$SE3M.^T2U0/MSM_<4
MJ<#MYS,Q< U_DO1/LY5O)>UX=QJQVPSS3'XT7E5/8 /OZ%:8%N9?E(W[D<I#
M)>E6#2H<_7B6*X*<^%YY%*=Z>@JTJ+:\S-7Z79\O6),98>QN[@K02%"!_:\G
M9V;;[!6(FA?>)+Q5R\#B<\T4*2MRSK:%6;\93B(<@.%.>-\KEON)].@UC5_0
M6V\A+N^P&K@9!L%U(JEB:[]07SI48Z,]M/^R%2DQ:UCP4$;D;3#QIL">YP.B
MUAO]4EO.1[FQ&D.NK![@@\4NYCE*=(3S@[XZ%._#O+"$"FG?4Z8$F>!O6M^U
M;0TX-%AK&0%5BIO2ZWWRR_Q<E/GXM+>F1H]*^97;K1ZX)6+. O &4N,O2KDP
M%H3/"-I/VQQ[Y:&L]FA1T[J30:'0$?DA<-8#=C0L-&"=8L;W5.5N%5VN=6M6
M2=?79Q^IX=VUK]XW9^+B._IC6I'2&,95Y-HSZ<>=81\AR%:=-S93[3/[.AH
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MU  I__B=>\_5[\XY,_.?F7/.W"$\^^'AS=J_W==:O[WV?B%\)TP!%Y05E!0
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M I]UN<$V75JL^^!E"_OE0CEK!1L;)AAWU":>9G*='Y/H&[1FHH>M.:C9WR0
M5D[AJ3B;-#1_0T<GS>WJ@7Q7Z#J]W? W&R>;^3BY_3=27?<99^ME/"0G2UJP
MW^![1)519C-.079!06[EG(5F?KH47SA77]@'-Q^PEH'<7MYWOGV[;3/MB;!9
M#OK"_IDL?^CT1;2*2+%=OT.'JET8$ 26?GR^_7Y+$9-GH:(2 7C;"</Y*!*
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M5\RDXVAC"!!W;O_*1+,'?19N-NP:'J;WCC=:2@U:/^&Q7I&SVB*%1+VOY:_
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MD:G)"W@&CPIC](^<'*MJ=;B5U/4(]=*FFJ*K_HVW9.36C5JP1-+.1 !ZSA
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M8NWS8\P)(N=H=5\S3__*R62),Z,U*0OZ70ZZ8S@$7D,3 "$.7#4!6#?XCB$
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M5'<$>@:?7M^+%.;8>[1:AHX/!L]9#1* U3T'W-GAD3\]&)BN,'_JIF#N!6E
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MZI6G6V'6UY"G!?X%$LF_W:/_M\,%.GR1 A,!M!J:#_\A98-V+^+ F7IY%PA
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MN=3DZ9%E+_<6G&;'_3(5&WT^)C>6BV)O XI2DZ-NB5\I#)H-PD9G$0EK);+
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MU.5Y0"$HVO^/N_>.BJI]TD4;09($29*#-(H"@N1, TH66G(.2J8EYRQ9LH"
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MG>X 9Q?D9V7#,G'2D^37OG(6IN3E+%6=K^C>%PK@+S$DT!P+8N7:9]" UM-
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M$/]LGL!C.:Q$:%KCG\5LS4W3+>L&$W> O3'#&\ 4[_JXAEDE8[*K3&\Z146
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MVOC)E?>!4<JM3[3H.JGD<]98W]BD/J%N16R&/2NKB/BO3-]!$:@O^ G'JSM
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M61%5@O2+33)3?BK[M,;&5*\VZHC@-=X8\[6,P'KG,7UM6J[959']9/PGH]-
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M KV7S2UQ[ZT!SLD6$#W:,/8D3VOZ<,9RSY"(KXJ#?JG[PP*/J6G.2Z@-J9'
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MR1-1'!2&OJ(BM35%U>:(>OF5X2D,^9>\D2HTX-^\U'A.>(64#!!2QD0W/K'
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M.V5@#*.V>[UMR-=CN(<]Y)0FPRGZR9TNQ3P(NL4? J&6:X\:/K_T4YD<$$_
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MAM.AM:3M;A<-07YJ)_B1<LJU($B-#(T\(_M=W^_?;0$Z>4$_-( W=_5C'3*
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MOR#@*-U\H1]4#$M73!H[GCZ@A (R=\VFV<><*C5)I@7H7JS]B/RZ121()(,
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M<($0IV &P0:.]KT9"?CL=%^$U#A6F1-PCB?W7T"QRG7(7EK@)1-_R\MYWEK
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MY=F8A(.N@=$T8 XKCR'7PYQG%0L7.UF2&ZHP=MS7'KW>'-6_YJ0ZATU:CED
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MAMP*T=KKJFZIH]0!U Q)!P?>OB7.>]C@^HJQG>I^4WM3:T=;!Y%[^ET5!1=
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M8+M*T6+ %E0U)J VNRQZDP*; I/C]W[4U<4E])/-K$7SB09YK&=MIYE,J2+
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MFZ;Y^J#T?9,@U6>[?]3HT9;?)4''FY+8T"EP[#H6X$YZ!6#Z<COG\DQ)3!6
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M*QMM<VIBU,,Y2O:(/,2##WC\SJ8*D,7MJ73!_L20,GR"X;E>5XQD*0MK$7+
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MS':VYO#.V62ZL3 3$6)[>Z%!CG!0U+K9G99_Q,%7=GE!1[X:DK"RATEMS_L
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MI[X,.[++(HJC$Y'#>A(<F!65D*3F6VV/DZ8LCLWL6ZB&_HHN3)A/(N] 9*[
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MS"/+BEIT[J4RY(ULLASC '!R4@:+OE"#09%S%C'P,3XM2T6'7#;2_1P)P<)
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M;E3\I@#!R7*IA4\A:<6PGE01@D\0(R[/ 7'6UF67<UD=9NC4I_8+,8IC8:H
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M_X4'29 /IDY?O0KPL.AAR&&--5JS=D7\\1(^;LA[5C-?YE)^(B"S7VX+HD\
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M_4E"PST0]C[D UHQ\SV4/>!)9G>55LEU6>P8"I0TL*&:Y2J#N4-TO?<"&E^
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M#[3,MHUU>\3W3V\P$^<1+[LE7+L21Q25%"QVOD ,4UHX_%H-\V)XFGUQ[C+
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M%RV86)1 _#];L2COEY$IY>52ME_;Z>K&4HYY9:WM.TW\[, !)HK&6]@11WB
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M_8)[JO// [R0\F"&-LG%=WO9[XKE5=EN0HL"N]^"F\_L<0 RA3.AP!+6=JY
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M^F$O)7B^R)[ZF7WA1M_'>"5*IMT^4D"I#F4;=9()7C :!*]OXH%=BMTH#HQ
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MGJA:2),B0):KB+KU<A J@0G+,RR8*4!?P;4?J=05%*ANW%!&\J_(*#B)K9J
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M>5W7FG/-J<;+A\6CJ88&TDJ_68-!7*NQU-DA00KBT6@\$*D(01,OQ;Y&\8>
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MQ:>A  JZ$K" \',6Z9<_NO- B38$Q_\+\-3GH"<!<S&.!^9A&T+A%9LK:M@
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MXZ;C*][X)^057\&WE9=#9'JMO'6Z+T00>U0K[.(!W%VFBO>L'LRV?I=\JIS
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MKT[I[IZ9)&'CKF"9^/1?J%=C/S1LFEGQG[%G"E9PG .NU1]WW:$<&1;.[O=
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M=+C=3?\V[_K_E\7*Q^4CDB$P#"ELXR0>4++>$]V2-Q0*^]FJK4_)$[A?@WV
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MZBC@K]6./!<07<I=/#]$ZS'S$I@I1XPQ*9?67JCA2_+*OT+%/K2O4P%"QM"
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ML&9_'N1.ZU+P-GR]]GBM33)AKE*L'#DE7"%^<2:[UU0QSVX/ITJ3<H!TQ)Z
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M0MV!V2B-)EHDP FZ?J_VVF:0TA%D2FBYHN&&2&%P07Y4D8]S4S&(A?HXTRN
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M%V]V7BMEWC/E,!WGD,$#\7DX*<B_ CIBOQ,E\R\O&:7?5F76Y)9T2P1?O*^
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MEY2*6?]4PF;D/RO-W?5_AE*:_YSK[3\-SOX+DCKYYUQO_VG_F-BA!@>PAN,
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MG/F9!;%PBZ^WD/7+ 0 96#J"TY6U>-W%HU#WW/S938G@=UA.>6FH#S+K!@Z
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M\V#X,XA#I>&N:\W'T_)W8[X,65;>^]B: ETOQNASCX:TH;CFG[];6K4_$!O
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ME67?.0C*GHUZO02WZA""YJ_561&F(:<#FH56+L,W1ZJ7*U4E@^.:SSD6"/K
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M(>/YADA08A4=+F(C0&1UM":]^3C 'ZQ?4:L?+ZKM+-DI^\[H6:?<@C9AK2^
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M.A./^4BN.($O0QL43 N,VV51Q7655@3>F2L0)EA)FP&^UA0+C9"@WY@)3HY
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MN5.;N>=O]KY_ Z%EW>VE!B#U6*?D<KPM[MQF+]=127AROW4<>!TG'7M&645
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M]W[W_'[O/?>><\_WUS?&NQF3D3UV8.^U]IS/?)XUY\).81<!=]25U90!>/@
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M9\:_!@T%'[T0:[J\<-@"ZQGV8@%WFE9_V$)/CQ9&ZA^"&25*F_!/)9,N@4O
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MMXGJPLA038Z.4V_Y2+[Z8!U2L-UYX)Q:6/#;*NG#=%2F1,#(';)8:L&(:&+
M72_V6AC*F.4F+D=,8M1Q@=%NR'4X:/IRMTB4;O" RZ%2 [/9FX=^?G"U:I@"
M 0TQMIN)_*S@82!),3$A2/&R4F!;F?1'350@#UTOUBT,*;AT8XG'2E7+VF-Y
M7I>D?[3@<_156&4U?UF'!42("I'E8<;&.,*4MTC11ZR^F2D^HVA#.'<P1,2G
M4*JPXN95A?G'?552D##_FD9R\AQ8QR?\,U==0VT<%^S70-</@A. WHOT/3$?
MZM!V'UF:C8:>PZ[6+0Z^:9LRO.%$.B14_ ;<&@N@@W#XLJD]L!?H86+\JDI_
MTIM(<.%D9FF+-.PPI+&51J39_ZH]LOA6'27%Q$N/MHV<K+BMTF:4;'V9Q:*W
MI!C!5,B[J; OP;%]VS[O16+,>R"%&4./E:\3V;!):YP"GP9E1&'F#0.6'U&5
MND980#1-.DX?CT W[S?X+'J$/E#.]OK1SR]6_L2>S6"5 Y\ ;Y/D X8%?45>
MB06P"2IB&K-P :[IK)>[N]'KKIM7H/@5A4&DH][@$&5%&0LH<?A#!A!F\#P_
M.FB/Q'#33C(NL7>6S%HV-SYGHNV\)J\*XX&+GK0B9,>;5D5\<5YY%[JIC&B%
MP]P<+L@6H)/M:9<4);LTNXM==I23"#(K;^7\I6ME4Q6-LH:8!U6%)L99@;<_
M?525,<S26&RZU4^I/,\\TEI-F)W!BR:AIVZ#X#PAQE87AT2#US&V8]E)/'JB
M99PVSX5_ ?K-S73TF;\A6!ZY)@POI5$C6*POJ9-LDZ3"/<D">(O+5 E/+ 9'
M8RX,$XUF^RP\;H^1ZUB]>\7Q9NRA)/$Q]>X"'<0NQ]2:H.W2[I>';D/!.9""
M++0PKMIQQ=UI-(?<MI,M6",Y=#'H5A\_H1)SCP1^_<_]YVD(Q[=4^EJ.5W<'
M%DU_*SA3Y26)1?/NQ:3HC1,E-/T6$"S^W!/&!9.K 1B&0XP/K]N_C'HZJ'_+
MK ZYY<7')-)TCH?97)'+Y?BQT9^K.?:%3Y8O05_B6/7DMNTR-$A4C8%7C+7R
M>7%E9@7X(0Q%.[<R*EGTTD\<9?3J<2,B_T[7O.<+V' /_,X01+( E7BUFZ2?
M.<BV-I.A+/L*1I!^>=;OEA32TD0]]9LQ7D.ZK+ VO2K^"^LGGIXSPBM#\W1E
M*;5MIR(E+UOJ]/UI8)BH Z5QQ;3FB0>CWZ5S29J^# RN:'1Z.)ZPMY[@RSR>
M<F0\V_K;4#$@"YJ:<#+8A@70JZPP [38GHX)=D=M<VT"W[/\(EXGV4MJ1;#^
MONHS]Z9+L]YO'"BK9798!@=5T,_/K[PXWK^SE%&E>(_) ^1Q6@2-8.&M&Y(!
M.5B8<[2YY)7G)TCP,_C7$Y=*QUONF%&D;QJ%A%8^':WHEMD)(?KYDD>?68W[
M1T%F" []YP/@H8Y?.&ER:[" UD-DYW63^7AIBOV1>=?DP7J=[*UE7-0J.E9-
M>'_4R)5X::G(^.ALD'CSMA<C^LZA>O,[6@;C*I&UHL'ZK5[S4SBHL:Q^!+Y6
M4?]Y;__'!REQ?5E;_9!,6;9?9NP58DER'24<70CA(=$]UI?##^#H1F7;FSH2
MD&_D&IU/T"U./7*5Q*UIM/W+#D#91O3\^\RW+<Q3Z)%[5T6^EY].!KU7Y/A1
MXN QB)I/\?245Y+KXX(CS0WEAQ1J#O%5G@0CM5LCZG"!N2)7O8*Y!U;\LT=\
ME\2MX+L-7#F>*NJE#>,-A5\%8SBURM5G7I(K/XFVW=C>WI5C0%7K_@RX'%0[
MMLN5/VR:?FO:Z\U$0VCH:_7$FK>>Q??FP.T:_K07G3L"MNQ,A8#FRT_/\^PH
M,LH"Q.DL(O5@3X@TS11V@[RXNV 7!-:LISBN=$D"-X9SHG#"ELV. X-@Q1$7
MZBI65%X;)?J^E_@G+&#5?0BZR_$G_&D010A$Y:C ^\;&[VQ501YJ'*E4T-2Y
MG54LX-:LDNWR',/RLE(4'?R'%W,4?EZ,&O<4Z98?!UH^KN.\S]82(7M_[G.D
M&MNOA84WZ) /:49[<*6Q)%-R/NH$/KM3'M1Q%ZW?H_&O^U8GW4SA+Z6<KL^P
M "M8WX]S^"+\QCRJZZ6QIW[L /OM\2ZKR2%HA5<SYN,DR.:G["RO&[^2_0A/
MXE/3#EJ9:.EH:<.)5.81UT;&)Y45P\-*J<V;*W$/E#WB9E,E,?$[>GJO,ZGX
M1.>\:M4218OY^IZ.OAD]0=$P6BE3JVRK[6NY&%IE-%0=%,KJ%6?(3*^T+Y#>
M7==+75 3X8^YO\?U>2[5&8+P*JEOG9QG'1--3&Y3LT_$-]!AJWY8@B9#9ZM(
M=$G $\7^'?'@/BBN/XHE[?2*&Q.0,&,6%B@99WF;=-]-TD@E<U)Z&<3D"6U=
MN)_M+3>DK%2A" G9)I[;6:#?T_>[A_J)TF@],I4WW!NMCOM 0DRFK$&Q">#>
M\9]'O$WU"9^IY4Y5NU_SK4^Z5&"@J_94C.HA9G0^L6/YD5S_49?+)IV?N*?!
M*W1UB,YGZ$9F<S94F?LD"_6E<.MRH[4^>4]X7SK9,HF-&:A8XZCRPFO3"RXQ
M*@?T+-<NOU+LL+.(28C:UBE9"/@$ZV*V_39^TFC;.DDK99#.5#7OR3@JJ1;_
M6)%@*"(*.#E?'<E@TA>S'<%E!N?0-1)A^1^Z*L7A]T6"_Q58:&Q=S"'4C&;H
M5/(/YSAZL#2SKG+F94S_HBU!1XIB'KXYSSOL=L48OO?XPJ*RFE.#GT.9DH!;
MNGF%:1T!0>'$)9>((190!;KDXJ?5&COU.@E&3B25-7AXL-BVX<<>,P&H5O+H
M!D!R\8DT#TC5(I?7Z&LJ?!"YAR&MWJ[K/!NU"/[QXK>]&[+"'0IH83Y3QN7)
M(+'P^&IQD5?J&Z1"'"2XQ.)Y-_.0O:$2<0M5^4&IV9CF"_W5P[3SM&<Q.';%
M<F &%=!1$&GCHXI]S+?M'2#!7B#A+6P0?O]ETI!'K%RO@>&+7@4=81(9"@TS
M,%*WG=+&C+5VQ/X=^;2+4+S6_-$,)Q!RQ^^C_Y9I4QA$D3@(+>U6,"!.]X5"
MY?H". ?^D(KY5B(YZI1V;X8T[,4&:PGJBPIR#CXM9KRY-W8]!A)INBJ0%.OH
M.6QJ[7G<43W.[ SR_)FS,-YRS=]::6?\8O)430B^$;N\;K"OUCQ(FOF3?I%T
M5Q0+^(3@;QK%C U/3\?6)][Z1MKM^Y/JHU^66TEE<"[15:=3@^:KIKG,WPV@
M0V";&><WN]V#=@_-\]<U8,&9*<M@N>8X4TW(I\+-2UA(I7CIF-W\]+8,$^68
M.UL4R3GU/HBDP<YI^1;O2>1S]R3,\-.8?HZ[(QTI3"EN.O(]DM(AZ44[;\;,
M!XG3L\DTXFOO%PTTF1VF^B\E?RT^#3^V$\AO)([A6+5DUE<MN%1I9[VU4Q=O
MY)Y<<+-DC3#+[^GG>D!<'P\S7HGMBD'H-"PP?2Q#V=IUR^.QM#+J]F4@&@].
M.NPF*6IGWZ<3:K'W_I4\YHQ<%:U"M?5F22=-V#NLA-UUV[DR_8Q(R<7E]O>B
M2<.[)(M!#&K,=7S^L5J+O'8;8=O3_*%,,CH_7-^@U945T(6!J)9BJ 6*Q=AJ
MAM+F+LD-::%Y\PLR:'-A$L5Z[.=QR;R.[EH<R)FW@$X8L(">5TVHL.V*ZR<S
M^J.+B/+H'CNID,C>A%E91WFQH\<)N1J%-A/>KO3']N]?QONGO%L!*4P@&BHJ
MPSH';JG2?GBH7-J)",L$^#VI:M<.DN9\$UPL5>T\E?1OBYR_ZI'S05#7<_&D
M!]]='%$+ A-Y^U-T])SOD( \T!(0.7A]*TD%@Z>"H\,3X]0F(_M: CZLO)[;
MT[>TF&QISH:ZR"AF[\2TI^NK, $DJ&?1=X=/^HVO/*Y4GE<T'"$&UZXSB.+>
M0WZM.$H,$*^9@-N%+G@8%JXAU2=P!10Q%B "O*Z'[AF=%%3O"FUZQ>M<=C1J
M:6(!@: VT,D#:U84$2X]4.H?G K=\KS[F\5SSS7/'DRP>Q9(_%HZ=')THH[O
M2 O&>G1C!+2SA%.R%"94<?EB]++DE\6ZG^(-<JVST$^05;7Y;;G6T[EI'H\/
M'H#*>VM;$V7*_(=83I-+T*^0G4%^9PY<_:O#W\M\8Z@#*%H(R_%2I=\C7$<K
M&8OYD*:_U=]^UQXV(9=WXW$Z"!:]TF35:_+?*!]U>'#OV8U8.OIQEU%.<O[R
M[>CG>YM.U\YVKP2U<B&/5HIO=10=;GTA?V"N]6AO_4E)8?-@^JI_"RBO^"KY
MJ\#>_/*VYV+ HR^QAJ0%LFHRI$<P_Z1[G[3&*K_IWM5DJX))=NNO-0FK7!^;
M-'4":30+4)$G+[G>O'G]I.Q3>YSY.O?6]\Q-+>^-,U)]$XXR*=GZ2"Y)^\&G
M. WLJ=YK$,5K?_ XA:8Z!-9<:C+^'Y X=B3\H]L@;5'LUJ$2<X5=9<D#N@+[
M3L>'-[DW);K[30YI6[$ "I3M\UC,FF")X%N.7S[6M^R(:PD)HL:;?OY(X_?^
MZN.]Y\*5?D+S:;F8LGVX?$O\<%:8K,&3;U-V;!$C5@YFM98J7O^<WY(W]6S8
MI'DF(03ZPE=A4\G7Q=S]RZ5OY>KKP)K/%B]\;@!@&R:H,):>P@\#$;)0F^_G
MRBSE*PMD*.@+V]NZ.E>R(WEO4Y_"6K9Z\ZD=GAR:?5Y^6<(UXA#4[CYU_++S
M,&C Z?SCB=@2B!ZTFJZ%$Q^'4+ZUDSFP?KA&[5#%@HA])OM-'6JNM4YYA2A'
M9V=B,Q!S9E#$CZS4'.&.7C$FHZ'S.>/E@\"3_"2JNJ2+L25$%YT;FBXZ%WG_
M6S;D-3(UU_FGS#F- )K?M)/:)>5U&4[/+?I,?E5!FG?$6B_OV,6JRK/_SF77
MRM7$Q:J_>PGY_HC/K9[B!QE6)?=<F$+G]/U;J+7;AF,K7@FW3X0W),!*8T94
M)U1_F]+A%^6R?9IE</-B;3ZXT^]F[IMNHM9HYR2&\ XT#P;_D."X7C%U:(??
M'5R"$O>[6:G/#;+/-"]:FC_DK%ZD;F(RY,P7TXW>C7RW=?5DHFGEX#;*WB
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M&+-,L<!\)KEG(5PK]_Q>UZRF&76B>)=O5@H!9[?$A8GM)+_T<A]XV<42(TA
M\O(G)3[+39_<KE7:O]3-%8=\RU6T@7/.NYKC425>:%A^E.4GT<'IPOFNI]L]
M(QL!_]]DH=O_E2S\7VJ*_[+_LD'@?UF-Y=\.NP OTZ+C;SM@$,:7AN]OK5C2
MB"^:Y>9"**K#=EJE.AK;;3F%9^-CZ-X)?VUFN\)!S0KX5O^2T%VM7#DC@JL^
M:^!AI[<?1[1OAW=7<]H%327H$HT%_*:IQMQ'R7OFMGTX&[8?VSWF0@SWP9:U
MVIUEFPOTO?@KSM[5F8T$V+IZ;;3 :2.E=:% ,U6ERA7[*DYD+!;@,?7P6OZT
MA+*3]4C:=N&,HN9/ \7+PVYD;VS[;NP]LJ)<(M5-A5T;VZO?E<S*ZY>+GV1_
M%8L&*>.]YTP!YI=4:O+6/LAES)NE8E6<]_OOE@+A<N #5I'A?]0"ZZX<@C"/
M&BJ#UV^S0D38>QA]<R@2.-@6$=Z&]\"FGK88)3L.3$,Z%C!$Y/Z67SU)D\G3
MYE'!=,QQ%YH/R@@=PMW\/N[J\HZT,5+HLXSD:Z%*.^G=LX[V-VC4PKHDVYN7
MJ9V(HG^J&@;)Z*V)T<0T/N/D(.;\?=SA^QU,-_E[[+#)<ET .'WAESO ^A<&
ML\C?])=ZGZX<A?69T9=(S<;K[XUC((N8AMIE\EHBKQ:Z?M<G)A5Z#5%>74GE
M,'='5\.)-&0(RA(3U,^!!0 R<0]ITU_EG_D*AS,E,6^(KYVKE#"*\S\OMW<=
M3ND]Y/R0W&VF*NV3T7-@!<&2J(=[_)$Y;R9OICZ'-@ZY+(1=RM&95P5(W)./
M44ZG4%%Z\9!(+FRUT$B?^?>D<H0U/UM&&#_'ZQ*-#BP * JFS4]T?3RY"*EV
M]*\YC'BXV99KYKD8%KX,C%Q'ZF?'#VUM>9Q]HR??<B=J)A[:D+SF#QWV$UO8
M9F$;W7NP^\&N*/>;>:)F?P)QQ&H*7JS46;_#\P0-E^:-?(.$B_NO;:$W9-1R
M[6-;?HRETW/TVL6^]BYT0N';AHY5:.JJ?.D=<[U*-NB$^E"\4'GV:2CL$I.T
M&:L\W%VPV1QL0$_(TFY0VJD&45]W:5% /^CJ#-UC+,RD=I,TT T YL%]4!HK
M,]_=+(;=O'Y5#^5^(QP\SWYV='._C6-;+J$+\A:)2%BZ-FC=>?99L&.[^UUU
MQ)L[^>"OY,W[6Z-K)="EXO;$A3LG[S__-#*G/S?0 6[:YF1$VIAT"8KSB7EI
M9;O!+_!L6$_W_C1LK%Q>$?QMD1P!*OII+&+B?BCWSVO>==.KB+\M>6>LO[&S
M%5W%YU!VB8OZ)&L;EMMY_7P:W&86TCE^\J7EX(+; 'HZ ;XFF^RO_/MY>@2&
M]=<Q$MQ^P23>!;T@WP*=[BY<4CN:W1ZA-#L,_I+3>S/,NB4:+R4#_0MTY[9'
M$S,6L"J=A05,ED,W]0<A[$H.GQF<.!+40L_DC($[SY.K6';*J94@2FFNOGP%
M>>EZ@!^O 1+X0?I*I#^(" !XS505AHG>N;VITD,J(3(6>2]56/I\,78U],V1
MM0#+46DHZ2FK__25R99A'=7 S0IV*[P!]T?2(4./@6A26)04@<F6@=$NS\V*
M^_3=N N,6D./5="D#2M+)=77(2N-4I:^/TW$?^?TO;;SNZ'UPRX7"== C<E@
M =W'M/M.+.!U=RR V:UXU#J)Z8.<O'T.RP9?6@X6\,N0 PF7-_7H/.NT$+1[
M*S?.S70WRXX80ZC0Y7C[K6?3RSC3P_?9?D<7H<=E[8KO2%I:_?<^\D\C;FUJ
MY'JJG4IR='2FWWO=_CIT<DW[8A\4F@&N3;=/9UTP;%(<L?T_=5N4MD ^S# B
MA72',7]K0@M:T;P)45H25-3Z7?<^M('9,T;9,+>)-=+KH!F,.IH$[62!>G:F
M;*7V"OHS3:1T,N+D1(B6XH43U>ZL4K3H@&+@19![)=!6E25-D!X7Y'=&>XLR
M(,;/8*6:#4-]C 5T,.-5"#'.)<@+PK6FTSER?_F]03W>ER4I!A.B!C09E\X_
M%]$LJK@PW+2["7DH3,%H=Q"3\"9J0VS<3&XB*?ZY%.69&)/%]<MUM$_Q;9_.
MNN_;#ZV>(O0X77G2>$!1(JC)?#1PB&9&J7[2PN#8?K:-1@5?3"9F)['[3Z>2
M;9N=779C?? $H9#HB(!3WO;+%+R+I,L#Y9'%85%;6>$I(-_T/3HV<R=FK;&4
MM,Y$/I/X,8J7+VO'7-Y57[HEYMM,5)]%S\G/?EV7[TLS8<&<]E<'RE#^F)O9
MCGWU<DK#?F8Y22W"IDCZ:$K6YTH'K7 (1=^;9[G24RTS>X[1KQ.7G^HQWY65
M/@2+F2UL&^UG;LR;F)C-JS\)6*UG2J56R=$"^%$'D0HG->Y&'E*G$]N:IJF
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M3$MVL#EO^J>6ET$,!?(2E=M>52=9?\5; _P,:1(ATJMZ%+.U8_8-"R %8G+
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M&'UH%Z B&*M2@!<E:ZMBP-*6>#DU^%MKYMA8([58B<HPU?L>CL_A_>%T_(?
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M T"4;M0/_S:65:1O_5I0P8_I+[HF^K2B*=XXSM,F]+G.("3]_N?BAL0M@M(
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M![I0A;ZM4?Y0?H\MA7+V#G!K'I&&**T<VWU?UNC/7?7-O8<QB@Z:>EW8*:.
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M@U8/+(O4;G#QVQJXS[.\%F#Z"*T+%,134B%A$@-'Q.V?&KD?"&U=2@R,('2
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MK!T1JP3PG'4,;\++BS6EWF<5WC7*''U:HK),@EHX4"B0389#9<-=8-R !W1
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MIE$V^),9'8B3'&U%6MU&D8A T%DMWX@(^ WF3VR^V5J5;\P5^)9V'!2>8!$
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ML$&QK]V!CX-^-XG8'*A#!QZ:9E.]P.T9)&<Z(*860?6"S1C]QG8K>>HR^4L
MCJ;%B2:>3/U1(_;_ >Y^*;1_9K#>4_HV1,)^1[B:QX7:BM>>BN--KFU"TVW'
MBGB"(*?-\IMI"E8+-N*$ZZ&3<IJX+P08]\&V:7L.[: [>]QQD<#80/"A0,7^
M(T*[CLA)>JE(CO=_@'W88Y8=0;&;!'&/RI4_T4S;8-^X^FB;<$6/ O.@M=0D
M*J2TXURXM9R;/=-L\O3287CF55_T9&R8^RLK&Y+_B?XR6=\/\:P?OP1Z1'M+
M#=W1<-KMZY*Q,AFNDJ Z',GC@,^5#678MP 4CZ^0=-E.=C]G6<OS8Q.N"JT3
MB+Z:]M^\W#_4<[:]7H&4P2"@DS9T %E!\UH/"KQ*T*'I>?\MS3[/M"#XBTDK
MQ+F<&91+UT[<R;:-DJ^I<40_7U@UW4NP(GKOQ%)DMI?3^J/[TS*Z@ILWF/+_
M7DIEV@^?!G%NE3G]E]/MWX(M-9L2X@;',5A\7K(6U0A>432G0E:0EP;!T]P!
M=, *]+64>8:V[^O@^NX%>)*_+WC2A%8- J?2@;H>(M40YVFHY1?1\[NJ&_H.
MOKG# HXVIN2!PU$$; X<;4HSE?IE:[[BV^KQIZ^&;0X2^QK[SF>>9IZV^PAE
M3KV<C\*=G7=L-&ZOLBU:)J?%:S$"2J,=P]Z2=S'8*;""Q##'N^(B&"=_$$1=
MF<!8!P\A5N5K"?6Y]QD:SFWI^@QOQ/??T*%(:C*NZ44B?*,#'B;V\]<U_^"W
MCYFGW_71/Z!==ZR5-^;[':VZ8\JHBB9]XN$MA&N)^I5Y(2H-1%Y%)&MS:?_F
MTZMXWCS32XD6D,(G\_O#@1!6#=;,HMO=S<-[S"YIDZ.O)BLQN[AR:":!O_MY
MHT+(9LJX/=ZKOT)\ZTF5UK6/I*CS Z[,?"F];=*"NT-V49J=3'.E9;/LU#RR
M%I4<9AEJ^=CO_?-_X'\..,Z^ W,''L4$F9:.F1&FJDWWF&A#F.VA\92SI+N8
MCDZX%L$A0HE3T;1?8GAHY=RI9,6&.;0@*";@1-DD:(]OQ"5G*E0O?'8F43J>
M/'E+%DSCE;K+>%JWN6Q>VJD91T W#">]<O-REXMI *D;9;,%/:VS\T5CRT/Y
MHKP<,!L!-9O8HP5AWJUBVLH.5;P?0??&=XIZ"ELX!TKCA:++(VZPY![?!IL<
MC'UN-RF0 D'I3ZW6C%[(8.K<?TWG]53=]N):Q:QY"X/D]30QOH[K;T[,5-QJ
ME\#>4EGNC_STFY?\KU-T)9J2N%%XQ\\9M"UN?8:NT4JAWOI:A&!600= ^;09
MK4GY?2.D[(8AH:1:E[T?#WBZ8:X!0BF6#-DV2 =NWU'RG-AD::(M6N:ENE%"
M&03D7?B+V691]6 <I ^.LN8*:B9#3_ZR1F6L[>3$/D$_(-G*\1A:S^W_/2%F
M;,(XKXO+U%MP*C,ZA:1#TW8&Y]),%X1^G:$A+!2VG^<X@6U4BZ'R-%PC#R$5
MR+_K!#B;A;B=AYV:>-)5[5S>7[X5E,]PZ6%^^?#NR^#E/"*;+-MC7Y/ OI/X
M3TF!ZAK/Q")2&&Q;.XB:*P!M#(+P2"6W31P+E6CS4DMGX+,H:,07*5^Y0@=(
MT-0*"C&41LZ@\<X6T@&-*U_?U3UP*&/!,W3+C7=F0PQ&!]A6S>A VFOXA G\
MET/ZA_$$&3R$NTS5UF,[Z #&QFEB=8AS:^&-%V*WS;QWE,=MPC%%EVV<JLT!
MO+:^B+,)L/Y'PZK)!Y"HPXH?(R,?JQRJM^Y\O=GI8":3;U7GJ>(;R)37R:97
M<KIL0&&SSI$._..44USVA0P=>M!V;C?"BBUQ34F?1:\%HM8,TZ['OEO;@[Q_
M\]:M<V_MH>70!_.PE:-?:^'<*;@1&07P[A/==""*\U1ZI&PE_LQ?@ A^X%^
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MPWZ9,%$>#ZU^1:'F39?]QNUW"C>FGT\2MDV'*_C6M%0-]EQ:Y8-XZOZ4?YJ
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M^9<>Q)>6I.JI#5NX37_$UVC?V%"LA=CFH_@)SV-@A2<.N2:*6%Q/I+(P>]&
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M;[9T'L0E?O_MV]%^_SWX_\K!0H=M&:_<WI?PPEZ^/[0B&S%\%D<#R/3),29
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MZ-*S_=]!B*>Q=@)10:]U8$4F]WL8DX7-AUP156/C3=+H2G+ ("X[@0;$F].
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MO8*,DY@GBIKP S+RXD'@@W6!^4/3GXZ4>O\[,^-_GG>P/S&>HL2V0HBN'F:
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M UWUP(8G/<TYQUNU,+DBX&0*.1C>>P"SW.&A'&JNL?[,]=SJO2BA_%4?-)D
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MK@.%!6=S"@OEE!TD3)V)H_Q-#R*Q@1.)"#)P KIKNU&_447,Z28#!G@OY_W
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MJ5.@2#@)#5^*FCGJS6Z$7<]UL<Y%VC)48@Z-MR3M.<9KA6Z]0$")D0>/K<Y
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M6X\P'8U1\UA :[1I#;<H*L\AOCPK"[J*Y#Z5BAP,4I+931BY9\FNV=^:7YV
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MC%2$=(R4D1J'L7X0378VDQQN-9L@/*P%Q$L=M:W:8*O/^=6-[+<70P"3+F+
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M> K?DVY/HS)?>MY],*9-I*DP$>HC38^$UNLXUV]/)*\B<OW9@-T#):O;29=
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MEC[&588[^.A@NN6># 0DGXD/F,]VO0[[4L_'XD02A2N@'[2L:'9?4'^R$KE
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M2E(&4T$-,> &2YH'-E+<ZC#<N_Z_[]GYA5_XA5_XA?_SH#C^]O\ 4$L#!!0
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MSY:9F7'U]KIUS"S;D$_>D"OV(:;M^B4)U!IA(X710.&XS4*&9NT/806X!]3
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M.-0$6!KNKB__&&X7=C_Z\< <2JM1TB''89GSZ4_*5AD]A1XF)9R.PT(/OIE
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MK3GPXL@K#P.5JC"T4;=?!#\N%1!D_[&_ @MA.<:P$DYX"UXK\.?">4P2:DB
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M=S/<FSAZW^/>B56;,QP=KVCQBR@VF#.SM :F=?O21M6NZ9=\:^AX*(F3'6W
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MVL%@\5\1I9/>]K<XFILF&Y=^4#1[[_Q^S8@),YYQ/!6]]5UC[8;K\9F^U$*
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M1E# V1'JU2J!M%U7N/O0H:Y=9<<3AOMT-39M0BF@3_H<^QLV',;YZMZ\S:Q
MYZD,#.%]Q0J*2B&R</_D[-(\(JUL=HDM7@384_C^M,GCO;OH:%+[,DJU^EI7
MM&,5OZQ<OR$L<DV!7N/V;]<S?NVV&KDRZZ\L6F%&<.T^',^A7DY_!# LK%<1
MCR'<!#U==BG>J9DBT\=A3NT&3,WJ:H==/FI<M&)Z(6CR,@$(P&<X4Q9?X>6
M\=4W<8\4?1_,8RX#%1ZP!L+#5Y$_(]R()3F!^&@AF1H&R&SH22>\/OB9),>0
M^=Y>DP=YWCGA5DX_.9*,8HZUPONC^)L05+M'C$$TB2(=>L+/N?[,)?B[;( H
MF?TTTK%N)$0M,(Y9JT,4#OXM58J0ZU -4E*Q+TR=7.6]MLFG4W1U=Q\_PY9
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M3Q$*6$8]OGL7_2KX[V\9H4 6EL+#M[AMPOH+. $VI'?!E&BRC)+0!S[(6UL
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M!4UK<@,XRZA&H]6-^-'9-.ERHFE=UVA"R-0%0>Z6(RF,:NP>."T21SQB@RD
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MW/9]2)&UIE0K8L4U7"6Z1I4?"<1A=V$J*52T:;E2KYRN,@I=F[1=\<TXVW3
M/S?J;*+4B'_2Y(]C<>5Q,O';FVIEWJZ,,&L3QE@M8>YJ0WC1\#<O81;](NN/
MTX+1,3A#[E93%>:A[Y_-7$W6# FVH%B'P.H^3[\Q=H;%\#T7_KC8RQE98ZW;
ML?F"N&QC8(I-N,R_B6YT^,@L_S5;R*MB*;94@,:BS1VMDM: 6+YT?NMUU+9I
M13F?5+AHJ;L&-Z4H0UM@K/H=&+/A@+?XUX>#HE*AA>VP_'7^IRZ8#V*1++WG
MA]'%9BX*S)B21I>($.ZA_S:HD^!?%SZE^U&BZ)49LV("*R(=/$9-<MAHVQIK
M:L#0>52>:4DE"A]Y!2ZG^?OS?AJ^<U@.K@T\B"L\Z]#F@:R.%M@E86&9(GXD
MBB\SC9<P6QUJD7< CK89Z4:D/IG:\W!\-UY!4U;1@5.,PT^@L6*;UE&R$YXA
M-]/[EN;F6*"ADAN8<$KB^2>'=:V!4N:!&^O\\UR5KFU0RTGBY#V)P.]%&;1B
M&P >+HG?6#*+!W<?'JR8&PYN<^IS@YV@X+R6P6LD?/V#F <E/J\2JH:&?@;Z
M/QCY]<=5S'>4SN%D3&5X7BW44HD6^MWL[64#=?B7Y/Z-.I.I13Y]L9MK(FVQ
MQ(04];4Y48@1?_*QN]?S\S;YWQ221YU'#_6XF!NZIQQQOWON3.-R6<D#1\D[
MT=5]E+9*Q/C\A7D(!K:)X9RJ$*9<%N;.+V'6544'R!=D-3A]X?L7JB0[<G6$
M5,,SG?H4ZO8<L8-K@C'DP=-G3?$<:6QKC30EKD[_!>/;_LMY7JKCU&>.HSM?
MC39NB4ER'+-RL+#;L$MCG;D\.6+UWUPC7:A(_<TW4C'LH"S*"NB@A<PA+6-G
MEC!6FCE8% %%&@#O4$7CA16HJZDM87HEBZ;B?E,1213#;<L0/L3/)(2$+6&.
M;2G)_^\3(W.^O!+%:4;@38$KMI"F [Q>CD.%U^^?YB\(DX  IC2L49?:?+-&
MBP_ VLGA.@L/ U]^#7B0+S.NEU7/]:*0S/E%F)6F3$X!+-.%2&WF57%%(6G>
MU'@\>(XJ/EU3U9Q5Z \KYHV3E @SG0;?CPP-6OMF;+[T4$]*(VL8B)%?-.+8
M,LZP].[0C+_2RX+OT;2]^=FF/(74P.?>X_(ITT*#R7?8A2HQB;'$J^3+#2;.
M2HQ %K5L$%:81E8U"DZ1^ZH(KVT;YY**PCE?O[_TN[&$*?=YW>A99!. U&A;
MQXAI>:JPU"RUDP^JQ0O6PSN%U8@"=-WEM; *\,6OA4]]>EF2&[Y6T$Q;Y2J_
M,V=53&+W<<1=Y^-,PEKMT6=_[Q-A@B=B1=EES2"3S^9IP>L/(ZLV\]XWT.1X
M,2VJNN/O.0Z19IJ.HU:/I^V:XE6";Q<G?XX[%?<T^O2;QHODFQ\I,R@/6%XI
M?%FRA/'3!D1% U'S%04RDVA;O=U4_10;R(K@5NK.C1)W_3Z/>H;433BD6^@N
M84RV!62EW,PA=._8)OXS@]_P]RSIP[",('B:"9ZB0QI?9N59@%1(?'NF:GX6
M3QG]%]DKWW''!C)'I*0[O-636^+J)>W=?V+8KHVB'JY9!/ $D]''#IZUYW1!
MVX+A]:G\.]WD3:2+/*V8+>#W5");>=_F7I+)TZ+8C8R1#\>&;U]=>WR[:9G_
MY:VTG^A0Z(CJ:"\7502J)K<!Y54M<W%X5($P +8?Y399)^2N[3HB@"7O/.^:
M%:Y]-BU0I[/(N5GOPY *_/B/35<1I^1Y15%QT%45O,/\3?$<XS8J(XQ[!2]#
MVXT^PO+]!2U8^?.,4(6AVZY^LQ=.Z&Y). ;]/HL96HU91FM#;[^-[D??&&+)
M_@6KR@CTH8)VM^U]\WY[F*RY>^E^A\_668=XZ!"?/8_\?B@A!=/Q^:'#%!!)
MW@\K0%F%'4](>Z$W[$?D'QM.]#I]97Q6--"X<+ONA?\QI4U>!4:B/LTKG(2I
M9F+D$2886#+#%1@C?=G+S31 _PHPQCGC3$];89#7EW(90I?,3S_/)/L1#6^F
M=@)78E,RX2;22A45_M*2@.7><^Q_H=IX6)P?'+ J)-ZN-^M$W2?E5@;M\:13
MV=.[>%W^][,X0]_@%=+M+G('<:<+QO*>NJP5R_MOPDQV6WB+<^G07@D<.$EE
MR.'F-].1/PX3MB&->-!V;LBX#5]*:.J2#ZGE:T*6SWTS8V[?&$D\;/>)ICQU
M?=3E7?=V'XUDULX96\U8C<Q49"VZAB+KD;>$U< EVU@":&LCUPJ :20[7OH=
M0T$QUCSYLJO8FN1WO6[5&D>:#'=NF0#/WG]N7I*%1V'(2!@BI<VV'2:*=M^1
M#>AJU+P"'V6/X%8--3^9[N1M^2@.7'GUS*JNDI0_T<@(57I^[VGXX!)F[9 H
M Q#HB8)1YMOL\!3X<0 'SE(@+0?A!GPC 3:ZA>(O]<'W  AB(=T X69R.WI1
M6L821M$2-A7_JY'",4(I>FV>YQ*FM5\VW.I??BBI7: **T.'06-D;50?K 2>
M8=O>A7&Y53."T'V])+W'(U/\MG,AOZPF#MZK35KIK+3W^1+FG^_I L"ROSA5
MLP=XZ'@=+^419CT%^XZ"]%9QULG'JR%_U6LZYC8U=<Y;?WIHD(;QNM?TSVQN
M$7Y[$K?CN PR>Q79*LP#O*@KB55J&W@Q[;824TYI62MJ^A:P,B.'#7<>W&1@
M<O=,)%;]\4MVC9<1+V,6U?@K$5'4-3$@,1-%>?("<_*[U\1Q ]Z!7A=B9@-O
MLI;(?R"K$>O\KJH^2:/)(DHR;F^7G0V&U"E*X_!5V%C?/AOT?"JXU,79A=QC
MG.(\:K[I1O*:*X>WJZRS#!P0^3MPB#0>-+Y+WA@"\)]#0:QBXYE;9C&\[V'2
MNGT?0TVS0AYOWQAPOVS/>K%TC8?7;,AU_R_Z/1SBD#'R-F%-W6;0U8B PJ-F
M@CA4U XPNI]F!K1(3?G-''T@/6GV-3^V*JI*_.9^GEL_80\R"H#G*$-2R*K.
MYU/[)6:)O!_,YL6V-]A'^5]O[K<?SPW7K+Z8?S.R=[O:WML27ZZ*[6B\9KY>
M[+<R*R . -W05<ZJI^WB620*#$A2J=QR:EE-8Q%TV>_:5^_ $$!@?7(+9Q]Y
ML&[T=]/8S0>2C+D?H*2P0!A'LA)<"BEAJ2:5"D))9B E&E$W6GCW;;_M[1(-
MZDGKP,T_E-2L//U:=SGK-,Z@0L401U:+DK*O"Y.!*]):R.K"?-)E7G!+ ([D
M"(E">^=B2.I@E^W&W'%O8G# ;M?0-5L49K96'!'"SUIB,8?L*X5^Z.6BG8$B
M\EL"> :WYELF?8;+>60G[7'0DR ;8MRZ\?RK <-'S!N=*R?MBH>YP2Z\A[R#
M.*M_&N8/>-")^$P'STH!RF]4&=SKIZV=[JA>PH2^^&R/B]U$-II?(*'X=,7C
MRKNH'=866%I>EWV;RYJL8Y^_?M=YNY+MIW783Z<DV@'P* [:Z07+2?$!$9T@
MR4/&O%Q^/V@;0SJ=$W*Z>*%8[G1]4'8OH?S#B,KRO2:.:O73"\:-;@9@>PM>
MP@>_SE3^17.A=\WWK)6/GWY3*/[S>_'EQ$MQ]OBQ2Y[N,\2?NQ%)4;E949L2
M?UA4M?HT208JY@7SU2 /#D&6Z";GLY!XW0D,+V[M_TSW?13<H?[8:^\I UMS
M0OZX'%AR%Y9BNQHWJF&[9V]TXBS[V*6]Y2,;CEQE.!^)W/LXT7)U7-SS]5<Q
MRR(,_S_Y&2CW7C.D?Z!/I'L-P6_.P;83(*,JY$0?5U'XL.H>?9Z9YS 535Z+
MZDT-@%7L)B)1'B1-* W$<?$SCWBI+I\J2A*=!N_Y!9CJL>731YUM5CRJ*=QM
MK1PPYOLEPD(IU/3V@A=\5%RP!Y6P) 0EA4=&EC _[.TNO17N>4+7)1U8PDB<
M0SK4=*I2?C8Q7V/;$T]N\-2WT:6RG?>E::B>_:-V$\ZCTQMH.44H"YT2K"7_
MXR-L3EW+3O[7H1RH[HVR,SK@T8I?3?>QC=V?$5E1O)+9RBS?^KC8I]*)GSWP
M:]GXI.2$S;N0M])1Y<GWK]J07Y_S_+\M72K)#,XCGR?MA +1A?5>2*ESY<XM
M0S[,"=0[P3E'Z';1-$VI&W;E^#FZ^%B'WNA[^R#&9\5GK[2T!Y%U+]??CL"?
M*?I!Y3J(&@^OS)FF*Y!L7I!\( IX$[?!E9AA%Y)I,L=8A@RP]1CG=L?<\8TK
MW9MZ\]2.:-,+-W*PE?0+<TIDIID>F%T?) A#L=+*V07OH&V#YH2HFK2%SM*J
M'S\F66-ENU*!@W5^+VOYSWCMLSH@D_W";+<P'5GSE;[.J$C5;KL19=6W\4W[
M+PTR+G>8LKWPZ;SX5\CIHW](#DG8O3N>"94AT@(0F"D$!2WX\N#;=/<B^4\T
M.1\4MA5+1)/\% JNARJ\ZKR0:*K?99B0VAZP]?2E!$SC7>OD:J%HW]8"^LF+
MYX<*'UXQ]0*CG%.;><R0$>M>V)5[C[1GL3G$^LBC(5??IAYQ)5+=EA\O"B=_
M)[QX9H[Y3>73A2]A14&04X@6VS;:3 5J$MB!77$KYMIPP[GV_3%WZ\X43742
M=VRZ[9FY;4$RETK\DY/U/LW!I&T4)TIS)\"2O*YF0J+:?E[);?QER@:2'+3O
M>4C8R0I1^AE!)23.Y'V'T;W)1R^#-LQRW[RQEDRP71^F<-G@]=R.:B6>7O2X
MJDB%K5@I?'(%N-R%(_?Y"<Z%2)OJA1830GX$+&]^\HV #7+,BSAOE%V2;WY%
M]OQ/O>_W?Q=]]DSJ%1,X\$]#JP2V2)?:ID]U,BC%?%P#/6)MF%]04ZSA!67/
MR3I^T)C4SFII8EI.S*=]LJXFM9;=%_L><>'"Z8.+_S'9V%A ALW!K:(: %N$
M%)+B$VC0JF[@!CTVD^OK9/,R;WW&N8BOQGL-6EXX[;IF!JH2OQ^'A<)JP L;
M0<726<_IKRGMP'(2#D12N;8*L-5 +L\X;J=A-9?6+V^H_*C(-,?_OG110FK"
M:HQPV5\%5!_06:]1Z8JC4^C\$T%XX7KB5.;O+$1*#V5J1:+$ZTOM**WKL8@X
M0.6C'#\U#,0)8VL(2,I1U]0U<5S "__;F"Y*8\CZ>QJ#3'+40=QJ<M-B6M4,
M!7V/O=!/P;)O,P,U>$H<R1ER5M;=DF+RQC31?\S@ZFJW4+MH):VN/\#U7M]?
M73,0U=79V77W*:0=!(8AJT/9Q',VSBRMI%RU;=EJ:Q#9_IO#WTII9C_:_]12
M^M@?Y[*F"N\_E9F87>P>\'QJ4,JH_H.V45T/-:TG8D?S4-1!!>]_$_(K.K;O
M@4?*K/^>B,S3@Q7TFA U7DD2^L8$2:C$HO)3>?T9_O.^8B,=LQ\R&L:[.MBS
M06[&9YJUMV^*^K11X"LJNAJ)CET'09@(S,R6EPAW$?\0^[RH^2N>SHIB*CX&
M;Y;Y%1,)I7,)%?*4(_V97C6I;-U"0RIO=L\UYK!LK3M.Z^WEQK=&B_IYWVZ1
M*]P#BJ:,N\><Q@Z5.8TZOU7;Y^&>%N3>N%PE<G]<%Q0%"AJI\G4RS^$]4"*[
MZ #1?-#P]Y6@1*W3$=;28W5Q]MP@TW7F)1$(%LKB!, R#MR;48(=L//  D$.
M>8_L'\SM(\M"',2B^@T4^LQEKV.YZJ'#Z42M^[-5U1>/A-55[GB^2VQ1QR5@
M5I1Q^IM+%\@%V0HUTFMW_%?27R[&%?GF?Q^ASZ @^Y)',W/17#Y<G[ ;-1I*
M^ G9)4Q9C#"9@@6FEMO/_P\;C>CQ5\6R8[2]1(*HI.49?B74S,5'JVGTUWGR
MPE@ODY^0/RSR,]@/YNX$V^3G1;<^W6V1L"E9]T/&SC=V[[\YBMLVX<6^0 36
MW! .614 CK!?EFFU=L60#7O)FB0+6LRA9!W8.+]3]5.&WX&![MN3P?JA8;%;
M=]?>SQ%:HBBV'P>>T6/$BT*OI/CHLT>2H0QV5\0-0I29:L^<J2<7BPNYY7J<
M*)BUZ-?EQ UH>(HI;/=8D63FZ7]K]1Q9ZJ_4D<FO>,4;TF'<F-E6T,L%S*/E
MRH6D6O?0-G010T,O8[O67U=*:E//77<P!UOUK]8BC.+1R+=(+V$=_A(5VFO)
M#X6FP';^C4&R-M')MNG 11,41?ISW]71Y#3G==^.N_PI4_0 ^_;:NOEI@C?0
M*-I"+6269\S6\BAVD#LO"ED5S9-B53[RR.D L+%UYY\K%7_W/*]N?B5WII3T
M>=^5[Z:;.77&_.(E3-ISP),N4,_66,+T'CA.MW-.CL,H?N_M^3?S=>9P:ILV
M:PD#;1^$%>/Y0<*H!6_R,I)&]W=$CW1U0,7Y*U7:5#4K5F?27[Y$;=?XL:YC
M#3[.@N<&+/'I$E0;E!,:4.KIQ4YZS*/P(Z&LIY!M\RV7L)<5-A>_6D3PCZJZ
M=ETZY<B7_WV8B])_ %[?CD@5<*V[;E-!*ZR4+VX5LJ+]Q@!YJS"G[K0OZ,IL
M6ZNAL+U92V+BV$]M' U,; @@R:%#J2-*#C]#O[=H.XM"G15<Z$%@D,?RR"]-
M0!D])B!;6N_HO8=W:G_\B=U%H:TK3\!@]905%X"&;'$0WXR5F$(PD!];>O?!
M[O(LSZK>^7"U-A.B\[&S[G9[<\5.'YS!Y& [4*9Y&)'L$:@"C;OHK%AJN>YC
M,+>Y+"2J_59&A.82YDX\QR&VLJO(5_; AZTGS/"!RL::<DK(EO;4&3IXDO![
M%_T.GF][@R[4.KZ A?9*(:=Z1)&'0W>7,(NGI4,#8+D_J= %YAUUW$_;<M%_
M/4M59Z ([\DAFBJ$2JCV610"\/T'@<6-#J/VX%Q#DP2L>J: NEA%I NE=UPZ
M:SOT;=N3IX]?F@Q^H<P&HX/P3/B2?IG.P+<2Q&DXH%&9O(-DV0,?"%798[:G
MNR)*-?]Y\9IK2NJ$4C.,U_9?E&WDM$6UD9HX)PP<@<*KXW7.SR%44)D56DE&
MU-4N7XTSZ>T^ ;KEUFUC1G=2S.MSKD>_WZQI*Y[<[3 M)*.FM/'E$-(O?%6V
MA+%4#5O"Y!B17_V_2-C4TJ ^]EP"_;7B3(FH:3JYSTQ4,R][V@W7_=+4BJVZ
MDLM6C#7;[)SK,_M4Y]5Y3F6*IW[ASJQ=NZP/&R14F@O3#VASZ-"V7VU,2.-<
MH> @:1=*C_R9XI!7.VY=G7LQ8PC"-3NXJ2$]=67$VNAHS>0_+@^L),FZ1ERX
MP^)$F(EB"%:1>PC@B3D,T&B!][$)\D(Q2V0&1S'6XQ--?%I--_;&M)]U\_O
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M9R41*D4A<IQS5 $!: PV4[=5BPH(Y)>L1#XB:C4A5PRAKAT!>_:LYR9&U+W
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M+?)>3),<^VYTF@WKS%S9">MK!#JWY*Z^EWNVZ9D*1ILO&X>!8_&@'VXV<R7
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M]$RZW&PGSRL>Y_#)/;%ZN_B)ST<<KYY?KZ\B:RG_HPJ6)S810"OIZWSFH!'
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MB2Y\6!?.%N#6P,<&W ;;G282GWC73/FMY&I[:@1C=[_^0C78ADRUA2&Q@VT
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M/H6?XEHRD,-SQDZ[^A^ P8_CTO8-S;RZ-74OKI1B'<S:KD7->/I@#Z^CA\1
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M'8@^@_JE+,V>1TP^FX367L'L?TQE3GY(@%1DPIJ.)(9+#=T0]C5$#7F8^@9
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MI382LRDJH7@DC$4X3+BQ5:MU";_GP*$!HE]:%[CYQ85>S(EYA'A,/(](*Q+
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M?3O_ZK?D.OBWC:*F_\Z3NW##R\<A#:]L43I0!;$,HR?&44QD'=SAE<_CMU3
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MUJL(2Y3Q<=^;E3.J(K_SO[7OZ),7<H8):('Q.8VG@5ZBP"\V!R6!+@QR=TJ
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MH02??S<TG[*^R^A;?GG NRGWZ:\/Q.\M!WW'U7;3-F.WK+UC4Y[!3Q!69 7
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M"@"U(+C8OVDO/(D?Y*=AORP(]S48H66P%.:AKK\1#="]'0<>0JY8\&&;+&5
M$QA'80;_KC664;N*\!I<L81_287<_5<1O.OM.U81MT]2Z<FHGX05FD#1A<IS
M_[LY*4+";?^F?=J_2H.2C/U_)\ZGEI]A+B$?GF/7 G*HW*-$=%MU>V,XVLB8
M&%AF'7)P_E3ZW8'HDHWK?YJQ?_]MO__Z3HC("R"-$\>_29(+5W* ?,$I3A+D
M7OS%4B-OTM_2G9):85U^1NE;;^[].T67UX6KRQH  C4+#@;NM^I_:5)7\@]
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M1+0$54.5Z8/?8<&_1C13(-KB"A6(0ETR>SV9A5<@/ELJ$&I,L2D,W\;:3^$
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MS+]#!G"3H"5/]%,9%! $#HM/"F@=&R?SSA!/EZ@#$VB=%)]'?0Y1C5#7S K
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M+/I<40K._P)02P$"% ,4    " #4@WQ89>7E*Z[Z @ X0B8 $0
M    @ $     96QD;BTR,#(S,3(S,2YH=&U02P$"% ,4    " #4@WQ8+[0$
M#C]5 0!53A0 $0              @ '=^@( 96QD;BTR,#(S,3(S,2YX<V10
M2P$"% ,4    " #4@WQ8["R/R]\5  #XL   $               @ %+4 0
M96QD;BUE>#$P7S(R+FAT;5!+ 0(4 Q0    ( -2#?%@"-$KI, H  ,I?   0
M              "  5AF! !E;&1N+65X,3!?,C,N:'1M4$L! A0#%     @
MU(-\6-CT?2(9!   -!4   \              ( !MG $ &5L9&XM97@R,U\Q
M+FAT;5!+ 0(4 Q0    ( -2#?%AZ?U2$4P@  'L\   /              "
M ?QT! !E;&1N+65X,S%?,2YH=&U02P$"% ,4    " #4@WQ8)LO4QVP(  !I
M/0  #P              @ %\?00 96QD;BUE>#,Q7S(N:'1M4$L! A0#%
M  @ U(-\6*5]',1-!0  JQ\   \              ( !%88$ &5L9&XM97@S
M,E\Q+FAT;5!+ 0(4 Q0    ( -2#?%A2G*<H2 4  )D?   /
M  "  8^+! !E;&1N+65X,S)?,BYH=&U02P$"% ,4    " #4@WQ8Q!0+JZT-
M   T6@  #P              @ $$D00 96QD;BUE>#DW7S$N:'1M4$L! A0#
M%     @ U(-\6&VYYHHE0 H 13\- !(              ( !WIX$ &EM9S$Q
M-C(P-C<T-E\P+FIP9U!+ 0(4 Q0    ( -2#?%@!V#RO0L4" +@D!0 2
M          "  3/?#@!I;6<Q,38R,#8W-#9?,2YJ<&=02P$"% ,4    " #4
M@WQ8^+?YSWXZ 0 %+ ( $@              @ &EI!$ :6UG,3$V,C V-S0V
M7S(N:G!G4$L! A0#%     @ U(-\6"#BS8TZ=0$ ^],! !(
M ( !4]\2 &EM9S$Q-C(P-C<T-E\S+FIP9U!+!08     #@ . &@#  "]5!0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>eldn-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:eldn="http://www.eledon.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eldn-20231231.xsd" xlink:type="simple"/>
    <context id="C_090932c3-ea52-4d70-b213-7b49b4e7f9bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f06bf133-70a4-416c-a4f6-115eb78648e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c33e93a8-92df-4580-a627-619828841106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eldn:CommonAndPreferredWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_36a0389b-10cb-49c8-b0e4-e5b3b2badc70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52ac3c7f-20e1-4753-802e-f4dad8d28acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c1011001-4cbb-4b9f-93e6-39793a44b86c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:WarrantsExchangedForSeriesX1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_05c23523-7806-4910-8de2-4ca513419180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4fc735f4-0e20-4c55-bc5a-1509ab504714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementThirdClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="C_07827eda-fb88-4fed-aae9-6ed17feba552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_349c064a-f323-4320-a562-2a08dbbdc3ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2aed4a90-b683-4eb4-a34b-231381f0b672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f240e52-3046-4a8c-8a48-212f2e92c63e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementSecondAndThirdClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="C_606d38b0-f6ba-43cf-b237-35fd69e618d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-21</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_157cedb9-5047-412b-85f9-6fbe8216f23c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_31d98449-23a4-498d-bc0e-c00c14f1718b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="C_ac320d24-5fbb-42d0-93dd-dad1bc9ba82d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d1c703b7-f5c2-420d-baed-484058777e18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eldn:TimeBasedAndPerformanceBasedVestingRequirementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_497f04cf-da0b-4b5e-b011-34361d789ace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="C_99647e68-33eb-417c-a4d5-0797361b24f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c4d5fab0-b529-4936-88f9-d28a56338778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1c94ca06-3730-4b18-9348-e88243d8d2e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2f480dcc-a0dc-4708-95ae-152e67a484fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="C_bd6fbf82-130d-405c-b4df-97d3c4f5ddb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_ac3741ad-2290-4551-8fd0-d8b0fd4e7b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cdaa1da2-6d2e-4920-84ee-ec3843c595c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eldn:AnelixisTherapeuticsLlcAndOticPharmaLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_539b64d7-b76a-4d73-b8da-2e58862a41c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8711094b-fadc-4a14-9f20-38420f00a8ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_95b9fc77-0964-46e8-8014-8c0dbfd4b766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b10db2e1-d9c6-4be4-9ba9-86c0ebed4c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_f0af738a-7254-4f32-bf85-c20c9f5d1f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f8d96f37-a27b-4675-8ac3-76423e39c728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_16a5f966-35bb-40a6-836a-438436efb35a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-14</instant>
        </period>
    </context>
    <context id="C_2338023d-7d9b-4ae4-860d-5a670fc77d43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="C_5fd780de-3625-4605-acfa-3c1d91d4974d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fdf8105d-12d9-4345-b55c-4de997687b56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a4dbd612-6707-4d02-a493-3e3587d5b602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed778020-ad3f-469d-86df-b93a95a7576c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5b4e4097-491a-4d6f-afa0-8dd0e72ce61a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="C_80ff1b22-a3d3-4e55-9ed1-30853a838cdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f6ce7cd5-abcb-4e3b-a08b-0f8a402a5e5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eldn:TimeBasedVestingRequirementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4d3a667-0d9f-40ac-bb0e-95f7b4b21745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_37373384-6f64-4549-9ed5-b285cc857da3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_65b7835c-8f67-4c38-a18d-054d0149baa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d5fba3f-307a-4a36-acdc-6c3371fb0c8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_79a2379f-7f54-4178-992c-73f84e1d8b73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3c6b3fdb-26ba-4381-9bb7-d9118f53631d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8dc70a81-570f-425e-8e77-d3cbed342a71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_57551459-8811-4b71-9e9a-189290d077cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b6eb2939-62e5-40db-a742-2c39943593d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_80152760-f5f1-49d1-818c-7be41d8bad59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_170abf46-8a87-4bdf-bc25-11d52fb87c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_37fbd92e-56b2-46ce-8389-9dbd29607f96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ac28187a-81e1-43da-a679-686dc898f95a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b395598c-4190-4835-bf33-91c539bcf3da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0abe5b3-eb23-480e-a655-192c844dd5f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="C_3f2ef666-c1cc-4c55-a513-878df085d0cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d7bc39d7-c639-45d4-a935-4c52633b71fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeriesX1ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-11</startDate>
            <endDate>2022-01-11</endDate>
        </period>
    </context>
    <context id="C_403020d7-be70-4c12-a4cc-8bc0abf4256e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_200cc8e1-5269-466a-876a-228fe7dd6936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5bcb3f59-3ee1-413a-b49d-33149e98e0b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_7fb153ff-f40b-425f-93b1-c594301d3610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9bd49aca-76b8-41b8-851c-421b99dd8a37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed539061-91d5-4d71-9cf6-98e903ea5f7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="C_cff03e8e-4e84-4751-8bed-4bbfff630a65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="C_e474f40b-c32d-4216-952d-084ee8fda28a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6ae6940e-5a6a-475f-9b2c-85a5e9f64183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a35f913d-d756-40df-9f78-a4912c356455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_509700d3-0809-447c-94e0-126e7520dc70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bd72c38d-208f-4865-8dad-4735385f07ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3a8b2ca6-ee48-4d8b-9174-016ccf545018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="C_9e831537-98aa-43d1-a911-7e2bb6a241d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eldn:AnelixisTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-14</startDate>
            <endDate>2020-09-14</endDate>
        </period>
    </context>
    <context id="C_bb8a89d8-fa9c-4eed-9f5a-4e41b1a1cdb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9a6202d9-fada-461a-bd65-85c4b8841070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="C_ccdb24f4-ddf1-43b9-891d-1a463b208bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7430787c-94a0-4f8c-8d53-714130bb6ed6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_85108846-892e-47c8-9754-3c7dfc301d1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_239720ec-ec16-4abc-a760-ebef1985ac2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aaa353e1-e2e4-4e48-84e1-87f26b1fe289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0214fd64-e27d-4163-83ae-6f06bab5710b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="C_0439d622-b345-4d2d-a148-7f5891bdb53e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0adbfddb-526c-4e99-8cac-1ee645fd34e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementSecondClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="C_d67b8fc7-20c1-4f9d-9bf3-e028f161e18b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="C_8a9a710c-7ac2-4558-9624-0a06bad3b9b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:FiveHundredMillionAggregateNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f427656a-338e-4bdd-9bad-d6f9b666e78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dec7f080-9ef4-430f-acea-1afbd5a8afda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7801a479-8e65-474f-81b3-70e988f0cb94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:BiotechnologyValueFundLPBiotechnologyValueFundIILPBiotechnologyValueTradingFundOSLPMSIBVFSPVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeriesX1ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-11</startDate>
            <endDate>2022-01-11</endDate>
        </period>
    </context>
    <context id="C_e0208a52-3605-4067-a592-6f1d7092a39c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:OneBillionAggregateNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a2215e8a-709f-4e4f-a87d-5319589f877a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_df5cb9c5-cc2b-4539-8abf-128c08a87c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f3213c02-d3c7-4370-aa17-1e548a1026d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9eda5a95-af05-48df-860c-3566c2e5b7b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cb8475f5-4660-40c0-8142-92caed57a7c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fc7dea4e-952b-4624-b726-7fb18eb4ecb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b1b6b20f-2b7f-4988-9b59-14ae1a547e10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_f448875a-e2e2-4f12-b2e3-7d76a53fa08d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_23d71061-54b9-42a6-9e17-5f08efea1eb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:WarrantsExchangedForSeriesX1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_58bb8acc-ddde-40c9-8a7d-dbf46fcb11f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eldn:AnelixisTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b1d46794-a5ff-4a00-a67a-113d1f5e5bb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b9deefa9-7710-433e-acac-3e9a0bd20f91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="C_b7d71759-5259-4d1d-9aa7-792cc31e7654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f418a451-c1a8-49bf-9510-a9346093387d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_514fb2b8-c4b0-4b5c-a2e4-0c1d1d0a3e36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17e67f10-b293-4956-8cef-526a32b65ef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3da60b1-bf6f-43ce-b8eb-e383f1879995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_2e3151e2-74b6-4f7c-b669-6a6d90422655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eldn:OticPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91677af4-ce57-4e73-97a4-b3d085786c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:OneBillionAggregateNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a19675bc-9e87-4fa8-a561-20689ac5db3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1db222f1-dbb0-49ac-9c1f-ef8b555d7efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_734d7e73-f1c6-4f08-8277-d9d136b29526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eldn:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_50fac1cc-803f-44be-b716-f8a6c9e0f8d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1772a59-3433-4d38-9a57-13a0ec38ee2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="C_5db2a782-5d40-4e38-afa2-a24096cf9b4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementThirdClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="C_326577f3-b56f-4806-864f-4daf1c2d3bdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f9a7cc9f-d6ce-4f09-85e0-f27ce671852a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c5ff90c2-7ab7-4323-9fa7-e9cdeca70a8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_eb638520-bde3-4a17-8789-c1c72e2e54f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b49914b8-f522-4af4-8c0b-fb6529f0205e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_564fb782-4618-449b-be0d-4a8c0d6e8c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eldn:CommonAndPreferredWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_148ad8a7-b70c-496a-95b6-25eb9918c6d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9cc0ccfc-b7a6-4b18-b60e-c2dd9520c8bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">eldn:FiveHundredMillionAggregateNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f447210b-d619-429a-aaa3-21f7e7229a49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:WarrantsExchangedForSeriesX1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bdc4a339-8142-476a-b3fb-e83a9b558bde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_84888892-87f5-4e23-bd7c-63309c46746a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_085ab3ce-d345-4414-8f9f-ec51eb1a7ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eldn:ArmisticeCapitalMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="C_10ef38e2-ed82-4422-8141-1f5959c9d8b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a45cdbc7-e8f2-4e4f-8f6f-ba8e618b1f4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c76111e5-5031-4f89-b4d4-0128b09d2e80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0357e8b8-b1b4-40e1-a1cf-ad729e9511b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eldn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_891105d4-f431-4944-af9d-ba738f8db8f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="C_12a2d2e1-2aaf-4445-a36c-14fb7b5c2325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eldn:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b7b00cf-f725-4f04-abf7-50d2422f6755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eldn:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="C_89b25922-7cb3-4412-b567-f46abca28cf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_94a7e619-bc0a-46f9-82d4-e85969a5f850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5deb814-b818-48f3-be71-4e54d19ae9f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesXNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_97e359d3-cfa5-442f-9a87-040db5c132e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22837696-6636-4174-85b7-968e5779be90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eldn:CormorantGlobalHealthcareMasterFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:ConversionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="C_35052766-c4e5-4be4-af90-aba8bb3300b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7aafb0bd-5f6d-4965-a2d7-c6a51e705c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_37fd87ac-684b-41cc-9625-693d26d0ebe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_90229839-dc48-46bd-88f4-a22efae9078c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SecuritiesPurchaseAgreementInitialClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <context id="C_08232590-c5fa-4b08-bc08-e606069533f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f301cf92-7fb0-4ba2-92cb-d9b6ab58209c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eldn:SeriesX1NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eldn:SeptemberTwoThousandTwentyOneWarrantExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-21</startDate>
            <endDate>2021-09-21</endDate>
        </period>
    </context>
    <context id="C_680c3de3-4af7-4781-b111-7a9f83940645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Reporting_Unit">
        <measure>eldn:Reporting_Unit</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>eldn:Segment</measure>
    </unit>
    <unit id="U_Milestone">
        <measure>eldn:Milestone</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_e5f04133-98dc-4ec1-8902-26951bc43866">0001404281</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_8a3435ff-6483-41a3-9517-72be74feb111">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_43205817-47d4-4fc9-aeae-d88a8e1b9cf1">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      id="F_8862ae79-21b9-4dd3-b094-5f0b37ca3bf5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      id="F_590f46c2-3850-4849-be6f-cc96373a70da"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      id="F_00a1069d-cd72-41cb-bc33-200863646b81"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      id="F_8e1d1e87-5ed8-4476-b947-d11cb0df1b47"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728"
      id="F_97b04c6c-0e31-4def-bdf9-a4dc995bb41f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7"
      id="F_3ca1e85d-199a-4c47-8f91-7bf01141c98f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_cf07bad8-684c-4366-801c-bed5331fe371">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_80cec1e4-5199-4fa9-a0b4-232e0d810e14">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_0430965d-dd53-4617-a41f-1bd602873cc0">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_1d11bf00-bf44-46a7-8c0d-765558bee926">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_67e3bc97-f5c9-4edc-b37d-0f65698c7f9d">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_77e5c273-3ada-4b7f-8b0f-7601e301da2c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_9a987da9-ef81-4581-bfed-9f4b13610e80">001-36620</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_3eed661c-940b-4f00-83e0-b264c5fc0e7a">ELEDON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_23defe9d-9e66-44cf-82a6-833b7cc67434">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_a1eb3df0-53fe-4a3b-95b7-3730df60c388">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_42436286-68e0-477c-8a6e-30e1d6f23780">19900 MacArthur Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_a4b53e8a-f140-47dd-b20e-f9d9c0207909">Suite 550</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_96968563-d4ec-4646-9b18-47fc84434fcd">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_45e869ac-9066-418b-9c51-ec5db6534566">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_20dea9de-d652-4c5b-84bc-4a478e88f94c">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_6d981c2c-35b3-4934-b45d-e1d88a1bbe8c">(949) </dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_164f850f-1d02-4f21-9b51-9d2e6e0d367f">238-8090</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_cd46d035-eaa7-4e87-bf8a-0649d3585430">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_a6becb21-c52a-4270-af77-0bf2438dc5c5">ELDN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_0d0afc42-974c-4d33-b548-ca9ff502e4ec">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_64ce2ad6-2921-457c-a845-f671d9fa204c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_a9b6a184-9930-47d2-8913-00ba6657d81a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_8698b141-4870-4843-be95-b05a0d7f6b8e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_04479a44-d43a-488b-877c-8ddf54791ef9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_029c62f2-5628-42fb-9d76-d832d429c1cf">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_d53b6406-181f-4231-a152-4e3ef7c51cb5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_78cc84ae-7bf6-4059-8db7-cbba01132307">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_ebc81cfe-ba35-4d19-832f-7e6e64129d6f">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_5399fac7-3a36-4b91-b547-9904eeffe888">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_377bf2f9-e5c3-44e7-9a5b-60ae5b673da6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_37fbd92e-56b2-46ce-8389-9dbd29607f96"
      decimals="0"
      id="F_018dd64b-8c13-4ba1-9e33-14703499d6d3"
      unitRef="U_USD">25607310</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_a0abe5b3-eb23-480e-a655-192c844dd5f1"
      decimals="INF"
      id="F_7502d1b6-fea9-4324-b912-3b64e7b0a4cb"
      unitRef="U_shares">24813130</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_cf32b772-91dc-45b9-afd5-7e6ed11b24f1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;, are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_2d94ec1a-495d-4257-a4e5-35daf8992ffd">170</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_6cb071c9-72f7-472b-ad68-d7cb15346d92">KMJ Corbin &amp; Company LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_d92aa12d-1297-4a3b-8b90-35f74dbf1d9d">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_2aa17541-c16d-4d61-96e5-33b17ed80913"
      unitRef="U_USD">4612000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_f97033f9-2e49-4a58-9032-d49608e2cc61"
      unitRef="U_USD">56409000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_670f7c38-9113-4826-9a51-0813371b5c8b"
      unitRef="U_USD">46490000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_c555b69f-1713-4026-8896-25d5f2127bf0"
      unitRef="U_USD">5027000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_0956aab9-0040-495a-954a-97f50362f898"
      unitRef="U_USD">3109000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_5d14259b-96e8-4827-bf2c-06a57b216c61"
      unitRef="U_USD">56129000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_2bf0c4b5-8e3f-4ac0-9526-11b9457d9388"
      unitRef="U_USD">59518000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_33c05a30-b15b-475a-ab36-336e72d4427f"
      unitRef="U_USD">365000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_4fe61d3e-d3be-4349-8206-7a48e3e8b467"
      unitRef="U_USD">739000</us-gaap:OperatingLeaseRightOfUseAsset>
    <eldn:InProcessResearchAndDevelopment
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_150a0183-2fa5-4ae6-b825-ba679c641fc6"
      unitRef="U_USD">32386000</eldn:InProcessResearchAndDevelopment>
    <eldn:InProcessResearchAndDevelopment
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_ce26d43f-63c2-4856-8e75-0e02f9bfcd4d"
      unitRef="U_USD">32386000</eldn:InProcessResearchAndDevelopment>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_6bede115-874b-428d-afd1-a8720001ad3c"
      unitRef="U_USD">186000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_107e5072-0bea-4eda-8cff-702217d52414"
      unitRef="U_USD">150000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_b6bbe112-8097-42ba-bea0-67cd5302a1a7"
      unitRef="U_USD">89066000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_62c98e1d-ab58-4c5d-adf7-0a9ae6eeea02"
      unitRef="U_USD">92793000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_41d116d4-4575-4c05-88cb-b6fedfb90e05"
      unitRef="U_USD">967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_fd3fe0be-e41a-4ac5-9920-6e872ec99c46"
      unitRef="U_USD">2200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_76b0168e-7b12-4712-bfe2-cdac537940cb"
      unitRef="U_USD">383000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_9c9222ec-6506-49ab-9a3e-108cadbbf3be"
      unitRef="U_USD">363000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_70b8c345-e8b2-4e0f-af1f-f380a6e39f38"
      unitRef="U_USD">2545000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_524221d4-0004-4ca4-abf0-60ca81d7f0e6"
      unitRef="U_USD">3912000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_6c096abf-3504-4073-b470-1f433691b27e"
      unitRef="U_USD">3895000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_4f91e4a5-2ae3-4a7b-966f-a74e662c0f7c"
      unitRef="U_USD">6475000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_3617bae0-c316-4877-9c06-1f1b51ef2b65"
      unitRef="U_USD">1752000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_6e9205fd-60e1-4917-bbd8-212da13d9997"
      unitRef="U_USD">1752000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_46e9cd31-c897-46a4-9fae-c0d43f2d4912"
      unitRef="U_USD">383000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_252f4feb-88af-452b-88b5-464456165f8d"
      unitRef="U_USD">5647000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_836e9c71-7555-4e3d-9b65-dd5274eace9e"
      unitRef="U_USD">8610000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_634cf72b-f91d-4977-bc49-4feb4cee8dba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_ecfbb060-3072-4fd4-8a1d-5bc12516fb7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_6e2bff72-7390-497d-a23f-ff0d8bcc5799"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_a53b2929-6211-47a9-aff5-d757e2b3202b"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_d388986f-e0dc-4aad-8b66-b2251ca97968"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_f2a90ec3-56cc-4649-b897-685511ed052e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_5e89025b-0a72-4c4a-a929-96fb82b26edc"
      unitRef="U_shares">515000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_dcdcd3b0-e03b-4e96-acc2-e649881fd482"
      unitRef="U_shares">515000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_0321c789-a8b0-4200-b4c9-e4d1e344db68"
      unitRef="U_shares">110086</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_ae30179a-b559-46be-a62c-90d9ea9daa81"
      unitRef="U_shares">110086</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_c132b11f-f994-44fd-ba79-212f5b646e2b"
      unitRef="U_shares">117970</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_6de91791-6a96-4b56-b7b0-75945a2de28e"
      unitRef="U_shares">117970</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728"
      decimals="INF"
      id="F_ba6ba3f7-ab34-4280-b431-22b378d7b55c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7"
      decimals="INF"
      id="F_b3df92b1-98a6-4862-bbdd-0c81a3aef3e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728"
      decimals="INF"
      id="F_63e8795f-0701-4b18-8441-f2f975dab1ad"
      unitRef="U_shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7"
      decimals="INF"
      id="F_453b78b1-b28d-432b-ab87-926abcc9db50"
      unitRef="U_shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728"
      decimals="INF"
      id="F_db5acc85-7bfe-4799-938f-60ff456d19a1"
      unitRef="U_shares">4422</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f8d96f37-a27b-4675-8ac3-76423e39c728"
      decimals="INF"
      id="F_e05e3b11-dd8f-4e4a-8b82-4145468f5696"
      unitRef="U_shares">4422</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7"
      decimals="INF"
      id="F_aeb95553-5d24-4315-9497-ba0c952b47a2"
      unitRef="U_shares">6204</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_59ce8659-0a3f-4fa6-bf7a-2ca725e7e2a7"
      decimals="INF"
      id="F_b5b9f84e-a2e7-4859-805a-d196e2293300"
      unitRef="U_shares">6204</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_ac471336-f8ec-459a-be1e-440c406575ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_bd16b8e4-d796-4a70-bc05-5d34a9d6eae8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_ca6a4b6f-5c73-4a3d-b10f-df1353218a08"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_3d16ea70-f7e0-4df3-92b9-3fbcd9192829"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_a71c806d-ba06-47b6-b0f1-0e7931a1ab5b"
      unitRef="U_shares">24213130</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_df82aaab-9f4e-4ad8-b944-09dfcc737414"
      unitRef="U_shares">24213130</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_0ee391e3-9bbd-4658-9233-28dd932671fb"
      unitRef="U_shares">13776788</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_2e5e0272-d4ee-4a1a-9aa2-c56d13b741d1"
      unitRef="U_shares">13776788</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_7c7665c1-c3b1-4275-a2d2-48d12d74626f"
      unitRef="U_USD">24000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_a024f9b7-1407-4932-a108-b93996338440"
      unitRef="U_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_96401be9-a88e-4864-b6d7-f73fa67cd55a"
      unitRef="U_USD">326586000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_2dff3189-3222-461b-8a0a-11e0e9706fa1"
      unitRef="U_USD">287034000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_6389da56-e80b-4374-8ff3-9c391e50741a"
      unitRef="U_USD">-243191000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_83c2bea9-e8cd-4641-b4eb-976dcf6b7697"
      unitRef="U_USD">-202865000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_817c936d-7509-45d9-894a-2a8abdb35854"
      unitRef="U_USD">83419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_1da74889-913a-4d42-89b8-0b6f63e515f5"
      unitRef="U_USD">84183000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_0fc14c5e-d3df-4d45-b033-c791e086be2c"
      unitRef="U_USD">89066000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_a1c574a2-196a-49b7-a7c3-4cbcb1512da3"
      unitRef="U_USD">92793000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_21b761ed-7df7-4b29-b470-a2b997dd168f"
      unitRef="U_USD">30312000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_f7b30a0f-abb6-42d1-9a09-d604dd3538ad"
      unitRef="U_USD">27080000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_58a02c00-1a0f-44ff-a141-bae80cb8cba0"
      unitRef="U_USD">12688000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_611edccb-d134-4e36-a260-e1dbcefccb9a"
      unitRef="U_USD">12700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_d79ffe4f-529b-4110-a568-b846985f1ed5"
      unitRef="U_USD">48648000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_84047d93-23fa-4ea5-ae41-74376ad1c9ab"
      unitRef="U_USD">43000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_82635281-a890-4eee-af54-66f3e37fa2fe"
      unitRef="U_USD">88428000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_b3cffaed-e726-4e05-8b87-0642e3939d03"
      unitRef="U_USD">-43000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_97504281-6be3-4194-a2cc-37ccc7adac93"
      unitRef="U_USD">-88428000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_47f428ab-c8c1-40f0-ba28-5c6a15c8ded4"
      unitRef="U_USD">2674000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_1e9f61e2-ec0f-4f9f-b1fb-73a559548b67"
      unitRef="U_USD">462000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_4b7fb375-8480-4bdb-ac85-0012147ea852"
      unitRef="U_USD">-40326000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_9ac1584d-1044-44f5-9e2a-a50a5297530c"
      unitRef="U_USD">-87966000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_cf0dfbc2-c96f-4367-8717-cfd9b488cb19"
      unitRef="U_USD">-40326000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_a406f864-4aab-4379-b77f-6cbe2faf1217"
      unitRef="U_USD">-87966000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_ed3774a0-804e-4aad-ab11-7af2aa64734c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_fca1f300-6c1b-4009-bbb5-5a7f35448b46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_2d645900-05ef-48be-9425-4159060c285a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_fafc21f7-23f3-450f-a67c-27baea893bf7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="0"
      id="F_98380704-9ab6-4240-935a-6cc3548a9494"
      unitRef="U_shares">24619197</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="0"
      id="F_45dd1926-1456-4b89-9efa-f0bfd2d5d084"
      unitRef="U_shares">24619197</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="0"
      id="F_b6fff231-29b7-4e19-be96-8fd8c280be73"
      unitRef="U_shares">14285254</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="0"
      id="F_7e3a8f8a-1396-4f88-9859-29f081867822"
      unitRef="U_shares">14285254</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_52ac3c7f-20e1-4753-802e-f4dad8d28acc"
      decimals="INF"
      id="F_e1f82e0b-15e0-4ad0-b03a-bd850fbc7604"
      unitRef="U_shares">108070</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_bd72c38d-208f-4865-8dad-4735385f07ae"
      decimals="INF"
      id="F_3aa1e827-1d10-4566-b1ef-de5b479af532"
      unitRef="U_shares">6204</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_37373384-6f64-4549-9ed5-b285cc857da3"
      decimals="INF"
      id="F_6b6ea693-a898-423e-8807-0b07f6201269"
      unitRef="U_shares">14306788</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_37373384-6f64-4549-9ed5-b285cc857da3"
      decimals="-3"
      id="F_3c38eac8-f35b-42c7-9b8d-22f677efef67"
      unitRef="U_USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_99647e68-33eb-417c-a4d5-0797361b24f5"
      decimals="-3"
      id="F_68b0d414-5714-4a0f-bccb-610d31d7003f"
      unitRef="U_USD">278880000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8711094b-fadc-4a14-9f20-38420f00a8ac"
      decimals="-3"
      id="F_370d204f-b4d0-4aa7-903d-e53543699274"
      unitRef="U_USD">-114899000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"
      decimals="-3"
      id="F_9485249a-75a9-43e6-96a2-6269ff0aa26b"
      unitRef="U_USD">163995000</us-gaap:StockholdersEquity>
    <eldn:CancellationOfCommonStockInExchangeForPreferredStockShares
      contextRef="C_b395598c-4190-4835-bf33-91c539bcf3da"
      decimals="INF"
      id="F_c000b5fd-32b5-48e3-a31d-5c81e9f928a1"
      unitRef="U_shares">9900</eldn:CancellationOfCommonStockInExchangeForPreferredStockShares>
    <eldn:CancellationOfCommonStockInExchangeForPreferredStockShares
      contextRef="C_80ff1b22-a3d3-4e55-9ed1-30853a838cdc"
      decimals="INF"
      id="F_0c8ae642-c0c9-4bf9-aaa6-a80057ad94ed"
      unitRef="U_shares">-550000</eldn:CancellationOfCommonStockInExchangeForPreferredStockShares>
    <eldn:CancellationOfCommonStockInExchangeForPreferredStockValue
      contextRef="C_7aafb0bd-5f6d-4965-a2d7-c6a51e705c60"
      decimals="-3"
      id="F_576c3bf5-4be9-4939-9d9b-26d5e084b5ee"
      unitRef="U_USD">1000</eldn:CancellationOfCommonStockInExchangeForPreferredStockValue>
    <eldn:CancellationOfCommonStockInExchangeForPreferredStockValue
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_b83be05d-cab6-4c5a-b4b7-78e0eca4df6a"
      unitRef="U_USD">1000</eldn:CancellationOfCommonStockInExchangeForPreferredStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_80ff1b22-a3d3-4e55-9ed1-30853a838cdc"
      decimals="INF"
      id="F_79c20bf1-4e6b-4c2e-8fc9-00a19ff93928"
      unitRef="U_shares">20000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7aafb0bd-5f6d-4965-a2d7-c6a51e705c60"
      decimals="-3"
      id="F_45d940eb-125e-4d65-915a-b58d77f785ce"
      unitRef="U_USD">8153000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_506bd908-e556-4607-8488-20ac44ce2e5a"
      unitRef="U_USD">8153000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_bb8a89d8-fa9c-4eed-9f5a-4e41b1a1cdb0"
      decimals="-3"
      id="F_5fd503c1-8c66-485d-92df-6a4a23762ba6"
      unitRef="U_USD">-87966000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_0023fb30-0d1c-458a-9af8-5a645060c6cd"
      unitRef="U_USD">-87966000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_2ecb72bf-d70a-46d6-bec8-2ad510dc30c1"
      unitRef="U_shares">117970</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde"
      decimals="INF"
      id="F_26c0a405-a99b-4310-9415-bc0ab660ccaf"
      unitRef="U_shares">6204</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_36a0389b-10cb-49c8-b0e4-e5b3b2badc70"
      decimals="INF"
      id="F_67e45b30-f1cf-42a4-b74d-b38f46637379"
      unitRef="U_shares">13776788</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_36a0389b-10cb-49c8-b0e4-e5b3b2badc70"
      decimals="-3"
      id="F_67106241-aa76-48c2-a29b-58eebb644349"
      unitRef="U_USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ac3741ad-2290-4551-8fd0-d8b0fd4e7b4a"
      decimals="-3"
      id="F_2c5206d8-0f21-4dc2-bc23-91ae1940e147"
      unitRef="U_USD">287034000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50fac1cc-803f-44be-b716-f8a6c9e0f8d2"
      decimals="-3"
      id="F_909f73b8-fdba-41a4-b683-4b4a0967bca8"
      unitRef="U_USD">-202865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_e8ebb939-d08c-4709-8c03-bb013adea62d"
      unitRef="U_USD">84183000</us-gaap:StockholdersEquity>
    <eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="INF"
      id="F_861df009-ad43-4717-8c12-179e90c25925"
      unitRef="U_shares">8730168</eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares>
    <eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="-3"
      id="F_8471e29d-b4ae-46fa-8140-56f21e7c613c"
      unitRef="U_USD">9000</eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue>
    <eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
      contextRef="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d"
      decimals="-3"
      id="F_b60da300-7a9b-4ccb-aaa4-df712bbe2846"
      unitRef="U_USD">33008000</eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue>
    <eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_d087058f-6a35-4ca1-8c13-8306541fe9f0"
      unitRef="U_USD">33017000</eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue>
    <eldn:IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares
      contextRef="C_a45cdbc7-e8f2-4e4f-8f6f-ba8e618b1f4d"
      decimals="INF"
      id="F_1e24b7f4-4c59-42b7-a189-ba0d33631d95"
      unitRef="U_shares">-1782</eldn:IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares>
    <eldn:IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="INF"
      id="F_11263c83-aff0-4f41-9373-2ca306a5564a"
      unitRef="U_shares">99000</eldn:IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares>
    <eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares
      contextRef="C_0357e8b8-b1b4-40e1-a1cf-ad729e9511b7"
      decimals="INF"
      id="F_e2524424-b1db-492d-a824-073ed6aa3d35"
      unitRef="U_shares">-7884</eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares>
    <eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="INF"
      id="F_d8a3aa48-dc26-41c7-bc11-28fb5e32c0f6"
      unitRef="U_shares">437977</eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares>
    <eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue
      contextRef="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d"
      decimals="-3"
      id="F_a8fd24d7-cc93-4bd4-8491-f8f06865ee77"
      unitRef="U_USD">-1000</eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue>
    <eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_4042218d-d192-4ccf-ba3c-fc3f349943f9"
      unitRef="U_USD">-1000</eldn:IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue>
    <eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="INF"
      id="F_b9e63bb2-753a-478e-b52b-ab4d02e05dc4"
      unitRef="U_shares">1154197</eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares>
    <eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="-3"
      id="F_7c00df0d-e293-4510-be21-e51c0688d162"
      unitRef="U_USD">1000</eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue>
    <eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_f4f4d0ae-fbf7-40e9-b748-ac08908a6a63"
      unitRef="U_USD">1000</eldn:IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_b6eb2939-62e5-40db-a742-2c39943593d4"
      decimals="INF"
      id="F_828d6705-bbef-4ef7-9b65-82735dd97aaa"
      unitRef="U_shares">15000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_74ba7c0a-31b0-4b12-a128-4c1344537d5d"
      decimals="-3"
      id="F_694900d2-1da6-4c83-bf85-30f7b59d237f"
      unitRef="U_USD">6545000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_af940dec-c753-4589-9156-6bd784f84d8f"
      unitRef="U_USD">6545000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_a19675bc-9e87-4fa8-a561-20689ac5db3f"
      decimals="-3"
      id="F_767f066e-7d1a-4441-9a9e-586d4ba30a8e"
      unitRef="U_USD">-40326000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_57ff46b9-82c2-4ec1-b3be-0c5b5f5f7642"
      unitRef="U_USD">-40326000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_c9f70a2b-f37a-458d-9902-e9ccc07115f6"
      unitRef="U_shares">110086</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6"
      decimals="INF"
      id="F_396364ec-6547-4fbb-ae3c-cc11297cfe61"
      unitRef="U_shares">4422</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_b7d71759-5259-4d1d-9aa7-792cc31e7654"
      decimals="INF"
      id="F_37c880da-4f99-4e02-a415-ba55c5e5da44"
      unitRef="U_shares">24213130</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b7d71759-5259-4d1d-9aa7-792cc31e7654"
      decimals="-3"
      id="F_ede8ce0d-443b-495d-8b3f-dd2289256a28"
      unitRef="U_USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c76111e5-5031-4f89-b4d4-0128b09d2e80"
      decimals="-3"
      id="F_a336fa04-f2dc-4b4a-8f49-100cfac2e507"
      unitRef="U_USD">326586000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_37fd87ac-684b-41cc-9625-693d26d0ebe0"
      decimals="-3"
      id="F_22090f12-3f44-4ea8-8f63-2e9ce6cf25d5"
      unitRef="U_USD">-243191000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_261fcf62-50eb-4514-b132-bec9536cdae3"
      unitRef="U_USD">83419000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_a28aafc3-838a-4854-a16f-c4ccbfe9e9bd"
      unitRef="U_USD">-40326000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_dd3525c8-ffad-406e-9682-c8eda9373f5e"
      unitRef="U_USD">-87966000</us-gaap:NetIncomeLoss>
    <eldn:AmortizationOfOperatingLeaseAsset
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_70a5cc06-2422-44f5-a89e-5242b9363234"
      unitRef="U_USD">374000</eldn:AmortizationOfOperatingLeaseAsset>
    <eldn:AmortizationOfOperatingLeaseAsset
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_abaecdfe-148f-4ab3-9241-2cd51790afda"
      unitRef="U_USD">373000</eldn:AmortizationOfOperatingLeaseAsset>
    <eldn:AccretionOnInvestmentDiscounts
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_d6ee1d80-d9dd-4de0-812e-a0f191528a32"
      unitRef="U_USD">-1203000</eldn:AccretionOnInvestmentDiscounts>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_757b9b1e-fbd1-4cfa-9061-b7d9eb85f36c"
      unitRef="U_USD">48648000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_2e96d558-b4b4-454f-a10c-3a66b4a740d3"
      unitRef="U_USD">6545000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_44ff5088-24d7-4f08-bc84-54e9dc28d0d7"
      unitRef="U_USD">8153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_7d6a3047-9c64-4ecf-915d-d5ed3150a0a6"
      unitRef="U_USD">1954000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_d8962cad-16f3-4e11-b1e9-57c51bc2b1ad"
      unitRef="U_USD">-654000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <eldn:AccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_86507b05-b40c-493b-9621-9226665e3680"
      unitRef="U_USD">-2600000</eldn:AccountsPayableAccruedExpensesAndOtherLiabilities>
    <eldn:AccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_63a7373e-234f-46ab-bc78-9092e2f52c71"
      unitRef="U_USD">2081000</eldn:AccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_edbcd797-24fc-48c0-830e-db8ad54d0004"
      unitRef="U_USD">-363000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_801273e7-2b3d-43ac-92c0-aedf52cf4c29"
      unitRef="U_USD">-367000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_f6d225fe-d881-4913-88ea-27c09db199cf"
      unitRef="U_USD">-39527000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_74fb3f9f-a308-4a59-a03f-b9200f8977e7"
      unitRef="U_USD">-28424000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_060a62c1-8589-4ada-991f-08b20211e974"
      unitRef="U_USD">78287000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_ca6beb4e-0fe7-4ee3-962a-1f817e48f9a5"
      unitRef="U_USD">33000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_7b0f3bb1-dc9d-47a8-9fcd-694011fd3f90"
      unitRef="U_USD">-45287000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <eldn:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_13b162d9-8252-42eb-b4e9-edde9d97adf8"
      unitRef="U_USD">33017000</eldn:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_ab25d478-85c0-4745-8ef5-1030700839eb"
      unitRef="U_USD">33017000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_84245ce5-b171-48c8-a85b-104abe90ca62"
      unitRef="U_USD">-51797000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_b0eb12cd-6735-4344-9de5-a6a84d692d06"
      unitRef="U_USD">-28424000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_f794ebf8-94de-4f4c-b74d-65729eab248d"
      unitRef="U_USD">56409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"
      decimals="-3"
      id="F_9f0494cd-642c-4e0d-9edb-311e740b728c"
      unitRef="U_USD">84833000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_55d0a8b8-ed44-4c38-a273-13d1ddfccd77"
      unitRef="U_USD">4612000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_366ae1e1-143d-4735-bccf-717df9b1d9fb"
      unitRef="U_USD">56409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <eldn:CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_488a361b-f83c-4bb9-bb1d-578341f63ef8"
      unitRef="U_USD">1000</eldn:CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock>
    <eldn:CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_6dad2c8a-1e7e-4c49-b3db-11e9bb45c7ab"
      unitRef="U_USD">1000</eldn:CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock>
    <eldn:IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_313ec41d-0b76-4b11-a8a7-a470275ac2ee"
      unitRef="U_USD">344000</eldn:IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_bada55aa-71b6-4fc3-9ff5-b6eb97ce101a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 1. Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (&#x201c;CD40L&#x201d; or &#x201c;CD154&#x201d;) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;). The Company&#x2019;s lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. Unless otherwise indicated, references to the terms &#x201c;Eledon,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; &#x201c;we,&#x201d; or the &#x201c;Company&#x201d; refer to Eledon Pharmaceuticals, Inc. and its wholly owned subsidiaries, on a consolidated basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 14, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Eledon acquired Anelixis Therapeutics, Inc. (&#x201c;Anelixis&#x201d;), a privately held clinical stage biotechnology company developing a next generation anti-CD40L antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. The Company maintains its corporate headquarters in Irvine, California and has research and development facilities in Burlington, Massachusetts.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1
      contextRef="C_9e831537-98aa-43d1-a911-7e2bb6a241d8"
      id="F_98295a7f-84a9-4140-8888-6ddf9a64f911">2020-09-14</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_fd63ef57-382a-4b04-9654-829f3d94a560">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 2. Going Concern and Management&#x2019;s Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company had a net loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023 and an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;243.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023, as a result of incurring losses since our inception. Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. The Company expects to continue to incur net losses into the foreseeable future in connection with its ongoing activities, particularly as the Company expands its clinical program with tegoprubart, continues the research and development of, and seeks marketing approval for, its product candidates. In addition, if the Company obtains marketing approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company has financed operations primarily by net proceeds from the sale of preferred and common stock and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 28, 2023, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain institutional and accredited investors (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the &#x201c;Private Placement&#x201d;) shares of common stock and warrants in a series of three potential closings. On May 5, 2023, the initial closing occurred and the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,730,168&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,421,350&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and additional common stock warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,151,518&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (or pre-funded warrants in lieu thereof). The Company may receive up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in tranche financing in a second and a third closing, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million assuming the exercise of all common stock warrants issued in the initial closing of the Private Placement. See Note 10. &#x201c;Stockholders&#x2019; Equity&#x201d; for further information regarding the Private Placement. Due to the contingent nature of the exercise of the common stock warrants and the second and third closings of the Private Placement, accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires the Company to exclude them from its going concern analysis. If these events do not occur or the Company is unable to secure additional capital or is unable to do so on acceptable terms, it will be forced to significantly alter its business strategy, substantially curtail its current operations, or liquidate and cease operations altogether.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; As of December 31, 2023, the Company had cash and cash equivalents and short-term investments of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Additionally, in view of the Company&#x2019;s expectation to incur significant losses for the foreseeable future, the Company will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company&#x2019;s access to, such resources is not assured. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, management believes that there is substantial doubt regarding the Company&#x2019;s ability to continue operating as a going concern through at least the next twelve months from the date of this filing.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-5"
      id="F_5be0fb9a-afe0-4460-ae02-ed8b5d2aadfc"
      unitRef="U_USD">-40300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-5"
      id="F_a5758a43-8464-48a3-b19b-4b8585d160a0"
      unitRef="U_USD">-243200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_90229839-dc48-46bd-88f4-a22efae9078c"
      decimals="-5"
      id="F_200a299a-34cf-4119-aa14-780c2e09a9c4"
      unitRef="U_USD">35000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2f480dcc-a0dc-4708-95ae-152e67a484fe"
      decimals="INF"
      id="F_a6627d82-cda8-4d52-9f06-a6f950de84f5"
      unitRef="U_shares">8730168</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9a6202d9-fada-461a-bd65-85c4b8841070"
      decimals="INF"
      id="F_f2176b9b-10ad-414e-b683-44635d4aef36"
      unitRef="U_shares">6421350</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2f480dcc-a0dc-4708-95ae-152e67a484fe"
      decimals="INF"
      id="F_d1c0a319-4084-4560-82b1-9a8eb07d339b"
      unitRef="U_shares">15151518</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_2f240e52-3046-4a8c-8a48-212f2e92c63e"
      decimals="-5"
      id="F_2051c421-5a94-4af6-ab59-5c3b5d9e2a62"
      unitRef="U_USD">105000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_8b7b00cf-f725-4f04-abf7-50d2422f6755"
      decimals="-5"
      id="F_05dae30e-7e1f-4eb4-b457-1986a7b13653"
      unitRef="U_USD">45500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-5"
      id="F_31082f2e-ad00-4d9f-8d04-f1cfa889540a"
      unitRef="U_USD">51100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_ef8378f1-1722-4882-918b-47b3317bd43f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 3. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with GAAP. Eledon, a Delaware corporation, owns &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (&#x201c;Otic&#x201d;). Otic owns &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company&#x2019;s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company&#x2019;s foreign subsidiary are not significant to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All significant intercompany accounts and transactions among the entities have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months or less&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, all of the Company&#x2019;s long-lived assets were located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s products will require approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company&#x2019;s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;all &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reportable Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments under GAAP are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer and the Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; business segment, which is the development of products for therapeutic medicines selectively targeting critical pathways associated with the underlying molecular pathogenesis for patients with severe inflammation and autoimmune diseases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired under the acquisition method of accounting. Goodwill is not amortized but is evaluated for impairment as of December 31 of each year or if indicators of impairment exist that would, more likely than not, reduce the fair value from its carrying amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company performs its goodwill impairment analysis at the reporting unit level, which aligns with the Company&#x2019;s reporting structure and availability of discrete financial information. The Company performs its annual impairment analysis by either comparing the reporting unit&#x2019;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#x2019;s fair value from the last quantitative assessment to determine if there is potential impairment. The Company may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#x2019;s estimated fair value was significantly in excess of the carrying value of its net assets and it does not believe there have been significant changes in the reporting unit&#x2019;s operations that would significantly decrease its estimated fair value or significantly increase its net assets. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies. Key assumptions for these projections include revenue growth, future gross and operating margin growth, and its weighted cost of capital and terminal growth rates. The revenue and margin growth is based on increased sales of new products as the Company maintains investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including timing and probability of regulatory approvals for Company products to be commercialized. The Company&#x2019;s market capitalization is also considered as a part of its analysis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s annual evaluation for impairment of goodwill consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reporting unit. In accordance with the Company&#x2019;s policy, the Company completed its annual evaluation for impairment using the quantitative assessment, utilizing the market approach and due to declining market conditions, determined that the fair value of the reporting unit was below its carrying value. As a result, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of goodwill impairment, reducing the goodwill balance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the year ended December 31, 2022, and accordingly, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; goodwill impairment was recorded for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which the carrying amount of an asset exceeds its fair value. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments of long-lived assets have been identified during the years presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (&#x201c;R&amp;amp;D&#x201d;) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company&#x2019;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company&#x2019;s prior period accrued estimates for clinical trial activities through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, incentive stock options, restricted stock units and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company&#x2019;s net loss position. Basic weighted average shares outstanding for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,776,270&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509,117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, shares underlying pre-funded warrants to purchase common shares. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the shares underlying these pre-funded warrants can be issued for little &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;consideration &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(an exercise price per share equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share), these shares are deemed to be issued for purposes of basic earnings per share.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.3%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.34%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,619,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,285,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The computation of diluted earnings per share excludes incentive stock options, restricted stock units, and warrants that are anti-dilutive. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a summary as of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:63.247%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.937%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.937%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding and other equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,909,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,012,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common and preferred warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,577,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,127,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,486,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,139,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. The expected dividend assumption was based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;) are measured and recognized based on the quoted market price of our common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. We assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. We have provided a valuation allowance on our deferred tax assets as of December 31, 2023 and 2022 because we believe it is more likely than not that a majority of our deferred tax assets will not be realized as of this date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company evaluates the accounting for uncertainty in income tax recognized in its consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;positions &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;where it is &#x201c;not more likely than not&#x201d; that a tax benefit will be sustained, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued any liabilities for any such uncertain tax positions as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or processes, if any. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The second step is to measure the tax benefit as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% likely of being realized upon settlement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Note 9. Income Taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements Issued But Not Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <eldn:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_c03c2b0b-3b08-45bd-9862-11761ccedbd8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements are prepared in accordance with GAAP. Eledon, a Delaware corporation, owns &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (&#x201c;Otic&#x201d;). Otic owns &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company&#x2019;s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company&#x2019;s foreign subsidiary are not significant to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All significant intercompany accounts and transactions among the entities have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</eldn:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="C_cdaa1da2-6d2e-4920-84ee-ec3843c595c9"
      decimals="INF"
      id="F_e889aa5c-8ce3-47da-9199-6a42da266161"
      unitRef="U_pure">1</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="C_2e3151e2-74b6-4f7c-b669-6a6d90422655"
      decimals="INF"
      id="F_dbcd0aa5-aa96-4d3a-a505-3a47d2a29e9f"
      unitRef="U_pure">1</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <us-gaap:UseOfEstimates
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_897e61eb-f84a-472b-80a6-7c1b830423a8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_f8d7cced-9b5d-4e4e-b781-8b2ab281b3c4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_c989a7ba-063e-494a-bf8f-b9323f73f979">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months or less&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <eldn:CashCashEquivalentsAndRestrictedCashMaturityPeriod
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_2433ff0c-4ff8-486b-8306-1ec1c902a84a">three months or less</eldn:CashCashEquivalentsAndRestrictedCashMaturityPeriod>
    <eldn:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_6fb390c2-3120-4ab9-83e2-19cb4ffa12ff">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, all of the Company&#x2019;s long-lived assets were located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s products will require approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company&#x2019;s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;all &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.&lt;/span&gt;&lt;/p&gt;</eldn:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_6f1a490b-2ef7-41d0-8b71-c8b06cf09e4c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reportable Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments under GAAP are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer and the Company has determined that it operates in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; business segment, which is the development of products for therapeutic medicines selectively targeting critical pathways associated with the underlying molecular pathogenesis for patients with severe inflammation and autoimmune diseases.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_dac78ce2-edb2-49aa-90e7-d6303aa5dcbe"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_a2305c6f-fec9-493d-b7ba-974d3a4a4ea2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired under the acquisition method of accounting. Goodwill is not amortized but is evaluated for impairment as of December 31 of each year or if indicators of impairment exist that would, more likely than not, reduce the fair value from its carrying amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company performs its goodwill impairment analysis at the reporting unit level, which aligns with the Company&#x2019;s reporting structure and availability of discrete financial information. The Company performs its annual impairment analysis by either comparing the reporting unit&#x2019;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#x2019;s fair value from the last quantitative assessment to determine if there is potential impairment. The Company may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#x2019;s estimated fair value was significantly in excess of the carrying value of its net assets and it does not believe there have been significant changes in the reporting unit&#x2019;s operations that would significantly decrease its estimated fair value or significantly increase its net assets. If a quantitative assessment is performed, the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies. Key assumptions for these projections include revenue growth, future gross and operating margin growth, and its weighted cost of capital and terminal growth rates. The revenue and margin growth is based on increased sales of new products as the Company maintains investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including timing and probability of regulatory approvals for Company products to be commercialized. The Company&#x2019;s market capitalization is also considered as a part of its analysis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s annual evaluation for impairment of goodwill consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reporting unit. In accordance with the Company&#x2019;s policy, the Company completed its annual evaluation for impairment using the quantitative assessment, utilizing the market approach and due to declining market conditions, determined that the fair value of the reporting unit was below its carrying value. As a result, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of goodwill impairment, reducing the goodwill balance to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the year ended December 31, 2022, and accordingly, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; goodwill impairment was recorded for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_35b62d03-a36f-461f-9f34-f4b348746d59"
      unitRef="U_Reporting_Unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-5"
      id="F_5f284be6-d3d6-4da9-b85e-946e916063e4"
      unitRef="U_USD">48600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_4f036fbc-a19a-4544-a4fe-5f0f423312e9"
      unitRef="U_USD">0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_2817d80d-a95b-4dbe-90dd-54aae9711b5f"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_566298c3-6d57-45cd-8d9c-c9f7e7fd2359">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Additions, major renewals and improvements are capitalized and repair and maintenance costs are charged to expense as incurred. Leasehold improvements are amortized over the remaining life of the initial lease term or the estimated useful lives of the assets, whichever is shorter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than its carrying amount. An impairment loss is measured as the amount&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which the carrying amount of an asset exceeds its fair value. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected cash flows. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairments of long-lived assets have been identified during the years presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_17a5e5f9-c4d0-4a92-8cad-cc24d7417e69"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="INF"
      id="F_512a67d5-4132-4940-afd1-48817cb66f3a"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_c0c30d25-bdba-4761-b39d-0b80fe3aaa46">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (&#x201c;R&amp;amp;D&#x201d;) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&amp;amp;D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges may occur in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capitalized IPR&amp;amp;D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors&#x2019; products could result in partial or full impairment of the related intangible assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_9d362df2-03e2-4282-b7bb-d63d40556ad5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company&#x2019;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company&#x2019;s prior period accrued estimates for clinical trial activities through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_0dd6b39f-c81d-4296-b960-d3c3ca10eb85">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, incentive stock options, restricted stock units and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company&#x2019;s net loss position. Basic weighted average shares outstanding for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,776,270&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509,117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, shares underlying pre-funded warrants to purchase common shares. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the shares underlying these pre-funded warrants can be issued for little &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;consideration &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(an exercise price per share equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share), these shares are deemed to be issued for purposes of basic earnings per share.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.3%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.34%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,619,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,285,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The computation of diluted earnings per share excludes incentive stock options, restricted stock units, and warrants that are anti-dilutive. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a summary as of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:63.247%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.937%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.937%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding and other equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,909,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,012,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common and preferred warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,577,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,127,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,486,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,139,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_403020d7-be70-4c12-a4cc-8bc0abf4256e"
      decimals="0"
      id="F_fe994004-078e-491e-b316-24c0019fb672"
      unitRef="U_shares">5776270</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3c6b3fdb-26ba-4381-9bb7-d9118f53631d"
      decimals="0"
      id="F_e4187fa1-9213-4986-80b2-5244ec8fcd96"
      unitRef="U_shares">509117</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_606c1d61-6f56-4761-81f1-5c5555b8b2d1">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the shares underlying these pre-funded warrants can be issued for little &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;consideration &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(an exercise price per share equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share), these shares are deemed to be issued for purposes of basic earnings per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:64.3%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.34%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average number of common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,619,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,285,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="3"
      id="F_9ddc6b20-996f-4d32-9560-7ff598e19eac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:NetIncomeLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_d4b78f38-1bae-446c-8e84-591f0a9b64ed"
      unitRef="U_USD">-40326000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_11330913-fe7f-42a0-8b98-9b4b5810078e"
      unitRef="U_USD">-87966000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_5e762d62-8e4e-4858-9881-09053b734307"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_709c177a-ab08-4716-9116-420e4eaeaa45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_1bef169c-1335-4b61-a68d-2de5d327595f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_6ac4cc73-a230-4f01-ab33-2721ed76cc95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="0"
      id="F_6a8ef3e9-e048-4a9e-87b6-d89b1aae6c82"
      unitRef="U_shares">24619197</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="0"
      id="F_44b98e6e-195f-4a00-9379-02ed4818c302"
      unitRef="U_shares">24619197</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="0"
      id="F_be8c09a1-ed57-4ff6-96b4-e46db9f8b57b"
      unitRef="U_shares">14285254</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="0"
      id="F_d2f98377-b2a6-4b5c-8e34-e87f58476269"
      unitRef="U_shares">14285254</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_25fb9f17-6e02-4565-89be-bf36e0fa6a49">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a summary as of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 common share equivalents that were excluded because their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:63.247%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.937%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.44%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:14.937%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding and other equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,909,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,012,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common and preferred warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,577,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,127,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,486,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,139,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6ae6940e-5a6a-475f-9b2c-85a5e9f64183"
      decimals="0"
      id="F_7065d340-5893-45fe-a932-5ceab07a0407"
      unitRef="U_shares">14909155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b1d46794-a5ff-4a00-a67a-113d1f5e5bb3"
      decimals="0"
      id="F_f286c04e-efdd-4538-b4da-cea51ec8e9cc"
      unitRef="U_shares">5012035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c33e93a8-92df-4580-a627-619828841106"
      decimals="0"
      id="F_81dc0f26-20c8-4031-8fd6-b4a819e08f52"
      unitRef="U_shares">18577332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_564fb782-4618-449b-be0d-4a8c0d6e8c89"
      decimals="0"
      id="F_e315ac22-2ffd-4a2c-95c6-992acc05594c"
      unitRef="U_shares">3127121</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="0"
      id="F_f8620a78-e11d-4abe-9095-e6499568bfe3"
      unitRef="U_shares">33486487</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="0"
      id="F_b4a129ab-18ef-482a-8c7b-f33a8414be28"
      unitRef="U_shares">8139156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_9204a36a-e421-49fd-8dff-1998c07c0302">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. The expected dividend assumption was based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;) are measured and recognized based on the quoted market price of our common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_11831e7c-c631-4339-81af-4b21cafc0b8a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. We assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting. We have provided a valuation allowance on our deferred tax assets as of December 31, 2023 and 2022 because we believe it is more likely than not that a majority of our deferred tax assets will not be realized as of this date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company evaluates the accounting for uncertainty in income tax recognized in its consolidated financial statements and determines whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its consolidated financial statements. For those tax&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;positions &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;where it is &#x201c;not more likely than not&#x201d; that a tax benefit will be sustained, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not accrued any liabilities for any such uncertain tax positions as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The Company is subject to U.S. federal and state tax authority examinations for all the years since inception due to net operating loss and tax credit carryforwards. The net operating losses and tax credits are subject to adjustment until the statute closes on the year the attributes are ultimately utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or processes, if any. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The second step is to measure the tax benefit as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% likely of being realized upon settlement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Note 9. Income Taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <eldn:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_fb14b65a-b590-4d81-acda-3caa2b968ef3"
      unitRef="U_USD">0</eldn:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_65c33f2a-dcfa-44a3-9f24-2015679a10a7">The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <eldn:IncomeTaxExaminationLikelihoodOfFavorableSettlement
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_59c85fea-8a5d-4673-950f-1a589ebacddf"
      unitRef="U_pure">0.50</eldn:IncomeTaxExaminationLikelihoodOfFavorableSettlement>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_591efb97-35e3-4b47-8870-6af069f55cca">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements Issued But Not Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_bab7abfd-04f1-4d2c-8070-95ce67c139ab">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 4. Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The objectives of the Company&#x2019;s investment policy are to preserve principal, meet the Company's liquidity requirements and safeguard invested funds. Short-term investments consist of U.S. government securities and U.S. government agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. Investments are&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following is a summary of short-term investments, which were classified as available-for-sale securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of the Company's available-for-sale securities have a stated maturity of less than one year. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t hold any short-term investments as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_1ff15270-e69c-4df2-b4ad-fa234cae7e4a">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following is a summary of short-term investments, which were classified as available-for-sale securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_89b25922-7cb3-4412-b567-f46abca28cf8"
      decimals="-3"
      id="F_75929201-9f66-4fae-88db-120d48a7a831"
      unitRef="U_USD">33213000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_89b25922-7cb3-4412-b567-f46abca28cf8"
      decimals="-3"
      id="F_2d16f9cd-0364-4d7f-afdd-0078b61f25da"
      unitRef="U_USD">33213000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_05c23523-7806-4910-8de2-4ca513419180"
      decimals="-3"
      id="F_5fb580dc-3cab-4415-a2f9-c812aec2f9c3"
      unitRef="U_USD">13277000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_05c23523-7806-4910-8de2-4ca513419180"
      decimals="-3"
      id="F_b4c27227-d126-48a7-841b-34198baf9039"
      unitRef="U_USD">13277000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_4dababdc-1c4f-4920-b6fa-88846c0bfd5c"
      unitRef="U_USD">46490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_55eb48f3-2bbf-46f4-8860-3e3d374712f8"
      unitRef="U_USD">46490000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ShortTermInvestments
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_77a69893-ae01-49f6-8cf0-13038109d744"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_78966eb7-c714-4395-8023-1347a051a46e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 5. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial assets and liabilities are recorded at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies fair value measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices (unadjusted) in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. These fair values are obtained from independent pricing services which utilize Level 1 and Level 2 inputs.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. Included within cash and cash equivalents on the consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.095%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.095%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_789ff192-05bb-48ce-9a85-9fa12d90bcc0">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. Included within cash and cash equivalents on the consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.095%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.095%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.641%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.245000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f06bf133-70a4-416c-a4f6-115eb78648e6"
      decimals="-3"
      id="F_e00306ab-f6f0-480f-8596-8cf585e8d26b"
      unitRef="U_USD">4246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_08232590-c5fa-4b08-bc08-e606069533f3"
      decimals="-3"
      id="F_5c839a69-49e0-4966-ab5e-fe2360d07120"
      unitRef="U_USD">4246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f427656a-338e-4bdd-9bad-d6f9b666e78f"
      decimals="-3"
      id="F_aa3df16a-9f16-477e-936a-b7092ca759da"
      unitRef="U_USD">4246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_85108846-892e-47c8-9754-3c7dfc301d1c"
      decimals="-3"
      id="F_ea77c7f2-e0e6-458a-a37e-ce5df3ed2468"
      unitRef="U_USD">4246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_ac320d24-5fbb-42d0-93dd-dad1bc9ba82d"
      decimals="-3"
      id="F_48aaa204-e5d0-4439-a4ed-fcd4118ca665"
      unitRef="U_USD">33213000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_200cc8e1-5269-466a-876a-228fe7dd6936"
      decimals="-3"
      id="F_115df286-815f-4bcd-9aed-1af2e85c2fdd"
      unitRef="U_USD">33213000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_514fb2b8-c4b0-4b5c-a2e4-0c1d1d0a3e36"
      decimals="-3"
      id="F_e7fd06e3-7ef3-4e25-b85b-b5ef4d122750"
      unitRef="U_USD">13277000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_680c3de3-4af7-4781-b111-7a9f83940645"
      decimals="-3"
      id="F_648790a9-5218-4305-ac74-aac65d4c0a52"
      unitRef="U_USD">13277000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_97e359d3-cfa5-442f-9a87-040db5c132e8"
      decimals="-3"
      id="F_2526ba2c-07ee-43ce-8e0d-07a8bc0ca45f"
      unitRef="U_USD">46490000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_85108846-892e-47c8-9754-3c7dfc301d1c"
      decimals="-3"
      id="F_706610a5-ecd0-41e1-90e1-338b224832fd"
      unitRef="U_USD">46490000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f427656a-338e-4bdd-9bad-d6f9b666e78f"
      decimals="-3"
      id="F_fb408008-c5aa-437c-a1bd-b39e0c3744ef"
      unitRef="U_USD">4246000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_97e359d3-cfa5-442f-9a87-040db5c132e8"
      decimals="-3"
      id="F_3695d138-f5c4-4cea-9e31-75b0f04e6f59"
      unitRef="U_USD">46490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_85108846-892e-47c8-9754-3c7dfc301d1c"
      decimals="-3"
      id="F_66c67ed9-1888-42cf-945a-c6f3c74019c0"
      unitRef="U_USD">50736000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f9a7cc9f-d6ce-4f09-85e0-f27ce671852a"
      decimals="-3"
      id="F_b175895c-d228-4403-976f-9517d748507b"
      unitRef="U_USD">9296000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_df5cb9c5-cc2b-4539-8abf-128c08a87c60"
      decimals="-3"
      id="F_452a5a97-867f-48fb-9ebf-1b2871d3a542"
      unitRef="U_USD">9296000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_65b7835c-8f67-4c38-a18d-054d0149baa8"
      decimals="-3"
      id="F_ae467995-0719-4024-86e1-802de458426b"
      unitRef="U_USD">9296000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_10ef38e2-ed82-4422-8141-1f5959c9d8b4"
      decimals="-3"
      id="F_3620ac9b-f0ec-4e1c-ac65-c0b4676c4115"
      unitRef="U_USD">9296000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_65b7835c-8f67-4c38-a18d-054d0149baa8"
      decimals="-3"
      id="F_ef30c832-e417-4f71-8c6f-99b172808de0"
      unitRef="U_USD">9296000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_10ef38e2-ed82-4422-8141-1f5959c9d8b4"
      decimals="-3"
      id="F_23d7cf72-6659-4281-8b15-e20348146d2a"
      unitRef="U_USD">9296000</us-gaap:AssetsFairValueDisclosure>
    <eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_75a4433a-af5f-4383-ac99-1441b220a8b6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 6. Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other liabilities consisted of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</eldn:PrepaidExpensesOtherAssetsAccruedExpensesAndOtherLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_839d1be0-c968-45f2-b87c-4bbd409b05fa">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_cbaaa5da-f7fc-4ff5-9db7-ea480d92af40"
      unitRef="U_USD">624000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_2da882f2-3280-4496-bc0a-9f5a0f716c8f"
      unitRef="U_USD">823000</us-gaap:PrepaidInsurance>
    <eldn:PrepaidClinicalExpense
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_3514016c-eeb1-437f-9316-067bdf96cbfe"
      unitRef="U_USD">4128000</eldn:PrepaidClinicalExpense>
    <eldn:PrepaidClinicalExpense
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_a2f07417-0c9f-48cc-aad3-b6aa928d2b8c"
      unitRef="U_USD">2115000</eldn:PrepaidClinicalExpense>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_7d5ad3c5-1cdc-4489-949c-be40ebe9e499"
      unitRef="U_USD">185000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_f74ac05b-b738-415c-bf17-046f6d982f9a"
      unitRef="U_USD">143000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_92bad184-ab76-46da-9b79-b3101487921a"
      unitRef="U_USD">90000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_db532db4-d3e5-433d-903b-2976761f111b"
      unitRef="U_USD">28000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_724b09aa-07c3-42e5-985a-1a69f47f6a87"
      unitRef="U_USD">5027000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_af87ae35-1b11-415f-afc1-a47fec0890f0"
      unitRef="U_USD">3109000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_0919702e-fa0f-4884-b4ac-8528be7192fa">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other liabilities consisted of the following as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_9731d953-d4bc-4740-af3c-cbf5751088f9"
      unitRef="U_USD">2003000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_34b27ed9-2c7f-468a-91f4-50d674c8b5a3"
      unitRef="U_USD">1909000</us-gaap:WorkersCompensationLiabilityCurrent>
    <eldn:AccruedClinicalCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_db714a31-6dee-45b1-a877-4f96fdfebdb6"
      unitRef="U_USD">451000</eldn:AccruedClinicalCurrent>
    <eldn:AccruedClinicalCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_0e5edd08-41e7-4970-abb8-39481799258d"
      unitRef="U_USD">1826000</eldn:AccruedClinicalCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_bc10d3a8-a505-44c0-8fb4-42c0b1d2b5cc"
      unitRef="U_USD">47000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_64eae932-bd2d-49bf-bfc9-25dd14bc8c34"
      unitRef="U_USD">65000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_ef5f6edb-8d0d-472b-b338-38243623275d"
      unitRef="U_USD">44000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_54237953-60fd-4f9d-bb8f-f1bdac2a3338"
      unitRef="U_USD">112000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_8838856a-25fb-43ad-b00e-e42a24e1fb3f"
      unitRef="U_USD">2545000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_083513fa-4a2f-4096-b525-d1efb8d30efd"
      unitRef="U_USD">3912000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:GoodwillDisclosureTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_3c226b90-918e-4330-b1b8-fff74050b118">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 7. Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2022, the Company determined that the sustained decrease in our market capitalization constituted an indicator of impairment and as a result, a quantitative goodwill impairment test, utilizing the market approach, determined that the fair value of the reporting unit was below its carrying value and the goodwill was fully impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded an impairment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022 for the full write-down of the goodwill recorded as part of the acquisition of Anelixis. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment was recorded for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_58bb8acc-ddde-40c9-8a7d-dbf46fcb11f2"
      decimals="-5"
      id="F_533cdab8-ccd3-42cc-874a-703fb6753111"
      unitRef="U_USD">48600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_783f52b2-6f1c-480f-93ff-06d7283b31b6"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_04e71cfd-2689-4f1b-a9f8-4fa301fc0daa">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"
      decimals="-3"
      id="F_e6a6e49e-a344-4e5a-80eb-1833cea91892"
      unitRef="U_USD">48648000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_8379acf1-9294-49e7-8e3c-15489eb9e001"
      unitRef="U_USD">48648000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_8a96f80d-7f84-42e0-be35-74bdbf453e45"
      unitRef="U_USD">0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_1c326e10-f54b-405c-ad7e-4c0dc40983f0"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_b7e30182-560a-4215-96f5-a3c8913f7ad5"
      unitRef="U_USD">0</us-gaap:Goodwill>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_52a9b461-0751-4913-b7b7-88a4b7c20af3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 8. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases office space under various operating leases. Total rent expense for all operating leases in the consolidated statements of operations and comprehensive loss was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each of the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has an operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,197&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space in Irvine, California, that expires on  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, as amended.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 4, 2021, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,138&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space in Burlington, Massachusetts, that expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 20, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if a contract contains a lease at inception. Our office leases have remaining terms of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and do not include options to extend the leases for additional periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities as adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental secured borrowing rates corresponding to the maturities of the leases. As we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; outstanding debt nor committed credit facilities, secured or otherwise, we estimate this rate based on prevailing financial market conditions, comparable company and credit analysis, and management&#x2019;s judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our leases contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce our right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;While we do not currently have any lease agreement with lease and non-lease components, we elected to account for lease and non-lease components as separate components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have elected the short-term lease recognition exemption for all applicable classes of underlying assets. Short-term disclosures include only those leases with a term greater than one month and 12 months or less, and expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less, that do not include an option to purchase the underlying asset that we are reasonably certain to exercise, are not recorded on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Includes variable operating lease expenses, which are immaterial.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other information related to leases was as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.367%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.466000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.486%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows from operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease asset obtained in exchange for lease liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.95&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.95&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Grants and Licenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ALS Therapy Development Foundation, Inc. License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2015, Anelixis executed a License Agreement (the &#x201c;Agreement&#x201d;), which is an exclusive patent rights agreement with ALS Therapy Development Foundation, Inc. (&#x201c;ALS TDI&#x201d;) for certain patents and &#x201c;know-how&#x201d; of ALS TDI. This agreement continues until the licensee terminates the agreement with ninety days written notice. The Agreement requires license fees payable to ALS TDI, subject to the achievement of certain milestones and other conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The first and second milestones of the Agreement are the dosing of the first subjects in a first toxicity study in non-human primates and the dosing of the first patient in a Phase I Clinical Trial, respectively. Both of these milestones were achieved as of December 31, 2018 and 2017. The fee due for the achievement of these milestones was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million each. During 2018 and 2017, Anelixis issued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million worth of its common stock in lieu of making a cash payment. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; milestones achieved during 2023 or 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Agreement was amended and restated in February 2020, and a first amendment to the restated license agreement was executed in September 2020. As amended in September 2020, the remaining milestone payments for a first licensed product total $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In the event that the Company develops a second licensed product, the Company is obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in additional milestone payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the milestone payments, the Company is required to pay ALS TDI an amended annual license maintenance fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million beginning on the earlier of January 1, 2022, the Company&#x2019;s first sublicense, or change in control, as defined in the Agreement. The Company made a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million annual license maintenance fee in each of 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Furthermore, the Company shall pay ALS TDI fees based on reaching certain levels of annual net sales of any product produced with the patent rights. A royalty in the low single digits will be due on aggregate net sales. Upon the first calendar year of reaching $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate net sales, the Company shall pay ALS TDI a one-time milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Upon the first calendar year of reaching $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion in aggregate net sales, the Company is obligated to pay ALS TDI a one-time milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lonza Sales AG Inc. License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2018, Anelixis executed a License Agreement (the &#x201c;Lonza Agreement&#x201d;), which is a manufacturing know-how rights agreement with Lonza Sales AG Inc. (&#x201c;Lonza&#x201d;) for the use of certain processes and know-how related to the manufacture of tegoprubart. The Lonza Agreement continues until the later of the last Valid Claim (as defined therein) or ten years from the First Commercial Sale of tegoprubart, as defined and subject to the conditions therein. A royalty in the low single digits will be due on aggregate net sales of tegoprubart that is manufactured by Lonza or any other third-party or licensee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;eGenesis, Inc. Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2022, and subsequently amended in January 2023, Eledon executed a non-exclusive collaborative research agreement with eGenesis, Inc. (the &#x201c;eGenesis Agreement&#x201d;), under which eGenesis will gain access to tegoprubart for eGenesis&#x2019; ongoing preclinical research and development xenotransplant studies of human-compatible organs and cells for the treatment of organ failure. eGenesis will pay Eledon for supplies of tegoprubart based on the number of study days per animal needed for the eGenesis preclinical xenotransplant studies. The eGenesis agreement continues until September 2025, unless terminated earlier by either party.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Matters&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company&#x2019;s results of operations, financial condition or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amounts associated with such indemnifications have been recorded to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; contingent liabilities requiring accrual at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-5"
      id="F_13cb91ca-cc63-4a46-8e07-c3992d4112f6"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-5"
      id="F_e0fe06e5-3dbc-458b-8b56-c657d3cb0ae8"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <eldn:AreaOfOfficeSpace
      contextRef="C_fdf8105d-12d9-4345-b55c-4de997687b56"
      decimals="INF"
      id="F_4d51b4cd-143d-49ae-8541-be8cc6f0b48c"
      unitRef="U_sqft">5197</eldn:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_b10db2e1-d9c6-4be4-9ba9-86c0ebed4c56"
      id="F_e2fd5b06-23e2-4579-b707-540f59e4cb29">2024-12-31</us-gaap:LeaseExpirationDate1>
    <eldn:AreaOfOfficeSpace
      contextRef="C_ed539061-91d5-4d71-9cf6-98e903ea5f7b"
      decimals="INF"
      id="F_7a2b5e5e-8787-40a6-a64a-cfc752c0f321"
      unitRef="U_sqft">6138</eldn:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_ed539061-91d5-4d71-9cf6-98e903ea5f7b"
      id="F_64d3e78c-0b1e-47cc-9fb5-d864b0ae8d61">2024-11-20</us-gaap:LeaseExpirationDate1>
    <eldn:LesseeOperatingLeaseRemainingTermOfContract
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_6d93d923-9af3-4fa0-84b6-c579f3faeb65">P12M</eldn:LesseeOperatingLeaseRemainingTermOfContract>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_f603cdc7-5d3b-4ad6-ae61-988f5044d235"
      unitRef="U_USD">0</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_1685f13d-1f54-40e0-94c1-e431ffb3e23f">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Includes variable operating lease expenses, which are immaterial.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_bd4a6b21-984b-45c2-befb-90363abb4caf"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_ebe75a57-d481-4a29-8b5b-999f85a42745"
      unitRef="U_USD">403000</us-gaap:OperatingLeaseCost>
    <eldn:OtherInformationRelatedToLeasesTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_afde88f3-d68d-43dc-b567-2b366d0f73f6">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other information related to leases was as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.367%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.466000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.486%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows from operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease asset obtained in exchange for lease liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.95&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.95&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</eldn:OtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_15a4389f-9f44-4969-837a-aae9da62fa08"
      unitRef="U_USD">378000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_b5634d83-a18b-4e13-9412-5d74430dfd04"
      unitRef="U_USD">387000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_78363493-fa7a-4511-9f40-937cc58f2b80"
      unitRef="U_USD">344000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      id="F_044bad78-bc74-421d-b9af-019b383efcb0">P0Y11M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      id="F_50bb3ca8-1ed3-4d77-b0ab-94da1c6f4a42">P1Y11M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="4"
      id="F_b8d250f7-2604-4e0d-a59b-38d349b39043"
      unitRef="U_pure">0.0249</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="4"
      id="F_045f0e55-3dad-4b95-9e68-f86c1e55aec3"
      unitRef="U_pure">0.0249</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_77190969-39c8-42b0-907b-d3a0c2ae0feb">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_f7dc6ca5-c7fa-47e8-bdf6-1c3808f6d67a"
      unitRef="U_USD">388000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_1a44b4d0-95e5-4df8-b6f3-32fd92a8c3a0"
      unitRef="U_USD">388000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_8968d6ba-88f5-421d-89d9-0091a0a84368"
      unitRef="U_USD">5000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_c71e3195-a273-4291-9884-b45580c59929"
      unitRef="U_USD">383000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_a00fa622-366b-42a4-9402-60270aeec8e7"
      unitRef="U_USD">383000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_1285f0c5-22bb-47ea-888b-a9d8b5de2446"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <eldn:FeeDueForMilestonesAchieved
      contextRef="C_80152760-f5f1-49d1-818c-7be41d8bad59"
      decimals="-5"
      id="F_eec89bbc-0eef-4eb4-98f5-8d404851d000"
      unitRef="U_USD">1000000.0</eldn:FeeDueForMilestonesAchieved>
    <eldn:FeeDueForMilestonesAchieved
      contextRef="C_bd6fbf82-130d-405c-b4df-97d3c4f5ddb1"
      decimals="-5"
      id="F_c0bcaa92-bfc3-4ada-a40a-b287965f4471"
      unitRef="U_USD">1000000.0</eldn:FeeDueForMilestonesAchieved>
    <us-gaap:StockIssued1
      contextRef="C_b1b6b20f-2b7f-4988-9b59-14ae1a547e10"
      decimals="-5"
      id="F_61472b9b-c013-42bf-8c8c-eca0a426f094"
      unitRef="U_USD">1000000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_e3da60b1-bf6f-43ce-b8eb-e383f1879995"
      decimals="-5"
      id="F_75faa493-4f58-413e-b437-14a39c4c9a00"
      unitRef="U_USD">1000000</us-gaap:StockIssued1>
    <eldn:NumberOfMilestonesAchieved
      contextRef="C_17e67f10-b293-4956-8cef-526a32b65ef4"
      decimals="INF"
      id="F_c667c10b-1d64-4b36-9b0b-9a2fe0ea435a"
      unitRef="U_Milestone">0</eldn:NumberOfMilestonesAchieved>
    <eldn:NumberOfMilestonesAchieved
      contextRef="C_1c94ca06-3730-4b18-9348-e88243d8d2e7"
      decimals="INF"
      id="F_e645bd29-28c5-49ae-8032-52496c8c69f9"
      unitRef="U_Milestone">0</eldn:NumberOfMilestonesAchieved>
    <eldn:RemainingMilestonePaymentsForFirstLicensedProduct
      contextRef="C_0214fd64-e27d-4163-83ae-6f06bab5710b"
      decimals="-5"
      id="F_8b345447-e609-4dfb-b40a-8758e6ff0f02"
      unitRef="U_USD">6000000</eldn:RemainingMilestonePaymentsForFirstLicensedProduct>
    <eldn:RegulatoryMilestonePaymentsObligation
      contextRef="C_e474f40b-c32d-4216-952d-084ee8fda28a"
      decimals="INF"
      id="F_8d01c33e-1160-4927-97ab-1f43dc745481"
      unitRef="U_USD">2500000</eldn:RegulatoryMilestonePaymentsObligation>
    <eldn:AnnualLicenseMaintenanceFee
      contextRef="C_c4d5fab0-b529-4936-88f9-d28a56338778"
      decimals="-5"
      id="F_7a017330-15a4-497b-b8a5-0e318100f8aa"
      unitRef="U_USD">100000</eldn:AnnualLicenseMaintenanceFee>
    <eldn:AnnualLicenseMaintenanceFee
      contextRef="C_17e67f10-b293-4956-8cef-526a32b65ef4"
      decimals="-5"
      id="F_41f351f9-561e-4990-af95-41abd367d8ac"
      unitRef="U_USD">100000</eldn:AnnualLicenseMaintenanceFee>
    <eldn:AnnualLicenseMaintenanceFee
      contextRef="C_1c94ca06-3730-4b18-9348-e88243d8d2e7"
      decimals="-5"
      id="F_51024e76-31a8-4e49-88e4-04bd7dd84a04"
      unitRef="U_USD">100000</eldn:AnnualLicenseMaintenanceFee>
    <eldn:AggregateNetSalesAchievement
      contextRef="C_9cc0ccfc-b7a6-4b18-b60e-c2dd9520c8bb"
      decimals="-5"
      id="F_b97e784f-07db-48e5-a5d7-8aac2ae028cd"
      unitRef="U_USD">500000000</eldn:AggregateNetSalesAchievement>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_8a9a710c-7ac2-4558-9624-0a06bad3b9b1"
      decimals="-5"
      id="F_f574257a-4681-4a3a-83e6-4c2a7d176c49"
      unitRef="U_USD">15000000.0</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <eldn:AggregateNetSalesAchievement
      contextRef="C_e0208a52-3605-4067-a592-6f1d7092a39c"
      decimals="-8"
      id="F_b42cc8ae-20c7-435e-9387-810ca0d1a336"
      unitRef="U_USD">1000000000.0</eldn:AggregateNetSalesAchievement>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_91677af4-ce57-4e73-97a4-b3d085786c69"
      decimals="-5"
      id="F_525cfd44-a0a1-48b0-9bf6-9ec0ec667715"
      unitRef="U_USD">30000000.0</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_8979e013-8d3d-4a88-878c-5c970de9a39f"
      unitRef="U_USD">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <eldn:ContingentLiability
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_69dd6d2a-45e5-42c8-ab6f-ec28d7b59e4d"
      unitRef="U_USD">0</eldn:ContingentLiability>
    <eldn:ContingentLiability
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_a435c4d0-4457-4f17-851a-c2f1a7c4d64c"
      unitRef="U_USD">0</eldn:ContingentLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_fc0346d0-cb67-4718-9e28-23d04fc49a70">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 9. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Loss before income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses before income taxes:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision (benefit) for income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to income taxes under U.S. tax laws. The Company is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;subject to an Israeli corporate tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% in 2020 and thereafter. The Company was subject to a blended U.S. tax rate (federal as well as state corporate tax) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant judgment is required in determining the Company&#x2019;s provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis, and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income after permanent differences, earnings history, and reliability of forecasting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on its review, the Company concluded that it was more likely than not that they would not realize the benefit of a portion of its deferred tax assets in the future. This conclusion was based on historical and projected operating performance, as well as the Company&#x2019;s expectation that its operations will not generate sufficient taxable income in future periods to realize the tax benefits associated with the deferred tax assets within the statutory carryover periods. Therefore, the Company has a valuation allowance on its deferred tax assets as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will continue to assess the need for a valuation allowance on its deferred tax assets by evaluating both positive and negative evidence that may exist. Any adjustment to the net deferred tax asset valuation allowance would be recorded in the statement of operations for the period that the adjustment is determined to be required.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.913%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.783000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.422%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;NOL true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the years presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions from tax positions taken in the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions from tax positions taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The deferred income tax assets have been offset by a valuation allowance, as realization is dependent on future earnings, if any, the timing and amount of which are uncertain. The net valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from December 31, 2022 to December 31, 2023. The net valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from December 31, 2021 to December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#x2019;s deferred tax assets, and the timing, likelihood, and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a valuation allowance has been established.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, available to reduce future taxable income. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company also has state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Both the federal and state net operating loss carryforwards incurred before 2018 begin expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, if not utilized. The federal net operating losses incurred since 2018 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million do not expire. The state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had Israeli net operating losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which carryforward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. If not utilized, the carryforwards will begin expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has state research and development credit carryforwards or approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, which will begin expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; if not utilized&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to Internal Revenue Code (&#x201c;IRC) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% occurs within a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Due to the existence of the valuation allowance, future changes in the Company&#x2019;s unrecognized tax benefits will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s ability to use its remaining net operating loss and tax credit carryforwards may be further limited if the Company experiences a Section 382 ownership change in connection with future changes in our stock ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the United States, the Company files income tax returns in the U.S. Federal jurisdiction, California and Massachusetts. The Company&#x2019;s tax years for 2018 and forward are subject to examination by the Federal and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrued interest and penalties associated with uncertain tax positions as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recorded any interest or penalties in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023 or 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_4ec88bdd-bfad-4ec7-931f-abbdd4206c06">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Loss before income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses before income taxes:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-U.S.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_fff2b6b2-7b51-4ff0-b84b-bd54b5d15874"
      unitRef="U_USD">-40525000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_29c1ac32-1a79-4d81-a4a5-967d483d12b4"
      unitRef="U_USD">-88159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_aa95a023-0e93-45fd-aa23-5983e65c422d"
      unitRef="U_USD">199000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_8941f030-46cc-4004-b3bb-a4810490eeee"
      unitRef="U_USD">193000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_9637abab-4235-43e9-bb01-10304d68af9b"
      unitRef="U_USD">-40326000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_6b6933dc-8f81-498c-b625-198b2501a047"
      unitRef="U_USD">-87966000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_369cb136-87c8-4a24-a429-d40c13105bdc">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision (benefit) for income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision (benefit) for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_148ad8a7-b70c-496a-95b6-25eb9918c6d2"
      decimals="2"
      id="F_96a825f1-f3b9-4c00-b44a-e7617d9b315f"
      unitRef="U_pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <eldn:EffectiveFederalAndStateIncomeTaxRate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_87b9ee6f-702a-4627-994a-082cb5a2b48a"
      unitRef="U_pure">0.21</eldn:EffectiveFederalAndStateIncomeTaxRate>
    <eldn:EffectiveFederalAndStateIncomeTaxRate
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_24f9e00e-8e00-481e-bf2b-550eac9b839b"
      unitRef="U_pure">0.21</eldn:EffectiveFederalAndStateIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_ab9ffac1-22ab-42df-95d9-b5cf7713b50f">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.913%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.783000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.422%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;NOL true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_5345da40-968f-424e-819e-f6bcfd23f5eb"
      unitRef="U_USD">-8468000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_d4812d1f-1756-483f-a226-182e58f0fc9f"
      unitRef="U_USD">-18473000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <eldn:StateIncomeTaxesNetOfFederalTaxBenefits
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_c9fd51e8-66b9-4027-b65a-a9b9d8cb5e86"
      unitRef="U_USD">-1097000</eldn:StateIncomeTaxesNetOfFederalTaxBenefits>
    <eldn:StateIncomeTaxesNetOfFederalTaxBenefits
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_73cc4ee7-2f9b-4bad-a622-4a4ff6bf4696"
      unitRef="U_USD">-2678000</eldn:StateIncomeTaxesNetOfFederalTaxBenefits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_beac2f22-0d3d-4923-aebc-5863ae4543c4"
      unitRef="U_USD">972000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_22f86536-f4c5-479f-bd97-9f7fdc2143b4"
      unitRef="U_USD">1046000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_0d0a97b4-e245-494f-8588-1262fdd40a18"
      unitRef="U_USD">728000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_b5803f6e-be3f-4a4f-924d-c599cf946d0e"
      unitRef="U_USD">986000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <eldn:IncomeTaxReconciliationPermanentItems
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_15c21510-9095-48aa-87fb-8b28828b6945"
      unitRef="U_USD">9000</eldn:IncomeTaxReconciliationPermanentItems>
    <eldn:IncomeTaxReconciliationPermanentItems
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_7c28f528-b0b6-4c94-afb0-c45765d4efaa"
      unitRef="U_USD">3000</eldn:IncomeTaxReconciliationPermanentItems>
    <eldn:IncomeTaxReconciliationStateTaxRateDifferential
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_01f11a74-f722-4035-ab26-21847da961b6"
      unitRef="U_USD">32000</eldn:IncomeTaxReconciliationStateTaxRateDifferential>
    <eldn:IncomeTaxReconciliationStateTaxRateDifferential
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_1226041f-d2dc-42da-8ff3-6b80f7970ff6"
      unitRef="U_USD">274000</eldn:IncomeTaxReconciliationStateTaxRateDifferential>
    <eldn:NOLTrueUp
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_63e2bdb7-52bf-4358-8877-b936e89a54ae"
      unitRef="U_USD">2000</eldn:NOLTrueUp>
    <eldn:NOLTrueUp
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_f20f06fd-aba3-4aa0-bbc4-aa841a9a38dd"
      unitRef="U_USD">-337000</eldn:NOLTrueUp>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_8f668584-44d0-4544-b667-e7a1f635202b"
      unitRef="U_USD">566000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_21e45250-644a-4b84-88e9-f05d24f8dc1c"
      unitRef="U_USD">114000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_9917f6e6-300c-4940-9a20-d9de8cd45ac5"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_f93a4481-e347-442e-87ac-cdb26aaf5504"
      unitRef="U_USD">11697000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_73865efe-e9d4-437e-99e6-0f05081ec762"
      unitRef="U_USD">9200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_7abe1af1-d28f-427d-9f00-a320e387ea94"
      unitRef="U_USD">9460000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_efb166c4-bfb4-48eb-9ca5-2c00efc89fc7"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_fa4f0508-51f3-4e4f-8bdf-cbb4e98a8ece"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_f884e9a2-c917-4242-9543-026cf13a39ef">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_e7b9a729-8397-4891-af25-f0a0e76f7fe1"
      unitRef="U_USD">18089000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_1e288e59-e37d-4136-a30d-7e7934fb237f"
      unitRef="U_USD">15230000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_a1b8b0da-24f2-4fcf-ba05-3f9aa092e925"
      unitRef="U_USD">3202000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_51a29037-05be-4ec1-ba2a-81ef8009f883"
      unitRef="U_USD">2294000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_a6c821c8-dbd8-4d44-8f80-288b065d2000"
      unitRef="U_USD">475000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_5c602c27-1a1a-4469-8a56-c44be6f32382"
      unitRef="U_USD">452000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_ec130425-36e4-40d6-bbbc-6bbf24551aa0"
      unitRef="U_USD">10567000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_e94e731f-4298-4c4e-8c39-122d7d7fa263"
      unitRef="U_USD">5264000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_448d7e7a-6ac6-4404-9a11-d11cc6571daa"
      unitRef="U_USD">3085000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_87ef1e0c-e3c7-42e1-b918-adb2d676a5d3"
      unitRef="U_USD">2874000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <eldn:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_c43ca884-da06-49d4-9b79-48b1b7bcb36d"
      unitRef="U_USD">1319000</eldn:DeferredTaxAssetsDepreciationAndAmortization>
    <eldn:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_d6b1b705-f7ad-4147-a66b-5d6bcb80846c"
      unitRef="U_USD">1595000</eldn:DeferredTaxAssetsDepreciationAndAmortization>
    <eldn:DeferredTaxAssetsLeaseLiability
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_3313328d-2009-456f-80e5-492386f91ee4"
      unitRef="U_USD">91000</eldn:DeferredTaxAssetsLeaseLiability>
    <eldn:DeferredTaxAssetsLeaseLiability
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_42427eb8-b130-4fb9-b0a8-944db630b351"
      unitRef="U_USD">179000</eldn:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_e2532339-9b00-4be2-9d8c-4ff96f1d17d7"
      unitRef="U_USD">36828000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_7d9c0d2d-1f22-4f6b-bd78-3f307a586049"
      unitRef="U_USD">27888000</us-gaap:DeferredTaxAssetsGross>
    <eldn:DeferredTaxAssetsRightOfUseAsset
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_9e2dab18-f656-4472-bca1-25031b589468"
      unitRef="U_USD">87000</eldn:DeferredTaxAssetsRightOfUseAsset>
    <eldn:DeferredTaxAssetsRightOfUseAsset
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_a2a2c575-1361-4677-95ad-b1fb29bfc0d6"
      unitRef="U_USD">178000</eldn:DeferredTaxAssetsRightOfUseAsset>
    <eldn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_b23b97a9-efec-4b8e-b570-4ec76f0cf674"
      unitRef="U_USD">7682000</eldn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <eldn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_afa85a54-684e-47f3-9a80-510cb00a3a46"
      unitRef="U_USD">7787000</eldn:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_5e2114b0-2438-4aab-ba64-8c6ad2953c54"
      unitRef="U_USD">7769000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_90c31700-14ea-4fbb-ba5b-d21216e69feb"
      unitRef="U_USD">7965000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_439484a7-c763-447c-8698-76842dd1276e"
      unitRef="U_USD">30811000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_4f1eb76a-c160-4da2-89a6-37a642624e9f"
      unitRef="U_USD">21675000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_0bcdb487-3cb3-4156-9af2-e380507b4f08"
      unitRef="U_USD">1752000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_febf2f4f-39f3-413f-9c36-c5a2234df58d"
      unitRef="U_USD">1752000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_3688dd32-3d1f-426e-bdda-7939ed632350">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the years presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions from tax positions taken in the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions from tax positions taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_8e8fb02e-a7c8-49dd-bdba-c8efbab81fc2"
      unitRef="U_USD">2664000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"
      decimals="-3"
      id="F_d9d8b728-b14f-48ae-8d40-37eadf2b3a2b"
      unitRef="U_USD">1469000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_a3db5e83-85bc-4462-8545-1f9282603b91"
      unitRef="U_USD">972000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_cbdbbdab-1792-4030-8cdc-bdfaf9d988aa"
      unitRef="U_USD">914000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_56d6da77-5323-42de-be1c-0ae40e73e17f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_7c1574c4-e098-4b01-9a6b-bdf31cac1d7d"
      unitRef="U_USD">281000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_ecc2558c-4921-40bf-9d19-435b8d38dba2"
      unitRef="U_USD">3636000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="-3"
      id="F_033e008f-ea24-4db6-b183-ab03aac36808"
      unitRef="U_USD">2664000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-5"
      id="F_c090cf5d-bcd6-438f-96e4-b8e37a141bc2"
      unitRef="U_USD">9100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-5"
      id="F_18aceca3-bd25-44f5-966c-7b24d1a4defd"
      unitRef="U_USD">9100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_a2215e8a-709f-4e4f-a87d-5319589f877a"
      decimals="-5"
      id="F_72e17236-98df-4cf6-bbb1-6e318ad5f457"
      unitRef="U_USD">9400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_8dc70a81-570f-425e-8e77-d3cbed342a71"
      decimals="-5"
      id="F_7055052f-6d77-4e78-9ac0-123a1ad88c11"
      unitRef="U_USD">68900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_ed778020-ad3f-469d-86df-b93a95a7576c"
      decimals="-5"
      id="F_fdda703f-6739-42b1-9611-8bbf05831602"
      unitRef="U_USD">56800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_f0af738a-7254-4f32-bf85-c20c9f5d1f80"
      decimals="-5"
      id="F_3a6081bc-dde0-422c-926f-41c9b8c0f721"
      unitRef="U_USD">30100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_ac28187a-81e1-43da-a679-686dc898f95a"
      decimals="-5"
      id="F_aa686741-7246-43b5-b2e8-139c6ed16ccc"
      unitRef="U_USD">25000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <eldn:NetOperatingLossCarryforwardsExpirationPeriod
      contextRef="C_9bd49aca-76b8-41b8-851c-421b99dd8a37"
      id="F_358d834c-f3d0-4c4d-8924-c0008ce53cb6">2035</eldn:NetOperatingLossCarryforwardsExpirationPeriod>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_8dc70a81-570f-425e-8e77-d3cbed342a71"
      decimals="-5"
      id="F_601da595-43d4-438d-9837-866b0b20c6d1"
      unitRef="U_USD">68000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <eldn:NetOperatingLossCarryforwardsExpirationPeriod
      contextRef="C_84888892-87f5-4e23-bd7c-63309c46746a"
      id="F_17e30db9-fc78-4f07-a1ba-fc3913346707">2035</eldn:NetOperatingLossCarryforwardsExpirationPeriod>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_f418a451-c1a8-49bf-9510-a9346093387d"
      decimals="-5"
      id="F_7cd43ac9-0ead-4fd5-8eee-88ff78606704"
      unitRef="U_USD">7900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_5fd780de-3625-4605-acfa-3c1d91d4974d"
      decimals="-5"
      id="F_d88fcc7f-d2ad-40dc-a851-9f7aa936b395"
      unitRef="U_USD">7900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_8dc70a81-570f-425e-8e77-d3cbed342a71"
      decimals="-5"
      id="F_5fa3fd50-7cd8-4f08-8fef-0b2d20d99380"
      unitRef="U_USD">4000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ed778020-ad3f-469d-86df-b93a95a7576c"
      decimals="-5"
      id="F_5209db54-afb4-4116-a639-40d308b8754f"
      unitRef="U_USD">2400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <eldn:TaxCreditCarryforwardExpirationPeriod
      contextRef="C_9bd49aca-76b8-41b8-851c-421b99dd8a37"
      id="F_04cc231b-d79f-4fe4-9d71-6815be157637">2036</eldn:TaxCreditCarryforwardExpirationPeriod>
    <eldn:TaxCreditCarryforwardExpirationDescription
      contextRef="C_1d5fba3f-307a-4a36-acdc-6c3371fb0c8a"
      id="F_767ec8d8-d85c-48b8-ad80-bae2f970ba02">As of December 31, 2023 and 2022, the Company has state research and development credit carryforwards or approximately $1.5 million and $1.2 million, respectively, which will begin expiring in 2030 if not utilized</eldn:TaxCreditCarryforwardExpirationDescription>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f0af738a-7254-4f32-bf85-c20c9f5d1f80"
      decimals="-5"
      id="F_2f85b072-4e75-4d9f-9891-074c41b343ed"
      unitRef="U_USD">1500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ac28187a-81e1-43da-a679-686dc898f95a"
      decimals="-5"
      id="F_fb25e494-52c3-4244-a1f3-3d74022dcc04"
      unitRef="U_USD">1200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <eldn:TaxCreditCarryforwardExpirationPeriod
      contextRef="C_1d5fba3f-307a-4a36-acdc-6c3371fb0c8a"
      id="F_86d38534-250e-4b53-9d7c-6eb185f32ca9">2030</eldn:TaxCreditCarryforwardExpirationPeriod>
    <eldn:PercentageOfCumulativeChangeInOwnership
      contextRef="C_fc7dea4e-952b-4624-b726-7fb18eb4ecb2"
      decimals="INF"
      id="F_649ff934-ef04-4faa-ac98-f05990f6e193"
      unitRef="U_pure">0.50</eldn:PercentageOfCumulativeChangeInOwnership>
    <eldn:PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_df75a998-0ebb-4ba6-8519-5538d1900d35">P3Y</eldn:PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_88b22af4-ae6f-42f5-8c53-a8b6f2d3a923"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_20e2cdfb-77cb-452f-aecc-c82137bd4e3f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_7e7c81bb-457f-47bc-bdf0-bbcbc60074fa"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="INF"
      id="F_a176d74a-ce97-47f7-845d-3ce07332ca49"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_4079bba3-c595-4671-bc45-6892350b3f24">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 10. Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; authorized shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; non-voting convertible preferred stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;515,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares designated; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110,086&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares issued and outstand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ing at December 31, 2023 and 2022, respectively; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Series X non-voting convertible preferred stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares designated; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,422&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,204&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares issued and outstanding at December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each share of the Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or X non-voting convertible preferred stock (the &#x201c;Preferred Stock&#x201d;) is convertible into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.5556&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, at the option of the holder at any time, subject to certain limitations, including, that the holder will be prohibited from converting the Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total common stock then issued and outstanding immediately following the conversion of such shares of Series X Preferred Stock or Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Preferred Stock, respectively. The holder of the Preferred Stock is entitled to receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to-common-stock basis and without regard to any beneficial ownership limitations) to and in the same form as dividends actually paid on shares of the common stock. No other dividends will be paid on shares of the Preferred Stock. In the event of any liquidation, dissolution or winding up, the holder of the Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Preferred Stock were fully converted to common stock, which amounts shall be paid pari passu with all holders of common stock. Shares of the Preferred Stock will generally have no voting rights, except as required by law and except that the consent of a majority of the holders of either series of outstanding Preferred Stock will be required to amend the terms of the such series.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Equity Distribution Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 31, 2021, the Company filed a registration statement on Form S-3 containing a prospectus and prospectus supplement (the "Prospectus") under which the Company may offer and sell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in shares of its common stock, from time to time, pursuant to an open market sale agreement with Jefferies LLC and by any method deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the &#x201c;ATM Program&#x201d;). Pursuant to the &#x201c;baby shelf rules&#x201d; promulgated by the SEC, if the Company&#x2019;s public float is less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of specified measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement, including pursuant to the ATM Program, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the Company&#x2019;s public float.  As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, due to the SEC&#x2019;s &#x201c;baby shelf rules,&#x201d; the Company was permitted to sell up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock pursuant to the ATM Program. The Company will remain subject to the &#x201c;baby shelf rules&#x201d; under the Form S-3 registration statement until such time as its public float exceeds $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. During the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;were sold&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;under &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Prospectus. This Form S-3 registration statement pursuant to which the ATM Program is registered will expire in May 2024, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock may be sold under the ATM Program after that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Warrant Exchange Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 21, 2021, the Company issued warrants exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,692&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock in exchange for warrants exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,376.456&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Non-Voting Convertible Preferred Stock previously issued as part of the Anelixis merger. These Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Non-Voting Convertible Preferred Stock warrants were replaced by Eledon for the outstanding warrants issued by Anelixis that were not settled upon completion of the merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 Exchange Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 11, 2022, the Company entered into an exchange agreement (the &#x201c;Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Exchange Agreement&#x201d;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, L.L.C. (collectively, the &#x201c;BVF Exchanging Stockholders&#x201d;), pursuant to which the Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Exchanging Stockholders exchanged (the &#x201c;Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Exchange&#x201d;) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;550,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,899.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Non-Voting Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Securities Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 28, 2023, the Company entered into the Securities Purchase Agreement with Purchasers, pursuant to which the Company agreed to issue and sell to the Purchasers in the Private Placement (i) in an initial closing, (a) an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,151,518&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value per share, or pre-funded warrants in lieu thereof (the &#x201c;Pre-Funded Warrants&#x201d;), and (b) common stock warrants exercisable into an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,151,518&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (or Pre-Funded Warrants in lieu thereof) (the &#x201c;Common Warrants&#x201d; and, together with the Pre-Funded Warrants, the &#x201c;Warrants&#x201d;); (ii) in a second closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,202,024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (or Pre-Funded Warrants); and (iii) in a third closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,252,530&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 5, 2023, the initial closing occurred and the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, or net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting offering costs, in exchange for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,730,168&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and Pre-Funded Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,421,350&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The Company may receive an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon sale of the shares to be issued in the second and third closings, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (&#x201c;Registration Statement&#x201d;) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The Registration Statement became effective on June 2, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Conversion Agreement of Non-Voting Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 16, 2023, Cormorant Global Healthcare Master Fund LP provided notice to convert (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,782&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series X Non-Voting Convertible Preferred Stock for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting Convertible Preferred Stock, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,883.586&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Non-Voting Convertible Preferred Stock for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,977&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Exercise of Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 10, 2023, Armistice Capital Master Fund Ltd. (the &#x201c;Exercising Stockholder&#x201d;), exercised Pre-Funded Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;501,197&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which were issued in conjunction with the Securities Purchase Agreement. On July 14, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;501,197&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to the Exercising Stockholder in accordance with such exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 2, 2023, Armistice Capital Master Fund Ltd. (the &#x201c;Exercising Stockholder&#x201d;), exercised Pre-Funded Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;653,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which were issued in conjunction with the Securities Purchase Agreement. On November 6, 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;653,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to the Exercising Stockholder in accordance with such exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,564,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants were exercisable into common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows the warrants to purchase common stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.074%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Roll Forward of Warrant Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Private placement warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Warrants exchanged for  Series X&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;337,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,145,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,151,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,421,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,572,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,489,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,776,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,564,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,207.419&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants exercisable into Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Preferred Stock which are convertible into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,789,301&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:41.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Roll Forward of Series X&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#160;Convertible Preferred Warrant Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,207.419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assumed and replaced&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,207.419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_cc7f483e-fe04-430b-a954-520a086c808f"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_bb6c09cd-929b-46d3-a623-1805e1c44264"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_37d79de2-91fa-459a-8599-fb1ff6ed25df"
      unitRef="U_shares">515000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_fb576c27-7c36-4671-9741-86c2c1f0b8a1"
      unitRef="U_shares">515000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_51b642aa-3930-46a2-86aa-1a543bb67ba6"
      unitRef="U_shares">110086</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_dc24d71c-7cc3-4e50-b784-c2e36f45f6d4"
      decimals="INF"
      id="F_cbd042f4-f654-4c2d-b567-2c927384d8e0"
      unitRef="U_shares">110086</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_bd85bc06-6cfe-4d7e-a715-06c0db747e72"
      unitRef="U_shares">117970</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_eb638520-bde3-4a17-8789-c1c72e2e54f3"
      decimals="INF"
      id="F_1111e993-df92-406f-970f-8ee57d611ad7"
      unitRef="U_shares">117970</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6"
      decimals="INF"
      id="F_d340f872-bdcc-4a02-9e80-01353d3705a1"
      unitRef="U_shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde"
      decimals="INF"
      id="F_aba4f1e2-2ff3-4811-8e2a-d0b37924b17f"
      unitRef="U_shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6"
      decimals="INF"
      id="F_1ae30458-5fb6-4380-8743-2dfeec898650"
      unitRef="U_shares">4422</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e3bde26f-2e1b-477c-888c-39b1e3623bc6"
      decimals="INF"
      id="F_54c5f5d3-dad8-4709-b21f-528dbe59336d"
      unitRef="U_shares">4422</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde"
      decimals="INF"
      id="F_ccd4c4f9-3729-4d1d-a58c-0d95bd2c5c29"
      unitRef="U_shares">6204</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_bdc4a339-8142-476a-b3fb-e83a9b558bde"
      decimals="INF"
      id="F_be8df7e1-689f-40ce-b997-ac475b0e4650"
      unitRef="U_shares">6204</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_b4d3a667-0d9f-40ac-bb0e-95f7b4b21745"
      decimals="INF"
      id="F_be7cda5d-2bab-43fb-ab2c-82ac6a81ffc5"
      unitRef="U_shares">55.5556</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_9eda5a95-af05-48df-860c-3566c2e5b7b4"
      decimals="INF"
      id="F_929efce6-4c7d-49b3-86b0-bb83616e6a85"
      unitRef="U_shares">55.5556</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <eldn:ConversionOfPreferredStockConversionBlockerPercent
      contextRef="C_539b64d7-b76a-4d73-b8da-2e58862a41c3"
      decimals="4"
      id="F_3d560fef-7109-47a7-b71f-a81d9d88361e"
      unitRef="U_pure">0.0999</eldn:ConversionOfPreferredStockConversionBlockerPercent>
    <eldn:ConversionOfPreferredStockConversionBlockerPercent
      contextRef="C_dec7f080-9ef4-430f-acea-1afbd5a8afda"
      decimals="4"
      id="F_9e9b97da-10b1-4ac9-840b-854fe3f5a68f"
      unitRef="U_pure">0.0999</eldn:ConversionOfPreferredStockConversionBlockerPercent>
    <eldn:ConversionOfPreferredStockConversionBlockerPercent
      contextRef="C_3f2ef666-c1cc-4c55-a513-878df085d0cc"
      decimals="3"
      id="F_c1dd96f0-8295-468f-b7ac-ef13d33806ee"
      unitRef="U_pure">0.099</eldn:ConversionOfPreferredStockConversionBlockerPercent>
    <eldn:ConversionOfPreferredStockConversionBlockerPercent
      contextRef="C_e5deb814-b818-48f3-be71-4e54d19ae9f1"
      decimals="3"
      id="F_62640bcf-e864-45ed-b726-25b85f078908"
      unitRef="U_pure">0.099</eldn:ConversionOfPreferredStockConversionBlockerPercent>
    <eldn:EquityDistributionAgreementMaximumValueOfCommonSharesIssuable
      contextRef="C_5bcb3f59-3ee1-413a-b49d-33149e98e0b2"
      decimals="-5"
      id="F_38dc2eee-6133-4b2a-8252-a4e6b3451911"
      unitRef="U_USD">75000000</eldn:EquityDistributionAgreementMaximumValueOfCommonSharesIssuable>
    <eldn:PublicFloatMinimumBalanceToBeMaintained
      contextRef="C_12a2d2e1-2aaf-4445-a36c-14fb7b5c2325"
      decimals="-5"
      id="F_76119121-601e-44a5-a233-7bca97678eff"
      unitRef="U_USD">75000000</eldn:PublicFloatMinimumBalanceToBeMaintained>
    <eldn:EquityDistributionAgreementMaximumValueOfCommonSharesIssuable
      contextRef="C_1db222f1-dbb0-49ac-9c1f-ef8b555d7efb"
      decimals="-5"
      id="F_1f1d3e1c-44ee-4e35-9666-7354eac0dbf5"
      unitRef="U_USD">12300000</eldn:EquityDistributionAgreementMaximumValueOfCommonSharesIssuable>
    <eldn:PublicFloatMinimumBalanceToBeMaintained
      contextRef="C_12a2d2e1-2aaf-4445-a36c-14fb7b5c2325"
      decimals="-5"
      id="F_27015a6f-156f-4317-a138-91bd38914af1"
      unitRef="U_USD">75000000</eldn:PublicFloatMinimumBalanceToBeMaintained>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ccdb24f4-ddf1-43b9-891d-1a463b208bfb"
      decimals="INF"
      id="F_9f0c4922-8f18-4544-a923-d3763298b004"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_23d71061-54b9-42a6-9e17-5f08efea1eb0"
      decimals="INF"
      id="F_a4e707ab-9c4a-45d7-a846-f6263d5001e8"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c5ff90c2-7ab7-4323-9fa7-e9cdeca70a8f"
      decimals="INF"
      id="F_4398531c-f290-415d-9eab-8a2edf0e5b6e"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
      contextRef="C_606d38b0-f6ba-43cf-b237-35fd69e618d0"
      decimals="INF"
      id="F_70b99c42-d489-4512-9805-25072589f507"
      unitRef="U_shares">298692</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
      contextRef="C_f301cf92-7fb0-4ba2-92cb-d9b6ab58209c"
      decimals="INF"
      id="F_4a077176-86ce-441b-8198-7633dc5e8eca"
      unitRef="U_shares">5376.456</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_7801a479-8e65-474f-81b3-70e988f0cb94"
      decimals="INF"
      id="F_28fff4f1-8b9d-408e-a95c-ea943128978b"
      unitRef="U_shares">550000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_d7bc39d7-c639-45d4-a935-4c52633b71fd"
      decimals="INF"
      id="F_9d377f00-d8d3-485e-a484-9505cf4ca2a7"
      unitRef="U_shares">9899.99</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cff03e8e-4e84-4751-8bed-4bbfff630a65"
      decimals="INF"
      id="F_244a6946-0c07-410d-8150-de89a46384b4"
      unitRef="U_shares">15151518</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_cff03e8e-4e84-4751-8bed-4bbfff630a65"
      decimals="INF"
      id="F_0fcd5cfa-fdeb-49ad-bbd0-bc5b03497294"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_cff03e8e-4e84-4751-8bed-4bbfff630a65"
      decimals="INF"
      id="F_93f4da79-3dfe-4f2f-92d7-39ea8f687c7e"
      unitRef="U_shares">15151518</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0adbfddb-526c-4e99-8cac-1ee645fd34e6"
      decimals="INF"
      id="F_4f7c6e3d-3de3-44c4-b417-dde220a36d7a"
      unitRef="U_shares">20202024</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5db2a782-5d40-4e38-afa2-a24096cf9b4c"
      decimals="INF"
      id="F_eb7e118f-7795-48bf-b453-def14091ae33"
      unitRef="U_shares">25252530</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3a8b2ca6-ee48-4d8b-9174-016ccf545018"
      decimals="2"
      id="F_492d115b-6321-47f6-8931-7f08a3a01b84"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_31d98449-23a4-498d-bc0e-c00c14f1718b"
      decimals="3"
      id="F_059f57e4-f9e1-46b8-8f56-b6448c39b666"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_90229839-dc48-46bd-88f4-a22efae9078c"
      decimals="-5"
      id="F_ca20fbc3-6272-4020-a86a-4d8c663fa33b"
      unitRef="U_USD">35000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <eldn:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
      contextRef="C_90229839-dc48-46bd-88f4-a22efae9078c"
      decimals="-5"
      id="F_19d861d8-5595-4296-9f35-9bfb99af9838"
      unitRef="U_USD">33000000</eldn:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b9deefa9-7710-433e-acac-3e9a0bd20f91"
      decimals="INF"
      id="F_e7448835-396f-486b-9850-e3b50e5dd841"
      unitRef="U_shares">8730168</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9a6202d9-fada-461a-bd65-85c4b8841070"
      decimals="INF"
      id="F_70817560-1b5b-4b47-b75f-e50c7708a38d"
      unitRef="U_shares">6421350</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_4fc735f4-0e20-4c55-bc5a-1509ab504714"
      decimals="-5"
      id="F_b5da965b-f4a8-46b6-91b0-997fc7c604d0"
      unitRef="U_USD">105000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_8b7b00cf-f725-4f04-abf7-50d2422f6755"
      decimals="-5"
      id="F_40c612be-185a-4f0e-9486-3662564aa7ea"
      unitRef="U_USD">45500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_d67b8fc7-20c1-4f9d-9bf3-e028f161e18b"
      decimals="INF"
      id="F_feae639d-325a-4b3a-a775-2250abd7dcc4"
      unitRef="U_shares">1782</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_f1772a59-3433-4d38-9a57-13a0ec38ee2b"
      decimals="INF"
      id="F_edb6d53f-6bd2-4cda-9214-539baed8e866"
      unitRef="U_shares">99000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_22837696-6636-4174-85b7-968e5779be90"
      decimals="INF"
      id="F_216ef66b-74e7-49e4-bab3-075625500014"
      unitRef="U_shares">7883.586</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_891105d4-f431-4944-af9d-ba738f8db8f6"
      decimals="INF"
      id="F_3f903687-f676-408d-a73e-5f29efb6efec"
      unitRef="U_shares">437977</us-gaap:ConversionOfStockSharesIssued1>
    <eldn:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_2338023d-7d9b-4ae4-860d-5a670fc77d43"
      decimals="INF"
      id="F_ae26f71e-1d67-45f7-b0fd-da91fb97bd80"
      unitRef="U_shares">501197</eldn:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2338023d-7d9b-4ae4-860d-5a670fc77d43"
      decimals="3"
      id="F_a1babefd-0104-46d9-b68c-0f8f8665cc21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_16a5f966-35bb-40a6-836a-438436efb35a"
      decimals="INF"
      id="F_17f303ab-560a-4536-bb01-a3ec86f20b38"
      unitRef="U_shares">501197</us-gaap:CommonStockSharesIssued>
    <eldn:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_5b4e4097-491a-4d6f-afa0-8dd0e72ce61a"
      decimals="INF"
      id="F_fc28621a-1925-41c6-a843-cc6911946677"
      unitRef="U_shares">653000</eldn:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5b4e4097-491a-4d6f-afa0-8dd0e72ce61a"
      decimals="3"
      id="F_c82fb231-7fef-4f1e-bc87-1e8ed7fe4f20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_085ab3ce-d345-4414-8f9f-ec51eb1a7ed0"
      decimals="INF"
      id="F_b910540e-3cb7-4acc-bc5a-0cbeba1d7f6d"
      unitRef="U_shares">653000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b7d71759-5259-4d1d-9aa7-792cc31e7654"
      decimals="INF"
      id="F_831f9d78-880b-48c7-a3c9-0d27da770451"
      unitRef="U_shares">21564302</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eldn:ScheduleOfWarrantActivityTableTextBlock
      contextRef="C_f448875a-e2e2-4f12-b2e3-7d76a53fa08d"
      id="F_384bfbd9-6532-4395-94c0-7d4ef3f3678a">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows the warrants to purchase common stock activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.074%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Roll Forward of Warrant Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Private placement warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Pre-funded warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Warrants exchanged for  Series X&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;337,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;509,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,145,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,151,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,421,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,572,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#d2effa;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,489,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,776,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,564,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</eldn:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_95b9fc77-0964-46e8-8014-8c0dbfd4b766"
      decimals="INF"
      id="F_13b7ddf5-0ea8-42b2-91f4-a6e22e222c29"
      unitRef="U_shares">337822</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f3213c02-d3c7-4370-aa17-1e548a1026d5"
      decimals="INF"
      id="F_01bebc93-c226-4096-883d-2fe2f3b83e07"
      unitRef="U_shares">509117</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f447210b-d619-429a-aaa3-21f7e7229a49"
      decimals="INF"
      id="F_79a2be02-bfb9-416d-9568-011846b30e45"
      unitRef="U_shares">298692</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_2aed4a90-b683-4eb4-a34b-231381f0b672"
      decimals="INF"
      id="F_5756f4ef-a424-4e34-abb0-8f25541c6864"
      unitRef="U_shares">1145631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
      contextRef="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f"
      decimals="INF"
      id="F_87bc9940-0cf6-4746-b45c-37d80053fc1c"
      unitRef="U_shares">15151518</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
      contextRef="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29"
      decimals="INF"
      id="F_ff6585bc-6829-493d-ac04-7fc47014f623"
      unitRef="U_shares">6421350</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
      contextRef="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94"
      decimals="INF"
      id="F_7b764d00-8d61-434c-903e-550e02279769"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued
      contextRef="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167"
      decimals="INF"
      id="F_705a82fe-40ed-4959-9a2b-bca1c160f052"
      unitRef="U_shares">21572868</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
      contextRef="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f"
      decimals="INF"
      id="F_82ab8e0b-ec31-42d0-85ca-0b0fced8f17e"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
      contextRef="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29"
      decimals="INF"
      id="F_5fbc8b93-fcfb-436a-81f2-6618d4a49f89"
      unitRef="U_shares">1154197</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
      contextRef="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94"
      decimals="INF"
      id="F_c8361d72-2788-42f5-8a72-7df7d2170619"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
      contextRef="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167"
      decimals="INF"
      id="F_13562481-befc-423d-aa91-fdec7a2f3c12"
      unitRef="U_shares">1154197</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
      contextRef="C_4c1a59aa-dca7-4016-b4af-4ed51527d33f"
      decimals="INF"
      id="F_93cb3bc4-37bc-48b0-bace-e97a1f5d1835"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
      contextRef="C_838af7e9-9b2d-407f-8e87-b6d0c7a3bd29"
      decimals="INF"
      id="F_cf81be00-9bee-4f81-a0a9-79c06034290d"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
      contextRef="C_37a1fa68-5da5-49a1-839d-c5c586cb7c94"
      decimals="INF"
      id="F_0be75af6-98d2-45b1-bce5-55e2271c2c26"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
      contextRef="C_0b803a63-fe8e-4362-8ecf-f4f5fcd3c167"
      decimals="INF"
      id="F_9daf19fa-f4b1-4cbd-9651-c0ff8d7f804f"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_94a7e619-bc0a-46f9-82d4-e85969a5f850"
      decimals="INF"
      id="F_82a80836-21c2-4f77-ac09-4375a2621ab7"
      unitRef="U_shares">15489340</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_157cedb9-5047-412b-85f9-6fbe8216f23c"
      decimals="INF"
      id="F_e2b42be9-780f-49c5-8d8f-8755931a20a6"
      unitRef="U_shares">5776270</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_c1011001-4cbb-4b9f-93e6-39793a44b86c"
      decimals="INF"
      id="F_77d4119f-3552-484f-b3f7-04a3eb59f2c6"
      unitRef="U_shares">298692</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_5c188ace-59ca-445c-b04e-c29d392b31a2"
      unitRef="U_shares">21564302</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eldn:ScheduleOfWarrantActivityTableTextBlock
      contextRef="C_326577f3-b56f-4806-864f-4daf1c2d3bdf"
      id="F_785ad75f-7734-4074-ae5d-40ddbb6adb68">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,207.419&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; warrants exercisable into Series X&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Preferred Stock which are convertible into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,789,301&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion blockers).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:41.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Roll Forward of Series X&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#160;Convertible Preferred Warrant Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,207.419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assumed and replaced&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#d2effa;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,207.419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</eldn:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_170abf46-8a87-4bdf-bc25-11d52fb87c8e"
      decimals="INF"
      id="F_4abee987-7f01-4724-b072-27631695de96"
      unitRef="U_shares">50207.419</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_170abf46-8a87-4bdf-bc25-11d52fb87c8e"
      decimals="INF"
      id="F_fc6c4f29-fcee-4d7b-8fe7-ec043742e5fb"
      unitRef="U_shares">2789301</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b49914b8-f522-4af4-8c0b-fb6529f0205e"
      decimals="INF"
      id="F_b00c2814-1c2e-40c9-ab96-c8d48ea2faca"
      unitRef="U_shares">50207.419</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced
      contextRef="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de"
      decimals="INF"
      id="F_9bf0b5a0-2637-44aa-a738-db6b505c8d0a"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised
      contextRef="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de"
      decimals="INF"
      id="F_29e3e0b1-b04c-41a4-b6c5-820345d3723a"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised>
    <eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired
      contextRef="C_3b4f3a99-5374-4bc9-82e3-904fd8f889de"
      decimals="INF"
      id="F_3df8f589-0288-443a-bdb3-84e69c840400"
      unitRef="U_shares">0</eldn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_07827eda-fb88-4fed-aae9-6ed17feba552"
      decimals="INF"
      id="F_0c29d86c-994b-40f7-b46f-94aac5c11ca8"
      unitRef="U_shares">50207.419</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_c726a467-c9b9-4454-9f8f-f15888d74636">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 11. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 21, 2023, the Company held its Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;). At the Annual Meeting, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s 2020 Long Term Incentive Plan (the &#x201c;2020 Plan&#x201d;). The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company&#x2019;s common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares so that the new aggregate share limit under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,460,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 26, 2033.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements totaling &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,381,857&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,476,372&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the granted stock options subject to the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;customary &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;time-based vesting schedule. The remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,905,485&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options granted are subje&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ct to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the second and third closings of the Private Placement as specified in the Securities Purchase Agreement. Further, for the performance-based stock options granted to senior management, upon such second and third closing, a full or prorated amount of each closing shall vest based on the percentage of funding received &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;relative to the total funding opportunity represented by the purchasers' second and third closing subscription amounts. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; specified clinical development milestones were achieved during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2014 Plan was closed to new grants following the approval of the 2020 Plan, and therefore, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares reserved for issuance under the 2014 Plan as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The number of shares reserved for issuance under the 2020 Plan and ESPP was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,093,742&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,077&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively, as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes all option activity under the 2007 Plan, 2014 Plan, 2020 Plan and inducement grants:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.020000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;br/&gt;Issuable&lt;br/&gt;Under Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,213,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,267,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,218,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,026,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;862,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,381,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested and expected to vest as of&lt;br/&gt;&#160;&#160;&#160;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,476,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,065,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that had exercise prices that were lower than the fair value per share of the common stock on the date of exercise. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; aggregate intrinsic value of options exercised during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.471%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.384%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.384%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life of options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Estimated dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The per share weighted average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 wa&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, r&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;espectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows the RSU activity, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;br/&gt;Issuable&lt;br/&gt;Under RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total compensation expense related to all of the Company&#x2019;s stock-based awards for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 was comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized stock-based compensation expense related to non-vested equity awards was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over an estimated weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_497f04cf-da0b-4b5e-b011-34361d789ace"
      decimals="INF"
      id="F_d5566e52-a84b-47e4-940e-8eee1c0affb9"
      unitRef="U_shares">9600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized
      contextRef="C_497f04cf-da0b-4b5e-b011-34361d789ace"
      decimals="INF"
      id="F_933a0956-c673-42e2-99cd-ad69d29d096c"
      unitRef="U_shares">14460000</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_d1c703b7-f5c2-420d-baed-484058777e18"
      decimals="INF"
      id="F_608056c4-8324-4c03-b229-8fa7701f7c21"
      unitRef="U_shares">7381857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f6ce7cd5-abcb-4e3b-a08b-0f8a402a5e5f"
      decimals="INF"
      id="F_5e68bab5-e128-4ff7-a62a-9e03753c984c"
      unitRef="U_shares">1476372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_d1c703b7-f5c2-420d-baed-484058777e18"
      decimals="INF"
      id="F_70738a62-669b-41b1-9b38-1bf079bb882e"
      unitRef="U_shares">5905485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <eldn:NumberOfSpecificClinicalDevelopmentMilestonesAchieved
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_ee2de176-1ae6-4b88-896b-3e2a535bbc51"
      unitRef="U_Milestone">0</eldn:NumberOfSpecificClinicalDevelopmentMilestonesAchieved>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79a2379f-7f54-4178-992c-73f84e1d8b73"
      decimals="INF"
      id="F_6cbe153d-0490-4074-8d6d-0ab524b3b7aa"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7fb153ff-f40b-425f-93b1-c594301d3610"
      decimals="INF"
      id="F_71837b2e-6dd4-44bf-938c-90c4a8a242d5"
      unitRef="U_shares">3093742</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_734d7e73-f1c6-4f08-8277-d9d136b29526"
      decimals="INF"
      id="F_b23fcfc3-09cd-41b1-94a7-f014507eba1a"
      unitRef="U_shares">24077</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_4b1c8438-f22a-4971-a87d-58c2f14711f4">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes all option activity under the 2007 Plan, 2014 Plan, 2020 Plan and inducement grants:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.020000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;br/&gt;Issuable&lt;br/&gt;Under Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,213,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,267,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,218,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,026,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;862,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,381,853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options vested and expected to vest as of&lt;br/&gt;&#160;&#160;&#160;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,476,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,065,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"
      decimals="INF"
      id="F_05e55ce5-fc8d-4e28-97c3-3f844ca59b55"
      unitRef="U_shares">4213977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3dc39ff0-819c-4113-af04-ef3f8a8e42d6"
      decimals="2"
      id="F_0832b427-9df5-4021-83f0-bcfcdf85e246"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a2215e8a-709f-4e4f-a87d-5319589f877a"
      id="F_a7427691-2236-47ea-91dc-00b8022e2b72">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="INF"
      id="F_388c5546-7518-466b-9ef7-0eb46bf07cfc"
      unitRef="U_shares">1267700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_f26cfd10-5146-43cb-a736-9036f76cb95f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="INF"
      id="F_f218a3bc-b213-45f8-bbd9-78999b27f386"
      unitRef="U_shares">263644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_3009fe31-42f3-493a-8737-790c5c32b9f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="INF"
      id="F_6c4f1f82-6da3-431c-a338-d55b2fc6a7bf"
      unitRef="U_shares">5218033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c5d1f09a-750c-4e0a-996b-ec8c451d166a"
      decimals="2"
      id="F_07d911e4-4d5a-490b-97e3-e5f37d3d78e6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      id="F_e6171437-1fd1-4bd1-877c-1b24ebfef367">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_fd6c72a9-e3f8-4354-a7f2-98d035e90363"
      unitRef="U_shares">11026451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_c39436a4-7648-4904-ad51-58b6c8e2aae3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_f9ef32e7-2935-4d6a-a070-dcd611ada7cf"
      unitRef="U_shares">862631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_f65159eb-d8a3-4a0b-8eea-90084dea179b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_3f64912e-99dc-44f2-90be-5e70c77f52de"
      unitRef="U_shares">15381853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="2"
      id="F_6d93901c-f411-4404-a541-cb918dd82afd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_c8035666-9db4-47fd-b055-fc4be88f93c5">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_74f32cd0-c384-400a-bdfb-9cacadd48524"
      unitRef="U_USD">235000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_db0a5360-41f9-4637-bb99-65cb6bb67896"
      unitRef="U_shares">9476369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="2"
      id="F_10ba948f-df44-49ad-ab57-9337fe1c3cb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_cf9c3141-f56c-414c-a79d-ddbe0734b18b">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_52c2ccaa-66f0-464c-ace5-5f3de664db7d"
      unitRef="U_USD">235000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="INF"
      id="F_e8d5bd97-a3ee-482d-9b39-268f42dd7d0c"
      unitRef="U_shares">4065023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="2"
      id="F_8078a832-54ac-4877-b947-4bc819ace5fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_da5ef851-2f60-491a-95bc-1358688946c2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-3"
      id="F_4990b182-71e9-4719-9a80-b0d1a3acccc8"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="INF"
      id="F_f73d105c-30c8-46bb-9a8d-0f850190cf19"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_8412f3c5-748c-423d-b692-1c3a493b3bd4">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.471%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.384%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.384%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life of options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Estimated dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="3"
      id="F_e364dda2-bda3-4870-9fc6-3363e42d0c4a"
      unitRef="U_pure">0.905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="3"
      id="F_90c0ae82-8d42-43ee-b65d-e3aaa487bced"
      unitRef="U_pure">0.839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="3"
      id="F_818f8766-8820-4dc1-9ad2-b4ff7cbf47dc"
      unitRef="U_pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="3"
      id="F_1016b991-ada0-4d6b-8eab-5112e67d06fa"
      unitRef="U_pure">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_40020ef9-2a4d-415b-96f8-b1d909ef1046">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      id="F_d1606ee9-874b-4955-b0b2-9c409e256ecb">P6Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_5fe9c1cb-ff7d-4cc1-a603-ca546ea2c5d1"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_0f8176aa-e350-4d63-a010-eefb7d45d7ef"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="2"
      id="F_6a0e32bb-a279-484d-84bb-f34ab854c646"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="2"
      id="F_968b3530-a956-41e1-944c-14b90294c2a9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_5e1f8df9-6559-41c6-abff-8edb3a307453">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows the RSU activity, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;br/&gt;Issuable&lt;br/&gt;Under RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited / Canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_cb8475f5-4660-40c0-8142-92caed57a7c8"
      decimals="INF"
      id="F_0d91a984-54e2-43a7-9e05-383475d89faf"
      unitRef="U_shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="C_cb8475f5-4660-40c0-8142-92caed57a7c8"
      decimals="2"
      id="F_7e966eee-d2a0-4750-a00b-e231321eb4d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.07</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8"
      decimals="INF"
      id="F_f7fce9a9-f58a-40c4-984d-238180ed4829"
      unitRef="U_shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8"
      decimals="2"
      id="F_1de3ec52-ee39-42ef-9cf0-5de279b2220a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8"
      decimals="INF"
      id="F_8523fd58-0310-4632-8ace-f59aa55de761"
      unitRef="U_shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="C_35052766-c4e5-4be4-af90-aba8bb3300b8"
      decimals="2"
      id="F_612e7ab9-77fd-48b3-847c-0d30e00e0cbd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.07</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_aaa353e1-e2e4-4e48-84e1-87f26b1fe289"
      decimals="INF"
      id="F_88841667-0f2e-4184-b5a3-6b88e5d01614"
      unitRef="U_shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="C_aaa353e1-e2e4-4e48-84e1-87f26b1fe289"
      decimals="2"
      id="F_238175c3-bb44-4f3d-bd2a-8f3e00347eee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0439d622-b345-4d2d-a148-7f5891bdb53e"
      decimals="INF"
      id="F_a8da6af3-70ac-4195-834d-184f4a6b39b3"
      unitRef="U_shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="C_0439d622-b345-4d2d-a148-7f5891bdb53e"
      decimals="2"
      id="F_a33e8a9a-b65d-47ea-a870-4b0a4d775a9e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7430787c-94a0-4f8c-8d53-714130bb6ed6"
      decimals="INF"
      id="F_b89a75cd-8416-4bda-9cc7-718c977c4a7c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice
      contextRef="C_7430787c-94a0-4f8c-8d53-714130bb6ed6"
      decimals="0"
      id="F_2a53580c-3780-4471-9c5c-a02dff03b9bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</eldn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_32237441-1438-4be3-8cf4-35463439776f">&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total compensation expense related to all of the Company&#x2019;s stock-based awards for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 was comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a4dbd612-6707-4d02-a493-3e3587d5b602"
      decimals="-3"
      id="F_b1735025-2b7a-4e9b-8d28-0f68db83d518"
      unitRef="U_USD">1491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_509700d3-0809-447c-94e0-126e7520dc70"
      decimals="-3"
      id="F_4113d219-cf31-4ba2-8d4e-d0ac5200d450"
      unitRef="U_USD">3230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_349c064a-f323-4320-a562-2a08dbbdc3ba"
      decimals="-3"
      id="F_d3c23089-7229-48d9-8354-5672be717dc2"
      unitRef="U_USD">5054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_090932c3-ea52-4d70-b213-7b49b4e7f9bc"
      decimals="-3"
      id="F_44cc118e-fd5f-49c1-a722-93cc54c44710"
      unitRef="U_USD">4923000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      decimals="-3"
      id="F_d7573098-940d-467c-9caa-caa790322325"
      unitRef="U_USD">6545000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_239720ec-ec16-4abc-a760-ebef1985ac2f"
      decimals="-3"
      id="F_534b6bfb-51e9-4f25-9927-caedf0a8ef98"
      unitRef="U_USD">8153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_a35f913d-d756-40df-9f78-a4912c356455"
      decimals="-5"
      id="F_97687e25-db8d-421b-a456-8cabe3c2e94d"
      unitRef="U_USD">12400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_3fd1d77b-88e6-4aad-b7c8-d5816e36b241">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_57551459-8811-4b71-9e9a-189290d077cf"
      id="F_3b943fa0-81cf-4226-a9e1-9639f8036433">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 12. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 30, 2024, Armistice Capital Master Fund Ltd. (the &#x201c;Exercising Stockholder&#x201d;), exercised Pre-Funded Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which were issued in conjunction with the Securities Purchase Agreement. On January 30, 2024, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to the Exercising Stockholder in accordance with such exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <eldn:NumberOfPreFundedWarrantsExercisedForCommonStock
      contextRef="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1"
      decimals="INF"
      id="F_29316969-4acf-46a1-b597-a5d8dbe7842e"
      unitRef="U_shares">600000</eldn:NumberOfPreFundedWarrantsExercisedForCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1"
      decimals="3"
      id="F_56cf46f0-6cd3-4e37-8570-d5618af76e03"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_46bbd5d5-2ad4-45f5-bea1-0267a6228af1"
      decimals="INF"
      id="F_4774a77a-7af4-4c3a-9d92-ae72f1c01554"
      unitRef="U_shares">600000</us-gaap:CommonStockSharesIssued>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
